| Description | Drug perturbation signatures created by profiling 4343 small molecules in the U2-OS cell line with the DRUG-seq platform |
| Measurement | gene expression by RNA-seq |
| Association | gene-drug perturbation associations by differential expression of gene following drug perturbation |
| Category | transcriptomics |
| Resource | Novartis Institutes for Biomedical Research |
| Citation(s) | |
| Last Updated | 2025 Apr 17 |
| Stats |
|
Gene Attribute
Gene Similarity
Attribute Similarity
UMAP
15960 sets of genes differentially expressed following drug perturbation from the NIBR DRUG-seq U2OS MoA Box dataset.
| Gene Set | Description |
|---|---|
| AA-01-JO26_0.01uM | Dose=0.01uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP |
| AA-01-JO26_0.1uM | Dose=0.1uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP |
| AA-01-JO26_10uM | Dose=10uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP |
| AA-01-JO26_1uM | Dose=1uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP |
| AA-01-PS31_0.01uM | Dose=0.01uM, US10336774, Example 52, SHP2 allosteric inhibitor targeting PTPN11 |
| AA-01-PS31_0.1uM | Dose=0.1uM, US10336774, Example 52, SHP2 allosteric inhibitor targeting PTPN11 |
| AA-01-PS31_10uM | Dose=10uM, US10336774, Example 52, SHP2 allosteric inhibitor targeting PTPN11 |
| AA-01-PS31_1uM | Dose=1uM, US10336774, Example 52, SHP2 allosteric inhibitor targeting PTPN11 |
| AA-01-XV28_0.01uM | Dose=0.01uM, 5-Benzoyloxy-1(2H)-isoquinolinone, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors targeting PARP2 |
| AA-01-XV28_0.1uM | Dose=0.1uM, 5-Benzoyloxy-1(2H)-isoquinolinone, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors targeting PARP2 |
| AA-01-XV28_10uM | Dose=10uM, 5-Benzoyloxy-1(2H)-isoquinolinone, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors targeting PARP2 |
| AA-01-XV28_1uM | Dose=1uM, 5-Benzoyloxy-1(2H)-isoquinolinone, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors targeting PARP2 |
| AA-02-FS13_0.01uM | Dose=0.01uM, Benzylhydrazine |
| AA-02-FS13_0.1uM | Dose=0.1uM, Benzylhydrazine |
| AA-02-FS13_10uM | Dose=10uM, Benzylhydrazine |
| AA-02-FS13_1uM | Dose=1uM, Benzylhydrazine |
| AA-03-QM41_0.01uM | Dose=0.01uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;IGF-1R Inhibitors targeting IGF1R |
| AA-03-QM41_0.1uM | Dose=0.1uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;IGF-1R Inhibitors targeting IGF1R |
| AA-03-QM41_10uM | Dose=10uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;IGF-1R Inhibitors targeting IGF1R |
| AA-03-QM41_1uM | Dose=1uM, Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;IGF-1R Inhibitors targeting IGF1R |
| AA-07-BW60_0.01uM | Dose=0.01uM, Moclobemide, MAO-A Inhibitors targeting MAOA |
| AA-07-BW60_0.1uM | Dose=0.1uM, Moclobemide, MAO-A Inhibitors targeting MAOA |
| AA-07-BW60_10uM | Dose=10uM, Moclobemide, MAO-A Inhibitors targeting MAOA |
| AA-07-BW60_1uM | Dose=1uM, Moclobemide, MAO-A Inhibitors targeting MAOA |
| AA-07-FZ97_0.01uM | Dose=0.01uM, Calcitriol, CYP27B1 metabolite targeting VDR, CYP27B1 |
| AA-07-FZ97_0.1uM | Dose=0.1uM, Calcitriol, CYP27B1 metabolite targeting VDR, CYP27B1 |
| AA-07-FZ97_10uM | Dose=10uM, Calcitriol, CYP27B1 metabolite targeting VDR, CYP27B1 |
| AA-07-FZ97_1uM | Dose=1uM, Calcitriol, CYP27B1 metabolite targeting VDR, CYP27B1 |
| AA-09-HG96_0.01uM | Dose=0.01uM, Pentoxifylline, Chitinase Inhibitors;TNF-alpha Production Inhibitors;Phosphodiesterase Inhibitors targeting PDE4A, PDE4B, TNF, PDE5A, CHIA |
| AA-09-HG96_0.1uM | Dose=0.1uM, Pentoxifylline, Chitinase Inhibitors;TNF-alpha Production Inhibitors;Phosphodiesterase Inhibitors targeting PDE4A, PDE4B, TNF, PDE5A, CHIA |
| AA-09-HG96_10uM | Dose=10uM, Pentoxifylline, Chitinase Inhibitors;TNF-alpha Production Inhibitors;Phosphodiesterase Inhibitors targeting PDE4A, PDE4B, TNF, PDE5A, CHIA |
| AA-09-HG96_1uM | Dose=1uM, Pentoxifylline, Chitinase Inhibitors;TNF-alpha Production Inhibitors;Phosphodiesterase Inhibitors targeting PDE4A, PDE4B, TNF, PDE5A, CHIA |
| AA-10-BH32_0.01uM | Dose=0.01uM, (2S)-N-[(1S)-2-[(3aR,7aS)-7-oxo-6-(2-phenylethyl)-2,3,3a,4,5,7a-hexahydropyrrolo[2,3-c]pyridin-1-yl]-1-cyclohexyl-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting XIAP |
| AA-10-BH32_0.1uM | Dose=0.1uM, (2S)-N-[(1S)-2-[(3aR,7aS)-7-oxo-6-(2-phenylethyl)-2,3,3a,4,5,7a-hexahydropyrrolo[2,3-c]pyridin-1-yl]-1-cyclohexyl-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting XIAP |
| AA-10-BH32_10uM | Dose=10uM, (2S)-N-[(1S)-2-[(3aR,7aS)-7-oxo-6-(2-phenylethyl)-2,3,3a,4,5,7a-hexahydropyrrolo[2,3-c]pyridin-1-yl]-1-cyclohexyl-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting XIAP |
| AA-10-BH32_1uM | Dose=1uM, (2S)-N-[(1S)-2-[(3aR,7aS)-7-oxo-6-(2-phenylethyl)-2,3,3a,4,5,7a-hexahydropyrrolo[2,3-c]pyridin-1-yl]-1-cyclohexyl-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting XIAP |
| AA-10-VR76_0.01uM | Dose=0.01uM, Hexachlorophene, Autotaxin) Inhibitors;Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2, SDHD |
| AA-10-VR76_0.1uM | Dose=0.1uM, Hexachlorophene, Autotaxin) Inhibitors;Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2, SDHD |
| AA-10-VR76_10uM | Dose=10uM, Hexachlorophene, Autotaxin) Inhibitors;Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2, SDHD |
| AA-11-RO46_0.01uM | Dose=0.01uM, Fascaplysin, DNA-Intercalating Drugs;CDC25B Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK6 Inhibitors targeting CCND1, CDK4, CDK6 |
| AA-11-RO46_0.1uM | Dose=0.1uM, Fascaplysin, DNA-Intercalating Drugs;CDC25B Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK6 Inhibitors targeting CCND1, CDK4, CDK6 |
| AA-11-RO46_10uM | Dose=10uM, Fascaplysin, DNA-Intercalating Drugs;CDC25B Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK6 Inhibitors targeting CCND1, CDK4, CDK6 |
| AA-11-RO46_1uM | Dose=1uM, Fascaplysin, DNA-Intercalating Drugs;CDC25B Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK6 Inhibitors targeting CCND1, CDK4, CDK6 |
| AA-12-SS68_0.01uM | Dose=0.01uM |
| AA-12-SS68_0.1uM | Dose=0.1uM |
| AA-12-SS68_10uM | Dose=10uM |
| AA-12-SS68_1uM | Dose=1uM |
| AA-12-VW53_0.01uM | Dose=0.01uM, (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine, BACE1 gene inhibitor targeting BACE1 |
| AA-12-VW53_0.1uM | Dose=0.1uM, (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine, BACE1 gene inhibitor targeting BACE1 |
| AA-12-VW53_10uM | Dose=10uM, (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine, BACE1 gene inhibitor targeting BACE1 |
| AA-12-VW53_1uM | Dose=1uM, (S)-4-(2,4-Difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine, BACE1 gene inhibitor targeting BACE1 |
| AA-13-DN24_0.01uM | Dose=0.01uM, Eliprodil, NMDA Antagonists targeting GRIN1 |
| AA-13-DN24_0.1uM | Dose=0.1uM, Eliprodil, NMDA Antagonists targeting GRIN1 |
| AA-13-DN24_10uM | Dose=10uM, Eliprodil, NMDA Antagonists targeting GRIN1 |
| AA-13-DN24_1uM | Dose=1uM, Eliprodil, NMDA Antagonists targeting GRIN1 |
| AA-13-FM86_0.01uM | Dose=0.01uM, Alagebrium |
| AA-13-FM86_1uM | Dose=1uM, Alagebrium |
| AA-14-DQ28_0.01uM | Dose=0.01uM, Estradiol |
| AA-14-DQ28_0.1uM | Dose=0.1uM, Estradiol |
| AA-14-DQ28_10uM | Dose=10uM, Estradiol |
| AA-14-DQ28_1uM | Dose=1uM, Estradiol |
| AA-14-SG39_0.01uM | Dose=0.01uM, (2R)-2-[(4-phenoxyphenyl)sulfonylamino]-5-(1,1,3-trioxo-1,2-benzothiazol-2-yl)pentanoic acid |
| AA-14-SG39_0.1uM | Dose=0.1uM, (2R)-2-[(4-phenoxyphenyl)sulfonylamino]-5-(1,1,3-trioxo-1,2-benzothiazol-2-yl)pentanoic acid |
| AA-14-SG39_10uM | Dose=10uM, (2R)-2-[(4-phenoxyphenyl)sulfonylamino]-5-(1,1,3-trioxo-1,2-benzothiazol-2-yl)pentanoic acid |
| AA-14-VK39_0.01uM | Dose=0.01uM, N-[4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butyl]-N-[[3-(4-chlorophenyl)phenyl]methyl]-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide |
| AA-14-VK39_0.1uM | Dose=0.1uM, N-[4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butyl]-N-[[3-(4-chlorophenyl)phenyl]methyl]-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide |
| AA-14-VK39_10uM | Dose=10uM, N-[4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butyl]-N-[[3-(4-chlorophenyl)phenyl]methyl]-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide |
| AA-15-HO31_0.1uM | Dose=0.1uM, Batimastat, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting FCER2, MMP14, MMP16, MMP11, FCER1A, MS4A2, MMP15, MMP17, MMP19, MMP23A, MMP20, MS4A7, MMP27, MMP28, MMP21 |
| AA-15-HO31_10uM | Dose=10uM, Batimastat, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting FCER2, MMP14, MMP16, MMP11, FCER1A, MS4A2, MMP15, MMP17, MMP19, MMP23A, MMP20, MS4A7, MMP27, MMP28, MMP21 |
| AA-15-HO31_1uM | Dose=1uM, Batimastat, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting FCER2, MMP14, MMP16, MMP11, FCER1A, MS4A2, MMP15, MMP17, MMP19, MMP23A, MMP20, MS4A7, MMP27, MMP28, MMP21 |
| AA-15-VA57_0.01uM | Dose=0.01uM, p-Tolueneboronic acid, Endothelial Lipase (EL) Inhibitors targeting LIPG |
| AA-15-VA57_0.1uM | Dose=0.1uM, p-Tolueneboronic acid, Endothelial Lipase (EL) Inhibitors targeting LIPG |
| AA-15-VA57_10uM | Dose=10uM, p-Tolueneboronic acid, Endothelial Lipase (EL) Inhibitors targeting LIPG |
| AA-15-VA57_1uM | Dose=1uM, p-Tolueneboronic acid, Endothelial Lipase (EL) Inhibitors targeting LIPG |
| AA-16-HV95_0.01uM | Dose=0.01uM |
| AA-16-HV95_0.1uM | Dose=0.1uM |
| AA-16-HV95_10uM | Dose=10uM |
| AA-16-HV95_1uM | Dose=1uM |
| AA-17-RC87_0.01uM | Dose=0.01uM, n-[2-(n,n-Dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide, MCHR1 antagonist targeting MCHR1 |
| AA-17-RC87_0.1uM | Dose=0.1uM, n-[2-(n,n-Dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide, MCHR1 antagonist targeting MCHR1 |
| AA-17-RC87_10uM | Dose=10uM, n-[2-(n,n-Dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide, MCHR1 antagonist targeting MCHR1 |
| AA-17-RC87_1uM | Dose=1uM, n-[2-(n,n-Dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide, MCHR1 antagonist targeting MCHR1 |
| AA-18-BW97_0.01uM | Dose=0.01uM, Phentolamine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| AA-18-BW97_10uM | Dose=10uM, Phentolamine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| AA-18-BW97_1uM | Dose=1uM, Phentolamine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| AA-18-GQ83_0.01uM | Dose=0.01uM, N-[5-(dimethylamino)pentyl]-5-thiophen-2-yl-1,2-oxazole-3-carboxamide |
| AA-18-GQ83_0.1uM | Dose=0.1uM, N-[5-(dimethylamino)pentyl]-5-thiophen-2-yl-1,2-oxazole-3-carboxamide |
| AA-18-GQ83_10uM | Dose=10uM, N-[5-(dimethylamino)pentyl]-5-thiophen-2-yl-1,2-oxazole-3-carboxamide |
| AA-18-GQ83_1uM | Dose=1uM, N-[5-(dimethylamino)pentyl]-5-thiophen-2-yl-1,2-oxazole-3-carboxamide |
| AA-19-EX72_0.01uM | Dose=0.01uM, (Z)-3,5-Diamino-6-chloro-N-((R)-4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)propyl)imidazolidin-2-ylidene)pyrazine-2-carboxamide targeting SCNN1A |
| AA-19-EX72_0.1uM | Dose=0.1uM, (Z)-3,5-Diamino-6-chloro-N-((R)-4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)propyl)imidazolidin-2-ylidene)pyrazine-2-carboxamide targeting SCNN1A |
| AA-19-EX72_10uM | Dose=10uM, (Z)-3,5-Diamino-6-chloro-N-((R)-4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)propyl)imidazolidin-2-ylidene)pyrazine-2-carboxamide targeting SCNN1A |
| AA-19-EX72_1uM | Dose=1uM, (Z)-3,5-Diamino-6-chloro-N-((R)-4-(3-(4-((S)-2,3-dihydroxypropoxy)phenyl)propyl)imidazolidin-2-ylidene)pyrazine-2-carboxamide targeting SCNN1A |
| AA-19-SX47_0.01uM | Dose=0.01uM, 2-(3,4-Dichlorophenyl)-1-[2-(1-pyrrolidinylmethyl)-1-piperidinyl]ethanone, OPRK1 agonist targeting OPRK1 |
| AA-19-SX47_0.1uM | Dose=0.1uM, 2-(3,4-Dichlorophenyl)-1-[2-(1-pyrrolidinylmethyl)-1-piperidinyl]ethanone, OPRK1 agonist targeting OPRK1 |
| AA-19-SX47_10uM | Dose=10uM, 2-(3,4-Dichlorophenyl)-1-[2-(1-pyrrolidinylmethyl)-1-piperidinyl]ethanone, OPRK1 agonist targeting OPRK1 |
| AA-19-SX47_1uM | Dose=1uM, 2-(3,4-Dichlorophenyl)-1-[2-(1-pyrrolidinylmethyl)-1-piperidinyl]ethanone, OPRK1 agonist targeting OPRK1 |
| AA-20-DK54_0.01uM | Dose=0.01uM, Verapamil, Dopamine D2 Antagonists;Calcium Channel Blockers;L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| AA-20-DK54_0.1uM | Dose=0.1uM, Verapamil, Dopamine D2 Antagonists;Calcium Channel Blockers;L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| AA-20-DK54_10uM | Dose=10uM, Verapamil, Dopamine D2 Antagonists;Calcium Channel Blockers;L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| AA-20-DK54_1uM | Dose=1uM, Verapamil, Dopamine D2 Antagonists;Calcium Channel Blockers;L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| AA-22-FS33_0.01uM | Dose=0.01uM, Vatalanib, VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;PDGFRbeta Inhibitors;VEGFR-1 (Flt-1) Inhibitors;KIT (C-KIT) Inhibitors;Inhibitors of Signal Transduction Pathways;Aromatase Inhibitors;Angiogenesis Inhibitors targeting FLT1, KDR, KIT |
| AA-22-FS33_10uM | Dose=10uM, Vatalanib, VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;PDGFRbeta Inhibitors;VEGFR-1 (Flt-1) Inhibitors;KIT (C-KIT) Inhibitors;Inhibitors of Signal Transduction Pathways;Aromatase Inhibitors;Angiogenesis Inhibitors targeting FLT1, KDR, KIT |
| AA-22-PQ14_0.01uM | Dose=0.01uM, trans-3,4,4a,5,10,10a-hexahydro-9-iodo-6-methoxy-4-methyl-2H-naphth[2,3-b]-1,4-oxazine, ADRA1A agonist targeting ADRA1A |
| AA-22-PQ14_0.1uM | Dose=0.1uM, trans-3,4,4a,5,10,10a-hexahydro-9-iodo-6-methoxy-4-methyl-2H-naphth[2,3-b]-1,4-oxazine, ADRA1A agonist targeting ADRA1A |
| AA-22-PQ14_10uM | Dose=10uM, trans-3,4,4a,5,10,10a-hexahydro-9-iodo-6-methoxy-4-methyl-2H-naphth[2,3-b]-1,4-oxazine, ADRA1A agonist targeting ADRA1A |
| AA-22-PQ14_1uM | Dose=1uM, trans-3,4,4a,5,10,10a-hexahydro-9-iodo-6-methoxy-4-methyl-2H-naphth[2,3-b]-1,4-oxazine, ADRA1A agonist targeting ADRA1A |
| AA-22-SF72_0.01uM | Dose=0.01uM, Jnj-38877605, c-Met) Inhibitors;Inhibitors of Signal Transduction Pathways;HGFR (MET targeting MET |
| AA-22-SF72_0.1uM | Dose=0.1uM, Jnj-38877605, c-Met) Inhibitors;Inhibitors of Signal Transduction Pathways;HGFR (MET targeting MET |
| AA-22-SF72_10uM | Dose=10uM, Jnj-38877605, c-Met) Inhibitors;Inhibitors of Signal Transduction Pathways;HGFR (MET targeting MET |
| AA-22-SF72_1uM | Dose=1uM, Jnj-38877605, c-Met) Inhibitors;Inhibitors of Signal Transduction Pathways;HGFR (MET targeting MET |
| AA-22-UI44_0.01uM | Dose=0.01uM, (E)-N-Hydroxy-3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide, HDAC inhibitor targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AA-22-UI44_0.1uM | Dose=0.1uM, (E)-N-Hydroxy-3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide, HDAC inhibitor targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AA-22-UI44_10uM | Dose=10uM, (E)-N-Hydroxy-3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide, HDAC inhibitor targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AA-22-UI44_1uM | Dose=1uM, (E)-N-Hydroxy-3-(4-{[2-(1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide, HDAC inhibitor targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AA-23-FM46_0.01uM | Dose=0.01uM, Dacinostat, HDAC 1/2/3/6/8/10/11;Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Antimitotic Drugs targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AA-23-FM46_0.1uM | Dose=0.1uM, Dacinostat, HDAC 1/2/3/6/8/10/11;Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Antimitotic Drugs targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AA-23-FM46_10uM | Dose=10uM, Dacinostat, HDAC 1/2/3/6/8/10/11;Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Antimitotic Drugs targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AA-23-FM46_1uM | Dose=1uM, Dacinostat, HDAC 1/2/3/6/8/10/11;Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Antimitotic Drugs targeting HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AA-24-EN31_0.01uM | Dose=0.01uM, (5R,8S)-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-7-[(2S)-2-[[(2S)-3,3-dimethyl-2-[[(2S)-1-propan-2-ylpiperidine-2-carbonyl]amino]butanoyl]amino]-3,3-dimethylbutanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| AA-24-EN31_10uM | Dose=10uM, (5R,8S)-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-7-[(2S)-2-[[(2S)-3,3-dimethyl-2-[[(2S)-1-propan-2-ylpiperidine-2-carbonyl]amino]butanoyl]amino]-3,3-dimethylbutanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| AA-24-EN31_1uM | Dose=1uM, (5R,8S)-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-7-[(2S)-2-[[(2S)-3,3-dimethyl-2-[[(2S)-1-propan-2-ylpiperidine-2-carbonyl]amino]butanoyl]amino]-3,3-dimethylbutanoyl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| AA-24-SQ13_0.01uM | Dose=0.01uM, SR 2640, Leukotriene Antagonists targeting CYSLTR1 |
| AA-24-SQ13_0.1uM | Dose=0.1uM, SR 2640, Leukotriene Antagonists targeting CYSLTR1 |
| AA-24-SQ13_10uM | Dose=10uM, SR 2640, Leukotriene Antagonists targeting CYSLTR1 |
| AA-24-SQ13_1uM | Dose=1uM, SR 2640, Leukotriene Antagonists targeting CYSLTR1 |
| AA-24-UO04_0.01uM | Dose=0.01uM, 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol, HTR1E agonist;HTR1F agonist targeting HTR1E, HTR1F |
| AA-24-UO04_0.1uM | Dose=0.1uM, 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol, HTR1E agonist;HTR1F agonist targeting HTR1E, HTR1F |
| AA-24-UO04_10uM | Dose=10uM, 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol, HTR1E agonist;HTR1F agonist targeting HTR1E, HTR1F |
| AA-24-UO04_1uM | Dose=1uM, 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol, HTR1E agonist;HTR1F agonist targeting HTR1E, HTR1F |
| AA-27-LG62_0.01uM | Dose=0.01uM, Raloxifene, ENG Expression Enhancers;ACVRL1 Expression Enhancers;Selective Estrogen Receptor Modulators (SERM) targeting ENG |
| AA-27-LG62_0.1uM | Dose=0.1uM, Raloxifene, ENG Expression Enhancers;ACVRL1 Expression Enhancers;Selective Estrogen Receptor Modulators (SERM) targeting ENG |
| AA-27-LG62_10uM | Dose=10uM, Raloxifene, ENG Expression Enhancers;ACVRL1 Expression Enhancers;Selective Estrogen Receptor Modulators (SERM) targeting ENG |
| AA-27-LG62_1uM | Dose=1uM, Raloxifene, ENG Expression Enhancers;ACVRL1 Expression Enhancers;Selective Estrogen Receptor Modulators (SERM) targeting ENG |
| AA-27-TF89_0.01uM | Dose=0.01uM, 1-(6-((2-((6-Amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one targeting GSK3B |
| AA-27-TF89_0.1uM | Dose=0.1uM, 1-(6-((2-((6-Amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one targeting GSK3B |
| AA-27-TF89_10uM | Dose=10uM, 1-(6-((2-((6-Amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one targeting GSK3B |
| AA-27-TF89_1uM | Dose=1uM, 1-(6-((2-((6-Amino-5-nitropyridin-2-yl)amino)ethyl)amino)-2-(2,4-dichlorophenyl)pyridin-3-yl)-4-methylpiperazin-2-one targeting GSK3B |
| AA-28-PM33_0.01uM | Dose=0.01uM, Cromolyn, Mediator Release Inhibitors targeting S100P |
| AA-28-PM33_0.1uM | Dose=0.1uM, Cromolyn, Mediator Release Inhibitors targeting S100P |
| AA-28-PM33_10uM | Dose=10uM, Cromolyn, Mediator Release Inhibitors targeting S100P |
| AA-28-PM33_1uM | Dose=1uM, Cromolyn, Mediator Release Inhibitors targeting S100P |
| AA-29-ZN08_0.01uM | Dose=0.01uM, 1-[2-(2-Ethyltetrazol-5-yl)ethyl]-3-[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]urea, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG |
| AA-29-ZN08_0.1uM | Dose=0.1uM, 1-[2-(2-Ethyltetrazol-5-yl)ethyl]-3-[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]urea, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG |
| AA-29-ZN08_10uM | Dose=10uM, 1-[2-(2-Ethyltetrazol-5-yl)ethyl]-3-[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]urea, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG |
| AA-29-ZN08_1uM | Dose=1uM, 1-[2-(2-Ethyltetrazol-5-yl)ethyl]-3-[5-(3-fluoro-4-methylsulfonylphenyl)-4-methyl-1,3-thiazol-2-yl]urea, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG |
| AA-30-BE85_10uM | Dose=10uM, 4,7-Dichloro-3-hydroxy-3-(2-(4-methoxyphenyl)-2-oxoethyl)indolin-2-one, EWS-FLI1 Inhibitors targeting EWSR1, FLI1 |
| AA-30-BE85_1uM | Dose=1uM, 4,7-Dichloro-3-hydroxy-3-(2-(4-methoxyphenyl)-2-oxoethyl)indolin-2-one, EWS-FLI1 Inhibitors targeting EWSR1, FLI1 |
| AA-31-NO26_0.01uM | Dose=0.01uM, Carbamazepine, Sodium Channel Blockers targeting SCN5A, SCN10A |
| AA-31-NO26_0.1uM | Dose=0.1uM, Carbamazepine, Sodium Channel Blockers targeting SCN5A, SCN10A |
| AA-31-NO26_1uM | Dose=1uM, Carbamazepine, Sodium Channel Blockers targeting SCN5A, SCN10A |
| AA-31-OE22_0.01uM | Dose=0.01uM, (8S,10R,13S,14S,17R)-10,13-dimethylspiro[2,8,12,14,15,16-hexahydro-1H-cyclopenta[a]phenanthrene-17,5\'-oxolane]-2\',3-dione |
| AA-31-OE22_0.1uM | Dose=0.1uM, (8S,10R,13S,14S,17R)-10,13-dimethylspiro[2,8,12,14,15,16-hexahydro-1H-cyclopenta[a]phenanthrene-17,5\'-oxolane]-2\',3-dione |
| AA-31-OE22_10uM | Dose=10uM, (8S,10R,13S,14S,17R)-10,13-dimethylspiro[2,8,12,14,15,16-hexahydro-1H-cyclopenta[a]phenanthrene-17,5\'-oxolane]-2\',3-dione |
| AA-31-OE22_1uM | Dose=1uM, (8S,10R,13S,14S,17R)-10,13-dimethylspiro[2,8,12,14,15,16-hexahydro-1H-cyclopenta[a]phenanthrene-17,5\'-oxolane]-2\',3-dione |
| AA-31-YE07_0.01uM | Dose=0.01uM, Chrysin, Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP;Antiinflammatory Drugs;ABCG2) Inhibitors;Antioxidants targeting ABCG2, HSD17B10, HSD17B7, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| AA-31-YE07_0.1uM | Dose=0.1uM, Chrysin, Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP;Antiinflammatory Drugs;ABCG2) Inhibitors;Antioxidants targeting ABCG2, HSD17B10, HSD17B7, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| AA-31-YE07_10uM | Dose=10uM, Chrysin, Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP;Antiinflammatory Drugs;ABCG2) Inhibitors;Antioxidants targeting ABCG2, HSD17B10, HSD17B7, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| AA-31-YE07_1uM | Dose=1uM, Chrysin, Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP;Antiinflammatory Drugs;ABCG2) Inhibitors;Antioxidants targeting ABCG2, HSD17B10, HSD17B7, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| AA-32-DP01_0.1uM | Dose=0.1uM, 1-(2,4-Dimethoxyphenyl)-3-(2,6-dimethylphenyl)-1-[6-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]urea, SIK1 gene inhibitor targeting SIK2, SIK3, SIK1 |
| AA-32-DP01_10uM | Dose=10uM, 1-(2,4-Dimethoxyphenyl)-3-(2,6-dimethylphenyl)-1-[6-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]urea, SIK1 gene inhibitor targeting SIK2, SIK3, SIK1 |
| AA-32-DP01_1uM | Dose=1uM, 1-(2,4-Dimethoxyphenyl)-3-(2,6-dimethylphenyl)-1-[6-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]urea, SIK1 gene inhibitor targeting SIK2, SIK3, SIK1 |
| AA-33-DN24_0.01uM | Dose=0.01uM, Olprinone |
| AA-33-DN24_0.1uM | Dose=0.1uM, Olprinone |
| AA-33-DN24_10uM | Dose=10uM, Olprinone |
| AA-33-DN24_1uM | Dose=1uM, Olprinone |
| AA-33-TW45_0.01uM | Dose=0.01uM, Lergotrile, Prolactin Secretion Inhibitors targeting PRL |
| AA-33-TW45_0.1uM | Dose=0.1uM, Lergotrile, Prolactin Secretion Inhibitors targeting PRL |
| AA-33-TW45_10uM | Dose=10uM, Lergotrile, Prolactin Secretion Inhibitors targeting PRL |
| AA-33-TW45_1uM | Dose=1uM, Lergotrile, Prolactin Secretion Inhibitors targeting PRL |
| AA-34-SG19_0.01uM | Dose=0.01uM, Abitesartan, Angiotensin AT1 Antagonists targeting AGTR1 |
| AA-34-SG19_10uM | Dose=10uM, Abitesartan, Angiotensin AT1 Antagonists targeting AGTR1 |
| AA-34-SG19_1uM | Dose=1uM, Abitesartan, Angiotensin AT1 Antagonists targeting AGTR1 |
| AA-35-LB45_0.01uM | Dose=0.01uM, Amoxapine, 5-HT Reuptake Inhibitors;5-HT2A Antagonists;Norepinephrine Reuptake Inhibitors targeting HTR2A, SLC6A2, SLC6A4 |
| AA-35-LB45_10uM | Dose=10uM, Amoxapine, 5-HT Reuptake Inhibitors;5-HT2A Antagonists;Norepinephrine Reuptake Inhibitors targeting HTR2A, SLC6A2, SLC6A4 |
| AA-35-LB45_1uM | Dose=1uM, Amoxapine, 5-HT Reuptake Inhibitors;5-HT2A Antagonists;Norepinephrine Reuptake Inhibitors targeting HTR2A, SLC6A2, SLC6A4 |
| AA-35-QK71_0.01uM | Dose=0.01uM, Nepicastat, Dopamine-β-hydroxylase inhibitor targeting DBH |
| AA-35-QK71_0.1uM | Dose=0.1uM, Nepicastat, Dopamine-β-hydroxylase inhibitor targeting DBH |
| AA-35-QK71_10uM | Dose=10uM, Nepicastat, Dopamine-β-hydroxylase inhibitor targeting DBH |
| AA-35-QK71_1uM | Dose=1uM, Nepicastat, Dopamine-β-hydroxylase inhibitor targeting DBH |
| AA-35-VH74_0.01uM | Dose=0.01uM, Piribedil, Dopamine D2 Agonists;alpha2-Adrenoceptor Antagonists;Dopamine D3 Agonists targeting DRD2, DRD3 |
| AA-35-VH74_0.1uM | Dose=0.1uM, Piribedil, Dopamine D2 Agonists;alpha2-Adrenoceptor Antagonists;Dopamine D3 Agonists targeting DRD2, DRD3 |
| AA-35-VH74_10uM | Dose=10uM, Piribedil, Dopamine D2 Agonists;alpha2-Adrenoceptor Antagonists;Dopamine D3 Agonists targeting DRD2, DRD3 |
| AA-35-VH74_1uM | Dose=1uM, Piribedil, Dopamine D2 Agonists;alpha2-Adrenoceptor Antagonists;Dopamine D3 Agonists targeting DRD2, DRD3 |
| AA-36-YV45_0.01uM | Dose=0.01uM, 5-Nitrosalicylaldehyde, Glucose-6-phosphatase Inhibitors targeting G6PC |
| AA-36-YV45_0.1uM | Dose=0.1uM, 5-Nitrosalicylaldehyde, Glucose-6-phosphatase Inhibitors targeting G6PC |
| AA-36-YV45_10uM | Dose=10uM, 5-Nitrosalicylaldehyde, Glucose-6-phosphatase Inhibitors targeting G6PC |
| AA-36-YV45_1uM | Dose=1uM, 5-Nitrosalicylaldehyde, Glucose-6-phosphatase Inhibitors targeting G6PC |
| AA-38-TT50_0.01uM | Dose=0.01uM, Anandamide, K(V)4.3 Channel Blocker;TRPV1 (Vanilloid VR1 Receptor) Agonists;Cannabinoid CB1 Agonists targeting CNR1, CNR2, TRPV1, GPR55 |
| AA-38-TT50_0.1uM | Dose=0.1uM, Anandamide, K(V)4.3 Channel Blocker;TRPV1 (Vanilloid VR1 Receptor) Agonists;Cannabinoid CB1 Agonists targeting CNR1, CNR2, TRPV1, GPR55 |
| AA-38-TT50_10uM | Dose=10uM, Anandamide, K(V)4.3 Channel Blocker;TRPV1 (Vanilloid VR1 Receptor) Agonists;Cannabinoid CB1 Agonists targeting CNR1, CNR2, TRPV1, GPR55 |
| AA-38-TT50_1uM | Dose=1uM, Anandamide, K(V)4.3 Channel Blocker;TRPV1 (Vanilloid VR1 Receptor) Agonists;Cannabinoid CB1 Agonists targeting CNR1, CNR2, TRPV1, GPR55 |
| AA-39-BD24_0.01uM | Dose=0.01uM, 2-Aminoethoxydiphenylborate, Inositol Triphosphate IP3 Receptor Antagonists;Gap junction modulators targeting ITPR2, ITPR3, ITPR1 |
| AA-39-BD24_0.1uM | Dose=0.1uM, 2-Aminoethoxydiphenylborate, Inositol Triphosphate IP3 Receptor Antagonists;Gap junction modulators targeting ITPR2, ITPR3, ITPR1 |
| AA-39-BD24_10uM | Dose=10uM, 2-Aminoethoxydiphenylborate, Inositol Triphosphate IP3 Receptor Antagonists;Gap junction modulators targeting ITPR2, ITPR3, ITPR1 |
| AA-39-BD24_1uM | Dose=1uM, 2-Aminoethoxydiphenylborate, Inositol Triphosphate IP3 Receptor Antagonists;Gap junction modulators targeting ITPR2, ITPR3, ITPR1 |
| AA-39-ZQ15_0.01uM | Dose=0.01uM, Phenylbutyric acid, Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers targeting HDAC3 |
| AA-39-ZQ15_0.1uM | Dose=0.1uM, Phenylbutyric acid, Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers targeting HDAC3 |
| AA-39-ZQ15_10uM | Dose=10uM, Phenylbutyric acid, Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers targeting HDAC3 |
| AA-39-ZQ15_1uM | Dose=1uM, Phenylbutyric acid, Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers targeting HDAC3 |
| AA-40-IA00_0.01uM | Dose=0.01uM, Lomerizine, Calcium Channel Blockers;P-Glycoprotein (MDR-1) Inhibitors targeting CACNA1A, ABCB1 |
| AA-40-IA00_0.1uM | Dose=0.1uM, Lomerizine, Calcium Channel Blockers;P-Glycoprotein (MDR-1) Inhibitors targeting CACNA1A, ABCB1 |
| AA-40-IA00_10uM | Dose=10uM, Lomerizine, Calcium Channel Blockers;P-Glycoprotein (MDR-1) Inhibitors targeting CACNA1A, ABCB1 |
| AA-40-IA00_1uM | Dose=1uM, Lomerizine, Calcium Channel Blockers;P-Glycoprotein (MDR-1) Inhibitors targeting CACNA1A, ABCB1 |
| AA-42-JP76_0.01uM | Dose=0.01uM, Imiquimod, Interferon Inducers;TLR7 Receptor Agonists targeting NQO2, TLR7 |
| AA-42-JP76_10uM | Dose=10uM, Imiquimod, Interferon Inducers;TLR7 Receptor Agonists targeting NQO2, TLR7 |
| AA-42-XZ05_0.01uM | Dose=0.01uM, 7-cyclopentyl-2-{5-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, CDK4 Inhibitors targeting CDK4 |
| AA-42-XZ05_0.1uM | Dose=0.1uM, 7-cyclopentyl-2-{5-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, CDK4 Inhibitors targeting CDK4 |
| AA-42-XZ05_10uM | Dose=10uM, 7-cyclopentyl-2-{5-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, CDK4 Inhibitors targeting CDK4 |
| AA-42-XZ05_1uM | Dose=1uM, 7-cyclopentyl-2-{5-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-pyridin-2-ylamino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, CDK4 Inhibitors targeting CDK4 |
| AA-43-BW50_0.01uM | Dose=0.01uM, Celecoxib, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors targeting PTGS2, SC5D, CASP3 |
| AA-43-BW50_0.1uM | Dose=0.1uM, Celecoxib, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors targeting PTGS2, SC5D, CASP3 |
| AA-43-BW50_10uM | Dose=10uM, Celecoxib, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors targeting PTGS2, SC5D, CASP3 |
| AA-43-BW50_1uM | Dose=1uM, Celecoxib, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors targeting PTGS2, SC5D, CASP3 |
| AA-43-TW35_0.01uM | Dose=0.01uM, 5-Methylurapidil, alpha1A-Adrenoceptor Antagonists targeting ADRA1B |
| AA-43-TW35_0.1uM | Dose=0.1uM, 5-Methylurapidil, alpha1A-Adrenoceptor Antagonists targeting ADRA1B |
| AA-43-TW35_10uM | Dose=10uM, 5-Methylurapidil, alpha1A-Adrenoceptor Antagonists targeting ADRA1B |
| AA-43-TW35_1uM | Dose=1uM, 5-Methylurapidil, alpha1A-Adrenoceptor Antagonists targeting ADRA1B |
| AA-44-BX20_0.01uM | Dose=0.01uM, 1-[2-[4-[[5-(4-Methoxyphenyl)pyrimidin-2-yl]amino]phenyl]ethyl]piperidine-4-carboxylic acid |
| AA-44-BX20_0.1uM | Dose=0.1uM, 1-[2-[4-[[5-(4-Methoxyphenyl)pyrimidin-2-yl]amino]phenyl]ethyl]piperidine-4-carboxylic acid |
| AA-44-BX20_10uM | Dose=10uM, 1-[2-[4-[[5-(4-Methoxyphenyl)pyrimidin-2-yl]amino]phenyl]ethyl]piperidine-4-carboxylic acid |
| AA-44-BX20_1uM | Dose=1uM, 1-[2-[4-[[5-(4-Methoxyphenyl)pyrimidin-2-yl]amino]phenyl]ethyl]piperidine-4-carboxylic acid |
| AA-45-AA67_0.01uM | Dose=0.01uM, Fluorouracil, thymidylate synthase targeting TYMS |
| AA-45-AA67_0.1uM | Dose=0.1uM, Fluorouracil, thymidylate synthase targeting TYMS |
| AA-45-AA67_10uM | Dose=10uM, Fluorouracil, thymidylate synthase targeting TYMS |
| AA-45-AA67_1uM | Dose=1uM, Fluorouracil, thymidylate synthase targeting TYMS |
| AA-45-BL29_0.01uM | Dose=0.01uM, DL-Tyrosine |
| AA-45-BL29_0.1uM | Dose=0.1uM, DL-Tyrosine |
| AA-45-BL29_10uM | Dose=10uM, DL-Tyrosine |
| AA-45-SU80_0.01uM | Dose=0.01uM, Phenylpiperazine |
| AA-45-SU80_0.1uM | Dose=0.1uM, Phenylpiperazine |
| AA-45-SU80_10uM | Dose=10uM, Phenylpiperazine |
| AA-45-SU80_1uM | Dose=1uM, Phenylpiperazine |
| AA-46-GL76_0.01uM | Dose=0.01uM, Chloroquine, Apoptosis Inducers;Thiamine uptake inhibitor targeting SLC19A3 |
| AA-46-GL76_0.1uM | Dose=0.1uM, Chloroquine, Apoptosis Inducers;Thiamine uptake inhibitor targeting SLC19A3 |
| AA-46-GL76_10uM | Dose=10uM, Chloroquine, Apoptosis Inducers;Thiamine uptake inhibitor targeting SLC19A3 |
| AA-46-GL76_1uM | Dose=1uM, Chloroquine, Apoptosis Inducers;Thiamine uptake inhibitor targeting SLC19A3 |
| AA-46-HS88_0.01uM | Dose=0.01uM, Cilostamide, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3 |
| AA-46-HS88_0.1uM | Dose=0.1uM, Cilostamide, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3 |
| AA-46-HS88_10uM | Dose=10uM, Cilostamide, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3 |
| AA-46-HS88_1uM | Dose=1uM, Cilostamide, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3 |
| AA-47-BS40_0.01uM | Dose=0.01uM, Zardaverine, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B |
| AA-47-BS40_0.1uM | Dose=0.1uM, Zardaverine, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B |
| AA-47-BS40_10uM | Dose=10uM, Zardaverine, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B |
| AA-47-BS40_1uM | Dose=1uM, Zardaverine, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B |
| AA-47-MP58_0.01uM | Dose=0.01uM, 1-Methylcyclopropyl 4-(((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119 |
| AA-47-MP58_0.1uM | Dose=0.1uM, 1-Methylcyclopropyl 4-(((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119 |
| AA-47-MP58_10uM | Dose=10uM, 1-Methylcyclopropyl 4-(((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119 |
| AA-47-MP58_1uM | Dose=1uM, 1-Methylcyclopropyl 4-(((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119 |
| AA-48-GT70_0.01uM | Dose=0.01uM, 1-[(6-Aminopyridin-3-yl)methyl]-3-[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]urea, NAMPT Inhibitor targeting NAMPT |
| AA-48-GT70_0.1uM | Dose=0.1uM, 1-[(6-Aminopyridin-3-yl)methyl]-3-[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]urea, NAMPT Inhibitor targeting NAMPT |
| AA-48-GT70_10uM | Dose=10uM, 1-[(6-Aminopyridin-3-yl)methyl]-3-[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]urea, NAMPT Inhibitor targeting NAMPT |
| AA-48-GT70_1uM | Dose=1uM, 1-[(6-Aminopyridin-3-yl)methyl]-3-[4-[(1,3-dioxoisoindol-2-yl)methyl]phenyl]urea, NAMPT Inhibitor targeting NAMPT |
| AA-48-XT80_0.01uM | Dose=0.01uM, [3-Chloro-5-(1-propyl-1H-benzoimidazol-2-yl)-pyridin-2-yl]-(4-methoxy-phenyl)-amine |
| AA-48-XT80_0.1uM | Dose=0.1uM, [3-Chloro-5-(1-propyl-1H-benzoimidazol-2-yl)-pyridin-2-yl]-(4-methoxy-phenyl)-amine |
| AA-48-XT80_10uM | Dose=10uM, [3-Chloro-5-(1-propyl-1H-benzoimidazol-2-yl)-pyridin-2-yl]-(4-methoxy-phenyl)-amine |
| AA-48-XT80_1uM | Dose=1uM, [3-Chloro-5-(1-propyl-1H-benzoimidazol-2-yl)-pyridin-2-yl]-(4-methoxy-phenyl)-amine |
| AA-49-BD04_0.1uM | Dose=0.1uM, Purvalanol A, CDK1/Cyclin B Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase (DYRK) Inhibitors;CDK2/Cyclin A Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK2/Cyclin E Inhibitors;CDK5 Inhibitors targeting CHUK, CCNA1, CCNB2, CCNE2, CCNB3 |
| AA-49-BD04_10uM | Dose=10uM, Purvalanol A, CDK1/Cyclin B Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase (DYRK) Inhibitors;CDK2/Cyclin A Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK2/Cyclin E Inhibitors;CDK5 Inhibitors targeting CHUK, CCNA1, CCNB2, CCNE2, CCNB3 |
| AA-49-BD04_1uM | Dose=1uM, Purvalanol A, CDK1/Cyclin B Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase (DYRK) Inhibitors;CDK2/Cyclin A Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK2/Cyclin E Inhibitors;CDK5 Inhibitors targeting CHUK, CCNA1, CCNB2, CCNE2, CCNB3 |
| AA-49-HG46_0.01uM | Dose=0.01uM |
| AA-49-HG46_0.1uM | Dose=0.1uM |
| AA-49-HG46_10uM | Dose=10uM |
| AA-49-HG46_1uM | Dose=1uM |
| AA-50-FY68_0.01uM | Dose=0.01uM |
| AA-50-FY68_0.1uM | Dose=0.1uM |
| AA-50-FY68_10uM | Dose=10uM |
| AA-50-FY68_1uM | Dose=1uM |
| AA-50-HR61_0.01uM | Dose=0.01uM, Rifampin, RNA Polymerase (Bacterial) Inhibitors;Enzyme Inducers;DNA-Directed RNA Polymerase Inhibitors targeting NR1I2, SLCO1B1, POLRMT |
| AA-50-HR61_0.1uM | Dose=0.1uM, Rifampin, RNA Polymerase (Bacterial) Inhibitors;Enzyme Inducers;DNA-Directed RNA Polymerase Inhibitors targeting NR1I2, SLCO1B1, POLRMT |
| AA-50-HR61_10uM | Dose=10uM, Rifampin, RNA Polymerase (Bacterial) Inhibitors;Enzyme Inducers;DNA-Directed RNA Polymerase Inhibitors targeting NR1I2, SLCO1B1, POLRMT |
| AA-51-RY00_0.01uM | Dose=0.01uM, Chlorambucil |
| AA-51-RY00_0.1uM | Dose=0.1uM, Chlorambucil |
| AA-51-RY00_10uM | Dose=10uM, Chlorambucil |
| AA-51-RY00_1uM | Dose=1uM, Chlorambucil |
| AA-52-JS03_0.01uM | Dose=0.01uM, Combretastatin A4, Microtubule Polymerization Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| AA-52-JS03_0.1uM | Dose=0.1uM, Combretastatin A4, Microtubule Polymerization Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| AA-52-JS03_10uM | Dose=10uM, Combretastatin A4, Microtubule Polymerization Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| AA-52-JS03_1uM | Dose=1uM, Combretastatin A4, Microtubule Polymerization Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| AA-54-WG39_0.01uM | Dose=0.01uM, 4-Aminobenzamide |
| AA-54-WG39_0.1uM | Dose=0.1uM, 4-Aminobenzamide |
| AA-54-WG39_10uM | Dose=10uM, 4-Aminobenzamide |
| AA-54-WG39_1uM | Dose=1uM, 4-Aminobenzamide |
| AA-56-AB37_0.01uM | Dose=0.01uM, Pfi-3, SMARCA2 gene inhibitor; hPB1;Protein Polybromo-1 (PBRM1;SMARCA2/4; BAF180) Inhibitors targeting SMARCA2, SMARCA4, PBRM1 |
| AA-56-AB37_0.1uM | Dose=0.1uM, Pfi-3, SMARCA2 gene inhibitor; hPB1;Protein Polybromo-1 (PBRM1;SMARCA2/4; BAF180) Inhibitors targeting SMARCA2, SMARCA4, PBRM1 |
| AA-56-AB37_10uM | Dose=10uM, Pfi-3, SMARCA2 gene inhibitor; hPB1;Protein Polybromo-1 (PBRM1;SMARCA2/4; BAF180) Inhibitors targeting SMARCA2, SMARCA4, PBRM1 |
| AA-56-AB37_1uM | Dose=1uM, Pfi-3, SMARCA2 gene inhibitor; hPB1;Protein Polybromo-1 (PBRM1;SMARCA2/4; BAF180) Inhibitors targeting SMARCA2, SMARCA4, PBRM1 |
| AA-56-DV95_0.01uM | Dose=0.01uM |
| AA-56-DV95_0.1uM | Dose=0.1uM |
| AA-56-DV95_10uM | Dose=10uM |
| AA-56-DV95_1uM | Dose=1uM |
| AA-56-JY17_0.01uM | Dose=0.01uM, Carglumic Acid, Carbamoyl Phosphate Synthetase 1 (CPS1) Activators targeting CPS1 |
| AA-56-JY17_0.1uM | Dose=0.1uM, Carglumic Acid, Carbamoyl Phosphate Synthetase 1 (CPS1) Activators targeting CPS1 |
| AA-56-JY17_10uM | Dose=10uM, Carglumic Acid, Carbamoyl Phosphate Synthetase 1 (CPS1) Activators targeting CPS1 |
| AA-56-JY17_1uM | Dose=1uM, Carglumic Acid, Carbamoyl Phosphate Synthetase 1 (CPS1) Activators targeting CPS1 |
| AA-56-KV80_0.01uM | Dose=0.01uM, Almorexant, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| AA-56-KV80_0.1uM | Dose=0.1uM, Almorexant, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| AA-56-KV80_10uM | Dose=10uM, Almorexant, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| AA-56-KV80_1uM | Dose=1uM, Almorexant, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| AA-56-QO38_0.01uM | Dose=0.01uM, (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| AA-56-QO38_0.1uM | Dose=0.1uM, (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| AA-56-QO38_10uM | Dose=10uM, (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| AA-56-QO38_1uM | Dose=1uM, (2-(2',6'-Dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| AA-57-CF49_0.01uM | Dose=0.01uM, Menadione, Oxidative stress inducer;Vitamin K3;Cell Division Cycle CDC25 Phosphatase Inhibitors targeting GGCX, VKORC1, VKORC1L1 |
| AA-57-CF49_0.1uM | Dose=0.1uM, Menadione, Oxidative stress inducer;Vitamin K3;Cell Division Cycle CDC25 Phosphatase Inhibitors targeting GGCX, VKORC1, VKORC1L1 |
| AA-57-CF49_10uM | Dose=10uM, Menadione, Oxidative stress inducer;Vitamin K3;Cell Division Cycle CDC25 Phosphatase Inhibitors targeting GGCX, VKORC1, VKORC1L1 |
| AA-57-CF49_1uM | Dose=1uM, Menadione, Oxidative stress inducer;Vitamin K3;Cell Division Cycle CDC25 Phosphatase Inhibitors targeting GGCX, VKORC1, VKORC1L1 |
| AA-57-FZ47_0.01uM | Dose=0.01uM, (4-(Cyclopentylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3 |
| AA-57-FZ47_0.1uM | Dose=0.1uM, (4-(Cyclopentylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3 |
| AA-57-FZ47_10uM | Dose=10uM, (4-(Cyclopentylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3 |
| AA-57-FZ47_1uM | Dose=1uM, (4-(Cyclopentylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3 |
| AA-58-BW57_0.01uM | Dose=0.01uM, Niguldipine, Adrenergic receptor modulator;Calcium Channel Blockers targeting ADRA1B, CACNA1I, CACNA1H, CACNA1G |
| AA-58-BW57_10uM | Dose=10uM, Niguldipine, Adrenergic receptor modulator;Calcium Channel Blockers targeting ADRA1B, CACNA1I, CACNA1H, CACNA1G |
| AA-58-BW57_1uM | Dose=1uM, Niguldipine, Adrenergic receptor modulator;Calcium Channel Blockers targeting ADRA1B, CACNA1I, CACNA1H, CACNA1G |
| AA-58-FJ71_0.01uM | Dose=0.01uM, Staurosporine, Signal transduction modulator;Protein Kinase C (PKC) Inhibitors targeting CAMK2B, CAMK2G, PRKACA, PRKACB, PRKACG, PRKCG, PRKCH, PRKCI, PRKCZ, MAPK7, MAPK12, CCNA1, MAPK15, MAPK6, MAPK4 |
| AA-58-FJ71_0.1uM | Dose=0.1uM, Staurosporine, Signal transduction modulator;Protein Kinase C (PKC) Inhibitors targeting CAMK2B, CAMK2G, PRKACA, PRKACB, PRKACG, PRKCG, PRKCH, PRKCI, PRKCZ, MAPK7, MAPK12, CCNA1, MAPK15, MAPK6, MAPK4 |
| AA-58-FJ71_10uM | Dose=10uM, Staurosporine, Signal transduction modulator;Protein Kinase C (PKC) Inhibitors targeting CAMK2B, CAMK2G, PRKACA, PRKACB, PRKACG, PRKCG, PRKCH, PRKCI, PRKCZ, MAPK7, MAPK12, CCNA1, MAPK15, MAPK6, MAPK4 |
| AA-58-FJ71_1uM | Dose=1uM, Staurosporine, Signal transduction modulator;Protein Kinase C (PKC) Inhibitors targeting CAMK2B, CAMK2G, PRKACA, PRKACB, PRKACG, PRKCG, PRKCH, PRKCI, PRKCZ, MAPK7, MAPK12, CCNA1, MAPK15, MAPK6, MAPK4 |
| AA-58-JC44_0.01uM | Dose=0.01uM, Moxilubant, Leukotriene BLT (LTB4) Antagonists targeting LTB4R, LTB4R2 |
| AA-58-JC44_0.1uM | Dose=0.1uM, Moxilubant, Leukotriene BLT (LTB4) Antagonists targeting LTB4R, LTB4R2 |
| AA-58-JC44_10uM | Dose=10uM, Moxilubant, Leukotriene BLT (LTB4) Antagonists targeting LTB4R, LTB4R2 |
| AA-58-JC44_1uM | Dose=1uM, Moxilubant, Leukotriene BLT (LTB4) Antagonists targeting LTB4R, LTB4R2 |
| AA-59-HG56_0.01uM | Dose=0.01uM, Metolazone, Carbonic Anhydrase Type VII Inhibitors targeting CA4, CA5A, CA7, CA12, CA5B |
| AA-59-HG56_0.1uM | Dose=0.1uM, Metolazone, Carbonic Anhydrase Type VII Inhibitors targeting CA4, CA5A, CA7, CA12, CA5B |
| AA-59-HG56_10uM | Dose=10uM, Metolazone, Carbonic Anhydrase Type VII Inhibitors targeting CA4, CA5A, CA7, CA12, CA5B |
| AA-59-HG56_1uM | Dose=1uM, Metolazone, Carbonic Anhydrase Type VII Inhibitors targeting CA4, CA5A, CA7, CA12, CA5B |
| AA-61-KE62_0.01uM | Dose=0.01uM, 3-[2-[[6-(2-Methoxyethoxy)pyrazin-2-yl]amino]-5-(1,2,4-triazol-1-yl)-1,3-thiazol-4-yl]benzonitrile, Adenosine A2B Antagonists;Adenosine A3 Antagonists targeting ADORA2B, ADORA3 |
| AA-61-KE62_0.1uM | Dose=0.1uM, 3-[2-[[6-(2-Methoxyethoxy)pyrazin-2-yl]amino]-5-(1,2,4-triazol-1-yl)-1,3-thiazol-4-yl]benzonitrile, Adenosine A2B Antagonists;Adenosine A3 Antagonists targeting ADORA2B, ADORA3 |
| AA-61-KE62_10uM | Dose=10uM, 3-[2-[[6-(2-Methoxyethoxy)pyrazin-2-yl]amino]-5-(1,2,4-triazol-1-yl)-1,3-thiazol-4-yl]benzonitrile, Adenosine A2B Antagonists;Adenosine A3 Antagonists targeting ADORA2B, ADORA3 |
| AA-62-HP31_0.01uM | Dose=0.01uM, Sapanisertib, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CD, PIK3CG |
| AA-62-HP31_0.1uM | Dose=0.1uM, Sapanisertib, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CD, PIK3CG |
| AA-62-HP31_10uM | Dose=10uM, Sapanisertib, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CD, PIK3CG |
| AA-62-HP31_1uM | Dose=1uM, Sapanisertib, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting MTOR, PIK3CA, PIK3CD, PIK3CG |
| AA-62-JP26_0.1uM | Dose=0.1uM, (7R)-2-amino-7-[4-fluoro-2-(2-methoxy-1,3-thiazol-4-yl)phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| AA-62-JP26_10uM | Dose=10uM, (7R)-2-amino-7-[4-fluoro-2-(2-methoxy-1,3-thiazol-4-yl)phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| AA-62-JP26_1uM | Dose=1uM, (7R)-2-amino-7-[4-fluoro-2-(2-methoxy-1,3-thiazol-4-yl)phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| AA-62-OC45_0.01uM | Dose=0.01uM |
| AA-62-OC45_10uM | Dose=10uM |
| AA-62-OC45_1uM | Dose=1uM |
| AA-62-XS38_0.01uM | Dose=0.01uM, Thioridazine, Dopamine D2 Antagonists targeting DRD2 |
| AA-62-XS38_0.1uM | Dose=0.1uM, Thioridazine, Dopamine D2 Antagonists targeting DRD2 |
| AA-62-XS38_10uM | Dose=10uM, Thioridazine, Dopamine D2 Antagonists targeting DRD2 |
| AA-62-XS38_1uM | Dose=1uM, Thioridazine, Dopamine D2 Antagonists targeting DRD2 |
| AA-64-WG29_0.01uM | Dose=0.01uM, Cgs-27023, Matrix metalloproteinase inhibitor;MMP-9 (Gelatinase B) Inhibitors;Angiogenesis Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP8, MMP9, MMP14, MMP16, MMP11, MMP15, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| AA-64-WG29_10uM | Dose=10uM, Cgs-27023, Matrix metalloproteinase inhibitor;MMP-9 (Gelatinase B) Inhibitors;Angiogenesis Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP8, MMP9, MMP14, MMP16, MMP11, MMP15, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| AA-64-WG29_1uM | Dose=1uM, Cgs-27023, Matrix metalloproteinase inhibitor;MMP-9 (Gelatinase B) Inhibitors;Angiogenesis Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP8, MMP9, MMP14, MMP16, MMP11, MMP15, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| AA-66-PC55_0.1uM | Dose=0.1uM, 9-Azapaullone, CDK9/Cyclin T1 Inhibitors;Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting CCNT1, CDK9, GSK3A |
| AA-66-PC55_10uM | Dose=10uM, 9-Azapaullone, CDK9/Cyclin T1 Inhibitors;Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting CCNT1, CDK9, GSK3A |
| AA-66-YY32_0.1uM | Dose=0.1uM, Serazapine, 5-HT2A Antagonists targeting HTR2A |
| AA-66-YY32_10uM | Dose=10uM, Serazapine, 5-HT2A Antagonists targeting HTR2A |
| AA-66-YY32_1uM | Dose=1uM, Serazapine, 5-HT2A Antagonists targeting HTR2A |
| AA-67-FZ57_10uM | Dose=10uM, Isothiourea-1a, HIV Attachment Inhibitors;Chemokine CXCR4 (SDF-1 Receptor) Antagonists targeting CXCR4 |
| AA-67-FZ57_1uM | Dose=1uM, Isothiourea-1a, HIV Attachment Inhibitors;Chemokine CXCR4 (SDF-1 Receptor) Antagonists targeting CXCR4 |
| AA-67-JI21_0.01uM | Dose=0.01uM, Tryptamine |
| AA-67-JI21_0.1uM | Dose=0.1uM, Tryptamine |
| AA-67-JI21_10uM | Dose=10uM, Tryptamine |
| AA-67-JI21_1uM | Dose=1uM, Tryptamine |
| AA-67-TF79_0.01uM | Dose=0.01uM, Warfarin, Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors targeting VKORC1 |
| AA-67-TF79_0.1uM | Dose=0.1uM, Warfarin, Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors targeting VKORC1 |
| AA-67-TF79_10uM | Dose=10uM, Warfarin, Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors targeting VKORC1 |
| AA-67-TF79_1uM | Dose=1uM, Warfarin, Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors targeting VKORC1 |
| AA-67-TP08_0.01uM | Dose=0.01uM, Rimonabant, IL-6 production inhibitor;CNR1 antagonist;Cannabinoid CB1 Inverse Agonists targeting CNR1 |
| AA-67-TP08_0.1uM | Dose=0.1uM, Rimonabant, IL-6 production inhibitor;CNR1 antagonist;Cannabinoid CB1 Inverse Agonists targeting CNR1 |
| AA-67-TP08_10uM | Dose=10uM, Rimonabant, IL-6 production inhibitor;CNR1 antagonist;Cannabinoid CB1 Inverse Agonists targeting CNR1 |
| AA-67-TP08_1uM | Dose=1uM, Rimonabant, IL-6 production inhibitor;CNR1 antagonist;Cannabinoid CB1 Inverse Agonists targeting CNR1 |
| AA-68-MW92_0.01uM | Dose=0.01uM, Rolipram, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4 |
| AA-68-MW92_0.1uM | Dose=0.1uM, Rolipram, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4 |
| AA-68-MW92_10uM | Dose=10uM, Rolipram, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4 |
| AA-68-MW92_1uM | Dose=1uM, Rolipram, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4 |
| AA-68-OJ16_0.01uM | Dose=0.01uM, (3R)-3-methyl-4-[5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-5-yl)-[1,3]thiazolo[5,4-d]pyrimidin-7-yl]morpholine |
| AA-68-OJ16_0.1uM | Dose=0.1uM, (3R)-3-methyl-4-[5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-5-yl)-[1,3]thiazolo[5,4-d]pyrimidin-7-yl]morpholine |
| AA-68-OJ16_10uM | Dose=10uM, (3R)-3-methyl-4-[5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-5-yl)-[1,3]thiazolo[5,4-d]pyrimidin-7-yl]morpholine |
| AA-68-OJ16_1uM | Dose=1uM, (3R)-3-methyl-4-[5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-5-yl)-[1,3]thiazolo[5,4-d]pyrimidin-7-yl]morpholine |
| AA-69-TD29_0.01uM | Dose=0.01uM, N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide targeting BRAF, RAF1 |
| AA-69-TD29_0.1uM | Dose=0.1uM, N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide targeting BRAF, RAF1 |
| AA-69-TD29_10uM | Dose=10uM, N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide targeting BRAF, RAF1 |
| AA-69-TD29_1uM | Dose=1uM, N-[6-methyl-5-[5-morpholin-4-yl-6-(oxan-4-yloxy)pyridin-3-yl]pyridin-3-yl]-3-(trifluoromethyl)benzamide targeting BRAF, RAF1 |
| AA-70-DH87_0.01uM | Dose=0.01uM, Laduviglusib, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A, GSK3B |
| AA-70-DH87_0.1uM | Dose=0.1uM, Laduviglusib, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A, GSK3B |
| AA-70-DH87_10uM | Dose=10uM, Laduviglusib, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A, GSK3B |
| AA-70-DH87_1uM | Dose=1uM, Laduviglusib, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A, GSK3B |
| AA-70-VU13_0.01uM | Dose=0.01uM |
| AA-70-VU13_0.1uM | Dose=0.1uM |
| AA-70-VU13_10uM | Dose=10uM |
| AA-70-VU13_1uM | Dose=1uM |
| AA-71-XO01_0.01uM | Dose=0.01uM, CD38 inhibitor;CD38 gene inhibitor targeting CD38 |
| AA-71-XO01_0.1uM | Dose=0.1uM, CD38 inhibitor;CD38 gene inhibitor targeting CD38 |
| AA-71-XO01_10uM | Dose=10uM, CD38 inhibitor;CD38 gene inhibitor targeting CD38 |
| AA-71-XO01_1uM | Dose=1uM, CD38 inhibitor;CD38 gene inhibitor targeting CD38 |
| AA-72-JP86_0.01uM | Dose=0.01uM, Delamanid |
| AA-72-JP86_0.1uM | Dose=0.1uM, Delamanid |
| AA-72-JP86_10uM | Dose=10uM, Delamanid |
| AA-72-JP86_1uM | Dose=1uM, Delamanid |
| AA-72-QI84_0.01uM | Dose=0.01uM, Phloretin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Antioxidants targeting ICAM1, VCAM1 |
| AA-72-QI84_0.1uM | Dose=0.1uM, Phloretin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Antioxidants targeting ICAM1, VCAM1 |
| AA-72-QI84_10uM | Dose=10uM, Phloretin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Antioxidants targeting ICAM1, VCAM1 |
| AA-72-QI84_1uM | Dose=1uM, Phloretin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Antioxidants targeting ICAM1, VCAM1 |
| AA-74-OG49_0.01uM | Dose=0.01uM, Aminoglutethimide, Antiglucocorticoids;Aromatase Inhibitors targeting CYP11A1, CYP19A1, NR3C1 |
| AA-74-OG49_0.1uM | Dose=0.1uM, Aminoglutethimide, Antiglucocorticoids;Aromatase Inhibitors targeting CYP11A1, CYP19A1, NR3C1 |
| AA-74-OG49_10uM | Dose=10uM, Aminoglutethimide, Antiglucocorticoids;Aromatase Inhibitors targeting CYP11A1, CYP19A1, NR3C1 |
| AA-74-ON06_0.01uM | Dose=0.01uM, (2S,4S,5S,7S)-5-amino-4-hydroxy-N-[(1S,2S)-2-hydroxycyclopentyl]-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide |
| AA-74-ON06_0.1uM | Dose=0.1uM, (2S,4S,5S,7S)-5-amino-4-hydroxy-N-[(1S,2S)-2-hydroxycyclopentyl]-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide |
| AA-74-ON06_10uM | Dose=10uM, (2S,4S,5S,7S)-5-amino-4-hydroxy-N-[(1S,2S)-2-hydroxycyclopentyl]-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide |
| AA-74-ON06_1uM | Dose=1uM, (2S,4S,5S,7S)-5-amino-4-hydroxy-N-[(1S,2S)-2-hydroxycyclopentyl]-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide |
| AA-75-JH89_0.01uM | Dose=0.01uM, BAY-598 R-isomer |
| AA-75-JH89_0.1uM | Dose=0.1uM, BAY-598 R-isomer |
| AA-75-JH89_10uM | Dose=10uM, BAY-598 R-isomer |
| AA-75-JH89_1uM | Dose=1uM, BAY-598 R-isomer |
| AA-76-CL76_0.01uM | Dose=0.01uM, 2-(5-bromo-2-hydroxyphenyl)-6-methyl-4H-chromen-4-one targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| AA-76-CL76_0.1uM | Dose=0.1uM, 2-(5-bromo-2-hydroxyphenyl)-6-methyl-4H-chromen-4-one targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| AA-76-CL76_10uM | Dose=10uM, 2-(5-bromo-2-hydroxyphenyl)-6-methyl-4H-chromen-4-one targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| AA-76-CL76_1uM | Dose=1uM, 2-(5-bromo-2-hydroxyphenyl)-6-methyl-4H-chromen-4-one targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| AA-76-VE74_0.01uM | Dose=0.01uM, SK&F 105809, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, PTGS1, PTGS2 |
| AA-76-VE74_0.1uM | Dose=0.1uM, SK&F 105809, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, PTGS1, PTGS2 |
| AA-76-VE74_10uM | Dose=10uM, SK&F 105809, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, PTGS1, PTGS2 |
| AA-76-VE74_1uM | Dose=1uM, SK&F 105809, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5, PTGS1, PTGS2 |
| AA-77-MP68_0.01uM | Dose=0.01uM, 5-{3-[4-(3-Amino-oxetan-3-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-2-isopropoxy-benzonitrile, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5 |
| AA-77-MP68_0.1uM | Dose=0.1uM, 5-{3-[4-(3-Amino-oxetan-3-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-2-isopropoxy-benzonitrile, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5 |
| AA-77-MP68_10uM | Dose=10uM, 5-{3-[4-(3-Amino-oxetan-3-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-2-isopropoxy-benzonitrile, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5 |
| AA-77-MP68_1uM | Dose=1uM, 5-{3-[4-(3-Amino-oxetan-3-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-2-isopropoxy-benzonitrile, Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR5 |
| AA-77-RI81_0.01uM | Dose=0.01uM, Haloperidol, Dopamine D2 receptor inverse agonist;ADRA1B antagonist;Dopamine D3 receptor inverse agonist targeting ADRA1B |
| AA-77-RI81_0.1uM | Dose=0.1uM, Haloperidol, Dopamine D2 receptor inverse agonist;ADRA1B antagonist;Dopamine D3 receptor inverse agonist targeting ADRA1B |
| AA-77-RI81_10uM | Dose=10uM, Haloperidol, Dopamine D2 receptor inverse agonist;ADRA1B antagonist;Dopamine D3 receptor inverse agonist targeting ADRA1B |
| AA-77-RI81_1uM | Dose=1uM, Haloperidol, Dopamine D2 receptor inverse agonist;ADRA1B antagonist;Dopamine D3 receptor inverse agonist targeting ADRA1B |
| AA-79-SX47_0.01uM | Dose=0.01uM, 4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol, Apoptosis Inducers;Sphingosine Kinase Inhibitors targeting VCP, DEGS1, SPHK1, SPHK2 |
| AA-79-SX47_0.1uM | Dose=0.1uM, 4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol, Apoptosis Inducers;Sphingosine Kinase Inhibitors targeting VCP, DEGS1, SPHK1, SPHK2 |
| AA-79-SX47_10uM | Dose=10uM, 4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol, Apoptosis Inducers;Sphingosine Kinase Inhibitors targeting VCP, DEGS1, SPHK1, SPHK2 |
| AA-79-SX47_1uM | Dose=1uM, 4-[[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol, Apoptosis Inducers;Sphingosine Kinase Inhibitors targeting VCP, DEGS1, SPHK1, SPHK2 |
| AA-80-IA90_0.01uM | Dose=0.01uM, Ethyl 4-amino-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3 |
| AA-80-IA90_0.1uM | Dose=0.1uM, Ethyl 4-amino-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3 |
| AA-80-IA90_10uM | Dose=10uM, Ethyl 4-amino-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3 |
| AA-80-IA90_1uM | Dose=1uM, Ethyl 4-amino-2-(methylthio)pyrimidine-5-carboxylate, CDK Inhibitors targeting CCND2, CCND3 |
| AA-80-XK94_0.01uM | Dose=0.01uM, 4-Hydroxy-1-methyl-3-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]quinolin-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AA-80-XK94_0.1uM | Dose=0.1uM, 4-Hydroxy-1-methyl-3-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]quinolin-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AA-80-XK94_10uM | Dose=10uM, 4-Hydroxy-1-methyl-3-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]quinolin-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AA-80-XK94_1uM | Dose=1uM, 4-Hydroxy-1-methyl-3-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]quinolin-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AA-81-CY65_0.01uM | Dose=0.01uM, N-Methyl-beta-carboline-3-carboxamide, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRG2, GABRA5, GABRA4, GABRA6, GABRG1, GABRG3 |
| AA-81-CY65_0.1uM | Dose=0.1uM, N-Methyl-beta-carboline-3-carboxamide, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRG2, GABRA5, GABRA4, GABRA6, GABRG1, GABRG3 |
| AA-81-CY65_10uM | Dose=10uM, N-Methyl-beta-carboline-3-carboxamide, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRG2, GABRA5, GABRA4, GABRA6, GABRG1, GABRG3 |
| AA-81-CY65_1uM | Dose=1uM, N-Methyl-beta-carboline-3-carboxamide, GABA(A) BZ Site Receptor Inverse Agonists targeting GABRA1, GABRA2, GABRA3, GABRG2, GABRA5, GABRA4, GABRA6, GABRG1, GABRG3 |
| AA-81-IB40_0.01uM | Dose=0.01uM, 3-amino-N-[3-(4-aminopiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethoxy)pyridin-2-yl]pyrazine-2-carboxamide, Kinase inhibitors;PKC inhibitor targeting PRKCA, PRKCQ, PRKCB, PRKCD, PRKCE |
| AA-81-IB40_0.1uM | Dose=0.1uM, 3-amino-N-[3-(4-aminopiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethoxy)pyridin-2-yl]pyrazine-2-carboxamide, Kinase inhibitors;PKC inhibitor targeting PRKCA, PRKCQ, PRKCB, PRKCD, PRKCE |
| AA-81-IB40_10uM | Dose=10uM, 3-amino-N-[3-(4-aminopiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethoxy)pyridin-2-yl]pyrazine-2-carboxamide, Kinase inhibitors;PKC inhibitor targeting PRKCA, PRKCQ, PRKCB, PRKCD, PRKCE |
| AA-81-IB40_1uM | Dose=1uM, 3-amino-N-[3-(4-aminopiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethoxy)pyridin-2-yl]pyrazine-2-carboxamide, Kinase inhibitors;PKC inhibitor targeting PRKCA, PRKCQ, PRKCB, PRKCD, PRKCE |
| AA-82-RM29_0.01uM | Dose=0.01uM, Ascomycin, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA |
| AA-82-RM29_10uM | Dose=10uM, Ascomycin, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA |
| AA-82-RM29_1uM | Dose=1uM, Ascomycin, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA |
| AA-83-TW85_0.01uM | Dose=0.01uM, 1,2-Dihydro-3H-naphtho(2,1-b)pyran-3-one, Histone Deacetylase SIRT2 Inhibitors targeting SIRT2 |
| AA-83-TW85_0.1uM | Dose=0.1uM, 1,2-Dihydro-3H-naphtho(2,1-b)pyran-3-one, Histone Deacetylase SIRT2 Inhibitors targeting SIRT2 |
| AA-83-TW85_1uM | Dose=1uM, 1,2-Dihydro-3H-naphtho(2,1-b)pyran-3-one, Histone Deacetylase SIRT2 Inhibitors targeting SIRT2 |
| AA-83-YJ04_0.01uM | Dose=0.01uM |
| AA-83-YJ04_0.1uM | Dose=0.1uM |
| AA-83-YJ04_10uM | Dose=10uM |
| AA-83-YJ04_1uM | Dose=1uM |
| AA-84-BX70_0.01uM | Dose=0.01uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(4-ethoxy-5-ethylpyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN |
| AA-84-BX70_0.1uM | Dose=0.1uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(4-ethoxy-5-ethylpyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN |
| AA-84-BX70_10uM | Dose=10uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(4-ethoxy-5-ethylpyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN |
| AA-84-BX70_1uM | Dose=1uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(4-ethoxy-5-ethylpyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN |
| AA-84-PX05_0.01uM | Dose=0.01uM, 2-Methylsulfinyl-8-pentan-3-ylpyrido[2,3-d]pyrimidin-7-one |
| AA-84-PX05_0.1uM | Dose=0.1uM, 2-Methylsulfinyl-8-pentan-3-ylpyrido[2,3-d]pyrimidin-7-one |
| AA-84-PX05_10uM | Dose=10uM, 2-Methylsulfinyl-8-pentan-3-ylpyrido[2,3-d]pyrimidin-7-one |
| AA-85-KR83_0.01uM | Dose=0.01uM, methyl 5-[(E)-(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate, GPR35 antagonist targeting GPR35 |
| AA-85-KR83_0.1uM | Dose=0.1uM, methyl 5-[(E)-(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate, GPR35 antagonist targeting GPR35 |
| AA-85-KR83_10uM | Dose=10uM, methyl 5-[(E)-(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate, GPR35 antagonist targeting GPR35 |
| AA-85-KR83_1uM | Dose=1uM, methyl 5-[(E)-(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate, GPR35 antagonist targeting GPR35 |
| AA-85-LB25_0.01uM | Dose=0.01uM, Floxuridine, Pyrimidine Antagonists targeting TYMS |
| AA-85-LB25_0.1uM | Dose=0.1uM, Floxuridine, Pyrimidine Antagonists targeting TYMS |
| AA-85-LB25_10uM | Dose=10uM, Floxuridine, Pyrimidine Antagonists targeting TYMS |
| AA-85-LB25_1uM | Dose=1uM, Floxuridine, Pyrimidine Antagonists targeting TYMS |
| AA-86-YV75_0.01uM | Dose=0.01uM, SD-208, TbetaR-I) Inhibitors;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1 |
| AA-86-YV75_0.1uM | Dose=0.1uM, SD-208, TbetaR-I) Inhibitors;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1 |
| AA-86-YV75_10uM | Dose=10uM, SD-208, TbetaR-I) Inhibitors;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1 |
| AA-86-YV75_1uM | Dose=1uM, SD-208, TbetaR-I) Inhibitors;Activin Receptor Like Kinase 5 (ALK5 targeting TGFBR1 |
| AA-86-YY62_0.01uM | Dose=0.01uM, Clioquinol, Antiamyloidogenic Agents;Chelating Agents;Carbonic Anhydrase Inhibitors targeting CA12 |
| AA-86-YY62_0.1uM | Dose=0.1uM, Clioquinol, Antiamyloidogenic Agents;Chelating Agents;Carbonic Anhydrase Inhibitors targeting CA12 |
| AA-86-YY62_10uM | Dose=10uM, Clioquinol, Antiamyloidogenic Agents;Chelating Agents;Carbonic Anhydrase Inhibitors targeting CA12 |
| AA-86-YY62_1uM | Dose=1uM, Clioquinol, Antiamyloidogenic Agents;Chelating Agents;Carbonic Anhydrase Inhibitors targeting CA12 |
| AA-87-EI21_0.01uM | Dose=0.01uM, Levetiracetam, Synaptic vesicle glycoprotein 2A modulator targeting CACNA1B, SV2A |
| AA-87-EI21_0.1uM | Dose=0.1uM, Levetiracetam, Synaptic vesicle glycoprotein 2A modulator targeting CACNA1B, SV2A |
| AA-87-EI21_10uM | Dose=10uM, Levetiracetam, Synaptic vesicle glycoprotein 2A modulator targeting CACNA1B, SV2A |
| AA-87-EI21_1uM | Dose=1uM, Levetiracetam, Synaptic vesicle glycoprotein 2A modulator targeting CACNA1B, SV2A |
| AA-87-MP18_0.1uM | Dose=0.1uM, N-(2-Chloro-4-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)phenyl)-6-methylpyridin-3-amine, mglu5 Receptor (mgluR5) Ligands targeting GRM5 |
| AA-87-MP18_10uM | Dose=10uM, N-(2-Chloro-4-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)phenyl)-6-methylpyridin-3-amine, mglu5 Receptor (mgluR5) Ligands targeting GRM5 |
| AA-87-MP18_1uM | Dose=1uM, N-(2-Chloro-4-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)phenyl)-6-methylpyridin-3-amine, mglu5 Receptor (mgluR5) Ligands targeting GRM5 |
| AA-88-PJ86_0.01uM | Dose=0.01uM, 3-chloro-5-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)-N-(6-methylpyridin-3-yl)pyridin-2-amine, mgluR5 Antagonists targeting GRM5 |
| AA-88-PJ86_0.1uM | Dose=0.1uM, 3-chloro-5-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)-N-(6-methylpyridin-3-yl)pyridin-2-amine, mgluR5 Antagonists targeting GRM5 |
| AA-88-PJ86_10uM | Dose=10uM, 3-chloro-5-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)-N-(6-methylpyridin-3-yl)pyridin-2-amine, mgluR5 Antagonists targeting GRM5 |
| AA-88-PJ86_1uM | Dose=1uM, 3-chloro-5-(7-chloro-1-propyl-1H-benzo[d]imidazol-2-yl)-N-(6-methylpyridin-3-yl)pyridin-2-amine, mgluR5 Antagonists targeting GRM5 |
| AA-89-HG56_0.01uM | Dose=0.01uM, Fluperlapine, Dopamine D2 Antagonists;5-HT2A Antagonists targeting DRD2, HTR2A |
| AA-89-HG56_0.1uM | Dose=0.1uM, Fluperlapine, Dopamine D2 Antagonists;5-HT2A Antagonists targeting DRD2, HTR2A |
| AA-89-HG56_10uM | Dose=10uM, Fluperlapine, Dopamine D2 Antagonists;5-HT2A Antagonists targeting DRD2, HTR2A |
| AA-89-HG56_1uM | Dose=1uM, Fluperlapine, Dopamine D2 Antagonists;5-HT2A Antagonists targeting DRD2, HTR2A |
| AA-90-AU53_0.01uM | Dose=0.01uM, Sumatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D, HTR1F |
| AA-90-AU53_0.1uM | Dose=0.1uM, Sumatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D, HTR1F |
| AA-90-AU53_10uM | Dose=10uM, Sumatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D, HTR1F |
| AA-90-AU53_1uM | Dose=1uM, Sumatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D, HTR1F |
| AA-90-YI00_0.01uM | Dose=0.01uM, 3-(5-(Aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| AA-90-YI00_0.1uM | Dose=0.1uM, 3-(5-(Aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| AA-90-YI00_10uM | Dose=10uM, 3-(5-(Aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| AA-90-YI00_1uM | Dose=1uM, 3-(5-(Aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| AA-91-SB25_0.01uM | Dose=0.01uM, Nms-P715, Ttk protein kinase inhibitor targeting TTK |
| AA-91-SB25_0.1uM | Dose=0.1uM, Nms-P715, Ttk protein kinase inhibitor targeting TTK |
| AA-91-SB25_10uM | Dose=10uM, Nms-P715, Ttk protein kinase inhibitor targeting TTK |
| AA-91-SB25_1uM | Dose=1uM, Nms-P715, Ttk protein kinase inhibitor targeting TTK |
| AA-91-WB95_0.01uM | Dose=0.01uM |
| AA-91-WB95_0.1uM | Dose=0.1uM |
| AA-91-WB95_10uM | Dose=10uM |
| AA-91-WB95_1uM | Dose=1uM |
| AA-91-XV98_0.01uM | Dose=0.01uM, Tolfenamic acid |
| AA-91-XV98_0.1uM | Dose=0.1uM, Tolfenamic acid |
| AA-91-XV98_10uM | Dose=10uM, Tolfenamic acid |
| AA-92-NW83_0.01uM | Dose=0.01uM, Lfa 878, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1 |
| AA-92-NW83_0.1uM | Dose=0.1uM, Lfa 878, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1 |
| AA-92-NW83_10uM | Dose=10uM, Lfa 878, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1 |
| AA-92-NW83_1uM | Dose=1uM, Lfa 878, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1 |
| AA-94-OG89_0.01uM | Dose=0.01uM, Detrothyronine targeting THRA |
| AA-94-OG89_0.1uM | Dose=0.1uM, Detrothyronine targeting THRA |
| AA-94-OG89_10uM | Dose=10uM, Detrothyronine targeting THRA |
| AA-94-TU18_0.01uM | Dose=0.01uM |
| AA-94-TU18_0.1uM | Dose=0.1uM |
| AA-94-TU18_10uM | Dose=10uM |
| AA-94-TU18_1uM | Dose=1uM |
| AA-97-XP63_0.01uM | Dose=0.01uM, Sertraline, 5-HT Reuptake Inhibitors targeting SLC6A3, SLC6A4 |
| AA-97-XP63_0.1uM | Dose=0.1uM, Sertraline, 5-HT Reuptake Inhibitors targeting SLC6A3, SLC6A4 |
| AA-97-XP63_10uM | Dose=10uM, Sertraline, 5-HT Reuptake Inhibitors targeting SLC6A3, SLC6A4 |
| AA-97-XP63_1uM | Dose=1uM, Sertraline, 5-HT Reuptake Inhibitors targeting SLC6A3, SLC6A4 |
| AA-98-FJ71_0.01uM | Dose=0.01uM, Anisindione, gamma carboxylation inhibitor targeting GGCX |
| AA-98-FJ71_0.1uM | Dose=0.1uM, Anisindione, gamma carboxylation inhibitor targeting GGCX |
| AA-98-FJ71_10uM | Dose=10uM, Anisindione, gamma carboxylation inhibitor targeting GGCX |
| AA-98-FJ71_1uM | Dose=1uM, Anisindione, gamma carboxylation inhibitor targeting GGCX |
| AA-98-HX85_0.01uM | Dose=0.01uM, N-(4-(pyrrolidine-1-sulfonyl)phenyl)prop-2-enamide |
| AA-98-HX85_0.1uM | Dose=0.1uM, N-(4-(pyrrolidine-1-sulfonyl)phenyl)prop-2-enamide |
| AA-98-HX85_10uM | Dose=10uM, N-(4-(pyrrolidine-1-sulfonyl)phenyl)prop-2-enamide |
| AA-98-HX85_1uM | Dose=1uM, N-(4-(pyrrolidine-1-sulfonyl)phenyl)prop-2-enamide |
| AA-98-MW52_0.01uM | Dose=0.01uM, Ibuprofen, Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PTGS1, PTGS2 |
| AA-98-MW52_0.1uM | Dose=0.1uM, Ibuprofen, Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PTGS1, PTGS2 |
| AA-98-MW52_10uM | Dose=10uM, Ibuprofen, Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PTGS1, PTGS2 |
| AA-98-MW52_1uM | Dose=1uM, Ibuprofen, Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PTGS1, PTGS2 |
| AA-98-PM63_0.01uM | Dose=0.01uM, Levodopa, Dopamine Precursors targeting DRD1, DRD2, DRD3, DRD4, DRD5 |
| AA-98-PM63_0.1uM | Dose=0.1uM, Levodopa, Dopamine Precursors targeting DRD1, DRD2, DRD3, DRD4, DRD5 |
| AA-98-PM63_10uM | Dose=10uM, Levodopa, Dopamine Precursors targeting DRD1, DRD2, DRD3, DRD4, DRD5 |
| AA-98-PM63_1uM | Dose=1uM, Levodopa, Dopamine Precursors targeting DRD1, DRD2, DRD3, DRD4, DRD5 |
| AA-99-HG56_0.01uM | Dose=0.01uM, Norketotifen, Histamine Receptor Antagonists targeting HRH1, HRH4, HRH2, HRH3 |
| AA-99-HG56_0.1uM | Dose=0.1uM, Norketotifen, Histamine Receptor Antagonists targeting HRH1, HRH4, HRH2, HRH3 |
| AA-99-HG56_10uM | Dose=10uM, Norketotifen, Histamine Receptor Antagonists targeting HRH1, HRH4, HRH2, HRH3 |
| AA-99-HG56_1uM | Dose=1uM, Norketotifen, Histamine Receptor Antagonists targeting HRH1, HRH4, HRH2, HRH3 |
| AA-99-HG96_0.01uM | Dose=0.01uM, Amperozide, Dopamine D2 Antagonists;5-HT2A Antagonists targeting HTR1E, HTR1F |
| AA-99-HG96_0.1uM | Dose=0.1uM, Amperozide, Dopamine D2 Antagonists;5-HT2A Antagonists targeting HTR1E, HTR1F |
| AA-99-HG96_10uM | Dose=10uM, Amperozide, Dopamine D2 Antagonists;5-HT2A Antagonists targeting HTR1E, HTR1F |
| AA-99-HG96_1uM | Dose=1uM, Amperozide, Dopamine D2 Antagonists;5-HT2A Antagonists targeting HTR1E, HTR1F |
| AA-99-HO76_0.01uM | Dose=0.01uM, (R)-6-(4-Chloro-3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-2-(3,5-dimethyl-1H-indazol-4-yl)-4-(4-methoxy-3,3-dimethylpiperidin-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine, C5a Receptor antagonist targeting C5AR1 |
| AA-99-HO76_0.1uM | Dose=0.1uM, (R)-6-(4-Chloro-3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-2-(3,5-dimethyl-1H-indazol-4-yl)-4-(4-methoxy-3,3-dimethylpiperidin-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine, C5a Receptor antagonist targeting C5AR1 |
| AA-99-HO76_10uM | Dose=10uM, (R)-6-(4-Chloro-3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-2-(3,5-dimethyl-1H-indazol-4-yl)-4-(4-methoxy-3,3-dimethylpiperidin-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine, C5a Receptor antagonist targeting C5AR1 |
| AA-99-HO76_1uM | Dose=1uM, (R)-6-(4-Chloro-3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-2-(3,5-dimethyl-1H-indazol-4-yl)-4-(4-methoxy-3,3-dimethylpiperidin-1-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine, C5a Receptor antagonist targeting C5AR1 |
| AA-99-OX27_0.01uM | Dose=0.01uM, Tolnaftate, Fungal Squalene Monooxygenase Inhibitors targeting SQLE |
| AA-99-OX27_1uM | Dose=1uM, Tolnaftate, Fungal Squalene Monooxygenase Inhibitors targeting SQLE |
| AA-99-PN83_0.01uM | Dose=0.01uM, 4-[[(7~{r})-8-Cyclopentyl-7-Ethyl-5-Methyl-6-Oxidanylidene-7~{h}-Pteridin-2-Yl]-Methyl-Amino]-3-Methoxy-~{n}-(1-Methylpiperidin-4-Yl)benzamide |
| AA-99-PN83_10uM | Dose=10uM, 4-[[(7~{r})-8-Cyclopentyl-7-Ethyl-5-Methyl-6-Oxidanylidene-7~{h}-Pteridin-2-Yl]-Methyl-Amino]-3-Methoxy-~{n}-(1-Methylpiperidin-4-Yl)benzamide |
| AA-99-PN83_1uM | Dose=1uM, 4-[[(7~{r})-8-Cyclopentyl-7-Ethyl-5-Methyl-6-Oxidanylidene-7~{h}-Pteridin-2-Yl]-Methyl-Amino]-3-Methoxy-~{n}-(1-Methylpiperidin-4-Yl)benzamide |
| AB-00-HA50_0.01uM | Dose=0.01uM |
| AB-00-HA50_0.1uM | Dose=0.1uM |
| AB-00-HA50_1uM | Dose=1uM |
| AB-00-IL62_0.01uM | Dose=0.01uM, Nky80, Adenylate Cyclase Type V Inhibitors targeting ADCY5 |
| AB-00-IL62_0.1uM | Dose=0.1uM, Nky80, Adenylate Cyclase Type V Inhibitors targeting ADCY5 |
| AB-00-IL62_10uM | Dose=10uM, Nky80, Adenylate Cyclase Type V Inhibitors targeting ADCY5 |
| AB-00-IL62_1uM | Dose=1uM, Nky80, Adenylate Cyclase Type V Inhibitors targeting ADCY5 |
| AB-00-VH52_0.01uM | Dose=0.01uM, 1-Methylcyclopropyl 4-(((5-(4-(((1-methylazetidin-3-yl)methyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119 |
| AB-00-VH52_0.1uM | Dose=0.1uM, 1-Methylcyclopropyl 4-(((5-(4-(((1-methylazetidin-3-yl)methyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119 |
| AB-00-VH52_10uM | Dose=10uM, 1-Methylcyclopropyl 4-(((5-(4-(((1-methylazetidin-3-yl)methyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119 |
| AB-00-VH52_1uM | Dose=1uM, 1-Methylcyclopropyl 4-(((5-(4-(((1-methylazetidin-3-yl)methyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate targeting GPR119 |
| AB-01-NB05_0.01uM | Dose=0.01uM, Rosiglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARA, PPARG |
| AB-01-NB05_0.1uM | Dose=0.1uM, Rosiglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARA, PPARG |
| AB-01-NB05_10uM | Dose=10uM, Rosiglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARA, PPARG |
| AB-01-NB05_1uM | Dose=1uM, Rosiglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARA, PPARG |
| AB-01-UY50_0.01uM | Dose=0.01uM, 1-(4-Fluorophenyl)-4-(8-fluoro-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl)butan-1-one, ADRA1B antagonist;HTR1 modulator targeting ADRA1B, HTR1E, HTR1F |
| AB-01-UY50_0.1uM | Dose=0.1uM, 1-(4-Fluorophenyl)-4-(8-fluoro-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl)butan-1-one, ADRA1B antagonist;HTR1 modulator targeting ADRA1B, HTR1E, HTR1F |
| AB-01-UY50_10uM | Dose=10uM, 1-(4-Fluorophenyl)-4-(8-fluoro-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl)butan-1-one, ADRA1B antagonist;HTR1 modulator targeting ADRA1B, HTR1E, HTR1F |
| AB-01-UY50_1uM | Dose=1uM, 1-(4-Fluorophenyl)-4-(8-fluoro-1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indol-2-yl)butan-1-one, ADRA1B antagonist;HTR1 modulator targeting ADRA1B, HTR1E, HTR1F |
| AB-02-CF97_0.01uM | Dose=0.01uM, CaCCinh-A01, Calcium activated chloride channel 1 inhibitor targeting ANO1 |
| AB-02-CF97_0.1uM | Dose=0.1uM, CaCCinh-A01, Calcium activated chloride channel 1 inhibitor targeting ANO1 |
| AB-02-CF97_10uM | Dose=10uM, CaCCinh-A01, Calcium activated chloride channel 1 inhibitor targeting ANO1 |
| AB-02-CF97_1uM | Dose=1uM, CaCCinh-A01, Calcium activated chloride channel 1 inhibitor targeting ANO1 |
| AB-02-TI14_0.01uM | Dose=0.01uM, (R)-N-[2-Chloro-4-(piperazinosulfonyl)phenyl]-2-methyl-2-hydroxy-3,3,3-trifluoropropionamide, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| AB-02-TI14_0.1uM | Dose=0.1uM, (R)-N-[2-Chloro-4-(piperazinosulfonyl)phenyl]-2-methyl-2-hydroxy-3,3,3-trifluoropropionamide, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| AB-02-TI14_10uM | Dose=10uM, (R)-N-[2-Chloro-4-(piperazinosulfonyl)phenyl]-2-methyl-2-hydroxy-3,3,3-trifluoropropionamide, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| AB-02-TI14_1uM | Dose=1uM, (R)-N-[2-Chloro-4-(piperazinosulfonyl)phenyl]-2-methyl-2-hydroxy-3,3,3-trifluoropropionamide, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| AB-04-HG24_0.01uM | Dose=0.01uM |
| AB-04-HG24_0.1uM | Dose=0.1uM |
| AB-04-HG24_1uM | Dose=1uM |
| AB-04-MQ83_0.01uM | Dose=0.01uM |
| AB-04-MQ83_0.1uM | Dose=0.1uM |
| AB-04-MQ83_10uM | Dose=10uM |
| AB-04-MQ83_1uM | Dose=1uM |
| AB-04-NN16_0.01uM | Dose=0.01uM, N,N'-(((1,1'-((Butane-1,4-diylbis(azanediyl))bis(carbonyl))bis(piperidine-4,1-diyl))bis(azanediyl))bis(iminomethylene))bis(3,5-diamino-6-chloropyrazine-2-carboxamide), Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G |
| AB-04-NN16_0.1uM | Dose=0.1uM, N,N'-(((1,1'-((Butane-1,4-diylbis(azanediyl))bis(carbonyl))bis(piperidine-4,1-diyl))bis(azanediyl))bis(iminomethylene))bis(3,5-diamino-6-chloropyrazine-2-carboxamide), Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G |
| AB-04-NN16_10uM | Dose=10uM, N,N'-(((1,1'-((Butane-1,4-diylbis(azanediyl))bis(carbonyl))bis(piperidine-4,1-diyl))bis(azanediyl))bis(iminomethylene))bis(3,5-diamino-6-chloropyrazine-2-carboxamide), Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G |
| AB-04-NN16_1uM | Dose=1uM, N,N'-(((1,1'-((Butane-1,4-diylbis(azanediyl))bis(carbonyl))bis(piperidine-4,1-diyl))bis(azanediyl))bis(iminomethylene))bis(3,5-diamino-6-chloropyrazine-2-carboxamide), Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G |
| AB-05-FB25_0.01uM | Dose=0.01uM, Pirenzepine, Muscarinic M1 Antagonists targeting CHRM1 |
| AB-05-FB25_0.1uM | Dose=0.1uM, Pirenzepine, Muscarinic M1 Antagonists targeting CHRM1 |
| AB-05-FB25_10uM | Dose=10uM, Pirenzepine, Muscarinic M1 Antagonists targeting CHRM1 |
| AB-05-FB25_1uM | Dose=1uM, Pirenzepine, Muscarinic M1 Antagonists targeting CHRM1 |
| AB-05-JR93_0.1uM | Dose=0.1uM, Ketoprofen, Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| AB-05-JR93_10uM | Dose=10uM, Ketoprofen, Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| AB-05-JR93_1uM | Dose=1uM, Ketoprofen, Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| AB-06-KB32_0.01uM | Dose=0.01uM |
| AB-06-KB32_0.1uM | Dose=0.1uM |
| AB-06-KB32_10uM | Dose=10uM |
| AB-06-KB32_1uM | Dose=1uM |
| AB-07-AZ97_0.1uM | Dose=0.1uM, CB1R antagonist 1, Pyruvate Kinase Isozyme M2 (PKM2) Activators targeting PKM |
| AB-07-AZ97_1uM | Dose=1uM, CB1R antagonist 1, Pyruvate Kinase Isozyme M2 (PKM2) Activators targeting PKM |
| AB-07-KC02_0.1uM | Dose=0.1uM, PT2399, HIF2A/EPAS1 inhibitor targeting EPAS1 |
| AB-07-KC02_10uM | Dose=10uM, PT2399, HIF2A/EPAS1 inhibitor targeting EPAS1 |
| AB-07-KC02_1uM | Dose=1uM, PT2399, HIF2A/EPAS1 inhibitor targeting EPAS1 |
| AB-07-WP43_0.01uM | Dose=0.01uM, Cidoxepin, Histamine H1 Receptor Antagonists;5-HT Reuptake Inhibitors;Histamine H2 Receptor Antagonists;Norepinephrine Reuptake Inhibitors targeting HRH1 |
| AB-07-WP43_0.1uM | Dose=0.1uM, Cidoxepin, Histamine H1 Receptor Antagonists;5-HT Reuptake Inhibitors;Histamine H2 Receptor Antagonists;Norepinephrine Reuptake Inhibitors targeting HRH1 |
| AB-07-WP43_1uM | Dose=1uM, Cidoxepin, Histamine H1 Receptor Antagonists;5-HT Reuptake Inhibitors;Histamine H2 Receptor Antagonists;Norepinephrine Reuptake Inhibitors targeting HRH1 |
| AB-08-HT45_0.01uM | Dose=0.01uM, Fenoldopam, Dopamine D1 Agonists targeting DRD1 |
| AB-08-HT45_0.1uM | Dose=0.1uM, Fenoldopam, Dopamine D1 Agonists targeting DRD1 |
| AB-08-HT45_10uM | Dose=10uM, Fenoldopam, Dopamine D1 Agonists targeting DRD1 |
| AB-08-HT45_1uM | Dose=1uM, Fenoldopam, Dopamine D1 Agonists targeting DRD1 |
| AB-09-AD74_0.01uM | Dose=0.01uM, (1S,3S)-3-[[3-[2-(3,5-dimethylpyrazol-1-yl)pyridin-4-yl]imidazo[1,2-a]pyridin-6-yl]amino]cyclohexan-1-ol, Activin Receptor Like Kinase 5 (ALK5 TbetaR-I) Inhibitors targeting TGFBR1 |
| AB-09-EA37_0.01uM | Dose=0.01uM |
| AB-09-EA37_0.1uM | Dose=0.1uM |
| AB-09-EA37_10uM | Dose=10uM |
| AB-09-EA37_1uM | Dose=1uM |
| AB-09-JN93_0.01uM | Dose=0.01uM |
| AB-09-JN93_0.1uM | Dose=0.1uM |
| AB-09-JN93_10uM | Dose=10uM |
| AB-09-NX37_0.01uM | Dose=0.01uM, 6-{4-[(2-methoxyethoxy)methyl]phenyl}-5-methyl-3-phenyl-4H,5H-[1,2]oxazolo[4,5-c]pyridin-4-one, Nuclear Receptor Subfamily 4 Group A Member 2 (NR4A2, NURR1) Agonists targeting NR4A2 |
| AB-09-NX37_10uM | Dose=10uM, 6-{4-[(2-methoxyethoxy)methyl]phenyl}-5-methyl-3-phenyl-4H,5H-[1,2]oxazolo[4,5-c]pyridin-4-one, Nuclear Receptor Subfamily 4 Group A Member 2 (NR4A2, NURR1) Agonists targeting NR4A2 |
| AB-09-NX37_1uM | Dose=1uM, 6-{4-[(2-methoxyethoxy)methyl]phenyl}-5-methyl-3-phenyl-4H,5H-[1,2]oxazolo[4,5-c]pyridin-4-one, Nuclear Receptor Subfamily 4 Group A Member 2 (NR4A2, NURR1) Agonists targeting NR4A2 |
| AB-09-PR28_0.01uM | Dose=0.01uM, Tacrine, Acetylcholinesterase Inhibitors;Butyrylcholinesterase Inhibitors targeting ACHE, BCHE, CHRNE |
| AB-09-PR28_0.1uM | Dose=0.1uM, Tacrine, Acetylcholinesterase Inhibitors;Butyrylcholinesterase Inhibitors targeting ACHE, BCHE, CHRNE |
| AB-09-PR28_10uM | Dose=10uM, Tacrine, Acetylcholinesterase Inhibitors;Butyrylcholinesterase Inhibitors targeting ACHE, BCHE, CHRNE |
| AB-09-PR28_1uM | Dose=1uM, Tacrine, Acetylcholinesterase Inhibitors;Butyrylcholinesterase Inhibitors targeting ACHE, BCHE, CHRNE |
| AB-09-YX02_0.01uM | Dose=0.01uM, p-Coumaric acid |
| AB-09-YX02_0.1uM | Dose=0.1uM, p-Coumaric acid |
| AB-09-YX02_10uM | Dose=10uM, p-Coumaric acid |
| AB-09-YX02_1uM | Dose=1uM, p-Coumaric acid |
| AB-10-RE65_0.01uM | Dose=0.01uM, 3-Hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]benzonitrile, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AB-10-RE65_0.1uM | Dose=0.1uM, 3-Hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]benzonitrile, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AB-10-RE65_10uM | Dose=10uM, 3-Hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]benzonitrile, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AB-10-RE65_1uM | Dose=1uM, 3-Hydroxy-4-[6-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl]benzonitrile, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AB-11-AY75_0.01uM | Dose=0.01uM, 5-(2,5-Dimethyl-pyrrol-1-yl)-2-hydroxy-benzoic acid, Pin1 Inhibitors targeting PIN1 |
| AB-11-AY75_0.1uM | Dose=0.1uM, 5-(2,5-Dimethyl-pyrrol-1-yl)-2-hydroxy-benzoic acid, Pin1 Inhibitors targeting PIN1 |
| AB-11-AY75_10uM | Dose=10uM, 5-(2,5-Dimethyl-pyrrol-1-yl)-2-hydroxy-benzoic acid, Pin1 Inhibitors targeting PIN1 |
| AB-11-MO96_0.01uM | Dose=0.01uM, 3-Chloro-6-piperazin-1-yl-11H-dibenzo[b,e]azepine, Dopamine D2 Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, HTR2A |
| AB-11-MO96_0.1uM | Dose=0.1uM, 3-Chloro-6-piperazin-1-yl-11H-dibenzo[b,e]azepine, Dopamine D2 Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, HTR2A |
| AB-11-MO96_10uM | Dose=10uM, 3-Chloro-6-piperazin-1-yl-11H-dibenzo[b,e]azepine, Dopamine D2 Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, HTR2A |
| AB-11-MO96_1uM | Dose=1uM, 3-Chloro-6-piperazin-1-yl-11H-dibenzo[b,e]azepine, Dopamine D2 Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, HTR2A |
| AB-11-QV43_0.01uM | Dose=0.01uM, N-[4-(2-aminopropan-2-yl)phenyl]-8-ethoxy-7-methoxy-2-oxochromene-3-carboxamide, S1PR1 agonist targeting S1PR1 |
| AB-11-QV43_0.1uM | Dose=0.1uM, N-[4-(2-aminopropan-2-yl)phenyl]-8-ethoxy-7-methoxy-2-oxochromene-3-carboxamide, S1PR1 agonist targeting S1PR1 |
| AB-11-QV43_10uM | Dose=10uM, N-[4-(2-aminopropan-2-yl)phenyl]-8-ethoxy-7-methoxy-2-oxochromene-3-carboxamide, S1PR1 agonist targeting S1PR1 |
| AB-11-QV43_1uM | Dose=1uM, N-[4-(2-aminopropan-2-yl)phenyl]-8-ethoxy-7-methoxy-2-oxochromene-3-carboxamide, S1PR1 agonist targeting S1PR1 |
| AB-11-VI02_0.01uM | Dose=0.01uM, Amlodipine |
| AB-11-VI02_0.1uM | Dose=0.1uM, Amlodipine |
| AB-11-VI02_1uM | Dose=1uM, Amlodipine |
| AB-12-IS33_0.01uM | Dose=0.01uM, Melphalan |
| AB-12-IS33_10uM | Dose=10uM, Melphalan |
| AB-12-IS33_1uM | Dose=1uM, Melphalan |
| AB-12-PP61_0.01uM | Dose=0.01uM, 4-(2,6-difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors targeting JAK1, JAK2, JAK3, TYK2 |
| AB-12-PP61_0.1uM | Dose=0.1uM, 4-(2,6-difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors targeting JAK1, JAK2, JAK3, TYK2 |
| AB-12-PP61_10uM | Dose=10uM, 4-(2,6-difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors targeting JAK1, JAK2, JAK3, TYK2 |
| AB-12-PP61_1uM | Dose=1uM, 4-(2,6-difluoro-4-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors targeting JAK1, JAK2, JAK3, TYK2 |
| AB-13-HC37_0.01uM | Dose=0.01uM, 2-{[4-(3-chloro-propoxy)-benzenesulfonyl]-(4-methoxy-benzyl)amino}-N-hydroxy-acetamide |
| AB-13-HC37_0.1uM | Dose=0.1uM, 2-{[4-(3-chloro-propoxy)-benzenesulfonyl]-(4-methoxy-benzyl)amino}-N-hydroxy-acetamide |
| AB-13-HC37_1uM | Dose=1uM, 2-{[4-(3-chloro-propoxy)-benzenesulfonyl]-(4-methoxy-benzyl)amino}-N-hydroxy-acetamide |
| AB-14-GQ48_0.01uM | Dose=0.01uM, Nitroarginine, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| AB-14-GQ48_0.1uM | Dose=0.1uM, Nitroarginine, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| AB-14-GQ48_10uM | Dose=10uM, Nitroarginine, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| AB-14-GQ48_1uM | Dose=1uM, Nitroarginine, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| AB-14-QA30_0.01uM | Dose=0.01uM |
| AB-14-QA30_0.1uM | Dose=0.1uM |
| AB-14-QA30_10uM | Dose=10uM |
| AB-14-QA30_1uM | Dose=1uM |
| AB-15-FB25_0.01uM | Dose=0.01uM, Labetalol, beta-Adrenoceptor Antagonists;alpha-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A, ADRB1 |
| AB-15-FB25_0.1uM | Dose=0.1uM, Labetalol, beta-Adrenoceptor Antagonists;alpha-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A, ADRB1 |
| AB-15-FB25_10uM | Dose=10uM, Labetalol, beta-Adrenoceptor Antagonists;alpha-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A, ADRB1 |
| AB-15-FB25_1uM | Dose=1uM, Labetalol, beta-Adrenoceptor Antagonists;alpha-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A, ADRB1 |
| AB-15-XR48_0.01uM | Dose=0.01uM, N-(2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl)acetamide, MTNR1B agonist;MTNR1A agonist targeting MTNR1A, MTNR1B |
| AB-15-XR48_0.1uM | Dose=0.1uM, N-(2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl)acetamide, MTNR1B agonist;MTNR1A agonist targeting MTNR1A, MTNR1B |
| AB-15-XR48_10uM | Dose=10uM, N-(2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl)acetamide, MTNR1B agonist;MTNR1A agonist targeting MTNR1A, MTNR1B |
| AB-15-XR48_1uM | Dose=1uM, N-(2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl)acetamide, MTNR1B agonist;MTNR1A agonist targeting MTNR1A, MTNR1B |
| AB-16-HE44_0.01uM | Dose=0.01uM, 2-Aminobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| AB-16-HE44_0.1uM | Dose=0.1uM, 2-Aminobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| AB-16-HE44_10uM | Dose=10uM, 2-Aminobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| AB-16-HE44_1uM | Dose=1uM, 2-Aminobenzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| AB-16-LY07_0.01uM | Dose=0.01uM, Nortriptyline, K(ir) 4.1 Blockers targeting KCNJ10 |
| AB-16-LY07_10uM | Dose=10uM, Nortriptyline, K(ir) 4.1 Blockers targeting KCNJ10 |
| AB-16-SB72_0.01uM | Dose=0.01uM, 3-(5-(4-(1H-Imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid, ADH5) Inhibitors;Alcohol Dehydrogenase class-3 (GSNOR targeting ADH5 |
| AB-16-SB72_0.1uM | Dose=0.1uM, 3-(5-(4-(1H-Imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid, ADH5) Inhibitors;Alcohol Dehydrogenase class-3 (GSNOR targeting ADH5 |
| AB-17-DF74_0.01uM | Dose=0.01uM, Monoacylglycerol Lipase Inhibitor 21, Monoacylglycerol Lipase inhibitor targeting MGLL |
| AB-17-DF74_0.1uM | Dose=0.1uM, Monoacylglycerol Lipase Inhibitor 21, Monoacylglycerol Lipase inhibitor targeting MGLL |
| AB-17-DF74_10uM | Dose=10uM, Monoacylglycerol Lipase Inhibitor 21, Monoacylglycerol Lipase inhibitor targeting MGLL |
| AB-17-DF74_1uM | Dose=1uM, Monoacylglycerol Lipase Inhibitor 21, Monoacylglycerol Lipase inhibitor targeting MGLL |
| AB-17-LS35_0.01uM | Dose=0.01uM, Prostanoid TP Antagonists |
| AB-17-LS35_0.1uM | Dose=0.1uM, Prostanoid TP Antagonists |
| AB-17-LS35_1uM | Dose=1uM, Prostanoid TP Antagonists |
| AB-17-WP43_0.01uM | Dose=0.01uM, Loperamide, mu-Opioid Agonists targeting OPRM1 |
| AB-17-WP43_0.1uM | Dose=0.1uM, Loperamide, mu-Opioid Agonists targeting OPRM1 |
| AB-17-WP43_10uM | Dose=10uM, Loperamide, mu-Opioid Agonists targeting OPRM1 |
| AB-17-WP43_1uM | Dose=1uM, Loperamide, mu-Opioid Agonists targeting OPRM1 |
| AB-17-ZZ77_0.01uM | Dose=0.01uM, Estradiol Valerate |
| AB-17-ZZ77_0.1uM | Dose=0.1uM, Estradiol Valerate |
| AB-17-ZZ77_10uM | Dose=10uM, Estradiol Valerate |
| AB-17-ZZ77_1uM | Dose=1uM, Estradiol Valerate |
| AB-18-YN11_0.01uM | Dose=0.01uM, Carfilzomib, Proteasome inhibitor targeting PSMB1, PSMB2, PSMB5, PSMB8, PSMB9, PSMB10 |
| AB-18-YN11_0.1uM | Dose=0.1uM, Carfilzomib, Proteasome inhibitor targeting PSMB1, PSMB2, PSMB5, PSMB8, PSMB9, PSMB10 |
| AB-18-YN11_10uM | Dose=10uM, Carfilzomib, Proteasome inhibitor targeting PSMB1, PSMB2, PSMB5, PSMB8, PSMB9, PSMB10 |
| AB-18-YN11_1uM | Dose=1uM, Carfilzomib, Proteasome inhibitor targeting PSMB1, PSMB2, PSMB5, PSMB8, PSMB9, PSMB10 |
| AB-21-CI37_0.1uM | Dose=0.1uM, Deferoxamine |
| AB-21-CI37_10uM | Dose=10uM, Deferoxamine |
| AB-21-CI37_1uM | Dose=1uM, Deferoxamine |
| AB-21-MV93_0.01uM | Dose=0.01uM, Dinoprostone targeting PTGER1, PTGER2, PTGER3, PTGER4 |
| AB-21-MV93_0.1uM | Dose=0.1uM, Dinoprostone targeting PTGER1, PTGER2, PTGER3, PTGER4 |
| AB-21-MV93_10uM | Dose=10uM, Dinoprostone targeting PTGER1, PTGER2, PTGER3, PTGER4 |
| AB-21-MV93_1uM | Dose=1uM, Dinoprostone targeting PTGER1, PTGER2, PTGER3, PTGER4 |
| AB-21-VE32_0.01uM | Dose=0.01uM, Nvs-SM2, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AB-21-VE32_0.1uM | Dose=0.1uM, Nvs-SM2, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AB-21-VE32_10uM | Dose=10uM, Nvs-SM2, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AB-21-VE32_1uM | Dose=1uM, Nvs-SM2, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AB-22-AI49_0.01uM | Dose=0.01uM, Arbaclofen, GABA(B) Agonists targeting GABBR1, GABBR2 |
| AB-22-AI49_0.1uM | Dose=0.1uM, Arbaclofen, GABA(B) Agonists targeting GABBR1, GABBR2 |
| AB-22-AI49_10uM | Dose=10uM, Arbaclofen, GABA(B) Agonists targeting GABBR1, GABBR2 |
| AB-22-AI49_1uM | Dose=1uM, Arbaclofen, GABA(B) Agonists targeting GABBR1, GABBR2 |
| AB-23-MN29_0.01uM | Dose=0.01uM, Disopyramide, Sodium Channel Blocker;Antiarrhythmic agent targeting CHRM1, CHRM2, CHRM3, KCND2, KCND3, SCN5A |
| AB-23-MN29_0.1uM | Dose=0.1uM, Disopyramide, Sodium Channel Blocker;Antiarrhythmic agent targeting CHRM1, CHRM2, CHRM3, KCND2, KCND3, SCN5A |
| AB-23-MN29_10uM | Dose=10uM, Disopyramide, Sodium Channel Blocker;Antiarrhythmic agent targeting CHRM1, CHRM2, CHRM3, KCND2, KCND3, SCN5A |
| AB-23-MN29_1uM | Dose=1uM, Disopyramide, Sodium Channel Blocker;Antiarrhythmic agent targeting CHRM1, CHRM2, CHRM3, KCND2, KCND3, SCN5A |
| AB-23-UX23_0.1uM | Dose=0.1uM, 2-Hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide, ADRB1 antagonist targeting ADRB1 |
| AB-23-UX23_10uM | Dose=10uM, 2-Hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide, ADRB1 antagonist targeting ADRB1 |
| AB-23-UX23_1uM | Dose=1uM, 2-Hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)imidazol-2-yl]phenoxy]propyl]amino]ethoxy]benzamide, ADRB1 antagonist targeting ADRB1 |
| AB-25-MR13_0.01uM | Dose=0.01uM, 5-(5-Methoxypyridin-3-Yl)-3-Methyl-8-[(Piperidin-4-Yl)amino]-1,2-Dihydro-1,7-Naphthyridin-2-One, ATAD2 inhibitor targeting ATAD2 |
| AB-25-MR13_0.1uM | Dose=0.1uM, 5-(5-Methoxypyridin-3-Yl)-3-Methyl-8-[(Piperidin-4-Yl)amino]-1,2-Dihydro-1,7-Naphthyridin-2-One, ATAD2 inhibitor targeting ATAD2 |
| AB-25-MR13_10uM | Dose=10uM, 5-(5-Methoxypyridin-3-Yl)-3-Methyl-8-[(Piperidin-4-Yl)amino]-1,2-Dihydro-1,7-Naphthyridin-2-One, ATAD2 inhibitor targeting ATAD2 |
| AB-25-MR13_1uM | Dose=1uM, 5-(5-Methoxypyridin-3-Yl)-3-Methyl-8-[(Piperidin-4-Yl)amino]-1,2-Dihydro-1,7-Naphthyridin-2-One, ATAD2 inhibitor targeting ATAD2 |
| AB-25-NK66_0.01uM | Dose=0.01uM, Adh-1, N-cadherin Inhibitor targeting CDH2 |
| AB-25-NK66_10uM | Dose=10uM, Adh-1, N-cadherin Inhibitor targeting CDH2 |
| AB-25-NK66_1uM | Dose=1uM, Adh-1, N-cadherin Inhibitor targeting CDH2 |
| AB-25-XU75_0.01uM | Dose=0.01uM, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide, Endothelin ETA Receptor Antagonists;EDNRA antagonist targeting EDNRA |
| AB-25-XU75_0.1uM | Dose=0.1uM, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide, Endothelin ETA Receptor Antagonists;EDNRA antagonist targeting EDNRA |
| AB-25-XU75_10uM | Dose=10uM, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide, Endothelin ETA Receptor Antagonists;EDNRA antagonist targeting EDNRA |
| AB-25-XU75_1uM | Dose=1uM, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide, Endothelin ETA Receptor Antagonists;EDNRA antagonist targeting EDNRA |
| AB-26-BE29_0.01uM | Dose=0.01uM, Bis(5-amidino-2-benzimidazolyl)methane targeting PLG, PROC, TPSAB1, TPSB2 |
| AB-26-BE29_0.1uM | Dose=0.1uM, Bis(5-amidino-2-benzimidazolyl)methane targeting PLG, PROC, TPSAB1, TPSB2 |
| AB-26-BE29_10uM | Dose=10uM, Bis(5-amidino-2-benzimidazolyl)methane targeting PLG, PROC, TPSAB1, TPSB2 |
| AB-26-BE29_1uM | Dose=1uM, Bis(5-amidino-2-benzimidazolyl)methane targeting PLG, PROC, TPSAB1, TPSB2 |
| AB-27-LS15_0.01uM | Dose=0.01uM, bisindolylmaleimide VIII, Protein Kinase C (PKC) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CAMK2D, PRKCA |
| AB-27-LS15_0.1uM | Dose=0.1uM, bisindolylmaleimide VIII, Protein Kinase C (PKC) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CAMK2D, PRKCA |
| AB-27-LS15_10uM | Dose=10uM, bisindolylmaleimide VIII, Protein Kinase C (PKC) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CAMK2D, PRKCA |
| AB-28-BT90_0.01uM | Dose=0.01uM, N-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]quinoline-8-sulfonamide, Angiogenesis Inhibitors;Aquaporin 1 (AQP1) Inhibitors targeting AQP1 |
| AB-28-BT90_10uM | Dose=10uM, N-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]quinoline-8-sulfonamide, Angiogenesis Inhibitors;Aquaporin 1 (AQP1) Inhibitors targeting AQP1 |
| AB-28-BT90_1uM | Dose=1uM, N-[3-[4-(2-fluorophenyl)piperazin-1-yl]propyl]quinoline-8-sulfonamide, Angiogenesis Inhibitors;Aquaporin 1 (AQP1) Inhibitors targeting AQP1 |
| AB-30-CR11_0.01uM | Dose=0.01uM, Bi-2536, Polo-like Kinase-1 (Plk-1) Inhibitors;Antimitotic Drugs targeting PLK1, BRD4 |
| AB-30-CR11_0.1uM | Dose=0.1uM, Bi-2536, Polo-like Kinase-1 (Plk-1) Inhibitors;Antimitotic Drugs targeting PLK1, BRD4 |
| AB-30-CR11_10uM | Dose=10uM, Bi-2536, Polo-like Kinase-1 (Plk-1) Inhibitors;Antimitotic Drugs targeting PLK1, BRD4 |
| AB-30-CR11_1uM | Dose=1uM, Bi-2536, Polo-like Kinase-1 (Plk-1) Inhibitors;Antimitotic Drugs targeting PLK1, BRD4 |
| AB-30-DA10_0.01uM | Dose=0.01uM, Diclofenac, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators;Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors targeting CXCR1, KCNQ2, KCNQ3, PTGS1, PTGS2 |
| AB-30-DA10_0.1uM | Dose=0.1uM, Diclofenac, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators;Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors targeting CXCR1, KCNQ2, KCNQ3, PTGS1, PTGS2 |
| AB-30-DA10_10uM | Dose=10uM, Diclofenac, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators;Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors targeting CXCR1, KCNQ2, KCNQ3, PTGS1, PTGS2 |
| AB-30-DA10_1uM | Dose=1uM, Diclofenac, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators;Non-Steroidal Antiinflammatory Drugs;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors targeting CXCR1, KCNQ2, KCNQ3, PTGS1, PTGS2 |
| AB-31-VZ28_0.01uM | Dose=0.01uM, Trifluoperazine, Dopamine D2 Antagonists;Nav1.4 (SkM1) Sodium Channel Blockers;Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting DRD2, S100A4, SCN4A, SCN9A |
| AB-31-VZ28_0.1uM | Dose=0.1uM, Trifluoperazine, Dopamine D2 Antagonists;Nav1.4 (SkM1) Sodium Channel Blockers;Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting DRD2, S100A4, SCN4A, SCN9A |
| AB-31-VZ28_10uM | Dose=10uM, Trifluoperazine, Dopamine D2 Antagonists;Nav1.4 (SkM1) Sodium Channel Blockers;Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting DRD2, S100A4, SCN4A, SCN9A |
| AB-31-VZ28_1uM | Dose=1uM, Trifluoperazine, Dopamine D2 Antagonists;Nav1.4 (SkM1) Sodium Channel Blockers;Nav1.7 ( PN1/hNE-Na) Sodium Channel Blockers targeting DRD2, S100A4, SCN4A, SCN9A |
| AB-32-QZ50_0.01uM | Dose=0.01uM |
| AB-32-QZ50_0.1uM | Dose=0.1uM |
| AB-32-QZ50_10uM | Dose=10uM |
| AB-32-QZ50_1uM | Dose=1uM |
| AB-32-WM54_0.01uM | Dose=0.01uM, Tretinoin, Retinoid RORbeta Ligands targeting RARA, RORB, RXRG |
| AB-32-WM54_0.1uM | Dose=0.1uM, Tretinoin, Retinoid RORbeta Ligands targeting RARA, RORB, RXRG |
| AB-32-WM54_10uM | Dose=10uM, Tretinoin, Retinoid RORbeta Ligands targeting RARA, RORB, RXRG |
| AB-32-WM54_1uM | Dose=1uM, Tretinoin, Retinoid RORbeta Ligands targeting RARA, RORB, RXRG |
| AB-33-EM56_0.01uM | Dose=0.01uM |
| AB-33-EM56_0.1uM | Dose=0.1uM |
| AB-33-EM56_10uM | Dose=10uM |
| AB-33-EM56_1uM | Dose=1uM |
| AB-33-VM36_0.01uM | Dose=0.01uM, Mizoribine, Immunosuppressive targeting ATIC, IMPDH1, IMPDH2, GMPS |
| AB-33-VM36_0.1uM | Dose=0.1uM, Mizoribine, Immunosuppressive targeting ATIC, IMPDH1, IMPDH2, GMPS |
| AB-33-VM36_10uM | Dose=10uM, Mizoribine, Immunosuppressive targeting ATIC, IMPDH1, IMPDH2, GMPS |
| AB-33-VM36_1uM | Dose=1uM, Mizoribine, Immunosuppressive targeting ATIC, IMPDH1, IMPDH2, GMPS |
| AB-34-DD27_0.01uM | Dose=0.01uM, 3-Hydroxyflavone, DNA binder;Drugs Acting on Beta-Amyloid targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| AB-34-DD27_0.1uM | Dose=0.1uM, 3-Hydroxyflavone, DNA binder;Drugs Acting on Beta-Amyloid targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| AB-34-DD27_10uM | Dose=10uM, 3-Hydroxyflavone, DNA binder;Drugs Acting on Beta-Amyloid targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| AB-34-DD27_1uM | Dose=1uM, 3-Hydroxyflavone, DNA binder;Drugs Acting on Beta-Amyloid targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| AB-34-RQ73_0.01uM | Dose=0.01uM, Oxaprotiline, Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| AB-34-RQ73_0.1uM | Dose=0.1uM, Oxaprotiline, Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| AB-34-RQ73_10uM | Dose=10uM, Oxaprotiline, Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| AB-34-RQ73_1uM | Dose=1uM, Oxaprotiline, Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| AB-35-RU30_0.01uM | Dose=0.01uM |
| AB-35-RU30_0.1uM | Dose=0.1uM |
| AB-35-RU30_10uM | Dose=10uM |
| AB-35-RU30_1uM | Dose=1uM |
| AB-36-NS83_0.01uM | Dose=0.01uM, 3-chloro-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-(thiophen-2-yl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide, Nav1.8 (SNS/PN3) Sodium Channel Blockers targeting SCN10A |
| AB-36-NS83_0.1uM | Dose=0.1uM, 3-chloro-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-(thiophen-2-yl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide, Nav1.8 (SNS/PN3) Sodium Channel Blockers targeting SCN10A |
| AB-37-JM16_0.01uM | Dose=0.01uM, (1aR,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one, NF-kappaB (NFKB) Activation Inhibitors targeting IKBKB |
| AB-37-JM16_0.1uM | Dose=0.1uM, (1aR,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one, NF-kappaB (NFKB) Activation Inhibitors targeting IKBKB |
| AB-37-JM16_10uM | Dose=10uM, (1aR,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one, NF-kappaB (NFKB) Activation Inhibitors targeting IKBKB |
| AB-37-JM16_1uM | Dose=1uM, (1aR,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one, NF-kappaB (NFKB) Activation Inhibitors targeting IKBKB |
| AB-38-CX25_0.01uM | Dose=0.01uM, Methiothepin targeting HTR1E, HTR1F |
| AB-38-CX25_10uM | Dose=10uM, Methiothepin targeting HTR1E, HTR1F |
| AB-39-ED84_0.01uM | Dose=0.01uM, (+)-Ketoconazole, Antifungal;CYP inhibitor targeting CYP2D6, CYP3A5, CYP24A1, CYP21A2 |
| AB-39-ED84_0.1uM | Dose=0.1uM, (+)-Ketoconazole, Antifungal;CYP inhibitor targeting CYP2D6, CYP3A5, CYP24A1, CYP21A2 |
| AB-39-ED84_10uM | Dose=10uM, (+)-Ketoconazole, Antifungal;CYP inhibitor targeting CYP2D6, CYP3A5, CYP24A1, CYP21A2 |
| AB-40-HA80_0.01uM | Dose=0.01uM, Metoclopramide, Dopamine Receptor Antagonists targeting DRD2 |
| AB-40-HA80_0.1uM | Dose=0.1uM, Metoclopramide, Dopamine Receptor Antagonists targeting DRD2 |
| AB-40-HA80_10uM | Dose=10uM, Metoclopramide, Dopamine Receptor Antagonists targeting DRD2 |
| AB-40-HA80_1uM | Dose=1uM, Metoclopramide, Dopamine Receptor Antagonists targeting DRD2 |
| AB-41-IO16_0.01uM | Dose=0.01uM |
| AB-41-IO16_0.1uM | Dose=0.1uM |
| AB-41-IO16_10uM | Dose=10uM |
| AB-41-IO16_1uM | Dose=1uM |
| AB-41-VZ28_0.01uM | Dose=0.01uM, Neostigmine, Acetylcholinesterase Inhibitors targeting ACHE |
| AB-41-VZ28_0.1uM | Dose=0.1uM, Neostigmine, Acetylcholinesterase Inhibitors targeting ACHE |
| AB-41-VZ28_10uM | Dose=10uM, Neostigmine, Acetylcholinesterase Inhibitors targeting ACHE |
| AB-42-AI99_0.01uM | Dose=0.01uM, NS 1619, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1 |
| AB-42-AI99_0.1uM | Dose=0.1uM, NS 1619, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1 |
| AB-42-AI99_1uM | Dose=1uM, NS 1619, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1 |
| AB-43-XJ34_0.01uM | Dose=0.01uM, (S)-3-(6,8-Dimethylimidazo[1,2-a]pyrazin-2-yl)-7-(3-methylpiperazin-1-yl)-2H-chromen-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AB-43-XJ34_0.1uM | Dose=0.1uM, (S)-3-(6,8-Dimethylimidazo[1,2-a]pyrazin-2-yl)-7-(3-methylpiperazin-1-yl)-2H-chromen-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AB-43-XJ34_10uM | Dose=10uM, (S)-3-(6,8-Dimethylimidazo[1,2-a]pyrazin-2-yl)-7-(3-methylpiperazin-1-yl)-2H-chromen-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AB-43-XJ34_1uM | Dose=1uM, (S)-3-(6,8-Dimethylimidazo[1,2-a]pyrazin-2-yl)-7-(3-methylpiperazin-1-yl)-2H-chromen-2-one, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| AB-44-GQ28_0.01uM | Dose=0.01uM, Vesnarinone, Apoptosis Inducers;Transitional Endoplasmic Reticulum ATPase (VCP, p97) Inhibitors;CDKN1A Expression Enhancers targeting CDKN1A, VCP, PDE3A |
| AB-44-GQ28_0.1uM | Dose=0.1uM, Vesnarinone, Apoptosis Inducers;Transitional Endoplasmic Reticulum ATPase (VCP, p97) Inhibitors;CDKN1A Expression Enhancers targeting CDKN1A, VCP, PDE3A |
| AB-44-GQ28_10uM | Dose=10uM, Vesnarinone, Apoptosis Inducers;Transitional Endoplasmic Reticulum ATPase (VCP, p97) Inhibitors;CDKN1A Expression Enhancers targeting CDKN1A, VCP, PDE3A |
| AB-44-GQ28_1uM | Dose=1uM, Vesnarinone, Apoptosis Inducers;Transitional Endoplasmic Reticulum ATPase (VCP, p97) Inhibitors;CDKN1A Expression Enhancers targeting CDKN1A, VCP, PDE3A |
| AB-46-GB72_0.01uM | Dose=0.01uM, HIV-1 inhibitor-46, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B |
| AB-46-GB72_0.1uM | Dose=0.1uM, HIV-1 inhibitor-46, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B |
| AB-46-GB72_10uM | Dose=10uM, HIV-1 inhibitor-46, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B |
| AB-46-GB72_1uM | Dose=1uM, HIV-1 inhibitor-46, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B |
| AB-47-BS00_0.01uM | Dose=0.01uM, Hydroxyurea, Ribonucleoside-Diphosphate Reductase Inhibitors;Antimetabolites;Nitric oxide donor targeting RRM1 |
| AB-47-BS00_10uM | Dose=10uM, Hydroxyurea, Ribonucleoside-Diphosphate Reductase Inhibitors;Antimetabolites;Nitric oxide donor targeting RRM1 |
| AB-47-BS00_1uM | Dose=1uM, Hydroxyurea, Ribonucleoside-Diphosphate Reductase Inhibitors;Antimetabolites;Nitric oxide donor targeting RRM1 |
| AB-50-OH27_0.01uM | Dose=0.01uM, methyl 2-[(1R,2S,4S,7E,10R,12R,13R,14E,16R)-2,12-dihydroxy-4-[(2S,3R,4E,6E,8E)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-1,13-dimethyl-6-oxo-5,17-dioxabicyclo[14.1.0]heptadeca-7,14-dien-10-yl]acetate, tubulin antagonist targeting TUBB |
| AB-50-OH27_0.1uM | Dose=0.1uM, methyl 2-[(1R,2S,4S,7E,10R,12R,13R,14E,16R)-2,12-dihydroxy-4-[(2S,3R,4E,6E,8E)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-1,13-dimethyl-6-oxo-5,17-dioxabicyclo[14.1.0]heptadeca-7,14-dien-10-yl]acetate, tubulin antagonist targeting TUBB |
| AB-50-OH27_1uM | Dose=1uM, methyl 2-[(1R,2S,4S,7E,10R,12R,13R,14E,16R)-2,12-dihydroxy-4-[(2S,3R,4E,6E,8E)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-1,13-dimethyl-6-oxo-5,17-dioxabicyclo[14.1.0]heptadeca-7,14-dien-10-yl]acetate, tubulin antagonist targeting TUBB |
| AB-51-WV08_0.01uM | Dose=0.01uM, GW9508, Free Fatty Acid Receptor 1 (FFAR1;FFAR1 agonist;GPR40) Agonists targeting FFAR1 |
| AB-51-WV08_0.1uM | Dose=0.1uM, GW9508, Free Fatty Acid Receptor 1 (FFAR1;FFAR1 agonist;GPR40) Agonists targeting FFAR1 |
| AB-51-WV08_10uM | Dose=10uM, GW9508, Free Fatty Acid Receptor 1 (FFAR1;FFAR1 agonist;GPR40) Agonists targeting FFAR1 |
| AB-51-WV08_1uM | Dose=1uM, GW9508, Free Fatty Acid Receptor 1 (FFAR1;FFAR1 agonist;GPR40) Agonists targeting FFAR1 |
| AB-53-AW00_0.01uM | Dose=0.01uM, Deferasirox |
| AB-53-AW00_0.1uM | Dose=0.1uM, Deferasirox |
| AB-53-AW00_10uM | Dose=10uM, Deferasirox |
| AB-53-AW00_1uM | Dose=1uM, Deferasirox |
| AB-55-DE17_10uM | Dose=10uM, (R)-6-((3-Chloro-5-cyanopyridin-2-yl)amino)-4-(cyclopropylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide, interleukin 1 receptor associated kinase 4 targeting IRAK4 |
| AB-55-DE17_1uM | Dose=1uM, (R)-6-((3-Chloro-5-cyanopyridin-2-yl)amino)-4-(cyclopropylamino)-N-(2-fluoro-3-hydroxy-3-methylbutyl)nicotinamide, interleukin 1 receptor associated kinase 4 targeting IRAK4 |
| AB-55-HO71_0.01uM | Dose=0.01uM, Pirfenidone, TGFb pathway inhibitor;antifibrotic;TNF alpha synthesis inhibitor targeting TNF |
| AB-55-HO71_0.1uM | Dose=0.1uM, Pirfenidone, TGFb pathway inhibitor;antifibrotic;TNF alpha synthesis inhibitor targeting TNF |
| AB-55-HO71_1uM | Dose=1uM, Pirfenidone, TGFb pathway inhibitor;antifibrotic;TNF alpha synthesis inhibitor targeting TNF |
| AB-57-IZ37_0.01uM | Dose=0.01uM |
| AB-57-IZ37_0.1uM | Dose=0.1uM |
| AB-57-IZ37_10uM | Dose=10uM |
| AB-57-IZ37_1uM | Dose=1uM |
| AB-61-FY15_0.01uM | Dose=0.01uM |
| AB-61-FY15_0.1uM | Dose=0.1uM |
| AB-61-FY15_10uM | Dose=10uM |
| AB-61-FY15_1uM | Dose=1uM |
| AB-61-VZ28_0.01uM | Dose=0.01uM, Phenylephrine, alpha1-Adrenoceptor Agonists;alpha1A-Adrenoceptor Ligands targeting ADRA1A |
| AB-61-VZ28_0.1uM | Dose=0.1uM, Phenylephrine, alpha1-Adrenoceptor Agonists;alpha1A-Adrenoceptor Ligands targeting ADRA1A |
| AB-61-VZ28_1uM | Dose=1uM, Phenylephrine, alpha1-Adrenoceptor Agonists;alpha1A-Adrenoceptor Ligands targeting ADRA1A |
| AB-62-TF27_0.01uM | Dose=0.01uM, (2S,4R)-N-[[2-(aminomethyl)-5-chlorophenyl]methyl]-4-[(4-chlorophenyl)methoxy]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]pyrrolidine-2-carboxamide |
| AB-62-TF27_0.1uM | Dose=0.1uM, (2S,4R)-N-[[2-(aminomethyl)-5-chlorophenyl]methyl]-4-[(4-chlorophenyl)methoxy]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]pyrrolidine-2-carboxamide |
| AB-62-TF27_1uM | Dose=1uM, (2S,4R)-N-[[2-(aminomethyl)-5-chlorophenyl]methyl]-4-[(4-chlorophenyl)methoxy]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]pyrrolidine-2-carboxamide |
| AB-63-HD20_0.01uM | Dose=0.01uM, Milrinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3 |
| AB-63-HD20_0.1uM | Dose=0.1uM, Milrinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3 |
| AB-63-HD20_10uM | Dose=10uM, Milrinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3 |
| AB-63-HD20_1uM | Dose=1uM, Milrinone, Phosphodiesterase III Inhibitors targeting PDE3A, PDE3B, ENPP3 |
| AB-63-OW35_0.1uM | Dose=0.1uM, Ketanserin, 5-HT2 Antagonists targeting HTR2A |
| AB-63-OW35_10uM | Dose=10uM, Ketanserin, 5-HT2 Antagonists targeting HTR2A |
| AB-63-OW35_1uM | Dose=1uM, Ketanserin, 5-HT2 Antagonists targeting HTR2A |
| AB-63-UJ99_0.01uM | Dose=0.01uM, Jak1 tyrosine kinase inhibitor;Jak3 tyrosine kinase inhibitor |
| AB-63-UJ99_0.1uM | Dose=0.1uM, Jak1 tyrosine kinase inhibitor;Jak3 tyrosine kinase inhibitor |
| AB-63-UJ99_10uM | Dose=10uM, Jak1 tyrosine kinase inhibitor;Jak3 tyrosine kinase inhibitor |
| AB-63-UJ99_1uM | Dose=1uM, Jak1 tyrosine kinase inhibitor;Jak3 tyrosine kinase inhibitor |
| AB-63-UX23_0.01uM | Dose=0.01uM, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine |
| AB-63-UX23_0.1uM | Dose=0.1uM, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine |
| AB-63-UX23_10uM | Dose=10uM, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine |
| AB-63-UX23_1uM | Dose=1uM, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine |
| AB-64-HD87_0.01uM | Dose=0.01uM |
| AB-64-HD87_0.1uM | Dose=0.1uM |
| AB-64-HD87_10uM | Dose=10uM |
| AB-64-HD87_1uM | Dose=1uM |
| AB-64-NN66_0.01uM | Dose=0.01uM, [1-(2-Chloro-4-ethanesulfonyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid, CRTh2 antagonist targeting PTGDR2 |
| AB-64-NN66_0.1uM | Dose=0.1uM, [1-(2-Chloro-4-ethanesulfonyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid, CRTh2 antagonist targeting PTGDR2 |
| AB-64-NN66_1uM | Dose=1uM, [1-(2-Chloro-4-ethanesulfonyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid, CRTh2 antagonist targeting PTGDR2 |
| AB-64-ZX70_0.01uM | Dose=0.01uM, Quinacrine, Secretory Phospholipase A2 (sPLA2) Inhibitors;Cytokine Production Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;TP53 Expression Enhancers targeting PLA2G2A, PRNP, TP53, PLA2G2D |
| AB-64-ZX70_0.1uM | Dose=0.1uM, Quinacrine, Secretory Phospholipase A2 (sPLA2) Inhibitors;Cytokine Production Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;TP53 Expression Enhancers targeting PLA2G2A, PRNP, TP53, PLA2G2D |
| AB-64-ZX70_10uM | Dose=10uM, Quinacrine, Secretory Phospholipase A2 (sPLA2) Inhibitors;Cytokine Production Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;TP53 Expression Enhancers targeting PLA2G2A, PRNP, TP53, PLA2G2D |
| AB-64-ZX70_1uM | Dose=1uM, Quinacrine, Secretory Phospholipase A2 (sPLA2) Inhibitors;Cytokine Production Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;TP53 Expression Enhancers targeting PLA2G2A, PRNP, TP53, PLA2G2D |
| AB-66-IL06_0.01uM | Dose=0.01uM, N-[2-[4-[[[2-[(Hydroxyamino)carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]ethyl]-2-benzofurancarboxamide, Angiogenesis Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP13 |
| AB-66-IL06_0.1uM | Dose=0.1uM, N-[2-[4-[[[2-[(Hydroxyamino)carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]ethyl]-2-benzofurancarboxamide, Angiogenesis Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP13 |
| AB-66-IL06_10uM | Dose=10uM, N-[2-[4-[[[2-[(Hydroxyamino)carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]ethyl]-2-benzofurancarboxamide, Angiogenesis Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP13 |
| AB-66-IL06_1uM | Dose=1uM, N-[2-[4-[[[2-[(Hydroxyamino)carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]ethyl]-2-benzofurancarboxamide, Angiogenesis Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP13 |
| AB-67-SF89_0.01uM | Dose=0.01uM |
| AB-67-SF89_0.1uM | Dose=0.1uM |
| AB-67-SF89_10uM | Dose=10uM |
| AB-67-SF89_1uM | Dose=1uM |
| AB-68-SC09_0.01uM | Dose=0.01uM, Bicifadine, Norepinephrine Transporter (NET) Inhibitors;NMDA Antagonists;Serotonin Transporter (SERT) Inhibitors targeting SLC6A2, SLC6A4 |
| AB-68-SC09_0.1uM | Dose=0.1uM, Bicifadine, Norepinephrine Transporter (NET) Inhibitors;NMDA Antagonists;Serotonin Transporter (SERT) Inhibitors targeting SLC6A2, SLC6A4 |
| AB-68-SC09_10uM | Dose=10uM, Bicifadine, Norepinephrine Transporter (NET) Inhibitors;NMDA Antagonists;Serotonin Transporter (SERT) Inhibitors targeting SLC6A2, SLC6A4 |
| AB-68-SC09_1uM | Dose=1uM, Bicifadine, Norepinephrine Transporter (NET) Inhibitors;NMDA Antagonists;Serotonin Transporter (SERT) Inhibitors targeting SLC6A2, SLC6A4 |
| AB-70-GR31_0.01uM | Dose=0.01uM, Alitretinoin, ABCA1 Expression Enhancers;Retinoid RAR Agonists;Retinoid RXR Agonists targeting ABCA1, RARA, RXRA |
| AB-70-GR31_0.1uM | Dose=0.1uM, Alitretinoin, ABCA1 Expression Enhancers;Retinoid RAR Agonists;Retinoid RXR Agonists targeting ABCA1, RARA, RXRA |
| AB-70-GR31_10uM | Dose=10uM, Alitretinoin, ABCA1 Expression Enhancers;Retinoid RAR Agonists;Retinoid RXR Agonists targeting ABCA1, RARA, RXRA |
| AB-70-GR31_1uM | Dose=1uM, Alitretinoin, ABCA1 Expression Enhancers;Retinoid RAR Agonists;Retinoid RXR Agonists targeting ABCA1, RARA, RXRA |
| AB-71-CI37_0.01uM | Dose=0.01uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| AB-71-CI37_0.1uM | Dose=0.1uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| AB-71-CI37_10uM | Dose=10uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| AB-71-CI37_1uM | Dose=1uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| AB-71-NB55_0.01uM | Dose=0.01uM, 4-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-oxazol-2-yl]-1-methyl-piperidin-4-ol, TNF-alpha Release Inhibitors;p38 MAPK Inhibitors targeting MAPK14 |
| AB-71-NB55_0.1uM | Dose=0.1uM, 4-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-oxazol-2-yl]-1-methyl-piperidin-4-ol, TNF-alpha Release Inhibitors;p38 MAPK Inhibitors targeting MAPK14 |
| AB-71-NB55_10uM | Dose=10uM, 4-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-oxazol-2-yl]-1-methyl-piperidin-4-ol, TNF-alpha Release Inhibitors;p38 MAPK Inhibitors targeting MAPK14 |
| AB-71-NB55_1uM | Dose=1uM, 4-[4-(4-Fluoro-phenyl)-5-pyridin-4-yl-oxazol-2-yl]-1-methyl-piperidin-4-ol, TNF-alpha Release Inhibitors;p38 MAPK Inhibitors targeting MAPK14 |
| AB-71-UV73_0.01uM | Dose=0.01uM, (3S)-3-amino-4-[5-[4-(4-chlorophenoxy)phenyl]tetrazol-2-yl]butanoic acid, inhibitor of leukotriene A4 hydrolase targeting LTA4H |
| AB-71-UV73_0.1uM | Dose=0.1uM, (3S)-3-amino-4-[5-[4-(4-chlorophenoxy)phenyl]tetrazol-2-yl]butanoic acid, inhibitor of leukotriene A4 hydrolase targeting LTA4H |
| AB-71-UV73_1uM | Dose=1uM, (3S)-3-amino-4-[5-[4-(4-chlorophenoxy)phenyl]tetrazol-2-yl]butanoic acid, inhibitor of leukotriene A4 hydrolase targeting LTA4H |
| AB-71-VZ28_0.01uM | Dose=0.01uM, Albuterol, beta2-Adrenoceptor Agonists targeting ADRB2 |
| AB-71-VZ28_0.1uM | Dose=0.1uM, Albuterol, beta2-Adrenoceptor Agonists targeting ADRB2 |
| AB-71-VZ28_10uM | Dose=10uM, Albuterol, beta2-Adrenoceptor Agonists targeting ADRB2 |
| AB-71-VZ28_1uM | Dose=1uM, Albuterol, beta2-Adrenoceptor Agonists targeting ADRB2 |
| AB-72-EP76_0.01uM | Dose=0.01uM, Prinaberel, Estrogen Receptor (ER) beta Agonists targeting ESR2 |
| AB-72-EP76_0.1uM | Dose=0.1uM, Prinaberel, Estrogen Receptor (ER) beta Agonists targeting ESR2 |
| AB-72-EP76_10uM | Dose=10uM, Prinaberel, Estrogen Receptor (ER) beta Agonists targeting ESR2 |
| AB-72-EP76_1uM | Dose=1uM, Prinaberel, Estrogen Receptor (ER) beta Agonists targeting ESR2 |
| AB-73-SW45_0.01uM | Dose=0.01uM, Citalopram, 5-HT Reuptake Inhibitors targeting SLC6A4 |
| AB-73-SW45_0.1uM | Dose=0.1uM, Citalopram, 5-HT Reuptake Inhibitors targeting SLC6A4 |
| AB-73-SW45_10uM | Dose=10uM, Citalopram, 5-HT Reuptake Inhibitors targeting SLC6A4 |
| AB-73-ZX03_0.01uM | Dose=0.01uM, N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-3-carboxamide, mgluR5 Antagonists targeting GRM5 |
| AB-73-ZX03_0.1uM | Dose=0.1uM, N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-3-carboxamide, mgluR5 Antagonists targeting GRM5 |
| AB-73-ZX03_10uM | Dose=10uM, N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-3-carboxamide, mgluR5 Antagonists targeting GRM5 |
| AB-73-ZX03_1uM | Dose=1uM, N-[(1R,3R)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]pyridine-3-carboxamide, mgluR5 Antagonists targeting GRM5 |
| AB-74-VK99_0.01uM | Dose=0.01uM, Mycophenolate Mofetil, HM74A) Receptor Agonists;GPR109A;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Nicotinic Acid (Niacin targeting IMPDH1, IMPDH2 |
| AB-74-VK99_0.1uM | Dose=0.1uM, Mycophenolate Mofetil, HM74A) Receptor Agonists;GPR109A;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Nicotinic Acid (Niacin targeting IMPDH1, IMPDH2 |
| AB-74-VK99_10uM | Dose=10uM, Mycophenolate Mofetil, HM74A) Receptor Agonists;GPR109A;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Nicotinic Acid (Niacin targeting IMPDH1, IMPDH2 |
| AB-74-VK99_1uM | Dose=1uM, Mycophenolate Mofetil, HM74A) Receptor Agonists;GPR109A;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Nicotinic Acid (Niacin targeting IMPDH1, IMPDH2 |
| AB-78-RM53_0.01uM | Dose=0.01uM, Nifedipine, Calcium Channel Blockers;Antioxidants targeting CACNA1C, CACNA1D, CACNA1S, CACNA1H, CACNA1E, CACNA1A, CACNB1, CACNB4, CACNG1 |
| AB-78-RM53_0.1uM | Dose=0.1uM, Nifedipine, Calcium Channel Blockers;Antioxidants targeting CACNA1C, CACNA1D, CACNA1S, CACNA1H, CACNA1E, CACNA1A, CACNB1, CACNB4, CACNG1 |
| AB-78-RM53_10uM | Dose=10uM, Nifedipine, Calcium Channel Blockers;Antioxidants targeting CACNA1C, CACNA1D, CACNA1S, CACNA1H, CACNA1E, CACNA1A, CACNB1, CACNB4, CACNG1 |
| AB-78-RM53_1uM | Dose=1uM, Nifedipine, Calcium Channel Blockers;Antioxidants targeting CACNA1C, CACNA1D, CACNA1S, CACNA1H, CACNA1E, CACNA1A, CACNB1, CACNB4, CACNG1 |
| AB-79-ZD24_0.01uM | Dose=0.01uM, Dopamine D4 receptor antagonist-1, DRD4 antagonist targeting DRD4 |
| AB-79-ZD24_0.1uM | Dose=0.1uM, Dopamine D4 receptor antagonist-1, DRD4 antagonist targeting DRD4 |
| AB-79-ZD24_10uM | Dose=10uM, Dopamine D4 receptor antagonist-1, DRD4 antagonist targeting DRD4 |
| AB-80-CK34_0.01uM | Dose=0.01uM, 1H-Pyrrole-2,5-dione, 3,4-bis(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4 |
| AB-80-CK34_0.1uM | Dose=0.1uM, 1H-Pyrrole-2,5-dione, 3,4-bis(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4 |
| AB-80-CK34_10uM | Dose=10uM, 1H-Pyrrole-2,5-dione, 3,4-bis(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4 |
| AB-80-CK34_1uM | Dose=1uM, 1H-Pyrrole-2,5-dione, 3,4-bis(1-methyl-1H-indol-3-yl)-, Protein Kinase C (PKC) Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CCNE1, CDK2, CDK4 |
| AB-82-EP26_0.01uM | Dose=0.01uM, 4-[1-[2-(Cyclopentylamino)pyrimidin-4-yl]-2-[3-(trifluoromethyl)phenyl]imidazol-4-yl]-1-methylpiperidin-4-ol, p38alpha MAPK Inhibitors targeting MAPK14 |
| AB-82-EP26_0.1uM | Dose=0.1uM, 4-[1-[2-(Cyclopentylamino)pyrimidin-4-yl]-2-[3-(trifluoromethyl)phenyl]imidazol-4-yl]-1-methylpiperidin-4-ol, p38alpha MAPK Inhibitors targeting MAPK14 |
| AB-82-EP26_10uM | Dose=10uM, 4-[1-[2-(Cyclopentylamino)pyrimidin-4-yl]-2-[3-(trifluoromethyl)phenyl]imidazol-4-yl]-1-methylpiperidin-4-ol, p38alpha MAPK Inhibitors targeting MAPK14 |
| AB-82-EP26_1uM | Dose=1uM, 4-[1-[2-(Cyclopentylamino)pyrimidin-4-yl]-2-[3-(trifluoromethyl)phenyl]imidazol-4-yl]-1-methylpiperidin-4-ol, p38alpha MAPK Inhibitors targeting MAPK14 |
| AB-82-ES53_0.01uM | Dose=0.01uM, Quercetin targeting SULT1A1 |
| AB-82-ES53_0.1uM | Dose=0.1uM, Quercetin targeting SULT1A1 |
| AB-82-ES53_10uM | Dose=10uM, Quercetin targeting SULT1A1 |
| AB-82-ES53_1uM | Dose=1uM, Quercetin targeting SULT1A1 |
| AB-83-EW00_0.01uM | Dose=0.01uM, 1,3-Dipropyl-7-methylxanthine |
| AB-83-EW00_0.1uM | Dose=0.1uM, 1,3-Dipropyl-7-methylxanthine |
| AB-83-EW00_10uM | Dose=10uM, 1,3-Dipropyl-7-methylxanthine |
| AB-83-EW00_1uM | Dose=1uM, 1,3-Dipropyl-7-methylxanthine |
| AB-84-PK04_0.01uM | Dose=0.01uM, 8-(2,4-dimethylpyrimidin-5-yl)-N-[(2-fluoro-6-methoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED |
| AB-84-PK04_0.1uM | Dose=0.1uM, 8-(2,4-dimethylpyrimidin-5-yl)-N-[(2-fluoro-6-methoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED |
| AB-84-PK04_10uM | Dose=10uM, 8-(2,4-dimethylpyrimidin-5-yl)-N-[(2-fluoro-6-methoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED |
| AB-84-PK04_1uM | Dose=1uM, 8-(2,4-dimethylpyrimidin-5-yl)-N-[(2-fluoro-6-methoxyphenyl)methyl]-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED |
| AB-85-JR73_0.01uM | Dose=0.01uM, 4-(3-Pyridin-2-yl)(1H)-pyrazol-4-yl quinoline, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5;p38 MAPK Inhibitors targeting TGFBR1, MAPK13 |
| AB-85-JR73_0.1uM | Dose=0.1uM, 4-(3-Pyridin-2-yl)(1H)-pyrazol-4-yl quinoline, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5;p38 MAPK Inhibitors targeting TGFBR1, MAPK13 |
| AB-85-JR73_10uM | Dose=10uM, 4-(3-Pyridin-2-yl)(1H)-pyrazol-4-yl quinoline, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5;p38 MAPK Inhibitors targeting TGFBR1, MAPK13 |
| AB-85-JR73_1uM | Dose=1uM, 4-(3-Pyridin-2-yl)(1H)-pyrazol-4-yl quinoline, TbetaR-I) Inhibitors;Inhibitors of Signal Transduction Pathways;Activin Receptor Like Kinase 5 (ALK5;p38 MAPK Inhibitors targeting TGFBR1, MAPK13 |
| AB-85-YK41_0.1uM | Dose=0.1uM, Racecadotril, Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting MME |
| AB-85-YK41_10uM | Dose=10uM, Racecadotril, Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting MME |
| AB-85-YK41_1uM | Dose=1uM, Racecadotril, Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting MME |
| AB-86-GB42_0.01uM | Dose=0.01uM, 3-(3-(2-(4-Fluorophenyl)pyridin-4-yl)imidazo[1,2-a]pyridin-7-yl)-N-methylbenzamide, ALK5 inhibitor targeting TGFBR1 |
| AB-86-GB42_10uM | Dose=10uM, 3-(3-(2-(4-Fluorophenyl)pyridin-4-yl)imidazo[1,2-a]pyridin-7-yl)-N-methylbenzamide, ALK5 inhibitor targeting TGFBR1 |
| AB-86-GB42_1uM | Dose=1uM, 3-(3-(2-(4-Fluorophenyl)pyridin-4-yl)imidazo[1,2-a]pyridin-7-yl)-N-methylbenzamide, ALK5 inhibitor targeting TGFBR1 |
| AB-86-XY72_0.01uM | Dose=0.01uM |
| AB-86-XY72_0.1uM | Dose=0.1uM |
| AB-86-XY72_10uM | Dose=10uM |
| AB-86-XY72_1uM | Dose=1uM |
| AB-87-II61_0.01uM | Dose=0.01uM, 2-(3,4-Dichlorobenzylidene)hydrazinecarboximidamide, Neuropeptide FF Receptor 2 (NPFF2) Agonists targeting NPFFR2 |
| AB-87-II61_0.1uM | Dose=0.1uM, 2-(3,4-Dichlorobenzylidene)hydrazinecarboximidamide, Neuropeptide FF Receptor 2 (NPFF2) Agonists targeting NPFFR2 |
| AB-87-II61_10uM | Dose=10uM, 2-(3,4-Dichlorobenzylidene)hydrazinecarboximidamide, Neuropeptide FF Receptor 2 (NPFF2) Agonists targeting NPFFR2 |
| AB-87-II61_1uM | Dose=1uM, 2-(3,4-Dichlorobenzylidene)hydrazinecarboximidamide, Neuropeptide FF Receptor 2 (NPFF2) Agonists targeting NPFFR2 |
| AB-87-KC82_0.01uM | Dose=0.01uM, 4-(4-Methylphenoxy)-2-phenylthieno[3,2-d]pyrimidine, Prostanoid EP4 Agonists targeting PTGER4 |
| AB-87-KC82_0.1uM | Dose=0.1uM, 4-(4-Methylphenoxy)-2-phenylthieno[3,2-d]pyrimidine, Prostanoid EP4 Agonists targeting PTGER4 |
| AB-87-KC82_10uM | Dose=10uM, 4-(4-Methylphenoxy)-2-phenylthieno[3,2-d]pyrimidine, Prostanoid EP4 Agonists targeting PTGER4 |
| AB-87-LJ34_0.01uM | Dose=0.01uM, (Z)-3-(5-((5-(4-nitrophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)propanoic acid targeting KRAS, AXIN1 |
| AB-87-LJ34_0.1uM | Dose=0.1uM, (Z)-3-(5-((5-(4-nitrophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)propanoic acid targeting KRAS, AXIN1 |
| AB-87-LJ34_10uM | Dose=10uM, (Z)-3-(5-((5-(4-nitrophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)propanoic acid targeting KRAS, AXIN1 |
| AB-87-LJ34_1uM | Dose=1uM, (Z)-3-(5-((5-(4-nitrophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)propanoic acid targeting KRAS, AXIN1 |
| AB-90-NH82_0.01uM | Dose=0.01uM, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1;Gardos channel, SK41, IK1) Channel Activators;Small Conductance SK(Ca) 2.1 (SK1, SKCa1) Channel Activators;Small Conductance SK(Ca) 2.2 (SK2, SKCa2) Channel Activators targeting KCNN1, KCNN2, KCNN3 |
| AB-90-NH82_0.1uM | Dose=0.1uM, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1;Gardos channel, SK41, IK1) Channel Activators;Small Conductance SK(Ca) 2.1 (SK1, SKCa1) Channel Activators;Small Conductance SK(Ca) 2.2 (SK2, SKCa2) Channel Activators targeting KCNN1, KCNN2, KCNN3 |
| AB-90-NH82_10uM | Dose=10uM, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1;Gardos channel, SK41, IK1) Channel Activators;Small Conductance SK(Ca) 2.1 (SK1, SKCa1) Channel Activators;Small Conductance SK(Ca) 2.2 (SK2, SKCa2) Channel Activators targeting KCNN1, KCNN2, KCNN3 |
| AB-90-YR46_0.01uM | Dose=0.01uM, Prazosin, ADRA1B antagonist;Apoptosis Inducers;CDK1 Inhibitors targeting ADRA1B, CDK1 |
| AB-90-YR46_0.1uM | Dose=0.1uM, Prazosin, ADRA1B antagonist;Apoptosis Inducers;CDK1 Inhibitors targeting ADRA1B, CDK1 |
| AB-90-YR46_10uM | Dose=10uM, Prazosin, ADRA1B antagonist;Apoptosis Inducers;CDK1 Inhibitors targeting ADRA1B, CDK1 |
| AB-90-YR46_1uM | Dose=1uM, Prazosin, ADRA1B antagonist;Apoptosis Inducers;CDK1 Inhibitors targeting ADRA1B, CDK1 |
| AB-92-GP61_0.01uM | Dose=0.01uM, JTE-607 free base |
| AB-92-GP61_0.1uM | Dose=0.1uM, JTE-607 free base |
| AB-92-GP61_10uM | Dose=10uM, JTE-607 free base |
| AB-92-GP61_1uM | Dose=1uM, JTE-607 free base |
| AB-92-LS83_0.01uM | Dose=0.01uM, Flurbiprofen targeting SC5D |
| AB-92-LS83_0.1uM | Dose=0.1uM, Flurbiprofen targeting SC5D |
| AB-92-LS83_10uM | Dose=10uM, Flurbiprofen targeting SC5D |
| AB-92-LS83_1uM | Dose=1uM, Flurbiprofen targeting SC5D |
| AB-95-LH34_0.01uM | Dose=0.01uM, Benzamide, N-[3-[6-amino-5-[[1-(1-oxo-2-propen-1-yl)-3-azetidinyl]oxy]-4-pyrimidinyl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluoro-, irreversible, covalent inhibitor of BTK;Btk tyrosine kinase inhibitor targeting BTK |
| AB-95-LH34_0.1uM | Dose=0.1uM, Benzamide, N-[3-[6-amino-5-[[1-(1-oxo-2-propen-1-yl)-3-azetidinyl]oxy]-4-pyrimidinyl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluoro-, irreversible, covalent inhibitor of BTK;Btk tyrosine kinase inhibitor targeting BTK |
| AB-95-LH34_10uM | Dose=10uM, Benzamide, N-[3-[6-amino-5-[[1-(1-oxo-2-propen-1-yl)-3-azetidinyl]oxy]-4-pyrimidinyl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluoro-, irreversible, covalent inhibitor of BTK;Btk tyrosine kinase inhibitor targeting BTK |
| AB-96-JV50_0.01uM | Dose=0.01uM, Zafirlukast, Leukotriene CysLT1 (LTD4) Antagonists targeting CYSLTR1, CYSLTR2 |
| AB-96-JV50_0.1uM | Dose=0.1uM, Zafirlukast, Leukotriene CysLT1 (LTD4) Antagonists targeting CYSLTR1, CYSLTR2 |
| AB-96-JV50_10uM | Dose=10uM, Zafirlukast, Leukotriene CysLT1 (LTD4) Antagonists targeting CYSLTR1, CYSLTR2 |
| AB-96-JV50_1uM | Dose=1uM, Zafirlukast, Leukotriene CysLT1 (LTD4) Antagonists targeting CYSLTR1, CYSLTR2 |
| AB-96-XV75_0.01uM | Dose=0.01uM, Dapsone |
| AB-96-XV75_0.1uM | Dose=0.1uM, Dapsone |
| AB-96-XV75_10uM | Dose=10uM, Dapsone |
| AB-96-XV75_1uM | Dose=1uM, Dapsone |
| AB-97-BI36_0.01uM | Dose=0.01uM, N-[4-(dimethylamino)phenyl]-N'-hydroxyoctanediamide |
| AB-97-BI36_0.1uM | Dose=0.1uM, N-[4-(dimethylamino)phenyl]-N'-hydroxyoctanediamide |
| AB-97-BI36_10uM | Dose=10uM, N-[4-(dimethylamino)phenyl]-N'-hydroxyoctanediamide |
| AB-97-BI36_1uM | Dose=1uM, N-[4-(dimethylamino)phenyl]-N'-hydroxyoctanediamide |
| AB-98-HT45_0.01uM | Dose=0.01uM, Capsaicin, Vanilloid receptor agonist targeting TRPV1 |
| AB-98-HT45_0.1uM | Dose=0.1uM, Capsaicin, Vanilloid receptor agonist targeting TRPV1 |
| AB-98-HT45_1uM | Dose=1uM, Capsaicin, Vanilloid receptor agonist targeting TRPV1 |
| AB-99-PR28_0.1uM | Dose=0.1uM, Ribavirin, Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Hepatitis C virus inhibitor targeting IMPDH1 |
| AB-99-PR28_10uM | Dose=10uM, Ribavirin, Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Hepatitis C virus inhibitor targeting IMPDH1 |
| AB-99-PR28_1uM | Dose=1uM, Ribavirin, Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Hepatitis C virus inhibitor targeting IMPDH1 |
| AC-00-BR21_0.01uM | Dose=0.01uM |
| AC-00-BR21_0.1uM | Dose=0.1uM |
| AC-00-BR21_10uM | Dose=10uM |
| AC-00-BR21_1uM | Dose=1uM |
| AC-00-KV26_0.01uM | Dose=0.01uM, N,N,N-trimethylglycinium |
| AC-00-KV26_0.1uM | Dose=0.1uM, N,N,N-trimethylglycinium |
| AC-00-KV26_10uM | Dose=10uM, N,N,N-trimethylglycinium |
| AC-00-KV26_1uM | Dose=1uM, N,N,N-trimethylglycinium |
| AC-02-SI74_0.01uM | Dose=0.01uM, N-(3,5-dichlorophenyl)guanidine, 5-HT3 Receptor agonist ligands targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AC-02-SI74_0.1uM | Dose=0.1uM, N-(3,5-dichlorophenyl)guanidine, 5-HT3 Receptor agonist ligands targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AC-02-SI74_10uM | Dose=10uM, N-(3,5-dichlorophenyl)guanidine, 5-HT3 Receptor agonist ligands targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AC-02-SI74_1uM | Dose=1uM, N-(3,5-dichlorophenyl)guanidine, 5-HT3 Receptor agonist ligands targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AC-05-MR83_0.01uM | Dose=0.01uM, (4-Amino-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thiazol-5-yl)(2,6-difluorophenyl)methanone, CDK4 Inhibitors targeting CCND3, CDK4, CCNA1, CCNB2, CCNB3 |
| AC-05-MR83_0.1uM | Dose=0.1uM, (4-Amino-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thiazol-5-yl)(2,6-difluorophenyl)methanone, CDK4 Inhibitors targeting CCND3, CDK4, CCNA1, CCNB2, CCNB3 |
| AC-05-MR83_10uM | Dose=10uM, (4-Amino-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thiazol-5-yl)(2,6-difluorophenyl)methanone, CDK4 Inhibitors targeting CCND3, CDK4, CCNA1, CCNB2, CCNB3 |
| AC-05-MR83_1uM | Dose=1uM, (4-Amino-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thiazol-5-yl)(2,6-difluorophenyl)methanone, CDK4 Inhibitors targeting CCND3, CDK4, CCNA1, CCNB2, CCNB3 |
| AC-06-FB12_0.01uM | Dose=0.01uM, 2,2,2-Trifluoro-N-(4-(2-methoxyphenoxy)phenyl)-N-(pyridin-3-ylmethyl)ethanesulfonamide, mgluR2 Agonists targeting GRM2 |
| AC-06-FB12_10uM | Dose=10uM, 2,2,2-Trifluoro-N-(4-(2-methoxyphenoxy)phenyl)-N-(pyridin-3-ylmethyl)ethanesulfonamide, mgluR2 Agonists targeting GRM2 |
| AC-06-FB12_1uM | Dose=1uM, 2,2,2-Trifluoro-N-(4-(2-methoxyphenoxy)phenyl)-N-(pyridin-3-ylmethyl)ethanesulfonamide, mgluR2 Agonists targeting GRM2 |
| AC-06-PO03_0.1uM | Dose=0.1uM, Erythromycin, NF-kappaB (NFKB) Activation Inhibitors;Motilin Receptor Agonists targeting MLNR |
| AC-06-PO03_10uM | Dose=10uM, Erythromycin, NF-kappaB (NFKB) Activation Inhibitors;Motilin Receptor Agonists targeting MLNR |
| AC-06-PO03_1uM | Dose=1uM, Erythromycin, NF-kappaB (NFKB) Activation Inhibitors;Motilin Receptor Agonists targeting MLNR |
| AC-09-DD24_1uM | Dose=1uM, 2-[2-(2-Bromo-4-methylphenoxy)ethylsulfanyl]pyrimidine, PRKA gene stimulator;AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1, PRKAB2 |
| AC-10-JK64_0.01uM | Dose=0.01uM |
| AC-10-JK64_0.1uM | Dose=0.1uM |
| AC-10-JK64_10uM | Dose=10uM |
| AC-10-JK64_1uM | Dose=1uM |
| AC-10-PK69_0.01uM | Dose=0.01uM, Etoricoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| AC-10-PK69_0.1uM | Dose=0.1uM, Etoricoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| AC-10-PK69_10uM | Dose=10uM, Etoricoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| AC-10-PK69_1uM | Dose=1uM, Etoricoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| AC-11-BO01_0.01uM | Dose=0.01uM, N-Phthalyl-L-tryptophan, DNMT direct inhibitor targeting DNMT1 |
| AC-11-BO01_0.1uM | Dose=0.1uM, N-Phthalyl-L-tryptophan, DNMT direct inhibitor targeting DNMT1 |
| AC-11-BO01_10uM | Dose=10uM, N-Phthalyl-L-tryptophan, DNMT direct inhibitor targeting DNMT1 |
| AC-11-BO01_1uM | Dose=1uM, N-Phthalyl-L-tryptophan, DNMT direct inhibitor targeting DNMT1 |
| AC-11-SE07_0.01uM | Dose=0.01uM, Asimadoline, kappa-Opioid Agonists targeting OPRK1 |
| AC-11-SE07_10uM | Dose=10uM, Asimadoline, kappa-Opioid Agonists targeting OPRK1 |
| AC-11-SE07_1uM | Dose=1uM, Asimadoline, kappa-Opioid Agonists targeting OPRK1 |
| AC-12-PZ00_0.01uM | Dose=0.01uM |
| AC-12-PZ00_0.1uM | Dose=0.1uM |
| AC-12-PZ00_1uM | Dose=1uM |
| AC-14-FX35_0.01uM | Dose=0.01uM, N-Ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)acetamide, Orexin OX-2 Antagonists targeting HCRTR2 |
| AC-14-FX35_0.1uM | Dose=0.1uM, N-Ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)acetamide, Orexin OX-2 Antagonists targeting HCRTR2 |
| AC-14-FX35_10uM | Dose=10uM, N-Ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)acetamide, Orexin OX-2 Antagonists targeting HCRTR2 |
| AC-14-FX35_1uM | Dose=1uM, N-Ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)acetamide, Orexin OX-2 Antagonists targeting HCRTR2 |
| AC-14-JQ68_0.01uM | Dose=0.01uM, 7-(4-Carbamimidoyl-benzoylamino)-3-(3-methyl-butyrylamino)-heptanoic acid (GPI 562) |
| AC-14-JQ68_0.1uM | Dose=0.1uM, 7-(4-Carbamimidoyl-benzoylamino)-3-(3-methyl-butyrylamino)-heptanoic acid (GPI 562) |
| AC-14-JQ68_10uM | Dose=10uM, 7-(4-Carbamimidoyl-benzoylamino)-3-(3-methyl-butyrylamino)-heptanoic acid (GPI 562) |
| AC-14-JQ68_1uM | Dose=1uM, 7-(4-Carbamimidoyl-benzoylamino)-3-(3-methyl-butyrylamino)-heptanoic acid (GPI 562) |
| AC-17-PC87_0.01uM | Dose=0.01uM, Chk2 Inhibitor II targeting CHEK2 |
| AC-17-PC87_0.1uM | Dose=0.1uM, Chk2 Inhibitor II targeting CHEK2 |
| AC-17-PC87_10uM | Dose=10uM, Chk2 Inhibitor II targeting CHEK2 |
| AC-17-PC87_1uM | Dose=1uM, Chk2 Inhibitor II targeting CHEK2 |
| AC-17-PI61_0.01uM | Dose=0.01uM, Papaverine, Phosphodiesterase PDE10A Inhibitors targeting PDE4C, PDE10A, ENPP6 |
| AC-17-PI61_0.1uM | Dose=0.1uM, Papaverine, Phosphodiesterase PDE10A Inhibitors targeting PDE4C, PDE10A, ENPP6 |
| AC-17-PI61_10uM | Dose=10uM, Papaverine, Phosphodiesterase PDE10A Inhibitors targeting PDE4C, PDE10A, ENPP6 |
| AC-17-PI61_1uM | Dose=1uM, Papaverine, Phosphodiesterase PDE10A Inhibitors targeting PDE4C, PDE10A, ENPP6 |
| AC-18-DC84_0.01uM | Dose=0.01uM, 7-Nitroindazole |
| AC-18-DC84_0.1uM | Dose=0.1uM, 7-Nitroindazole |
| AC-18-DC84_10uM | Dose=10uM, 7-Nitroindazole |
| AC-18-DC84_1uM | Dose=1uM, 7-Nitroindazole |
| AC-19-TH24_0.1uM | Dose=0.1uM, Vigabatrin, GABA Aminotransferase Inhibitors targeting ABAT |
| AC-19-TH24_10uM | Dose=10uM, Vigabatrin, GABA Aminotransferase Inhibitors targeting ABAT |
| AC-19-TH24_1uM | Dose=1uM, Vigabatrin, GABA Aminotransferase Inhibitors targeting ABAT |
| AC-20-SO29_0.01uM | Dose=0.01uM, Fluvoxamine, 5-HT Reuptake Inhibitors targeting SLC6A4 |
| AC-20-SO29_0.1uM | Dose=0.1uM, Fluvoxamine, 5-HT Reuptake Inhibitors targeting SLC6A4 |
| AC-20-SO29_10uM | Dose=10uM, Fluvoxamine, 5-HT Reuptake Inhibitors targeting SLC6A4 |
| AC-20-SO29_1uM | Dose=1uM, Fluvoxamine, 5-HT Reuptake Inhibitors targeting SLC6A4 |
| AC-21-IE62_0.01uM | Dose=0.01uM, Mitoguazone, Polyamine Biosynthesis Inhibitors;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| AC-21-IE62_0.1uM | Dose=0.1uM, Mitoguazone, Polyamine Biosynthesis Inhibitors;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| AC-21-IE62_10uM | Dose=10uM, Mitoguazone, Polyamine Biosynthesis Inhibitors;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| AC-21-IE62_1uM | Dose=1uM, Mitoguazone, Polyamine Biosynthesis Inhibitors;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| AC-21-PO16_0.01uM | Dose=0.01uM, (6-Oxo-[1]benzofuro[3,2-c]chromen-9-yl) sulfamate |
| AC-21-PO16_0.1uM | Dose=0.1uM, (6-Oxo-[1]benzofuro[3,2-c]chromen-9-yl) sulfamate |
| AC-21-PO16_10uM | Dose=10uM, (6-Oxo-[1]benzofuro[3,2-c]chromen-9-yl) sulfamate |
| AC-21-PO16_1uM | Dose=1uM, (6-Oxo-[1]benzofuro[3,2-c]chromen-9-yl) sulfamate |
| AC-22-PZ30_0.01uM | Dose=0.01uM, Eed226, PRC2/EED targeting EED |
| AC-22-PZ30_0.1uM | Dose=0.1uM, Eed226, PRC2/EED targeting EED |
| AC-22-PZ30_10uM | Dose=10uM, Eed226, PRC2/EED targeting EED |
| AC-22-PZ30_1uM | Dose=1uM, Eed226, PRC2/EED targeting EED |
| AC-24-NX95_0.01uM | Dose=0.01uM, (S)-blebbistatin, MYH9 gene inhibitor;MYH10 gene inhibitor targeting MYH9, MYH10 |
| AC-24-NX95_0.1uM | Dose=0.1uM, (S)-blebbistatin, MYH9 gene inhibitor;MYH10 gene inhibitor targeting MYH9, MYH10 |
| AC-24-NX95_10uM | Dose=10uM, (S)-blebbistatin, MYH9 gene inhibitor;MYH10 gene inhibitor targeting MYH9, MYH10 |
| AC-24-NX95_1uM | Dose=1uM, (S)-blebbistatin, MYH9 gene inhibitor;MYH10 gene inhibitor targeting MYH9, MYH10 |
| AC-24-QG69_0.01uM | Dose=0.01uM, Myricetin, Cytochrome P450 CYP3A4 Inhibitors;Androgen Receptor Ligands;Antioxidants targeting AR, CYP3A4 |
| AC-24-QG69_0.1uM | Dose=0.1uM, Myricetin, Cytochrome P450 CYP3A4 Inhibitors;Androgen Receptor Ligands;Antioxidants targeting AR, CYP3A4 |
| AC-24-QG69_10uM | Dose=10uM, Myricetin, Cytochrome P450 CYP3A4 Inhibitors;Androgen Receptor Ligands;Antioxidants targeting AR, CYP3A4 |
| AC-24-QG69_1uM | Dose=1uM, Myricetin, Cytochrome P450 CYP3A4 Inhibitors;Androgen Receptor Ligands;Antioxidants targeting AR, CYP3A4 |
| AC-28-IT60_10uM | Dose=10uM, US10934285, Example 23, SHP2 allosteric inhibitor targeting PTPN11 |
| AC-28-IT60_1uM | Dose=1uM, US10934285, Example 23, SHP2 allosteric inhibitor targeting PTPN11 |
| AC-28-RT00_0.01uM | Dose=0.01uM, N-[(3S)-3-amino-4-fluorobutyl]-N-[(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)imidazol-2-yl]-2,2-dimethylpropyl]-2-hydroxyacetamide, Kinesin-Like Spindle Protein (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| AC-28-RT00_0.1uM | Dose=0.1uM, N-[(3S)-3-amino-4-fluorobutyl]-N-[(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)imidazol-2-yl]-2,2-dimethylpropyl]-2-hydroxyacetamide, Kinesin-Like Spindle Protein (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| AC-28-RT00_10uM | Dose=10uM, N-[(3S)-3-amino-4-fluorobutyl]-N-[(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)imidazol-2-yl]-2,2-dimethylpropyl]-2-hydroxyacetamide, Kinesin-Like Spindle Protein (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| AC-28-RT00_1uM | Dose=1uM, N-[(3S)-3-amino-4-fluorobutyl]-N-[(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)imidazol-2-yl]-2,2-dimethylpropyl]-2-hydroxyacetamide, Kinesin-Like Spindle Protein (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| AC-29-ZR23_0.01uM | Dose=0.01uM, Nicotine, Nicotinic alpha7 Partial Agonists targeting CHRNA3, CHRNB4 |
| AC-29-ZR23_0.1uM | Dose=0.1uM, Nicotine, Nicotinic alpha7 Partial Agonists targeting CHRNA3, CHRNB4 |
| AC-29-ZR23_10uM | Dose=10uM, Nicotine, Nicotinic alpha7 Partial Agonists targeting CHRNA3, CHRNB4 |
| AC-29-ZR23_1uM | Dose=1uM, Nicotine, Nicotinic alpha7 Partial Agonists targeting CHRNA3, CHRNB4 |
| AC-30-XU83_0.01uM | Dose=0.01uM, Bortezomib, Apoptosis Inducers;Proteasome Inhibitors;Proteasome inhibitor;Caspase 3 Activators;NF-kappaB (NFKB) Activation Inhibitors targeting CASP3, CTRB1, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, CTRC, PSMB11, PSMA8 |
| AC-30-XU83_0.1uM | Dose=0.1uM, Bortezomib, Apoptosis Inducers;Proteasome Inhibitors;Proteasome inhibitor;Caspase 3 Activators;NF-kappaB (NFKB) Activation Inhibitors targeting CASP3, CTRB1, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, CTRC, PSMB11, PSMA8 |
| AC-30-XU83_10uM | Dose=10uM, Bortezomib, Apoptosis Inducers;Proteasome Inhibitors;Proteasome inhibitor;Caspase 3 Activators;NF-kappaB (NFKB) Activation Inhibitors targeting CASP3, CTRB1, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, CTRC, PSMB11, PSMA8 |
| AC-30-XU83_1uM | Dose=1uM, Bortezomib, Apoptosis Inducers;Proteasome Inhibitors;Proteasome inhibitor;Caspase 3 Activators;NF-kappaB (NFKB) Activation Inhibitors targeting CASP3, CTRB1, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, CTRC, PSMB11, PSMA8 |
| AC-31-AY35_0.01uM | Dose=0.01uM, 1,2-Ethanedione, 1,2-bis(4-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| AC-31-AY35_0.1uM | Dose=0.1uM, 1,2-Ethanedione, 1,2-bis(4-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| AC-31-AY35_10uM | Dose=10uM, 1,2-Ethanedione, 1,2-bis(4-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| AC-31-AY35_1uM | Dose=1uM, 1,2-Ethanedione, 1,2-bis(4-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| AC-31-PL89_0.01uM | Dose=0.01uM, Mycophenolic Acid, IMPDH inhibitor;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;antiviral;Immunosuppressant targeting IMPDH1, IMPDH2 |
| AC-31-PL89_0.1uM | Dose=0.1uM, Mycophenolic Acid, IMPDH inhibitor;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;antiviral;Immunosuppressant targeting IMPDH1, IMPDH2 |
| AC-31-PL89_10uM | Dose=10uM, Mycophenolic Acid, IMPDH inhibitor;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;antiviral;Immunosuppressant targeting IMPDH1, IMPDH2 |
| AC-31-PL89_1uM | Dose=1uM, Mycophenolic Acid, IMPDH inhibitor;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;antiviral;Immunosuppressant targeting IMPDH1, IMPDH2 |
| AC-31-SL44_0.01uM | Dose=0.01uM, Melatonin, Apoptosis Inducers;NOS2 Expression Inhibitors;Free Radical Scavengers;TH Expression Enhancers;Antioxidants targeting MTNR1A, MTNR1B |
| AC-31-SL44_0.1uM | Dose=0.1uM, Melatonin, Apoptosis Inducers;NOS2 Expression Inhibitors;Free Radical Scavengers;TH Expression Enhancers;Antioxidants targeting MTNR1A, MTNR1B |
| AC-31-SL44_10uM | Dose=10uM, Melatonin, Apoptosis Inducers;NOS2 Expression Inhibitors;Free Radical Scavengers;TH Expression Enhancers;Antioxidants targeting MTNR1A, MTNR1B |
| AC-31-SL44_1uM | Dose=1uM, Melatonin, Apoptosis Inducers;NOS2 Expression Inhibitors;Free Radical Scavengers;TH Expression Enhancers;Antioxidants targeting MTNR1A, MTNR1B |
| AC-33-YJ09_0.01uM | Dose=0.01uM, 9-Methoxy-2-[2-methoxyethyl(methyl)amino]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one, Inhibitors of Signal Transduction Pathways;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| AC-33-YJ09_0.1uM | Dose=0.1uM, 9-Methoxy-2-[2-methoxyethyl(methyl)amino]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one, Inhibitors of Signal Transduction Pathways;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| AC-33-YJ09_10uM | Dose=10uM, 9-Methoxy-2-[2-methoxyethyl(methyl)amino]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one, Inhibitors of Signal Transduction Pathways;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| AC-33-YJ09_1uM | Dose=1uM, 9-Methoxy-2-[2-methoxyethyl(methyl)amino]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one, Inhibitors of Signal Transduction Pathways;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| AC-35-CK01_10uM | Dose=10uM, Mitonafide |
| AC-35-CK01_1uM | Dose=1uM, Mitonafide |
| AC-35-JA42_0.01uM | Dose=0.01uM, Terbutaline, beta2-Adrenoceptor Agonists targeting ADRB2 |
| AC-35-JA42_0.1uM | Dose=0.1uM, Terbutaline, beta2-Adrenoceptor Agonists targeting ADRB2 |
| AC-35-JA42_10uM | Dose=10uM, Terbutaline, beta2-Adrenoceptor Agonists targeting ADRB2 |
| AC-35-JA42_1uM | Dose=1uM, Terbutaline, beta2-Adrenoceptor Agonists targeting ADRB2 |
| AC-36-FB52_0.01uM | Dose=0.01uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(2R)-1-propan-2-ylpiperidine-2-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| AC-36-FB52_0.1uM | Dose=0.1uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(2R)-1-propan-2-ylpiperidine-2-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| AC-36-FB52_10uM | Dose=10uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(2R)-1-propan-2-ylpiperidine-2-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| AC-36-FB52_1uM | Dose=1uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(2R)-1-propan-2-ylpiperidine-2-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| AC-36-SY22_0.01uM | Dose=0.01uM, Benzeneboronic acid, Carbonic anhydrase inhibitor targeting CA4 |
| AC-36-SY22_0.1uM | Dose=0.1uM, Benzeneboronic acid, Carbonic anhydrase inhibitor targeting CA4 |
| AC-36-SY22_10uM | Dose=10uM, Benzeneboronic acid, Carbonic anhydrase inhibitor targeting CA4 |
| AC-36-SY22_1uM | Dose=1uM, Benzeneboronic acid, Carbonic anhydrase inhibitor targeting CA4 |
| AC-36-TL21_0.01uM | Dose=0.01uM, 7-Ethyl-10-hydroxycamptothecin, DNA Topoisomerase I Inhibitors;Apoptosis Inducers targeting TOP1 |
| AC-36-TL21_0.1uM | Dose=0.1uM, 7-Ethyl-10-hydroxycamptothecin, DNA Topoisomerase I Inhibitors;Apoptosis Inducers targeting TOP1 |
| AC-36-TL21_10uM | Dose=10uM, 7-Ethyl-10-hydroxycamptothecin, DNA Topoisomerase I Inhibitors;Apoptosis Inducers targeting TOP1 |
| AC-36-TL21_1uM | Dose=1uM, 7-Ethyl-10-hydroxycamptothecin, DNA Topoisomerase I Inhibitors;Apoptosis Inducers targeting TOP1 |
| AC-37-OZ52_0.01uM | Dose=0.01uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxyphenyl)-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)quinoxaline-5-carboxamide, FGFR3 gene inhibitor targeting FGFR3 |
| AC-37-OZ52_0.1uM | Dose=0.1uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxyphenyl)-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)quinoxaline-5-carboxamide, FGFR3 gene inhibitor targeting FGFR3 |
| AC-37-OZ52_10uM | Dose=10uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxyphenyl)-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)quinoxaline-5-carboxamide, FGFR3 gene inhibitor targeting FGFR3 |
| AC-37-OZ52_1uM | Dose=1uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxyphenyl)-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)quinoxaline-5-carboxamide, FGFR3 gene inhibitor targeting FGFR3 |
| AC-38-WM38_0.01uM | Dose=0.01uM |
| AC-38-WM38_0.1uM | Dose=0.1uM |
| AC-38-WM38_10uM | Dose=10uM |
| AC-38-WM38_1uM | Dose=1uM |
| AC-40-DU58_0.01uM | Dose=0.01uM, ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate, Known LNPEP targeting LNPEP |
| AC-40-DU58_0.1uM | Dose=0.1uM, ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate, Known LNPEP targeting LNPEP |
| AC-40-DU58_10uM | Dose=10uM, ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate, Known LNPEP targeting LNPEP |
| AC-40-DU58_1uM | Dose=1uM, ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate, Known LNPEP targeting LNPEP |
| AC-40-KV26_0.01uM | Dose=0.01uM, Felodipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA1A, CACNA1E, CACNB1, CACNB4, CACNG1 |
| AC-40-KV26_0.1uM | Dose=0.1uM, Felodipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA1A, CACNA1E, CACNB1, CACNB4, CACNG1 |
| AC-40-KV26_10uM | Dose=10uM, Felodipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA1A, CACNA1E, CACNB1, CACNB4, CACNG1 |
| AC-40-KV26_1uM | Dose=1uM, Felodipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA1A, CACNA1E, CACNB1, CACNB4, CACNG1 |
| AC-40-PV46_0.01uM | Dose=0.01uM, 3-Dimethylcarbamoylmethyl-5-fluoro-1-naphthalen-1-ylmethyl-1H-indole-2-carboxylic acid, Known Chymase inhibitor targeting CMA1 |
| AC-40-PV46_0.1uM | Dose=0.1uM, 3-Dimethylcarbamoylmethyl-5-fluoro-1-naphthalen-1-ylmethyl-1H-indole-2-carboxylic acid, Known Chymase inhibitor targeting CMA1 |
| AC-40-PV46_10uM | Dose=10uM, 3-Dimethylcarbamoylmethyl-5-fluoro-1-naphthalen-1-ylmethyl-1H-indole-2-carboxylic acid, Known Chymase inhibitor targeting CMA1 |
| AC-40-PV46_1uM | Dose=1uM, 3-Dimethylcarbamoylmethyl-5-fluoro-1-naphthalen-1-ylmethyl-1H-indole-2-carboxylic acid, Known Chymase inhibitor targeting CMA1 |
| AC-41-IB85_0.01uM | Dose=0.01uM, 25-Hydroxycholesterol, Apoptosis Inducers;IL-8 Modulators;TNF-alpha Release Inhibitors;Cholesterol Biosynthesis Inhibitors;3-hydroxy-3-methylglutaryl-CoA reductase Inhibitors targeting HMGCR, RORC, RORA |
| AC-41-IB85_0.1uM | Dose=0.1uM, 25-Hydroxycholesterol, Apoptosis Inducers;IL-8 Modulators;TNF-alpha Release Inhibitors;Cholesterol Biosynthesis Inhibitors;3-hydroxy-3-methylglutaryl-CoA reductase Inhibitors targeting HMGCR, RORC, RORA |
| AC-41-IB85_10uM | Dose=10uM, 25-Hydroxycholesterol, Apoptosis Inducers;IL-8 Modulators;TNF-alpha Release Inhibitors;Cholesterol Biosynthesis Inhibitors;3-hydroxy-3-methylglutaryl-CoA reductase Inhibitors targeting HMGCR, RORC, RORA |
| AC-41-IB85_1uM | Dose=1uM, 25-Hydroxycholesterol, Apoptosis Inducers;IL-8 Modulators;TNF-alpha Release Inhibitors;Cholesterol Biosynthesis Inhibitors;3-hydroxy-3-methylglutaryl-CoA reductase Inhibitors targeting HMGCR, RORC, RORA |
| AC-41-MB45_0.01uM | Dose=0.01uM |
| AC-41-MB45_10uM | Dose=10uM |
| AC-41-MB45_1uM | Dose=1uM |
| AC-42-LW33_0.01uM | Dose=0.01uM, (S)-3-[4-(4-chloro-phenoxy)-phenyl]-1-(2-methanesulfonyl-ethyl)-4-(3-trifluoromethyl-phenyl)-imidazolidin-2-one |
| AC-42-LW33_10uM | Dose=10uM, (S)-3-[4-(4-chloro-phenoxy)-phenyl]-1-(2-methanesulfonyl-ethyl)-4-(3-trifluoromethyl-phenyl)-imidazolidin-2-one |
| AC-42-LW33_1uM | Dose=1uM, (S)-3-[4-(4-chloro-phenoxy)-phenyl]-1-(2-methanesulfonyl-ethyl)-4-(3-trifluoromethyl-phenyl)-imidazolidin-2-one |
| AC-42-SI74_0.01uM | Dose=0.01uM, 1H-1,2,3-benzotriazol-1-yl N,N-dimethylcarbamate, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF |
| AC-42-SI74_0.1uM | Dose=0.1uM, 1H-1,2,3-benzotriazol-1-yl N,N-dimethylcarbamate, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF |
| AC-42-SI74_10uM | Dose=10uM, 1H-1,2,3-benzotriazol-1-yl N,N-dimethylcarbamate, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF |
| AC-42-SI74_1uM | Dose=1uM, 1H-1,2,3-benzotriazol-1-yl N,N-dimethylcarbamate, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors targeting LIPC, LIPE, LIPG, LIPF |
| AC-43-YW30_10uM | Dose=10uM, Pindolol, beta-Adrenoceptor Antagonists targeting ADRB1 |
| AC-43-ZC52_0.01uM | Dose=0.01uM, (R)-OH-N-propylnoraporphine, Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D2 Receptor Ligands targeting DRD1, DRD2, DRD3 |
| AC-43-ZC52_0.1uM | Dose=0.1uM, (R)-OH-N-propylnoraporphine, Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D2 Receptor Ligands targeting DRD1, DRD2, DRD3 |
| AC-43-ZC52_10uM | Dose=10uM, (R)-OH-N-propylnoraporphine, Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D2 Receptor Ligands targeting DRD1, DRD2, DRD3 |
| AC-43-ZC52_1uM | Dose=1uM, (R)-OH-N-propylnoraporphine, Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D2 Receptor Ligands targeting DRD1, DRD2, DRD3 |
| AC-44-UR36_0.01uM | Dose=0.01uM, N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting FLT1, KDR, KIT |
| AC-44-UR36_0.1uM | Dose=0.1uM, N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting FLT1, KDR, KIT |
| AC-44-UR36_10uM | Dose=10uM, N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting FLT1, KDR, KIT |
| AC-44-UR36_1uM | Dose=1uM, N-(4-Chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting FLT1, KDR, KIT |
| AC-45-EE32_0.01uM | Dose=0.01uM, 3-Hydroxy-15-methyl-2-(13-methyltetradecanoylamino)hexadecane-1-sulfonic acid |
| AC-45-EE32_0.1uM | Dose=0.1uM, 3-Hydroxy-15-methyl-2-(13-methyltetradecanoylamino)hexadecane-1-sulfonic acid |
| AC-45-EE32_10uM | Dose=10uM, 3-Hydroxy-15-methyl-2-(13-methyltetradecanoylamino)hexadecane-1-sulfonic acid |
| AC-45-EE32_1uM | Dose=1uM, 3-Hydroxy-15-methyl-2-(13-methyltetradecanoylamino)hexadecane-1-sulfonic acid |
| AC-45-YY00_0.01uM | Dose=0.01uM, 4-[3-Amino-1-[4-chloro-5-methyl-6-(methylamino)pyridin-3-yl]-5-fluoroindazol-6-yl]naphthalen-1-ol |
| AC-45-YY00_0.1uM | Dose=0.1uM, 4-[3-Amino-1-[4-chloro-5-methyl-6-(methylamino)pyridin-3-yl]-5-fluoroindazol-6-yl]naphthalen-1-ol |
| AC-45-YY00_10uM | Dose=10uM, 4-[3-Amino-1-[4-chloro-5-methyl-6-(methylamino)pyridin-3-yl]-5-fluoroindazol-6-yl]naphthalen-1-ol |
| AC-45-YY00_1uM | Dose=1uM, 4-[3-Amino-1-[4-chloro-5-methyl-6-(methylamino)pyridin-3-yl]-5-fluoroindazol-6-yl]naphthalen-1-ol |
| AC-47-YZ27_0.01uM | Dose=0.01uM, (2~{S})-4-methyl-1-[5-(3-methyl-2~{H}-indazol-5-yl)pyridin-3-yl]oxy-pentan-2-amine, CDC-like kinase-2 inhibitors targeting CLK2 |
| AC-47-YZ27_0.1uM | Dose=0.1uM, (2~{S})-4-methyl-1-[5-(3-methyl-2~{H}-indazol-5-yl)pyridin-3-yl]oxy-pentan-2-amine, CDC-like kinase-2 inhibitors targeting CLK2 |
| AC-47-YZ27_10uM | Dose=10uM, (2~{S})-4-methyl-1-[5-(3-methyl-2~{H}-indazol-5-yl)pyridin-3-yl]oxy-pentan-2-amine, CDC-like kinase-2 inhibitors targeting CLK2 |
| AC-47-YZ27_1uM | Dose=1uM, (2~{S})-4-methyl-1-[5-(3-methyl-2~{H}-indazol-5-yl)pyridin-3-yl]oxy-pentan-2-amine, CDC-like kinase-2 inhibitors targeting CLK2 |
| AC-47-ZI16_0.1uM | Dose=0.1uM, Beta-Aminopropionitrile, LOX inhibitor targeting LOX, LOXL2 |
| AC-47-ZI16_10uM | Dose=10uM, Beta-Aminopropionitrile, LOX inhibitor targeting LOX, LOXL2 |
| AC-49-NG46_0.01uM | Dose=0.01uM, Lonapalene, Lipoxygenase Inhibitors targeting ALOX5 |
| AC-49-NG46_0.1uM | Dose=0.1uM, Lonapalene, Lipoxygenase Inhibitors targeting ALOX5 |
| AC-49-NG46_10uM | Dose=10uM, Lonapalene, Lipoxygenase Inhibitors targeting ALOX5 |
| AC-49-NG46_1uM | Dose=1uM, Lonapalene, Lipoxygenase Inhibitors targeting ALOX5 |
| AC-49-ZR23_0.01uM | Dose=0.01uM, SB 206553, 5-HT2C Antagonists;5-HT1A Receptor Partial Agonists;5-HT2B Antagonists targeting HTR1A, HTR2B, HTR2C |
| AC-49-ZR23_0.1uM | Dose=0.1uM, SB 206553, 5-HT2C Antagonists;5-HT1A Receptor Partial Agonists;5-HT2B Antagonists targeting HTR1A, HTR2B, HTR2C |
| AC-49-ZR23_10uM | Dose=10uM, SB 206553, 5-HT2C Antagonists;5-HT1A Receptor Partial Agonists;5-HT2B Antagonists targeting HTR1A, HTR2B, HTR2C |
| AC-49-ZR23_1uM | Dose=1uM, SB 206553, 5-HT2C Antagonists;5-HT1A Receptor Partial Agonists;5-HT2B Antagonists targeting HTR1A, HTR2B, HTR2C |
| AC-50-FR41_0.01uM | Dose=0.01uM, (7R)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-5H,6H,7H,8H-pyrido(4,3-d)pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| AC-50-FR41_0.1uM | Dose=0.1uM, (7R)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-5H,6H,7H,8H-pyrido(4,3-d)pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| AC-50-FR41_10uM | Dose=10uM, (7R)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-5H,6H,7H,8H-pyrido(4,3-d)pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| AC-50-FR41_1uM | Dose=1uM, (7R)-2-amino-7-(4-fluoro-2-(6-methoxypyrazin-2-yl)phenyl)-4-methyl-5H,6H,7H,8H-pyrido(4,3-d)pyrimidin-5-one, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| AC-50-JK54_0.01uM | Dose=0.01uM, Clomipramine, Serotonin Transporter (SERT) Inhibitors targeting SLC6A4 |
| AC-50-JK54_0.1uM | Dose=0.1uM, Clomipramine, Serotonin Transporter (SERT) Inhibitors targeting SLC6A4 |
| AC-50-JK54_10uM | Dose=10uM, Clomipramine, Serotonin Transporter (SERT) Inhibitors targeting SLC6A4 |
| AC-50-JK54_1uM | Dose=1uM, Clomipramine, Serotonin Transporter (SERT) Inhibitors targeting SLC6A4 |
| AC-50-TU13_0.01uM | Dose=0.01uM, 1,4-Dihydroxy-2-naphthoic acid, Tau Aggregation Inhibitors targeting MAPT |
| AC-50-TU13_0.1uM | Dose=0.1uM, 1,4-Dihydroxy-2-naphthoic acid, Tau Aggregation Inhibitors targeting MAPT |
| AC-50-TU13_10uM | Dose=10uM, 1,4-Dihydroxy-2-naphthoic acid, Tau Aggregation Inhibitors targeting MAPT |
| AC-51-PY60_0.01uM | Dose=0.01uM, 4-methyl-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide, Kynurenine 3-Monooxygenase Inhibitors targeting KMO |
| AC-51-PY60_0.1uM | Dose=0.1uM, 4-methyl-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide, Kynurenine 3-Monooxygenase Inhibitors targeting KMO |
| AC-51-PY60_10uM | Dose=10uM, 4-methyl-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide, Kynurenine 3-Monooxygenase Inhibitors targeting KMO |
| AC-51-PY60_1uM | Dose=1uM, 4-methyl-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide, Kynurenine 3-Monooxygenase Inhibitors targeting KMO |
| AC-51-PY70_0.01uM | Dose=0.01uM, FPL-55712 free base, Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1, CYSLTR2 |
| AC-51-PY70_0.1uM | Dose=0.1uM, FPL-55712 free base, Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1, CYSLTR2 |
| AC-51-PY70_10uM | Dose=10uM, FPL-55712 free base, Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1, CYSLTR2 |
| AC-51-PY70_1uM | Dose=1uM, FPL-55712 free base, Leukotriene Synthesis Inhibitors;Leukotriene Antagonists targeting CYSLTR1, CYSLTR2 |
| AC-51-WE57_0.01uM | Dose=0.01uM, Diphenhydramine, Histamine H1 Receptor Antagonists targeting HRH1 |
| AC-51-WE57_0.1uM | Dose=0.1uM, Diphenhydramine, Histamine H1 Receptor Antagonists targeting HRH1 |
| AC-51-WE57_10uM | Dose=10uM, Diphenhydramine, Histamine H1 Receptor Antagonists targeting HRH1 |
| AC-51-WE57_1uM | Dose=1uM, Diphenhydramine, Histamine H1 Receptor Antagonists targeting HRH1 |
| AC-53-HJ29_0.01uM | Dose=0.01uM, Cilengitide, Integrin binder;Integrin alphavbeta5 Antagonists;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5, ITGA6 |
| AC-53-HJ29_0.1uM | Dose=0.1uM, Cilengitide, Integrin binder;Integrin alphavbeta5 Antagonists;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5, ITGA6 |
| AC-53-HJ29_10uM | Dose=10uM, Cilengitide, Integrin binder;Integrin alphavbeta5 Antagonists;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5, ITGA6 |
| AC-53-HJ29_1uM | Dose=1uM, Cilengitide, Integrin binder;Integrin alphavbeta5 Antagonists;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5, ITGA6 |
| AC-53-OM41_0.01uM | Dose=0.01uM, Prucalopride, 5-HT4 Agonists targeting HTR4 |
| AC-53-OM41_0.1uM | Dose=0.1uM, Prucalopride, 5-HT4 Agonists targeting HTR4 |
| AC-53-OM41_10uM | Dose=10uM, Prucalopride, 5-HT4 Agonists targeting HTR4 |
| AC-53-OM41_1uM | Dose=1uM, Prucalopride, 5-HT4 Agonists targeting HTR4 |
| AC-53-RC32_0.01uM | Dose=0.01uM, N-[(2S)-1-[[(1S)-1-cyano-3-phenylpropyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]morpholine-4-carboxamide |
| AC-53-RC32_0.1uM | Dose=0.1uM, N-[(2S)-1-[[(1S)-1-cyano-3-phenylpropyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]morpholine-4-carboxamide |
| AC-53-RC32_10uM | Dose=10uM, N-[(2S)-1-[[(1S)-1-cyano-3-phenylpropyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]morpholine-4-carboxamide |
| AC-53-RC32_1uM | Dose=1uM, N-[(2S)-1-[[(1S)-1-cyano-3-phenylpropyl]amino]-3-cyclohexyl-1-oxopropan-2-yl]morpholine-4-carboxamide |
| AC-53-YM36_0.01uM | Dose=0.01uM, N-[1-(Cyanomethyl-carbamoyl)-cyclohexyl]-4-[1-(2-methoxy-ethyl)-piperidin-4-yl]-benzamide, Cathepsin K Inhibitors targeting CTSK |
| AC-53-YM36_0.1uM | Dose=0.1uM, N-[1-(Cyanomethyl-carbamoyl)-cyclohexyl]-4-[1-(2-methoxy-ethyl)-piperidin-4-yl]-benzamide, Cathepsin K Inhibitors targeting CTSK |
| AC-53-YM36_1uM | Dose=1uM, N-[1-(Cyanomethyl-carbamoyl)-cyclohexyl]-4-[1-(2-methoxy-ethyl)-piperidin-4-yl]-benzamide, Cathepsin K Inhibitors targeting CTSK |
| AC-54-FR31_0.01uM | Dose=0.01uM, Miglustat, Ceramide Glucosyltransferase Inhibitors;SGLT-3 Activators;alpha-Glucosidase Inhibitors;Pharmacological Chaperones targeting GAA, SLC5A4, UGCG |
| AC-54-FR31_0.1uM | Dose=0.1uM, Miglustat, Ceramide Glucosyltransferase Inhibitors;SGLT-3 Activators;alpha-Glucosidase Inhibitors;Pharmacological Chaperones targeting GAA, SLC5A4, UGCG |
| AC-54-FR31_10uM | Dose=10uM, Miglustat, Ceramide Glucosyltransferase Inhibitors;SGLT-3 Activators;alpha-Glucosidase Inhibitors;Pharmacological Chaperones targeting GAA, SLC5A4, UGCG |
| AC-54-FR31_1uM | Dose=1uM, Miglustat, Ceramide Glucosyltransferase Inhibitors;SGLT-3 Activators;alpha-Glucosidase Inhibitors;Pharmacological Chaperones targeting GAA, SLC5A4, UGCG |
| AC-54-UG49_0.01uM | Dose=0.01uM, Proadifen, Cytochrome P450 Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors;Potassium Channel Blockers targeting NOS1 |
| AC-54-UG49_0.1uM | Dose=0.1uM, Proadifen, Cytochrome P450 Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors;Potassium Channel Blockers targeting NOS1 |
| AC-54-UG49_10uM | Dose=10uM, Proadifen, Cytochrome P450 Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors;Potassium Channel Blockers targeting NOS1 |
| AC-54-UG49_1uM | Dose=1uM, Proadifen, Cytochrome P450 Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors;Potassium Channel Blockers targeting NOS1 |
| AC-55-CK61_0.01uM | Dose=0.01uM, (2E,6E)-2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone, Antiinflammatory Drugs;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP;TNF Expression Inhibitors targeting ABCG2 |
| AC-55-CK61_0.1uM | Dose=0.1uM, (2E,6E)-2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone, Antiinflammatory Drugs;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP;TNF Expression Inhibitors targeting ABCG2 |
| AC-55-CK61_10uM | Dose=10uM, (2E,6E)-2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone, Antiinflammatory Drugs;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP;TNF Expression Inhibitors targeting ABCG2 |
| AC-55-CK61_1uM | Dose=1uM, (2E,6E)-2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone, Antiinflammatory Drugs;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP;TNF Expression Inhibitors targeting ABCG2 |
| AC-55-GO91_0.01uM | Dose=0.01uM, Acetamide, N-[5-[3-(1H-imidazol-1-YL)-4-(methylsulfonyl)phenyl]-4-methyl-2-thiazolyl]-, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting PIK3CG |
| AC-55-GO91_0.1uM | Dose=0.1uM, Acetamide, N-[5-[3-(1H-imidazol-1-YL)-4-(methylsulfonyl)phenyl]-4-methyl-2-thiazolyl]-, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting PIK3CG |
| AC-55-GO91_10uM | Dose=10uM, Acetamide, N-[5-[3-(1H-imidazol-1-YL)-4-(methylsulfonyl)phenyl]-4-methyl-2-thiazolyl]-, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting PIK3CG |
| AC-55-GO91_1uM | Dose=1uM, Acetamide, N-[5-[3-(1H-imidazol-1-YL)-4-(methylsulfonyl)phenyl]-4-methyl-2-thiazolyl]-, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting PIK3CG |
| AC-55-XA97_0.01uM | Dose=0.01uM, Brequinar, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| AC-55-XA97_0.1uM | Dose=0.1uM, Brequinar, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| AC-55-XA97_10uM | Dose=10uM, Brequinar, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| AC-55-XA97_1uM | Dose=1uM, Brequinar, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| AC-56-ZV05_0.01uM | Dose=0.01uM, BAY-61-3606 free base, Syk Kinase Inhibitors targeting SYK |
| AC-56-ZV05_0.1uM | Dose=0.1uM, BAY-61-3606 free base, Syk Kinase Inhibitors targeting SYK |
| AC-56-ZV05_10uM | Dose=10uM, BAY-61-3606 free base, Syk Kinase Inhibitors targeting SYK |
| AC-56-ZV05_1uM | Dose=1uM, BAY-61-3606 free base, Syk Kinase Inhibitors targeting SYK |
| AC-57-ZF49_0.01uM | Dose=0.01uM, SB 221284, 5-HT2C Antagonists;5-HT2B Antagonists targeting CYP2D6 |
| AC-57-ZF49_0.1uM | Dose=0.1uM, SB 221284, 5-HT2C Antagonists;5-HT2B Antagonists targeting CYP2D6 |
| AC-57-ZF49_10uM | Dose=10uM, SB 221284, 5-HT2C Antagonists;5-HT2B Antagonists targeting CYP2D6 |
| AC-57-ZF49_1uM | Dose=1uM, SB 221284, 5-HT2C Antagonists;5-HT2B Antagonists targeting CYP2D6 |
| AC-58-RM63_0.01uM | Dose=0.01uM, Sibenadet, Dopamine D2 Agonists;Dual acting dopamine D2 / beta-2 adrenoceptor agonist;beta2-Adrenoceptor Agonists targeting ADRB2, DRD2 |
| AC-58-RM63_0.1uM | Dose=0.1uM, Sibenadet, Dopamine D2 Agonists;Dual acting dopamine D2 / beta-2 adrenoceptor agonist;beta2-Adrenoceptor Agonists targeting ADRB2, DRD2 |
| AC-58-RM63_10uM | Dose=10uM, Sibenadet, Dopamine D2 Agonists;Dual acting dopamine D2 / beta-2 adrenoceptor agonist;beta2-Adrenoceptor Agonists targeting ADRB2, DRD2 |
| AC-58-RM63_1uM | Dose=1uM, Sibenadet, Dopamine D2 Agonists;Dual acting dopamine D2 / beta-2 adrenoceptor agonist;beta2-Adrenoceptor Agonists targeting ADRB2, DRD2 |
| AC-59-ZD79_0.01uM | Dose=0.01uM, N6-Methyladenosine |
| AC-59-ZD79_0.1uM | Dose=0.1uM, N6-Methyladenosine |
| AC-59-ZD79_10uM | Dose=10uM, N6-Methyladenosine |
| AC-59-ZD79_1uM | Dose=1uM, N6-Methyladenosine |
| AC-60-EU98_0.01uM | Dose=0.01uM, Amodiaquine, Antimalarial;Histamine Methyltransferase Inhibitor targeting HNMT |
| AC-60-EU98_0.1uM | Dose=0.1uM, Amodiaquine, Antimalarial;Histamine Methyltransferase Inhibitor targeting HNMT |
| AC-60-EU98_10uM | Dose=10uM, Amodiaquine, Antimalarial;Histamine Methyltransferase Inhibitor targeting HNMT |
| AC-60-EU98_1uM | Dose=1uM, Amodiaquine, Antimalarial;Histamine Methyltransferase Inhibitor targeting HNMT |
| AC-61-ZY25_10uM | Dose=10uM, EP (PGE2) Receptor Antagonists;EP (PGE1) Receptor Antagonists;EP (PGE2) Receptor Antagonists;EP (PGE1) Receptor Antagonists |
| AC-61-ZY25_1uM | Dose=1uM, EP (PGE2) Receptor Antagonists;EP (PGE1) Receptor Antagonists;EP (PGE2) Receptor Antagonists;EP (PGE1) Receptor Antagonists |
| AC-63-DM46_0.01uM | Dose=0.01uM |
| AC-63-DM46_0.1uM | Dose=0.1uM |
| AC-63-DM46_10uM | Dose=10uM |
| AC-63-DM46_1uM | Dose=1uM |
| AC-63-OM41_0.01uM | Dose=0.01uM, Dipeptidyl nitrile inhibitor, 26, Cathepsin L Inhibitors targeting CTSV, CTSL3P |
| AC-63-OM41_0.1uM | Dose=0.1uM, Dipeptidyl nitrile inhibitor, 26, Cathepsin L Inhibitors targeting CTSV, CTSL3P |
| AC-63-OM41_10uM | Dose=10uM, Dipeptidyl nitrile inhibitor, 26, Cathepsin L Inhibitors targeting CTSV, CTSL3P |
| AC-63-OM41_1uM | Dose=1uM, Dipeptidyl nitrile inhibitor, 26, Cathepsin L Inhibitors targeting CTSV, CTSL3P |
| AC-65-TK51_0.01uM | Dose=0.01uM, NS-398, Cyclooxygenase-2 Inhibitors targeting SC5D |
| AC-65-TK51_0.1uM | Dose=0.1uM, NS-398, Cyclooxygenase-2 Inhibitors targeting SC5D |
| AC-65-TK51_1uM | Dose=1uM, NS-398, Cyclooxygenase-2 Inhibitors targeting SC5D |
| AC-67-PZ77_0.01uM | Dose=0.01uM, Lorlatinib, inhibitor of ALK targeting ALK, ROS1 |
| AC-67-PZ77_0.1uM | Dose=0.1uM, Lorlatinib, inhibitor of ALK targeting ALK, ROS1 |
| AC-67-PZ77_10uM | Dose=10uM, Lorlatinib, inhibitor of ALK targeting ALK, ROS1 |
| AC-67-PZ77_1uM | Dose=1uM, Lorlatinib, inhibitor of ALK targeting ALK, ROS1 |
| AC-67-TM11_0.01uM | Dose=0.01uM, ML323, USP1–UAF1 inhibitor targeting USP1, WDR48 |
| AC-67-TM11_0.1uM | Dose=0.1uM, ML323, USP1–UAF1 inhibitor targeting USP1, WDR48 |
| AC-67-TM11_10uM | Dose=10uM, ML323, USP1–UAF1 inhibitor targeting USP1, WDR48 |
| AC-67-TM11_1uM | Dose=1uM, ML323, USP1–UAF1 inhibitor targeting USP1, WDR48 |
| AC-67-ZF49_0.01uM | Dose=0.01uM, Mirtazapine, 5-HT3 Antagonists;5-HT2A Antagonists;alpha2-Adrenoceptor Antagonists targeting HTR2A |
| AC-67-ZF49_0.1uM | Dose=0.1uM, Mirtazapine, 5-HT3 Antagonists;5-HT2A Antagonists;alpha2-Adrenoceptor Antagonists targeting HTR2A |
| AC-67-ZF49_10uM | Dose=10uM, Mirtazapine, 5-HT3 Antagonists;5-HT2A Antagonists;alpha2-Adrenoceptor Antagonists targeting HTR2A |
| AC-67-ZF49_1uM | Dose=1uM, Mirtazapine, 5-HT3 Antagonists;5-HT2A Antagonists;alpha2-Adrenoceptor Antagonists targeting HTR2A |
| AC-70-KV26_0.01uM | Dose=0.01uM, 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F |
| AC-70-KV26_0.1uM | Dose=0.1uM, 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F |
| AC-70-KV26_10uM | Dose=10uM, 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F |
| AC-70-KV26_1uM | Dose=1uM, 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F |
| AC-71-VV28_0.01uM | Dose=0.01uM, 2-(4-(2-Chloro-4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenoxy)piperidin-1-yl)-5-ethylpyrimidine, GPR119 agonist targeting GPR119 |
| AC-71-VV28_0.1uM | Dose=0.1uM, 2-(4-(2-Chloro-4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenoxy)piperidin-1-yl)-5-ethylpyrimidine, GPR119 agonist targeting GPR119 |
| AC-71-VV28_10uM | Dose=10uM, 2-(4-(2-Chloro-4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenoxy)piperidin-1-yl)-5-ethylpyrimidine, GPR119 agonist targeting GPR119 |
| AC-71-VV28_1uM | Dose=1uM, 2-(4-(2-Chloro-4-((1-(methylsulfonyl)piperidin-4-yl)methyl)phenoxy)piperidin-1-yl)-5-ethylpyrimidine, GPR119 agonist targeting GPR119 |
| AC-71-YF45_0.01uM | Dose=0.01uM |
| AC-71-YF45_0.1uM | Dose=0.1uM |
| AC-71-YF45_10uM | Dose=10uM |
| AC-71-YF45_1uM | Dose=1uM |
| AC-72-HZ80_0.01uM | Dose=0.01uM, N-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| AC-72-HZ80_0.1uM | Dose=0.1uM, N-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| AC-72-HZ80_10uM | Dose=10uM, N-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| AC-72-HZ80_1uM | Dose=1uM, N-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| AC-73-DW50_0.01uM | Dose=0.01uM, Fexofenadine, Histamine H1 Receptor Antagonists targeting HRH1 |
| AC-73-DW50_0.1uM | Dose=0.1uM, Fexofenadine, Histamine H1 Receptor Antagonists targeting HRH1 |
| AC-73-DW50_10uM | Dose=10uM, Fexofenadine, Histamine H1 Receptor Antagonists targeting HRH1 |
| AC-73-DW50_1uM | Dose=1uM, Fexofenadine, Histamine H1 Receptor Antagonists targeting HRH1 |
| AC-73-GJ74_0.01uM | Dose=0.01uM, KU-55933, ATM Kinase Inhibitors;DNA Repair Inhibitors targeting ATM |
| AC-73-GJ74_0.1uM | Dose=0.1uM, KU-55933, ATM Kinase Inhibitors;DNA Repair Inhibitors targeting ATM |
| AC-73-GJ74_10uM | Dose=10uM, KU-55933, ATM Kinase Inhibitors;DNA Repair Inhibitors targeting ATM |
| AC-73-GJ74_1uM | Dose=1uM, KU-55933, ATM Kinase Inhibitors;DNA Repair Inhibitors targeting ATM |
| AC-74-BQ48_0.01uM | Dose=0.01uM, 4-[5-[4-(N'-benzoylcarbamimidoyl)phenoxy]pentoxy]-3-methoxy-N,N-di(propan-2-yl)benzamide, Non-Steroidal Antiinflammatory Drugs;Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R |
| AC-74-BQ48_0.1uM | Dose=0.1uM, 4-[5-[4-(N'-benzoylcarbamimidoyl)phenoxy]pentoxy]-3-methoxy-N,N-di(propan-2-yl)benzamide, Non-Steroidal Antiinflammatory Drugs;Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R |
| AC-74-BQ48_10uM | Dose=10uM, 4-[5-[4-(N'-benzoylcarbamimidoyl)phenoxy]pentoxy]-3-methoxy-N,N-di(propan-2-yl)benzamide, Non-Steroidal Antiinflammatory Drugs;Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R |
| AC-74-BQ48_1uM | Dose=1uM, 4-[5-[4-(N'-benzoylcarbamimidoyl)phenoxy]pentoxy]-3-methoxy-N,N-di(propan-2-yl)benzamide, Non-Steroidal Antiinflammatory Drugs;Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R |
| AC-74-UR36_0.01uM | Dose=0.01uM, Apixaban, Known FactorXa inhibitor targeting F10 |
| AC-74-UR36_0.1uM | Dose=0.1uM, Apixaban, Known FactorXa inhibitor targeting F10 |
| AC-74-UR36_10uM | Dose=10uM, Apixaban, Known FactorXa inhibitor targeting F10 |
| AC-74-UR36_1uM | Dose=1uM, Apixaban, Known FactorXa inhibitor targeting F10 |
| AC-74-ZA35_0.01uM | Dose=0.01uM, Golgicide A, Golgi-Specific Brefeldin A-Resistance Guanine Nucleotide Exchange Factor 1 (GBF1) Inhibitors targeting GBF1 |
| AC-74-ZA35_10uM | Dose=10uM, Golgicide A, Golgi-Specific Brefeldin A-Resistance Guanine Nucleotide Exchange Factor 1 (GBF1) Inhibitors targeting GBF1 |
| AC-74-ZA35_1uM | Dose=1uM, Golgicide A, Golgi-Specific Brefeldin A-Resistance Guanine Nucleotide Exchange Factor 1 (GBF1) Inhibitors targeting GBF1 |
| AC-75-CE67_0.01uM | Dose=0.01uM |
| AC-75-CE67_10uM | Dose=10uM |
| AC-75-CE67_1uM | Dose=1uM |
| AC-75-LR63_0.01uM | Dose=0.01uM, N-(1-benzoylpiperidin-4-yl)-2-chloro-N-phenylacetamide, covalent modifier of catalytic cysteine of pro-CASP8 and pro-CASP10 targeting CASP8, CASP10 |
| AC-75-LR63_0.1uM | Dose=0.1uM, N-(1-benzoylpiperidin-4-yl)-2-chloro-N-phenylacetamide, covalent modifier of catalytic cysteine of pro-CASP8 and pro-CASP10 targeting CASP8, CASP10 |
| AC-75-LR63_10uM | Dose=10uM, N-(1-benzoylpiperidin-4-yl)-2-chloro-N-phenylacetamide, covalent modifier of catalytic cysteine of pro-CASP8 and pro-CASP10 targeting CASP8, CASP10 |
| AC-75-LR63_1uM | Dose=1uM, N-(1-benzoylpiperidin-4-yl)-2-chloro-N-phenylacetamide, covalent modifier of catalytic cysteine of pro-CASP8 and pro-CASP10 targeting CASP8, CASP10 |
| AC-76-BB02_0.01uM | Dose=0.01uM, 4-(4-Fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole, p38alpha MAPK Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting MAPK14 |
| AC-76-BB02_0.1uM | Dose=0.1uM, 4-(4-Fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole, p38alpha MAPK Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting MAPK14 |
| AC-76-BB02_10uM | Dose=10uM, 4-(4-Fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole, p38alpha MAPK Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting MAPK14 |
| AC-76-BB02_1uM | Dose=1uM, 4-(4-Fluorophenyl)-5-(pyridin-4-yl)-1H-imidazole, p38alpha MAPK Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting MAPK14 |
| AC-76-BB72_0.01uM | Dose=0.01uM, Norepinephrine, alpha-Adrenoceptor Agonists;beta-Adrenoceptor Agonists targeting ADRA1D, ADRA1B, ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, TAAR1 |
| AC-76-BB72_0.1uM | Dose=0.1uM, Norepinephrine, alpha-Adrenoceptor Agonists;beta-Adrenoceptor Agonists targeting ADRA1D, ADRA1B, ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, TAAR1 |
| AC-76-BB72_10uM | Dose=10uM, Norepinephrine, alpha-Adrenoceptor Agonists;beta-Adrenoceptor Agonists targeting ADRA1D, ADRA1B, ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, TAAR1 |
| AC-76-BB72_1uM | Dose=1uM, Norepinephrine, alpha-Adrenoceptor Agonists;beta-Adrenoceptor Agonists targeting ADRA1D, ADRA1B, ADRA1A, ADRA2A, ADRA2B, ADRA2C, ADRB3, TAAR1 |
| AC-76-JB92_0.01uM | Dose=0.01uM, Aurora-A (ARK1) Kinase Inhibitors;Heat Shock Protein 27 (hsp27) Inhibitors;TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting AURKA, MAPKAPK5, MAPKAPK2 |
| AC-76-JB92_0.1uM | Dose=0.1uM, Aurora-A (ARK1) Kinase Inhibitors;Heat Shock Protein 27 (hsp27) Inhibitors;TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting AURKA, MAPKAPK5, MAPKAPK2 |
| AC-76-JB92_10uM | Dose=10uM, Aurora-A (ARK1) Kinase Inhibitors;Heat Shock Protein 27 (hsp27) Inhibitors;TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting AURKA, MAPKAPK5, MAPKAPK2 |
| AC-76-JB92_1uM | Dose=1uM, Aurora-A (ARK1) Kinase Inhibitors;Heat Shock Protein 27 (hsp27) Inhibitors;TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting AURKA, MAPKAPK5, MAPKAPK2 |
| AC-77-BC52_0.01uM | Dose=0.01uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-anilino-1,3,5-triazin-2-yl]guanidine |
| AC-77-BC52_0.1uM | Dose=0.1uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-anilino-1,3,5-triazin-2-yl]guanidine |
| AC-77-BC52_10uM | Dose=10uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-anilino-1,3,5-triazin-2-yl]guanidine |
| AC-77-BC52_1uM | Dose=1uM, 2-[4-[2-amino-4-(2-methylpropyl)-5-oxo-4H-imidazol-3-yl]-6-anilino-1,3,5-triazin-2-yl]guanidine |
| AC-77-VS60_0.01uM | Dose=0.01uM, Reserpine, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors;Norepinephrine Uptake Inhibitor targeting SLC18A1, SLC18A2 |
| AC-77-VS60_0.1uM | Dose=0.1uM, Reserpine, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors;Norepinephrine Uptake Inhibitor targeting SLC18A1, SLC18A2 |
| AC-77-VS60_10uM | Dose=10uM, Reserpine, Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors;Norepinephrine Uptake Inhibitor targeting SLC18A1, SLC18A2 |
| AC-78-GT35_0.01uM | Dose=0.01uM, (2R)-2-amino-2-methyl-4-(6-propoxynaphthalen-2-yl)butan-1-ol targeting S1PR1 |
| AC-78-GT35_0.1uM | Dose=0.1uM, (2R)-2-amino-2-methyl-4-(6-propoxynaphthalen-2-yl)butan-1-ol targeting S1PR1 |
| AC-78-GT35_10uM | Dose=10uM, (2R)-2-amino-2-methyl-4-(6-propoxynaphthalen-2-yl)butan-1-ol targeting S1PR1 |
| AC-78-GT35_1uM | Dose=1uM, (2R)-2-amino-2-methyl-4-(6-propoxynaphthalen-2-yl)butan-1-ol targeting S1PR1 |
| AC-79-CQ25_0.01uM | Dose=0.01uM, 1-(1-Acetylpyrazol-3-yl)-6,6-dimethyl-3-methylsulfanyl-5,7-dihydro-2-benzothiophen-4-one targeting GABRA5 |
| AC-79-CQ25_0.1uM | Dose=0.1uM, 1-(1-Acetylpyrazol-3-yl)-6,6-dimethyl-3-methylsulfanyl-5,7-dihydro-2-benzothiophen-4-one targeting GABRA5 |
| AC-79-CQ25_10uM | Dose=10uM, 1-(1-Acetylpyrazol-3-yl)-6,6-dimethyl-3-methylsulfanyl-5,7-dihydro-2-benzothiophen-4-one targeting GABRA5 |
| AC-79-CQ25_1uM | Dose=1uM, 1-(1-Acetylpyrazol-3-yl)-6,6-dimethyl-3-methylsulfanyl-5,7-dihydro-2-benzothiophen-4-one targeting GABRA5 |
| AC-80-DI95_0.01uM | Dose=0.01uM, Mafenide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10 |
| AC-80-DI95_0.1uM | Dose=0.1uM, Mafenide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10 |
| AC-80-DI95_1uM | Dose=1uM, Mafenide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10 |
| AC-82-PZ00_0.01uM | Dose=0.01uM, 1,2,3,4,8,9,10,11-Octahydro-[1,4]diazepino[6,7,1-jk]carbazole, 5-HT2C Agonists;HTR2C agonist targeting HTR2C |
| AC-82-PZ00_0.1uM | Dose=0.1uM, 1,2,3,4,8,9,10,11-Octahydro-[1,4]diazepino[6,7,1-jk]carbazole, 5-HT2C Agonists;HTR2C agonist targeting HTR2C |
| AC-82-PZ00_10uM | Dose=10uM, 1,2,3,4,8,9,10,11-Octahydro-[1,4]diazepino[6,7,1-jk]carbazole, 5-HT2C Agonists;HTR2C agonist targeting HTR2C |
| AC-82-PZ00_1uM | Dose=1uM, 1,2,3,4,8,9,10,11-Octahydro-[1,4]diazepino[6,7,1-jk]carbazole, 5-HT2C Agonists;HTR2C agonist targeting HTR2C |
| AC-83-LN99_0.01uM | Dose=0.01uM, CID 14335632, Lymphangiogenesis Inducer;Lymphangiogenesis Inducers targeting PRKCA, RASGRP3 |
| AC-83-LN99_0.1uM | Dose=0.1uM, CID 14335632, Lymphangiogenesis Inducer;Lymphangiogenesis Inducers targeting PRKCA, RASGRP3 |
| AC-83-LN99_10uM | Dose=10uM, CID 14335632, Lymphangiogenesis Inducer;Lymphangiogenesis Inducers targeting PRKCA, RASGRP3 |
| AC-83-LN99_1uM | Dose=1uM, CID 14335632, Lymphangiogenesis Inducer;Lymphangiogenesis Inducers targeting PRKCA, RASGRP3 |
| AC-84-QG99_0.01uM | Dose=0.01uM |
| AC-84-QG99_0.1uM | Dose=0.1uM |
| AC-84-QG99_10uM | Dose=10uM |
| AC-84-QG99_1uM | Dose=1uM |
| AC-85-MR73_0.01uM | Dose=0.01uM, Xylometazoline, alpha2C-Adrenoceptor Agonists;alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA2A, ADRA2B, ADRA2C |
| AC-85-MR73_0.1uM | Dose=0.1uM, Xylometazoline, alpha2C-Adrenoceptor Agonists;alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA2A, ADRA2B, ADRA2C |
| AC-85-MR73_10uM | Dose=10uM, Xylometazoline, alpha2C-Adrenoceptor Agonists;alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA2A, ADRA2B, ADRA2C |
| AC-85-MR73_1uM | Dose=1uM, Xylometazoline, alpha2C-Adrenoceptor Agonists;alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA2A, ADRA2B, ADRA2C |
| AC-86-KF37_0.01uM | Dose=0.01uM, Capzimin, Proteasome inhibitor targeting PSMD14 |
| AC-86-KF37_0.1uM | Dose=0.1uM, Capzimin, Proteasome inhibitor targeting PSMD14 |
| AC-86-KF37_10uM | Dose=10uM, Capzimin, Proteasome inhibitor targeting PSMD14 |
| AC-86-KF37_1uM | Dose=1uM, Capzimin, Proteasome inhibitor targeting PSMD14 |
| AC-86-XI84_0.01uM | Dose=0.01uM |
| AC-86-XI84_0.1uM | Dose=0.1uM |
| AC-86-XI84_10uM | Dose=10uM |
| AC-86-XI84_1uM | Dose=1uM |
| AC-90-GY03_0.01uM | Dose=0.01uM |
| AC-90-GY03_0.1uM | Dose=0.1uM |
| AC-90-GY03_10uM | Dose=10uM |
| AC-90-GY03_1uM | Dose=1uM |
| AC-90-QA75_0.01uM | Dose=0.01uM, Benzenesulfonamide, 4-amino-3,5-dichloro- |
| AC-90-QA75_0.1uM | Dose=0.1uM, Benzenesulfonamide, 4-amino-3,5-dichloro- |
| AC-90-QA75_10uM | Dose=10uM, Benzenesulfonamide, 4-amino-3,5-dichloro- |
| AC-90-QA75_1uM | Dose=1uM, Benzenesulfonamide, 4-amino-3,5-dichloro- |
| AC-91-AV48_0.01uM | Dose=0.01uM |
| AC-91-AV48_0.1uM | Dose=0.1uM |
| AC-91-AV48_10uM | Dose=10uM |
| AC-91-AV48_1uM | Dose=1uM |
| AC-91-ME22_0.01uM | Dose=0.01uM, (R)-Aminoglutethimide |
| AC-91-ME22_0.1uM | Dose=0.1uM, (R)-Aminoglutethimide |
| AC-91-ME22_10uM | Dose=10uM, (R)-Aminoglutethimide |
| AC-91-ME22_1uM | Dose=1uM, (R)-Aminoglutethimide |
| AC-91-TS36_0.01uM | Dose=0.01uM |
| AC-91-TS36_0.1uM | Dose=0.1uM |
| AC-91-TS36_10uM | Dose=10uM |
| AC-91-TS36_1uM | Dose=1uM |
| AC-91-WE67_0.01uM | Dose=0.01uM, Acetovanillone, NADPH Oxidase Inhibitors targeting NOX3, NOX1 |
| AC-91-WE67_0.1uM | Dose=0.1uM, Acetovanillone, NADPH Oxidase Inhibitors targeting NOX3, NOX1 |
| AC-91-WE67_10uM | Dose=10uM, Acetovanillone, NADPH Oxidase Inhibitors targeting NOX3, NOX1 |
| AC-91-WE67_1uM | Dose=1uM, Acetovanillone, NADPH Oxidase Inhibitors targeting NOX3, NOX1 |
| AC-92-HS43_0.01uM | Dose=0.01uM, Colforsin, Adenylate Cyclase Activators targeting ADCY1, ADCY2, ADCY3, ADCY6, ADCY8, ADCYAP1, ADCY4 |
| AC-92-HS43_0.1uM | Dose=0.1uM, Colforsin, Adenylate Cyclase Activators targeting ADCY1, ADCY2, ADCY3, ADCY6, ADCY8, ADCYAP1, ADCY4 |
| AC-92-HS43_10uM | Dose=10uM, Colforsin, Adenylate Cyclase Activators targeting ADCY1, ADCY2, ADCY3, ADCY6, ADCY8, ADCYAP1, ADCY4 |
| AC-92-HS43_1uM | Dose=1uM, Colforsin, Adenylate Cyclase Activators targeting ADCY1, ADCY2, ADCY3, ADCY6, ADCY8, ADCYAP1, ADCY4 |
| AC-92-ZW28_0.01uM | Dose=0.01uM |
| AC-92-ZW28_10uM | Dose=10uM |
| AC-92-ZW28_1uM | Dose=1uM |
| AC-93-LT43_0.01uM | Dose=0.01uM, US11458138, Example 133, LATS inhibitor;Yap pathway activator targeting LATS1, LATS2 |
| AC-93-LT43_0.1uM | Dose=0.1uM, US11458138, Example 133, LATS inhibitor;Yap pathway activator targeting LATS1, LATS2 |
| AC-93-LT43_10uM | Dose=10uM, US11458138, Example 133, LATS inhibitor;Yap pathway activator targeting LATS1, LATS2 |
| AC-93-LT43_1uM | Dose=1uM, US11458138, Example 133, LATS inhibitor;Yap pathway activator targeting LATS1, LATS2 |
| AC-93-OJ74_0.01uM | Dose=0.01uM, Coumestrol, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;AGE Inhibitors (Maillard's Reaction Inhibitors) targeting ESR1, ESR2 |
| AC-93-OJ74_0.1uM | Dose=0.1uM, Coumestrol, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;AGE Inhibitors (Maillard's Reaction Inhibitors) targeting ESR1, ESR2 |
| AC-93-OJ74_10uM | Dose=10uM, Coumestrol, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;AGE Inhibitors (Maillard's Reaction Inhibitors) targeting ESR1, ESR2 |
| AC-93-OJ74_1uM | Dose=1uM, Coumestrol, Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;AGE Inhibitors (Maillard's Reaction Inhibitors) targeting ESR1, ESR2 |
| AC-93-QD45_0.01uM | Dose=0.01uM, targeting CGAS |
| AC-93-QD45_0.1uM | Dose=0.1uM, targeting CGAS |
| AC-93-QD45_10uM | Dose=10uM, targeting CGAS |
| AC-93-QD45_1uM | Dose=1uM, targeting CGAS |
| AC-94-JQ48_0.1uM | Dose=0.1uM, 5-[(R)-2-Cyano-2-((S)-2-phenylamino-3-m-tolyl-propionylamino)-ethoxymethyl]-2-fluoro-benzoic acid, Cathepsin B Inhibitors targeting CTSB |
| AC-94-JQ48_10uM | Dose=10uM, 5-[(R)-2-Cyano-2-((S)-2-phenylamino-3-m-tolyl-propionylamino)-ethoxymethyl]-2-fluoro-benzoic acid, Cathepsin B Inhibitors targeting CTSB |
| AC-94-JQ48_1uM | Dose=1uM, 5-[(R)-2-Cyano-2-((S)-2-phenylamino-3-m-tolyl-propionylamino)-ethoxymethyl]-2-fluoro-benzoic acid, Cathepsin B Inhibitors targeting CTSB |
| AC-94-SN51_0.01uM | Dose=0.01uM, US9815842, Example 21, MALT1 protease inhibitor targeting MALT1 |
| AC-94-SN51_0.1uM | Dose=0.1uM, US9815842, Example 21, MALT1 protease inhibitor targeting MALT1 |
| AC-94-SN51_10uM | Dose=10uM, US9815842, Example 21, MALT1 protease inhibitor targeting MALT1 |
| AC-94-SN51_1uM | Dose=1uM, US9815842, Example 21, MALT1 protease inhibitor targeting MALT1 |
| AC-94-YX80_0.01uM | Dose=0.01uM, Loratadine |
| AC-94-YX80_0.1uM | Dose=0.1uM, Loratadine |
| AC-94-YX80_10uM | Dose=10uM, Loratadine |
| AC-94-YX80_1uM | Dose=1uM, Loratadine |
| AC-95-MR73_0.01uM | Dose=0.01uM, Cyclizine, Drugs Acting on Histamine Receptors targeting HRH1, SULT1E1 |
| AC-95-MR73_0.1uM | Dose=0.1uM, Cyclizine, Drugs Acting on Histamine Receptors targeting HRH1, SULT1E1 |
| AC-95-MR73_10uM | Dose=10uM, Cyclizine, Drugs Acting on Histamine Receptors targeting HRH1, SULT1E1 |
| AC-95-MR73_1uM | Dose=1uM, Cyclizine, Drugs Acting on Histamine Receptors targeting HRH1, SULT1E1 |
| AC-95-MU00_0.01uM | Dose=0.01uM, Ranolazine, Sodium Channel Blockers targeting SCN5A, SCN9A |
| AC-95-MU00_0.1uM | Dose=0.1uM, Ranolazine, Sodium Channel Blockers targeting SCN5A, SCN9A |
| AC-95-MU00_10uM | Dose=10uM, Ranolazine, Sodium Channel Blockers targeting SCN5A, SCN9A |
| AC-95-MU00_1uM | Dose=1uM, Ranolazine, Sodium Channel Blockers targeting SCN5A, SCN9A |
| AC-95-NR38_0.01uM | Dose=0.01uM |
| AC-95-NR38_0.1uM | Dose=0.1uM |
| AC-95-NR38_10uM | Dose=10uM |
| AC-95-NR38_1uM | Dose=1uM |
| AC-95-TK81_0.01uM | Dose=0.01uM, Climbazole, Cyp Enzyme Inducers;Antifungal targeting CYP3A4 |
| AC-95-TK81_0.1uM | Dose=0.1uM, Climbazole, Cyp Enzyme Inducers;Antifungal targeting CYP3A4 |
| AC-95-TK81_10uM | Dose=10uM, Climbazole, Cyp Enzyme Inducers;Antifungal targeting CYP3A4 |
| AC-95-TK81_1uM | Dose=1uM, Climbazole, Cyp Enzyme Inducers;Antifungal targeting CYP3A4 |
| AC-96-OO08_0.01uM | Dose=0.01uM, cyclosporin A, Cyclophilin D Inhibitors;binds to cyclophilin;Cyclophilin modulator;Calcineurin inhibitor;Cyclphilin A Inhibitors targeting PPIA, PPID, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| AC-96-OO08_0.1uM | Dose=0.1uM, cyclosporin A, Cyclophilin D Inhibitors;binds to cyclophilin;Cyclophilin modulator;Calcineurin inhibitor;Cyclphilin A Inhibitors targeting PPIA, PPID, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| AC-96-OO08_10uM | Dose=10uM, cyclosporin A, Cyclophilin D Inhibitors;binds to cyclophilin;Cyclophilin modulator;Calcineurin inhibitor;Cyclphilin A Inhibitors targeting PPIA, PPID, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| AC-96-OO08_1uM | Dose=1uM, cyclosporin A, Cyclophilin D Inhibitors;binds to cyclophilin;Cyclophilin modulator;Calcineurin inhibitor;Cyclphilin A Inhibitors targeting PPIA, PPID, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| AC-97-KP88_0.01uM | Dose=0.01uM, 3-(6-(6-Methoxypyridin-3-ylamino)-2-morpholinopyrimidin-4-yl)phenol, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CA, PIK3CD |
| AC-97-KP88_0.1uM | Dose=0.1uM, 3-(6-(6-Methoxypyridin-3-ylamino)-2-morpholinopyrimidin-4-yl)phenol, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CA, PIK3CD |
| AC-97-KP88_10uM | Dose=10uM, 3-(6-(6-Methoxypyridin-3-ylamino)-2-morpholinopyrimidin-4-yl)phenol, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CA, PIK3CD |
| AC-97-KP88_1uM | Dose=1uM, 3-(6-(6-Methoxypyridin-3-ylamino)-2-morpholinopyrimidin-4-yl)phenol, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CA, PIK3CD |
| AC-98-QW77_0.01uM | Dose=0.01uM, CGC-11047 free base |
| AC-98-QW77_0.1uM | Dose=0.1uM, CGC-11047 free base |
| AC-98-QW77_10uM | Dose=10uM, CGC-11047 free base |
| AC-98-QW77_1uM | Dose=1uM, CGC-11047 free base |
| AC-98-UW57_0.01uM | Dose=0.01uM, Suplatast |
| AC-98-UW57_0.1uM | Dose=0.1uM, Suplatast |
| AC-98-UW57_10uM | Dose=10uM, Suplatast |
| AC-98-UW57_1uM | Dose=1uM, Suplatast |
| AC-99-ZN13_0.01uM | Dose=0.01uM, Ethoxzolamide, CA2 inhibitor;CA4 inhibitor;CA1 inhibitor;CA7 inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10 |
| AC-99-ZN13_10uM | Dose=10uM, Ethoxzolamide, CA2 inhibitor;CA4 inhibitor;CA1 inhibitor;CA7 inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10 |
| AC-99-ZN13_1uM | Dose=1uM, Ethoxzolamide, CA2 inhibitor;CA4 inhibitor;CA1 inhibitor;CA7 inhibitor targeting CA1, CA3, CA4, CA5A, CA7, CA8, CA11, CA5B, CA10 |
| AD-00-WA10_0.1uM | Dose=0.1uM, 1-{4-[N-(2-isopropyloxyethyl)-N-chloroacetylamino]benzoyl}-4-[2-(4-chlorophenyl)ethyl]piperazine |
| AD-00-WA10_10uM | Dose=10uM, 1-{4-[N-(2-isopropyloxyethyl)-N-chloroacetylamino]benzoyl}-4-[2-(4-chlorophenyl)ethyl]piperazine |
| AD-00-WA10_1uM | Dose=1uM, 1-{4-[N-(2-isopropyloxyethyl)-N-chloroacetylamino]benzoyl}-4-[2-(4-chlorophenyl)ethyl]piperazine |
| AD-00-ZK94_0.01uM | Dose=0.01uM, 3-[(2,4-Dichlorophenyl)methylsulfanyl]-1,6-dimethylpyridazino[4,5-e][1,3,4]thiadiazin-5-one targeting GPR65 |
| AD-00-ZK94_0.1uM | Dose=0.1uM, 3-[(2,4-Dichlorophenyl)methylsulfanyl]-1,6-dimethylpyridazino[4,5-e][1,3,4]thiadiazin-5-one targeting GPR65 |
| AD-00-ZK94_10uM | Dose=10uM, 3-[(2,4-Dichlorophenyl)methylsulfanyl]-1,6-dimethylpyridazino[4,5-e][1,3,4]thiadiazin-5-one targeting GPR65 |
| AD-02-XI19_0.01uM | Dose=0.01uM, 1-[4-(Dimethylamino)phenyl]-3-(1,5-naphthyridin-4-yl)urea, Orexin 1 receptor antagonist targeting HCRT |
| AD-02-XI19_0.1uM | Dose=0.1uM, 1-[4-(Dimethylamino)phenyl]-3-(1,5-naphthyridin-4-yl)urea, Orexin 1 receptor antagonist targeting HCRT |
| AD-02-XI19_10uM | Dose=10uM, 1-[4-(Dimethylamino)phenyl]-3-(1,5-naphthyridin-4-yl)urea, Orexin 1 receptor antagonist targeting HCRT |
| AD-02-XI19_1uM | Dose=1uM, 1-[4-(Dimethylamino)phenyl]-3-(1,5-naphthyridin-4-yl)urea, Orexin 1 receptor antagonist targeting HCRT |
| AD-06-OB47_0.01uM | Dose=0.01uM, N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide, CYP2C19 gene modulator targeting CYP2C19 |
| AD-06-OB47_0.1uM | Dose=0.1uM, N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide, CYP2C19 gene modulator targeting CYP2C19 |
| AD-06-OB47_10uM | Dose=10uM, N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide, CYP2C19 gene modulator targeting CYP2C19 |
| AD-06-OB47_1uM | Dose=1uM, N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide, CYP2C19 gene modulator targeting CYP2C19 |
| AD-07-US30_0.01uM | Dose=0.01uM, Emodin, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B |
| AD-07-US30_0.1uM | Dose=0.1uM, Emodin, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B |
| AD-07-US30_10uM | Dose=10uM, Emodin, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B |
| AD-07-US30_1uM | Dose=1uM, Emodin, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B |
| AD-07-YF79_0.01uM | Dose=0.01uM, N-(4-fluoro-2-methylphenyl)-3-methyl-N-[(2-methyl-1H-indol-4-yl)methyl]pyridine-4-carboxamide, GPBAR1 agonist;TGR5 agonist targeting GPBAR1 |
| AD-07-YF79_1uM | Dose=1uM, N-(4-fluoro-2-methylphenyl)-3-methyl-N-[(2-methyl-1H-indol-4-yl)methyl]pyridine-4-carboxamide, GPBAR1 agonist;TGR5 agonist targeting GPBAR1 |
| AD-09-MD49_0.01uM | Dose=0.01uM, 2-Chloro-4-[(3s,3as,4s)-4-Hydroxy-3-Methoxy-3a,4,5,6-Tetrahydro-3h-Pyrrolo[1,2-B]pyrazol-2-Yl]-3-Methylbenzonitrile, Androgen receptor modulator targeting AR |
| AD-09-MD49_0.1uM | Dose=0.1uM, 2-Chloro-4-[(3s,3as,4s)-4-Hydroxy-3-Methoxy-3a,4,5,6-Tetrahydro-3h-Pyrrolo[1,2-B]pyrazol-2-Yl]-3-Methylbenzonitrile, Androgen receptor modulator targeting AR |
| AD-09-MD49_10uM | Dose=10uM, 2-Chloro-4-[(3s,3as,4s)-4-Hydroxy-3-Methoxy-3a,4,5,6-Tetrahydro-3h-Pyrrolo[1,2-B]pyrazol-2-Yl]-3-Methylbenzonitrile, Androgen receptor modulator targeting AR |
| AD-09-MD49_1uM | Dose=1uM, 2-Chloro-4-[(3s,3as,4s)-4-Hydroxy-3-Methoxy-3a,4,5,6-Tetrahydro-3h-Pyrrolo[1,2-B]pyrazol-2-Yl]-3-Methylbenzonitrile, Androgen receptor modulator targeting AR |
| AD-09-TD34_0.01uM | Dose=0.01uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(5-isopropyl-4-methoxypyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN |
| AD-09-TD34_0.1uM | Dose=0.1uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(5-isopropyl-4-methoxypyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN |
| AD-09-TD34_1uM | Dose=1uM, (3R,5S)-N3-Cyclopropyl-N5-((R)-1-ethoxy-4-methylpentan-2-yl)-N3-(5-isopropyl-4-methoxypyridin-2-yl)piperidine-3,5-dicarboxamide, Renin Inhibitors targeting REN |
| AD-10-TH32_0.01uM | Dose=0.01uM, (R)-5-(6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide, Inhibitor of the BMP1/TLL1/TLL2 family of Proteases targeting BMP1 |
| AD-10-TH32_0.1uM | Dose=0.1uM, (R)-5-(6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide, Inhibitor of the BMP1/TLL1/TLL2 family of Proteases targeting BMP1 |
| AD-10-TH32_10uM | Dose=10uM, (R)-5-(6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide, Inhibitor of the BMP1/TLL1/TLL2 family of Proteases targeting BMP1 |
| AD-10-TH32_1uM | Dose=1uM, (R)-5-(6-cyclohexyl-1-(hydroxyamino)-1-oxohexan-3-yl)-1,2,4-oxadiazole-3-carboxamide, Inhibitor of the BMP1/TLL1/TLL2 family of Proteases targeting BMP1 |
| AD-10-ZS64_0.01uM | Dose=0.01uM, Ivabradine |
| AD-10-ZS64_0.1uM | Dose=0.1uM, Ivabradine |
| AD-10-ZS64_10uM | Dose=10uM, Ivabradine |
| AD-10-ZS64_1uM | Dose=1uM, Ivabradine |
| AD-11-FZ23_0.01uM | Dose=0.01uM, Alfuzosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| AD-11-FZ23_0.1uM | Dose=0.1uM, Alfuzosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| AD-11-FZ23_10uM | Dose=10uM, Alfuzosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| AD-11-FZ23_1uM | Dose=1uM, Alfuzosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| AD-11-HV98_0.01uM | Dose=0.01uM, Balicatib, Cathepsin K Inhibitors targeting CTSK |
| AD-11-HV98_0.1uM | Dose=0.1uM, Balicatib, Cathepsin K Inhibitors targeting CTSK |
| AD-11-HV98_10uM | Dose=10uM, Balicatib, Cathepsin K Inhibitors targeting CTSK |
| AD-11-HV98_1uM | Dose=1uM, Balicatib, Cathepsin K Inhibitors targeting CTSK |
| AD-11-RL84_0.01uM | Dose=0.01uM, 4-({2-[(4-bromophenyl)(methyl)amino]-1H-1,3-benzodiazol-5-yl}oxy)-N-methylpyridine-2-carboxamide, Raf kinase B Inhibitors;Raf kinase C Inhibitors targeting BRAF, RAF1 |
| AD-11-RL84_0.1uM | Dose=0.1uM, 4-({2-[(4-bromophenyl)(methyl)amino]-1H-1,3-benzodiazol-5-yl}oxy)-N-methylpyridine-2-carboxamide, Raf kinase B Inhibitors;Raf kinase C Inhibitors targeting BRAF, RAF1 |
| AD-11-RL84_10uM | Dose=10uM, 4-({2-[(4-bromophenyl)(methyl)amino]-1H-1,3-benzodiazol-5-yl}oxy)-N-methylpyridine-2-carboxamide, Raf kinase B Inhibitors;Raf kinase C Inhibitors targeting BRAF, RAF1 |
| AD-11-RL84_1uM | Dose=1uM, 4-({2-[(4-bromophenyl)(methyl)amino]-1H-1,3-benzodiazol-5-yl}oxy)-N-methylpyridine-2-carboxamide, Raf kinase B Inhibitors;Raf kinase C Inhibitors targeting BRAF, RAF1 |
| AD-11-VE17_0.01uM | Dose=0.01uM, (Z)-2-amino-4-methyl-5-phosphonopent-3-enoic acid, Kainate receptor antagonist targeting GRIK1, GRIK2, GRIK3, GRIK4, GRIK5 |
| AD-11-VE17_0.1uM | Dose=0.1uM, (Z)-2-amino-4-methyl-5-phosphonopent-3-enoic acid, Kainate receptor antagonist targeting GRIK1, GRIK2, GRIK3, GRIK4, GRIK5 |
| AD-11-VE17_10uM | Dose=10uM, (Z)-2-amino-4-methyl-5-phosphonopent-3-enoic acid, Kainate receptor antagonist targeting GRIK1, GRIK2, GRIK3, GRIK4, GRIK5 |
| AD-12-YF12_0.01uM | Dose=0.01uM, Umbelliferone, Carbonic Anhydrase Type XII Inhibitors;Cyclooxygenase-2 Inhibitors;Carbonic Anhydrase Type IX Inhibitors;Antioxidants targeting CA9, CA12, PTGS2 |
| AD-12-YF12_0.1uM | Dose=0.1uM, Umbelliferone, Carbonic Anhydrase Type XII Inhibitors;Cyclooxygenase-2 Inhibitors;Carbonic Anhydrase Type IX Inhibitors;Antioxidants targeting CA9, CA12, PTGS2 |
| AD-12-YF12_10uM | Dose=10uM, Umbelliferone, Carbonic Anhydrase Type XII Inhibitors;Cyclooxygenase-2 Inhibitors;Carbonic Anhydrase Type IX Inhibitors;Antioxidants targeting CA9, CA12, PTGS2 |
| AD-14-QD12_0.01uM | Dose=0.01uM, 5-[1-Fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein tyrosine phosphatase-1B inhibitor;T-cell protein tyrosine phosphatase inhibitor targeting PTPN1, PTPN2 |
| AD-14-QD12_0.1uM | Dose=0.1uM, 5-[1-Fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein tyrosine phosphatase-1B inhibitor;T-cell protein tyrosine phosphatase inhibitor targeting PTPN1, PTPN2 |
| AD-14-QD12_10uM | Dose=10uM, 5-[1-Fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein tyrosine phosphatase-1B inhibitor;T-cell protein tyrosine phosphatase inhibitor targeting PTPN1, PTPN2 |
| AD-14-QD12_1uM | Dose=1uM, 5-[1-Fluoro-3-hydroxy-7-(4-hydroxy-4-methylpentyl)naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein tyrosine phosphatase-1B inhibitor;T-cell protein tyrosine phosphatase inhibitor targeting PTPN1, PTPN2 |
| AD-15-VR38_0.01uM | Dose=0.01uM, (2S,4R)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-4-[(4-chlorophenyl)methoxy]-1-[2-(5-methyl-2-piperidin-4-yl-1,3-thiazol-4-yl)acetyl]pyrrolidine-2-carboxamide, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14 |
| AD-15-VR38_0.1uM | Dose=0.1uM, (2S,4R)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-4-[(4-chlorophenyl)methoxy]-1-[2-(5-methyl-2-piperidin-4-yl-1,3-thiazol-4-yl)acetyl]pyrrolidine-2-carboxamide, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14 |
| AD-15-VR38_10uM | Dose=10uM, (2S,4R)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-4-[(4-chlorophenyl)methoxy]-1-[2-(5-methyl-2-piperidin-4-yl-1,3-thiazol-4-yl)acetyl]pyrrolidine-2-carboxamide, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14 |
| AD-15-VR38_1uM | Dose=1uM, (2S,4R)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-4-[(4-chlorophenyl)methoxy]-1-[2-(5-methyl-2-piperidin-4-yl-1,3-thiazol-4-yl)acetyl]pyrrolidine-2-carboxamide, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14 |
| AD-16-HL96_0.01uM | Dose=0.01uM, Nannocystin A, Elongation factor 1 alpha 1 inhibitor targeting EEF1A1 |
| AD-16-HL96_0.1uM | Dose=0.1uM, Nannocystin A, Elongation factor 1 alpha 1 inhibitor targeting EEF1A1 |
| AD-16-HL96_10uM | Dose=10uM, Nannocystin A, Elongation factor 1 alpha 1 inhibitor targeting EEF1A1 |
| AD-16-HL96_1uM | Dose=1uM, Nannocystin A, Elongation factor 1 alpha 1 inhibitor targeting EEF1A1 |
| AD-16-OE34_0.01uM | Dose=0.01uM, Octopamine |
| AD-16-OE34_0.1uM | Dose=0.1uM, Octopamine |
| AD-16-OE34_10uM | Dose=10uM, Octopamine |
| AD-16-OE34_1uM | Dose=1uM, Octopamine |
| AD-18-VX25_0.01uM | Dose=0.01uM, Arecoline, Muscarinic Receptor Agonists;Potassium Channel Subfamily K Member 18 (TRESK KCNK18) Blockers targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, KCNK18 |
| AD-18-VX25_0.1uM | Dose=0.1uM, Arecoline, Muscarinic Receptor Agonists;Potassium Channel Subfamily K Member 18 (TRESK KCNK18) Blockers targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, KCNK18 |
| AD-18-VX25_10uM | Dose=10uM, Arecoline, Muscarinic Receptor Agonists;Potassium Channel Subfamily K Member 18 (TRESK KCNK18) Blockers targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, KCNK18 |
| AD-18-VX25_1uM | Dose=1uM, Arecoline, Muscarinic Receptor Agonists;Potassium Channel Subfamily K Member 18 (TRESK KCNK18) Blockers targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, KCNK18 |
| AD-18-XC14_0.01uM | Dose=0.01uM, 10-Deazaaminopterin, Folate Antagonists targeting FOLR1 |
| AD-18-XC14_0.1uM | Dose=0.1uM, 10-Deazaaminopterin, Folate Antagonists targeting FOLR1 |
| AD-18-XC14_10uM | Dose=10uM, 10-Deazaaminopterin, Folate Antagonists targeting FOLR1 |
| AD-18-XC14_1uM | Dose=1uM, 10-Deazaaminopterin, Folate Antagonists targeting FOLR1 |
| AD-19-GH34_0.01uM | Dose=0.01uM, Gsk-lsd1, KDM1A/B targeting KDM1A |
| AD-19-GH34_0.1uM | Dose=0.1uM, Gsk-lsd1, KDM1A/B targeting KDM1A |
| AD-19-GH34_10uM | Dose=10uM, Gsk-lsd1, KDM1A/B targeting KDM1A |
| AD-20-AA40_0.01uM | Dose=0.01uM, Cdc2-like kinase inhibitor, CDC-like kinase-1 inhibitors targeting CLK1, CLK2, CLK4 |
| AD-20-AA40_10uM | Dose=10uM, Cdc2-like kinase inhibitor, CDC-like kinase-1 inhibitors targeting CLK1, CLK2, CLK4 |
| AD-20-AA40_1uM | Dose=1uM, Cdc2-like kinase inhibitor, CDC-like kinase-1 inhibitors targeting CLK1, CLK2, CLK4 |
| AD-20-CH42_0.01uM | Dose=0.01uM, 4-[3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide, CDC42 Rho GTPase inhibitor targeting CDC42 |
| AD-20-CH42_0.1uM | Dose=0.1uM, 4-[3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide, CDC42 Rho GTPase inhibitor targeting CDC42 |
| AD-20-CH42_10uM | Dose=10uM, 4-[3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide, CDC42 Rho GTPase inhibitor targeting CDC42 |
| AD-20-CH42_1uM | Dose=1uM, 4-[3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide, CDC42 Rho GTPase inhibitor targeting CDC42 |
| AD-20-KA75_10uM | Dose=10uM, 1H-1,4-Diazepine, hexahydro-1-((5-iodo-1-naphthalenyl)sulfonyl)-, Myosin Light Chain Kinase (MLCK) Inhibitors targeting MYLK, MYLK2, MYLK3, MYLK4 |
| AD-20-KA75_1uM | Dose=1uM, 1H-1,4-Diazepine, hexahydro-1-((5-iodo-1-naphthalenyl)sulfonyl)-, Myosin Light Chain Kinase (MLCK) Inhibitors targeting MYLK, MYLK2, MYLK3, MYLK4 |
| AD-20-YO14_0.01uM | Dose=0.01uM, Ars-1620 targeting KRAS |
| AD-20-YO14_0.1uM | Dose=0.1uM, Ars-1620 targeting KRAS |
| AD-20-YO14_10uM | Dose=10uM, Ars-1620 targeting KRAS |
| AD-20-YO14_1uM | Dose=1uM, Ars-1620 targeting KRAS |
| AD-21-WS76_0.01uM | Dose=0.01uM, 7-(4-bromo-2-fluoroanilino)-N-(cyclopropylmethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide |
| AD-21-WS76_0.1uM | Dose=0.1uM, 7-(4-bromo-2-fluoroanilino)-N-(cyclopropylmethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide |
| AD-21-WS76_10uM | Dose=10uM, 7-(4-bromo-2-fluoroanilino)-N-(cyclopropylmethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide |
| AD-21-WS76_1uM | Dose=1uM, 7-(4-bromo-2-fluoroanilino)-N-(cyclopropylmethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide |
| AD-23-AN14_0.01uM | Dose=0.01uM, Tranilast, Urate Transporter 1 (URAT1) Inhibitors;Indoleamine 2,3-dioxygenase Activators;IFN-gamma Production Inhibitors;IL-2 Production Inhibitors;TNF-alpha Production Inhibitors;IL-10 Production Enhancers;IL-4 Modulators;Signal Transduction Modulators targeting HEXB, IDO1, TRPV2, SLC22A12 |
| AD-23-AN14_0.1uM | Dose=0.1uM, Tranilast, Urate Transporter 1 (URAT1) Inhibitors;Indoleamine 2,3-dioxygenase Activators;IFN-gamma Production Inhibitors;IL-2 Production Inhibitors;TNF-alpha Production Inhibitors;IL-10 Production Enhancers;IL-4 Modulators;Signal Transduction Modulators targeting HEXB, IDO1, TRPV2, SLC22A12 |
| AD-23-AN14_10uM | Dose=10uM, Tranilast, Urate Transporter 1 (URAT1) Inhibitors;Indoleamine 2,3-dioxygenase Activators;IFN-gamma Production Inhibitors;IL-2 Production Inhibitors;TNF-alpha Production Inhibitors;IL-10 Production Enhancers;IL-4 Modulators;Signal Transduction Modulators targeting HEXB, IDO1, TRPV2, SLC22A12 |
| AD-24-KU93_0.01uM | Dose=0.01uM, (6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl){2-[(4-methoxyphenyl)amino]-1,3-thiazol-4-yl}methanone |
| AD-24-KU93_0.1uM | Dose=0.1uM, (6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl){2-[(4-methoxyphenyl)amino]-1,3-thiazol-4-yl}methanone |
| AD-24-KU93_10uM | Dose=10uM, (6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl){2-[(4-methoxyphenyl)amino]-1,3-thiazol-4-yl}methanone |
| AD-24-KU93_1uM | Dose=1uM, (6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl){2-[(4-methoxyphenyl)amino]-1,3-thiazol-4-yl}methanone |
| AD-26-RY42_0.01uM | Dose=0.01uM, 5-[[Pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid |
| AD-26-RY42_0.1uM | Dose=0.1uM, 5-[[Pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid |
| AD-26-RY42_10uM | Dose=10uM, 5-[[Pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid |
| AD-26-RY42_1uM | Dose=1uM, 5-[[Pyridin-3-yl-[3-(trifluoromethyl)phenyl]methylidene]amino]oxypentanoic acid |
| AD-26-SL71_0.1uM | Dose=0.1uM, 6-(2,2-Diphenylethylamino)-9-[(2r,3r,4s,5s)-5-(Ethylcarbamoyl)-3,4-Dihydroxy-Oxolan-2-Yl]-N-[2-[(1-Pyridin-2-Ylpiperidin-4-Yl)carbamoylamino]ethyl]purine-2-Carboxamide, Adenosine A2A Agonists targeting ADORA2A |
| AD-26-SL71_10uM | Dose=10uM, 6-(2,2-Diphenylethylamino)-9-[(2r,3r,4s,5s)-5-(Ethylcarbamoyl)-3,4-Dihydroxy-Oxolan-2-Yl]-N-[2-[(1-Pyridin-2-Ylpiperidin-4-Yl)carbamoylamino]ethyl]purine-2-Carboxamide, Adenosine A2A Agonists targeting ADORA2A |
| AD-26-SL71_1uM | Dose=1uM, 6-(2,2-Diphenylethylamino)-9-[(2r,3r,4s,5s)-5-(Ethylcarbamoyl)-3,4-Dihydroxy-Oxolan-2-Yl]-N-[2-[(1-Pyridin-2-Ylpiperidin-4-Yl)carbamoylamino]ethyl]purine-2-Carboxamide, Adenosine A2A Agonists targeting ADORA2A |
| AD-27-JS45_0.01uM | Dose=0.01uM, 4-Methylhistamine, HRH4 agonist targeting HRH4 |
| AD-27-JS45_0.1uM | Dose=0.1uM, 4-Methylhistamine, HRH4 agonist targeting HRH4 |
| AD-27-JS45_10uM | Dose=10uM, 4-Methylhistamine, HRH4 agonist targeting HRH4 |
| AD-27-JS45_1uM | Dose=1uM, 4-Methylhistamine, HRH4 agonist targeting HRH4 |
| AD-28-GJ71_0.01uM | Dose=0.01uM, 2-(4-(2-Carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine, Adenosine A2A Agonists targeting ADORA2A |
| AD-28-GJ71_0.1uM | Dose=0.1uM, 2-(4-(2-Carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine, Adenosine A2A Agonists targeting ADORA2A |
| AD-28-GJ71_10uM | Dose=10uM, 2-(4-(2-Carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine, Adenosine A2A Agonists targeting ADORA2A |
| AD-29-IG16_0.01uM | Dose=0.01uM, Dibenzalacetone, N-Myristoyltransferase 1 (NMT1) Inhibitors targeting NMT1 |
| AD-29-IG16_0.1uM | Dose=0.1uM, Dibenzalacetone, N-Myristoyltransferase 1 (NMT1) Inhibitors targeting NMT1 |
| AD-29-IG16_10uM | Dose=10uM, Dibenzalacetone, N-Myristoyltransferase 1 (NMT1) Inhibitors targeting NMT1 |
| AD-29-IG16_1uM | Dose=1uM, Dibenzalacetone, N-Myristoyltransferase 1 (NMT1) Inhibitors targeting NMT1 |
| AD-29-MQ00_0.01uM | Dose=0.01uM, (2S)-4-amino-2-[[2-chloro-4-[1-(3-hydroxyphenyl)ethylcarbamoyl]benzoyl]amino]-4-oxobutanoic acid |
| AD-29-MQ00_0.1uM | Dose=0.1uM, (2S)-4-amino-2-[[2-chloro-4-[1-(3-hydroxyphenyl)ethylcarbamoyl]benzoyl]amino]-4-oxobutanoic acid |
| AD-29-MQ00_10uM | Dose=10uM, (2S)-4-amino-2-[[2-chloro-4-[1-(3-hydroxyphenyl)ethylcarbamoyl]benzoyl]amino]-4-oxobutanoic acid |
| AD-29-MQ00_1uM | Dose=1uM, (2S)-4-amino-2-[[2-chloro-4-[1-(3-hydroxyphenyl)ethylcarbamoyl]benzoyl]amino]-4-oxobutanoic acid |
| AD-30-OK99_0.01uM | Dose=0.01uM, 3-Isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3,7-dihydro-purine-2,6-dione, Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A |
| AD-30-OK99_0.1uM | Dose=0.1uM, 3-Isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3,7-dihydro-purine-2,6-dione, Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A |
| AD-30-OK99_10uM | Dose=10uM, 3-Isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3,7-dihydro-purine-2,6-dione, Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A |
| AD-30-OK99_1uM | Dose=1uM, 3-Isobutyl-8-(6-methoxy-isoquinolin-4-ylmethyl)-1-methyl-3,7-dihydro-purine-2,6-dione, Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A |
| AD-30-SU93_0.01uM | Dose=0.01uM, Isoloxapine, Dopamine D2 Receptor Ligands;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D4 Receptor Ligands;5-HT2A Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| AD-30-SU93_0.1uM | Dose=0.1uM, Isoloxapine, Dopamine D2 Receptor Ligands;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D4 Receptor Ligands;5-HT2A Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| AD-30-SU93_10uM | Dose=10uM, Isoloxapine, Dopamine D2 Receptor Ligands;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D4 Receptor Ligands;5-HT2A Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| AD-30-SU93_1uM | Dose=1uM, Isoloxapine, Dopamine D2 Receptor Ligands;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;Dopamine D4 Receptor Ligands;5-HT2A Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| AD-30-TH52_0.01uM | Dose=0.01uM, 5-[2-Methoxy-5-(4-pyridinyl)phenyl]-2,1,3-benzoxadiazole, Phosphodiesterase PDE4D Inhibitors;TNF-alpha Production Inhibitors targeting PDE4D |
| AD-30-TH52_10uM | Dose=10uM, 5-[2-Methoxy-5-(4-pyridinyl)phenyl]-2,1,3-benzoxadiazole, Phosphodiesterase PDE4D Inhibitors;TNF-alpha Production Inhibitors targeting PDE4D |
| AD-30-TH52_1uM | Dose=1uM, 5-[2-Methoxy-5-(4-pyridinyl)phenyl]-2,1,3-benzoxadiazole, Phosphodiesterase PDE4D Inhibitors;TNF-alpha Production Inhibitors targeting PDE4D |
| AD-30-TH82_0.1uM | Dose=0.1uM, Vadimezan, Interferon Inducers;Vascular Disrupting Agents (VDA);Mouse STING agonist targeting STING1 |
| AD-30-TH82_10uM | Dose=10uM, Vadimezan, Interferon Inducers;Vascular Disrupting Agents (VDA);Mouse STING agonist targeting STING1 |
| AD-30-TH82_1uM | Dose=1uM, Vadimezan, Interferon Inducers;Vascular Disrupting Agents (VDA);Mouse STING agonist targeting STING1 |
| AD-30-VB23_10uM | Dose=10uM, Rotenone, Apoptosis Inducers;NADH-Ubiquinone Oxidoreductase (Complex I) Inhibitors;Non-Steroidal Antiinflammatory Drugs;Electron Transport Chain Inhibitors;Electron transport chain inhibitor targeting NDUFS1, NOX4, NOX5 |
| AD-30-VB23_1uM | Dose=1uM, Rotenone, Apoptosis Inducers;NADH-Ubiquinone Oxidoreductase (Complex I) Inhibitors;Non-Steroidal Antiinflammatory Drugs;Electron Transport Chain Inhibitors;Electron transport chain inhibitor targeting NDUFS1, NOX4, NOX5 |
| AD-31-GO06_0.01uM | Dose=0.01uM, 7-chloro-3-[3-(dimethylamino)propyl]-2-sulfanylidene-1H-quinazolin-4-one |
| AD-31-GO06_0.1uM | Dose=0.1uM, 7-chloro-3-[3-(dimethylamino)propyl]-2-sulfanylidene-1H-quinazolin-4-one |
| AD-31-GO06_10uM | Dose=10uM, 7-chloro-3-[3-(dimethylamino)propyl]-2-sulfanylidene-1H-quinazolin-4-one |
| AD-31-GO06_1uM | Dose=1uM, 7-chloro-3-[3-(dimethylamino)propyl]-2-sulfanylidene-1H-quinazolin-4-one |
| AD-31-PI82_0.01uM | Dose=0.01uM, 2-(benzyloxy)-5-(2-fluoropyridin-4-yl)-N-(pyridin-3-yl)benzamide, LRRK2 gene inhibitor targeting LRRK2 |
| AD-31-PI82_0.1uM | Dose=0.1uM, 2-(benzyloxy)-5-(2-fluoropyridin-4-yl)-N-(pyridin-3-yl)benzamide, LRRK2 gene inhibitor targeting LRRK2 |
| AD-31-PI82_10uM | Dose=10uM, 2-(benzyloxy)-5-(2-fluoropyridin-4-yl)-N-(pyridin-3-yl)benzamide, LRRK2 gene inhibitor targeting LRRK2 |
| AD-31-PI82_1uM | Dose=1uM, 2-(benzyloxy)-5-(2-fluoropyridin-4-yl)-N-(pyridin-3-yl)benzamide, LRRK2 gene inhibitor targeting LRRK2 |
| AD-32-RF17_0.01uM | Dose=0.01uM, (3s,4r,5r)-N-Cyclopropyl-N'-[(2r)-1-Ethoxy-4-Methylpentan-2-Yl]-4-Hydroxy-N-[5-(Propan-2-Yl)pyridin-2-Yl]piperidine-3,5-Dicarboxamide, Renin Inhibitors;direct renin inhibitor targeting REN |
| AD-32-RF17_0.1uM | Dose=0.1uM, (3s,4r,5r)-N-Cyclopropyl-N'-[(2r)-1-Ethoxy-4-Methylpentan-2-Yl]-4-Hydroxy-N-[5-(Propan-2-Yl)pyridin-2-Yl]piperidine-3,5-Dicarboxamide, Renin Inhibitors;direct renin inhibitor targeting REN |
| AD-32-RF17_10uM | Dose=10uM, (3s,4r,5r)-N-Cyclopropyl-N'-[(2r)-1-Ethoxy-4-Methylpentan-2-Yl]-4-Hydroxy-N-[5-(Propan-2-Yl)pyridin-2-Yl]piperidine-3,5-Dicarboxamide, Renin Inhibitors;direct renin inhibitor targeting REN |
| AD-32-RF17_1uM | Dose=1uM, (3s,4r,5r)-N-Cyclopropyl-N'-[(2r)-1-Ethoxy-4-Methylpentan-2-Yl]-4-Hydroxy-N-[5-(Propan-2-Yl)pyridin-2-Yl]piperidine-3,5-Dicarboxamide, Renin Inhibitors;direct renin inhibitor targeting REN |
| AD-33-YW85_0.01uM | Dose=0.01uM, (3-Aminopropyl)(n-butyl)phosphinic acid |
| AD-33-YW85_0.1uM | Dose=0.1uM, (3-Aminopropyl)(n-butyl)phosphinic acid |
| AD-33-YW85_10uM | Dose=10uM, (3-Aminopropyl)(n-butyl)phosphinic acid |
| AD-33-YW85_1uM | Dose=1uM, (3-Aminopropyl)(n-butyl)phosphinic acid |
| AD-34-TG29_0.01uM | Dose=0.01uM, 3-(Indol-3-yl)propionic acid, beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Free Radical Scavengers targeting APP |
| AD-34-TG29_0.1uM | Dose=0.1uM, 3-(Indol-3-yl)propionic acid, beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Free Radical Scavengers targeting APP |
| AD-34-TG29_10uM | Dose=10uM, 3-(Indol-3-yl)propionic acid, beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Free Radical Scavengers targeting APP |
| AD-34-TG29_1uM | Dose=1uM, 3-(Indol-3-yl)propionic acid, beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Free Radical Scavengers targeting APP |
| AD-34-WD27_0.01uM | Dose=0.01uM, 7-Bromo-1,2,3,4-tetrahydroisoquinoline, Phenylethanolamine N-methyltransferase inhibitor targeting PNMT |
| AD-34-WD27_0.1uM | Dose=0.1uM, 7-Bromo-1,2,3,4-tetrahydroisoquinoline, Phenylethanolamine N-methyltransferase inhibitor targeting PNMT |
| AD-34-WD27_10uM | Dose=10uM, 7-Bromo-1,2,3,4-tetrahydroisoquinoline, Phenylethanolamine N-methyltransferase inhibitor targeting PNMT |
| AD-34-WD27_1uM | Dose=1uM, 7-Bromo-1,2,3,4-tetrahydroisoquinoline, Phenylethanolamine N-methyltransferase inhibitor targeting PNMT |
| AD-37-DF79_0.01uM | Dose=0.01uM, mGluR4-PAM-1, MGLUR4 positive allosteric modulator targeting GRM4 |
| AD-37-DF79_0.1uM | Dose=0.1uM, mGluR4-PAM-1, MGLUR4 positive allosteric modulator targeting GRM4 |
| AD-37-DF79_10uM | Dose=10uM, mGluR4-PAM-1, MGLUR4 positive allosteric modulator targeting GRM4 |
| AD-37-DF79_1uM | Dose=1uM, mGluR4-PAM-1, MGLUR4 positive allosteric modulator targeting GRM4 |
| AD-37-UF49_0.01uM | Dose=0.01uM, (S)-N1-(4-Methyl-5-(2-(1-methylcyclopropyl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| AD-37-UF49_0.1uM | Dose=0.1uM, (S)-N1-(4-Methyl-5-(2-(1-methylcyclopropyl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| AD-37-UF49_10uM | Dose=10uM, (S)-N1-(4-Methyl-5-(2-(1-methylcyclopropyl)pyridin-4-yl)thiazol-2-yl)pyrrolidine-1,2-dicarboxamide, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| AD-38-OG44_0.01uM | Dose=0.01uM, Bempedoic Acid, ATP citrate lyase inhibitor targeting ACLY |
| AD-38-OG44_0.1uM | Dose=0.1uM, Bempedoic Acid, ATP citrate lyase inhibitor targeting ACLY |
| AD-38-OG44_10uM | Dose=10uM, Bempedoic Acid, ATP citrate lyase inhibitor targeting ACLY |
| AD-38-OG44_1uM | Dose=1uM, Bempedoic Acid, ATP citrate lyase inhibitor targeting ACLY |
| AD-39-JN68_0.01uM | Dose=0.01uM, PI3K|A inhibitor 4, PI3 kinase p85 regulatory subunit gamma inhibitor targeting PIK3CG |
| AD-39-JN68_0.1uM | Dose=0.1uM, PI3K|A inhibitor 4, PI3 kinase p85 regulatory subunit gamma inhibitor targeting PIK3CG |
| AD-39-JN68_10uM | Dose=10uM, PI3K|A inhibitor 4, PI3 kinase p85 regulatory subunit gamma inhibitor targeting PIK3CG |
| AD-39-JN68_1uM | Dose=1uM, PI3K|A inhibitor 4, PI3 kinase p85 regulatory subunit gamma inhibitor targeting PIK3CG |
| AD-39-QQ00_0.01uM | Dose=0.01uM, S-Methyl-L-thiocitrulline, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| AD-39-QQ00_0.1uM | Dose=0.1uM, S-Methyl-L-thiocitrulline, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| AD-39-QQ00_1uM | Dose=1uM, S-Methyl-L-thiocitrulline, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| AD-40-WB93_0.01uM | Dose=0.01uM, Avutometinib, MEK1 Inhibitors targeting MAP2K1 |
| AD-40-WB93_0.1uM | Dose=0.1uM, Avutometinib, MEK1 Inhibitors targeting MAP2K1 |
| AD-40-WB93_10uM | Dose=10uM, Avutometinib, MEK1 Inhibitors targeting MAP2K1 |
| AD-40-WB93_1uM | Dose=1uM, Avutometinib, MEK1 Inhibitors targeting MAP2K1 |
| AD-41-WB70_0.01uM | Dose=0.01uM, {5-[2-(2,6-Dichloro-phenyl)-3H-benzoimidazol-5-yl]-[1,3,4]oxadiazol-2-yl}-(6-methyl-pyridin-3-yl)-amine, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| AD-41-WB70_0.1uM | Dose=0.1uM, {5-[2-(2,6-Dichloro-phenyl)-3H-benzoimidazol-5-yl]-[1,3,4]oxadiazol-2-yl}-(6-methyl-pyridin-3-yl)-amine, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| AD-41-WB70_10uM | Dose=10uM, {5-[2-(2,6-Dichloro-phenyl)-3H-benzoimidazol-5-yl]-[1,3,4]oxadiazol-2-yl}-(6-methyl-pyridin-3-yl)-amine, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| AD-41-WB70_1uM | Dose=1uM, {5-[2-(2,6-Dichloro-phenyl)-3H-benzoimidazol-5-yl]-[1,3,4]oxadiazol-2-yl}-(6-methyl-pyridin-3-yl)-amine, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| AD-42-OW73_0.01uM | Dose=0.01uM, SB 415286 targeting GSK3A, GSK3B |
| AD-42-OW73_0.1uM | Dose=0.1uM, SB 415286 targeting GSK3A, GSK3B |
| AD-42-OW73_10uM | Dose=10uM, SB 415286 targeting GSK3A, GSK3B |
| AD-42-OW73_1uM | Dose=1uM, SB 415286 targeting GSK3A, GSK3B |
| AD-42-US78_0.01uM | Dose=0.01uM, Isoproterenol, beta-Adrenoceptor Agonists targeting ADRB1, ADRB2, ADRB3 |
| AD-42-US78_0.1uM | Dose=0.1uM, Isoproterenol, beta-Adrenoceptor Agonists targeting ADRB1, ADRB2, ADRB3 |
| AD-42-US78_10uM | Dose=10uM, Isoproterenol, beta-Adrenoceptor Agonists targeting ADRB1, ADRB2, ADRB3 |
| AD-42-US78_1uM | Dose=1uM, Isoproterenol, beta-Adrenoceptor Agonists targeting ADRB1, ADRB2, ADRB3 |
| AD-42-VF57_0.01uM | Dose=0.01uM, [[[[(2R,3S,4R,5R)-5-(6-amino-2-propylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]-dichloromethyl]phosphonic acid, P2RY12 (P2T) Antagonists targeting P2RY12 |
| AD-42-VF57_0.1uM | Dose=0.1uM, [[[[(2R,3S,4R,5R)-5-(6-amino-2-propylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]-dichloromethyl]phosphonic acid, P2RY12 (P2T) Antagonists targeting P2RY12 |
| AD-43-EQ11_0.01uM | Dose=0.01uM, 5-[(dimethylamino)methyl]-2-[(1S)-1-(4-ethoxy-5-fluoropyridin-2-yl)ethyl]-7-[[2-(methylamino)imidazol-1-yl]methyl]-3,4-dihydroisoquinolin-1-one |
| AD-43-EQ11_0.1uM | Dose=0.1uM, 5-[(dimethylamino)methyl]-2-[(1S)-1-(4-ethoxy-5-fluoropyridin-2-yl)ethyl]-7-[[2-(methylamino)imidazol-1-yl]methyl]-3,4-dihydroisoquinolin-1-one |
| AD-43-EQ11_10uM | Dose=10uM, 5-[(dimethylamino)methyl]-2-[(1S)-1-(4-ethoxy-5-fluoropyridin-2-yl)ethyl]-7-[[2-(methylamino)imidazol-1-yl]methyl]-3,4-dihydroisoquinolin-1-one |
| AD-43-EQ11_1uM | Dose=1uM, 5-[(dimethylamino)methyl]-2-[(1S)-1-(4-ethoxy-5-fluoropyridin-2-yl)ethyl]-7-[[2-(methylamino)imidazol-1-yl]methyl]-3,4-dihydroisoquinolin-1-one |
| AD-43-WX13_0.01uM | Dose=0.01uM, (2e,3ar,14as)-9-Bromo-2-Imino-1,2,3,5,6,14a-Hexahydro-4h,8h-Imidazo[4',5':5,6]pyrrolo[1',2':4,5]pyrazino[1,2-A]indol-8-One, Proteasome beta-5 subunit inhibitor targeting PSMB5 |
| AD-43-WX13_10uM | Dose=10uM, (2e,3ar,14as)-9-Bromo-2-Imino-1,2,3,5,6,14a-Hexahydro-4h,8h-Imidazo[4',5':5,6]pyrrolo[1',2':4,5]pyrazino[1,2-A]indol-8-One, Proteasome beta-5 subunit inhibitor targeting PSMB5 |
| AD-43-XJ59_0.01uM | Dose=0.01uM, Lucerastat, Ceramide Glucosyltransferase Inhibitors targeting UGCG |
| AD-43-XJ59_0.1uM | Dose=0.1uM, Lucerastat, Ceramide Glucosyltransferase Inhibitors targeting UGCG |
| AD-43-XJ59_10uM | Dose=10uM, Lucerastat, Ceramide Glucosyltransferase Inhibitors targeting UGCG |
| AD-43-XJ59_1uM | Dose=1uM, Lucerastat, Ceramide Glucosyltransferase Inhibitors targeting UGCG |
| AD-45-DA82_10uM | Dose=10uM, Niemann-Pick C1-like protein 1 (NPC1L1) Inhibitors;Cholesterol Absorption Inhibitors |
| AD-45-YB25_0.01uM | Dose=0.01uM, Buspirone, 5-HT1A Receptor Agonists;ADRA1B partial agonist targeting ADRA1B, HTR1A |
| AD-45-YB25_0.1uM | Dose=0.1uM, Buspirone, 5-HT1A Receptor Agonists;ADRA1B partial agonist targeting ADRA1B, HTR1A |
| AD-45-YB25_10uM | Dose=10uM, Buspirone, 5-HT1A Receptor Agonists;ADRA1B partial agonist targeting ADRA1B, HTR1A |
| AD-45-YB25_1uM | Dose=1uM, Buspirone, 5-HT1A Receptor Agonists;ADRA1B partial agonist targeting ADRA1B, HTR1A |
| AD-49-MG76_0.01uM | Dose=0.01uM, Clozapine, 5-HT2 Antagonists;Dopamine D4 Antagonists;ADRA1B gene inhibitor targeting ADRA1B, CHRM5, DRD4, HTR1E, HTR1F |
| AD-49-MG76_0.1uM | Dose=0.1uM, Clozapine, 5-HT2 Antagonists;Dopamine D4 Antagonists;ADRA1B gene inhibitor targeting ADRA1B, CHRM5, DRD4, HTR1E, HTR1F |
| AD-49-MG76_10uM | Dose=10uM, Clozapine, 5-HT2 Antagonists;Dopamine D4 Antagonists;ADRA1B gene inhibitor targeting ADRA1B, CHRM5, DRD4, HTR1E, HTR1F |
| AD-50-WA90_0.01uM | Dose=0.01uM, Sulfanilamide, MEK1 Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| AD-50-WA90_0.1uM | Dose=0.1uM, Sulfanilamide, MEK1 Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| AD-50-WA90_10uM | Dose=10uM, Sulfanilamide, MEK1 Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| AD-50-WA90_1uM | Dose=1uM, Sulfanilamide, MEK1 Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| AD-51-BB90_0.01uM | Dose=0.01uM, Sulfisoxazole, Endothelin Receptor Antagonists targeting EDNRA |
| AD-51-BB90_0.1uM | Dose=0.1uM, Sulfisoxazole, Endothelin Receptor Antagonists targeting EDNRA |
| AD-51-BB90_10uM | Dose=10uM, Sulfisoxazole, Endothelin Receptor Antagonists targeting EDNRA |
| AD-51-BB90_1uM | Dose=1uM, Sulfisoxazole, Endothelin Receptor Antagonists targeting EDNRA |
| AD-51-FB60_0.01uM | Dose=0.01uM, 1-C-Ethylaminoadamantane |
| AD-51-FB60_0.1uM | Dose=0.1uM, 1-C-Ethylaminoadamantane |
| AD-51-FB60_10uM | Dose=10uM, 1-C-Ethylaminoadamantane |
| AD-51-FB60_1uM | Dose=1uM, 1-C-Ethylaminoadamantane |
| AD-51-LE62_0.01uM | Dose=0.01uM, Racepinephrine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| AD-51-LE62_0.1uM | Dose=0.1uM, Racepinephrine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| AD-51-LE62_10uM | Dose=10uM, Racepinephrine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| AD-51-LE62_1uM | Dose=1uM, Racepinephrine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| AD-51-SS86_0.01uM | Dose=0.01uM, Ack1 inhibitor 37, ACK tyrosine kinase inhibitor targeting TNK2 |
| AD-51-SS86_0.1uM | Dose=0.1uM, Ack1 inhibitor 37, ACK tyrosine kinase inhibitor targeting TNK2 |
| AD-51-SS86_10uM | Dose=10uM, Ack1 inhibitor 37, ACK tyrosine kinase inhibitor targeting TNK2 |
| AD-51-SS86_1uM | Dose=1uM, Ack1 inhibitor 37, ACK tyrosine kinase inhibitor targeting TNK2 |
| AD-51-ZE47_0.01uM | Dose=0.01uM, Sulpiride, Dopamine D2 Antagonists;Carbonic Anhydrase Type VII Inhibitors targeting CA7, CA12, DRD2 |
| AD-51-ZE47_0.1uM | Dose=0.1uM, Sulpiride, Dopamine D2 Antagonists;Carbonic Anhydrase Type VII Inhibitors targeting CA7, CA12, DRD2 |
| AD-51-ZE47_10uM | Dose=10uM, Sulpiride, Dopamine D2 Antagonists;Carbonic Anhydrase Type VII Inhibitors targeting CA7, CA12, DRD2 |
| AD-51-ZE47_1uM | Dose=1uM, Sulpiride, Dopamine D2 Antagonists;Carbonic Anhydrase Type VII Inhibitors targeting CA7, CA12, DRD2 |
| AD-52-UZ45_0.01uM | Dose=0.01uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| AD-52-UZ45_0.1uM | Dose=0.1uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| AD-52-UZ45_10uM | Dose=10uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| AD-52-UZ45_1uM | Dose=1uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| AD-53-VC77_0.01uM | Dose=0.01uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-[[(6S)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]oxy]indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| AD-53-VC77_10uM | Dose=10uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-[[(6S)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]oxy]indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| AD-53-VC77_1uM | Dose=1uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-[[(6S)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]oxy]indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| AD-54-FG24_0.01uM | Dose=0.01uM, Perhexiline, Carnitine O-Palmitoyltransferase Inhibitors;NOX2 Inhibitors targeting CPT1A, CPT2, CYBB |
| AD-54-FG24_0.1uM | Dose=0.1uM, Perhexiline, Carnitine O-Palmitoyltransferase Inhibitors;NOX2 Inhibitors targeting CPT1A, CPT2, CYBB |
| AD-54-FG24_10uM | Dose=10uM, Perhexiline, Carnitine O-Palmitoyltransferase Inhibitors;NOX2 Inhibitors targeting CPT1A, CPT2, CYBB |
| AD-54-IH37_0.01uM | Dose=0.01uM, Entacapone, COMT Inhibitors targeting COMT |
| AD-54-IH37_0.1uM | Dose=0.1uM, Entacapone, COMT Inhibitors targeting COMT |
| AD-54-IH37_10uM | Dose=10uM, Entacapone, COMT Inhibitors targeting COMT |
| AD-54-IH37_1uM | Dose=1uM, Entacapone, COMT Inhibitors targeting COMT |
| AD-55-EA62_0.01uM | Dose=0.01uM, D-AP4 |
| AD-55-EA62_0.1uM | Dose=0.1uM, D-AP4 |
| AD-55-EA62_10uM | Dose=10uM, D-AP4 |
| AD-55-EA62_1uM | Dose=1uM, D-AP4 |
| AD-55-HH69_0.01uM | Dose=0.01uM, 1,2-Ethanedione, 1,2-bis(2-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| AD-55-HH69_0.1uM | Dose=0.1uM, 1,2-Ethanedione, 1,2-bis(2-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| AD-55-HH69_10uM | Dose=10uM, 1,2-Ethanedione, 1,2-bis(2-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| AD-55-HH69_1uM | Dose=1uM, 1,2-Ethanedione, 1,2-bis(2-chlorophenyl)-, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| AD-55-WK61_0.01uM | Dose=0.01uM, N-(4-(tert-Butyl)phenyl)-4-(pyridin-4-ylmethyl)isoquinolin-1-amine, RAF Inhibitor targeting BRAF, RAF1 |
| AD-55-WK61_0.1uM | Dose=0.1uM, N-(4-(tert-Butyl)phenyl)-4-(pyridin-4-ylmethyl)isoquinolin-1-amine, RAF Inhibitor targeting BRAF, RAF1 |
| AD-55-WK61_10uM | Dose=10uM, N-(4-(tert-Butyl)phenyl)-4-(pyridin-4-ylmethyl)isoquinolin-1-amine, RAF Inhibitor targeting BRAF, RAF1 |
| AD-55-WK61_1uM | Dose=1uM, N-(4-(tert-Butyl)phenyl)-4-(pyridin-4-ylmethyl)isoquinolin-1-amine, RAF Inhibitor targeting BRAF, RAF1 |
| AD-56-VO78_0.01uM | Dose=0.01uM, Serotonin, Serotonin receptor agonist targeting HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, HTR3B, HTR3C, HTR3D, HTR3E |
| AD-56-VO78_0.1uM | Dose=0.1uM, Serotonin, Serotonin receptor agonist targeting HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, HTR3B, HTR3C, HTR3D, HTR3E |
| AD-56-VO78_10uM | Dose=10uM, Serotonin, Serotonin receptor agonist targeting HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, HTR3B, HTR3C, HTR3D, HTR3E |
| AD-56-VO78_1uM | Dose=1uM, Serotonin, Serotonin receptor agonist targeting HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, HTR3B, HTR3C, HTR3D, HTR3E |
| AD-58-PW17_0.01uM | Dose=0.01uM, Epothilone B, Apoptosis Inducers;Microtubule-Stabilizing Agents;Antimitotic Drugs targeting TUBB |
| AD-58-PW17_0.1uM | Dose=0.1uM, Epothilone B, Apoptosis Inducers;Microtubule-Stabilizing Agents;Antimitotic Drugs targeting TUBB |
| AD-58-PW17_10uM | Dose=10uM, Epothilone B, Apoptosis Inducers;Microtubule-Stabilizing Agents;Antimitotic Drugs targeting TUBB |
| AD-58-PW17_1uM | Dose=1uM, Epothilone B, Apoptosis Inducers;Microtubule-Stabilizing Agents;Antimitotic Drugs targeting TUBB |
| AD-59-IN33_0.01uM | Dose=0.01uM, 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one, Ubiquitin C-terminal Hydrolase 14 (USP14) Inhibitors targeting USP14 |
| AD-59-IN33_0.1uM | Dose=0.1uM, 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one, Ubiquitin C-terminal Hydrolase 14 (USP14) Inhibitors targeting USP14 |
| AD-59-IN33_10uM | Dose=10uM, 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one, Ubiquitin C-terminal Hydrolase 14 (USP14) Inhibitors targeting USP14 |
| AD-59-IN33_1uM | Dose=1uM, 1-[1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl]-2-(pyrrolidin-1-yl)ethan-1-one, Ubiquitin C-terminal Hydrolase 14 (USP14) Inhibitors targeting USP14 |
| AD-65-WK61_0.01uM | Dose=0.01uM, 3-{2-Cyano-2-[2-(2,4-difluoro-benzoylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin B Inhibitors targeting CTSV, CTSL3P |
| AD-65-WK61_0.1uM | Dose=0.1uM, 3-{2-Cyano-2-[2-(2,4-difluoro-benzoylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin B Inhibitors targeting CTSV, CTSL3P |
| AD-65-WK61_10uM | Dose=10uM, 3-{2-Cyano-2-[2-(2,4-difluoro-benzoylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin B Inhibitors targeting CTSV, CTSL3P |
| AD-65-WK61_1uM | Dose=1uM, 3-{2-Cyano-2-[2-(2,4-difluoro-benzoylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin B Inhibitors targeting CTSV, CTSL3P |
| AD-66-NO48_0.01uM | Dose=0.01uM, Glyburide, K(ATP) Channel Blockers targeting KCNJ8, KCNJ11, ABCC8, ABCC9 |
| AD-66-NO48_0.1uM | Dose=0.1uM, Glyburide, K(ATP) Channel Blockers targeting KCNJ8, KCNJ11, ABCC8, ABCC9 |
| AD-66-NO48_10uM | Dose=10uM, Glyburide, K(ATP) Channel Blockers targeting KCNJ8, KCNJ11, ABCC8, ABCC9 |
| AD-66-NO48_1uM | Dose=1uM, Glyburide, K(ATP) Channel Blockers targeting KCNJ8, KCNJ11, ABCC8, ABCC9 |
| AD-66-NV75_0.01uM | Dose=0.01uM, 3-amino-N-[4-[(3S)-3-aminopiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)pyridine-2-carboxamide, Pim Kinase Inhibitors targeting PIM1, PIM2, PIM3 |
| AD-66-NV75_0.1uM | Dose=0.1uM, 3-amino-N-[4-[(3S)-3-aminopiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)pyridine-2-carboxamide, Pim Kinase Inhibitors targeting PIM1, PIM2, PIM3 |
| AD-66-NV75_10uM | Dose=10uM, 3-amino-N-[4-[(3S)-3-aminopiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)pyridine-2-carboxamide, Pim Kinase Inhibitors targeting PIM1, PIM2, PIM3 |
| AD-66-NV75_1uM | Dose=1uM, 3-amino-N-[4-[(3S)-3-aminopiperidin-1-yl]pyridin-3-yl]-6-(2,6-difluorophenyl)pyridine-2-carboxamide, Pim Kinase Inhibitors targeting PIM1, PIM2, PIM3 |
| AD-70-DU18_0.01uM | Dose=0.01uM |
| AD-70-DU18_0.1uM | Dose=0.1uM |
| AD-70-DU18_10uM | Dose=10uM |
| AD-70-DU18_1uM | Dose=1uM |
| AD-70-LA75_0.01uM | Dose=0.01uM, Thiotepa, DNA alkylating agent;Cytochrome P450 Oxidase Inhibitors targeting CYP2B6, CYP2A6 |
| AD-70-LA75_0.1uM | Dose=0.1uM, Thiotepa, DNA alkylating agent;Cytochrome P450 Oxidase Inhibitors targeting CYP2B6, CYP2A6 |
| AD-70-LA75_10uM | Dose=10uM, Thiotepa, DNA alkylating agent;Cytochrome P450 Oxidase Inhibitors targeting CYP2B6, CYP2A6 |
| AD-70-LA75_1uM | Dose=1uM, Thiotepa, DNA alkylating agent;Cytochrome P450 Oxidase Inhibitors targeting CYP2B6, CYP2A6 |
| AD-70-TH82_0.01uM | Dose=0.01uM, (4R)-2-amino-4-(4-fluoro-3-(2-fluoropyridin-3-yl)phenyl)-4-(4-methoxy-3-methylphenyl)-1-methyl-1H-imidazol-5(4H)-one, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1 |
| AD-70-TH82_10uM | Dose=10uM, (4R)-2-amino-4-(4-fluoro-3-(2-fluoropyridin-3-yl)phenyl)-4-(4-methoxy-3-methylphenyl)-1-methyl-1H-imidazol-5(4H)-one, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1 |
| AD-70-TH82_1uM | Dose=1uM, (4R)-2-amino-4-(4-fluoro-3-(2-fluoropyridin-3-yl)phenyl)-4-(4-methoxy-3-methylphenyl)-1-methyl-1H-imidazol-5(4H)-one, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1 |
| AD-72-MJ27_0.01uM | Dose=0.01uM, Thalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting TNF, CRBN |
| AD-72-MJ27_0.1uM | Dose=0.1uM, Thalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting TNF, CRBN |
| AD-72-MJ27_10uM | Dose=10uM, Thalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting TNF, CRBN |
| AD-72-MJ27_1uM | Dose=1uM, Thalidomide, Angiogenesis Inhibitors;TNF-alpha Production Inhibitors;DDB1-CRBN modulator targeting TNF, CRBN |
| AD-72-OW33_0.01uM | Dose=0.01uM, 2-[2-[[3-[(3~{S})-3-azanyl-2,3-dihydro-1-benzofuran-5-yl]-5-(2-cyanopropan-2-yl)phenyl]methoxy]phenyl]ethanoic acid |
| AD-72-OW33_0.1uM | Dose=0.1uM, 2-[2-[[3-[(3~{S})-3-azanyl-2,3-dihydro-1-benzofuran-5-yl]-5-(2-cyanopropan-2-yl)phenyl]methoxy]phenyl]ethanoic acid |
| AD-72-OW33_10uM | Dose=10uM, 2-[2-[[3-[(3~{S})-3-azanyl-2,3-dihydro-1-benzofuran-5-yl]-5-(2-cyanopropan-2-yl)phenyl]methoxy]phenyl]ethanoic acid |
| AD-72-OW33_1uM | Dose=1uM, 2-[2-[[3-[(3~{S})-3-azanyl-2,3-dihydro-1-benzofuran-5-yl]-5-(2-cyanopropan-2-yl)phenyl]methoxy]phenyl]ethanoic acid |
| AD-72-RI24_0.01uM | Dose=0.01uM, 3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ |
| AD-72-RI24_0.1uM | Dose=0.1uM, 3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ |
| AD-72-RI24_10uM | Dose=10uM, 3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ |
| AD-72-RI24_1uM | Dose=1uM, 3-(8-((Dimethylamino)methyl)-6,7,8,9-tetrahydropyrido(1,2-a)indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH, PRKCZ |
| AD-77-UF99_0.01uM | Dose=0.01uM, (R)-1-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)pyridin-2-yl)pyrimidin-2-yl)pyrrolidin-3-ol, TRKB Inhibitors;ALK Inhibitors;TRKA Inhibitors targeting ALK, NTRK1, NTRK2 |
| AD-77-UF99_10uM | Dose=10uM, (R)-1-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)pyridin-2-yl)pyrimidin-2-yl)pyrrolidin-3-ol, TRKB Inhibitors;ALK Inhibitors;TRKA Inhibitors targeting ALK, NTRK1, NTRK2 |
| AD-77-UF99_1uM | Dose=1uM, (R)-1-(4-(6-(6-((R)-2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)pyridin-2-yl)pyrimidin-2-yl)pyrrolidin-3-ol, TRKB Inhibitors;ALK Inhibitors;TRKA Inhibitors targeting ALK, NTRK1, NTRK2 |
| AD-79-UU60_0.01uM | Dose=0.01uM, Het0016, 20-HETE receptor antagonist targeting CYP4A11 |
| AD-79-UU60_10uM | Dose=10uM, Het0016, 20-HETE receptor antagonist targeting CYP4A11 |
| AD-79-UU60_1uM | Dose=1uM, Het0016, 20-HETE receptor antagonist targeting CYP4A11 |
| AD-82-AM64_0.01uM | Dose=0.01uM |
| AD-82-AM64_10uM | Dose=10uM |
| AD-82-AM64_1uM | Dose=1uM |
| AD-82-OW73_0.01uM | Dose=0.01uM, 4-[6-Tert-butylsulfonyl-7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-6-chloropyridin-2-amine, Receptor-Interacting Serine/Threonine-Protein (RIP-2) Kinase 2 Inhibitors;SELECTIVE INHIBITOR OF RIPK2 targeting RIPK2 |
| AD-82-OW73_0.1uM | Dose=0.1uM, 4-[6-Tert-butylsulfonyl-7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-6-chloropyridin-2-amine, Receptor-Interacting Serine/Threonine-Protein (RIP-2) Kinase 2 Inhibitors;SELECTIVE INHIBITOR OF RIPK2 targeting RIPK2 |
| AD-82-OW73_10uM | Dose=10uM, 4-[6-Tert-butylsulfonyl-7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-6-chloropyridin-2-amine, Receptor-Interacting Serine/Threonine-Protein (RIP-2) Kinase 2 Inhibitors;SELECTIVE INHIBITOR OF RIPK2 targeting RIPK2 |
| AD-82-OW73_1uM | Dose=1uM, 4-[6-Tert-butylsulfonyl-7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-6-chloropyridin-2-amine, Receptor-Interacting Serine/Threonine-Protein (RIP-2) Kinase 2 Inhibitors;SELECTIVE INHIBITOR OF RIPK2 targeting RIPK2 |
| AD-83-MW95_0.01uM | Dose=0.01uM, Caffeine, Adenosine A2a receptor antagonist;Chitinase antagonist targeting ADORA2A, CHIA |
| AD-83-MW95_0.1uM | Dose=0.1uM, Caffeine, Adenosine A2a receptor antagonist;Chitinase antagonist targeting ADORA2A, CHIA |
| AD-83-MW95_10uM | Dose=10uM, Caffeine, Adenosine A2a receptor antagonist;Chitinase antagonist targeting ADORA2A, CHIA |
| AD-83-MW95_1uM | Dose=1uM, Caffeine, Adenosine A2a receptor antagonist;Chitinase antagonist targeting ADORA2A, CHIA |
| AD-84-LG49_0.01uM | Dose=0.01uM |
| AD-84-LG49_0.1uM | Dose=0.1uM |
| AD-84-LG49_10uM | Dose=10uM |
| AD-84-LG49_1uM | Dose=1uM |
| AD-85-ME82_0.01uM | Dose=0.01uM, 15-O-Desmethylascomycin |
| AD-85-ME82_0.1uM | Dose=0.1uM, 15-O-Desmethylascomycin |
| AD-85-ME82_10uM | Dose=10uM, 15-O-Desmethylascomycin |
| AD-85-ME82_1uM | Dose=1uM, 15-O-Desmethylascomycin |
| AD-86-ES28_0.01uM | Dose=0.01uM, LY2033298, M4 positive allosteric modulator targeting CHRM4 |
| AD-86-ES28_0.1uM | Dose=0.1uM, LY2033298, M4 positive allosteric modulator targeting CHRM4 |
| AD-86-ES28_10uM | Dose=10uM, LY2033298, M4 positive allosteric modulator targeting CHRM4 |
| AD-86-ES28_1uM | Dose=1uM, LY2033298, M4 positive allosteric modulator targeting CHRM4 |
| AD-86-OB47_0.01uM | Dose=0.01uM, Icilin, TRPM8 agonist;Induction of Brown Adipose Tissue (BAT) thermogenesis;TRPA1 Agonists targeting TRPA1, TRPM8 |
| AD-86-OB47_0.1uM | Dose=0.1uM, Icilin, TRPM8 agonist;Induction of Brown Adipose Tissue (BAT) thermogenesis;TRPA1 Agonists targeting TRPA1, TRPM8 |
| AD-86-OB47_10uM | Dose=10uM, Icilin, TRPM8 agonist;Induction of Brown Adipose Tissue (BAT) thermogenesis;TRPA1 Agonists targeting TRPA1, TRPM8 |
| AD-86-OB87_0.01uM | Dose=0.01uM, Tirbanibulin, c-src allosteric inihitor;Tubulin polymerization inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways;Src Kinase Inhibitors;allosteric Src inhibitor targeting SRC, TUBG2 |
| AD-86-OB87_0.1uM | Dose=0.1uM, Tirbanibulin, c-src allosteric inihitor;Tubulin polymerization inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways;Src Kinase Inhibitors;allosteric Src inhibitor targeting SRC, TUBG2 |
| AD-86-OB87_10uM | Dose=10uM, Tirbanibulin, c-src allosteric inihitor;Tubulin polymerization inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways;Src Kinase Inhibitors;allosteric Src inhibitor targeting SRC, TUBG2 |
| AD-86-OB87_1uM | Dose=1uM, Tirbanibulin, c-src allosteric inihitor;Tubulin polymerization inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways;Src Kinase Inhibitors;allosteric Src inhibitor targeting SRC, TUBG2 |
| AD-86-XL96_0.01uM | Dose=0.01uM, Lansoprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B |
| AD-86-XL96_0.1uM | Dose=0.1uM, Lansoprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B |
| AD-86-XL96_10uM | Dose=10uM, Lansoprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B |
| AD-86-XL96_1uM | Dose=1uM, Lansoprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B |
| AD-88-WG84_0.01uM | Dose=0.01uM, 2-Bromo-N-(3-butyramidophenyl)benzamide, PAR-1 antagonist targeting F2R |
| AD-88-WG84_10uM | Dose=10uM, 2-Bromo-N-(3-butyramidophenyl)benzamide, PAR-1 antagonist targeting F2R |
| AD-88-WG84_1uM | Dose=1uM, 2-Bromo-N-(3-butyramidophenyl)benzamide, PAR-1 antagonist targeting F2R |
| AD-89-ID99_0.01uM | Dose=0.01uM, Furosemide [USAN:USP:INN:BAN:JAN], Antidiuretic targeting CA1, CA4, CA5A, TPMT, CA5B |
| AD-89-ID99_0.1uM | Dose=0.1uM, Furosemide [USAN:USP:INN:BAN:JAN], Antidiuretic targeting CA1, CA4, CA5A, TPMT, CA5B |
| AD-89-ID99_10uM | Dose=10uM, Furosemide [USAN:USP:INN:BAN:JAN], Antidiuretic targeting CA1, CA4, CA5A, TPMT, CA5B |
| AD-89-ID99_1uM | Dose=1uM, Furosemide [USAN:USP:INN:BAN:JAN], Antidiuretic targeting CA1, CA4, CA5A, TPMT, CA5B |
| AD-89-LX67_0.01uM | Dose=0.01uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(3R)-1-ethylpiperidine-3-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| AD-89-LX67_0.1uM | Dose=0.1uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(3R)-1-ethylpiperidine-3-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| AD-89-LX67_10uM | Dose=10uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(3R)-1-ethylpiperidine-3-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| AD-89-LX67_1uM | Dose=1uM, (5R,8S)-7-[(2S)-2-[[(2S)-2-cyclohexyl-2-[[(3R)-1-ethylpiperidine-3-carbonyl]amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-10,10-dimethyl-7-azadispiro[3.0.45.14]decane-8-carboxamide |
| AD-89-XG11_0.01uM | Dose=0.01uM, Ethyl Beta-Carboline-3-Carboxylate, receptor blocker targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2 |
| AD-89-XG11_0.1uM | Dose=0.1uM, Ethyl Beta-Carboline-3-Carboxylate, receptor blocker targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2 |
| AD-89-XG11_10uM | Dose=10uM, Ethyl Beta-Carboline-3-Carboxylate, receptor blocker targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2 |
| AD-89-XG11_1uM | Dose=1uM, Ethyl Beta-Carboline-3-Carboxylate, receptor blocker targeting GABRA1, GABRA2, GABRA3, GABRB3, GABRG2 |
| AD-90-PA45_0.01uM | Dose=0.01uM, Carbamoylcholine, Cholinergics targeting CHRM1, CHRM5 |
| AD-90-PA45_0.1uM | Dose=0.1uM, Carbamoylcholine, Cholinergics targeting CHRM1, CHRM5 |
| AD-90-PA45_10uM | Dose=10uM, Carbamoylcholine, Cholinergics targeting CHRM1, CHRM5 |
| AD-90-PA45_1uM | Dose=1uM, Carbamoylcholine, Cholinergics targeting CHRM1, CHRM5 |
| AD-91-FB70_0.1uM | Dose=0.1uM, LPA2 antagonist 1, Lysophosphatidate-2 receptor antagonist targeting LPAR2 |
| AD-91-FB70_10uM | Dose=10uM, LPA2 antagonist 1, Lysophosphatidate-2 receptor antagonist targeting LPAR2 |
| AD-91-FB70_1uM | Dose=1uM, LPA2 antagonist 1, Lysophosphatidate-2 receptor antagonist targeting LPAR2 |
| AD-91-FZ23_0.01uM | Dose=0.01uM, Piracetam, AMPA Receptor Postiive Allosteric Modulators;Nootropic targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| AD-91-FZ23_0.1uM | Dose=0.1uM, Piracetam, AMPA Receptor Postiive Allosteric Modulators;Nootropic targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| AD-91-FZ23_10uM | Dose=10uM, Piracetam, AMPA Receptor Postiive Allosteric Modulators;Nootropic targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| AD-91-LE02_0.01uM | Dose=0.01uM, Felbamate, GABA(A) Receptor Modulators targeting GRIN2A, GRIN2B, GRIN3A |
| AD-91-LE02_0.1uM | Dose=0.1uM, Felbamate, GABA(A) Receptor Modulators targeting GRIN2A, GRIN2B, GRIN3A |
| AD-91-LE02_10uM | Dose=10uM, Felbamate, GABA(A) Receptor Modulators targeting GRIN2A, GRIN2B, GRIN3A |
| AD-91-LE02_1uM | Dose=1uM, Felbamate, GABA(A) Receptor Modulators targeting GRIN2A, GRIN2B, GRIN3A |
| AD-92-AP11_0.1uM | Dose=0.1uM, Chenodiol, Farnesoid X Receptor (FXR) Agonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1, NR1H4 |
| AD-92-AP11_10uM | Dose=10uM, Chenodiol, Farnesoid X Receptor (FXR) Agonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1, NR1H4 |
| AD-92-QZ55_0.01uM | Dose=0.01uM, Tmc-353121 |
| AD-92-QZ55_0.1uM | Dose=0.1uM, Tmc-353121 |
| AD-92-QZ55_10uM | Dose=10uM, Tmc-353121 |
| AD-92-QZ55_1uM | Dose=1uM, Tmc-353121 |
| AD-93-VC77_0.01uM | Dose=0.01uM, 4-(1-((1-Naphthyl)methyl)benzimidazole-2-ylthio)butyric acid, Known Chymase inhibitor targeting CMA1 |
| AD-93-VC77_0.1uM | Dose=0.1uM, 4-(1-((1-Naphthyl)methyl)benzimidazole-2-ylthio)butyric acid, Known Chymase inhibitor targeting CMA1 |
| AD-93-VC77_10uM | Dose=10uM, 4-(1-((1-Naphthyl)methyl)benzimidazole-2-ylthio)butyric acid, Known Chymase inhibitor targeting CMA1 |
| AD-93-VC77_1uM | Dose=1uM, 4-(1-((1-Naphthyl)methyl)benzimidazole-2-ylthio)butyric acid, Known Chymase inhibitor targeting CMA1 |
| AD-94-EX35_0.01uM | Dose=0.01uM, Pretomanid |
| AD-94-EX35_0.1uM | Dose=0.1uM, Pretomanid |
| AD-94-EX35_10uM | Dose=10uM, Pretomanid |
| AD-94-EX35_1uM | Dose=1uM, Pretomanid |
| AD-94-TN76_0.01uM | Dose=0.01uM, Probucol, Serine Protease Hepsin Inhibitors;ABCA1-mediated cellular lipid efflux inhibitor;Antioxidants targeting ABCA1, HPN |
| AD-94-TN76_0.1uM | Dose=0.1uM, Probucol, Serine Protease Hepsin Inhibitors;ABCA1-mediated cellular lipid efflux inhibitor;Antioxidants targeting ABCA1, HPN |
| AD-94-TN76_10uM | Dose=10uM, Probucol, Serine Protease Hepsin Inhibitors;ABCA1-mediated cellular lipid efflux inhibitor;Antioxidants targeting ABCA1, HPN |
| AD-94-TN76_1uM | Dose=1uM, Probucol, Serine Protease Hepsin Inhibitors;ABCA1-mediated cellular lipid efflux inhibitor;Antioxidants targeting ABCA1, HPN |
| AD-98-UM13_0.01uM | Dose=0.01uM, 1-Benzyl-5-methyl-2-piperazin-1-ylbenzimidazole, 5-HT3 Antagonists targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AD-98-UM13_0.1uM | Dose=0.1uM, 1-Benzyl-5-methyl-2-piperazin-1-ylbenzimidazole, 5-HT3 Antagonists targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AD-98-UM13_10uM | Dose=10uM, 1-Benzyl-5-methyl-2-piperazin-1-ylbenzimidazole, 5-HT3 Antagonists targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AD-98-UM13_1uM | Dose=1uM, 1-Benzyl-5-methyl-2-piperazin-1-ylbenzimidazole, 5-HT3 Antagonists targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AD-99-SN88_0.01uM | Dose=0.01uM, Bisindolylmaleimide I, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CDK4, PRKCG, PRKCH, PRKCI, PRKCZ, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KB2, LRRK2 |
| AD-99-SN88_0.1uM | Dose=0.1uM, Bisindolylmaleimide I, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CDK4, PRKCG, PRKCH, PRKCI, PRKCZ, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KB2, LRRK2 |
| AD-99-SN88_10uM | Dose=10uM, Bisindolylmaleimide I, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CDK4, PRKCG, PRKCH, PRKCI, PRKCZ, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KB2, LRRK2 |
| AD-99-SN88_1uM | Dose=1uM, Bisindolylmaleimide I, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK4/Cyclin D1 Inhibitors targeting CCND1, CDK4, PRKCG, PRKCH, PRKCI, PRKCZ, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KB2, LRRK2 |
| AE-00-DK14_10uM | Dose=10uM, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists |
| AE-00-NY23_0.01uM | Dose=0.01uM, Englerin A, TRPC4 gene stimulator targeting TRPC4 |
| AE-00-NY23_0.1uM | Dose=0.1uM, Englerin A, TRPC4 gene stimulator targeting TRPC4 |
| AE-00-NY23_10uM | Dose=10uM, Englerin A, TRPC4 gene stimulator targeting TRPC4 |
| AE-00-NY23_1uM | Dose=1uM, Englerin A, TRPC4 gene stimulator targeting TRPC4 |
| AE-00-WU78_0.01uM | Dose=0.01uM, 1H-Benzimidazol-2-amine, 6-chloro-, 5-HT3 receptor ligand targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AE-00-WU78_0.1uM | Dose=0.1uM, 1H-Benzimidazol-2-amine, 6-chloro-, 5-HT3 receptor ligand targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AE-00-WU78_10uM | Dose=10uM, 1H-Benzimidazol-2-amine, 6-chloro-, 5-HT3 receptor ligand targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AE-00-WU78_1uM | Dose=1uM, 1H-Benzimidazol-2-amine, 6-chloro-, 5-HT3 receptor ligand targeting HTR3B, HTR3C, HTR3D, HTR3E |
| AE-00-YK74_0.1uM | Dose=0.1uM, ApoB Secretion Inhibitors |
| AE-02-OC25_0.01uM | Dose=0.01uM, Caffeic Acid Phenethyl Ester |
| AE-02-OC25_0.1uM | Dose=0.1uM, Caffeic Acid Phenethyl Ester |
| AE-02-OC25_10uM | Dose=10uM, Caffeic Acid Phenethyl Ester |
| AE-02-OC25_1uM | Dose=1uM, Caffeic Acid Phenethyl Ester |
| AE-03-BM76_0.01uM | Dose=0.01uM, Gamma-Aminobutyric Acid targeting GABRR1 |
| AE-03-BM76_0.1uM | Dose=0.1uM, Gamma-Aminobutyric Acid targeting GABRR1 |
| AE-03-BM76_10uM | Dose=10uM, Gamma-Aminobutyric Acid targeting GABRR1 |
| AE-03-BM76_1uM | Dose=1uM, Gamma-Aminobutyric Acid targeting GABRR1 |
| AE-03-MJ64_0.01uM | Dose=0.01uM, Acetic acid, 2-[4-[[4-(6-methoxy-3-pyridinyl)-5-[4-(trifluoromethoxy)phenyl]-2-thiazolyl]methoxy]-2-methylphenoxy]-, PPARdelta Agonists targeting PPARD |
| AE-03-MJ64_0.1uM | Dose=0.1uM, Acetic acid, 2-[4-[[4-(6-methoxy-3-pyridinyl)-5-[4-(trifluoromethoxy)phenyl]-2-thiazolyl]methoxy]-2-methylphenoxy]-, PPARdelta Agonists targeting PPARD |
| AE-03-MJ64_10uM | Dose=10uM, Acetic acid, 2-[4-[[4-(6-methoxy-3-pyridinyl)-5-[4-(trifluoromethoxy)phenyl]-2-thiazolyl]methoxy]-2-methylphenoxy]-, PPARdelta Agonists targeting PPARD |
| AE-03-MJ64_1uM | Dose=1uM, Acetic acid, 2-[4-[[4-(6-methoxy-3-pyridinyl)-5-[4-(trifluoromethoxy)phenyl]-2-thiazolyl]methoxy]-2-methylphenoxy]-, PPARdelta Agonists targeting PPARD |
| AE-04-DX45_0.01uM | Dose=0.01uM, (R)-2,3,4,5-Tetrahydro-8-chloro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol, DRD5 antagonist;Dopamine D5 Antagonists;DRD1 antagonist;Dopamine D1 Antagonists targeting DRD1, DRD5 |
| AE-04-DX45_0.1uM | Dose=0.1uM, (R)-2,3,4,5-Tetrahydro-8-chloro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol, DRD5 antagonist;Dopamine D5 Antagonists;DRD1 antagonist;Dopamine D1 Antagonists targeting DRD1, DRD5 |
| AE-04-DX45_10uM | Dose=10uM, (R)-2,3,4,5-Tetrahydro-8-chloro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol, DRD5 antagonist;Dopamine D5 Antagonists;DRD1 antagonist;Dopamine D1 Antagonists targeting DRD1, DRD5 |
| AE-04-SN76_0.01uM | Dose=0.01uM, Palbociclib, CDK4 Inhibitors;CDK6 Inhibitors targeting CDK4, CDK6 |
| AE-04-SN76_0.1uM | Dose=0.1uM, Palbociclib, CDK4 Inhibitors;CDK6 Inhibitors targeting CDK4, CDK6 |
| AE-04-SN76_10uM | Dose=10uM, Palbociclib, CDK4 Inhibitors;CDK6 Inhibitors targeting CDK4, CDK6 |
| AE-04-SN76_1uM | Dose=1uM, Palbociclib, CDK4 Inhibitors;CDK6 Inhibitors targeting CDK4, CDK6 |
| AE-05-CB45_0.01uM | Dose=0.01uM, Tubastatin A, Histone deacetylase-6 inhibitor;HDAC 6/8 targeting HDAC6 |
| AE-05-CB45_0.1uM | Dose=0.1uM, Tubastatin A, Histone deacetylase-6 inhibitor;HDAC 6/8 targeting HDAC6 |
| AE-05-CB45_10uM | Dose=10uM, Tubastatin A, Histone deacetylase-6 inhibitor;HDAC 6/8 targeting HDAC6 |
| AE-05-CB45_1uM | Dose=1uM, Tubastatin A, Histone deacetylase-6 inhibitor;HDAC 6/8 targeting HDAC6 |
| AE-05-GR23_0.1uM | Dose=0.1uM, Gnf-5, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, ABL2 |
| AE-05-GR23_10uM | Dose=10uM, Gnf-5, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, ABL2 |
| AE-05-GR23_1uM | Dose=1uM, Gnf-5, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, ABL2 |
| AE-05-HA92_0.1uM | Dose=0.1uM, 12-(4-methylpiperazin-1-yl)-6H-indolo[2,1-c][1,4]benzodiazepine, Mediator Release Inhibitors;GnRH (LHRH) Antagonists targeting GNRHR, GNRH1 |
| AE-05-HA92_10uM | Dose=10uM, 12-(4-methylpiperazin-1-yl)-6H-indolo[2,1-c][1,4]benzodiazepine, Mediator Release Inhibitors;GnRH (LHRH) Antagonists targeting GNRHR, GNRH1 |
| AE-05-HA92_1uM | Dose=1uM, 12-(4-methylpiperazin-1-yl)-6H-indolo[2,1-c][1,4]benzodiazepine, Mediator Release Inhibitors;GnRH (LHRH) Antagonists targeting GNRHR, GNRH1 |
| AE-06-FY47_0.01uM | Dose=0.01uM, Xamoterol, ADRB1 agonist targeting ADRB1 |
| AE-06-FY47_0.1uM | Dose=0.1uM, Xamoterol, ADRB1 agonist targeting ADRB1 |
| AE-06-FY47_10uM | Dose=10uM, Xamoterol, ADRB1 agonist targeting ADRB1 |
| AE-06-FY47_1uM | Dose=1uM, Xamoterol, ADRB1 agonist targeting ADRB1 |
| AE-06-JY57_0.01uM | Dose=0.01uM, Argyrin B, Inhibitor of mitochondrial translation targeting GFM1 |
| AE-06-JY57_0.1uM | Dose=0.1uM, Argyrin B, Inhibitor of mitochondrial translation targeting GFM1 |
| AE-06-JY57_10uM | Dose=10uM, Argyrin B, Inhibitor of mitochondrial translation targeting GFM1 |
| AE-06-JY57_1uM | Dose=1uM, Argyrin B, Inhibitor of mitochondrial translation targeting GFM1 |
| AE-07-IZ32_0.01uM | Dose=0.01uM, 7-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]pyridin-3-yl]pyrrolo[2,3-d]pyrimidin-2-amine targeting JAK2 |
| AE-07-IZ32_0.1uM | Dose=0.1uM, 7-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]pyridin-3-yl]pyrrolo[2,3-d]pyrimidin-2-amine targeting JAK2 |
| AE-07-IZ32_10uM | Dose=10uM, 7-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]pyridin-3-yl]pyrrolo[2,3-d]pyrimidin-2-amine targeting JAK2 |
| AE-07-IZ32_1uM | Dose=1uM, 7-[3,5-difluoro-4-(morpholin-4-ylmethyl)phenyl]-N-[6-[(3S,5R)-3,5-dimethylpiperazin-1-yl]pyridin-3-yl]pyrrolo[2,3-d]pyrimidin-2-amine targeting JAK2 |
| AE-09-IN08_0.01uM | Dose=0.01uM, 5-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-amine, ERK2 Inhibitors;ERK1 Inhibitors targeting MAPK1, MAPK3 |
| AE-09-IN08_0.1uM | Dose=0.1uM, 5-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-amine, ERK2 Inhibitors;ERK1 Inhibitors targeting MAPK1, MAPK3 |
| AE-09-IN08_10uM | Dose=10uM, 5-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-amine, ERK2 Inhibitors;ERK1 Inhibitors targeting MAPK1, MAPK3 |
| AE-09-IN08_1uM | Dose=1uM, 5-(2-Phenylpyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-amine, ERK2 Inhibitors;ERK1 Inhibitors targeting MAPK1, MAPK3 |
| AE-09-SG21_0.01uM | Dose=0.01uM, Tarenflurbil, Antiamyloidogenic Agents;NF-kappaB (NFKB) Modulators;gamma-Secretase Inhibitors targeting PTGS1, PTGS2, APP |
| AE-09-SG21_0.1uM | Dose=0.1uM, Tarenflurbil, Antiamyloidogenic Agents;NF-kappaB (NFKB) Modulators;gamma-Secretase Inhibitors targeting PTGS1, PTGS2, APP |
| AE-09-SG21_10uM | Dose=10uM, Tarenflurbil, Antiamyloidogenic Agents;NF-kappaB (NFKB) Modulators;gamma-Secretase Inhibitors targeting PTGS1, PTGS2, APP |
| AE-09-SG21_1uM | Dose=1uM, Tarenflurbil, Antiamyloidogenic Agents;NF-kappaB (NFKB) Modulators;gamma-Secretase Inhibitors targeting PTGS1, PTGS2, APP |
| AE-10-FH02_0.01uM | Dose=0.01uM, Baz2-icr, Dual BAZ2A/BAZ2B inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B |
| AE-10-FH02_0.1uM | Dose=0.1uM, Baz2-icr, Dual BAZ2A/BAZ2B inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B |
| AE-10-FH02_10uM | Dose=10uM, Baz2-icr, Dual BAZ2A/BAZ2B inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B |
| AE-11-BF25_0.01uM | Dose=0.01uM, Pentamidine |
| AE-11-BF25_0.1uM | Dose=0.1uM, Pentamidine |
| AE-11-BF25_10uM | Dose=10uM, Pentamidine |
| AE-11-VB80_0.1uM | Dose=0.1uM, N-[(2s,3r)-3-Hydroxy-1-(Hydroxyamino)-1-Oxobutan-2-Yl]-4-(Phenylethynyl)benzamide |
| AE-11-VB80_10uM | Dose=10uM, N-[(2s,3r)-3-Hydroxy-1-(Hydroxyamino)-1-Oxobutan-2-Yl]-4-(Phenylethynyl)benzamide |
| AE-11-VB80_1uM | Dose=1uM, N-[(2s,3r)-3-Hydroxy-1-(Hydroxyamino)-1-Oxobutan-2-Yl]-4-(Phenylethynyl)benzamide |
| AE-13-CX28_0.01uM | Dose=0.01uM, Pevonedistat, NEDD8-Activating Enzyme (NAE) Inhibitors targeting NAE1, UBA3 |
| AE-13-CX28_0.1uM | Dose=0.1uM, Pevonedistat, NEDD8-Activating Enzyme (NAE) Inhibitors targeting NAE1, UBA3 |
| AE-13-CX28_10uM | Dose=10uM, Pevonedistat, NEDD8-Activating Enzyme (NAE) Inhibitors targeting NAE1, UBA3 |
| AE-13-CX28_1uM | Dose=1uM, Pevonedistat, NEDD8-Activating Enzyme (NAE) Inhibitors targeting NAE1, UBA3 |
| AE-13-WW30_0.01uM | Dose=0.01uM, CID 14403147, 5-HT3 Antagonists targeting HTR3A |
| AE-13-WW30_0.1uM | Dose=0.1uM, CID 14403147, 5-HT3 Antagonists targeting HTR3A |
| AE-13-WW30_1uM | Dose=1uM, CID 14403147, 5-HT3 Antagonists targeting HTR3A |
| AE-14-NN26_0.01uM | Dose=0.01uM, Irinotecan, DNA Topoisomerase I Inhibitors targeting TOP1 |
| AE-14-NN26_0.1uM | Dose=0.1uM, Irinotecan, DNA Topoisomerase I Inhibitors targeting TOP1 |
| AE-14-NN26_10uM | Dose=10uM, Irinotecan, DNA Topoisomerase I Inhibitors targeting TOP1 |
| AE-14-NN26_1uM | Dose=1uM, Irinotecan, DNA Topoisomerase I Inhibitors targeting TOP1 |
| AE-15-HA32_10uM | Dose=10uM, (3S,4R)-3-hydroxy-2,2-dimethyl-4-(3-oxocyclopenten-1-yl)oxy-3,4-dihydrochromene-6-carbonitrile |
| AE-15-HA32_1uM | Dose=1uM, (3S,4R)-3-hydroxy-2,2-dimethyl-4-(3-oxocyclopenten-1-yl)oxy-3,4-dihydrochromene-6-carbonitrile |
| AE-15-KH69_0.01uM | Dose=0.01uM, CyPPA, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators targeting KCNN2, KCNN3 |
| AE-15-KH69_0.1uM | Dose=0.1uM, CyPPA, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators targeting KCNN2, KCNN3 |
| AE-15-KH69_10uM | Dose=10uM, CyPPA, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators targeting KCNN2, KCNN3 |
| AE-15-KH69_1uM | Dose=1uM, CyPPA, Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators targeting KCNN2, KCNN3 |
| AE-17-IZ62_0.01uM | Dose=0.01uM, 5-(4-Meo-PH)-2H-pyrazole-3-carboxylic acid (3,4,5-tri-meo-benzylidene)-hydrazide |
| AE-17-IZ62_0.1uM | Dose=0.1uM, 5-(4-Meo-PH)-2H-pyrazole-3-carboxylic acid (3,4,5-tri-meo-benzylidene)-hydrazide |
| AE-17-IZ62_10uM | Dose=10uM, 5-(4-Meo-PH)-2H-pyrazole-3-carboxylic acid (3,4,5-tri-meo-benzylidene)-hydrazide |
| AE-17-IZ62_1uM | Dose=1uM, 5-(4-Meo-PH)-2H-pyrazole-3-carboxylic acid (3,4,5-tri-meo-benzylidene)-hydrazide |
| AE-18-RD27_0.01uM | Dose=0.01uM, 2-Methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester, 5-HT4 and 5-HT3 antagonist targeting HTR4, HTR3B, HTR3C, HTR3D, HTR3E |
| AE-18-RD27_0.1uM | Dose=0.1uM, 2-Methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester, 5-HT4 and 5-HT3 antagonist targeting HTR4, HTR3B, HTR3C, HTR3D, HTR3E |
| AE-18-RD27_10uM | Dose=10uM, 2-Methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester, 5-HT4 and 5-HT3 antagonist targeting HTR4, HTR3B, HTR3C, HTR3D, HTR3E |
| AE-18-RD27_1uM | Dose=1uM, 2-Methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester, 5-HT4 and 5-HT3 antagonist targeting HTR4, HTR3B, HTR3C, HTR3D, HTR3E |
| AE-18-ZM98_0.01uM | Dose=0.01uM, (4-(3,4-difluorophenyl)piperazin-1-yl)((4S,4aS,8aR)-2-((S)-3-(6-methoxypyridin-3-yl)-2-methylpropyl)decahydroisoquinolin-4-yl)methanone fumarate, Somatostatin srif1C (sst3) Antagonists targeting SSTR3 |
| AE-18-ZM98_0.1uM | Dose=0.1uM, (4-(3,4-difluorophenyl)piperazin-1-yl)((4S,4aS,8aR)-2-((S)-3-(6-methoxypyridin-3-yl)-2-methylpropyl)decahydroisoquinolin-4-yl)methanone fumarate, Somatostatin srif1C (sst3) Antagonists targeting SSTR3 |
| AE-18-ZM98_10uM | Dose=10uM, (4-(3,4-difluorophenyl)piperazin-1-yl)((4S,4aS,8aR)-2-((S)-3-(6-methoxypyridin-3-yl)-2-methylpropyl)decahydroisoquinolin-4-yl)methanone fumarate, Somatostatin srif1C (sst3) Antagonists targeting SSTR3 |
| AE-18-ZM98_1uM | Dose=1uM, (4-(3,4-difluorophenyl)piperazin-1-yl)((4S,4aS,8aR)-2-((S)-3-(6-methoxypyridin-3-yl)-2-methylpropyl)decahydroisoquinolin-4-yl)methanone fumarate, Somatostatin srif1C (sst3) Antagonists targeting SSTR3 |
| AE-19-BK71_0.01uM | Dose=0.01uM, Hoe 33342, BCL2L1 gene inhibitor targeting BCL2L1 |
| AE-19-BK71_0.1uM | Dose=0.1uM, Hoe 33342, BCL2L1 gene inhibitor targeting BCL2L1 |
| AE-19-BK71_10uM | Dose=10uM, Hoe 33342, BCL2L1 gene inhibitor targeting BCL2L1 |
| AE-19-BK71_1uM | Dose=1uM, Hoe 33342, BCL2L1 gene inhibitor targeting BCL2L1 |
| AE-19-XO96_10uM | Dose=10uM, Nlrp3-IN-5 |
| AE-19-ZK31_0.01uM | Dose=0.01uM, Prinomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9, MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| AE-19-ZK31_0.1uM | Dose=0.1uM, Prinomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9, MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| AE-19-ZK31_1uM | Dose=1uM, Prinomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9, MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| AE-21-BF25_0.01uM | Dose=0.01uM, (2S)-2-amino-4-phosphonobutanoic acid, mgluR8 Agonists;mgluR4 Agonists targeting GRM4, GRM8 |
| AE-21-BF25_0.1uM | Dose=0.1uM, (2S)-2-amino-4-phosphonobutanoic acid, mgluR8 Agonists;mgluR4 Agonists targeting GRM4, GRM8 |
| AE-21-BF25_10uM | Dose=10uM, (2S)-2-amino-4-phosphonobutanoic acid, mgluR8 Agonists;mgluR4 Agonists targeting GRM4, GRM8 |
| AE-21-BF25_1uM | Dose=1uM, (2S)-2-amino-4-phosphonobutanoic acid, mgluR8 Agonists;mgluR4 Agonists targeting GRM4, GRM8 |
| AE-21-GE72_0.01uM | Dose=0.01uM, Ozagrel, Thromboxane Synthase Inhibitors targeting TBXAS1 |
| AE-21-GE72_0.1uM | Dose=0.1uM, Ozagrel, Thromboxane Synthase Inhibitors targeting TBXAS1 |
| AE-21-GE72_1uM | Dose=1uM, Ozagrel, Thromboxane Synthase Inhibitors targeting TBXAS1 |
| AE-22-QI24_0.1uM | Dose=0.1uM, Mozavaptan, Vasopressin (AVP) V2 Antagonists targeting AVPR2 |
| AE-22-QI24_10uM | Dose=10uM, Mozavaptan, Vasopressin (AVP) V2 Antagonists targeting AVPR2 |
| AE-26-JY57_0.01uM | Dose=0.01uM, 1-Methanesulfonyl-N-(5-phenyl-2-pyrazinyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide, Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R |
| AE-26-JY57_0.1uM | Dose=0.1uM, 1-Methanesulfonyl-N-(5-phenyl-2-pyrazinyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide, Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R |
| AE-26-JY57_10uM | Dose=10uM, 1-Methanesulfonyl-N-(5-phenyl-2-pyrazinyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide, Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R |
| AE-26-JY57_1uM | Dose=1uM, 1-Methanesulfonyl-N-(5-phenyl-2-pyrazinyl)spiro[indoline-3,4'-piperidine]-1'-carboxamide, Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R |
| AE-28-IQ88_0.01uM | Dose=0.01uM, Lificiguat, Apoptosis Inhibitors;Angiogenesis Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Guanylate Cyclase Activators targeting GUCY1B2, GUCY1A2, GUCY1A1, GUCY1B1, STAT2 |
| AE-28-IQ88_0.1uM | Dose=0.1uM, Lificiguat, Apoptosis Inhibitors;Angiogenesis Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Guanylate Cyclase Activators targeting GUCY1B2, GUCY1A2, GUCY1A1, GUCY1B1, STAT2 |
| AE-28-IQ88_10uM | Dose=10uM, Lificiguat, Apoptosis Inhibitors;Angiogenesis Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Guanylate Cyclase Activators targeting GUCY1B2, GUCY1A2, GUCY1A1, GUCY1B1, STAT2 |
| AE-28-IQ88_1uM | Dose=1uM, Lificiguat, Apoptosis Inhibitors;Angiogenesis Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Guanylate Cyclase Activators targeting GUCY1B2, GUCY1A2, GUCY1A1, GUCY1B1, STAT2 |
| AE-28-LX10_0.01uM | Dose=0.01uM, n-Hexadecylphosphonocholine, Angiogenesis Inhibitors, proliferation inhibitor targeting PCYT1A |
| AE-28-LX10_0.1uM | Dose=0.1uM, n-Hexadecylphosphonocholine, Angiogenesis Inhibitors, proliferation inhibitor targeting PCYT1A |
| AE-28-LX10_10uM | Dose=10uM, n-Hexadecylphosphonocholine, Angiogenesis Inhibitors, proliferation inhibitor targeting PCYT1A |
| AE-28-LX10_1uM | Dose=1uM, n-Hexadecylphosphonocholine, Angiogenesis Inhibitors, proliferation inhibitor targeting PCYT1A |
| AE-28-WC14_0.01uM | Dose=0.01uM, Trichlorfon, Butyrylcholinesterase Inhibitors targeting BCHE |
| AE-28-WC14_0.1uM | Dose=0.1uM, Trichlorfon, Butyrylcholinesterase Inhibitors targeting BCHE |
| AE-28-WC14_10uM | Dose=10uM, Trichlorfon, Butyrylcholinesterase Inhibitors targeting BCHE |
| AE-32-DP61_0.01uM | Dose=0.01uM, Cpi-203, BRD4 gene inhibitor targeting BRD4 |
| AE-32-DP61_0.1uM | Dose=0.1uM, Cpi-203, BRD4 gene inhibitor targeting BRD4 |
| AE-32-DP61_10uM | Dose=10uM, Cpi-203, BRD4 gene inhibitor targeting BRD4 |
| AE-32-DP61_1uM | Dose=1uM, Cpi-203, BRD4 gene inhibitor targeting BRD4 |
| AE-32-NZ70_0.01uM | Dose=0.01uM, ATX inhibitor 7, Autotaxin inhibitor targeting ENPP2 |
| AE-32-NZ70_0.1uM | Dose=0.1uM, ATX inhibitor 7, Autotaxin inhibitor targeting ENPP2 |
| AE-32-NZ70_10uM | Dose=10uM, ATX inhibitor 7, Autotaxin inhibitor targeting ENPP2 |
| AE-32-UP21_0.01uM | Dose=0.01uM, Cinaciguat, Soluble Guanylyl Cyclase (sGC) Activators;Soluble guanylate cyclase activator targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| AE-32-UP21_0.1uM | Dose=0.1uM, Cinaciguat, Soluble Guanylyl Cyclase (sGC) Activators;Soluble guanylate cyclase activator targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| AE-32-UP21_10uM | Dose=10uM, Cinaciguat, Soluble Guanylyl Cyclase (sGC) Activators;Soluble guanylate cyclase activator targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| AE-32-UP21_1uM | Dose=1uM, Cinaciguat, Soluble Guanylyl Cyclase (sGC) Activators;Soluble guanylate cyclase activator targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| AE-34-SK19_0.01uM | Dose=0.01uM, 3-{[(5-Chloro-3-methyl-1-benzothien-2-yl)sulfonyl]amino}benzoic acid, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) Inhibitors targeting PFKFB3, PFKFB4 |
| AE-34-SK19_0.1uM | Dose=0.1uM, 3-{[(5-Chloro-3-methyl-1-benzothien-2-yl)sulfonyl]amino}benzoic acid, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) Inhibitors targeting PFKFB3, PFKFB4 |
| AE-34-SK19_10uM | Dose=10uM, 3-{[(5-Chloro-3-methyl-1-benzothien-2-yl)sulfonyl]amino}benzoic acid, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) Inhibitors targeting PFKFB3, PFKFB4 |
| AE-34-SK19_1uM | Dose=1uM, 3-{[(5-Chloro-3-methyl-1-benzothien-2-yl)sulfonyl]amino}benzoic acid, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) Inhibitors targeting PFKFB3, PFKFB4 |
| AE-36-GL26_0.01uM | Dose=0.01uM, 2-(2,6-dichlorophenyl)-1H-indole-6-carboxylic acid quinolin-2-ylamide |
| AE-36-GL26_0.1uM | Dose=0.1uM, 2-(2,6-dichlorophenyl)-1H-indole-6-carboxylic acid quinolin-2-ylamide |
| AE-36-GL26_10uM | Dose=10uM, 2-(2,6-dichlorophenyl)-1H-indole-6-carboxylic acid quinolin-2-ylamide |
| AE-36-GL26_1uM | Dose=1uM, 2-(2,6-dichlorophenyl)-1H-indole-6-carboxylic acid quinolin-2-ylamide |
| AE-36-JB67_0.01uM | Dose=0.01uM, protein kinase inhibitor H89, Voltage-Gated K(V) Channel Blockers;Protein Kinase B (PKB/Akt) Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG |
| AE-36-JB67_0.1uM | Dose=0.1uM, protein kinase inhibitor H89, Voltage-Gated K(V) Channel Blockers;Protein Kinase B (PKB/Akt) Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG |
| AE-36-JB67_10uM | Dose=10uM, protein kinase inhibitor H89, Voltage-Gated K(V) Channel Blockers;Protein Kinase B (PKB/Akt) Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG |
| AE-36-JB67_1uM | Dose=1uM, protein kinase inhibitor H89, Voltage-Gated K(V) Channel Blockers;Protein Kinase B (PKB/Akt) Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG |
| AE-36-TF52_0.01uM | Dose=0.01uM, 3-(2,7-Dimethoxyacridin-9-ylthio)propan-1-amine, Serine/Threonine Kinase Haspin (Gsg2) Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 2 (DYRK2) Inhibitors targeting DYRK3, DYRK2, HASPIN |
| AE-36-TF52_0.1uM | Dose=0.1uM, 3-(2,7-Dimethoxyacridin-9-ylthio)propan-1-amine, Serine/Threonine Kinase Haspin (Gsg2) Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 2 (DYRK2) Inhibitors targeting DYRK3, DYRK2, HASPIN |
| AE-36-TF52_10uM | Dose=10uM, 3-(2,7-Dimethoxyacridin-9-ylthio)propan-1-amine, Serine/Threonine Kinase Haspin (Gsg2) Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 2 (DYRK2) Inhibitors targeting DYRK3, DYRK2, HASPIN |
| AE-36-TF52_1uM | Dose=1uM, 3-(2,7-Dimethoxyacridin-9-ylthio)propan-1-amine, Serine/Threonine Kinase Haspin (Gsg2) Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 2 (DYRK2) Inhibitors targeting DYRK3, DYRK2, HASPIN |
| AE-37-KS50_0.01uM | Dose=0.01uM, Cgp 52432 |
| AE-37-KS50_10uM | Dose=10uM, Cgp 52432 |
| AE-37-KS50_1uM | Dose=1uM, Cgp 52432 |
| AE-37-MC27_0.01uM | Dose=0.01uM, Tamoxifen, Selective Estrogen Receptor Modulator (SERM) targeting ESR1, ESR2, EBP |
| AE-37-MC27_0.1uM | Dose=0.1uM, Tamoxifen, Selective Estrogen Receptor Modulator (SERM) targeting ESR1, ESR2, EBP |
| AE-37-MC27_10uM | Dose=10uM, Tamoxifen, Selective Estrogen Receptor Modulator (SERM) targeting ESR1, ESR2, EBP |
| AE-37-MC27_1uM | Dose=1uM, Tamoxifen, Selective Estrogen Receptor Modulator (SERM) targeting ESR1, ESR2, EBP |
| AE-38-EW02_0.01uM | Dose=0.01uM, Apoptosis Inducers;NF-kappaB (NFKB) Activation Inhibitors;5-HT3 antagonist;Apoptosis Inducers;NF-kappaB (NFKB) Activation Inhibitors;5-HT3 antagonist |
| AE-38-EW82_0.01uM | Dose=0.01uM |
| AE-38-EW82_0.1uM | Dose=0.1uM |
| AE-38-EW82_10uM | Dose=10uM |
| AE-38-EW82_1uM | Dose=1uM |
| AE-38-LX10_0.01uM | Dose=0.01uM, 3-{[(1r,2s)-2-Aminocyclohexyl]amino}-5-(1h-Indol-7-Ylamino)-1,2,4-Triazine-6-Carboxamide, Syk tyrosine kinase inhibitor;selective SYK inhibitor targeting SYK |
| AE-38-LX10_0.1uM | Dose=0.1uM, 3-{[(1r,2s)-2-Aminocyclohexyl]amino}-5-(1h-Indol-7-Ylamino)-1,2,4-Triazine-6-Carboxamide, Syk tyrosine kinase inhibitor;selective SYK inhibitor targeting SYK |
| AE-38-LX10_10uM | Dose=10uM, 3-{[(1r,2s)-2-Aminocyclohexyl]amino}-5-(1h-Indol-7-Ylamino)-1,2,4-Triazine-6-Carboxamide, Syk tyrosine kinase inhibitor;selective SYK inhibitor targeting SYK |
| AE-38-LX10_1uM | Dose=1uM, 3-{[(1r,2s)-2-Aminocyclohexyl]amino}-5-(1h-Indol-7-Ylamino)-1,2,4-Triazine-6-Carboxamide, Syk tyrosine kinase inhibitor;selective SYK inhibitor targeting SYK |
| AE-38-QT35_0.01uM | Dose=0.01uM, ML324, KDM4E targeting KDM4E |
| AE-38-QT35_0.1uM | Dose=0.1uM, ML324, KDM4E targeting KDM4E |
| AE-38-QT35_10uM | Dose=10uM, ML324, KDM4E targeting KDM4E |
| AE-38-QT35_1uM | Dose=1uM, ML324, KDM4E targeting KDM4E |
| AE-38-ZM08_0.01uM | Dose=0.01uM |
| AE-38-ZM08_0.1uM | Dose=0.1uM |
| AE-38-ZM08_10uM | Dose=10uM |
| AE-38-ZM08_1uM | Dose=1uM |
| AE-39-DG66_0.01uM | Dose=0.01uM, (E)-3-[4-[[2-(5-fluoro-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AE-39-DG66_0.1uM | Dose=0.1uM, (E)-3-[4-[[2-(5-fluoro-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AE-39-DG66_10uM | Dose=10uM, (E)-3-[4-[[2-(5-fluoro-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AE-39-DG66_1uM | Dose=1uM, (E)-3-[4-[[2-(5-fluoro-1H-indol-3-yl)ethylamino]methyl]phenyl]-N-hydroxyprop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AE-39-SG01_0.01uM | Dose=0.01uM, Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate, P2RY12 antagonist targeting P2RY12 |
| AE-39-SG01_0.1uM | Dose=0.1uM, Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate, P2RY12 antagonist targeting P2RY12 |
| AE-39-SG01_10uM | Dose=10uM, Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate, P2RY12 antagonist targeting P2RY12 |
| AE-39-SG01_1uM | Dose=1uM, Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate, P2RY12 antagonist targeting P2RY12 |
| AE-41-GB05_0.01uM | Dose=0.01uM, Ave5638, Known Tryptase inhibitor targeting TPSB2 |
| AE-41-GB05_0.1uM | Dose=0.1uM, Ave5638, Known Tryptase inhibitor targeting TPSB2 |
| AE-41-GB05_10uM | Dose=10uM, Ave5638, Known Tryptase inhibitor targeting TPSB2 |
| AE-41-GB05_1uM | Dose=1uM, Ave5638, Known Tryptase inhibitor targeting TPSB2 |
| AE-42-HT01_0.01uM | Dose=0.01uM, Ibudilast, Mediator Release Inhibitors;Leukotriene CysLT1 (LTD4) Antagonists;Phosphodiesterase Inhibitors;TLR4 (LPS) Receptor Antagonists targeting PDE4A, PDE4B, PDE4C, PDE4D, TLR4, CYSLTR1 |
| AE-42-HT01_0.1uM | Dose=0.1uM, Ibudilast, Mediator Release Inhibitors;Leukotriene CysLT1 (LTD4) Antagonists;Phosphodiesterase Inhibitors;TLR4 (LPS) Receptor Antagonists targeting PDE4A, PDE4B, PDE4C, PDE4D, TLR4, CYSLTR1 |
| AE-42-HT01_10uM | Dose=10uM, Ibudilast, Mediator Release Inhibitors;Leukotriene CysLT1 (LTD4) Antagonists;Phosphodiesterase Inhibitors;TLR4 (LPS) Receptor Antagonists targeting PDE4A, PDE4B, PDE4C, PDE4D, TLR4, CYSLTR1 |
| AE-42-HT01_1uM | Dose=1uM, Ibudilast, Mediator Release Inhibitors;Leukotriene CysLT1 (LTD4) Antagonists;Phosphodiesterase Inhibitors;TLR4 (LPS) Receptor Antagonists targeting PDE4A, PDE4B, PDE4C, PDE4D, TLR4, CYSLTR1 |
| AE-43-UJ94_0.01uM | Dose=0.01uM |
| AE-43-UJ94_0.1uM | Dose=0.1uM |
| AE-43-UJ94_10uM | Dose=10uM |
| AE-43-UJ94_1uM | Dose=1uM |
| AE-43-WW30_0.1uM | Dose=0.1uM, Hyoscyamine, Muscarinic receptor antagonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| AE-43-WW30_10uM | Dose=10uM, Hyoscyamine, Muscarinic receptor antagonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| AE-43-WW30_1uM | Dose=1uM, Hyoscyamine, Muscarinic receptor antagonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| AE-48-EW32_0.01uM | Dose=0.01uM, gamma-Secretase Inhibitors |
| AE-48-EW32_10uM | Dose=10uM, gamma-Secretase Inhibitors |
| AE-51-ZO26_0.01uM | Dose=0.01uM, PF-06446846, pcsk9 translation inhbitor targeting RPL17, PCSK9 |
| AE-51-ZO26_0.1uM | Dose=0.1uM, PF-06446846, pcsk9 translation inhbitor targeting RPL17, PCSK9 |
| AE-51-ZO26_10uM | Dose=10uM, PF-06446846, pcsk9 translation inhbitor targeting RPL17, PCSK9 |
| AE-51-ZO26_1uM | Dose=1uM, PF-06446846, pcsk9 translation inhbitor targeting RPL17, PCSK9 |
| AE-52-FP96_0.01uM | Dose=0.01uM, 1-(4-Chlorophenyl)sulfonyl-2-thiophen-2-ylpyrrolidine, GRM1 antagonist targeting GRM1 |
| AE-52-FP96_0.1uM | Dose=0.1uM, 1-(4-Chlorophenyl)sulfonyl-2-thiophen-2-ylpyrrolidine, GRM1 antagonist targeting GRM1 |
| AE-52-FP96_10uM | Dose=10uM, 1-(4-Chlorophenyl)sulfonyl-2-thiophen-2-ylpyrrolidine, GRM1 antagonist targeting GRM1 |
| AE-52-FP96_1uM | Dose=1uM, 1-(4-Chlorophenyl)sulfonyl-2-thiophen-2-ylpyrrolidine, GRM1 antagonist targeting GRM1 |
| AE-52-NW93_0.01uM | Dose=0.01uM, Lly-507, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2 |
| AE-52-NW93_0.1uM | Dose=0.1uM, Lly-507, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2 |
| AE-52-NW93_10uM | Dose=10uM, Lly-507, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2 |
| AE-52-NW93_1uM | Dose=1uM, Lly-507, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2 |
| AE-52-XF72_0.01uM | Dose=0.01uM, Dichlorphenamide, Carbonic Anhydrase Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10 |
| AE-52-XF72_0.1uM | Dose=0.1uM, Dichlorphenamide, Carbonic Anhydrase Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10 |
| AE-52-XF72_10uM | Dose=10uM, Dichlorphenamide, Carbonic Anhydrase Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10 |
| AE-52-XF72_1uM | Dose=1uM, Dichlorphenamide, Carbonic Anhydrase Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10 |
| AE-53-IJ74_0.01uM | Dose=0.01uM, Desipramine, Norepinephrine Transporter (NET) Inhibitors;Sodium Channel Blockers targeting SLC6A2 |
| AE-53-IJ74_0.1uM | Dose=0.1uM, Desipramine, Norepinephrine Transporter (NET) Inhibitors;Sodium Channel Blockers targeting SLC6A2 |
| AE-53-IJ74_10uM | Dose=10uM, Desipramine, Norepinephrine Transporter (NET) Inhibitors;Sodium Channel Blockers targeting SLC6A2 |
| AE-54-BN96_0.01uM | Dose=0.01uM, 8-Ethyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one, CDK Inhibitors targeting CCND2, CCND3 |
| AE-54-BN96_0.1uM | Dose=0.1uM, 8-Ethyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one, CDK Inhibitors targeting CCND2, CCND3 |
| AE-54-BN96_10uM | Dose=10uM, 8-Ethyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one, CDK Inhibitors targeting CCND2, CCND3 |
| AE-54-BN96_1uM | Dose=1uM, 8-Ethyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one, CDK Inhibitors targeting CCND2, CCND3 |
| AE-56-RB57_0.01uM | Dose=0.01uM |
| AE-56-RB57_0.1uM | Dose=0.1uM |
| AE-56-RB57_10uM | Dose=10uM |
| AE-56-RB57_1uM | Dose=1uM |
| AE-56-SL06_0.01uM | Dose=0.01uM, 4,5-Dibromo-2-(m-tolyl)pyridazin-3(2H)-one, SOD1 gene inhibitor targeting SOD1 |
| AE-56-SL06_0.1uM | Dose=0.1uM, 4,5-Dibromo-2-(m-tolyl)pyridazin-3(2H)-one, SOD1 gene inhibitor targeting SOD1 |
| AE-56-SL06_10uM | Dose=10uM, 4,5-Dibromo-2-(m-tolyl)pyridazin-3(2H)-one, SOD1 gene inhibitor targeting SOD1 |
| AE-56-SL06_1uM | Dose=1uM, 4,5-Dibromo-2-(m-tolyl)pyridazin-3(2H)-one, SOD1 gene inhibitor targeting SOD1 |
| AE-57-PS55_0.01uM | Dose=0.01uM, 4-[[2-[[(1S,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide, CSF1R gene antagonist targeting CSF1R |
| AE-57-PS55_0.1uM | Dose=0.1uM, 4-[[2-[[(1S,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide, CSF1R gene antagonist targeting CSF1R |
| AE-57-PS55_10uM | Dose=10uM, 4-[[2-[[(1S,2R)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-N-methylpyridine-2-carboxamide, CSF1R gene antagonist targeting CSF1R |
| AE-59-ZQ55_0.01uM | Dose=0.01uM, Vofopitant, Tachykinin NK1 Antagonists targeting CYP2D6, TACR1 |
| AE-59-ZQ55_0.1uM | Dose=0.1uM, Vofopitant, Tachykinin NK1 Antagonists targeting CYP2D6, TACR1 |
| AE-59-ZQ55_10uM | Dose=10uM, Vofopitant, Tachykinin NK1 Antagonists targeting CYP2D6, TACR1 |
| AE-59-ZQ55_1uM | Dose=1uM, Vofopitant, Tachykinin NK1 Antagonists targeting CYP2D6, TACR1 |
| AE-61-UO01_0.01uM | Dose=0.01uM, BOC-piperidinyl glycine derivative, 9, MMP-13 (Collagenase 3) Inhibitors targeting MMP13 |
| AE-61-UO01_0.1uM | Dose=0.1uM, BOC-piperidinyl glycine derivative, 9, MMP-13 (Collagenase 3) Inhibitors targeting MMP13 |
| AE-61-UO01_10uM | Dose=10uM, BOC-piperidinyl glycine derivative, 9, MMP-13 (Collagenase 3) Inhibitors targeting MMP13 |
| AE-61-UO01_1uM | Dose=1uM, BOC-piperidinyl glycine derivative, 9, MMP-13 (Collagenase 3) Inhibitors targeting MMP13 |
| AE-62-QI94_0.01uM | Dose=0.01uM, Zankiren, Renin Inhibitors targeting REN |
| AE-62-QI94_0.1uM | Dose=0.1uM, Zankiren, Renin Inhibitors targeting REN |
| AE-62-QI94_10uM | Dose=10uM, Zankiren, Renin Inhibitors targeting REN |
| AE-63-ST43_0.01uM | Dose=0.01uM, Ipsapirone, HTR1A agonist;ADRA1B gene modulator;5-HT1A Receptor Agonists targeting ADRA1B, HTR1A |
| AE-63-ST43_0.1uM | Dose=0.1uM, Ipsapirone, HTR1A agonist;ADRA1B gene modulator;5-HT1A Receptor Agonists targeting ADRA1B, HTR1A |
| AE-63-ST43_10uM | Dose=10uM, Ipsapirone, HTR1A agonist;ADRA1B gene modulator;5-HT1A Receptor Agonists targeting ADRA1B, HTR1A |
| AE-63-ST43_1uM | Dose=1uM, Ipsapirone, HTR1A agonist;ADRA1B gene modulator;5-HT1A Receptor Agonists targeting ADRA1B, HTR1A |
| AE-64-IK64_0.01uM | Dose=0.01uM |
| AE-64-IK64_0.1uM | Dose=0.1uM |
| AE-64-IK64_10uM | Dose=10uM |
| AE-64-IK64_1uM | Dose=1uM |
| AE-64-KN26_0.01uM | Dose=0.01uM |
| AE-64-KN26_0.1uM | Dose=0.1uM |
| AE-64-KN26_10uM | Dose=10uM |
| AE-64-KN26_1uM | Dose=1uM |
| AE-65-KK96_0.01uM | Dose=0.01uM, 1-(1,3-Benzodioxol-5-ylcarbonyl)piperidine, AMPA Receptor Postiive Allosteric Modulators targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| AE-65-KK96_0.1uM | Dose=0.1uM, 1-(1,3-Benzodioxol-5-ylcarbonyl)piperidine, AMPA Receptor Postiive Allosteric Modulators targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| AE-65-KK96_1uM | Dose=1uM, 1-(1,3-Benzodioxol-5-ylcarbonyl)piperidine, AMPA Receptor Postiive Allosteric Modulators targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| AE-65-LV28_0.01uM | Dose=0.01uM, Ketotifen |
| AE-65-LV28_0.1uM | Dose=0.1uM, Ketotifen |
| AE-65-LV28_10uM | Dose=10uM, Ketotifen |
| AE-66-YB82_0.01uM | Dose=0.01uM, 1-N,4-N-bis[4-[[amino-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]methylidene]amino]butyl]benzene-1,4-dicarboxamide, Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A |
| AE-66-YB82_0.1uM | Dose=0.1uM, 1-N,4-N-bis[4-[[amino-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]methylidene]amino]butyl]benzene-1,4-dicarboxamide, Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A |
| AE-66-YB82_10uM | Dose=10uM, 1-N,4-N-bis[4-[[amino-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]methylidene]amino]butyl]benzene-1,4-dicarboxamide, Epithelial Sodium Channels (ENaC) Blockers targeting SCNN1A |
| AE-67-DS75_0.1uM | Dose=0.1uM, (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide, SMYD2 gene inhibitor;SMYD2 inhibitor targeting SMYD2 |
| AE-67-DS75_10uM | Dose=10uM, (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide, SMYD2 gene inhibitor;SMYD2 inhibitor targeting SMYD2 |
| AE-67-DS75_1uM | Dose=1uM, (R)-N-cyclohexyl-3-((3,4-dichlorophenethyl)amino)-N-(2-((2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethyl)amino)ethyl)propanamide, SMYD2 gene inhibitor;SMYD2 inhibitor targeting SMYD2 |
| AE-67-FF84_0.01uM | Dose=0.01uM, 4-(4-(3-(Trifluoromethyl)phenyl)-2-thiazolyl)benzoic acid, Retinoid RXRalpha Agonists;Retinoid RARalpha Agonists targeting RARA, RXRA |
| AE-67-FF84_0.1uM | Dose=0.1uM, 4-(4-(3-(Trifluoromethyl)phenyl)-2-thiazolyl)benzoic acid, Retinoid RXRalpha Agonists;Retinoid RARalpha Agonists targeting RARA, RXRA |
| AE-67-FF84_10uM | Dose=10uM, 4-(4-(3-(Trifluoromethyl)phenyl)-2-thiazolyl)benzoic acid, Retinoid RXRalpha Agonists;Retinoid RARalpha Agonists targeting RARA, RXRA |
| AE-67-FF84_1uM | Dose=1uM, 4-(4-(3-(Trifluoromethyl)phenyl)-2-thiazolyl)benzoic acid, Retinoid RXRalpha Agonists;Retinoid RARalpha Agonists targeting RARA, RXRA |
| AE-69-CH29_0.01uM | Dose=0.01uM, 3-Pyridinecarboxylic acid, 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-, GAT-1 Inhibitors targeting SLC6A12 |
| AE-69-CH29_0.1uM | Dose=0.1uM, 3-Pyridinecarboxylic acid, 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-, GAT-1 Inhibitors targeting SLC6A12 |
| AE-69-CH29_10uM | Dose=10uM, 3-Pyridinecarboxylic acid, 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-, GAT-1 Inhibitors targeting SLC6A12 |
| AE-69-CH29_1uM | Dose=1uM, 3-Pyridinecarboxylic acid, 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-, GAT-1 Inhibitors targeting SLC6A12 |
| AE-70-QB23_0.01uM | Dose=0.01uM, Trifluperidol targeting CYP2D6 |
| AE-70-QB23_0.1uM | Dose=0.1uM, Trifluperidol targeting CYP2D6 |
| AE-70-QB23_10uM | Dose=10uM, Trifluperidol targeting CYP2D6 |
| AE-70-QB23_1uM | Dose=1uM, Trifluperidol targeting CYP2D6 |
| AE-71-CB15_0.01uM | Dose=0.01uM, Ubenimex, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting ANPEP, LTA4H, LAP3 |
| AE-71-CB15_0.1uM | Dose=0.1uM, Ubenimex, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting ANPEP, LTA4H, LAP3 |
| AE-71-CB15_10uM | Dose=10uM, Ubenimex, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting ANPEP, LTA4H, LAP3 |
| AE-71-CB15_1uM | Dose=1uM, Ubenimex, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting ANPEP, LTA4H, LAP3 |
| AE-71-VB70_0.1uM | Dose=0.1uM, Dipyridamole, Phosphodiesterase III Inhibitors;Adenosine Transporter Inhibitor;Phosphodiesterase V (PDE5A) Inhibitors targeting ADA, SLC29A1, SLC29A2, PDE2A, PDE5A, ENPP6 |
| AE-71-VB70_10uM | Dose=10uM, Dipyridamole, Phosphodiesterase III Inhibitors;Adenosine Transporter Inhibitor;Phosphodiesterase V (PDE5A) Inhibitors targeting ADA, SLC29A1, SLC29A2, PDE2A, PDE5A, ENPP6 |
| AE-71-VB70_1uM | Dose=1uM, Dipyridamole, Phosphodiesterase III Inhibitors;Adenosine Transporter Inhibitor;Phosphodiesterase V (PDE5A) Inhibitors targeting ADA, SLC29A1, SLC29A2, PDE2A, PDE5A, ENPP6 |
| AE-72-UP91_0.01uM | Dose=0.01uM, 6-Chloro-2-hydroxy-N-methoxy-N-methyl-3-{2-[(R)-1-((2R,5R)-5-methyl-tetrahydro-furan-2-yl)-propylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzene sulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| AE-72-UP91_0.1uM | Dose=0.1uM, 6-Chloro-2-hydroxy-N-methoxy-N-methyl-3-{2-[(R)-1-((2R,5R)-5-methyl-tetrahydro-furan-2-yl)-propylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzene sulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| AE-72-UP91_10uM | Dose=10uM, 6-Chloro-2-hydroxy-N-methoxy-N-methyl-3-{2-[(R)-1-((2R,5R)-5-methyl-tetrahydro-furan-2-yl)-propylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzene sulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| AE-72-UP91_1uM | Dose=1uM, 6-Chloro-2-hydroxy-N-methoxy-N-methyl-3-{2-[(R)-1-((2R,5R)-5-methyl-tetrahydro-furan-2-yl)-propylamino]-3,4-dioxo-cyclobut-1-enylamino}-benzene sulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| AE-73-KX58_0.01uM | Dose=0.01uM, Lubiprostone, ClC-2 Channel Activators targeting CLCN2 |
| AE-73-KX58_0.1uM | Dose=0.1uM, Lubiprostone, ClC-2 Channel Activators targeting CLCN2 |
| AE-73-KX58_10uM | Dose=10uM, Lubiprostone, ClC-2 Channel Activators targeting CLCN2 |
| AE-73-KX58_1uM | Dose=1uM, Lubiprostone, ClC-2 Channel Activators targeting CLCN2 |
| AE-74-SQ33_0.01uM | Dose=0.01uM, Pralnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| AE-74-SQ33_0.1uM | Dose=0.1uM, Pralnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| AE-74-SQ33_10uM | Dose=10uM, Pralnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| AE-74-SQ33_1uM | Dose=1uM, Pralnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| AE-78-XJ76_0.01uM | Dose=0.01uM, 3-(3-Amino-2-methylphenyl)-1-(trans-4-hydroxycyclohexyl)-6-methyl-1H-indole-5-carbonitrile, KDM1A/B targeting KDM1A |
| AE-78-XJ76_0.1uM | Dose=0.1uM, 3-(3-Amino-2-methylphenyl)-1-(trans-4-hydroxycyclohexyl)-6-methyl-1H-indole-5-carbonitrile, KDM1A/B targeting KDM1A |
| AE-78-XJ76_10uM | Dose=10uM, 3-(3-Amino-2-methylphenyl)-1-(trans-4-hydroxycyclohexyl)-6-methyl-1H-indole-5-carbonitrile, KDM1A/B targeting KDM1A |
| AE-78-XJ76_1uM | Dose=1uM, 3-(3-Amino-2-methylphenyl)-1-(trans-4-hydroxycyclohexyl)-6-methyl-1H-indole-5-carbonitrile, KDM1A/B targeting KDM1A |
| AE-79-LG46_0.01uM | Dose=0.01uM, Gepirone |
| AE-79-LG46_0.1uM | Dose=0.1uM, Gepirone |
| AE-79-LG46_10uM | Dose=10uM, Gepirone |
| AE-79-LG46_1uM | Dose=1uM, Gepirone |
| AE-80-WH32_0.01uM | Dose=0.01uM |
| AE-80-WH32_0.1uM | Dose=0.1uM |
| AE-80-WH32_10uM | Dose=10uM |
| AE-80-WH32_1uM | Dose=1uM |
| AE-84-YK54_0.01uM | Dose=0.01uM |
| AE-84-YK54_0.1uM | Dose=0.1uM |
| AE-84-YK54_1uM | Dose=1uM |
| AE-85-KE62_0.01uM | Dose=0.01uM, Belinostat, Apoptosis Inducers;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Angiogenesis Inhibitors targeting HDAC1, HDAC2, HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AE-85-KE62_0.1uM | Dose=0.1uM, Belinostat, Apoptosis Inducers;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Angiogenesis Inhibitors targeting HDAC1, HDAC2, HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AE-85-KE62_10uM | Dose=10uM, Belinostat, Apoptosis Inducers;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Angiogenesis Inhibitors targeting HDAC1, HDAC2, HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AE-85-KE62_1uM | Dose=1uM, Belinostat, Apoptosis Inducers;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Angiogenesis Inhibitors targeting HDAC1, HDAC2, HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| AE-85-LR48_0.01uM | Dose=0.01uM, SB-435495, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors;Signal Transduction Modulators targeting PLA2G7 |
| AE-85-LR48_0.1uM | Dose=0.1uM, SB-435495, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors;Signal Transduction Modulators targeting PLA2G7 |
| AE-85-LR48_10uM | Dose=10uM, SB-435495, Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors;Signal Transduction Modulators targeting PLA2G7 |
| AE-87-GP03_0.01uM | Dose=0.01uM, 4-(benzyloxymethyl)-2-(2-chlorophenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, NADPH Oxidase Inhibitors targeting NOX1, NOX4 |
| AE-87-GP03_0.1uM | Dose=0.1uM, 4-(benzyloxymethyl)-2-(2-chlorophenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, NADPH Oxidase Inhibitors targeting NOX1, NOX4 |
| AE-87-GP03_10uM | Dose=10uM, 4-(benzyloxymethyl)-2-(2-chlorophenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, NADPH Oxidase Inhibitors targeting NOX1, NOX4 |
| AE-87-GP03_1uM | Dose=1uM, 4-(benzyloxymethyl)-2-(2-chlorophenyl)-5-(pyrazin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, NADPH Oxidase Inhibitors targeting NOX1, NOX4 |
| AE-88-WQ63_0.01uM | Dose=0.01uM, Pictilisib, panPI3K inhibitor targeting PIK3CA, PIK3CB |
| AE-88-WQ63_0.1uM | Dose=0.1uM, Pictilisib, panPI3K inhibitor targeting PIK3CA, PIK3CB |
| AE-88-WQ63_10uM | Dose=10uM, Pictilisib, panPI3K inhibitor targeting PIK3CA, PIK3CB |
| AE-88-WQ63_1uM | Dose=1uM, Pictilisib, panPI3K inhibitor targeting PIK3CA, PIK3CB |
| AE-89-KX47_0.01uM | Dose=0.01uM |
| AE-89-KX47_0.1uM | Dose=0.1uM |
| AE-89-KX47_10uM | Dose=10uM |
| AE-89-KX47_1uM | Dose=1uM |
| AE-90-RS19_0.01uM | Dose=0.01uM, Pasireotide, Somatostatin SRIF1B (sst5) inhibitor targeting SSTR3, SSTR5 |
| AE-90-RS19_0.1uM | Dose=0.1uM, Pasireotide, Somatostatin SRIF1B (sst5) inhibitor targeting SSTR3, SSTR5 |
| AE-90-RS19_10uM | Dose=10uM, Pasireotide, Somatostatin SRIF1B (sst5) inhibitor targeting SSTR3, SSTR5 |
| AE-90-RS19_1uM | Dose=1uM, Pasireotide, Somatostatin SRIF1B (sst5) inhibitor targeting SSTR3, SSTR5 |
| AE-91-BF25_0.01uM | Dose=0.01uM, Imetit, HRH3 agonist targeting HRH3 |
| AE-91-BF25_0.1uM | Dose=0.1uM, Imetit, HRH3 agonist targeting HRH3 |
| AE-91-BF25_10uM | Dose=10uM, Imetit, HRH3 agonist targeting HRH3 |
| AE-91-BF25_1uM | Dose=1uM, Imetit, HRH3 agonist targeting HRH3 |
| AE-93-WW90_0.01uM | Dose=0.01uM, Piclamilast, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4 |
| AE-93-WW90_10uM | Dose=10uM, Piclamilast, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4 |
| AE-93-WW90_1uM | Dose=1uM, Piclamilast, Phosphodiesterase IV Inhibitors targeting PDE4C, ENPP4 |
| AE-94-OX50_0.01uM | Dose=0.01uM, N-(2,6-Dichloro-pyridin-4-yl)-2-{3-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-2,4-dioxo-3,4-dihydro-2H-quinazolin-1-yl}-acetamide, S1PR2 antagonist;S1PR4 antagonist targeting S1PR4 |
| AE-94-OX50_0.1uM | Dose=0.1uM, N-(2,6-Dichloro-pyridin-4-yl)-2-{3-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-2,4-dioxo-3,4-dihydro-2H-quinazolin-1-yl}-acetamide, S1PR2 antagonist;S1PR4 antagonist targeting S1PR4 |
| AE-94-OX50_10uM | Dose=10uM, N-(2,6-Dichloro-pyridin-4-yl)-2-{3-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-2,4-dioxo-3,4-dihydro-2H-quinazolin-1-yl}-acetamide, S1PR2 antagonist;S1PR4 antagonist targeting S1PR4 |
| AE-94-ZD47_0.01uM | Dose=0.01uM, SB 203580, p38 MAPK Inhibitors;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors;Calcium Channel Activators targeting MAPK14, CSNK1D, GAK, MAPK11, MAPK12, RIPK2 |
| AE-94-ZD47_0.1uM | Dose=0.1uM, SB 203580, p38 MAPK Inhibitors;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors;Calcium Channel Activators targeting MAPK14, CSNK1D, GAK, MAPK11, MAPK12, RIPK2 |
| AE-94-ZD47_10uM | Dose=10uM, SB 203580, p38 MAPK Inhibitors;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors;Calcium Channel Activators targeting MAPK14, CSNK1D, GAK, MAPK11, MAPK12, RIPK2 |
| AE-94-ZD47_1uM | Dose=1uM, SB 203580, p38 MAPK Inhibitors;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors;Calcium Channel Activators targeting MAPK14, CSNK1D, GAK, MAPK11, MAPK12, RIPK2 |
| AE-95-HR68_0.01uM | Dose=0.01uM, AdipoRon, Adiponectin Receptor 1 (ADIPOR1) and Adiponectin Receptor 2 (ADIPOR2) Agonist. targeting ADIPOR1, ADIPOR2 |
| AE-95-HR68_0.1uM | Dose=0.1uM, AdipoRon, Adiponectin Receptor 1 (ADIPOR1) and Adiponectin Receptor 2 (ADIPOR2) Agonist. targeting ADIPOR1, ADIPOR2 |
| AE-95-HR68_10uM | Dose=10uM, AdipoRon, Adiponectin Receptor 1 (ADIPOR1) and Adiponectin Receptor 2 (ADIPOR2) Agonist. targeting ADIPOR1, ADIPOR2 |
| AE-95-HR68_1uM | Dose=1uM, AdipoRon, Adiponectin Receptor 1 (ADIPOR1) and Adiponectin Receptor 2 (ADIPOR2) Agonist. targeting ADIPOR1, ADIPOR2 |
| AE-95-KU30_0.01uM | Dose=0.01uM, Kmup-1, Guanylate Cyclase Activators;Phosphodiesterase Inhibitors;Potassium Channel Activators targeting HTR2A, HTR2B, HTR2C |
| AE-95-KU30_0.1uM | Dose=0.1uM, Kmup-1, Guanylate Cyclase Activators;Phosphodiesterase Inhibitors;Potassium Channel Activators targeting HTR2A, HTR2B, HTR2C |
| AE-95-KU30_10uM | Dose=10uM, Kmup-1, Guanylate Cyclase Activators;Phosphodiesterase Inhibitors;Potassium Channel Activators targeting HTR2A, HTR2B, HTR2C |
| AE-95-KU30_1uM | Dose=1uM, Kmup-1, Guanylate Cyclase Activators;Phosphodiesterase Inhibitors;Potassium Channel Activators targeting HTR2A, HTR2B, HTR2C |
| AE-95-UU45_10uM | Dose=10uM, Terguride, Prolactin Secretion Inhibitors;5-HT2A Antagonists;5-HT2B Antagonists targeting DRD2, HTR2A, HTR2B, PRL |
| AE-95-UU45_1uM | Dose=1uM, Terguride, Prolactin Secretion Inhibitors;5-HT2A Antagonists;5-HT2B Antagonists targeting DRD2, HTR2A, HTR2B, PRL |
| AE-95-ZK81_0.01uM | Dose=0.01uM, Domperidone, Dopamine Receptor Antagonists targeting DRD2, DRD3 |
| AE-95-ZK81_0.1uM | Dose=0.1uM, Domperidone, Dopamine Receptor Antagonists targeting DRD2, DRD3 |
| AE-95-ZK81_10uM | Dose=10uM, Domperidone, Dopamine Receptor Antagonists targeting DRD2, DRD3 |
| AE-95-ZK81_1uM | Dose=1uM, Domperidone, Dopamine Receptor Antagonists targeting DRD2, DRD3 |
| AE-97-TS20_0.01uM | Dose=0.01uM, Nicorandil, Natriuretic peptide receptor A agonist;Nitrate;Vasodilator;K(ATP) Channel Activators targeting NPR1 |
| AE-97-TS20_0.1uM | Dose=0.1uM, Nicorandil, Natriuretic peptide receptor A agonist;Nitrate;Vasodilator;K(ATP) Channel Activators targeting NPR1 |
| AE-97-TS20_10uM | Dose=10uM, Nicorandil, Natriuretic peptide receptor A agonist;Nitrate;Vasodilator;K(ATP) Channel Activators targeting NPR1 |
| AE-97-TS20_1uM | Dose=1uM, Nicorandil, Natriuretic peptide receptor A agonist;Nitrate;Vasodilator;K(ATP) Channel Activators targeting NPR1 |
| AF-00-QK19_0.01uM | Dose=0.01uM, 1-methyl-3-[(Z)-(4-oxo-3-prop-2-enyl-1,3-thiazolidin-2-ylidene)amino]thiourea, Apoptosis Inducers targeting RORA |
| AF-00-QK19_0.1uM | Dose=0.1uM, 1-methyl-3-[(Z)-(4-oxo-3-prop-2-enyl-1,3-thiazolidin-2-ylidene)amino]thiourea, Apoptosis Inducers targeting RORA |
| AF-00-QK19_10uM | Dose=10uM, 1-methyl-3-[(Z)-(4-oxo-3-prop-2-enyl-1,3-thiazolidin-2-ylidene)amino]thiourea, Apoptosis Inducers targeting RORA |
| AF-00-QK19_1uM | Dose=1uM, 1-methyl-3-[(Z)-(4-oxo-3-prop-2-enyl-1,3-thiazolidin-2-ylidene)amino]thiourea, Apoptosis Inducers targeting RORA |
| AF-01-FE42_0.01uM | Dose=0.01uM, 5-ethoxy-N,N-dipropyl-3,4-dihydro-2H-thiochromen-3-amine, 5-HT1A Receptor Agonists targeting HTR1A |
| AF-01-FE42_0.1uM | Dose=0.1uM, 5-ethoxy-N,N-dipropyl-3,4-dihydro-2H-thiochromen-3-amine, 5-HT1A Receptor Agonists targeting HTR1A |
| AF-01-FE42_10uM | Dose=10uM, 5-ethoxy-N,N-dipropyl-3,4-dihydro-2H-thiochromen-3-amine, 5-HT1A Receptor Agonists targeting HTR1A |
| AF-01-FE42_1uM | Dose=1uM, 5-ethoxy-N,N-dipropyl-3,4-dihydro-2H-thiochromen-3-amine, 5-HT1A Receptor Agonists targeting HTR1A |
| AF-06-AY37_0.01uM | Dose=0.01uM, 3-(1,2,3,4-Tetrahydro-carbazol-9-yl)-propionic acid |
| AF-06-AY37_0.1uM | Dose=0.1uM, 3-(1,2,3,4-Tetrahydro-carbazol-9-yl)-propionic acid |
| AF-06-AY37_10uM | Dose=10uM, 3-(1,2,3,4-Tetrahydro-carbazol-9-yl)-propionic acid |
| AF-06-AY37_1uM | Dose=1uM, 3-(1,2,3,4-Tetrahydro-carbazol-9-yl)-propionic acid |
| AF-06-ME04_0.01uM | Dose=0.01uM, Tecalcet, Calcium-Sensing Receptor (CaSR) Agonists targeting CASR |
| AF-06-ME04_0.1uM | Dose=0.1uM, Tecalcet, Calcium-Sensing Receptor (CaSR) Agonists targeting CASR |
| AF-06-ME04_10uM | Dose=10uM, Tecalcet, Calcium-Sensing Receptor (CaSR) Agonists targeting CASR |
| AF-06-ME04_1uM | Dose=1uM, Tecalcet, Calcium-Sensing Receptor (CaSR) Agonists targeting CASR |
| AF-07-LS35_0.1uM | Dose=0.1uM, Somatostatin srif2B (sst4) Agonists |
| AF-07-LS35_10uM | Dose=10uM, Somatostatin srif2B (sst4) Agonists |
| AF-10-BU38_0.01uM | Dose=0.01uM, 2,4-Dichloro-5-sulfamoylbenzoic acid, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors targeting CA2 |
| AF-10-BU38_0.1uM | Dose=0.1uM, 2,4-Dichloro-5-sulfamoylbenzoic acid, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors targeting CA2 |
| AF-10-BU38_10uM | Dose=10uM, 2,4-Dichloro-5-sulfamoylbenzoic acid, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors targeting CA2 |
| AF-10-BU38_1uM | Dose=1uM, 2,4-Dichloro-5-sulfamoylbenzoic acid, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors targeting CA2 |
| AF-10-QK79_0.01uM | Dose=0.01uM, Baclofen, GABA(B) Agonists targeting GABBR1, GABBR2 |
| AF-10-QK79_0.1uM | Dose=0.1uM, Baclofen, GABA(B) Agonists targeting GABBR1, GABBR2 |
| AF-10-QK79_10uM | Dose=10uM, Baclofen, GABA(B) Agonists targeting GABBR1, GABBR2 |
| AF-10-QK79_1uM | Dose=1uM, Baclofen, GABA(B) Agonists targeting GABBR1, GABBR2 |
| AF-11-IL39_0.01uM | Dose=0.01uM, (S)-2-Methyl-1-((4-methyl-5-isoquinoline)sulfonyl)-homopiperazine, PKC Kinase nhibitor;ROCK gene inhibitor targeting PRKACA, ROCK1, ROCK2 |
| AF-11-IL39_0.1uM | Dose=0.1uM, (S)-2-Methyl-1-((4-methyl-5-isoquinoline)sulfonyl)-homopiperazine, PKC Kinase nhibitor;ROCK gene inhibitor targeting PRKACA, ROCK1, ROCK2 |
| AF-11-IL39_10uM | Dose=10uM, (S)-2-Methyl-1-((4-methyl-5-isoquinoline)sulfonyl)-homopiperazine, PKC Kinase nhibitor;ROCK gene inhibitor targeting PRKACA, ROCK1, ROCK2 |
| AF-11-IL39_1uM | Dose=1uM, (S)-2-Methyl-1-((4-methyl-5-isoquinoline)sulfonyl)-homopiperazine, PKC Kinase nhibitor;ROCK gene inhibitor targeting PRKACA, ROCK1, ROCK2 |
| AF-12-IW93_0.01uM | Dose=0.01uM, 5-(2,4-Dichlorobenzyl)-2-(2-pyridinyl)-4,6-pyrimidinediamine, Hepcidin (LEAP-1) Antagonists;Antianemic;Ferroportin antagonist targeting SLC40A1 |
| AF-12-IW93_0.1uM | Dose=0.1uM, 5-(2,4-Dichlorobenzyl)-2-(2-pyridinyl)-4,6-pyrimidinediamine, Hepcidin (LEAP-1) Antagonists;Antianemic;Ferroportin antagonist targeting SLC40A1 |
| AF-12-IW93_10uM | Dose=10uM, 5-(2,4-Dichlorobenzyl)-2-(2-pyridinyl)-4,6-pyrimidinediamine, Hepcidin (LEAP-1) Antagonists;Antianemic;Ferroportin antagonist targeting SLC40A1 |
| AF-12-IW93_1uM | Dose=1uM, 5-(2,4-Dichlorobenzyl)-2-(2-pyridinyl)-4,6-pyrimidinediamine, Hepcidin (LEAP-1) Antagonists;Antianemic;Ferroportin antagonist targeting SLC40A1 |
| AF-13-LM61_0.01uM | Dose=0.01uM, Cyproheptadine, Histamine H1 Receptor Antagonists;5-HT2B Antagonists targeting HRH1, HTR2B |
| AF-13-LM61_0.1uM | Dose=0.1uM, Cyproheptadine, Histamine H1 Receptor Antagonists;5-HT2B Antagonists targeting HRH1, HTR2B |
| AF-13-LM61_10uM | Dose=10uM, Cyproheptadine, Histamine H1 Receptor Antagonists;5-HT2B Antagonists targeting HRH1, HTR2B |
| AF-13-LM61_1uM | Dose=1uM, Cyproheptadine, Histamine H1 Receptor Antagonists;5-HT2B Antagonists targeting HRH1, HTR2B |
| AF-16-GB72_0.01uM | Dose=0.01uM, SR9238, LXR inverse agonist;Inverse agonist of LXR;NR1H3 gene modulator targeting NR1H2, NR1H3 |
| AF-16-GB72_0.1uM | Dose=0.1uM, SR9238, LXR inverse agonist;Inverse agonist of LXR;NR1H3 gene modulator targeting NR1H2, NR1H3 |
| AF-16-GB72_10uM | Dose=10uM, SR9238, LXR inverse agonist;Inverse agonist of LXR;NR1H3 gene modulator targeting NR1H2, NR1H3 |
| AF-16-GB72_1uM | Dose=1uM, SR9238, LXR inverse agonist;Inverse agonist of LXR;NR1H3 gene modulator targeting NR1H2, NR1H3 |
| AF-16-IB77_0.01uM | Dose=0.01uM, Sew2871, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| AF-16-IB77_0.1uM | Dose=0.1uM, Sew2871, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| AF-16-IB77_10uM | Dose=10uM, Sew2871, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| AF-16-IB77_1uM | Dose=1uM, Sew2871, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| AF-18-FX20_0.01uM | Dose=0.01uM, Etiron, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| AF-18-FX20_0.1uM | Dose=0.1uM, Etiron, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| AF-18-FX20_10uM | Dose=10uM, Etiron, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| AF-18-FX20_1uM | Dose=1uM, Etiron, Nitric Oxide Synthase Inhibitors targeting NOS3 |
| AF-19-KN63_0.01uM | Dose=0.01uM, Atosiban, Oxytocin (OT) Antagonists targeting AVPR1A, OXTR |
| AF-19-KN63_0.1uM | Dose=0.1uM, Atosiban, Oxytocin (OT) Antagonists targeting AVPR1A, OXTR |
| AF-19-KN63_10uM | Dose=10uM, Atosiban, Oxytocin (OT) Antagonists targeting AVPR1A, OXTR |
| AF-19-KN63_1uM | Dose=1uM, Atosiban, Oxytocin (OT) Antagonists targeting AVPR1A, OXTR |
| AF-19-OG56_0.01uM | Dose=0.01uM, N-(4-((4-(Cyclopentanecarbonyl)piperazin-1-yl)sulfonyl)phenyl)acrylamide, Tissue transglutaminase inhibitor targeting TGM2 |
| AF-19-OG56_10uM | Dose=10uM, N-(4-((4-(Cyclopentanecarbonyl)piperazin-1-yl)sulfonyl)phenyl)acrylamide, Tissue transglutaminase inhibitor targeting TGM2 |
| AF-19-OG56_1uM | Dose=1uM, N-(4-((4-(Cyclopentanecarbonyl)piperazin-1-yl)sulfonyl)phenyl)acrylamide, Tissue transglutaminase inhibitor targeting TGM2 |
| AF-20-MK39_0.01uM | Dose=0.01uM, Gabapentin, Calcium Channels (Voltage-Gated) alpha2/delta-2 Subunit Ligands;Calcium Channels (Voltage-Gated) alpha2/delta-1 Subunit Ligands targeting CACNA1D, CACNA2D1, CACNA2D2, CACNA2D3 |
| AF-20-MK39_0.1uM | Dose=0.1uM, Gabapentin, Calcium Channels (Voltage-Gated) alpha2/delta-2 Subunit Ligands;Calcium Channels (Voltage-Gated) alpha2/delta-1 Subunit Ligands targeting CACNA1D, CACNA2D1, CACNA2D2, CACNA2D3 |
| AF-20-MK39_1uM | Dose=1uM, Gabapentin, Calcium Channels (Voltage-Gated) alpha2/delta-2 Subunit Ligands;Calcium Channels (Voltage-Gated) alpha2/delta-1 Subunit Ligands targeting CACNA1D, CACNA2D1, CACNA2D2, CACNA2D3 |
| AF-23-HJ84_0.01uM | Dose=0.01uM, 2-(1-(4-Amino-3,5-diethoxybenzyl)piperidin-4-ylamino)benzo[d]oxazole-5-sulfonamide, Somatostatin SRIF1B (sst5) Antagonists targeting SSTR5 |
| AF-23-HJ84_0.1uM | Dose=0.1uM, 2-(1-(4-Amino-3,5-diethoxybenzyl)piperidin-4-ylamino)benzo[d]oxazole-5-sulfonamide, Somatostatin SRIF1B (sst5) Antagonists targeting SSTR5 |
| AF-23-HJ84_10uM | Dose=10uM, 2-(1-(4-Amino-3,5-diethoxybenzyl)piperidin-4-ylamino)benzo[d]oxazole-5-sulfonamide, Somatostatin SRIF1B (sst5) Antagonists targeting SSTR5 |
| AF-23-HJ84_1uM | Dose=1uM, 2-(1-(4-Amino-3,5-diethoxybenzyl)piperidin-4-ylamino)benzo[d]oxazole-5-sulfonamide, Somatostatin SRIF1B (sst5) Antagonists targeting SSTR5 |
| AF-23-RM26_0.01uM | Dose=0.01uM, 2-[(1-Oxido-4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR Inhibitors targeting KDR |
| AF-23-RM26_0.1uM | Dose=0.1uM, 2-[(1-Oxido-4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR Inhibitors targeting KDR |
| AF-23-RM26_10uM | Dose=10uM, 2-[(1-Oxido-4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR Inhibitors targeting KDR |
| AF-23-RM26_1uM | Dose=1uM, 2-[(1-Oxido-4-pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR Inhibitors targeting KDR |
| AF-25-BS76_0.01uM | Dose=0.01uM, Alectinib, ALK Tyrosine Kinase Receptor Inhibitors;Echinoderm Microtubule-Associated Protein-like 4-ALK Tyrosine Kinase Receptor (EML4- ALK) Inhibitors targeting ALK, EML4 |
| AF-25-BS76_0.1uM | Dose=0.1uM, Alectinib, ALK Tyrosine Kinase Receptor Inhibitors;Echinoderm Microtubule-Associated Protein-like 4-ALK Tyrosine Kinase Receptor (EML4- ALK) Inhibitors targeting ALK, EML4 |
| AF-25-BS76_10uM | Dose=10uM, Alectinib, ALK Tyrosine Kinase Receptor Inhibitors;Echinoderm Microtubule-Associated Protein-like 4-ALK Tyrosine Kinase Receptor (EML4- ALK) Inhibitors targeting ALK, EML4 |
| AF-25-BS76_1uM | Dose=1uM, Alectinib, ALK Tyrosine Kinase Receptor Inhibitors;Echinoderm Microtubule-Associated Protein-like 4-ALK Tyrosine Kinase Receptor (EML4- ALK) Inhibitors targeting ALK, EML4 |
| AF-28-FX20_0.01uM | Dose=0.01uM, Probenecid, TRPV2 (Vanilloid VR2 Receptor) Agonists;MRP-1 Inhibitors targeting ABCC1, SLC22A6, TRPV2 |
| AF-28-FX20_0.1uM | Dose=0.1uM, Probenecid, TRPV2 (Vanilloid VR2 Receptor) Agonists;MRP-1 Inhibitors targeting ABCC1, SLC22A6, TRPV2 |
| AF-28-FX20_10uM | Dose=10uM, Probenecid, TRPV2 (Vanilloid VR2 Receptor) Agonists;MRP-1 Inhibitors targeting ABCC1, SLC22A6, TRPV2 |
| AF-28-FX20_1uM | Dose=1uM, Probenecid, TRPV2 (Vanilloid VR2 Receptor) Agonists;MRP-1 Inhibitors targeting ABCC1, SLC22A6, TRPV2 |
| AF-30-GH67_0.01uM | Dose=0.01uM, 7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, BRD4 gene inhibitor;BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| AF-30-GH67_0.1uM | Dose=0.1uM, 7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, BRD4 gene inhibitor;BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| AF-30-GH67_10uM | Dose=10uM, 7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, BRD4 gene inhibitor;BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| AF-30-GH67_1uM | Dose=1uM, 7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, BRD4 gene inhibitor;BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| AF-31-RV78_0.01uM | Dose=0.01uM, targeting NOS3, PAH, TH, TPH1 |
| AF-31-RV78_0.1uM | Dose=0.1uM, targeting NOS3, PAH, TH, TPH1 |
| AF-31-RV78_10uM | Dose=10uM, targeting NOS3, PAH, TH, TPH1 |
| AF-31-RV78_1uM | Dose=1uM, targeting NOS3, PAH, TH, TPH1 |
| AF-33-AM86_0.01uM | Dose=0.01uM, Diltiazem, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| AF-33-AM86_0.1uM | Dose=0.1uM, Diltiazem, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| AF-33-AM86_10uM | Dose=10uM, Diltiazem, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| AF-33-AM86_1uM | Dose=1uM, Diltiazem, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| AF-33-GW65_0.01uM | Dose=0.01uM, Diazoxide, potassium channel activator;K(ATP) Channel Activators targeting CA1, KCNJ11 |
| AF-33-GW65_0.1uM | Dose=0.1uM, Diazoxide, potassium channel activator;K(ATP) Channel Activators targeting CA1, KCNJ11 |
| AF-33-GW65_10uM | Dose=10uM, Diazoxide, potassium channel activator;K(ATP) Channel Activators targeting CA1, KCNJ11 |
| AF-33-HJ54_0.01uM | Dose=0.01uM, 7-chloro-N-cyclohexyl-1-(2-morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, CNR2 agonist targeting CNR2 |
| AF-33-HJ54_0.1uM | Dose=0.1uM, 7-chloro-N-cyclohexyl-1-(2-morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, CNR2 agonist targeting CNR2 |
| AF-33-HJ54_10uM | Dose=10uM, 7-chloro-N-cyclohexyl-1-(2-morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, CNR2 agonist targeting CNR2 |
| AF-33-HJ54_1uM | Dose=1uM, 7-chloro-N-cyclohexyl-1-(2-morpholinoethyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, CNR2 agonist targeting CNR2 |
| AF-40-QU33_0.01uM | Dose=0.01uM, N-[4-[(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline-1-carbonyl]phenyl]-4-fluorobenzamide, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1 |
| AF-40-QU33_0.1uM | Dose=0.1uM, N-[4-[(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline-1-carbonyl]phenyl]-4-fluorobenzamide, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1 |
| AF-40-QU33_10uM | Dose=10uM, N-[4-[(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline-1-carbonyl]phenyl]-4-fluorobenzamide, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1 |
| AF-40-QU33_1uM | Dose=1uM, N-[4-[(4aR,8aS)-3,4,4a,5,6,7,8,8a-octahydro-2H-quinoline-1-carbonyl]phenyl]-4-fluorobenzamide, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1 |
| AF-41-BY55_0.01uM | Dose=0.01uM, Diethylstilbestrol, Chloride Channel Blockers;Estrogen Receptor (ER) Agonists targeting ESR1, ESR2 |
| AF-41-BY55_0.1uM | Dose=0.1uM, Diethylstilbestrol, Chloride Channel Blockers;Estrogen Receptor (ER) Agonists targeting ESR1, ESR2 |
| AF-41-BY55_10uM | Dose=10uM, Diethylstilbestrol, Chloride Channel Blockers;Estrogen Receptor (ER) Agonists targeting ESR1, ESR2 |
| AF-41-BY55_1uM | Dose=1uM, Diethylstilbestrol, Chloride Channel Blockers;Estrogen Receptor (ER) Agonists targeting ESR1, ESR2 |
| AF-41-QY60_0.01uM | Dose=0.01uM, Lomitapide, Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP |
| AF-41-QY60_0.1uM | Dose=0.1uM, Lomitapide, Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP |
| AF-41-QY60_10uM | Dose=10uM, Lomitapide, Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP |
| AF-41-QY60_1uM | Dose=1uM, Lomitapide, Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting MTTP |
| AF-42-MP86_0.01uM | Dose=0.01uM, N-(4-{5-[(cyclopropylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)cyclopropanecarboxamide |
| AF-42-MP86_0.1uM | Dose=0.1uM, N-(4-{5-[(cyclopropylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)cyclopropanecarboxamide |
| AF-42-MP86_10uM | Dose=10uM, N-(4-{5-[(cyclopropylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)cyclopropanecarboxamide |
| AF-42-MP86_1uM | Dose=1uM, N-(4-{5-[(cyclopropylcarbonyl)amino]-1H-benzimidazol-2-yl}phenyl)cyclopropanecarboxamide |
| AF-48-FX20_0.01uM | Dose=0.01uM, Clotrimazole, Gardos channel, SK41, IK1) Channel Blockers;Angiogenesis Inhibitors;Intermediate Conductance K(Ca) 3.1 (IKCa1;Lanosterol 14alpha-demethylase Inhibitors targeting CYP51A1, KCNN4 |
| AF-48-FX20_0.1uM | Dose=0.1uM, Clotrimazole, Gardos channel, SK41, IK1) Channel Blockers;Angiogenesis Inhibitors;Intermediate Conductance K(Ca) 3.1 (IKCa1;Lanosterol 14alpha-demethylase Inhibitors targeting CYP51A1, KCNN4 |
| AF-48-FX20_10uM | Dose=10uM, Clotrimazole, Gardos channel, SK41, IK1) Channel Blockers;Angiogenesis Inhibitors;Intermediate Conductance K(Ca) 3.1 (IKCa1;Lanosterol 14alpha-demethylase Inhibitors targeting CYP51A1, KCNN4 |
| AF-48-FX20_1uM | Dose=1uM, Clotrimazole, Gardos channel, SK41, IK1) Channel Blockers;Angiogenesis Inhibitors;Intermediate Conductance K(Ca) 3.1 (IKCa1;Lanosterol 14alpha-demethylase Inhibitors targeting CYP51A1, KCNN4 |
| AF-53-GC97_0.01uM | Dose=0.01uM |
| AF-53-GC97_0.1uM | Dose=0.1uM |
| AF-53-GC97_10uM | Dose=10uM |
| AF-53-GC97_1uM | Dose=1uM |
| AF-60-GR11_0.01uM | Dose=0.01uM, 4-(4-Benzylphenylamino)-6-(2-morpholinoethylamino)-1,7-naphthyridine-3-carbonitrile, Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8 |
| AF-60-GR11_0.1uM | Dose=0.1uM, 4-(4-Benzylphenylamino)-6-(2-morpholinoethylamino)-1,7-naphthyridine-3-carbonitrile, Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8 |
| AF-60-GR11_10uM | Dose=10uM, 4-(4-Benzylphenylamino)-6-(2-morpholinoethylamino)-1,7-naphthyridine-3-carbonitrile, Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8 |
| AF-60-GR11_1uM | Dose=1uM, 4-(4-Benzylphenylamino)-6-(2-morpholinoethylamino)-1,7-naphthyridine-3-carbonitrile, Tpl-2/Cot (MAP3K8) Kinase Inhibitors targeting MAP3K8 |
| AF-62-PI84_0.1uM | Dose=0.1uM, Ethanone, 1-[1,1'-biphenyl]-4-yl-2-(1H-1,2,4-triazol-1-yl)-, Heme Oxygenase 1 (HO-1) Inhibitors targeting HMOX1 |
| AF-62-PI84_10uM | Dose=10uM, Ethanone, 1-[1,1'-biphenyl]-4-yl-2-(1H-1,2,4-triazol-1-yl)-, Heme Oxygenase 1 (HO-1) Inhibitors targeting HMOX1 |
| AF-62-PI84_1uM | Dose=1uM, Ethanone, 1-[1,1'-biphenyl]-4-yl-2-(1H-1,2,4-triazol-1-yl)-, Heme Oxygenase 1 (HO-1) Inhibitors targeting HMOX1 |
| AF-64-CQ08_0.01uM | Dose=0.01uM, 3,4-Dihydroxybenzoic acid, Apoptosis Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Dihydroorotate Dehydrogenase (DHODH) Inhibitors;Antioxidants targeting DHODH |
| AF-64-CQ08_0.1uM | Dose=0.1uM, 3,4-Dihydroxybenzoic acid, Apoptosis Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Dihydroorotate Dehydrogenase (DHODH) Inhibitors;Antioxidants targeting DHODH |
| AF-64-CQ08_1uM | Dose=1uM, 3,4-Dihydroxybenzoic acid, Apoptosis Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Dihydroorotate Dehydrogenase (DHODH) Inhibitors;Antioxidants targeting DHODH |
| AF-65-CU85_0.01uM | Dose=0.01uM, 2-Amino-4-phosphonobutyric acid, mgluR6 Antagonists targeting GRM6 |
| AF-65-CU85_0.1uM | Dose=0.1uM, 2-Amino-4-phosphonobutyric acid, mgluR6 Antagonists targeting GRM6 |
| AF-65-CU85_10uM | Dose=10uM, 2-Amino-4-phosphonobutyric acid, mgluR6 Antagonists targeting GRM6 |
| AF-65-CU85_1uM | Dose=1uM, 2-Amino-4-phosphonobutyric acid, mgluR6 Antagonists targeting GRM6 |
| AF-67-LZ82_0.01uM | Dose=0.01uM, 5-(2,6-Dimorpholin-4-ylpyrimidin-4-yl)pyrimidine-2,4-diamine, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| AF-67-LZ82_0.1uM | Dose=0.1uM, 5-(2,6-Dimorpholin-4-ylpyrimidin-4-yl)pyrimidine-2,4-diamine, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| AF-67-LZ82_10uM | Dose=10uM, 5-(2,6-Dimorpholin-4-ylpyrimidin-4-yl)pyrimidine-2,4-diamine, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| AF-67-LZ82_1uM | Dose=1uM, 5-(2,6-Dimorpholin-4-ylpyrimidin-4-yl)pyrimidine-2,4-diamine, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| AF-71-GL94_0.01uM | Dose=0.01uM, 2-(5-chloro-2-methyl-N-methylsulfonylanilino)-N-(2,6-difluorophenyl)acetamide |
| AF-71-GL94_0.1uM | Dose=0.1uM, 2-(5-chloro-2-methyl-N-methylsulfonylanilino)-N-(2,6-difluorophenyl)acetamide |
| AF-71-GL94_10uM | Dose=10uM, 2-(5-chloro-2-methyl-N-methylsulfonylanilino)-N-(2,6-difluorophenyl)acetamide |
| AF-71-GL94_1uM | Dose=1uM, 2-(5-chloro-2-methyl-N-methylsulfonylanilino)-N-(2,6-difluorophenyl)acetamide |
| AF-72-PP21_0.01uM | Dose=0.01uM, Donepezil, Acetylcholinesterase Inhibitors targeting ACHE |
| AF-72-PP21_0.1uM | Dose=0.1uM, Donepezil, Acetylcholinesterase Inhibitors targeting ACHE |
| AF-72-PP21_10uM | Dose=10uM, Donepezil, Acetylcholinesterase Inhibitors targeting ACHE |
| AF-73-HJ84_0.01uM | Dose=0.01uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-(pyridin-3-ylmethyl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein-related Peptidase 7 (KLK7) Inhibitor targeting KLK7 |
| AF-73-HJ84_0.1uM | Dose=0.1uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-(pyridin-3-ylmethyl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein-related Peptidase 7 (KLK7) Inhibitor targeting KLK7 |
| AF-73-HJ84_10uM | Dose=10uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-(pyridin-3-ylmethyl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein-related Peptidase 7 (KLK7) Inhibitor targeting KLK7 |
| AF-73-HJ84_1uM | Dose=1uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-(pyridin-3-ylmethyl)-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein-related Peptidase 7 (KLK7) Inhibitor targeting KLK7 |
| AF-73-ON54_0.01uM | Dose=0.01uM, Benazepril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| AF-73-ON54_0.1uM | Dose=0.1uM, Benazepril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| AF-73-ON54_10uM | Dose=10uM, Benazepril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| AF-73-ON54_1uM | Dose=1uM, Benazepril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| AF-76-AY17_0.01uM | Dose=0.01uM, (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-(2-cyanopropan-2-yl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2 |
| AF-76-AY17_0.1uM | Dose=0.1uM, (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-(2-cyanopropan-2-yl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2 |
| AF-76-AY17_10uM | Dose=10uM, (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-(2-cyanopropan-2-yl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2 |
| AF-76-AY17_1uM | Dose=1uM, (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-(2-cyanopropan-2-yl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2 |
| AF-76-BV30_0.01uM | Dose=0.01uM, Dalcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP |
| AF-76-BV30_0.1uM | Dose=0.1uM, Dalcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP |
| AF-76-BV30_10uM | Dose=10uM, Dalcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP |
| AF-76-BV30_1uM | Dose=1uM, Dalcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP |
| AF-76-FL46_0.01uM | Dose=0.01uM, Gabexate, NF-kappaB (NFKB) Activation Inhibitors;MATE1 Inhibitors;Tryptase Inhibitors;AP-1 Inhibitors targeting TPSAB1, SLC47A1, JUN |
| AF-76-FL46_0.1uM | Dose=0.1uM, Gabexate, NF-kappaB (NFKB) Activation Inhibitors;MATE1 Inhibitors;Tryptase Inhibitors;AP-1 Inhibitors targeting TPSAB1, SLC47A1, JUN |
| AF-76-FL46_10uM | Dose=10uM, Gabexate, NF-kappaB (NFKB) Activation Inhibitors;MATE1 Inhibitors;Tryptase Inhibitors;AP-1 Inhibitors targeting TPSAB1, SLC47A1, JUN |
| AF-76-FL46_1uM | Dose=1uM, Gabexate, NF-kappaB (NFKB) Activation Inhibitors;MATE1 Inhibitors;Tryptase Inhibitors;AP-1 Inhibitors targeting TPSAB1, SLC47A1, JUN |
| AF-79-OK66_0.01uM | Dose=0.01uM, Gsk583, RIPK2 inhibitor targeting RIPK2 |
| AF-79-OK66_10uM | Dose=10uM, Gsk583, RIPK2 inhibitor targeting RIPK2 |
| AF-80-GK24_0.01uM | Dose=0.01uM, cyclo[Abu-Sar-N(Me)xiIle-Val-N(Me)Leu-Ala-D-Ala-N(Me)Leu-N(Me)Leu-N(Me)Val-N(Me)Bmt(E)] |
| AF-80-GK24_0.1uM | Dose=0.1uM, cyclo[Abu-Sar-N(Me)xiIle-Val-N(Me)Leu-Ala-D-Ala-N(Me)Leu-N(Me)Leu-N(Me)Val-N(Me)Bmt(E)] |
| AF-80-GK24_10uM | Dose=10uM, cyclo[Abu-Sar-N(Me)xiIle-Val-N(Me)Leu-Ala-D-Ala-N(Me)Leu-N(Me)Leu-N(Me)Val-N(Me)Bmt(E)] |
| AF-80-GK24_1uM | Dose=1uM, cyclo[Abu-Sar-N(Me)xiIle-Val-N(Me)Leu-Ala-D-Ala-N(Me)Leu-N(Me)Leu-N(Me)Val-N(Me)Bmt(E)] |
| AF-80-QK39_0.01uM | Dose=0.01uM, Diphenidol, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands;Muscarinic M1 Receptor Ligands targeting CHRM1, CHRM3, CHRM4 |
| AF-80-QK39_0.1uM | Dose=0.1uM, Diphenidol, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands;Muscarinic M1 Receptor Ligands targeting CHRM1, CHRM3, CHRM4 |
| AF-80-QK39_10uM | Dose=10uM, Diphenidol, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands;Muscarinic M1 Receptor Ligands targeting CHRM1, CHRM3, CHRM4 |
| AF-81-IV73_0.01uM | Dose=0.01uM, Acetazolamide, Carbonic Anhydrase Type XIII Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VI Inhibitors;Carbonic Anhydrase Type XV Inhibitors;Carbonic Anhydrase Type XIV Inhibitors targeting AQP4, CA1, CA2, CA3, CA4, CA5A, CA6, CA8, CA11, CA12, CA5B, CA14, CA10, CA13 |
| AF-81-IV73_0.1uM | Dose=0.1uM, Acetazolamide, Carbonic Anhydrase Type XIII Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VI Inhibitors;Carbonic Anhydrase Type XV Inhibitors;Carbonic Anhydrase Type XIV Inhibitors targeting AQP4, CA1, CA2, CA3, CA4, CA5A, CA6, CA8, CA11, CA12, CA5B, CA14, CA10, CA13 |
| AF-81-IV73_10uM | Dose=10uM, Acetazolamide, Carbonic Anhydrase Type XIII Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VI Inhibitors;Carbonic Anhydrase Type XV Inhibitors;Carbonic Anhydrase Type XIV Inhibitors targeting AQP4, CA1, CA2, CA3, CA4, CA5A, CA6, CA8, CA11, CA12, CA5B, CA14, CA10, CA13 |
| AF-81-IV73_1uM | Dose=1uM, Acetazolamide, Carbonic Anhydrase Type XIII Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VI Inhibitors;Carbonic Anhydrase Type XV Inhibitors;Carbonic Anhydrase Type XIV Inhibitors targeting AQP4, CA1, CA2, CA3, CA4, CA5A, CA6, CA8, CA11, CA12, CA5B, CA14, CA10, CA13 |
| AF-81-JB15_0.01uM | Dose=0.01uM, Ketoconazole |
| AF-81-JB15_0.1uM | Dose=0.1uM, Ketoconazole |
| AF-81-JB15_10uM | Dose=10uM, Ketoconazole |
| AF-81-JB15_1uM | Dose=1uM, Ketoconazole |
| AF-83-BX08_0.01uM | Dose=0.01uM |
| AF-83-BX08_0.1uM | Dose=0.1uM |
| AF-83-BX08_10uM | Dose=10uM |
| AF-83-BX08_1uM | Dose=1uM |
| AF-87-II41_0.01uM | Dose=0.01uM, N-(p-Amylcinnamoyl)anthranilic acid, Phospholipase A2 (PLA2) Inhibitors;TRPC6 Inhibitors;TRPM8 (TRP-p8| CMR1) Antagonists;TRPM2 Antagonists targeting TRPC6, TRPM2, TRPM8, PLA2G10 |
| AF-87-II41_0.1uM | Dose=0.1uM, N-(p-Amylcinnamoyl)anthranilic acid, Phospholipase A2 (PLA2) Inhibitors;TRPC6 Inhibitors;TRPM8 (TRP-p8| CMR1) Antagonists;TRPM2 Antagonists targeting TRPC6, TRPM2, TRPM8, PLA2G10 |
| AF-87-II41_10uM | Dose=10uM, N-(p-Amylcinnamoyl)anthranilic acid, Phospholipase A2 (PLA2) Inhibitors;TRPC6 Inhibitors;TRPM8 (TRP-p8| CMR1) Antagonists;TRPM2 Antagonists targeting TRPC6, TRPM2, TRPM8, PLA2G10 |
| AF-87-II41_1uM | Dose=1uM, N-(p-Amylcinnamoyl)anthranilic acid, Phospholipase A2 (PLA2) Inhibitors;TRPC6 Inhibitors;TRPM8 (TRP-p8| CMR1) Antagonists;TRPM2 Antagonists targeting TRPC6, TRPM2, TRPM8, PLA2G10 |
| AF-89-AD94_0.01uM | Dose=0.01uM, 5-Carboxamidotryptamine targeting HTR1F, HTR7 |
| AF-89-AD94_0.1uM | Dose=0.1uM, 5-Carboxamidotryptamine targeting HTR1F, HTR7 |
| AF-89-AD94_10uM | Dose=10uM, 5-Carboxamidotryptamine targeting HTR1F, HTR7 |
| AF-89-AD94_1uM | Dose=1uM, 5-Carboxamidotryptamine targeting HTR1F, HTR7 |
| AF-92-EP16_0.01uM | Dose=0.01uM, (2S,4R)-N-[(2S)-1-(1,3-benzoxazol-2-yl)-1-oxobutan-2-yl]-4-[(4-bromo-2-fluorophenyl)methoxy]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]pyrrolidine-2-carboxamide |
| AF-92-EP16_0.1uM | Dose=0.1uM, (2S,4R)-N-[(2S)-1-(1,3-benzoxazol-2-yl)-1-oxobutan-2-yl]-4-[(4-bromo-2-fluorophenyl)methoxy]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]pyrrolidine-2-carboxamide |
| AF-99-HA02_0.01uM | Dose=0.01uM, At-7519, CDK1/Cyclin B Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2/Cyclin A Inhibitors;Apoptosis Inducers targeting CCNA2, CCNB1, CDK1, CDK2 |
| AF-99-HA02_0.1uM | Dose=0.1uM, At-7519, CDK1/Cyclin B Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2/Cyclin A Inhibitors;Apoptosis Inducers targeting CCNA2, CCNB1, CDK1, CDK2 |
| AF-99-HA02_10uM | Dose=10uM, At-7519, CDK1/Cyclin B Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2/Cyclin A Inhibitors;Apoptosis Inducers targeting CCNA2, CCNB1, CDK1, CDK2 |
| AF-99-HA02_1uM | Dose=1uM, At-7519, CDK1/Cyclin B Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2/Cyclin A Inhibitors;Apoptosis Inducers targeting CCNA2, CCNB1, CDK1, CDK2 |
| AW-10-0667_0.01uM | Dose=0.01uM, Clofibrate |
| AW-10-0667_0.1uM | Dose=0.1uM, Clofibrate |
| AW-10-0667_10uM | Dose=10uM, Clofibrate |
| AW-10-0667_1uM | Dose=1uM, Clofibrate |
| AW-13-3788_0.01uM | Dose=0.01uM, N,N-dimethyl-4,4-diphenylbut-3-en-1-amine, Nav1.2 (Brain Type II) Sodium Channel Blockers targeting SCN2A |
| AW-13-3788_0.1uM | Dose=0.1uM, N,N-dimethyl-4,4-diphenylbut-3-en-1-amine, Nav1.2 (Brain Type II) Sodium Channel Blockers targeting SCN2A |
| AW-13-3788_1uM | Dose=1uM, N,N-dimethyl-4,4-diphenylbut-3-en-1-amine, Nav1.2 (Brain Type II) Sodium Channel Blockers targeting SCN2A |
| AW-14-3219_0.01uM | Dose=0.01uM, 8-Chloro-5-methyl-11-(piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine, Dopamine D2 Agonists;Muscarinic M1 Agonists targeting CHRM1, DRD2 |
| AW-14-3219_0.1uM | Dose=0.1uM, 8-Chloro-5-methyl-11-(piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine, Dopamine D2 Agonists;Muscarinic M1 Agonists targeting CHRM1, DRD2 |
| AW-14-3219_10uM | Dose=10uM, 8-Chloro-5-methyl-11-(piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine, Dopamine D2 Agonists;Muscarinic M1 Agonists targeting CHRM1, DRD2 |
| AW-14-3219_1uM | Dose=1uM, 8-Chloro-5-methyl-11-(piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine, Dopamine D2 Agonists;Muscarinic M1 Agonists targeting CHRM1, DRD2 |
| AW-15-2439_0.01uM | Dose=0.01uM, 4-(Naphthalen-1-yl)-2-aminothiazole, 5-HT2B Antagonists targeting HTR2B |
| AW-15-2439_0.1uM | Dose=0.1uM, 4-(Naphthalen-1-yl)-2-aminothiazole, 5-HT2B Antagonists targeting HTR2B |
| AW-15-2439_10uM | Dose=10uM, 4-(Naphthalen-1-yl)-2-aminothiazole, 5-HT2B Antagonists targeting HTR2B |
| AW-15-2439_1uM | Dose=1uM, 4-(Naphthalen-1-yl)-2-aminothiazole, 5-HT2B Antagonists targeting HTR2B |
| AW-16-2259_0.01uM | Dose=0.01uM, 6-chloro-3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one, NOX2 inhibitors targeting CYBB |
| AW-16-2259_0.1uM | Dose=0.1uM, 6-chloro-3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one, NOX2 inhibitors targeting CYBB |
| AW-16-2259_10uM | Dose=10uM, 6-chloro-3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one, NOX2 inhibitors targeting CYBB |
| AW-16-2259_1uM | Dose=1uM, 6-chloro-3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one, NOX2 inhibitors targeting CYBB |
| BA-02-FS63_0.01uM | Dose=0.01uM, (6aR,9R)-N9,N9-diethyl-N7-methyl-N7-phenyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-7,9(4H)-dicarboxamide |
| BA-02-FS63_0.1uM | Dose=0.1uM, (6aR,9R)-N9,N9-diethyl-N7-methyl-N7-phenyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-7,9(4H)-dicarboxamide |
| BA-02-FS63_10uM | Dose=10uM, (6aR,9R)-N9,N9-diethyl-N7-methyl-N7-phenyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-7,9(4H)-dicarboxamide |
| BA-02-FS63_1uM | Dose=1uM, (6aR,9R)-N9,N9-diethyl-N7-methyl-N7-phenyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-7,9(4H)-dicarboxamide |
| BA-02-RG00_0.01uM | Dose=0.01uM |
| BA-02-RG00_0.1uM | Dose=0.1uM |
| BA-02-RG00_10uM | Dose=10uM |
| BA-02-RG00_1uM | Dose=1uM |
| BA-02-RI19_0.01uM | Dose=0.01uM, Sitagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| BA-02-RI19_0.1uM | Dose=0.1uM, Sitagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| BA-02-RI19_10uM | Dose=10uM, Sitagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| BA-02-RI19_1uM | Dose=1uM, Sitagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| BA-04-IG64_0.01uM | Dose=0.01uM, 2-{[1-(2-Mercapto-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-3-(4-pyrimidin-5-yl-phenyl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| BA-04-IG64_0.1uM | Dose=0.1uM, 2-{[1-(2-Mercapto-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-3-(4-pyrimidin-5-yl-phenyl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| BA-04-IG64_10uM | Dose=10uM, 2-{[1-(2-Mercapto-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-3-(4-pyrimidin-5-yl-phenyl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| BA-04-IG64_1uM | Dose=1uM, 2-{[1-(2-Mercapto-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-3-(4-pyrimidin-5-yl-phenyl)-propionic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| BA-06-GI09_0.1uM | Dose=0.1uM, 1-(3-Pyridin-3-ylisoxazol-5-YL)methanamine, Cytochrome P450 CYP2A6 Inhibitors targeting CYP2A6 |
| BA-06-GI09_10uM | Dose=10uM, 1-(3-Pyridin-3-ylisoxazol-5-YL)methanamine, Cytochrome P450 CYP2A6 Inhibitors targeting CYP2A6 |
| BA-06-RE84_0.01uM | Dose=0.01uM, 2-Oxo-1-phenacyl-4-[4-(thiophene-2-carbonyl)piperazin-1-yl]quinoline-3-carbonitrile, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF |
| BA-06-RE84_0.1uM | Dose=0.1uM, 2-Oxo-1-phenacyl-4-[4-(thiophene-2-carbonyl)piperazin-1-yl]quinoline-3-carbonitrile, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF |
| BA-06-RE84_10uM | Dose=10uM, 2-Oxo-1-phenacyl-4-[4-(thiophene-2-carbonyl)piperazin-1-yl]quinoline-3-carbonitrile, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF |
| BA-06-RE84_1uM | Dose=1uM, 2-Oxo-1-phenacyl-4-[4-(thiophene-2-carbonyl)piperazin-1-yl]quinoline-3-carbonitrile, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF |
| BA-07-GC72_0.01uM | Dose=0.01uM, Flutamide, Androgen Receptor Antagonists targeting AR, CYP1B1 |
| BA-07-GC72_10uM | Dose=10uM, Flutamide, Androgen Receptor Antagonists targeting AR, CYP1B1 |
| BA-07-GC72_1uM | Dose=1uM, Flutamide, Androgen Receptor Antagonists targeting AR, CYP1B1 |
| BA-09-PG96_0.01uM | Dose=0.01uM, GABA(A) BZ Site Receptor Antagonists;Non-Steroidal Antiinflammatory Drugs targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2, GABRG1, GABRG3 |
| BA-09-PG96_0.1uM | Dose=0.1uM, GABA(A) BZ Site Receptor Antagonists;Non-Steroidal Antiinflammatory Drugs targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2, GABRG1, GABRG3 |
| BA-09-PG96_10uM | Dose=10uM, GABA(A) BZ Site Receptor Antagonists;Non-Steroidal Antiinflammatory Drugs targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2, GABRG1, GABRG3 |
| BA-09-PG96_1uM | Dose=1uM, GABA(A) BZ Site Receptor Antagonists;Non-Steroidal Antiinflammatory Drugs targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2, GABRG1, GABRG3 |
| BA-09-ZX42_0.01uM | Dose=0.01uM, 4-(Phenylamino)benzoic acid |
| BA-09-ZX42_0.1uM | Dose=0.1uM, 4-(Phenylamino)benzoic acid |
| BA-09-ZX42_10uM | Dose=10uM, 4-(Phenylamino)benzoic acid |
| BA-09-ZX42_1uM | Dose=1uM, 4-(Phenylamino)benzoic acid |
| BA-10-WH12_0.01uM | Dose=0.01uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| BA-10-WH12_0.1uM | Dose=0.1uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| BA-10-WH12_10uM | Dose=10uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| BA-10-WH12_1uM | Dose=1uM, N-[5-(1-methylcyclopropyl)-1H-pyrazol-3-yl]-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| BA-10-WH72_0.01uM | Dose=0.01uM, 4-tert-Butyl-N-[4-chloro-2-(hydroxy-pyridin-4-yl-methyl)-phenyl]-benzenesulfonamide, Chemokine CCR9 Receptor Ligands targeting CCR9 |
| BA-10-WH72_0.1uM | Dose=0.1uM, 4-tert-Butyl-N-[4-chloro-2-(hydroxy-pyridin-4-yl-methyl)-phenyl]-benzenesulfonamide, Chemokine CCR9 Receptor Ligands targeting CCR9 |
| BA-10-WH72_10uM | Dose=10uM, 4-tert-Butyl-N-[4-chloro-2-(hydroxy-pyridin-4-yl-methyl)-phenyl]-benzenesulfonamide, Chemokine CCR9 Receptor Ligands targeting CCR9 |
| BA-10-WH72_1uM | Dose=1uM, 4-tert-Butyl-N-[4-chloro-2-(hydroxy-pyridin-4-yl-methyl)-phenyl]-benzenesulfonamide, Chemokine CCR9 Receptor Ligands targeting CCR9 |
| BA-13-CC32_0.01uM | Dose=0.01uM, [(3R)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| BA-13-CC32_0.1uM | Dose=0.1uM, [(3R)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| BA-13-CC32_10uM | Dose=10uM, [(3R)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| BA-13-CC32_1uM | Dose=1uM, [(3R)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| BA-15-LA22_0.01uM | Dose=0.01uM |
| BA-15-LA22_0.1uM | Dose=0.1uM |
| BA-15-LA22_10uM | Dose=10uM |
| BA-15-LA22_1uM | Dose=1uM |
| BA-15-VE07_0.01uM | Dose=0.01uM, SB 216763, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A |
| BA-15-VE07_0.1uM | Dose=0.1uM, SB 216763, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A |
| BA-15-VE07_10uM | Dose=10uM, SB 216763, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A |
| BA-15-VE07_1uM | Dose=1uM, SB 216763, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A |
| BA-16-AB67_0.01uM | Dose=0.01uM, Repaglinide, Insulin Secretagogues targeting ABCC8 |
| BA-16-AB67_0.1uM | Dose=0.1uM, Repaglinide, Insulin Secretagogues targeting ABCC8 |
| BA-16-AB67_10uM | Dose=10uM, Repaglinide, Insulin Secretagogues targeting ABCC8 |
| BA-16-AB67_1uM | Dose=1uM, Repaglinide, Insulin Secretagogues targeting ABCC8 |
| BA-16-GI09_0.01uM | Dose=0.01uM, Tram-34, Gardos channel, SK41, IK1) Channel Blockers;Intermediate Conductance K(Ca) 3.1 (IKCa1 targeting KCNN4 |
| BA-16-GI09_0.1uM | Dose=0.1uM, Tram-34, Gardos channel, SK41, IK1) Channel Blockers;Intermediate Conductance K(Ca) 3.1 (IKCa1 targeting KCNN4 |
| BA-16-GI09_10uM | Dose=10uM, Tram-34, Gardos channel, SK41, IK1) Channel Blockers;Intermediate Conductance K(Ca) 3.1 (IKCa1 targeting KCNN4 |
| BA-18-SW37_0.01uM | Dose=0.01uM, Ciluprevir |
| BA-18-SW37_0.1uM | Dose=0.1uM, Ciluprevir |
| BA-18-SW37_10uM | Dose=10uM, Ciluprevir |
| BA-19-VU85_0.01uM | Dose=0.01uM, Irbesartan, Angiotensin AT1 Antagonists targeting AGTR1 |
| BA-19-VU85_0.1uM | Dose=0.1uM, Irbesartan, Angiotensin AT1 Antagonists targeting AGTR1 |
| BA-19-VU85_10uM | Dose=10uM, Irbesartan, Angiotensin AT1 Antagonists targeting AGTR1 |
| BA-19-VU85_1uM | Dose=1uM, Irbesartan, Angiotensin AT1 Antagonists targeting AGTR1 |
| BA-23-MC77_0.01uM | Dose=0.01uM, Oxcarbazepine, Sodium Channel Blockers targeting AQP4, SCN5A |
| BA-23-MC77_10uM | Dose=10uM, Oxcarbazepine, Sodium Channel Blockers targeting AQP4, SCN5A |
| BA-23-XC02_0.01uM | Dose=0.01uM, Indoramin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F |
| BA-23-XC02_0.1uM | Dose=0.1uM, Indoramin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F |
| BA-23-XC02_10uM | Dose=10uM, Indoramin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F |
| BA-24-BX40_0.1uM | Dose=0.1uM, 2-(2-Imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3-yl)-1-(4-methylphenyl)ethanone targeting ATAD5 |
| BA-24-BX40_10uM | Dose=10uM, 2-(2-Imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3-yl)-1-(4-methylphenyl)ethanone targeting ATAD5 |
| BA-24-BX40_1uM | Dose=1uM, 2-(2-Imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3-yl)-1-(4-methylphenyl)ethanone targeting ATAD5 |
| BA-26-GI09_0.01uM | Dose=0.01uM, Asarone, HMG-CoA Reductase Inhibitors;Acetylcholinesterase Inhibitors targeting ACHE, HMGCR |
| BA-26-GI09_0.1uM | Dose=0.1uM, Asarone, HMG-CoA Reductase Inhibitors;Acetylcholinesterase Inhibitors targeting ACHE, HMGCR |
| BA-26-GI09_10uM | Dose=10uM, Asarone, HMG-CoA Reductase Inhibitors;Acetylcholinesterase Inhibitors targeting ACHE, HMGCR |
| BA-26-GI09_1uM | Dose=1uM, Asarone, HMG-CoA Reductase Inhibitors;Acetylcholinesterase Inhibitors targeting ACHE, HMGCR |
| BA-28-JD87_0.01uM | Dose=0.01uM, Imatinib, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1, DDR1, KIT, PDGFRA, PDGFRB, PPARG |
| BA-28-JD87_0.1uM | Dose=0.1uM, Imatinib, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1, DDR1, KIT, PDGFRA, PDGFRB, PPARG |
| BA-28-JD87_10uM | Dose=10uM, Imatinib, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1, DDR1, KIT, PDGFRA, PDGFRB, PPARG |
| BA-28-JD87_1uM | Dose=1uM, Imatinib, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1, DDR1, KIT, PDGFRA, PDGFRB, PPARG |
| BA-28-XM73_0.1uM | Dose=0.1uM, N-(4-methyl-3-(1-(6-(4-methylpiperazin-1-ylamino)pyrimidin-4-yl)-1H-imidazol-2-ylamino)phenyl)-3-(trifluoromethyl)benzamide |
| BA-28-XM73_10uM | Dose=10uM, N-(4-methyl-3-(1-(6-(4-methylpiperazin-1-ylamino)pyrimidin-4-yl)-1H-imidazol-2-ylamino)phenyl)-3-(trifluoromethyl)benzamide |
| BA-28-XM73_1uM | Dose=1uM, N-(4-methyl-3-(1-(6-(4-methylpiperazin-1-ylamino)pyrimidin-4-yl)-1H-imidazol-2-ylamino)phenyl)-3-(trifluoromethyl)benzamide |
| BA-29-GH49_0.01uM | Dose=0.01uM, Orforglipron targeting GLP1R |
| BA-29-GH49_10uM | Dose=10uM, Orforglipron targeting GLP1R |
| BA-29-OX17_0.01uM | Dose=0.01uM, 2-(Ethylamino)-1-[4-[5-methoxy-2-methyl-4-[[4-(2-propan-2-ylsulfonylanilino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino]phenyl]piperidin-1-yl]ethanone, ALK Inhibitors targeting ALK |
| BA-29-OX17_0.1uM | Dose=0.1uM, 2-(Ethylamino)-1-[4-[5-methoxy-2-methyl-4-[[4-(2-propan-2-ylsulfonylanilino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino]phenyl]piperidin-1-yl]ethanone, ALK Inhibitors targeting ALK |
| BA-29-OX17_10uM | Dose=10uM, 2-(Ethylamino)-1-[4-[5-methoxy-2-methyl-4-[[4-(2-propan-2-ylsulfonylanilino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino]phenyl]piperidin-1-yl]ethanone, ALK Inhibitors targeting ALK |
| BA-29-OX17_1uM | Dose=1uM, 2-(Ethylamino)-1-[4-[5-methoxy-2-methyl-4-[[4-(2-propan-2-ylsulfonylanilino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino]phenyl]piperidin-1-yl]ethanone, ALK Inhibitors targeting ALK |
| BA-30-VU53_0.01uM | Dose=0.01uM |
| BA-30-VU53_0.1uM | Dose=0.1uM |
| BA-30-VU53_10uM | Dose=10uM |
| BA-30-VU53_1uM | Dose=1uM |
| BA-31-AB30_0.01uM | Dose=0.01uM, Avosentan, Endothelin ETA Receptor Antagonists targeting EDNRA |
| BA-31-AB30_0.1uM | Dose=0.1uM, Avosentan, Endothelin ETA Receptor Antagonists targeting EDNRA |
| BA-31-AB30_10uM | Dose=10uM, Avosentan, Endothelin ETA Receptor Antagonists targeting EDNRA |
| BA-31-AB30_1uM | Dose=1uM, Avosentan, Endothelin ETA Receptor Antagonists targeting EDNRA |
| BA-31-KY85_0.01uM | Dose=0.01uM, 4-((Piperindin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid, P2RY14 inhibitor targeting P2RY14 |
| BA-31-KY85_0.1uM | Dose=0.1uM, 4-((Piperindin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid, P2RY14 inhibitor targeting P2RY14 |
| BA-31-KY85_10uM | Dose=10uM, 4-((Piperindin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid, P2RY14 inhibitor targeting P2RY14 |
| BA-31-KY85_1uM | Dose=1uM, 4-((Piperindin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid, P2RY14 inhibitor targeting P2RY14 |
| BA-34-BQ43_0.01uM | Dose=0.01uM, Azd-1152hqpa, Aurora-C (ARK3) Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting AURKC, AURKB |
| BA-34-BQ43_0.1uM | Dose=0.1uM, Azd-1152hqpa, Aurora-C (ARK3) Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting AURKC, AURKB |
| BA-34-BQ43_10uM | Dose=10uM, Azd-1152hqpa, Aurora-C (ARK3) Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting AURKC, AURKB |
| BA-34-BQ43_1uM | Dose=1uM, Azd-1152hqpa, Aurora-C (ARK3) Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Aurora-B (ARK2) Kinase Inhibitors;Antimitotic Drugs targeting AURKC, AURKB |
| BA-37-NF64_10uM | Dose=10uM, Fenofibrate, APOA1 Expression Enhancers;PPARalpha Agonists targeting PPARA |
| BA-37-NF64_1uM | Dose=1uM, Fenofibrate, APOA1 Expression Enhancers;PPARalpha Agonists targeting PPARA |
| BA-38-MT25_0.01uM | Dose=0.01uM, (2R)-3-[4-[(E)-3-[4-[(2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl]phenyl]prop-2-enyl]piperazin-1-yl]propane-1,2-diol |
| BA-38-MT25_0.1uM | Dose=0.1uM, (2R)-3-[4-[(E)-3-[4-[(2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl]phenyl]prop-2-enyl]piperazin-1-yl]propane-1,2-diol |
| BA-38-MT25_10uM | Dose=10uM, (2R)-3-[4-[(E)-3-[4-[(2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl]phenyl]prop-2-enyl]piperazin-1-yl]propane-1,2-diol |
| BA-38-XM43_0.01uM | Dose=0.01uM, Paxilline targeting KCNMA1, KCNMB1 |
| BA-38-XM43_10uM | Dose=10uM, Paxilline targeting KCNMA1, KCNMB1 |
| BA-38-XM43_1uM | Dose=1uM, Paxilline targeting KCNMA1, KCNMB1 |
| BA-39-HG26_0.01uM | Dose=0.01uM, Methoxsalen, Cytochrome P450 CYP1A2 Inhibitors;DNA-Damaging Drugs targeting CYP1A2 |
| BA-39-HG26_0.1uM | Dose=0.1uM, Methoxsalen, Cytochrome P450 CYP1A2 Inhibitors;DNA-Damaging Drugs targeting CYP1A2 |
| BA-39-HG26_10uM | Dose=10uM, Methoxsalen, Cytochrome P450 CYP1A2 Inhibitors;DNA-Damaging Drugs targeting CYP1A2 |
| BA-39-HG26_1uM | Dose=1uM, Methoxsalen, Cytochrome P450 CYP1A2 Inhibitors;DNA-Damaging Drugs targeting CYP1A2 |
| BA-39-LQ60_0.01uM | Dose=0.01uM, 3,3'-(Phenylmethylene)bis(4-hydroxy-2H-1-benzopyran-2-one) |
| BA-39-LQ60_0.1uM | Dose=0.1uM, 3,3'-(Phenylmethylene)bis(4-hydroxy-2H-1-benzopyran-2-one) |
| BA-39-LQ60_10uM | Dose=10uM, 3,3'-(Phenylmethylene)bis(4-hydroxy-2H-1-benzopyran-2-one) |
| BA-39-LQ60_1uM | Dose=1uM, 3,3'-(Phenylmethylene)bis(4-hydroxy-2H-1-benzopyran-2-one) |
| BA-39-OX47_0.01uM | Dose=0.01uM, N-[(3S)-3-[benzoyl(methyl)amino]-4-phenylbutyl]isoquinoline-3-carboxamide |
| BA-39-OX47_0.1uM | Dose=0.1uM, N-[(3S)-3-[benzoyl(methyl)amino]-4-phenylbutyl]isoquinoline-3-carboxamide |
| BA-39-OX47_10uM | Dose=10uM, N-[(3S)-3-[benzoyl(methyl)amino]-4-phenylbutyl]isoquinoline-3-carboxamide |
| BA-39-OX47_1uM | Dose=1uM, N-[(3S)-3-[benzoyl(methyl)amino]-4-phenylbutyl]isoquinoline-3-carboxamide |
| BA-40-IU73_0.01uM | Dose=0.01uM, Nvp-baw2881, Inhibitors of Signal Transduction Pathways;Protein Kinase Inhibitors targeting KDR |
| BA-40-IU73_0.1uM | Dose=0.1uM, Nvp-baw2881, Inhibitors of Signal Transduction Pathways;Protein Kinase Inhibitors targeting KDR |
| BA-40-IU73_10uM | Dose=10uM, Nvp-baw2881, Inhibitors of Signal Transduction Pathways;Protein Kinase Inhibitors targeting KDR |
| BA-40-IU73_1uM | Dose=1uM, Nvp-baw2881, Inhibitors of Signal Transduction Pathways;Protein Kinase Inhibitors targeting KDR |
| BA-40-KU28_0.01uM | Dose=0.01uM |
| BA-40-KU28_0.1uM | Dose=0.1uM |
| BA-40-KU28_10uM | Dose=10uM |
| BA-40-KU28_1uM | Dose=1uM |
| BA-41-QF30_0.01uM | Dose=0.01uM, N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2-phenylacetamide |
| BA-41-QF30_0.1uM | Dose=0.1uM, N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2-phenylacetamide |
| BA-41-QF30_10uM | Dose=10uM, N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2-phenylacetamide |
| BA-41-QF30_1uM | Dose=1uM, N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]-2-phenylacetamide |
| BA-41-VY30_0.01uM | Dose=0.01uM, 2-methyl-5-HT targeting HTR1F |
| BA-41-VY30_0.1uM | Dose=0.1uM, 2-methyl-5-HT targeting HTR1F |
| BA-41-VY30_10uM | Dose=10uM, 2-methyl-5-HT targeting HTR1F |
| BA-44-SG89_0.01uM | Dose=0.01uM, {4-[4-(6-Isopropoxypyridin-3-yl)-5-(4-trifluoromethoxyphenyl)-oxazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARA, PPARD |
| BA-44-SG89_0.1uM | Dose=0.1uM, {4-[4-(6-Isopropoxypyridin-3-yl)-5-(4-trifluoromethoxyphenyl)-oxazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARA, PPARD |
| BA-44-SG89_10uM | Dose=10uM, {4-[4-(6-Isopropoxypyridin-3-yl)-5-(4-trifluoromethoxyphenyl)-oxazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARA, PPARD |
| BA-44-SG89_1uM | Dose=1uM, {4-[4-(6-Isopropoxypyridin-3-yl)-5-(4-trifluoromethoxyphenyl)-oxazol-2-ylmethoxy]-2-methylphenoxy}acetic Acid targeting PPARA, PPARD |
| BA-44-WG29_0.01uM | Dose=0.01uM, Oxprenolol, beta-Adrenoceptor Antagonists targeting ADRB1, ADRB2 |
| BA-44-WG29_0.1uM | Dose=0.1uM, Oxprenolol, beta-Adrenoceptor Antagonists targeting ADRB1, ADRB2 |
| BA-44-WG29_10uM | Dose=10uM, Oxprenolol, beta-Adrenoceptor Antagonists targeting ADRB1, ADRB2 |
| BA-46-AB67_0.01uM | Dose=0.01uM, Zantac, Histamine H2 Receptor Antagonists targeting HRH2 |
| BA-46-AB67_0.1uM | Dose=0.1uM, Zantac, Histamine H2 Receptor Antagonists targeting HRH2 |
| BA-46-AB67_10uM | Dose=10uM, Zantac, Histamine H2 Receptor Antagonists targeting HRH2 |
| BA-46-AB67_1uM | Dose=1uM, Zantac, Histamine H2 Receptor Antagonists targeting HRH2 |
| BA-46-QO78_0.01uM | Dose=0.01uM, 4-(2-Acetyl-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-3-fluorobenzoic acid, Retinoid RXR Antagonists targeting RXRA |
| BA-46-QO78_0.1uM | Dose=0.1uM, 4-(2-Acetyl-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-3-fluorobenzoic acid, Retinoid RXR Antagonists targeting RXRA |
| BA-46-QO78_10uM | Dose=10uM, 4-(2-Acetyl-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-3-fluorobenzoic acid, Retinoid RXR Antagonists targeting RXRA |
| BA-46-QO78_1uM | Dose=1uM, 4-(2-Acetyl-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-3-fluorobenzoic acid, Retinoid RXR Antagonists targeting RXRA |
| BA-46-RB17_0.01uM | Dose=0.01uM, GPR4 antagonist 1, GPR4 antagonist;G Protein-Coupled Receptor GPR4 Antagonists targeting GPR4, HRH3 |
| BA-46-RB17_0.1uM | Dose=0.1uM, GPR4 antagonist 1, GPR4 antagonist;G Protein-Coupled Receptor GPR4 Antagonists targeting GPR4, HRH3 |
| BA-46-RB17_10uM | Dose=10uM, GPR4 antagonist 1, GPR4 antagonist;G Protein-Coupled Receptor GPR4 Antagonists targeting GPR4, HRH3 |
| BA-46-RB17_1uM | Dose=1uM, GPR4 antagonist 1, GPR4 antagonist;G Protein-Coupled Receptor GPR4 Antagonists targeting GPR4, HRH3 |
| BA-46-YF32_0.01uM | Dose=0.01uM, 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine, Drugs Acting on Ryanodine Receptor (RyR) Channels;Ryanodine receptor modulator;RyR1/FKBP12 Complex Stabilzer targeting RYR1, RYR2 |
| BA-46-YF32_0.1uM | Dose=0.1uM, 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine, Drugs Acting on Ryanodine Receptor (RyR) Channels;Ryanodine receptor modulator;RyR1/FKBP12 Complex Stabilzer targeting RYR1, RYR2 |
| BA-46-YF32_10uM | Dose=10uM, 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine, Drugs Acting on Ryanodine Receptor (RyR) Channels;Ryanodine receptor modulator;RyR1/FKBP12 Complex Stabilzer targeting RYR1, RYR2 |
| BA-46-YF32_1uM | Dose=1uM, 2,3,4,5-Tetrahydro-7-methoxy-4-methyl-1,4-benzothiazepine, Drugs Acting on Ryanodine Receptor (RyR) Channels;Ryanodine receptor modulator;RyR1/FKBP12 Complex Stabilzer targeting RYR1, RYR2 |
| BA-50-HH67_0.01uM | Dose=0.01uM, Tomatidine |
| BA-50-HH67_0.1uM | Dose=0.1uM, Tomatidine |
| BA-50-HH67_10uM | Dose=10uM, Tomatidine |
| BA-51-DL54_0.01uM | Dose=0.01uM, 6-Methyl-5-(2-(trifluoromethyl)phenyl)-1H-indazole, TRPA1 antagonist targeting TRPA1 |
| BA-51-DL54_0.1uM | Dose=0.1uM, 6-Methyl-5-(2-(trifluoromethyl)phenyl)-1H-indazole, TRPA1 antagonist targeting TRPA1 |
| BA-51-DL54_10uM | Dose=10uM, 6-Methyl-5-(2-(trifluoromethyl)phenyl)-1H-indazole, TRPA1 antagonist targeting TRPA1 |
| BA-52-FW03_0.01uM | Dose=0.01uM, Adenosine, Adenosine Receptor Agonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3 |
| BA-52-FW03_0.1uM | Dose=0.1uM, Adenosine, Adenosine Receptor Agonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3 |
| BA-52-FW03_10uM | Dose=10uM, Adenosine, Adenosine Receptor Agonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3 |
| BA-52-FW03_1uM | Dose=1uM, Adenosine, Adenosine Receptor Agonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3 |
| BA-53-FM66_0.01uM | Dose=0.01uM, N-({(3s,4s)-4-[(Benzylsulfonyl)amino]pyrrolidin-3-Yl}methyl)-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, REN inhibitor targeting REN |
| BA-53-FM66_0.1uM | Dose=0.1uM, N-({(3s,4s)-4-[(Benzylsulfonyl)amino]pyrrolidin-3-Yl}methyl)-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, REN inhibitor targeting REN |
| BA-53-FM66_10uM | Dose=10uM, N-({(3s,4s)-4-[(Benzylsulfonyl)amino]pyrrolidin-3-Yl}methyl)-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, REN inhibitor targeting REN |
| BA-53-FM66_1uM | Dose=1uM, N-({(3s,4s)-4-[(Benzylsulfonyl)amino]pyrrolidin-3-Yl}methyl)-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, REN inhibitor targeting REN |
| BA-55-OU30_0.01uM | Dose=0.01uM, 6-[(1E,3E,5E,7E)-8-[(2R,3S,4S,5S)-3,4-Dihydroxy-2,4,5-trimethyloxolan-2-yl]-7-methylocta-1,3,5,7-tetraenyl]-4-methoxy-5-methylpyran-2-one, Inhibitor of mitochondrial ATPase targeting ATP5F1B |
| BA-55-OU30_0.1uM | Dose=0.1uM, 6-[(1E,3E,5E,7E)-8-[(2R,3S,4S,5S)-3,4-Dihydroxy-2,4,5-trimethyloxolan-2-yl]-7-methylocta-1,3,5,7-tetraenyl]-4-methoxy-5-methylpyran-2-one, Inhibitor of mitochondrial ATPase targeting ATP5F1B |
| BA-55-OU30_10uM | Dose=10uM, 6-[(1E,3E,5E,7E)-8-[(2R,3S,4S,5S)-3,4-Dihydroxy-2,4,5-trimethyloxolan-2-yl]-7-methylocta-1,3,5,7-tetraenyl]-4-methoxy-5-methylpyran-2-one, Inhibitor of mitochondrial ATPase targeting ATP5F1B |
| BA-55-OU30_1uM | Dose=1uM, 6-[(1E,3E,5E,7E)-8-[(2R,3S,4S,5S)-3,4-Dihydroxy-2,4,5-trimethyloxolan-2-yl]-7-methylocta-1,3,5,7-tetraenyl]-4-methoxy-5-methylpyran-2-one, Inhibitor of mitochondrial ATPase targeting ATP5F1B |
| BA-56-QV45_0.01uM | Dose=0.01uM, Dorsomorphin, AMPK Inhibitor targeting PRKAA1 |
| BA-56-QV45_0.1uM | Dose=0.1uM, Dorsomorphin, AMPK Inhibitor targeting PRKAA1 |
| BA-56-QV45_10uM | Dose=10uM, Dorsomorphin, AMPK Inhibitor targeting PRKAA1 |
| BA-56-QV45_1uM | Dose=1uM, Dorsomorphin, AMPK Inhibitor targeting PRKAA1 |
| BA-59-EN38_0.01uM | Dose=0.01uM |
| BA-59-EN38_0.1uM | Dose=0.1uM |
| BA-59-EN38_10uM | Dose=10uM |
| BA-59-EN38_1uM | Dose=1uM |
| BA-59-QN98_0.01uM | Dose=0.01uM, AX-024 targeting NCK1, NCK2 |
| BA-59-QN98_0.1uM | Dose=0.1uM, AX-024 targeting NCK1, NCK2 |
| BA-59-QN98_10uM | Dose=10uM, AX-024 targeting NCK1, NCK2 |
| BA-59-QN98_1uM | Dose=1uM, AX-024 targeting NCK1, NCK2 |
| BA-60-DK24_0.01uM | Dose=0.01uM, 4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexane-1-carboxylic Acid, Phosphodiesterase IV Inhibitors targeting PDE4D |
| BA-60-DK24_0.1uM | Dose=0.1uM, 4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexane-1-carboxylic Acid, Phosphodiesterase IV Inhibitors targeting PDE4D |
| BA-60-DK24_10uM | Dose=10uM, 4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexane-1-carboxylic Acid, Phosphodiesterase IV Inhibitors targeting PDE4D |
| BA-60-DK24_1uM | Dose=1uM, 4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexane-1-carboxylic Acid, Phosphodiesterase IV Inhibitors targeting PDE4D |
| BA-60-DR11_0.01uM | Dose=0.01uM, Scd1-IN-1, SCD inhibitor targeting SCD |
| BA-60-DR11_0.1uM | Dose=0.1uM, Scd1-IN-1, SCD inhibitor targeting SCD |
| BA-60-DR11_10uM | Dose=10uM, Scd1-IN-1, SCD inhibitor targeting SCD |
| BA-60-DR11_1uM | Dose=1uM, Scd1-IN-1, SCD inhibitor targeting SCD |
| BA-60-RH02_0.01uM | Dose=0.01uM, 3-(4-(8-Amino-3-tert-butylimidazo(1,5-a)pyrazin-1-yl)naphthalen-1-yl)-1-(3-(trifluoromethyl)phenyl)urea, IRE1 RNase Allosteric Inhibitor targeting ERN1 |
| BA-60-RH02_0.1uM | Dose=0.1uM, 3-(4-(8-Amino-3-tert-butylimidazo(1,5-a)pyrazin-1-yl)naphthalen-1-yl)-1-(3-(trifluoromethyl)phenyl)urea, IRE1 RNase Allosteric Inhibitor targeting ERN1 |
| BA-60-RH02_10uM | Dose=10uM, 3-(4-(8-Amino-3-tert-butylimidazo(1,5-a)pyrazin-1-yl)naphthalen-1-yl)-1-(3-(trifluoromethyl)phenyl)urea, IRE1 RNase Allosteric Inhibitor targeting ERN1 |
| BA-60-RH02_1uM | Dose=1uM, 3-(4-(8-Amino-3-tert-butylimidazo(1,5-a)pyrazin-1-yl)naphthalen-1-yl)-1-(3-(trifluoromethyl)phenyl)urea, IRE1 RNase Allosteric Inhibitor targeting ERN1 |
| BA-64-PX65_0.01uM | Dose=0.01uM, Carnosine |
| BA-64-PX65_0.1uM | Dose=0.1uM, Carnosine |
| BA-64-PX65_10uM | Dose=10uM, Carnosine |
| BA-64-PX65_1uM | Dose=1uM, Carnosine |
| BA-65-YU05_0.01uM | Dose=0.01uM, 7-(tert-Butyl)-3-(2,5-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine, GABA(A) BZ Site Receptor Antagonists;GABA(A) BZ Site Receptor Agonists targeting GABRA2, GABRA3 |
| BA-65-YU05_1uM | Dose=1uM, 7-(tert-Butyl)-3-(2,5-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine, GABA(A) BZ Site Receptor Antagonists;GABA(A) BZ Site Receptor Agonists targeting GABRA2, GABRA3 |
| BA-65-YU25_0.1uM | Dose=0.1uM, 5-Methyl-2-(2',4'-dichloro-3'-methylanilino)phenylacetic acid, Cyclooxygenase-2 Inhibitors targeting PTGS2 |
| BA-65-YU25_10uM | Dose=10uM, 5-Methyl-2-(2',4'-dichloro-3'-methylanilino)phenylacetic acid, Cyclooxygenase-2 Inhibitors targeting PTGS2 |
| BA-65-YU25_1uM | Dose=1uM, 5-Methyl-2-(2',4'-dichloro-3'-methylanilino)phenylacetic acid, Cyclooxygenase-2 Inhibitors targeting PTGS2 |
| BA-66-BL56_0.01uM | Dose=0.01uM, 1-(3-Hydroxy-5-(thiophen-2-yl)phenyl)-3-(naphthalen-2-yl)urea, frizzled-4 anatagonist targeting FZD4 |
| BA-66-BL56_10uM | Dose=10uM, 1-(3-Hydroxy-5-(thiophen-2-yl)phenyl)-3-(naphthalen-2-yl)urea, frizzled-4 anatagonist targeting FZD4 |
| BA-66-BL56_1uM | Dose=1uM, 1-(3-Hydroxy-5-(thiophen-2-yl)phenyl)-3-(naphthalen-2-yl)urea, frizzled-4 anatagonist targeting FZD4 |
| BA-68-FJ41_0.01uM | Dose=0.01uM, 8-(1H-indol-4-yl)-2,6-bis((3R)-3-methylmorpholin-4-yl)-7H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| BA-68-FJ41_0.1uM | Dose=0.1uM, 8-(1H-indol-4-yl)-2,6-bis((3R)-3-methylmorpholin-4-yl)-7H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| BA-68-FJ41_10uM | Dose=10uM, 8-(1H-indol-4-yl)-2,6-bis((3R)-3-methylmorpholin-4-yl)-7H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| BA-68-FJ41_1uM | Dose=1uM, 8-(1H-indol-4-yl)-2,6-bis((3R)-3-methylmorpholin-4-yl)-7H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| BA-69-DU95_0.01uM | Dose=0.01uM, Doconexent, PPARalpha Agonists targeting PPARA |
| BA-69-DU95_0.1uM | Dose=0.1uM, Doconexent, PPARalpha Agonists targeting PPARA |
| BA-69-DU95_10uM | Dose=10uM, Doconexent, PPARalpha Agonists targeting PPARA |
| BA-69-DU95_1uM | Dose=1uM, Doconexent, PPARalpha Agonists targeting PPARA |
| BA-69-TQ80_0.01uM | Dose=0.01uM, Aeg-3482, Apoptosis Inhibitors;Heat Shock Protein 70 (hsp70) Inducers;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors targeting HSPA1A |
| BA-69-TQ80_0.1uM | Dose=0.1uM, Aeg-3482, Apoptosis Inhibitors;Heat Shock Protein 70 (hsp70) Inducers;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors targeting HSPA1A |
| BA-69-TQ80_10uM | Dose=10uM, Aeg-3482, Apoptosis Inhibitors;Heat Shock Protein 70 (hsp70) Inducers;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors targeting HSPA1A |
| BA-69-TQ80_1uM | Dose=1uM, Aeg-3482, Apoptosis Inhibitors;Heat Shock Protein 70 (hsp70) Inducers;Stress-Activated Protein (SAP/Jun) Kinase Inhibitors targeting HSPA1A |
| BA-70-LV41_0.1uM | Dose=0.1uM, Rosmarinic acid, Angiogenesis Inhibitors;4-aminobutyrate transaminase inhibitor;Antioxidants targeting ABAT |
| BA-70-LV41_1uM | Dose=1uM, Rosmarinic acid, Angiogenesis Inhibitors;4-aminobutyrate transaminase inhibitor;Antioxidants targeting ABAT |
| BA-71-BE32_0.01uM | Dose=0.01uM, Sad-448, Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists targeting CNR1 |
| BA-71-BE32_0.1uM | Dose=0.1uM, Sad-448, Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists targeting CNR1 |
| BA-71-BE32_10uM | Dose=10uM, Sad-448, Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists targeting CNR1 |
| BA-71-BE32_1uM | Dose=1uM, Sad-448, Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists targeting CNR1 |
| BA-72-YP01_0.01uM | Dose=0.01uM, Methyl 2-[(4-fluorobenzoyl)amino]benzoate, Golgi ARF 1 (ADP-Ribosylation Factor) GTPase activator targeting ARF1 |
| BA-72-YP01_0.1uM | Dose=0.1uM, Methyl 2-[(4-fluorobenzoyl)amino]benzoate, Golgi ARF 1 (ADP-Ribosylation Factor) GTPase activator targeting ARF1 |
| BA-72-YP01_10uM | Dose=10uM, Methyl 2-[(4-fluorobenzoyl)amino]benzoate, Golgi ARF 1 (ADP-Ribosylation Factor) GTPase activator targeting ARF1 |
| BA-72-YP01_1uM | Dose=1uM, Methyl 2-[(4-fluorobenzoyl)amino]benzoate, Golgi ARF 1 (ADP-Ribosylation Factor) GTPase activator targeting ARF1 |
| BA-73-MC77_0.01uM | Dose=0.01uM, Nolpitantium, Tachykinin NK1 Antagonists targeting TACR1 |
| BA-73-MC77_0.1uM | Dose=0.1uM, Nolpitantium, Tachykinin NK1 Antagonists targeting TACR1 |
| BA-73-MC77_10uM | Dose=10uM, Nolpitantium, Tachykinin NK1 Antagonists targeting TACR1 |
| BA-73-MC77_1uM | Dose=1uM, Nolpitantium, Tachykinin NK1 Antagonists targeting TACR1 |
| BA-74-BQ33_0.01uM | Dose=0.01uM, Cevoglitazar, PPARgamma Agonists;PPARalpha Agonists targeting PPARA, PPARG |
| BA-74-BQ33_0.1uM | Dose=0.1uM, Cevoglitazar, PPARgamma Agonists;PPARalpha Agonists targeting PPARA, PPARG |
| BA-74-BQ33_10uM | Dose=10uM, Cevoglitazar, PPARgamma Agonists;PPARalpha Agonists targeting PPARA, PPARG |
| BA-74-EG74_0.01uM | Dose=0.01uM, Cardarine, Insulin Sensitizers;PPARdelta Agonists targeting PPARD |
| BA-74-EG74_0.1uM | Dose=0.1uM, Cardarine, Insulin Sensitizers;PPARdelta Agonists targeting PPARD |
| BA-74-EG74_10uM | Dose=10uM, Cardarine, Insulin Sensitizers;PPARdelta Agonists targeting PPARD |
| BA-74-EG74_1uM | Dose=1uM, Cardarine, Insulin Sensitizers;PPARdelta Agonists targeting PPARD |
| BA-74-WG29_0.01uM | Dose=0.01uM, Dantrolene, Ryanodine 2 receptor antagonist;Ryanodine 1 receptor antagonist targeting RGS4, RYR1, RYR2 |
| BA-74-WG29_0.1uM | Dose=0.1uM, Dantrolene, Ryanodine 2 receptor antagonist;Ryanodine 1 receptor antagonist targeting RGS4, RYR1, RYR2 |
| BA-74-WG29_10uM | Dose=10uM, Dantrolene, Ryanodine 2 receptor antagonist;Ryanodine 1 receptor antagonist targeting RGS4, RYR1, RYR2 |
| BA-74-WG29_1uM | Dose=1uM, Dantrolene, Ryanodine 2 receptor antagonist;Ryanodine 1 receptor antagonist targeting RGS4, RYR1, RYR2 |
| BA-75-MA47_0.1uM | Dose=0.1uM, Selurampanel, AMPA Antagonists targeting GRIA1 |
| BA-75-MA47_10uM | Dose=10uM, Selurampanel, AMPA Antagonists targeting GRIA1 |
| BA-75-VA57_0.01uM | Dose=0.01uM, 7-[[5-chloro-2-(2,4-dimethoxyanilino)pyrimidin-4-yl]amino]-2-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3H-isoindol-1-one, FAK inhibitor targeting PTK2 |
| BA-75-VA57_0.1uM | Dose=0.1uM, 7-[[5-chloro-2-(2,4-dimethoxyanilino)pyrimidin-4-yl]amino]-2-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3H-isoindol-1-one, FAK inhibitor targeting PTK2 |
| BA-75-VA57_10uM | Dose=10uM, 7-[[5-chloro-2-(2,4-dimethoxyanilino)pyrimidin-4-yl]amino]-2-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3H-isoindol-1-one, FAK inhibitor targeting PTK2 |
| BA-75-VA57_1uM | Dose=1uM, 7-[[5-chloro-2-(2,4-dimethoxyanilino)pyrimidin-4-yl]amino]-2-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3H-isoindol-1-one, FAK inhibitor targeting PTK2 |
| BA-77-IP18_0.01uM | Dose=0.01uM, (r)-n-((5-(3-Chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide, CYP11B2 gene inhibitor targeting CYP11B2 |
| BA-77-IP18_0.1uM | Dose=0.1uM, (r)-n-((5-(3-Chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide, CYP11B2 gene inhibitor targeting CYP11B2 |
| BA-77-IP18_10uM | Dose=10uM, (r)-n-((5-(3-Chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide, CYP11B2 gene inhibitor targeting CYP11B2 |
| BA-77-IP18_1uM | Dose=1uM, (r)-n-((5-(3-Chloro-4-cyanophenyl)pyridin-3-yl)(cyclopropyl)methyl)ethanesulfonamide, CYP11B2 gene inhibitor targeting CYP11B2 |
| BA-77-NI61_0.01uM | Dose=0.01uM, [6-(2-Chloro-4-methylphenyl)-3-morpholin-4-ylimidazo[1,2-a]pyridin-7-yl]methanamine |
| BA-77-NI61_0.1uM | Dose=0.1uM, [6-(2-Chloro-4-methylphenyl)-3-morpholin-4-ylimidazo[1,2-a]pyridin-7-yl]methanamine |
| BA-77-NI61_10uM | Dose=10uM, [6-(2-Chloro-4-methylphenyl)-3-morpholin-4-ylimidazo[1,2-a]pyridin-7-yl]methanamine |
| BA-77-NI61_1uM | Dose=1uM, [6-(2-Chloro-4-methylphenyl)-3-morpholin-4-ylimidazo[1,2-a]pyridin-7-yl]methanamine |
| BA-77-US35_0.01uM | Dose=0.01uM, 2-(3,5-dimethoxybenzoyl)-N-(1-naphthyl)hydrazinecarboxamide, Drugs Acting on Orphan G-Protein Coupled Receptors (GPR);GPR139 agonist targeting GPR139 |
| BA-77-US35_0.1uM | Dose=0.1uM, 2-(3,5-dimethoxybenzoyl)-N-(1-naphthyl)hydrazinecarboxamide, Drugs Acting on Orphan G-Protein Coupled Receptors (GPR);GPR139 agonist targeting GPR139 |
| BA-77-US35_10uM | Dose=10uM, 2-(3,5-dimethoxybenzoyl)-N-(1-naphthyl)hydrazinecarboxamide, Drugs Acting on Orphan G-Protein Coupled Receptors (GPR);GPR139 agonist targeting GPR139 |
| BA-77-US35_1uM | Dose=1uM, 2-(3,5-dimethoxybenzoyl)-N-(1-naphthyl)hydrazinecarboxamide, Drugs Acting on Orphan G-Protein Coupled Receptors (GPR);GPR139 agonist targeting GPR139 |
| BA-79-ZR48_0.01uM | Dose=0.01uM, Caffeic Acid, 5-Lipoxygenase Inhibitors;HIV Integrase Inhibitors;Antioxidants targeting ALOX5 |
| BA-79-ZR48_0.1uM | Dose=0.1uM, Caffeic Acid, 5-Lipoxygenase Inhibitors;HIV Integrase Inhibitors;Antioxidants targeting ALOX5 |
| BA-79-ZR48_10uM | Dose=10uM, Caffeic Acid, 5-Lipoxygenase Inhibitors;HIV Integrase Inhibitors;Antioxidants targeting ALOX5 |
| BA-79-ZR48_1uM | Dose=1uM, Caffeic Acid, 5-Lipoxygenase Inhibitors;HIV Integrase Inhibitors;Antioxidants targeting ALOX5 |
| BA-84-TD72_0.01uM | Dose=0.01uM, Azd-8055, mTOR Complex 2 (mTORC2) Inhibitors;catalytic mTOR inhibitor;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR |
| BA-84-TD72_0.1uM | Dose=0.1uM, Azd-8055, mTOR Complex 2 (mTORC2) Inhibitors;catalytic mTOR inhibitor;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR |
| BA-84-TD72_10uM | Dose=10uM, Azd-8055, mTOR Complex 2 (mTORC2) Inhibitors;catalytic mTOR inhibitor;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR |
| BA-84-TD72_1uM | Dose=1uM, Azd-8055, mTOR Complex 2 (mTORC2) Inhibitors;catalytic mTOR inhibitor;mTOR Complex 1 (mTORC1) Inhibitors targeting MTOR |
| BA-84-WN26_0.01uM | Dose=0.01uM, Triptolide, from Tripterygium wilfordii, >=98% (HPLC), solid, ERCC3 (TFIIH subunit) targeting ERCC3 |
| BA-84-WN26_0.1uM | Dose=0.1uM, Triptolide, from Tripterygium wilfordii, >=98% (HPLC), solid, ERCC3 (TFIIH subunit) targeting ERCC3 |
| BA-84-WN26_10uM | Dose=10uM, Triptolide, from Tripterygium wilfordii, >=98% (HPLC), solid, ERCC3 (TFIIH subunit) targeting ERCC3 |
| BA-84-WN26_1uM | Dose=1uM, Triptolide, from Tripterygium wilfordii, >=98% (HPLC), solid, ERCC3 (TFIIH subunit) targeting ERCC3 |
| BA-85-ZA57_0.01uM | Dose=0.01uM, Pimecrolimus, Rotamase (FKBP12) Inhibitors;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA |
| BA-85-ZA57_0.1uM | Dose=0.1uM, Pimecrolimus, Rotamase (FKBP12) Inhibitors;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA |
| BA-85-ZA57_10uM | Dose=10uM, Pimecrolimus, Rotamase (FKBP12) Inhibitors;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA |
| BA-85-ZA57_1uM | Dose=1uM, Pimecrolimus, Rotamase (FKBP12) Inhibitors;Calcineurin inhibitor targeting FKBP1A, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PPP3CA |
| BA-86-AL61_0.1uM | Dose=0.1uM, Dasatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Src Kinase Inhibitors;Bruton's Tyrosine Kinase (BTK) Inhibitors targeting ABL1, ABL2, BTK, FYN, LCK, MAPK12, SRC, YES1 |
| BA-86-AL61_10uM | Dose=10uM, Dasatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Src Kinase Inhibitors;Bruton's Tyrosine Kinase (BTK) Inhibitors targeting ABL1, ABL2, BTK, FYN, LCK, MAPK12, SRC, YES1 |
| BA-86-AL61_1uM | Dose=1uM, Dasatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors;Src Kinase Inhibitors;Bruton's Tyrosine Kinase (BTK) Inhibitors targeting ABL1, ABL2, BTK, FYN, LCK, MAPK12, SRC, YES1 |
| BA-86-YY52_0.01uM | Dose=0.01uM, (2S,7R)-4-methyl-4,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),12(16),13-triene, 5-HT2C Antagonists;5-HT2B Antagonists targeting HTR2B, HTR2C |
| BA-86-YY52_0.1uM | Dose=0.1uM, (2S,7R)-4-methyl-4,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),12(16),13-triene, 5-HT2C Antagonists;5-HT2B Antagonists targeting HTR2B, HTR2C |
| BA-86-YY52_1uM | Dose=1uM, (2S,7R)-4-methyl-4,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),12(16),13-triene, 5-HT2C Antagonists;5-HT2B Antagonists targeting HTR2B, HTR2C |
| BA-87-NF64_0.01uM | Dose=0.01uM, Naftopidil, alpha1D-Adrenoceptor Antagonists targeting ADRA1D |
| BA-87-NF64_0.1uM | Dose=0.1uM, Naftopidil, alpha1D-Adrenoceptor Antagonists targeting ADRA1D |
| BA-87-NF64_10uM | Dose=10uM, Naftopidil, alpha1D-Adrenoceptor Antagonists targeting ADRA1D |
| BA-87-NF64_1uM | Dose=1uM, Naftopidil, alpha1D-Adrenoceptor Antagonists targeting ADRA1D |
| BA-88-HT15_0.01uM | Dose=0.01uM, Xmu-MP-1, MST1/2 inhibitor targeting STK3, STK4 |
| BA-88-HT15_0.1uM | Dose=0.1uM, Xmu-MP-1, MST1/2 inhibitor targeting STK3, STK4 |
| BA-88-HT15_10uM | Dose=10uM, Xmu-MP-1, MST1/2 inhibitor targeting STK3, STK4 |
| BA-88-HT15_1uM | Dose=1uM, Xmu-MP-1, MST1/2 inhibitor targeting STK3, STK4 |
| BA-89-SR63_0.01uM | Dose=0.01uM, Pexidartinib, CSF1R inhibitor targeting CSF1R |
| BA-89-SR63_0.1uM | Dose=0.1uM, Pexidartinib, CSF1R inhibitor targeting CSF1R |
| BA-89-SR63_10uM | Dose=10uM, Pexidartinib, CSF1R inhibitor targeting CSF1R |
| BA-89-SR63_1uM | Dose=1uM, Pexidartinib, CSF1R inhibitor targeting CSF1R |
| BA-90-AA10_0.01uM | Dose=0.01uM, S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate |
| BA-90-AA10_0.1uM | Dose=0.1uM, S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate |
| BA-90-AA10_10uM | Dose=10uM, S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate |
| BA-90-AA10_1uM | Dose=1uM, S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate |
| BA-92-CZ75_0.01uM | Dose=0.01uM |
| BA-92-CZ75_0.1uM | Dose=0.1uM |
| BA-92-CZ75_10uM | Dose=10uM |
| BA-92-CZ75_1uM | Dose=1uM |
| BA-92-YC70_0.01uM | Dose=0.01uM, Temozolomide |
| BA-92-YC70_0.1uM | Dose=0.1uM, Temozolomide |
| BA-92-YC70_10uM | Dose=10uM, Temozolomide |
| BA-92-YC70_1uM | Dose=1uM, Temozolomide |
| BA-94-PX65_0.01uM | Dose=0.01uM, Olanzapine, Dopamine D2 Antagonists;5-HT2A Inverse Agonist;ADRA1B gene inhibitor targeting ADRA1B, CHRM5, DRD2, HTR2A |
| BA-94-PX65_10uM | Dose=10uM, Olanzapine, Dopamine D2 Antagonists;5-HT2A Inverse Agonist;ADRA1B gene inhibitor targeting ADRA1B, CHRM5, DRD2, HTR2A |
| BA-95-YU85_0.01uM | Dose=0.01uM, Bag-956, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting AKT1, PDPK1, PIK3CA, PIK3CD, ATR |
| BA-95-YU85_0.1uM | Dose=0.1uM, Bag-956, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting AKT1, PDPK1, PIK3CA, PIK3CD, ATR |
| BA-95-YU85_10uM | Dose=10uM, Bag-956, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting AKT1, PDPK1, PIK3CA, PIK3CD, ATR |
| BA-95-YU85_1uM | Dose=1uM, Bag-956, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Phosphoinositide dependent Kinase (PDK) 1 Inhibitors targeting AKT1, PDPK1, PIK3CA, PIK3CD, ATR |
| BA-96-YB32_0.01uM | Dose=0.01uM |
| BA-96-YB32_0.1uM | Dose=0.1uM |
| BA-96-YB32_10uM | Dose=10uM |
| BA-96-YB32_1uM | Dose=1uM |
| BA-97-CI76_0.01uM | Dose=0.01uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclohexyl-2-hydroxy-2-phenylacetate |
| BA-97-CI76_0.1uM | Dose=0.1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclohexyl-2-hydroxy-2-phenylacetate |
| BA-97-CI76_10uM | Dose=10uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclohexyl-2-hydroxy-2-phenylacetate |
| BA-97-CI76_1uM | Dose=1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclohexyl-2-hydroxy-2-phenylacetate |
| BA-98-JJ31_0.01uM | Dose=0.01uM, Quinine |
| BA-98-JJ31_0.1uM | Dose=0.1uM, Quinine |
| BA-98-JJ31_10uM | Dose=10uM, Quinine |
| BA-98-JJ31_1uM | Dose=1uM, Quinine |
| BB-00-UK69_0.01uM | Dose=0.01uM, Metyrapone, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Mineralocorticoid Receptor (MR) Antagonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting CYP11B1, HSD11B1, NR3C2 |
| BB-00-UK69_0.1uM | Dose=0.1uM, Metyrapone, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Mineralocorticoid Receptor (MR) Antagonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting CYP11B1, HSD11B1, NR3C2 |
| BB-00-UK69_10uM | Dose=10uM, Metyrapone, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Mineralocorticoid Receptor (MR) Antagonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting CYP11B1, HSD11B1, NR3C2 |
| BB-00-UK69_1uM | Dose=1uM, Metyrapone, Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Mineralocorticoid Receptor (MR) Antagonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting CYP11B1, HSD11B1, NR3C2 |
| BB-01-IO76_0.01uM | Dose=0.01uM, Aspartic Acid |
| BB-01-IO76_0.1uM | Dose=0.1uM, Aspartic Acid |
| BB-01-IO76_10uM | Dose=10uM, Aspartic Acid |
| BB-01-IO76_1uM | Dose=1uM, Aspartic Acid |
| BB-03-FT18_10uM | Dose=10uM, Tmp269 targeting HDAC9, HDAC4, HDAC5, HDAC7 |
| BB-04-KA05_0.01uM | Dose=0.01uM, N-[4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl]-3,5-dimethyl-1,2-oxazole-4-carboxamide, IL-5 Production Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, IL5 |
| BB-04-KA05_0.1uM | Dose=0.1uM, N-[4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl]-3,5-dimethyl-1,2-oxazole-4-carboxamide, IL-5 Production Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, IL5 |
| BB-04-KA05_10uM | Dose=10uM, N-[4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl]-3,5-dimethyl-1,2-oxazole-4-carboxamide, IL-5 Production Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, IL5 |
| BB-04-KA05_1uM | Dose=1uM, N-[4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl]-3,5-dimethyl-1,2-oxazole-4-carboxamide, IL-5 Production Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, IL5 |
| BB-04-TN61_0.01uM | Dose=0.01uM, Cloperastine |
| BB-04-TN61_0.1uM | Dose=0.1uM, Cloperastine |
| BB-04-TN61_10uM | Dose=10uM, Cloperastine |
| BB-04-TN61_1uM | Dose=1uM, Cloperastine |
| BB-05-NK66_0.01uM | Dose=0.01uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate |
| BB-05-NK66_0.1uM | Dose=0.1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate |
| BB-05-NK66_10uM | Dose=10uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate |
| BB-05-NK66_1uM | Dose=1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate |
| BB-08-WM33_0.01uM | Dose=0.01uM, AM 281, CNR1 antagonist targeting CNR1 |
| BB-08-WM33_0.1uM | Dose=0.1uM, AM 281, CNR1 antagonist targeting CNR1 |
| BB-08-WM33_10uM | Dose=10uM, AM 281, CNR1 antagonist targeting CNR1 |
| BB-08-WM33_1uM | Dose=1uM, AM 281, CNR1 antagonist targeting CNR1 |
| BB-09-GD09_0.1uM | Dose=0.1uM, Sunitinib targeting PTK2B, RET, FGFR3P1 |
| BB-09-GD09_10uM | Dose=10uM, Sunitinib targeting PTK2B, RET, FGFR3P1 |
| BB-09-GD09_1uM | Dose=1uM, Sunitinib targeting PTK2B, RET, FGFR3P1 |
| BB-10-PR06_0.01uM | Dose=0.01uM, (4r)-4-Methyl-6-[1-Methyl-3-(1-Methyl-1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]-1,3,4,5-Tetrahydro-2h-1,5-Benzodiazepin-2-One, dual CBP/EP300 inhibitor targeting CREBBP, EP300 |
| BB-10-PR06_0.1uM | Dose=0.1uM, (4r)-4-Methyl-6-[1-Methyl-3-(1-Methyl-1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]-1,3,4,5-Tetrahydro-2h-1,5-Benzodiazepin-2-One, dual CBP/EP300 inhibitor targeting CREBBP, EP300 |
| BB-10-PR06_10uM | Dose=10uM, (4r)-4-Methyl-6-[1-Methyl-3-(1-Methyl-1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]-1,3,4,5-Tetrahydro-2h-1,5-Benzodiazepin-2-One, dual CBP/EP300 inhibitor targeting CREBBP, EP300 |
| BB-10-PR06_1uM | Dose=1uM, (4r)-4-Methyl-6-[1-Methyl-3-(1-Methyl-1h-Pyrazol-4-Yl)-1h-Indazol-5-Yl]-1,3,4,5-Tetrahydro-2h-1,5-Benzodiazepin-2-One, dual CBP/EP300 inhibitor targeting CREBBP, EP300 |
| BB-11-JI42_0.01uM | Dose=0.01uM, 8-(1H-indol-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]-2-[(3S)-3-methylmorpholin-4-yl]-9H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| BB-11-JI42_0.1uM | Dose=0.1uM, 8-(1H-indol-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]-2-[(3S)-3-methylmorpholin-4-yl]-9H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| BB-11-JI42_10uM | Dose=10uM, 8-(1H-indol-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]-2-[(3S)-3-methylmorpholin-4-yl]-9H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| BB-11-JI42_1uM | Dose=1uM, 8-(1H-indol-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]-2-[(3S)-3-methylmorpholin-4-yl]-9H-purine, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR |
| BB-11-XO81_0.01uM | Dose=0.01uM, 7-Hydroxy-3-(4-Methoxyphenyl)-3,4-Dihydro-2h-1,3-Benzoxazin-2-One, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF |
| BB-11-XO81_0.1uM | Dose=0.1uM, 7-Hydroxy-3-(4-Methoxyphenyl)-3,4-Dihydro-2h-1,3-Benzoxazin-2-One, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF |
| BB-11-XO81_10uM | Dose=10uM, 7-Hydroxy-3-(4-Methoxyphenyl)-3,4-Dihydro-2h-1,3-Benzoxazin-2-One, Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF |
| BB-14-KA05_0.01uM | Dose=0.01uM, Droxidopa, Norepinephrine Precursors targeting ADRA1D, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
| BB-14-KA05_0.1uM | Dose=0.1uM, Droxidopa, Norepinephrine Precursors targeting ADRA1D, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
| BB-14-KA05_10uM | Dose=10uM, Droxidopa, Norepinephrine Precursors targeting ADRA1D, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
| BB-14-KA05_1uM | Dose=1uM, Droxidopa, Norepinephrine Precursors targeting ADRA1D, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
| BB-16-BE49_0.01uM | Dose=0.01uM, Indacaterol, beta2-Adrenoceptor Agonists targeting ADRB2 |
| BB-16-BE49_0.1uM | Dose=0.1uM, Indacaterol, beta2-Adrenoceptor Agonists targeting ADRB2 |
| BB-16-BE49_10uM | Dose=10uM, Indacaterol, beta2-Adrenoceptor Agonists targeting ADRB2 |
| BB-16-BE49_1uM | Dose=1uM, Indacaterol, beta2-Adrenoceptor Agonists targeting ADRB2 |
| BB-17-GC12_0.01uM | Dose=0.01uM, Tributyl-{4-[(R)-2-(N'',N''''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-benzyl}-phosphonium, BDKRB2 antagonist targeting BDKRB2 |
| BB-17-GC12_0.1uM | Dose=0.1uM, Tributyl-{4-[(R)-2-(N'',N''''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-benzyl}-phosphonium, BDKRB2 antagonist targeting BDKRB2 |
| BB-17-GC12_10uM | Dose=10uM, Tributyl-{4-[(R)-2-(N'',N''''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-benzyl}-phosphonium, BDKRB2 antagonist targeting BDKRB2 |
| BB-17-GC12_1uM | Dose=1uM, Tributyl-{4-[(R)-2-(N'',N''''-dicyclohexyl-guanidino)-3-naphthalen-2-yl-propionylamino]-benzyl}-phosphonium, BDKRB2 antagonist targeting BDKRB2 |
| BB-18-OM53_0.01uM | Dose=0.01uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| BB-18-OM53_0.1uM | Dose=0.1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| BB-18-OM53_1uM | Dose=1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-cyclopropyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| BB-19-ZK81_0.01uM | Dose=0.01uM, 2,4-Dihydro-4-(phenylmethyl)-5-(3-pyridinyl)-3H-1,2,4-triazole-3-thione, Dopamine beta-monooxygenase Inhibitors targeting DBH |
| BB-19-ZK81_0.1uM | Dose=0.1uM, 2,4-Dihydro-4-(phenylmethyl)-5-(3-pyridinyl)-3H-1,2,4-triazole-3-thione, Dopamine beta-monooxygenase Inhibitors targeting DBH |
| BB-19-ZK81_10uM | Dose=10uM, 2,4-Dihydro-4-(phenylmethyl)-5-(3-pyridinyl)-3H-1,2,4-triazole-3-thione, Dopamine beta-monooxygenase Inhibitors targeting DBH |
| BB-19-ZK81_1uM | Dose=1uM, 2,4-Dihydro-4-(phenylmethyl)-5-(3-pyridinyl)-3H-1,2,4-triazole-3-thione, Dopamine beta-monooxygenase Inhibitors targeting DBH |
| BB-20-UU03_0.01uM | Dose=0.01uM, Myxothiazol, cytochrome c reductase;Electron Transport Chain Inhibitors targeting UQCRC1 |
| BB-20-UU03_0.1uM | Dose=0.1uM, Myxothiazol, cytochrome c reductase;Electron Transport Chain Inhibitors targeting UQCRC1 |
| BB-20-UU03_10uM | Dose=10uM, Myxothiazol, cytochrome c reductase;Electron Transport Chain Inhibitors targeting UQCRC1 |
| BB-20-UU03_1uM | Dose=1uM, Myxothiazol, cytochrome c reductase;Electron Transport Chain Inhibitors targeting UQCRC1 |
| BB-21-KE77_0.01uM | Dose=0.01uM, Enzastaurin, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCH, PRKCZ, RPS6KB1 |
| BB-21-KE77_0.1uM | Dose=0.1uM, Enzastaurin, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCH, PRKCZ, RPS6KB1 |
| BB-21-KE77_10uM | Dose=10uM, Enzastaurin, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCH, PRKCZ, RPS6KB1 |
| BB-21-KE77_1uM | Dose=1uM, Enzastaurin, Protein Kinase PKC beta Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting PRKCB, PRKCH, PRKCZ, RPS6KB1 |
| BB-21-XL84_0.01uM | Dose=0.01uM, KB-130015, Antithyroid Drugs targeting CHRM2, THRA |
| BB-21-XL84_0.1uM | Dose=0.1uM, KB-130015, Antithyroid Drugs targeting CHRM2, THRA |
| BB-21-XL84_10uM | Dose=10uM, KB-130015, Antithyroid Drugs targeting CHRM2, THRA |
| BB-21-XL84_1uM | Dose=1uM, KB-130015, Antithyroid Drugs targeting CHRM2, THRA |
| BB-23-AJ69_10uM | Dose=10uM |
| BB-23-PM31_0.1uM | Dose=0.1uM, 4-(1-Methylpiperidin-4-yl)oxy-5-propan-2-yl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS |
| BB-23-PM31_10uM | Dose=10uM, 4-(1-Methylpiperidin-4-yl)oxy-5-propan-2-yl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS |
| BB-23-PM31_1uM | Dose=1uM, 4-(1-Methylpiperidin-4-yl)oxy-5-propan-2-yl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS |
| BB-25-NU80_0.01uM | Dose=0.01uM, 7-tert-butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1 |
| BB-25-NU80_0.1uM | Dose=0.1uM, 7-tert-butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1 |
| BB-25-NU80_10uM | Dose=10uM, 7-tert-butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1 |
| BB-25-NU80_1uM | Dose=1uM, 7-tert-butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, TRPV1 (Vanilloid VR1 Receptor) Antagonists targeting TRPV1 |
| BB-26-JS03_0.01uM | Dose=0.01uM |
| BB-26-JS03_10uM | Dose=10uM |
| BB-26-JS03_1uM | Dose=1uM |
| BB-27-MC77_0.01uM | Dose=0.01uM |
| BB-27-MC77_0.1uM | Dose=0.1uM |
| BB-27-MC77_10uM | Dose=10uM |
| BB-27-MC77_1uM | Dose=1uM |
| BB-28-CT35_0.01uM | Dose=0.01uM, (1R)-9-[(3R,4R)-1,3-dimethylpiperidin-4-yl]-8-(2-fluoro-4-methoxyphenyl)-1-methyl-3,5-dihydro-1H-[1,2,4]triazino[3,4-c][1,4]benzoxazin-2-one, PKC theta inhibitor targeting PRKCQ |
| BB-28-CT35_0.1uM | Dose=0.1uM, (1R)-9-[(3R,4R)-1,3-dimethylpiperidin-4-yl]-8-(2-fluoro-4-methoxyphenyl)-1-methyl-3,5-dihydro-1H-[1,2,4]triazino[3,4-c][1,4]benzoxazin-2-one, PKC theta inhibitor targeting PRKCQ |
| BB-28-CT35_10uM | Dose=10uM, (1R)-9-[(3R,4R)-1,3-dimethylpiperidin-4-yl]-8-(2-fluoro-4-methoxyphenyl)-1-methyl-3,5-dihydro-1H-[1,2,4]triazino[3,4-c][1,4]benzoxazin-2-one, PKC theta inhibitor targeting PRKCQ |
| BB-28-CT35_1uM | Dose=1uM, (1R)-9-[(3R,4R)-1,3-dimethylpiperidin-4-yl]-8-(2-fluoro-4-methoxyphenyl)-1-methyl-3,5-dihydro-1H-[1,2,4]triazino[3,4-c][1,4]benzoxazin-2-one, PKC theta inhibitor targeting PRKCQ |
| BB-28-MC54_0.01uM | Dose=0.01uM, GPBAR1 agonist targeting GPBAR1 |
| BB-28-MC54_0.1uM | Dose=0.1uM, GPBAR1 agonist targeting GPBAR1 |
| BB-28-MC54_10uM | Dose=10uM, GPBAR1 agonist targeting GPBAR1 |
| BB-28-MC54_1uM | Dose=1uM, GPBAR1 agonist targeting GPBAR1 |
| BB-29-VD14_0.01uM | Dose=0.01uM, N-(4-bromo-2,6-dimethylphenyl)hexanamide, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators targeting KCNQ2, KCNQ3 |
| BB-29-VD14_0.1uM | Dose=0.1uM, N-(4-bromo-2,6-dimethylphenyl)hexanamide, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators targeting KCNQ2, KCNQ3 |
| BB-29-VD14_10uM | Dose=10uM, N-(4-bromo-2,6-dimethylphenyl)hexanamide, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators targeting KCNQ2, KCNQ3 |
| BB-29-VD14_1uM | Dose=1uM, N-(4-bromo-2,6-dimethylphenyl)hexanamide, Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators targeting KCNQ2, KCNQ3 |
| BB-31-EB45_0.01uM | Dose=0.01uM, Pfi-4, BRPF1B;BRPF1B inhibitor targeting BRPF1 |
| BB-31-EB45_0.1uM | Dose=0.1uM, Pfi-4, BRPF1B;BRPF1B inhibitor targeting BRPF1 |
| BB-31-EB45_10uM | Dose=10uM, Pfi-4, BRPF1B;BRPF1B inhibitor targeting BRPF1 |
| BB-32-IZ10_0.01uM | Dose=0.01uM |
| BB-32-IZ10_0.1uM | Dose=0.1uM |
| BB-32-IZ10_10uM | Dose=10uM |
| BB-32-IZ10_1uM | Dose=1uM |
| BB-33-HC27_0.01uM | Dose=0.01uM, 2-cyano-4-(2-hydroxyethoxy)-N-methyl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-5-carboxamide, Cathepsin S Inhibitors targeting CTSS |
| BB-33-HC27_0.1uM | Dose=0.1uM, 2-cyano-4-(2-hydroxyethoxy)-N-methyl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-5-carboxamide, Cathepsin S Inhibitors targeting CTSS |
| BB-33-HC27_10uM | Dose=10uM, 2-cyano-4-(2-hydroxyethoxy)-N-methyl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-5-carboxamide, Cathepsin S Inhibitors targeting CTSS |
| BB-33-HC27_1uM | Dose=1uM, 2-cyano-4-(2-hydroxyethoxy)-N-methyl-6-(spiro[3.5]nonan-7-ylmethylamino)pyrimidine-5-carboxamide, Cathepsin S Inhibitors targeting CTSS |
| BB-36-JL06_0.01uM | Dose=0.01uM, N-[5-(6-Chloro-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| BB-36-JL06_0.1uM | Dose=0.1uM, N-[5-(6-Chloro-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| BB-36-JL06_10uM | Dose=10uM, N-[5-(6-Chloro-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| BB-36-LB57_0.01uM | Dose=0.01uM |
| BB-36-LB57_0.1uM | Dose=0.1uM |
| BB-36-LB57_10uM | Dose=10uM |
| BB-36-LB57_1uM | Dose=1uM |
| BB-37-LS05_0.01uM | Dose=0.01uM, Gaboxadol, GABA(A) Receptor Partial Agonists;Selective GABAA-delta agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| BB-37-LS05_0.1uM | Dose=0.1uM, Gaboxadol, GABA(A) Receptor Partial Agonists;Selective GABAA-delta agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| BB-37-LS05_10uM | Dose=10uM, Gaboxadol, GABA(A) Receptor Partial Agonists;Selective GABAA-delta agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| BB-37-LS05_1uM | Dose=1uM, Gaboxadol, GABA(A) Receptor Partial Agonists;Selective GABAA-delta agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| BB-39-DQ95_0.01uM | Dose=0.01uM, 5-methyl-3,6-diphenylisoxazolo[4,5-c]pyridin-4(5H)-one, mgluR7 Antagonists targeting GRM7 |
| BB-39-DQ95_0.1uM | Dose=0.1uM, 5-methyl-3,6-diphenylisoxazolo[4,5-c]pyridin-4(5H)-one, mgluR7 Antagonists targeting GRM7 |
| BB-39-DQ95_10uM | Dose=10uM, 5-methyl-3,6-diphenylisoxazolo[4,5-c]pyridin-4(5H)-one, mgluR7 Antagonists targeting GRM7 |
| BB-39-DQ95_1uM | Dose=1uM, 5-methyl-3,6-diphenylisoxazolo[4,5-c]pyridin-4(5H)-one, mgluR7 Antagonists targeting GRM7 |
| BB-39-YQ35_0.01uM | Dose=0.01uM, Apraclonidine, alpha2-Adrenoceptor Agonists targeting ADRA1A, ADRA2A |
| BB-39-YQ35_0.1uM | Dose=0.1uM, Apraclonidine, alpha2-Adrenoceptor Agonists targeting ADRA1A, ADRA2A |
| BB-39-YQ35_10uM | Dose=10uM, Apraclonidine, alpha2-Adrenoceptor Agonists targeting ADRA1A, ADRA2A |
| BB-39-YQ35_1uM | Dose=1uM, Apraclonidine, alpha2-Adrenoceptor Agonists targeting ADRA1A, ADRA2A |
| BB-40-DA70_0.1uM | Dose=0.1uM, (3R)-3-[6-(2,5-difluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane targeting CHRNA7 |
| BB-40-DA70_1uM | Dose=1uM, (3R)-3-[6-(2,5-difluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane targeting CHRNA7 |
| BB-40-KK84_0.01uM | Dose=0.01uM, N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide, Calmodulin Antagonists;K(V)11.1 (erg1) Channel Blockers;K(V)1.5 Channel Blockers targeting CALM1, KCNA5, KCNH2 |
| BB-40-KK84_0.1uM | Dose=0.1uM, N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide, Calmodulin Antagonists;K(V)11.1 (erg1) Channel Blockers;K(V)1.5 Channel Blockers targeting CALM1, KCNA5, KCNH2 |
| BB-40-KK84_10uM | Dose=10uM, N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide, Calmodulin Antagonists;K(V)11.1 (erg1) Channel Blockers;K(V)1.5 Channel Blockers targeting CALM1, KCNA5, KCNH2 |
| BB-40-KK84_1uM | Dose=1uM, N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide, Calmodulin Antagonists;K(V)11.1 (erg1) Channel Blockers;K(V)1.5 Channel Blockers targeting CALM1, KCNA5, KCNH2 |
| BB-41-XE67_0.01uM | Dose=0.01uM, (3R)-3-[6-(2-fluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane, Nicotinic alpha7 Agonists targeting CHRNA7 |
| BB-41-XE67_0.1uM | Dose=0.1uM, (3R)-3-[6-(2-fluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane, Nicotinic alpha7 Agonists targeting CHRNA7 |
| BB-41-XE67_10uM | Dose=10uM, (3R)-3-[6-(2-fluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane, Nicotinic alpha7 Agonists targeting CHRNA7 |
| BB-41-XE67_1uM | Dose=1uM, (3R)-3-[6-(2-fluoro-4-methylphenyl)pyridazin-3-yl]oxy-1-azabicyclo[2.2.2]octane, Nicotinic alpha7 Agonists targeting CHRNA7 |
| BB-42-FF52_0.01uM | Dose=0.01uM, Midostaurin, Flt3 (FLK2/STK1) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors targeting FLT3, PRKCQ |
| BB-42-FF52_0.1uM | Dose=0.1uM, Midostaurin, Flt3 (FLK2/STK1) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors targeting FLT3, PRKCQ |
| BB-42-FF52_10uM | Dose=10uM, Midostaurin, Flt3 (FLK2/STK1) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors targeting FLT3, PRKCQ |
| BB-42-FF52_1uM | Dose=1uM, Midostaurin, Flt3 (FLK2/STK1) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways;Protein Kinase C (PKC) Inhibitors targeting FLT3, PRKCQ |
| BB-43-YQ76_0.01uM | Dose=0.01uM, Oxymetazoline, alpha1A-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA1A, ADRA2A, HTR1E |
| BB-43-YQ76_0.1uM | Dose=0.1uM, Oxymetazoline, alpha1A-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA1A, ADRA2A, HTR1E |
| BB-43-YQ76_10uM | Dose=10uM, Oxymetazoline, alpha1A-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA1A, ADRA2A, HTR1E |
| BB-43-YQ76_1uM | Dose=1uM, Oxymetazoline, alpha1A-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA1B, ADRA1A, ADRA2A, HTR1E |
| BB-44-CQ48_10uM | Dose=10uM, Resveratrol, Antioxidant;Anti-inflammatory targeting NQO2, TTR |
| BB-44-SX65_0.01uM | Dose=0.01uM, Dactinomycin, Transcription Inhibitors;DNA-Directed RNA Polymerase Inhibitors;RNA synthesis inhbitor targeting POLRMT, CDK9 |
| BB-44-SX65_0.1uM | Dose=0.1uM, Dactinomycin, Transcription Inhibitors;DNA-Directed RNA Polymerase Inhibitors;RNA synthesis inhbitor targeting POLRMT, CDK9 |
| BB-44-SX65_10uM | Dose=10uM, Dactinomycin, Transcription Inhibitors;DNA-Directed RNA Polymerase Inhibitors;RNA synthesis inhbitor targeting POLRMT, CDK9 |
| BB-44-SX65_1uM | Dose=1uM, Dactinomycin, Transcription Inhibitors;DNA-Directed RNA Polymerase Inhibitors;RNA synthesis inhbitor targeting POLRMT, CDK9 |
| BB-45-NH69_0.01uM | Dose=0.01uM, Mosapride, 5-HT4 Agonists targeting HTR4 |
| BB-45-NH69_0.1uM | Dose=0.1uM, Mosapride, 5-HT4 Agonists targeting HTR4 |
| BB-45-NH69_10uM | Dose=10uM, Mosapride, 5-HT4 Agonists targeting HTR4 |
| BB-45-NH69_1uM | Dose=1uM, Mosapride, 5-HT4 Agonists targeting HTR4 |
| BB-47-YI31_0.01uM | Dose=0.01uM, Dapt, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| BB-47-YI31_0.1uM | Dose=0.1uM, Dapt, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| BB-47-YI31_10uM | Dose=10uM, Dapt, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| BB-47-YI31_1uM | Dose=1uM, Dapt, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| BB-48-VW67_0.01uM | Dose=0.01uM, 7-(2-cyclohexylethyl)-6-[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxymethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS |
| BB-48-VW67_0.1uM | Dose=0.1uM, 7-(2-cyclohexylethyl)-6-[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxymethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS |
| BB-48-VW67_10uM | Dose=10uM, 7-(2-cyclohexylethyl)-6-[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxymethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin S Inhibitors targeting CTSS |
| BB-49-OQ60_0.01uM | Dose=0.01uM, Doramapimod, Inhibitors of Signal Transduction Pathways;SAPK2 (p38beta) Inhibitors;p38 MAPK Inhibitors targeting MAPK14, MAPK11, MAPK13, MAPK12 |
| BB-49-OQ60_10uM | Dose=10uM, Doramapimod, Inhibitors of Signal Transduction Pathways;SAPK2 (p38beta) Inhibitors;p38 MAPK Inhibitors targeting MAPK14, MAPK11, MAPK13, MAPK12 |
| BB-49-OQ60_1uM | Dose=1uM, Doramapimod, Inhibitors of Signal Transduction Pathways;SAPK2 (p38beta) Inhibitors;p38 MAPK Inhibitors targeting MAPK14, MAPK11, MAPK13, MAPK12 |
| BB-50-CR51_0.01uM | Dose=0.01uM, 1,7-dimethyl-3-(2-methyl-5-(5-(pyridin-2-yl)-1,2,4-oxadiazol-3-ylamino)phenyl)-1,6-naphthyridin-2(1H)-one, KIT (C-KIT) Inhibitors targeting KIT |
| BB-50-CR51_10uM | Dose=10uM, 1,7-dimethyl-3-(2-methyl-5-(5-(pyridin-2-yl)-1,2,4-oxadiazol-3-ylamino)phenyl)-1,6-naphthyridin-2(1H)-one, KIT (C-KIT) Inhibitors targeting KIT |
| BB-50-CR51_1uM | Dose=1uM, 1,7-dimethyl-3-(2-methyl-5-(5-(pyridin-2-yl)-1,2,4-oxadiazol-3-ylamino)phenyl)-1,6-naphthyridin-2(1H)-one, KIT (C-KIT) Inhibitors targeting KIT |
| BB-51-DP49_0.01uM | Dose=0.01uM, 2-[(4-but-3-enoxyphenyl)sulfonyl-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]amino]-N-hydroxyacetamide, MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9 |
| BB-51-DP49_0.1uM | Dose=0.1uM, 2-[(4-but-3-enoxyphenyl)sulfonyl-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]amino]-N-hydroxyacetamide, MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9 |
| BB-51-DP49_10uM | Dose=10uM, 2-[(4-but-3-enoxyphenyl)sulfonyl-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]amino]-N-hydroxyacetamide, MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9 |
| BB-51-DP49_1uM | Dose=1uM, 2-[(4-but-3-enoxyphenyl)sulfonyl-[[4-(1,2,4-triazol-1-yl)phenyl]methyl]amino]-N-hydroxyacetamide, MMP-9 (Gelatinase B) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP9 |
| BB-51-ML99_0.01uM | Dose=0.01uM, [1-(Pyridin-2-ylmethyl)indol-3-yl]methanol, SULT1A1 prodrug targeting SULT1A1, TP53 |
| BB-51-ML99_0.1uM | Dose=0.1uM, [1-(Pyridin-2-ylmethyl)indol-3-yl]methanol, SULT1A1 prodrug targeting SULT1A1, TP53 |
| BB-51-ML99_10uM | Dose=10uM, [1-(Pyridin-2-ylmethyl)indol-3-yl]methanol, SULT1A1 prodrug targeting SULT1A1, TP53 |
| BB-51-ML99_1uM | Dose=1uM, [1-(Pyridin-2-ylmethyl)indol-3-yl]methanol, SULT1A1 prodrug targeting SULT1A1, TP53 |
| BB-52-LF37_0.01uM | Dose=0.01uM, Saxagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| BB-52-LF37_0.1uM | Dose=0.1uM, Saxagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| BB-52-LF37_10uM | Dose=10uM, Saxagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| BB-52-LF37_1uM | Dose=1uM, Saxagliptin, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| BB-52-UP66_0.01uM | Dose=0.01uM, Bopindolol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| BB-52-UP66_10uM | Dose=10uM, Bopindolol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| BB-52-UP66_1uM | Dose=1uM, Bopindolol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| BB-53-SW55_0.01uM | Dose=0.01uM, Glycopyrronium, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3 |
| BB-53-SW55_10uM | Dose=10uM, Glycopyrronium, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3 |
| BB-53-SW55_1uM | Dose=1uM, Glycopyrronium, Muscarinic Antagonists targeting CHRM1, CHRM2, CHRM3 |
| BB-55-JH29_0.01uM | Dose=0.01uM |
| BB-55-JH29_0.1uM | Dose=0.1uM |
| BB-55-JH29_10uM | Dose=10uM |
| BB-55-JH29_1uM | Dose=1uM |
| BB-56-DB67_0.01uM | Dose=0.01uM, AG 490, Jak2 Inhibitors;Antiinflammatory Drugs;STAT-3 Inhibitors;Jak3 Inhibitors targeting JAK2, JAK3, STAT3 |
| BB-56-DB67_0.1uM | Dose=0.1uM, AG 490, Jak2 Inhibitors;Antiinflammatory Drugs;STAT-3 Inhibitors;Jak3 Inhibitors targeting JAK2, JAK3, STAT3 |
| BB-56-DB67_10uM | Dose=10uM, AG 490, Jak2 Inhibitors;Antiinflammatory Drugs;STAT-3 Inhibitors;Jak3 Inhibitors targeting JAK2, JAK3, STAT3 |
| BB-56-DB67_1uM | Dose=1uM, AG 490, Jak2 Inhibitors;Antiinflammatory Drugs;STAT-3 Inhibitors;Jak3 Inhibitors targeting JAK2, JAK3, STAT3 |
| BB-57-AZ77_0.01uM | Dose=0.01uM |
| BB-57-AZ77_0.1uM | Dose=0.1uM |
| BB-57-AZ77_10uM | Dose=10uM |
| BB-57-AZ77_1uM | Dose=1uM |
| BB-57-NT83_0.01uM | Dose=0.01uM, 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, DRD2 agonist targeting DRD2 |
| BB-57-NT83_0.1uM | Dose=0.1uM, 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, DRD2 agonist targeting DRD2 |
| BB-57-NT83_10uM | Dose=10uM, 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, DRD2 agonist targeting DRD2 |
| BB-57-NT83_1uM | Dose=1uM, 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, DRD2 agonist targeting DRD2 |
| BB-58-LW82_0.01uM | Dose=0.01uM, 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester |
| BB-58-LW82_0.1uM | Dose=0.1uM, 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester |
| BB-58-LW82_10uM | Dose=10uM, 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester |
| BB-58-LW82_1uM | Dose=1uM, 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester |
| BB-62-MS83_0.01uM | Dose=0.01uM, (R)-3-Cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-N-(5-morpholin-4-yl-thiazolo[5,4-b]pyridin-2-yl)-propionamide targeting GCK |
| BB-62-MS83_0.1uM | Dose=0.1uM, (R)-3-Cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-N-(5-morpholin-4-yl-thiazolo[5,4-b]pyridin-2-yl)-propionamide targeting GCK |
| BB-62-MS83_10uM | Dose=10uM, (R)-3-Cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-N-(5-morpholin-4-yl-thiazolo[5,4-b]pyridin-2-yl)-propionamide targeting GCK |
| BB-62-MS83_1uM | Dose=1uM, (R)-3-Cyclopentyl-2-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-N-(5-morpholin-4-yl-thiazolo[5,4-b]pyridin-2-yl)-propionamide targeting GCK |
| BB-62-SZ35_0.01uM | Dose=0.01uM, 1-(3,4-dichlorophenyl)-2-[2-imino-3-(2-methylbenzyl)-2,3-dihydro-1H-benzimidazol-1-yl]ethanol targeting CBX7 |
| BB-62-SZ35_0.1uM | Dose=0.1uM, 1-(3,4-dichlorophenyl)-2-[2-imino-3-(2-methylbenzyl)-2,3-dihydro-1H-benzimidazol-1-yl]ethanol targeting CBX7 |
| BB-62-SZ35_10uM | Dose=10uM, 1-(3,4-dichlorophenyl)-2-[2-imino-3-(2-methylbenzyl)-2,3-dihydro-1H-benzimidazol-1-yl]ethanol targeting CBX7 |
| BB-62-SZ35_1uM | Dose=1uM, 1-(3,4-dichlorophenyl)-2-[2-imino-3-(2-methylbenzyl)-2,3-dihydro-1H-benzimidazol-1-yl]ethanol targeting CBX7 |
| BB-63-AW70_0.01uM | Dose=0.01uM, 9-Chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine, Adenosine Receptor Antagonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3 |
| BB-63-AW70_0.1uM | Dose=0.1uM, 9-Chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine, Adenosine Receptor Antagonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3 |
| BB-63-AW70_10uM | Dose=10uM, 9-Chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine, Adenosine Receptor Antagonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3 |
| BB-63-AW70_1uM | Dose=1uM, 9-Chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine, Adenosine Receptor Antagonists targeting ADORA1, ADORA2A, ADORA2B, ADORA3 |
| BB-64-EE60_0.01uM | Dose=0.01uM, US10112926, Example 7, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG |
| BB-64-EE60_0.1uM | Dose=0.1uM, US10112926, Example 7, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG |
| BB-64-EE60_10uM | Dose=10uM, US10112926, Example 7, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG |
| BB-64-EE60_1uM | Dose=1uM, US10112926, Example 7, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors targeting PIK3CG |
| BB-65-JH59_10uM | Dose=10uM, 2,9-Diazaspiro[5.5]undecan-1-one, 2-(1H-indol-3-ylMethyl)-9-(4-Methoxy-2-pyriMidinyl)- |
| BB-65-JH59_1uM | Dose=1uM, 2,9-Diazaspiro[5.5]undecan-1-one, 2-(1H-indol-3-ylMethyl)-9-(4-Methoxy-2-pyriMidinyl)- |
| BB-65-SY95_0.01uM | Dose=0.01uM, 4-fluoro-N-(4-sulfamoylphenyl)benzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2 |
| BB-65-SY95_0.1uM | Dose=0.1uM, 4-fluoro-N-(4-sulfamoylphenyl)benzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2 |
| BB-65-SY95_10uM | Dose=10uM, 4-fluoro-N-(4-sulfamoylphenyl)benzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2 |
| BB-65-SY95_1uM | Dose=1uM, 4-fluoro-N-(4-sulfamoylphenyl)benzenesulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2 |
| BB-69-WN73_0.01uM | Dose=0.01uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| BB-69-WN73_0.1uM | Dose=0.1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| BB-69-WN73_10uM | Dose=10uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| BB-69-WN73_1uM | Dose=1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| BB-69-YQ35_0.01uM | Dose=0.01uM, (3-Morpholin-4-yl-1-oxa-2-aza-3-azoniacyclopenta-2,4-dien-5-yl)azanide, Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| BB-69-YQ35_0.1uM | Dose=0.1uM, (3-Morpholin-4-yl-1-oxa-2-aza-3-azoniacyclopenta-2,4-dien-5-yl)azanide, Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| BB-69-YQ35_10uM | Dose=10uM, (3-Morpholin-4-yl-1-oxa-2-aza-3-azoniacyclopenta-2,4-dien-5-yl)azanide, Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| BB-69-YQ35_1uM | Dose=1uM, (3-Morpholin-4-yl-1-oxa-2-aza-3-azoniacyclopenta-2,4-dien-5-yl)azanide, Nitric Oxide Donors targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| BB-72-TP61_0.01uM | Dose=0.01uM, 4-methoxy-N-[1-methyl-3-(naphthalen-1-yl)-4-oxo-1,4-dihydroquinolin-2-yl]benzamide |
| BB-72-TP61_0.1uM | Dose=0.1uM, 4-methoxy-N-[1-methyl-3-(naphthalen-1-yl)-4-oxo-1,4-dihydroquinolin-2-yl]benzamide |
| BB-72-TP61_10uM | Dose=10uM, 4-methoxy-N-[1-methyl-3-(naphthalen-1-yl)-4-oxo-1,4-dihydroquinolin-2-yl]benzamide |
| BB-72-TP61_1uM | Dose=1uM, 4-methoxy-N-[1-methyl-3-(naphthalen-1-yl)-4-oxo-1,4-dihydroquinolin-2-yl]benzamide |
| BB-73-OX38_0.01uM | Dose=0.01uM, R-1663, Known FactorXa inhibitor targeting F10 |
| BB-73-OX38_0.1uM | Dose=0.1uM, R-1663, Known FactorXa inhibitor targeting F10 |
| BB-73-OX38_10uM | Dose=10uM, R-1663, Known FactorXa inhibitor targeting F10 |
| BB-73-OX38_1uM | Dose=1uM, R-1663, Known FactorXa inhibitor targeting F10 |
| BB-73-ZW70_0.01uM | Dose=0.01uM |
| BB-73-ZW70_0.1uM | Dose=0.1uM |
| BB-73-ZW70_10uM | Dose=10uM |
| BB-73-ZW70_1uM | Dose=1uM |
| BB-74-RX30_0.01uM | Dose=0.01uM, N-[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]-4-[4-[[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]carbamoyl]phenyl]benzamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors targeting BIRC2 |
| BB-74-RX30_0.1uM | Dose=0.1uM, N-[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]-4-[4-[[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]carbamoyl]phenyl]benzamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors targeting BIRC2 |
| BB-74-RX30_10uM | Dose=10uM, N-[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]-4-[4-[[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]carbamoyl]phenyl]benzamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors targeting BIRC2 |
| BB-74-RX30_1uM | Dose=1uM, N-[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]-4-[4-[[(5S)-6-[(2S)-2-[5-(4-fluorobenzoyl)pyridin-3-yl]pyrrolidin-1-yl]-5-[[(2S)-2-(methylamino)propanoyl]amino]-6-oxohexyl]carbamoyl]phenyl]benzamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors targeting BIRC2 |
| BB-75-JK26_0.01uM | Dose=0.01uM, 2-Amino-4-{[2-(3,5-dimethyl-1h-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| BB-75-JK26_0.1uM | Dose=0.1uM, 2-Amino-4-{[2-(3,5-dimethyl-1h-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| BB-75-JK26_10uM | Dose=10uM, 2-Amino-4-{[2-(3,5-dimethyl-1h-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| BB-75-JK26_1uM | Dose=1uM, 2-Amino-4-{[2-(3,5-dimethyl-1h-pyrazol-1-yl)-2-oxoethyl]thio}-6-(methylthio)pyrimidine-5-carbonitrile targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| BB-75-UH54_0.01uM | Dose=0.01uM, 2-(2-Chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting ABCA1, NR1H2 |
| BB-75-UH54_0.1uM | Dose=0.1uM, 2-(2-Chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting ABCA1, NR1H2 |
| BB-75-UH54_10uM | Dose=10uM, 2-(2-Chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting ABCA1, NR1H2 |
| BB-75-UH54_1uM | Dose=1uM, 2-(2-Chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting ABCA1, NR1H2 |
| BB-75-XU05_0.01uM | Dose=0.01uM, Scopoletin, LDL Antioxidants;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nicotinic Receptor Agonists;Acetylcholinesterase Inhibitors targeting ACHE, NOS2 |
| BB-75-XU05_0.1uM | Dose=0.1uM, Scopoletin, LDL Antioxidants;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nicotinic Receptor Agonists;Acetylcholinesterase Inhibitors targeting ACHE, NOS2 |
| BB-75-XU05_10uM | Dose=10uM, Scopoletin, LDL Antioxidants;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Nicotinic Receptor Agonists;Acetylcholinesterase Inhibitors targeting ACHE, NOS2 |
| BB-75-YK01_0.01uM | Dose=0.01uM, 4-Phenylmethoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one |
| BB-75-YK01_0.1uM | Dose=0.1uM, 4-Phenylmethoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one |
| BB-75-YK01_10uM | Dose=10uM, 4-Phenylmethoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one |
| BB-75-YK01_1uM | Dose=1uM, 4-Phenylmethoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one |
| BB-77-IG67_0.01uM | Dose=0.01uM, 1-(5-chloro-6-methoxypyridin-3-yl)-3-[6-cyano-4-[(3S)-3-methylmorpholin-4-yl]quinolin-3-yl]urea |
| BB-77-IG67_0.1uM | Dose=0.1uM, 1-(5-chloro-6-methoxypyridin-3-yl)-3-[6-cyano-4-[(3S)-3-methylmorpholin-4-yl]quinolin-3-yl]urea |
| BB-77-IG67_10uM | Dose=10uM, 1-(5-chloro-6-methoxypyridin-3-yl)-3-[6-cyano-4-[(3S)-3-methylmorpholin-4-yl]quinolin-3-yl]urea |
| BB-77-IG67_1uM | Dose=1uM, 1-(5-chloro-6-methoxypyridin-3-yl)-3-[6-cyano-4-[(3S)-3-methylmorpholin-4-yl]quinolin-3-yl]urea |
| BB-77-QQ71_0.01uM | Dose=0.01uM, Ricolinostat, HDAC6 targeting HDAC6 |
| BB-77-QQ71_0.1uM | Dose=0.1uM, Ricolinostat, HDAC6 targeting HDAC6 |
| BB-77-QQ71_10uM | Dose=10uM, Ricolinostat, HDAC6 targeting HDAC6 |
| BB-77-QQ71_1uM | Dose=1uM, Ricolinostat, HDAC6 targeting HDAC6 |
| BB-78-LT85_0.01uM | Dose=0.01uM |
| BB-78-LT85_0.1uM | Dose=0.1uM |
| BB-78-LT85_10uM | Dose=10uM |
| BB-78-LT85_1uM | Dose=1uM |
| BB-79-AG41_0.01uM | Dose=0.01uM, Nvp-bbd130, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting AKT1, AKT2, PIK3CA, PIK3CD, AKT3, PIK3CB |
| BB-79-AG41_0.1uM | Dose=0.1uM, Nvp-bbd130, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting AKT1, AKT2, PIK3CA, PIK3CD, AKT3, PIK3CB |
| BB-79-AG41_10uM | Dose=10uM, Nvp-bbd130, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting AKT1, AKT2, PIK3CA, PIK3CD, AKT3, PIK3CB |
| BB-79-AG41_1uM | Dose=1uM, Nvp-bbd130, Phosphatidylinositol 3-Kinase (PI3K) Inhibitors targeting AKT1, AKT2, PIK3CA, PIK3CD, AKT3, PIK3CB |
| BB-79-GA42_0.01uM | Dose=0.01uM, Pratol |
| BB-79-GA42_0.1uM | Dose=0.1uM, Pratol |
| BB-79-GA42_10uM | Dose=10uM, Pratol |
| BB-79-GA42_1uM | Dose=1uM, Pratol |
| BB-80-NH42_0.01uM | Dose=0.01uM, Jtv-519 free base, RyR2/FKBP12.6 Complex Antagonists;Calcium Channel Blockers targeting RYR2 |
| BB-80-NH42_0.1uM | Dose=0.1uM, Jtv-519 free base, RyR2/FKBP12.6 Complex Antagonists;Calcium Channel Blockers targeting RYR2 |
| BB-80-NH42_10uM | Dose=10uM, Jtv-519 free base, RyR2/FKBP12.6 Complex Antagonists;Calcium Channel Blockers targeting RYR2 |
| BB-80-NH42_1uM | Dose=1uM, Jtv-519 free base, RyR2/FKBP12.6 Complex Antagonists;Calcium Channel Blockers targeting RYR2 |
| BB-82-TP51_0.01uM | Dose=0.01uM, Tegobuvir |
| BB-82-TP51_0.1uM | Dose=0.1uM, Tegobuvir |
| BB-82-TP51_10uM | Dose=10uM, Tegobuvir |
| BB-82-TP51_1uM | Dose=1uM, Tegobuvir |
| BB-83-OX58_0.01uM | Dose=0.01uM |
| BB-83-OX58_0.1uM | Dose=0.1uM |
| BB-83-OX58_10uM | Dose=10uM |
| BB-83-OX58_1uM | Dose=1uM |
| BB-83-ZM06_0.01uM | Dose=0.01uM, 6-N-(4-methylsulfonylphenyl)-2-N-(pyridin-2-ylmethyl)-9-(1,3-thiazol-4-yl)purine-2,6-diamine, Tyrosine Kinase Inhibitors targeting FLT3 |
| BB-83-ZM06_0.1uM | Dose=0.1uM, 6-N-(4-methylsulfonylphenyl)-2-N-(pyridin-2-ylmethyl)-9-(1,3-thiazol-4-yl)purine-2,6-diamine, Tyrosine Kinase Inhibitors targeting FLT3 |
| BB-83-ZM06_10uM | Dose=10uM, 6-N-(4-methylsulfonylphenyl)-2-N-(pyridin-2-ylmethyl)-9-(1,3-thiazol-4-yl)purine-2,6-diamine, Tyrosine Kinase Inhibitors targeting FLT3 |
| BB-83-ZM06_1uM | Dose=1uM, 6-N-(4-methylsulfonylphenyl)-2-N-(pyridin-2-ylmethyl)-9-(1,3-thiazol-4-yl)purine-2,6-diamine, Tyrosine Kinase Inhibitors targeting FLT3 |
| BB-84-DG64_0.01uM | Dose=0.01uM |
| BB-84-DG64_0.1uM | Dose=0.1uM |
| BB-84-DG64_10uM | Dose=10uM |
| BB-84-DG64_1uM | Dose=1uM |
| BB-85-NU70_0.01uM | Dose=0.01uM, Sotrastaurin, Protein Kinase PKC beta Inhibitors;Protein Kinase PKC alpha Inhibitors;Protein Kinase PKC epsilon Inhibitors;Protein Kinase PKC delta Inhibitors;Protein Kinase PKC theta Inhibitors targeting PRKCA, PRKCB, PRKCD, PRKCE, PRKCQ |
| BB-85-NU70_10uM | Dose=10uM, Sotrastaurin, Protein Kinase PKC beta Inhibitors;Protein Kinase PKC alpha Inhibitors;Protein Kinase PKC epsilon Inhibitors;Protein Kinase PKC delta Inhibitors;Protein Kinase PKC theta Inhibitors targeting PRKCA, PRKCB, PRKCD, PRKCE, PRKCQ |
| BB-85-NU70_1uM | Dose=1uM, Sotrastaurin, Protein Kinase PKC beta Inhibitors;Protein Kinase PKC alpha Inhibitors;Protein Kinase PKC epsilon Inhibitors;Protein Kinase PKC delta Inhibitors;Protein Kinase PKC theta Inhibitors targeting PRKCA, PRKCB, PRKCD, PRKCE, PRKCQ |
| BB-86-BE19_0.01uM | Dose=0.01uM, (2s)-1-{[5-(3-Methyl-1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-Phenylpropan-2-Amine, Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG |
| BB-86-BE19_0.1uM | Dose=0.1uM, (2s)-1-{[5-(3-Methyl-1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-Phenylpropan-2-Amine, Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG |
| BB-86-BE19_10uM | Dose=10uM, (2s)-1-{[5-(3-Methyl-1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-Phenylpropan-2-Amine, Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG |
| BB-86-BE19_1uM | Dose=1uM, (2s)-1-{[5-(3-Methyl-1h-Indazol-5-Yl)pyridin-3-Yl]oxy}-3-Phenylpropan-2-Amine, Inhibitors of Signal Transduction Pathways;PKB alpha/Akt1 Inhibitors;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA, PRKACB, PRKACG |
| BB-86-BE39_0.01uM | Dose=0.01uM, Colchicine, Tubulin Polymerase Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| BB-86-BE39_0.1uM | Dose=0.1uM, Colchicine, Tubulin Polymerase Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| BB-86-BE39_10uM | Dose=10uM, Colchicine, Tubulin Polymerase Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| BB-86-BE39_1uM | Dose=1uM, Colchicine, Tubulin Polymerase Inhibitors targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| BB-86-MY27_0.01uM | Dose=0.01uM, Fpl 64176, Calcium channel stimulator L-type;L-Type Calcium Channel Activators targeting CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| BB-86-MY27_0.1uM | Dose=0.1uM, Fpl 64176, Calcium channel stimulator L-type;L-Type Calcium Channel Activators targeting CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| BB-86-MY27_10uM | Dose=10uM, Fpl 64176, Calcium channel stimulator L-type;L-Type Calcium Channel Activators targeting CACNA1C, CACNA1D, CACNA1F, CACNA1S |
| BB-86-UL91_0.01uM | Dose=0.01uM, 2-(5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyridin-2-ylamino)-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, CDK4 Inhibitors targeting CDK4 |
| BB-86-UL91_0.1uM | Dose=0.1uM, 2-(5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyridin-2-ylamino)-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, CDK4 Inhibitors targeting CDK4 |
| BB-86-UL91_10uM | Dose=10uM, 2-(5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyridin-2-ylamino)-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, CDK4 Inhibitors targeting CDK4 |
| BB-86-UL91_1uM | Dose=1uM, 2-(5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)pyridin-2-ylamino)-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, CDK4 Inhibitors targeting CDK4 |
| BB-87-SF89_0.01uM | Dose=0.01uM, Sepantronium, BIRC5 gene inhibitor targeting BIRC5 |
| BB-87-SF89_0.1uM | Dose=0.1uM, Sepantronium, BIRC5 gene inhibitor targeting BIRC5 |
| BB-87-SF89_10uM | Dose=10uM, Sepantronium, BIRC5 gene inhibitor targeting BIRC5 |
| BB-87-SF89_1uM | Dose=1uM, Sepantronium, BIRC5 gene inhibitor targeting BIRC5 |
| BB-87-YF54_0.01uM | Dose=0.01uM, 2-[(6-Methylpyridin-2-yl)carbamoyl]-4-(trifluoromethyl)benzoic acid |
| BB-87-YF54_0.1uM | Dose=0.1uM, 2-[(6-Methylpyridin-2-yl)carbamoyl]-4-(trifluoromethyl)benzoic acid |
| BB-87-YF54_10uM | Dose=10uM, 2-[(6-Methylpyridin-2-yl)carbamoyl]-4-(trifluoromethyl)benzoic acid |
| BB-87-YF54_1uM | Dose=1uM, 2-[(6-Methylpyridin-2-yl)carbamoyl]-4-(trifluoromethyl)benzoic acid |
| BB-89-GD49_0.01uM | Dose=0.01uM, phosphodiesterase PDE5A Inhibitors targeting PDE6A, PDE6G, PDE6H, PDE5A |
| BB-89-GD49_0.1uM | Dose=0.1uM, phosphodiesterase PDE5A Inhibitors targeting PDE6A, PDE6G, PDE6H, PDE5A |
| BB-89-GD49_10uM | Dose=10uM, phosphodiesterase PDE5A Inhibitors targeting PDE6A, PDE6G, PDE6H, PDE5A |
| BB-89-GD49_1uM | Dose=1uM, phosphodiesterase PDE5A Inhibitors targeting PDE6A, PDE6G, PDE6H, PDE5A |
| BB-89-HE42_0.01uM | Dose=0.01uM, 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline, GPER antagonist targeting GPER1 |
| BB-89-HE42_0.1uM | Dose=0.1uM, 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline, GPER antagonist targeting GPER1 |
| BB-89-HE42_10uM | Dose=10uM, 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline, GPER antagonist targeting GPER1 |
| BB-89-HE42_1uM | Dose=1uM, 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline, GPER antagonist targeting GPER1 |
| BB-93-VT73_0.01uM | Dose=0.01uM, 2-Benzyl-3-mercaptopropanoic acid targeting CPA1 |
| BB-93-VT73_0.1uM | Dose=0.1uM, 2-Benzyl-3-mercaptopropanoic acid targeting CPA1 |
| BB-93-VT73_1uM | Dose=1uM, 2-Benzyl-3-mercaptopropanoic acid targeting CPA1 |
| BB-94-HN41_0.01uM | Dose=0.01uM, N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor targeting SMURF1 |
| BB-94-HN41_0.1uM | Dose=0.1uM, N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor targeting SMURF1 |
| BB-94-HN41_10uM | Dose=10uM, N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor targeting SMURF1 |
| BB-94-HN41_1uM | Dose=1uM, N-(1-cyclohexyl-2,3-dimethyl-5-oxopyrazol-4-yl)-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor targeting SMURF1 |
| BB-99-UN48_0.01uM | Dose=0.01uM, 1-(2,6-Dichlorophenyl)-2-(furan-2-yl)-5-methyl-4-(2-methylpropyl)imidazole |
| BB-99-UN48_0.1uM | Dose=0.1uM, 1-(2,6-Dichlorophenyl)-2-(furan-2-yl)-5-methyl-4-(2-methylpropyl)imidazole |
| BB-99-UN48_10uM | Dose=10uM, 1-(2,6-Dichlorophenyl)-2-(furan-2-yl)-5-methyl-4-(2-methylpropyl)imidazole |
| BB-99-UN48_1uM | Dose=1uM, 1-(2,6-Dichlorophenyl)-2-(furan-2-yl)-5-methyl-4-(2-methylpropyl)imidazole |
| BC-00-YH62_0.01uM | Dose=0.01uM, Nocodazole, Tubulin polymerization inhibitors;Tubulin modulator;Antimitotic Drugs;Tubulin polymerization inhibitor targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| BC-00-YH62_0.1uM | Dose=0.1uM, Nocodazole, Tubulin polymerization inhibitors;Tubulin modulator;Antimitotic Drugs;Tubulin polymerization inhibitor targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| BC-00-YH62_10uM | Dose=10uM, Nocodazole, Tubulin polymerization inhibitors;Tubulin modulator;Antimitotic Drugs;Tubulin polymerization inhibitor targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| BC-00-YH62_1uM | Dose=1uM, Nocodazole, Tubulin polymerization inhibitors;Tubulin modulator;Antimitotic Drugs;Tubulin polymerization inhibitor targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| BC-01-JL64_0.01uM | Dose=0.01uM, Calcimycin |
| BC-01-JL64_0.1uM | Dose=0.1uM, Calcimycin |
| BC-01-JL64_10uM | Dose=10uM, Calcimycin |
| BC-01-JL64_1uM | Dose=1uM, Calcimycin |
| BC-01-VL44_0.01uM | Dose=0.01uM, Lipoic acid, Pyruvate Dehydrogenase Activators targeting DLAT, PDHA1, PDHA2, PDHB |
| BC-01-VL44_0.1uM | Dose=0.1uM, Lipoic acid, Pyruvate Dehydrogenase Activators targeting DLAT, PDHA1, PDHA2, PDHB |
| BC-01-VL44_10uM | Dose=10uM, Lipoic acid, Pyruvate Dehydrogenase Activators targeting DLAT, PDHA1, PDHA2, PDHB |
| BC-01-VL44_1uM | Dose=1uM, Lipoic acid, Pyruvate Dehydrogenase Activators targeting DLAT, PDHA1, PDHA2, PDHB |
| BC-01-WO51_0.1uM | Dose=0.1uM, 2-[[(2S)-2-aminopropanoyl]amino]ethyl N-[4-(3-chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]carbamate |
| BC-01-WO51_10uM | Dose=10uM, 2-[[(2S)-2-aminopropanoyl]amino]ethyl N-[4-(3-chlorophenyl)pyrimidin-2-yl]-N-[4-(trifluoromethyl)phenyl]carbamate |
| BC-02-SI44_0.01uM | Dose=0.01uM, Importazole, Importin beta inhibitor targeting KPNB1 |
| BC-02-SI44_0.1uM | Dose=0.1uM, Importazole, Importin beta inhibitor targeting KPNB1 |
| BC-02-SI44_10uM | Dose=10uM, Importazole, Importin beta inhibitor targeting KPNB1 |
| BC-02-SI44_1uM | Dose=1uM, Importazole, Importin beta inhibitor targeting KPNB1 |
| BC-02-WF67_0.01uM | Dose=0.01uM, Dilazep, Adenosine Reuptake Inhibitor targeting SLC29A1, SLC29A2 |
| BC-02-WF67_0.1uM | Dose=0.1uM, Dilazep, Adenosine Reuptake Inhibitor targeting SLC29A1, SLC29A2 |
| BC-02-WF67_10uM | Dose=10uM, Dilazep, Adenosine Reuptake Inhibitor targeting SLC29A1, SLC29A2 |
| BC-02-WF67_1uM | Dose=1uM, Dilazep, Adenosine Reuptake Inhibitor targeting SLC29A1, SLC29A2 |
| BC-03-OQ01_0.01uM | Dose=0.01uM, C.I. Natural Red 20, Apoptosis Inducers;Drugs Acting on Chemokine Receptors;Non-Steroidal Antiinflammatory Drugs;Angiogenesis Inhibitors;TNF Expression Inhibitors targeting PKM |
| BC-03-OQ01_0.1uM | Dose=0.1uM, C.I. Natural Red 20, Apoptosis Inducers;Drugs Acting on Chemokine Receptors;Non-Steroidal Antiinflammatory Drugs;Angiogenesis Inhibitors;TNF Expression Inhibitors targeting PKM |
| BC-03-OQ01_10uM | Dose=10uM, C.I. Natural Red 20, Apoptosis Inducers;Drugs Acting on Chemokine Receptors;Non-Steroidal Antiinflammatory Drugs;Angiogenesis Inhibitors;TNF Expression Inhibitors targeting PKM |
| BC-03-OQ01_1uM | Dose=1uM, C.I. Natural Red 20, Apoptosis Inducers;Drugs Acting on Chemokine Receptors;Non-Steroidal Antiinflammatory Drugs;Angiogenesis Inhibitors;TNF Expression Inhibitors targeting PKM |
| BC-06-CP81_0.01uM | Dose=0.01uM, Amitriptyline, 5-HT Reuptake Inhibitors;Nav1.4 (SkM1) Sodium Channel Blockers;Norepinephrine Reuptake Inhibitors targeting SCN4A |
| BC-06-CP81_10uM | Dose=10uM, Amitriptyline, 5-HT Reuptake Inhibitors;Nav1.4 (SkM1) Sodium Channel Blockers;Norepinephrine Reuptake Inhibitors targeting SCN4A |
| BC-06-IL96_0.01uM | Dose=0.01uM |
| BC-06-IL96_0.1uM | Dose=0.1uM |
| BC-06-IL96_10uM | Dose=10uM |
| BC-06-IL96_1uM | Dose=1uM |
| BC-06-OP01_0.01uM | Dose=0.01uM, Ubo-Qic |
| BC-06-OP01_0.1uM | Dose=0.1uM, Ubo-Qic |
| BC-06-OP01_10uM | Dose=10uM, Ubo-Qic |
| BC-06-OP01_1uM | Dose=1uM, Ubo-Qic |
| BC-07-FZ32_0.01uM | Dose=0.01uM, PF-573228, Inhibitor of fibronectin-directed migration;Co-Inducer of apoptosis in pancreatic cancer;FAK inhbitor targeting PTK2 |
| BC-07-FZ32_0.1uM | Dose=0.1uM, PF-573228, Inhibitor of fibronectin-directed migration;Co-Inducer of apoptosis in pancreatic cancer;FAK inhbitor targeting PTK2 |
| BC-07-FZ32_10uM | Dose=10uM, PF-573228, Inhibitor of fibronectin-directed migration;Co-Inducer of apoptosis in pancreatic cancer;FAK inhbitor targeting PTK2 |
| BC-07-FZ32_1uM | Dose=1uM, PF-573228, Inhibitor of fibronectin-directed migration;Co-Inducer of apoptosis in pancreatic cancer;FAK inhbitor targeting PTK2 |
| BC-08-RC39_0.01uM | Dose=0.01uM, [(2R)-1-methyl-1-(2-phenylethyl)pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate, CHRM3 antagonist targeting CHRM3 |
| BC-08-RC39_0.1uM | Dose=0.1uM, [(2R)-1-methyl-1-(2-phenylethyl)pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate, CHRM3 antagonist targeting CHRM3 |
| BC-08-RC39_10uM | Dose=10uM, [(2R)-1-methyl-1-(2-phenylethyl)pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate, CHRM3 antagonist targeting CHRM3 |
| BC-08-RC39_1uM | Dose=1uM, [(2R)-1-methyl-1-(2-phenylethyl)pyrrolidin-1-ium-2-yl]methyl 2-hydroxy-2,2-diphenylacetate, CHRM3 antagonist targeting CHRM3 |
| BC-09-JG96_0.01uM | Dose=0.01uM, Cgs 23885, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| BC-09-JG96_0.1uM | Dose=0.1uM, Cgs 23885, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| BC-09-JG96_10uM | Dose=10uM, Cgs 23885, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| BC-09-JG96_1uM | Dose=1uM, Cgs 23885, Lipoxygenase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting ALOX5 |
| BC-09-XN48_0.01uM | Dose=0.01uM, 2-[[(1S,2R)-2-[4-[(4-chlorophenyl)methoxy]phenyl]cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)ethanone, KDM1A/B targeting KDM1A |
| BC-09-XN48_0.1uM | Dose=0.1uM, 2-[[(1S,2R)-2-[4-[(4-chlorophenyl)methoxy]phenyl]cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)ethanone, KDM1A/B targeting KDM1A |
| BC-09-XN48_10uM | Dose=10uM, 2-[[(1S,2R)-2-[4-[(4-chlorophenyl)methoxy]phenyl]cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)ethanone, KDM1A/B targeting KDM1A |
| BC-09-XN48_1uM | Dose=1uM, 2-[[(1S,2R)-2-[4-[(4-chlorophenyl)methoxy]phenyl]cyclopropyl]amino]-1-(4-methylpiperazin-1-yl)ethanone, KDM1A/B targeting KDM1A |
| BC-09-XQ45_0.01uM | Dose=0.01uM, (R)-6-(4-((4-Ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting EGFR, ERBB2 |
| BC-09-XQ45_10uM | Dose=10uM, (R)-6-(4-((4-Ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting EGFR, ERBB2 |
| BC-09-XQ45_1uM | Dose=1uM, (R)-6-(4-((4-Ethylpiperazin-1-yl)methyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;erbB1) Inhibitors;EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting EGFR, ERBB2 |
| BC-10-OR76_0.01uM | Dose=0.01uM, Methyl 3-(2-amino-5-nitro-3-phenylmethoxyphenyl)prop-2-ynoate |
| BC-10-OR76_0.1uM | Dose=0.1uM, Methyl 3-(2-amino-5-nitro-3-phenylmethoxyphenyl)prop-2-ynoate |
| BC-10-OR76_10uM | Dose=10uM, Methyl 3-(2-amino-5-nitro-3-phenylmethoxyphenyl)prop-2-ynoate |
| BC-10-OR76_1uM | Dose=1uM, Methyl 3-(2-amino-5-nitro-3-phenylmethoxyphenyl)prop-2-ynoate |
| BC-10-SB73_0.01uM | Dose=0.01uM, 3-((4-(1-Isopropyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methylbenzamide, NFkappaB-inducing kinase (NIK;MAP3K14) Inhibitors targeting MAP3K14 |
| BC-10-SB73_0.1uM | Dose=0.1uM, 3-((4-(1-Isopropyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methylbenzamide, NFkappaB-inducing kinase (NIK;MAP3K14) Inhibitors targeting MAP3K14 |
| BC-10-SB73_10uM | Dose=10uM, 3-((4-(1-Isopropyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methylbenzamide, NFkappaB-inducing kinase (NIK;MAP3K14) Inhibitors targeting MAP3K14 |
| BC-10-SB73_1uM | Dose=1uM, 3-((4-(1-Isopropyl-1H-pyrrolo[2,3-c]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methylbenzamide, NFkappaB-inducing kinase (NIK;MAP3K14) Inhibitors targeting MAP3K14 |
| BC-11-LL59_0.01uM | Dose=0.01uM, Riluzole, Glutamate Release Inhibitors;K(V)4.3 Channel Blockers;Cystine Glutamate Transporter Inducer;Sodium Channel Blockers targeting SCN5A, SLC1A1, SLC1A3, SLC7A11, KCND3 |
| BC-11-LL59_0.1uM | Dose=0.1uM, Riluzole, Glutamate Release Inhibitors;K(V)4.3 Channel Blockers;Cystine Glutamate Transporter Inducer;Sodium Channel Blockers targeting SCN5A, SLC1A1, SLC1A3, SLC7A11, KCND3 |
| BC-11-LL59_10uM | Dose=10uM, Riluzole, Glutamate Release Inhibitors;K(V)4.3 Channel Blockers;Cystine Glutamate Transporter Inducer;Sodium Channel Blockers targeting SCN5A, SLC1A1, SLC1A3, SLC7A11, KCND3 |
| BC-11-LL59_1uM | Dose=1uM, Riluzole, Glutamate Release Inhibitors;K(V)4.3 Channel Blockers;Cystine Glutamate Transporter Inducer;Sodium Channel Blockers targeting SCN5A, SLC1A1, SLC1A3, SLC7A11, KCND3 |
| BC-12-VG35_0.01uM | Dose=0.01uM, N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide, reversible BTK inhibitor targeting BTK |
| BC-12-VG35_0.1uM | Dose=0.1uM, N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide, reversible BTK inhibitor targeting BTK |
| BC-12-VG35_10uM | Dose=10uM, N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide, reversible BTK inhibitor targeting BTK |
| BC-12-VG35_1uM | Dose=1uM, N-{3-[6-(3,6-Dihydro-2H-pyran-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-5-fluoro-2-methyl-phenyl}-2-fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzamide, reversible BTK inhibitor targeting BTK |
| BC-13-GC37_0.01uM | Dose=0.01uM, N-{[(3s,4s)-4-Benzylpyrrolidin-3-Yl]methyl}-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, Renin Inhibitors targeting REN |
| BC-13-GC37_0.1uM | Dose=0.1uM, N-{[(3s,4s)-4-Benzylpyrrolidin-3-Yl]methyl}-4-Methoxy-3-(3-Methoxypropoxy)-N-(Propan-2-Yl)benzamide, Renin Inhibitors targeting REN |
| BC-13-OQ01_0.01uM | Dose=0.01uM, Ispinesib, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| BC-13-OQ01_0.1uM | Dose=0.1uM, Ispinesib, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| BC-13-OQ01_10uM | Dose=10uM, Ispinesib, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| BC-13-OQ01_1uM | Dose=1uM, Ispinesib, Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitors;Antimitotic Drugs targeting KIF11 |
| BC-14-CG34_0.01uM | Dose=0.01uM, 2-[[5-chloro-2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyanilino]pyrimidin-4-yl]amino]-N-cyclobutylbenzenesulfonamide |
| BC-14-CG34_0.1uM | Dose=0.1uM, 2-[[5-chloro-2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyanilino]pyrimidin-4-yl]amino]-N-cyclobutylbenzenesulfonamide |
| BC-14-CG34_10uM | Dose=10uM, 2-[[5-chloro-2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyanilino]pyrimidin-4-yl]amino]-N-cyclobutylbenzenesulfonamide |
| BC-14-CG34_1uM | Dose=1uM, 2-[[5-chloro-2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyanilino]pyrimidin-4-yl]amino]-N-cyclobutylbenzenesulfonamide |
| BC-15-BY15_0.01uM | Dose=0.01uM |
| BC-15-BY15_0.1uM | Dose=0.1uM |
| BC-15-BY15_10uM | Dose=10uM |
| BC-15-BY15_1uM | Dose=1uM |
| BC-15-EL49_0.01uM | Dose=0.01uM, 3-(4-Morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol, Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| BC-15-EL49_0.1uM | Dose=0.1uM, 3-(4-Morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol, Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| BC-15-EL49_10uM | Dose=10uM, 3-(4-Morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol, Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| BC-15-EL49_1uM | Dose=1uM, 3-(4-Morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol, Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| BC-15-MR23_0.01uM | Dose=0.01uM, Masitinib, Angiogenesis Inhibitors;FGFR3 Inhibitors;Inhibitors of Signal Transduction Pathways;KIT (C-KIT) Inhibitors targeting FGFR3, KIT |
| BC-15-MR23_0.1uM | Dose=0.1uM, Masitinib, Angiogenesis Inhibitors;FGFR3 Inhibitors;Inhibitors of Signal Transduction Pathways;KIT (C-KIT) Inhibitors targeting FGFR3, KIT |
| BC-15-MR23_10uM | Dose=10uM, Masitinib, Angiogenesis Inhibitors;FGFR3 Inhibitors;Inhibitors of Signal Transduction Pathways;KIT (C-KIT) Inhibitors targeting FGFR3, KIT |
| BC-15-MR23_1uM | Dose=1uM, Masitinib, Angiogenesis Inhibitors;FGFR3 Inhibitors;Inhibitors of Signal Transduction Pathways;KIT (C-KIT) Inhibitors targeting FGFR3, KIT |
| BC-19-GQ25_0.1uM | Dose=0.1uM, Aripiprazole, Dopamine D2 Receptor Partial Agonists;ADRA1B gene inhibitor;HTR2A gene inhibitor;5-HT1A Receptor Partial Agonists targeting ADRA1B, DRD2, HTR1A, HTR2A, SRC |
| BC-19-GQ25_10uM | Dose=10uM, Aripiprazole, Dopamine D2 Receptor Partial Agonists;ADRA1B gene inhibitor;HTR2A gene inhibitor;5-HT1A Receptor Partial Agonists targeting ADRA1B, DRD2, HTR1A, HTR2A, SRC |
| BC-19-GQ25_1uM | Dose=1uM, Aripiprazole, Dopamine D2 Receptor Partial Agonists;ADRA1B gene inhibitor;HTR2A gene inhibitor;5-HT1A Receptor Partial Agonists targeting ADRA1B, DRD2, HTR1A, HTR2A, SRC |
| BC-20-WA90_0.01uM | Dose=0.01uM, Smarca2-IN-7, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| BC-20-WA90_0.1uM | Dose=0.1uM, Smarca2-IN-7, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| BC-20-WA90_10uM | Dose=10uM, Smarca2-IN-7, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| BC-20-WA90_1uM | Dose=1uM, Smarca2-IN-7, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| BC-21-EB65_0.01uM | Dose=0.01uM, Uridine-5'-Diphosphate, P2Y6 purinoceptor antagonist targeting P2RY6 |
| BC-21-EB65_0.1uM | Dose=0.1uM, Uridine-5'-Diphosphate, P2Y6 purinoceptor antagonist targeting P2RY6 |
| BC-21-EB65_10uM | Dose=10uM, Uridine-5'-Diphosphate, P2Y6 purinoceptor antagonist targeting P2RY6 |
| BC-21-EB65_1uM | Dose=1uM, Uridine-5'-Diphosphate, P2Y6 purinoceptor antagonist targeting P2RY6 |
| BC-22-DS93_0.01uM | Dose=0.01uM, 4-(2-Cyano-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid, Retinoid RXRalpha Antagonists targeting RXRA |
| BC-22-DS93_0.1uM | Dose=0.1uM, 4-(2-Cyano-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid, Retinoid RXRalpha Antagonists targeting RXRA |
| BC-22-DS93_10uM | Dose=10uM, 4-(2-Cyano-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid, Retinoid RXRalpha Antagonists targeting RXRA |
| BC-22-DS93_1uM | Dose=1uM, 4-(2-Cyano-5-ethyl-7,7,10,10-tetramethyl-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)-2-fluorobenzoic acid, Retinoid RXRalpha Antagonists targeting RXRA |
| BC-22-LS63_0.01uM | Dose=0.01uM |
| BC-22-LS63_10uM | Dose=10uM |
| BC-22-LS63_1uM | Dose=1uM |
| BC-22-OI74_0.01uM | Dose=0.01uM, HhAntag, Hedgehog Signaling Inhibitors targeting SHH, SMO, IHH, DHH |
| BC-22-OI74_0.1uM | Dose=0.1uM, HhAntag, Hedgehog Signaling Inhibitors targeting SHH, SMO, IHH, DHH |
| BC-22-OI74_10uM | Dose=10uM, HhAntag, Hedgehog Signaling Inhibitors targeting SHH, SMO, IHH, DHH |
| BC-22-OI74_1uM | Dose=1uM, HhAntag, Hedgehog Signaling Inhibitors targeting SHH, SMO, IHH, DHH |
| BC-22-RZ85_0.01uM | Dose=0.01uM, n,n-Bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1h-imidazole-5-methanamine, C5a Antagonists targeting C5AR1 |
| BC-22-RZ85_10uM | Dose=10uM, n,n-Bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1h-imidazole-5-methanamine, C5a Antagonists targeting C5AR1 |
| BC-25-VR48_0.01uM | Dose=0.01uM, N-[(2R,6R)-2,6-dimethylpiperidin-4-yl]-4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-amine, IKBKB inhibitor targeting IKBKB |
| BC-25-VR48_0.1uM | Dose=0.1uM, N-[(2R,6R)-2,6-dimethylpiperidin-4-yl]-4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-amine, IKBKB inhibitor targeting IKBKB |
| BC-25-VR48_10uM | Dose=10uM, N-[(2R,6R)-2,6-dimethylpiperidin-4-yl]-4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-amine, IKBKB inhibitor targeting IKBKB |
| BC-25-VR48_1uM | Dose=1uM, N-[(2R,6R)-2,6-dimethylpiperidin-4-yl]-4-(7-fluoro-1H-indol-3-yl)pyrimidin-2-amine, IKBKB inhibitor targeting IKBKB |
| BC-26-LE04_0.01uM | Dose=0.01uM, Venlafaxine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4 |
| BC-26-LE04_0.1uM | Dose=0.1uM, Venlafaxine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4 |
| BC-26-LE04_10uM | Dose=10uM, Venlafaxine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4 |
| BC-26-LE04_1uM | Dose=1uM, Venlafaxine, 5-HT Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2, SLC6A4 |
| BC-28-NG89_0.01uM | Dose=0.01uM, Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists |
| BC-28-NG89_0.1uM | Dose=0.1uM, Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists |
| BC-28-NG89_10uM | Dose=10uM, Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists |
| BC-28-NG89_1uM | Dose=1uM, Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists |
| BC-30-IU38_0.1uM | Dose=0.1uM, N-(6-chloro-9h-pyrido[3,4-b]indol-8-yl)-3-pyridinecarboxamide, Apoptosis Inducers;IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKG |
| BC-30-IU38_10uM | Dose=10uM, N-(6-chloro-9h-pyrido[3,4-b]indol-8-yl)-3-pyridinecarboxamide, Apoptosis Inducers;IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKG |
| BC-30-IU38_1uM | Dose=1uM, N-(6-chloro-9h-pyrido[3,4-b]indol-8-yl)-3-pyridinecarboxamide, Apoptosis Inducers;IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKG |
| BC-31-JL64_0.1uM | Dose=0.1uM, Deferiprone |
| BC-31-JL64_10uM | Dose=10uM, Deferiprone |
| BC-31-JL64_1uM | Dose=1uM, Deferiprone |
| BC-32-DI69_0.01uM | Dose=0.01uM, 7-(4-Chlorophenyl)-6-isopropyl-2,3-dihydro-1H-1-aza-4,5-dioxa-phenanthren-8-one targeting TRPV1 |
| BC-32-DI69_0.1uM | Dose=0.1uM, 7-(4-Chlorophenyl)-6-isopropyl-2,3-dihydro-1H-1-aza-4,5-dioxa-phenanthren-8-one targeting TRPV1 |
| BC-32-DI69_10uM | Dose=10uM, 7-(4-Chlorophenyl)-6-isopropyl-2,3-dihydro-1H-1-aza-4,5-dioxa-phenanthren-8-one targeting TRPV1 |
| BC-32-DI69_1uM | Dose=1uM, 7-(4-Chlorophenyl)-6-isopropyl-2,3-dihydro-1H-1-aza-4,5-dioxa-phenanthren-8-one targeting TRPV1 |
| BC-33-BM51_0.01uM | Dose=0.01uM, 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-N-[(2S)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7 |
| BC-33-BM51_0.1uM | Dose=0.1uM, 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-N-[(2S)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7 |
| BC-33-BM51_10uM | Dose=10uM, 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-N-[(2S)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7 |
| BC-33-BM51_1uM | Dose=1uM, 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-N-[(2S)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7 |
| BC-34-IH52_0.01uM | Dose=0.01uM, Bromodomain inhibitor-9, bET inhibitor BD1 selective targeting BRD4 |
| BC-34-IH52_0.1uM | Dose=0.1uM, Bromodomain inhibitor-9, bET inhibitor BD1 selective targeting BRD4 |
| BC-34-IH52_10uM | Dose=10uM, Bromodomain inhibitor-9, bET inhibitor BD1 selective targeting BRD4 |
| BC-34-IH52_1uM | Dose=1uM, Bromodomain inhibitor-9, bET inhibitor BD1 selective targeting BRD4 |
| BC-36-PL31_0.01uM | Dose=0.01uM, Idelalisib, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| BC-36-PL31_0.1uM | Dose=0.1uM, Idelalisib, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| BC-36-PL31_10uM | Dose=10uM, Idelalisib, lipid kinase inhibitor;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| BC-37-HI51_0.01uM | Dose=0.01uM, Adenosine antagonist-1, Adenosine A2B Antagonists;Adenosine A3 Antagonists targeting ADORA2B, ADORA3 |
| BC-37-HI51_10uM | Dose=10uM, Adenosine antagonist-1, Adenosine A2B Antagonists;Adenosine A3 Antagonists targeting ADORA2B, ADORA3 |
| BC-37-HI51_1uM | Dose=1uM, Adenosine antagonist-1, Adenosine A2B Antagonists;Adenosine A3 Antagonists targeting ADORA2B, ADORA3 |
| BC-38-UW37_0.01uM | Dose=0.01uM, Tyrosine, Tyrosine hydroxylase inhibitor targeting TH |
| BC-38-UW37_0.1uM | Dose=0.1uM, Tyrosine, Tyrosine hydroxylase inhibitor targeting TH |
| BC-38-UW37_10uM | Dose=10uM, Tyrosine, Tyrosine hydroxylase inhibitor targeting TH |
| BC-38-UW37_1uM | Dose=1uM, Tyrosine, Tyrosine hydroxylase inhibitor targeting TH |
| BC-39-JG96_0.01uM | Dose=0.01uM, Gemfibrozil, PPARalpha Agonists targeting PPARA |
| BC-39-JG96_0.1uM | Dose=0.1uM, Gemfibrozil, PPARalpha Agonists targeting PPARA |
| BC-39-JG96_10uM | Dose=10uM, Gemfibrozil, PPARalpha Agonists targeting PPARA |
| BC-39-JG96_1uM | Dose=1uM, Gemfibrozil, PPARalpha Agonists targeting PPARA |
| BC-40-TU13_0.01uM | Dose=0.01uM, N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine, alpha2C-Adrenoceptor Antagonists;ADRA2C antagonist targeting ADRA2C |
| BC-40-TU13_0.1uM | Dose=0.1uM, N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine, alpha2C-Adrenoceptor Antagonists;ADRA2C antagonist targeting ADRA2C |
| BC-40-TU13_10uM | Dose=10uM, N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine, alpha2C-Adrenoceptor Antagonists;ADRA2C antagonist targeting ADRA2C |
| BC-40-TU13_1uM | Dose=1uM, N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine, alpha2C-Adrenoceptor Antagonists;ADRA2C antagonist targeting ADRA2C |
| BC-43-HJ69_0.01uM | Dose=0.01uM, Phenelzine, MAO Inhibitors targeting MAOA |
| BC-43-HJ69_0.1uM | Dose=0.1uM, Phenelzine, MAO Inhibitors targeting MAOA |
| BC-43-HJ69_10uM | Dose=10uM, Phenelzine, MAO Inhibitors targeting MAOA |
| BC-43-HJ69_1uM | Dose=1uM, Phenelzine, MAO Inhibitors targeting MAOA |
| BC-43-JW95_0.01uM | Dose=0.01uM, Phenylalanine |
| BC-43-JW95_0.1uM | Dose=0.1uM, Phenylalanine |
| BC-43-JW95_10uM | Dose=10uM, Phenylalanine |
| BC-43-JW95_1uM | Dose=1uM, Phenylalanine |
| BC-43-PD20_0.01uM | Dose=0.01uM, GPR52 agonist-1, GPR52 agonist targeting GPR52 |
| BC-43-PD20_0.1uM | Dose=0.1uM, GPR52 agonist-1, GPR52 agonist targeting GPR52 |
| BC-43-PD20_10uM | Dose=10uM, GPR52 agonist-1, GPR52 agonist targeting GPR52 |
| BC-43-PD20_1uM | Dose=1uM, GPR52 agonist-1, GPR52 agonist targeting GPR52 |
| BC-45-VY95_0.01uM | Dose=0.01uM, Hydroflumethiazide, Carbonic anhydrase inhibitor targeting CA5B |
| BC-45-VY95_0.1uM | Dose=0.1uM, Hydroflumethiazide, Carbonic anhydrase inhibitor targeting CA5B |
| BC-45-VY95_10uM | Dose=10uM, Hydroflumethiazide, Carbonic anhydrase inhibitor targeting CA5B |
| BC-45-VY95_1uM | Dose=1uM, Hydroflumethiazide, Carbonic anhydrase inhibitor targeting CA5B |
| BC-48-WT15_0.01uM | Dose=0.01uM, Thymidine Phosphorylase Inhibitors targeting TYMP |
| BC-48-WT15_0.1uM | Dose=0.1uM, Thymidine Phosphorylase Inhibitors targeting TYMP |
| BC-48-WT15_10uM | Dose=10uM, Thymidine Phosphorylase Inhibitors targeting TYMP |
| BC-48-WT15_1uM | Dose=1uM, Thymidine Phosphorylase Inhibitors targeting TYMP |
| BC-50-TK39_0.01uM | Dose=0.01uM, Vpc23019, Lysophospholipid edg3 (S1P3) Receptor Antagonists;Lysophospholipid edg8 (S1P5) Receptor Partial Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Antagonists targeting S1PR1, S1PR3, S1PR4, S1PR5 |
| BC-50-TK39_0.1uM | Dose=0.1uM, Vpc23019, Lysophospholipid edg3 (S1P3) Receptor Antagonists;Lysophospholipid edg8 (S1P5) Receptor Partial Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Antagonists targeting S1PR1, S1PR3, S1PR4, S1PR5 |
| BC-50-TK39_10uM | Dose=10uM, Vpc23019, Lysophospholipid edg3 (S1P3) Receptor Antagonists;Lysophospholipid edg8 (S1P5) Receptor Partial Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Antagonists targeting S1PR1, S1PR3, S1PR4, S1PR5 |
| BC-51-ME52_0.01uM | Dose=0.01uM, 3,3'-Diindolylmethane, Indoleamine 2,3-dioxygenase Inhibitors;Androgen Receptor Antagonists;Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR, AR, IDO1 |
| BC-51-ME52_0.1uM | Dose=0.1uM, 3,3'-Diindolylmethane, Indoleamine 2,3-dioxygenase Inhibitors;Androgen Receptor Antagonists;Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR, AR, IDO1 |
| BC-51-ME52_10uM | Dose=10uM, 3,3'-Diindolylmethane, Indoleamine 2,3-dioxygenase Inhibitors;Androgen Receptor Antagonists;Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR, AR, IDO1 |
| BC-51-ME52_1uM | Dose=1uM, 3,3'-Diindolylmethane, Indoleamine 2,3-dioxygenase Inhibitors;Androgen Receptor Antagonists;Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR, AR, IDO1 |
| BC-52-NW28_0.01uM | Dose=0.01uM, Icmt-IN-1, Isoprenylcysteine Carboxyl Methyltransferase Inhibitors targeting ICMT |
| BC-52-NW28_0.1uM | Dose=0.1uM, Icmt-IN-1, Isoprenylcysteine Carboxyl Methyltransferase Inhibitors targeting ICMT |
| BC-52-NW28_1uM | Dose=1uM, Icmt-IN-1, Isoprenylcysteine Carboxyl Methyltransferase Inhibitors targeting ICMT |
| BC-52-WF67_0.01uM | Dose=0.01uM, Proglumide, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR |
| BC-52-WF67_0.1uM | Dose=0.1uM, Proglumide, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR |
| BC-52-WF67_10uM | Dose=10uM, Proglumide, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR |
| BC-52-WF67_1uM | Dose=1uM, Proglumide, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR |
| BC-53-HT63_0.01uM | Dose=0.01uM, Olomoucine, CDK1 Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK1, CDK2, CDK5 |
| BC-53-HT63_0.1uM | Dose=0.1uM, Olomoucine, CDK1 Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK1, CDK2, CDK5 |
| BC-53-HT63_10uM | Dose=10uM, Olomoucine, CDK1 Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK1, CDK2, CDK5 |
| BC-53-HT63_1uM | Dose=1uM, Olomoucine, CDK1 Inhibitors;Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK1, CDK2, CDK5 |
| BC-54-ON71_0.01uM | Dose=0.01uM, CID 9958520, Reported to be a general HDAC inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC5 |
| BC-54-ON71_0.1uM | Dose=0.1uM, CID 9958520, Reported to be a general HDAC inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC5 |
| BC-54-ON71_10uM | Dose=10uM, CID 9958520, Reported to be a general HDAC inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC5 |
| BC-54-ON71_1uM | Dose=1uM, CID 9958520, Reported to be a general HDAC inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC5 |
| BC-55-CK01_0.1uM | Dose=0.1uM, 3-(Benzofuran-2-yl)-1-azabicyclo[2.2.2]oct-2-ene, Muscarinic M1 Agonists targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| BC-55-CK01_10uM | Dose=10uM, 3-(Benzofuran-2-yl)-1-azabicyclo[2.2.2]oct-2-ene, Muscarinic M1 Agonists targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| BC-56-BB82_0.01uM | Dose=0.01uM, N-(5-(1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyramide, LIM kinase-1 inhibitor;LIM kinase-2 inhibitor targeting LIMK1, LIMK2 |
| BC-56-BB82_10uM | Dose=10uM, N-(5-(1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyramide, LIM kinase-1 inhibitor;LIM kinase-2 inhibitor targeting LIMK1, LIMK2 |
| BC-56-BB82_1uM | Dose=1uM, N-(5-(1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyramide, LIM kinase-1 inhibitor;LIM kinase-2 inhibitor targeting LIMK1, LIMK2 |
| BC-56-CP81_0.01uM | Dose=0.01uM, Adefovir Dipivoxil |
| BC-56-CP81_0.1uM | Dose=0.1uM, Adefovir Dipivoxil |
| BC-56-CP81_10uM | Dose=10uM, Adefovir Dipivoxil |
| BC-56-CP81_1uM | Dose=1uM, Adefovir Dipivoxil |
| BC-56-WO88_0.01uM | Dose=0.01uM, (E)-3-(2-(6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone O-methyl oxime, mgluR5 Antagonists targeting GRM5 |
| BC-56-WO88_0.1uM | Dose=0.1uM, (E)-3-(2-(6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone O-methyl oxime, mgluR5 Antagonists targeting GRM5 |
| BC-56-WO88_10uM | Dose=10uM, (E)-3-(2-(6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone O-methyl oxime, mgluR5 Antagonists targeting GRM5 |
| BC-56-WO88_1uM | Dose=1uM, (E)-3-(2-(6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone O-methyl oxime, mgluR5 Antagonists targeting GRM5 |
| BC-57-KZ72_0.01uM | Dose=0.01uM, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1 |
| BC-57-KZ72_0.1uM | Dose=0.1uM, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1 |
| BC-57-KZ72_10uM | Dose=10uM, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1 |
| BC-57-KZ72_1uM | Dose=1uM, AMP-Activated Protein Kinase (AMPK) Activators targeting PRKAA1, PRKAA2, PRKAB1 |
| BC-60-TS99_0.01uM | Dose=0.01uM, 1-[4-[4-[1-methyl-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-4-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid, Lysophospholipid edg2 (LPA1) Receptor Antagonists targeting LPAR1 |
| BC-60-TS99_10uM | Dose=10uM, 1-[4-[4-[1-methyl-5-[[(1R)-1-phenylethoxy]carbonylamino]pyrazol-4-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid, Lysophospholipid edg2 (LPA1) Receptor Antagonists targeting LPAR1 |
| BC-61-BE07_0.01uM | Dose=0.01uM, Dithiipin-1,1,4,4-tetroxide analogue 7, Galanin GAL1 Antagonists targeting GALR1 |
| BC-61-BE07_0.1uM | Dose=0.1uM, Dithiipin-1,1,4,4-tetroxide analogue 7, Galanin GAL1 Antagonists targeting GALR1 |
| BC-61-BE07_10uM | Dose=10uM, Dithiipin-1,1,4,4-tetroxide analogue 7, Galanin GAL1 Antagonists targeting GALR1 |
| BC-61-BE07_1uM | Dose=1uM, Dithiipin-1,1,4,4-tetroxide analogue 7, Galanin GAL1 Antagonists targeting GALR1 |
| BC-61-ZY95_0.01uM | Dose=0.01uM |
| BC-61-ZY95_0.1uM | Dose=0.1uM |
| BC-61-ZY95_10uM | Dose=10uM |
| BC-61-ZY95_1uM | Dose=1uM |
| BC-62-RZ55_0.01uM | Dose=0.01uM, Flavopereirine, 5-HT Reuptake Inhibitors;Acetylcholinesterase Inhibitors;DNA-Intercalating Drugs targeting ACHE, SLC6A4 |
| BC-62-RZ55_0.1uM | Dose=0.1uM, Flavopereirine, 5-HT Reuptake Inhibitors;Acetylcholinesterase Inhibitors;DNA-Intercalating Drugs targeting ACHE, SLC6A4 |
| BC-62-RZ55_10uM | Dose=10uM, Flavopereirine, 5-HT Reuptake Inhibitors;Acetylcholinesterase Inhibitors;DNA-Intercalating Drugs targeting ACHE, SLC6A4 |
| BC-62-RZ55_1uM | Dose=1uM, Flavopereirine, 5-HT Reuptake Inhibitors;Acetylcholinesterase Inhibitors;DNA-Intercalating Drugs targeting ACHE, SLC6A4 |
| BC-63-DM76_0.01uM | Dose=0.01uM, Cgs 22745 |
| BC-63-DM76_0.1uM | Dose=0.1uM, Cgs 22745 |
| BC-63-DM76_10uM | Dose=10uM, Cgs 22745 |
| BC-63-DM76_1uM | Dose=1uM, Cgs 22745 |
| BC-65-QR83_0.01uM | Dose=0.01uM, Pregnanolone, GABA(A) Receptor Modulators targeting GABRA1, GABRB2 |
| BC-65-QR83_0.1uM | Dose=0.1uM, Pregnanolone, GABA(A) Receptor Modulators targeting GABRA1, GABRB2 |
| BC-65-QR83_1uM | Dose=1uM, Pregnanolone, GABA(A) Receptor Modulators targeting GABRA1, GABRB2 |
| BC-69-CQ95_0.1uM | Dose=0.1uM |
| BC-69-CQ95_1uM | Dose=1uM |
| BC-70-BH47_0.01uM | Dose=0.01uM, Treprostinil, Prostacyclin Analogs targeting PTGIR |
| BC-70-BH47_0.1uM | Dose=0.1uM, Treprostinil, Prostacyclin Analogs targeting PTGIR |
| BC-70-BH47_10uM | Dose=10uM, Treprostinil, Prostacyclin Analogs targeting PTGIR |
| BC-72-DZ30_0.01uM | Dose=0.01uM, Kinetin, PINK1 agonist;IKBKAP mRNA splicing corrector targeting ELP1, PINK1 |
| BC-72-DZ30_0.1uM | Dose=0.1uM, Kinetin, PINK1 agonist;IKBKAP mRNA splicing corrector targeting ELP1, PINK1 |
| BC-72-DZ30_10uM | Dose=10uM, Kinetin, PINK1 agonist;IKBKAP mRNA splicing corrector targeting ELP1, PINK1 |
| BC-72-DZ30_1uM | Dose=1uM, Kinetin, PINK1 agonist;IKBKAP mRNA splicing corrector targeting ELP1, PINK1 |
| BC-74-QN56_0.01uM | Dose=0.01uM, (1S,2R)-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-2-phenylcyclopropan-1-amine, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A |
| BC-74-QN56_0.1uM | Dose=0.1uM, (1S,2R)-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-2-phenylcyclopropan-1-amine, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A |
| BC-74-QN56_10uM | Dose=10uM, (1S,2R)-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-2-phenylcyclopropan-1-amine, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A |
| BC-74-QN56_1uM | Dose=1uM, (1S,2R)-N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-2-phenylcyclopropan-1-amine, Lysine-Dependent Demethylase 1A (LSD1) Inhibitors targeting KDM1A |
| BC-75-CK91_0.01uM | Dose=0.01uM, 2-Methoxy-6-[[2-[4-methyl-3-(methylamino)anilino]pyrimidin-4-yl]amino]benzenesulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70, SYK |
| BC-75-CK91_0.1uM | Dose=0.1uM, 2-Methoxy-6-[[2-[4-methyl-3-(methylamino)anilino]pyrimidin-4-yl]amino]benzenesulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70, SYK |
| BC-75-CK91_10uM | Dose=10uM, 2-Methoxy-6-[[2-[4-methyl-3-(methylamino)anilino]pyrimidin-4-yl]amino]benzenesulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70, SYK |
| BC-75-CK91_1uM | Dose=1uM, 2-Methoxy-6-[[2-[4-methyl-3-(methylamino)anilino]pyrimidin-4-yl]amino]benzenesulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70, SYK |
| BC-75-FA82_0.01uM | Dose=0.01uM, (3S,14R,16S)-16-[(1R)-1-hydroxy-2-{[3-(1-methylethyl)benzyl]amino}ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1 |
| BC-75-FA82_0.1uM | Dose=0.1uM, (3S,14R,16S)-16-[(1R)-1-hydroxy-2-{[3-(1-methylethyl)benzyl]amino}ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1 |
| BC-75-FA82_10uM | Dose=10uM, (3S,14R,16S)-16-[(1R)-1-hydroxy-2-{[3-(1-methylethyl)benzyl]amino}ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1 |
| BC-75-FA82_1uM | Dose=1uM, (3S,14R,16S)-16-[(1R)-1-hydroxy-2-{[3-(1-methylethyl)benzyl]amino}ethyl]-3,4,14-trimethyl-1,4-diazacyclohexadecane-2,5-dione, beta-Secretase 1 (BACE1) Inhibitors targeting BACE1 |
| BC-76-HY47_0.01uM | Dose=0.01uM, Nvp-aew541, IGF1R inhibitor;MTH1 inhibitor targeting IGF1R, NUDT1 |
| BC-76-HY47_0.1uM | Dose=0.1uM, Nvp-aew541, IGF1R inhibitor;MTH1 inhibitor targeting IGF1R, NUDT1 |
| BC-76-HY47_10uM | Dose=10uM, Nvp-aew541, IGF1R inhibitor;MTH1 inhibitor targeting IGF1R, NUDT1 |
| BC-76-HY47_1uM | Dose=1uM, Nvp-aew541, IGF1R inhibitor;MTH1 inhibitor targeting IGF1R, NUDT1 |
| BC-78-NC89_0.01uM | Dose=0.01uM, [(1R,3R)-1-methyl-1-(3-phenylpropyl)piperidin-1-ium-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| BC-78-NC89_0.1uM | Dose=0.1uM, [(1R,3R)-1-methyl-1-(3-phenylpropyl)piperidin-1-ium-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| BC-78-NC89_1uM | Dose=1uM, [(1R,3R)-1-methyl-1-(3-phenylpropyl)piperidin-1-ium-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| BC-80-FK74_0.01uM | Dose=0.01uM, Cyclopropylmethyl-[7-(5,7-dimethyl-benzo[1,2,5]thiadiazol-4-yl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propyl-amine, CRF1 Antagonists targeting CRHR1 |
| BC-80-FK74_0.1uM | Dose=0.1uM, Cyclopropylmethyl-[7-(5,7-dimethyl-benzo[1,2,5]thiadiazol-4-yl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propyl-amine, CRF1 Antagonists targeting CRHR1 |
| BC-80-FK74_10uM | Dose=10uM, Cyclopropylmethyl-[7-(5,7-dimethyl-benzo[1,2,5]thiadiazol-4-yl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propyl-amine, CRF1 Antagonists targeting CRHR1 |
| BC-80-FK74_1uM | Dose=1uM, Cyclopropylmethyl-[7-(5,7-dimethyl-benzo[1,2,5]thiadiazol-4-yl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-propyl-amine, CRF1 Antagonists targeting CRHR1 |
| BC-81-LO06_0.01uM | Dose=0.01uM, 4-(1H-1,2,3-Triazol-1-YL)benzaldehyde |
| BC-81-LO06_0.1uM | Dose=0.1uM, 4-(1H-1,2,3-Triazol-1-YL)benzaldehyde |
| BC-81-LO06_10uM | Dose=10uM, 4-(1H-1,2,3-Triazol-1-YL)benzaldehyde |
| BC-81-LO06_1uM | Dose=1uM, 4-(1H-1,2,3-Triazol-1-YL)benzaldehyde |
| BC-82-PP66_0.01uM | Dose=0.01uM, (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, KDM1A inhibitor;KDM1A (LSD1) inhibitor targeting KDM1A |
| BC-82-PP66_0.1uM | Dose=0.1uM, (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, KDM1A inhibitor;KDM1A (LSD1) inhibitor targeting KDM1A |
| BC-82-PP66_10uM | Dose=10uM, (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, KDM1A inhibitor;KDM1A (LSD1) inhibitor targeting KDM1A |
| BC-82-PP66_1uM | Dose=1uM, (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide, KDM1A inhibitor;KDM1A (LSD1) inhibitor targeting KDM1A |
| BC-84-BQ58_0.01uM | Dose=0.01uM, N(6)-cyclohexyl-2-O-methyladenosine, Adenosine A1 Agonists;ADORA1 agonist targeting ADORA1 |
| BC-84-BQ58_0.1uM | Dose=0.1uM, N(6)-cyclohexyl-2-O-methyladenosine, Adenosine A1 Agonists;ADORA1 agonist targeting ADORA1 |
| BC-84-BQ58_10uM | Dose=10uM, N(6)-cyclohexyl-2-O-methyladenosine, Adenosine A1 Agonists;ADORA1 agonist targeting ADORA1 |
| BC-84-BQ58_1uM | Dose=1uM, N(6)-cyclohexyl-2-O-methyladenosine, Adenosine A1 Agonists;ADORA1 agonist targeting ADORA1 |
| BC-85-QR33_0.01uM | Dose=0.01uM, Encorafenib, Mutant Raf kinase B Inhibitors targeting BRAF |
| BC-85-QR33_0.1uM | Dose=0.1uM, Encorafenib, Mutant Raf kinase B Inhibitors targeting BRAF |
| BC-85-QR33_10uM | Dose=10uM, Encorafenib, Mutant Raf kinase B Inhibitors targeting BRAF |
| BC-85-QR33_1uM | Dose=1uM, Encorafenib, Mutant Raf kinase B Inhibitors targeting BRAF |
| BC-86-PL11_0.01uM | Dose=0.01uM, 2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide, Peptide Deformylase (PDF) Inhibitors;Mitochondrial Translation Inhibitors;Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP, PDF |
| BC-86-PL11_0.1uM | Dose=0.1uM, 2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide, Peptide Deformylase (PDF) Inhibitors;Mitochondrial Translation Inhibitors;Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP, PDF |
| BC-86-PL11_10uM | Dose=10uM, 2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide, Peptide Deformylase (PDF) Inhibitors;Mitochondrial Translation Inhibitors;Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP, PDF |
| BC-86-PL11_1uM | Dose=1uM, 2-[(Formyl-Hydroxy-Amino)-Methyl]-Heptanoic Acid [1-(2-Hydroxymethyl-Pyrrolidine-1-Carbonyl)-2-Methyl-Propyl]-Amide, Peptide Deformylase (PDF) Inhibitors;Mitochondrial Translation Inhibitors;Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP, PDF |
| BC-87-PJ84_10uM | Dose=10uM, Urapidil, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| BC-87-PJ84_1uM | Dose=1uM, Urapidil, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| BC-87-ZP43_0.01uM | Dose=0.01uM, alpha-Cyano-4-hydroxycinnamic acid, Monocarboxylate Transporter 1 (MCT1) Inhibitors targeting SLC16A1 |
| BC-87-ZP43_0.1uM | Dose=0.1uM, alpha-Cyano-4-hydroxycinnamic acid, Monocarboxylate Transporter 1 (MCT1) Inhibitors targeting SLC16A1 |
| BC-87-ZP43_10uM | Dose=10uM, alpha-Cyano-4-hydroxycinnamic acid, Monocarboxylate Transporter 1 (MCT1) Inhibitors targeting SLC16A1 |
| BC-87-ZP43_1uM | Dose=1uM, alpha-Cyano-4-hydroxycinnamic acid, Monocarboxylate Transporter 1 (MCT1) Inhibitors targeting SLC16A1 |
| BC-88-KT45_0.01uM | Dose=0.01uM, Agk-2, SIRT2;SIRT inhibitor NAD dependent targeting SIRT2 |
| BC-88-KT45_0.1uM | Dose=0.1uM, Agk-2, SIRT2;SIRT inhibitor NAD dependent targeting SIRT2 |
| BC-88-KT45_10uM | Dose=10uM, Agk-2, SIRT2;SIRT inhibitor NAD dependent targeting SIRT2 |
| BC-88-KT45_1uM | Dose=1uM, Agk-2, SIRT2;SIRT inhibitor NAD dependent targeting SIRT2 |
| BC-91-YI62_0.01uM | Dose=0.01uM, 1-(1-(2-(4-Chlorophenyl)-2-oxoethyl)piperidin-4-yl)-5-(2H-tetrazol-5-yl)-1H-benzo[d]imidazol-2(3H)-one, Serine Palmitoyltransferase (SPT) Inhibitors targeting SPTLC2, SPTLC1, SPTLC3 |
| BC-91-YI62_0.1uM | Dose=0.1uM, 1-(1-(2-(4-Chlorophenyl)-2-oxoethyl)piperidin-4-yl)-5-(2H-tetrazol-5-yl)-1H-benzo[d]imidazol-2(3H)-one, Serine Palmitoyltransferase (SPT) Inhibitors targeting SPTLC2, SPTLC1, SPTLC3 |
| BC-91-YI62_10uM | Dose=10uM, 1-(1-(2-(4-Chlorophenyl)-2-oxoethyl)piperidin-4-yl)-5-(2H-tetrazol-5-yl)-1H-benzo[d]imidazol-2(3H)-one, Serine Palmitoyltransferase (SPT) Inhibitors targeting SPTLC2, SPTLC1, SPTLC3 |
| BC-91-YI62_1uM | Dose=1uM, 1-(1-(2-(4-Chlorophenyl)-2-oxoethyl)piperidin-4-yl)-5-(2H-tetrazol-5-yl)-1H-benzo[d]imidazol-2(3H)-one, Serine Palmitoyltransferase (SPT) Inhibitors targeting SPTLC2, SPTLC1, SPTLC3 |
| BC-94-GN01_0.01uM | Dose=0.01uM, Pyrimethamine, Dihydrofolate Reductase (DHFR) Inhibitors;Pharmacological Chaperones targeting DHFR, GSTP1 |
| BC-94-GN01_0.1uM | Dose=0.1uM, Pyrimethamine, Dihydrofolate Reductase (DHFR) Inhibitors;Pharmacological Chaperones targeting DHFR, GSTP1 |
| BC-94-GN01_10uM | Dose=10uM, Pyrimethamine, Dihydrofolate Reductase (DHFR) Inhibitors;Pharmacological Chaperones targeting DHFR, GSTP1 |
| BC-94-GN01_1uM | Dose=1uM, Pyrimethamine, Dihydrofolate Reductase (DHFR) Inhibitors;Pharmacological Chaperones targeting DHFR, GSTP1 |
| BC-94-PR16_10uM | Dose=10uM, 5-[({3-[(3,4-Dichlorobenzyl)sulfanyl]thiophen-2-Yl}carbonyl)sulfamoyl]-2-Methoxybenzoic Acid targeting PTPRG |
| BC-95-MO06_0.01uM | Dose=0.01uM, Indomethacin, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGER2, PTGS1, PTGS2, SC5D |
| BC-95-MO06_0.1uM | Dose=0.1uM, Indomethacin, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGER2, PTGS1, PTGS2, SC5D |
| BC-95-MO06_10uM | Dose=10uM, Indomethacin, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGER2, PTGS1, PTGS2, SC5D |
| BC-95-MO06_1uM | Dose=1uM, Indomethacin, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-3 Inhibitors;Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGER2, PTGS1, PTGS2, SC5D |
| BC-97-SZ42_0.01uM | Dose=0.01uM, (R)-N-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-4-methyl-2-phenyl-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine, Known Gamma secretase modulator targeting PSEN2 |
| BC-97-SZ42_10uM | Dose=10uM, (R)-N-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-4-methyl-2-phenyl-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine, Known Gamma secretase modulator targeting PSEN2 |
| BC-97-SZ42_1uM | Dose=1uM, (R)-N-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-4-methyl-2-phenyl-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine, Known Gamma secretase modulator targeting PSEN2 |
| BD-01-HE32_0.01uM | Dose=0.01uM |
| BD-01-HE32_1uM | Dose=1uM |
| BD-01-RI07_0.01uM | Dose=0.01uM, Src kinase inhibitor PP2, Src Kinase Inhibitors targeting FYN, HCK, SRC |
| BD-01-RI07_0.1uM | Dose=0.1uM, Src kinase inhibitor PP2, Src Kinase Inhibitors targeting FYN, HCK, SRC |
| BD-01-RI07_10uM | Dose=10uM, Src kinase inhibitor PP2, Src Kinase Inhibitors targeting FYN, HCK, SRC |
| BD-01-RI07_1uM | Dose=1uM, Src kinase inhibitor PP2, Src Kinase Inhibitors targeting FYN, HCK, SRC |
| BD-02-US28_0.01uM | Dose=0.01uM, Nvp-qav-680, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting PTGDR2 |
| BD-02-US28_0.1uM | Dose=0.1uM, Nvp-qav-680, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting PTGDR2 |
| BD-02-US28_10uM | Dose=10uM, Nvp-qav-680, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting PTGDR2 |
| BD-04-IN11_0.01uM | Dose=0.01uM, 3-Bromo-9-phenyl-5,7-dihydro-10-oxa-5,8-diaza-benzo[a]azulen-6-one, P2X4 Receptor Antagonists targeting P2RX4 |
| BD-04-IN11_10uM | Dose=10uM, 3-Bromo-9-phenyl-5,7-dihydro-10-oxa-5,8-diaza-benzo[a]azulen-6-one, P2X4 Receptor Antagonists targeting P2RX4 |
| BD-04-NG34_0.01uM | Dose=0.01uM, Azd-7762, DNA Repair Inhibitor;Checkpoint Kinase 1 (Chk1) Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK1, CHEK2 |
| BD-04-NG34_0.1uM | Dose=0.1uM, Azd-7762, DNA Repair Inhibitor;Checkpoint Kinase 1 (Chk1) Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK1, CHEK2 |
| BD-04-NG34_10uM | Dose=10uM, Azd-7762, DNA Repair Inhibitor;Checkpoint Kinase 1 (Chk1) Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK1, CHEK2 |
| BD-04-NG34_1uM | Dose=1uM, Azd-7762, DNA Repair Inhibitor;Checkpoint Kinase 1 (Chk1) Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors targeting CHEK1, CHEK2 |
| BD-06-VI74_0.1uM | Dose=0.1uM, Bezafibrate, PPARgamma Agonists;PPARalpha Agonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors;PPARdelta Agonists;HSD11B1 Expression Inhibitors targeting HSD11B1, PPARA, PPARD, PPARG |
| BD-06-VI74_10uM | Dose=10uM, Bezafibrate, PPARgamma Agonists;PPARalpha Agonists;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors;PPARdelta Agonists;HSD11B1 Expression Inhibitors targeting HSD11B1, PPARA, PPARD, PPARG |
| BD-07-IW65_0.01uM | Dose=0.01uM |
| BD-07-IW65_0.1uM | Dose=0.1uM |
| BD-07-IW65_10uM | Dose=10uM |
| BD-07-IW65_1uM | Dose=1uM |
| BD-10-ZH17_0.1uM | Dose=0.1uM, 2-[3-[[(2R)-2-(4,5-diphenyl-1,3-oxazol-2-yl)pyrrolidin-1-yl]methyl]phenoxy]acetic acid, Prostanoid IP Agonists targeting PTGIR |
| BD-10-ZH17_10uM | Dose=10uM, 2-[3-[[(2R)-2-(4,5-diphenyl-1,3-oxazol-2-yl)pyrrolidin-1-yl]methyl]phenoxy]acetic acid, Prostanoid IP Agonists targeting PTGIR |
| BD-10-ZH17_1uM | Dose=1uM, 2-[3-[[(2R)-2-(4,5-diphenyl-1,3-oxazol-2-yl)pyrrolidin-1-yl]methyl]phenoxy]acetic acid, Prostanoid IP Agonists targeting PTGIR |
| BD-11-DV28_10uM | Dose=10uM |
| BD-12-CM09_0.01uM | Dose=0.01uM, 3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid, Lysophospholipid edg2 (LPA1) Receptor Antagonists;LPAR1 antagonist;Lysophospholipid edg7 (LPA3) Receptor Antagonists;LPAR3 antagonist targeting LPAR1, LPAR3 |
| BD-12-CM09_0.1uM | Dose=0.1uM, 3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid, Lysophospholipid edg2 (LPA1) Receptor Antagonists;LPAR1 antagonist;Lysophospholipid edg7 (LPA3) Receptor Antagonists;LPAR3 antagonist targeting LPAR1, LPAR3 |
| BD-12-CM09_10uM | Dose=10uM, 3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid, Lysophospholipid edg2 (LPA1) Receptor Antagonists;LPAR1 antagonist;Lysophospholipid edg7 (LPA3) Receptor Antagonists;LPAR3 antagonist targeting LPAR1, LPAR3 |
| BD-12-CM09_1uM | Dose=1uM, 3-[({4-[4-({[1-(2-Chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid, Lysophospholipid edg2 (LPA1) Receptor Antagonists;LPAR1 antagonist;Lysophospholipid edg7 (LPA3) Receptor Antagonists;LPAR3 antagonist targeting LPAR1, LPAR3 |
| BD-15-VR68_0.01uM | Dose=0.01uM, N-[[4-(3-methylphenyl)phenyl]methyl]-4-(1,8-naphthyridin-2-yl)butanamide, Succinate Receptor 1 (SUCNR1, GPR91) Antagonists targeting SUCNR1 |
| BD-15-VR68_0.1uM | Dose=0.1uM, N-[[4-(3-methylphenyl)phenyl]methyl]-4-(1,8-naphthyridin-2-yl)butanamide, Succinate Receptor 1 (SUCNR1, GPR91) Antagonists targeting SUCNR1 |
| BD-15-VR68_10uM | Dose=10uM, N-[[4-(3-methylphenyl)phenyl]methyl]-4-(1,8-naphthyridin-2-yl)butanamide, Succinate Receptor 1 (SUCNR1, GPR91) Antagonists targeting SUCNR1 |
| BD-15-VR68_1uM | Dose=1uM, N-[[4-(3-methylphenyl)phenyl]methyl]-4-(1,8-naphthyridin-2-yl)butanamide, Succinate Receptor 1 (SUCNR1, GPR91) Antagonists targeting SUCNR1 |
| BD-17-LT43_0.01uM | Dose=0.01uM, 3-((6-((5-Chloropyridin-2-yl)amino)pyrimidin-4-yl)amino)-4-(ethylsulfonyl)-N-methylbenzenesulfonamide, Tnni3 kinase inhibitor targeting TNNI3K |
| BD-17-LT43_0.1uM | Dose=0.1uM, 3-((6-((5-Chloropyridin-2-yl)amino)pyrimidin-4-yl)amino)-4-(ethylsulfonyl)-N-methylbenzenesulfonamide, Tnni3 kinase inhibitor targeting TNNI3K |
| BD-17-LT43_10uM | Dose=10uM, 3-((6-((5-Chloropyridin-2-yl)amino)pyrimidin-4-yl)amino)-4-(ethylsulfonyl)-N-methylbenzenesulfonamide, Tnni3 kinase inhibitor targeting TNNI3K |
| BD-18-FM58_0.01uM | Dose=0.01uM, Auy954, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| BD-18-FM58_0.1uM | Dose=0.1uM, Auy954, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| BD-18-FM58_10uM | Dose=10uM, Auy954, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| BD-18-FM58_1uM | Dose=1uM, Auy954, S1PR1 agonist;Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| BD-18-MM33_0.01uM | Dose=0.01uM, 3-[4-(Biphenyl-4-sulfonylamino)-phenyl]-N-hydroxy-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BD-18-MM33_0.1uM | Dose=0.1uM, 3-[4-(Biphenyl-4-sulfonylamino)-phenyl]-N-hydroxy-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BD-18-MM33_10uM | Dose=10uM, 3-[4-(Biphenyl-4-sulfonylamino)-phenyl]-N-hydroxy-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BD-18-MM33_1uM | Dose=1uM, 3-[4-(Biphenyl-4-sulfonylamino)-phenyl]-N-hydroxy-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BD-18-XC74_0.01uM | Dose=0.01uM, Nitrendipine, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| BD-18-XC74_10uM | Dose=10uM, Nitrendipine, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| BD-18-XC74_1uM | Dose=1uM, Nitrendipine, L-Type Calcium Channel Blockers targeting CACNA1C, CACNA1S |
| BD-19-MD69_0.01uM | Dose=0.01uM, l-Isoleucine, CRHR1 agonist;Apoptosis Inhibitors;Branched Chain Amino Acid;Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands targeting ACADSB, BCAT1, BCAT2, CACNA2D1, CRHR1, CACNA2D2, CACNA2D3, CACNA2D4 |
| BD-19-MD69_0.1uM | Dose=0.1uM, l-Isoleucine, CRHR1 agonist;Apoptosis Inhibitors;Branched Chain Amino Acid;Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands targeting ACADSB, BCAT1, BCAT2, CACNA2D1, CRHR1, CACNA2D2, CACNA2D3, CACNA2D4 |
| BD-19-MD69_10uM | Dose=10uM, l-Isoleucine, CRHR1 agonist;Apoptosis Inhibitors;Branched Chain Amino Acid;Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands targeting ACADSB, BCAT1, BCAT2, CACNA2D1, CRHR1, CACNA2D2, CACNA2D3, CACNA2D4 |
| BD-19-MD69_1uM | Dose=1uM, l-Isoleucine, CRHR1 agonist;Apoptosis Inhibitors;Branched Chain Amino Acid;Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands targeting ACADSB, BCAT1, BCAT2, CACNA2D1, CRHR1, CACNA2D2, CACNA2D3, CACNA2D4 |
| BD-22-KS33_0.01uM | Dose=0.01uM, Aptazapine, ADRA2A antagonist targeting ADRA2A |
| BD-22-KS33_0.1uM | Dose=0.1uM, Aptazapine, ADRA2A antagonist targeting ADRA2A |
| BD-22-KS33_10uM | Dose=10uM, Aptazapine, ADRA2A antagonist targeting ADRA2A |
| BD-22-KS33_1uM | Dose=1uM, Aptazapine, ADRA2A antagonist targeting ADRA2A |
| BD-23-MT28_0.01uM | Dose=0.01uM, Mifepristone, Glucocorticoid Receptor (GR) Antagonists;Androgen Receptor Ligands;Progesterone Receptor Antagonists;Internal Ribosomal Entry Site (IRES) Inhibitors targeting ALPI, ALPL, ALPP, AR, NR3C1, PGR |
| BD-23-MT28_0.1uM | Dose=0.1uM, Mifepristone, Glucocorticoid Receptor (GR) Antagonists;Androgen Receptor Ligands;Progesterone Receptor Antagonists;Internal Ribosomal Entry Site (IRES) Inhibitors targeting ALPI, ALPL, ALPP, AR, NR3C1, PGR |
| BD-23-MT28_10uM | Dose=10uM, Mifepristone, Glucocorticoid Receptor (GR) Antagonists;Androgen Receptor Ligands;Progesterone Receptor Antagonists;Internal Ribosomal Entry Site (IRES) Inhibitors targeting ALPI, ALPL, ALPP, AR, NR3C1, PGR |
| BD-23-MT28_1uM | Dose=1uM, Mifepristone, Glucocorticoid Receptor (GR) Antagonists;Androgen Receptor Ligands;Progesterone Receptor Antagonists;Internal Ribosomal Entry Site (IRES) Inhibitors targeting ALPI, ALPL, ALPP, AR, NR3C1, PGR |
| BD-25-SA37_0.01uM | Dose=0.01uM, 2-((5-chloro-2-((2-methoxy-4-morpholin-4-ylphenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide, IGF-1R Inhibitors;Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| BD-25-SA37_0.1uM | Dose=0.1uM, 2-((5-chloro-2-((2-methoxy-4-morpholin-4-ylphenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide, IGF-1R Inhibitors;Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| BD-25-SA37_10uM | Dose=10uM, 2-((5-chloro-2-((2-methoxy-4-morpholin-4-ylphenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide, IGF-1R Inhibitors;Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| BD-25-SA37_1uM | Dose=1uM, 2-((5-chloro-2-((2-methoxy-4-morpholin-4-ylphenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide, IGF-1R Inhibitors;Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| BD-26-EO58_0.01uM | Dose=0.01uM, Norharman, Indoleamine 2,3-dioxygenase Inhibitors;MAO-B Inhibitors targeting IDO1, MAOB |
| BD-26-EO58_0.1uM | Dose=0.1uM, Norharman, Indoleamine 2,3-dioxygenase Inhibitors;MAO-B Inhibitors targeting IDO1, MAOB |
| BD-26-EO58_1uM | Dose=1uM, Norharman, Indoleamine 2,3-dioxygenase Inhibitors;MAO-B Inhibitors targeting IDO1, MAOB |
| BD-27-CC87_0.01uM | Dose=0.01uM, Amlexanox, Mediator Release Inhibitors targeting S100A12, S100A13 |
| BD-27-CC87_0.1uM | Dose=0.1uM, Amlexanox, Mediator Release Inhibitors targeting S100A12, S100A13 |
| BD-27-CC87_10uM | Dose=10uM, Amlexanox, Mediator Release Inhibitors targeting S100A12, S100A13 |
| BD-27-CC87_1uM | Dose=1uM, Amlexanox, Mediator Release Inhibitors targeting S100A12, S100A13 |
| BD-29-IQ20_0.01uM | Dose=0.01uM, Tyrphostin AG 555, CDK2 Inhibitors;Tyrosine Kinase Inhibitors targeting CDK2 |
| BD-29-IQ20_0.1uM | Dose=0.1uM, Tyrphostin AG 555, CDK2 Inhibitors;Tyrosine Kinase Inhibitors targeting CDK2 |
| BD-29-IQ20_10uM | Dose=10uM, Tyrphostin AG 555, CDK2 Inhibitors;Tyrosine Kinase Inhibitors targeting CDK2 |
| BD-29-IQ20_1uM | Dose=1uM, Tyrphostin AG 555, CDK2 Inhibitors;Tyrosine Kinase Inhibitors targeting CDK2 |
| BD-31-AE17_0.01uM | Dose=0.01uM, 1H-indol-4-ylmethanol, OPRL1 antagonist targeting OPRL1 |
| BD-31-AE17_0.1uM | Dose=0.1uM, 1H-indol-4-ylmethanol, OPRL1 antagonist targeting OPRL1 |
| BD-31-AE17_10uM | Dose=10uM, 1H-indol-4-ylmethanol, OPRL1 antagonist targeting OPRL1 |
| BD-31-AE17_1uM | Dose=1uM, 1H-indol-4-ylmethanol, OPRL1 antagonist targeting OPRL1 |
| BD-32-GI59_0.01uM | Dose=0.01uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethanol, Phosphodiesterase IV Inhibitors targeting PDE4A, PDE4B, PDE4D |
| BD-32-GI59_0.1uM | Dose=0.1uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethanol, Phosphodiesterase IV Inhibitors targeting PDE4A, PDE4B, PDE4D |
| BD-32-GI59_10uM | Dose=10uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethanol, Phosphodiesterase IV Inhibitors targeting PDE4A, PDE4B, PDE4D |
| BD-32-GI59_1uM | Dose=1uM, 2-[1-[3,5-Di(propan-2-yloxy)phenyl]-3-ethyl-7-methoxyisoquinolin-6-yl]oxyethanol, Phosphodiesterase IV Inhibitors targeting PDE4A, PDE4B, PDE4D |
| BD-33-HT38_0.01uM | Dose=0.01uM, Epacadostat, Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immunooncolog;Epacadostat is an investigational cancer drug.[1] Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1) (IDO1).[1][2] targeting IDO1 |
| BD-33-HT38_0.1uM | Dose=0.1uM, Epacadostat, Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immunooncolog;Epacadostat is an investigational cancer drug.[1] Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1) (IDO1).[1][2] targeting IDO1 |
| BD-33-HT38_10uM | Dose=10uM, Epacadostat, Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immunooncolog;Epacadostat is an investigational cancer drug.[1] Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1) (IDO1).[1][2] targeting IDO1 |
| BD-33-HT38_1uM | Dose=1uM, Epacadostat, Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immunooncolog;Epacadostat is an investigational cancer drug.[1] Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1) (IDO1).[1][2] targeting IDO1 |
| BD-34-PN26_0.01uM | Dose=0.01uM |
| BD-34-PN26_0.1uM | Dose=0.1uM |
| BD-34-PN26_10uM | Dose=10uM |
| BD-34-PN26_1uM | Dose=1uM |
| BD-36-VB52_0.01uM | Dose=0.01uM, Galeterone, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Receptor Antagonists targeting AR, CYP17A1 |
| BD-36-VB52_0.1uM | Dose=0.1uM, Galeterone, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Receptor Antagonists targeting AR, CYP17A1 |
| BD-36-VB52_10uM | Dose=10uM, Galeterone, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Receptor Antagonists targeting AR, CYP17A1 |
| BD-36-VB52_1uM | Dose=1uM, Galeterone, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Receptor Antagonists targeting AR, CYP17A1 |
| BD-38-GC64_0.01uM | Dose=0.01uM, Fingolimod phosphate, Lysophospholipid edg3 (S1P3) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR3, S1PR4, S1PR5 |
| BD-38-GC64_0.1uM | Dose=0.1uM, Fingolimod phosphate, Lysophospholipid edg3 (S1P3) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR3, S1PR4, S1PR5 |
| BD-38-GC64_10uM | Dose=10uM, Fingolimod phosphate, Lysophospholipid edg3 (S1P3) Receptor Agonists;Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists targeting S1PR1, S1PR3, S1PR4, S1PR5 |
| BD-38-QC39_0.01uM | Dose=0.01uM, Chelerythrine, Apoptosis Inducers;Protein Kinase C (PKC) Inhibitors;Rho GTPase Inhibitors;Bcl-xl Inhibitors;P2X7 Receptor Antagonists targeting BCL2L1, P2RX7 |
| BD-38-QC39_0.1uM | Dose=0.1uM, Chelerythrine, Apoptosis Inducers;Protein Kinase C (PKC) Inhibitors;Rho GTPase Inhibitors;Bcl-xl Inhibitors;P2X7 Receptor Antagonists targeting BCL2L1, P2RX7 |
| BD-38-QC39_10uM | Dose=10uM, Chelerythrine, Apoptosis Inducers;Protein Kinase C (PKC) Inhibitors;Rho GTPase Inhibitors;Bcl-xl Inhibitors;P2X7 Receptor Antagonists targeting BCL2L1, P2RX7 |
| BD-38-QC39_1uM | Dose=1uM, Chelerythrine, Apoptosis Inducers;Protein Kinase C (PKC) Inhibitors;Rho GTPase Inhibitors;Bcl-xl Inhibitors;P2X7 Receptor Antagonists targeting BCL2L1, P2RX7 |
| BD-39-KG21_0.01uM | Dose=0.01uM, Selegiline, MAO-B Inhibitors targeting MAOB |
| BD-39-KG21_0.1uM | Dose=0.1uM, Selegiline, MAO-B Inhibitors targeting MAOB |
| BD-39-KG21_10uM | Dose=10uM, Selegiline, MAO-B Inhibitors targeting MAOB |
| BD-39-KG21_1uM | Dose=1uM, Selegiline, MAO-B Inhibitors targeting MAOB |
| BD-40-EK64_0.01uM | Dose=0.01uM, Terbuficin, LDL Antioxidants targeting ABCA1 |
| BD-40-EK64_10uM | Dose=10uM, Terbuficin, LDL Antioxidants targeting ABCA1 |
| BD-40-EK64_1uM | Dose=1uM, Terbuficin, LDL Antioxidants targeting ABCA1 |
| BD-41-DB55_0.01uM | Dose=0.01uM, Akt Inhibitor MK2206, AKT inhibitor;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1, AKT2, AKT3 |
| BD-41-DB55_0.1uM | Dose=0.1uM, Akt Inhibitor MK2206, AKT inhibitor;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1, AKT2, AKT3 |
| BD-41-DB55_10uM | Dose=10uM, Akt Inhibitor MK2206, AKT inhibitor;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1, AKT2, AKT3 |
| BD-41-DB55_1uM | Dose=1uM, Akt Inhibitor MK2206, AKT inhibitor;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1, AKT2, AKT3 |
| BD-41-DI77_0.01uM | Dose=0.01uM, Harmine, Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (DYRK1A) Inhibitors;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK2, CDK5, DYRK1A |
| BD-41-DI77_0.1uM | Dose=0.1uM, Harmine, Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (DYRK1A) Inhibitors;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK2, CDK5, DYRK1A |
| BD-41-DI77_10uM | Dose=10uM, Harmine, Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (DYRK1A) Inhibitors;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK2, CDK5, DYRK1A |
| BD-41-DI77_1uM | Dose=1uM, Harmine, Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (DYRK1A) Inhibitors;CDK2 Inhibitors;CDK5 Inhibitors targeting CDK2, CDK5, DYRK1A |
| BD-44-FH87_0.01uM | Dose=0.01uM, Dicyclomine, Muscarinic M1 Antagonists targeting CHRM1 |
| BD-44-FH87_0.1uM | Dose=0.1uM, Dicyclomine, Muscarinic M1 Antagonists targeting CHRM1 |
| BD-44-FH87_10uM | Dose=10uM, Dicyclomine, Muscarinic M1 Antagonists targeting CHRM1 |
| BD-44-FH87_1uM | Dose=1uM, Dicyclomine, Muscarinic M1 Antagonists targeting CHRM1 |
| BD-45-EU45_0.01uM | Dose=0.01uM, 3-fluoro-4-[(5S)-7-[(4-fluorophenyl)methyl]-6-oxo-5-propyl-8H-imidazo[1,5-a]pyrazin-5-yl]benzonitrile |
| BD-45-EU45_0.1uM | Dose=0.1uM, 3-fluoro-4-[(5S)-7-[(4-fluorophenyl)methyl]-6-oxo-5-propyl-8H-imidazo[1,5-a]pyrazin-5-yl]benzonitrile |
| BD-45-EU45_10uM | Dose=10uM, 3-fluoro-4-[(5S)-7-[(4-fluorophenyl)methyl]-6-oxo-5-propyl-8H-imidazo[1,5-a]pyrazin-5-yl]benzonitrile |
| BD-45-WH14_0.01uM | Dose=0.01uM, HC067047, TRPV4 gene inhibitor targeting TRPV4 |
| BD-45-WH14_0.1uM | Dose=0.1uM, HC067047, TRPV4 gene inhibitor targeting TRPV4 |
| BD-45-WH14_10uM | Dose=10uM, HC067047, TRPV4 gene inhibitor targeting TRPV4 |
| BD-45-WH14_1uM | Dose=1uM, HC067047, TRPV4 gene inhibitor targeting TRPV4 |
| BD-46-RY02_0.01uM | Dose=0.01uM, Indolophenanthridine, Dopamine D1 Agonists targeting DRD1 |
| BD-46-RY02_0.1uM | Dose=0.1uM, Indolophenanthridine, Dopamine D1 Agonists targeting DRD1 |
| BD-46-RY02_10uM | Dose=10uM, Indolophenanthridine, Dopamine D1 Agonists targeting DRD1 |
| BD-46-RY02_1uM | Dose=1uM, Indolophenanthridine, Dopamine D1 Agonists targeting DRD1 |
| BD-47-DS20_0.01uM | Dose=0.01uM, Cgs 22652, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1 |
| BD-47-DS20_0.1uM | Dose=0.1uM, Cgs 22652, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1 |
| BD-47-DS20_1uM | Dose=1uM, Cgs 22652, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1 |
| BD-47-NP88_0.01uM | Dose=0.01uM, A-967079, TRPA1 Antagonists targeting TRPA1 |
| BD-47-NP88_0.1uM | Dose=0.1uM, A-967079, TRPA1 Antagonists targeting TRPA1 |
| BD-47-NP88_10uM | Dose=10uM, A-967079, TRPA1 Antagonists targeting TRPA1 |
| BD-47-NP88_1uM | Dose=1uM, A-967079, TRPA1 Antagonists targeting TRPA1 |
| BD-48-JW52_0.01uM | Dose=0.01uM, (R)-6-(4-(Morpholinomethyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, Inhibitors of Signal Transduction Pathways;Receptor Tyrosine Kinase Inhibitors targeting EGFR, ERBB2, KDR |
| BD-48-JW52_0.1uM | Dose=0.1uM, (R)-6-(4-(Morpholinomethyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, Inhibitors of Signal Transduction Pathways;Receptor Tyrosine Kinase Inhibitors targeting EGFR, ERBB2, KDR |
| BD-48-JW52_10uM | Dose=10uM, (R)-6-(4-(Morpholinomethyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, Inhibitors of Signal Transduction Pathways;Receptor Tyrosine Kinase Inhibitors targeting EGFR, ERBB2, KDR |
| BD-48-JW52_1uM | Dose=1uM, (R)-6-(4-(Morpholinomethyl)phenyl)-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, Inhibitors of Signal Transduction Pathways;Receptor Tyrosine Kinase Inhibitors targeting EGFR, ERBB2, KDR |
| BD-48-ZT65_0.01uM | Dose=0.01uM, (E)-3-(3-chlorophenyl)-N-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)(methyl)amino)-2-oxoethyl)acrylamide |
| BD-48-ZT65_0.1uM | Dose=0.1uM, (E)-3-(3-chlorophenyl)-N-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)(methyl)amino)-2-oxoethyl)acrylamide |
| BD-48-ZT65_10uM | Dose=10uM, (E)-3-(3-chlorophenyl)-N-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)(methyl)amino)-2-oxoethyl)acrylamide |
| BD-48-ZT65_1uM | Dose=1uM, (E)-3-(3-chlorophenyl)-N-(2-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)(methyl)amino)-2-oxoethyl)acrylamide |
| BD-49-MD69_0.01uM | Dose=0.01uM, Cgp-60474, CDK2 Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2 |
| BD-49-MD69_0.1uM | Dose=0.1uM, Cgp-60474, CDK2 Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2 |
| BD-49-MD69_10uM | Dose=10uM, Cgp-60474, CDK2 Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2 |
| BD-49-MD69_1uM | Dose=1uM, Cgp-60474, CDK2 Inhibitors;Protein Kinase C (PKC) Inhibitors;CDK1 Inhibitors targeting CDK1, CDK2 |
| BD-50-HU68_0.01uM | Dose=0.01uM, Meclizine, PCYT2 inhibitor targeting NR1I3, PCYT2 |
| BD-50-HU68_0.1uM | Dose=0.1uM, Meclizine, PCYT2 inhibitor targeting NR1I3, PCYT2 |
| BD-50-HU68_10uM | Dose=10uM, Meclizine, PCYT2 inhibitor targeting NR1I3, PCYT2 |
| BD-50-HU68_1uM | Dose=1uM, Meclizine, PCYT2 inhibitor targeting NR1I3, PCYT2 |
| BD-51-DB15_0.01uM | Dose=0.01uM, 2-Hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid |
| BD-51-DB15_0.1uM | Dose=0.1uM, 2-Hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid |
| BD-51-DB15_10uM | Dose=10uM, 2-Hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid |
| BD-51-DB15_1uM | Dose=1uM, 2-Hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid |
| BD-58-PT20_0.01uM | Dose=0.01uM, Cdn1163, activator of ATP2A2 (SERCA2) targeting ATP2A2 |
| BD-58-PT20_0.1uM | Dose=0.1uM, Cdn1163, activator of ATP2A2 (SERCA2) targeting ATP2A2 |
| BD-58-PT20_10uM | Dose=10uM, Cdn1163, activator of ATP2A2 (SERCA2) targeting ATP2A2 |
| BD-58-PT20_1uM | Dose=1uM, Cdn1163, activator of ATP2A2 (SERCA2) targeting ATP2A2 |
| BD-58-PW57_10uM | Dose=10uM, Carbonyl Cyanide m-Chlorophenyl Hydrazone |
| BD-58-PW57_1uM | Dose=1uM, Carbonyl Cyanide m-Chlorophenyl Hydrazone |
| BD-59-MG06_0.01uM | Dose=0.01uM, Resiquimod, TLR8 Receptor Agonists;Interferon Inducers;TNF-alpha Production Inducers;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| BD-59-MG06_0.1uM | Dose=0.1uM, Resiquimod, TLR8 Receptor Agonists;Interferon Inducers;TNF-alpha Production Inducers;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| BD-59-MG06_10uM | Dose=10uM, Resiquimod, TLR8 Receptor Agonists;Interferon Inducers;TNF-alpha Production Inducers;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| BD-59-MG06_1uM | Dose=1uM, Resiquimod, TLR8 Receptor Agonists;Interferon Inducers;TNF-alpha Production Inducers;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| BD-59-TG01_0.1uM | Dose=0.1uM, 4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| BD-59-TG01_10uM | Dose=10uM, 4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| BD-59-TG01_1uM | Dose=1uM, 4-(2'-methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| BD-60-DR81_0.01uM | Dose=0.01uM, KDM5A inhibitor targeting KDM5A |
| BD-60-DR81_0.1uM | Dose=0.1uM, KDM5A inhibitor targeting KDM5A |
| BD-60-DR81_10uM | Dose=10uM, KDM5A inhibitor targeting KDM5A |
| BD-60-DR81_1uM | Dose=1uM, KDM5A inhibitor targeting KDM5A |
| BD-60-XA25_0.01uM | Dose=0.01uM, N-[5-(7-chloro-1-propylbenzimidazol-2-yl)pyridin-2-yl]-6-methylpyridin-3-amine |
| BD-60-XA25_0.1uM | Dose=0.1uM, N-[5-(7-chloro-1-propylbenzimidazol-2-yl)pyridin-2-yl]-6-methylpyridin-3-amine |
| BD-60-XA25_10uM | Dose=10uM, N-[5-(7-chloro-1-propylbenzimidazol-2-yl)pyridin-2-yl]-6-methylpyridin-3-amine |
| BD-60-ZK54_0.01uM | Dose=0.01uM, 4-[4-(4-(6-Chloronaphthalene-2-sulfonyl)piperazine-1-carbonyl)phenyl]pyridine 1-oxide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10 |
| BD-60-ZK54_0.1uM | Dose=0.1uM, 4-[4-(4-(6-Chloronaphthalene-2-sulfonyl)piperazine-1-carbonyl)phenyl]pyridine 1-oxide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10 |
| BD-60-ZK54_10uM | Dose=10uM, 4-[4-(4-(6-Chloronaphthalene-2-sulfonyl)piperazine-1-carbonyl)phenyl]pyridine 1-oxide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10 |
| BD-60-ZK54_1uM | Dose=1uM, 4-[4-(4-(6-Chloronaphthalene-2-sulfonyl)piperazine-1-carbonyl)phenyl]pyridine 1-oxide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10 |
| BD-61-OO16_0.01uM | Dose=0.01uM, 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-N-propan-2-ylbenzenesulfonamide, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| BD-61-OO16_0.1uM | Dose=0.1uM, 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-N-propan-2-ylbenzenesulfonamide, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| BD-61-OO16_10uM | Dose=10uM, 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-N-propan-2-ylbenzenesulfonamide, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| BD-61-OO16_1uM | Dose=1uM, 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-N-propan-2-ylbenzenesulfonamide, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| BD-62-ZF67_0.01uM | Dose=0.01uM, Halobetasol Propionate, Antiinflammatory Drugs targeting NR3C1 |
| BD-62-ZF67_0.1uM | Dose=0.1uM, Halobetasol Propionate, Antiinflammatory Drugs targeting NR3C1 |
| BD-62-ZF67_10uM | Dose=10uM, Halobetasol Propionate, Antiinflammatory Drugs targeting NR3C1 |
| BD-62-ZF67_1uM | Dose=1uM, Halobetasol Propionate, Antiinflammatory Drugs targeting NR3C1 |
| BD-63-JC77_0.01uM | Dose=0.01uM, [3-(4-Bromo-2,6-difluoro-benzyloxy)4-carbamoyl-isothiazol-5-yl]-carbamic acid phenyl ester |
| BD-63-JC77_0.1uM | Dose=0.1uM, [3-(4-Bromo-2,6-difluoro-benzyloxy)4-carbamoyl-isothiazol-5-yl]-carbamic acid phenyl ester |
| BD-63-JC77_10uM | Dose=10uM, [3-(4-Bromo-2,6-difluoro-benzyloxy)4-carbamoyl-isothiazol-5-yl]-carbamic acid phenyl ester |
| BD-63-JC77_1uM | Dose=1uM, [3-(4-Bromo-2,6-difluoro-benzyloxy)4-carbamoyl-isothiazol-5-yl]-carbamic acid phenyl ester |
| BD-63-KJ69_0.01uM | Dose=0.01uM, Calcipotriene, Vitamin D analog targeting BGLAP, VDR |
| BD-63-KJ69_0.1uM | Dose=0.1uM, Calcipotriene, Vitamin D analog targeting BGLAP, VDR |
| BD-63-KJ69_10uM | Dose=10uM, Calcipotriene, Vitamin D analog targeting BGLAP, VDR |
| BD-63-KJ69_1uM | Dose=1uM, Calcipotriene, Vitamin D analog targeting BGLAP, VDR |
| BD-65-VV48_0.01uM | Dose=0.01uM, Mesalamine, PPAR Gamma Inhibitor;Non-Steroidal Antiinflammatory Drugs targeting PPARG |
| BD-65-VV48_10uM | Dose=10uM, Mesalamine, PPAR Gamma Inhibitor;Non-Steroidal Antiinflammatory Drugs targeting PPARG |
| BD-65-VV48_1uM | Dose=1uM, Mesalamine, PPAR Gamma Inhibitor;Non-Steroidal Antiinflammatory Drugs targeting PPARG |
| BD-66-QO48_0.01uM | Dose=0.01uM, 2-[[1-Cyclopentyl-5-[1-(Oxetan-3-Yl)piperidin-4-Yl]pyrazol-3-Yl]amino]pyridine-4-Carbonitrile, DLK Inhibitor targeting MAP3K12 |
| BD-66-QO48_0.1uM | Dose=0.1uM, 2-[[1-Cyclopentyl-5-[1-(Oxetan-3-Yl)piperidin-4-Yl]pyrazol-3-Yl]amino]pyridine-4-Carbonitrile, DLK Inhibitor targeting MAP3K12 |
| BD-66-QO48_10uM | Dose=10uM, 2-[[1-Cyclopentyl-5-[1-(Oxetan-3-Yl)piperidin-4-Yl]pyrazol-3-Yl]amino]pyridine-4-Carbonitrile, DLK Inhibitor targeting MAP3K12 |
| BD-66-TZ80_0.01uM | Dose=0.01uM, Bicalutamide, Androgen Receptor Antagonists targeting AR, CYP27A1 |
| BD-66-TZ80_0.1uM | Dose=0.1uM, Bicalutamide, Androgen Receptor Antagonists targeting AR, CYP27A1 |
| BD-66-TZ80_1uM | Dose=1uM, Bicalutamide, Androgen Receptor Antagonists targeting AR, CYP27A1 |
| BD-68-PM33_0.01uM | Dose=0.01uM, Crt 0066101, protein kinase d inhibitor targeting PKD1 |
| BD-68-PM33_0.1uM | Dose=0.1uM, Crt 0066101, protein kinase d inhibitor targeting PKD1 |
| BD-68-PM33_10uM | Dose=10uM, Crt 0066101, protein kinase d inhibitor targeting PKD1 |
| BD-68-PM33_1uM | Dose=1uM, Crt 0066101, protein kinase d inhibitor targeting PKD1 |
| BD-68-ZT55_0.01uM | Dose=0.01uM, Triclosan |
| BD-68-ZT55_0.1uM | Dose=0.1uM, Triclosan |
| BD-68-ZT55_10uM | Dose=10uM, Triclosan |
| BD-68-ZT55_1uM | Dose=1uM, Triclosan |
| BD-69-GX17_0.01uM | Dose=0.01uM, 5-Iodotubercidin, Adenosine kinase inhibitor targeting ADK, AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK6 |
| BD-69-GX17_0.1uM | Dose=0.1uM, 5-Iodotubercidin, Adenosine kinase inhibitor targeting ADK, AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK6 |
| BD-69-GX17_10uM | Dose=10uM, 5-Iodotubercidin, Adenosine kinase inhibitor targeting ADK, AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK6 |
| BD-69-GX17_1uM | Dose=1uM, 5-Iodotubercidin, Adenosine kinase inhibitor targeting ADK, AK1, AK2, AK4, AK5, AK3, AK7, AK8, AK6 |
| BD-69-XG81_0.01uM | Dose=0.01uM, Yuanhuacin, Protein kinase C alpha stimulator;DNA topoisomerase I inhibitor;PKC activator targeting PRKCA, TOP1 |
| BD-69-XG81_0.1uM | Dose=0.1uM, Yuanhuacin, Protein kinase C alpha stimulator;DNA topoisomerase I inhibitor;PKC activator targeting PRKCA, TOP1 |
| BD-69-XG81_10uM | Dose=10uM, Yuanhuacin, Protein kinase C alpha stimulator;DNA topoisomerase I inhibitor;PKC activator targeting PRKCA, TOP1 |
| BD-69-XG81_1uM | Dose=1uM, Yuanhuacin, Protein kinase C alpha stimulator;DNA topoisomerase I inhibitor;PKC activator targeting PRKCA, TOP1 |
| BD-69-YD09_0.01uM | Dose=0.01uM, FK-1706, Neurotrophic Agents targeting FKBP1A, FKBP4 |
| BD-69-YD09_0.1uM | Dose=0.1uM, FK-1706, Neurotrophic Agents targeting FKBP1A, FKBP4 |
| BD-69-YD09_10uM | Dose=10uM, FK-1706, Neurotrophic Agents targeting FKBP1A, FKBP4 |
| BD-70-EK54_0.01uM | Dose=0.01uM |
| BD-70-EK54_0.1uM | Dose=0.1uM |
| BD-70-EK54_10uM | Dose=10uM |
| BD-70-EK54_1uM | Dose=1uM |
| BD-70-PH02_0.01uM | Dose=0.01uM |
| BD-70-PH02_0.1uM | Dose=0.1uM |
| BD-70-PH02_10uM | Dose=10uM |
| BD-70-PH02_1uM | Dose=1uM |
| BD-73-TX58_0.01uM | Dose=0.01uM, 5-Aminoquinolin-8-Ol, Apoptosis Inducers;Proteasome Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PSMB5, NFKB1, NFKB2, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, PSMB11, PSMA8 |
| BD-73-TX58_0.1uM | Dose=0.1uM, 5-Aminoquinolin-8-Ol, Apoptosis Inducers;Proteasome Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PSMB5, NFKB1, NFKB2, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, PSMB11, PSMA8 |
| BD-73-TX58_10uM | Dose=10uM, 5-Aminoquinolin-8-Ol, Apoptosis Inducers;Proteasome Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PSMB5, NFKB1, NFKB2, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, PSMB11, PSMA8 |
| BD-73-TX58_1uM | Dose=1uM, 5-Aminoquinolin-8-Ol, Apoptosis Inducers;Proteasome Inhibitors;NF-kappaB (NFKB) Activation Inhibitors targeting PSMB5, NFKB1, NFKB2, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB2, PSMB3, PSMB4, PSMB6, PSMB7, PSMB8, PSMB9, PSMB10, PSMC3, PSMC5, PSMD1, PSMD2, PSMD3, PSMD4, PSMD7, PSMD8, PSMD11, PSMD13, PSMB11, PSMA8 |
| BD-74-LH52_0.01uM | Dose=0.01uM, 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(1-phenylpyrazol-3-yl)azetidine-1-carboxylate targeting MGLL |
| BD-74-LH52_0.1uM | Dose=0.1uM, 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(1-phenylpyrazol-3-yl)azetidine-1-carboxylate targeting MGLL |
| BD-74-LH52_10uM | Dose=10uM, 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(1-phenylpyrazol-3-yl)azetidine-1-carboxylate targeting MGLL |
| BD-74-LH52_1uM | Dose=1uM, 1,1,1,3,3,3-Hexafluoropropan-2-yl 3-(1-phenylpyrazol-3-yl)azetidine-1-carboxylate targeting MGLL |
| BD-78-MJ16_0.01uM | Dose=0.01uM, Adenosine Phosphate, AMPK activator;nucleotide targeting PRKAG1, FBP2, PRKAG2, PRKAG3 |
| BD-78-MJ16_0.1uM | Dose=0.1uM, Adenosine Phosphate, AMPK activator;nucleotide targeting PRKAG1, FBP2, PRKAG2, PRKAG3 |
| BD-78-MJ16_10uM | Dose=10uM, Adenosine Phosphate, AMPK activator;nucleotide targeting PRKAG1, FBP2, PRKAG2, PRKAG3 |
| BD-78-MJ16_1uM | Dose=1uM, Adenosine Phosphate, AMPK activator;nucleotide targeting PRKAG1, FBP2, PRKAG2, PRKAG3 |
| BD-80-SK69_0.01uM | Dose=0.01uM, (-)-Isolongifolol, UGT2B7 gene inhibitor targeting UGT2B7 |
| BD-80-SK69_0.1uM | Dose=0.1uM, (-)-Isolongifolol, UGT2B7 gene inhibitor targeting UGT2B7 |
| BD-80-SK69_10uM | Dose=10uM, (-)-Isolongifolol, UGT2B7 gene inhibitor targeting UGT2B7 |
| BD-80-SK69_1uM | Dose=1uM, (-)-Isolongifolol, UGT2B7 gene inhibitor targeting UGT2B7 |
| BD-81-FB30_0.01uM | Dose=0.01uM |
| BD-81-FB30_0.1uM | Dose=0.1uM |
| BD-81-FB30_10uM | Dose=10uM |
| BD-81-FB30_1uM | Dose=1uM |
| BD-81-LB65_0.01uM | Dose=0.01uM, Azd-4547, FGFR1 gene inhibitor targeting FGFR1 |
| BD-81-LB65_0.1uM | Dose=0.1uM, Azd-4547, FGFR1 gene inhibitor targeting FGFR1 |
| BD-81-LB65_10uM | Dose=10uM, Azd-4547, FGFR1 gene inhibitor targeting FGFR1 |
| BD-81-LB65_1uM | Dose=1uM, Azd-4547, FGFR1 gene inhibitor targeting FGFR1 |
| BD-82-NF37_0.1uM | Dose=0.1uM |
| BD-82-NF37_10uM | Dose=10uM |
| BD-82-NF37_1uM | Dose=1uM |
| BD-83-QC82_0.01uM | Dose=0.01uM, (S)-Ethyl 2-(1-((S)-2-(acetylthio)-3-methylbutanamido)cyclopentanecarboxamido)-3-(4-methoxyphenyl)propanoate, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| BD-83-QC82_0.1uM | Dose=0.1uM, (S)-Ethyl 2-(1-((S)-2-(acetylthio)-3-methylbutanamido)cyclopentanecarboxamido)-3-(4-methoxyphenyl)propanoate, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| BD-83-QC82_10uM | Dose=10uM, (S)-Ethyl 2-(1-((S)-2-(acetylthio)-3-methylbutanamido)cyclopentanecarboxamido)-3-(4-methoxyphenyl)propanoate, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| BD-83-QC82_1uM | Dose=1uM, (S)-Ethyl 2-(1-((S)-2-(acetylthio)-3-methylbutanamido)cyclopentanecarboxamido)-3-(4-methoxyphenyl)propanoate, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| BD-83-UC82_0.01uM | Dose=0.01uM, 7-((R)-2-((1S,2S)-2-(benzyloxy)cyclopentylamino)-1-hydroxyethyl)-4-hydroxybenzo[d]thiazol-2(3H)-one, ADRB2 gene stimulator;ADRB2 agonist targeting ADRB1, ADRB2 |
| BD-83-UC82_0.1uM | Dose=0.1uM, 7-((R)-2-((1S,2S)-2-(benzyloxy)cyclopentylamino)-1-hydroxyethyl)-4-hydroxybenzo[d]thiazol-2(3H)-one, ADRB2 gene stimulator;ADRB2 agonist targeting ADRB1, ADRB2 |
| BD-83-UC82_10uM | Dose=10uM, 7-((R)-2-((1S,2S)-2-(benzyloxy)cyclopentylamino)-1-hydroxyethyl)-4-hydroxybenzo[d]thiazol-2(3H)-one, ADRB2 gene stimulator;ADRB2 agonist targeting ADRB1, ADRB2 |
| BD-83-UC82_1uM | Dose=1uM, 7-((R)-2-((1S,2S)-2-(benzyloxy)cyclopentylamino)-1-hydroxyethyl)-4-hydroxybenzo[d]thiazol-2(3H)-one, ADRB2 gene stimulator;ADRB2 agonist targeting ADRB1, ADRB2 |
| BD-84-ZR31_0.01uM | Dose=0.01uM, (1S,2S,5S,8R,9S,10S,11R,15S)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one targeting NLRP3 |
| BD-84-ZR31_0.1uM | Dose=0.1uM, (1S,2S,5S,8R,9S,10S,11R,15S)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one targeting NLRP3 |
| BD-84-ZR31_10uM | Dose=10uM, (1S,2S,5S,8R,9S,10S,11R,15S)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one targeting NLRP3 |
| BD-85-AU55_10uM | Dose=10uM, N-[1-[4-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]phenyl]cyclopropyl]acetamide |
| BD-85-GY20_0.01uM | Dose=0.01uM, 3-Benzyl-7-hydroxy-4-methyl-2H-chromen-2-one, 17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors targeting HSD17B3 |
| BD-85-GY20_0.1uM | Dose=0.1uM, 3-Benzyl-7-hydroxy-4-methyl-2H-chromen-2-one, 17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors targeting HSD17B3 |
| BD-85-GY20_10uM | Dose=10uM, 3-Benzyl-7-hydroxy-4-methyl-2H-chromen-2-one, 17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors targeting HSD17B3 |
| BD-85-GY20_1uM | Dose=1uM, 3-Benzyl-7-hydroxy-4-methyl-2H-chromen-2-one, 17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors targeting HSD17B3 |
| BD-85-IA32_0.01uM | Dose=0.01uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| BD-85-IA32_0.1uM | Dose=0.1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| BD-85-IA32_10uM | Dose=10uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| BD-85-IA32_1uM | Dose=1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-2-methyl-2H-pyrazol-3-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| BD-85-OV63_0.01uM | Dose=0.01uM, Laropiprant, Prostanoid DP (DP1) Antagonists targeting PTGDR |
| BD-85-OV63_0.1uM | Dose=0.1uM, Laropiprant, Prostanoid DP (DP1) Antagonists targeting PTGDR |
| BD-85-OV63_10uM | Dose=10uM, Laropiprant, Prostanoid DP (DP1) Antagonists targeting PTGDR |
| BD-85-OV63_1uM | Dose=1uM, Laropiprant, Prostanoid DP (DP1) Antagonists targeting PTGDR |
| BD-85-VR28_0.01uM | Dose=0.01uM, (2S)-2-[[3-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-yl]amino]-3-pyridin-3-ylpropan-1-ol |
| BD-85-VR28_0.1uM | Dose=0.1uM, (2S)-2-[[3-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-yl]amino]-3-pyridin-3-ylpropan-1-ol |
| BD-85-VR28_10uM | Dose=10uM, (2S)-2-[[3-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-yl]amino]-3-pyridin-3-ylpropan-1-ol |
| BD-85-VR28_1uM | Dose=1uM, (2S)-2-[[3-(4-methylphenyl)imidazo[1,2-a]pyrazin-8-yl]amino]-3-pyridin-3-ylpropan-1-ol |
| BD-90-DK64_0.01uM | Dose=0.01uM, A-366, EHMT1/2 inhibitor targeting EHMT2, EHMT1 |
| BD-90-DK64_0.1uM | Dose=0.1uM, A-366, EHMT1/2 inhibitor targeting EHMT2, EHMT1 |
| BD-90-DK64_10uM | Dose=10uM, A-366, EHMT1/2 inhibitor targeting EHMT2, EHMT1 |
| BD-90-DK64_1uM | Dose=1uM, A-366, EHMT1/2 inhibitor targeting EHMT2, EHMT1 |
| BD-90-SE75_0.1uM | Dose=0.1uM, Rilmenidine, Imidazoline I1 Receptor Agonists targeting NISCH |
| BD-90-SE75_10uM | Dose=10uM, Rilmenidine, Imidazoline I1 Receptor Agonists targeting NISCH |
| BD-90-SE75_1uM | Dose=1uM, Rilmenidine, Imidazoline I1 Receptor Agonists targeting NISCH |
| BD-93-AM31_0.01uM | Dose=0.01uM, Veliparib targeting PARP1, PARP2 |
| BD-93-AM31_0.1uM | Dose=0.1uM, Veliparib targeting PARP1, PARP2 |
| BD-93-AM31_10uM | Dose=10uM, Veliparib targeting PARP1, PARP2 |
| BD-93-AM31_1uM | Dose=1uM, Veliparib targeting PARP1, PARP2 |
| BD-94-KU93_0.01uM | Dose=0.01uM, Pulmonary surfactant;lysosomal exocytosis targeting GBA |
| BD-94-KU93_0.1uM | Dose=0.1uM, Pulmonary surfactant;lysosomal exocytosis targeting GBA |
| BD-94-KU93_10uM | Dose=10uM, Pulmonary surfactant;lysosomal exocytosis targeting GBA |
| BD-94-KU93_1uM | Dose=1uM, Pulmonary surfactant;lysosomal exocytosis targeting GBA |
| BD-96-HO33_0.01uM | Dose=0.01uM, 3-(4-Chloro-benzenesulfonyl)-1-(3,4-dimethyl-phenyl)-imidazolidine-2,4-dione, Known Chymase inhibitor targeting CMA1 |
| BD-96-HO33_0.1uM | Dose=0.1uM, 3-(4-Chloro-benzenesulfonyl)-1-(3,4-dimethyl-phenyl)-imidazolidine-2,4-dione, Known Chymase inhibitor targeting CMA1 |
| BD-96-HO33_10uM | Dose=10uM, 3-(4-Chloro-benzenesulfonyl)-1-(3,4-dimethyl-phenyl)-imidazolidine-2,4-dione, Known Chymase inhibitor targeting CMA1 |
| BD-96-HO33_1uM | Dose=1uM, 3-(4-Chloro-benzenesulfonyl)-1-(3,4-dimethyl-phenyl)-imidazolidine-2,4-dione, Known Chymase inhibitor targeting CMA1 |
| BD-97-PP33_0.01uM | Dose=0.01uM, Sonlicromanol |
| BD-97-PP33_0.1uM | Dose=0.1uM, Sonlicromanol |
| BD-97-PP33_10uM | Dose=10uM, Sonlicromanol |
| BD-97-PP33_1uM | Dose=1uM, Sonlicromanol |
| BD-98-TG79_0.01uM | Dose=0.01uM, Glipizide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| BD-98-TG79_0.1uM | Dose=0.1uM, Glipizide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| BD-98-TG79_10uM | Dose=10uM, Glipizide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| BD-98-TG79_1uM | Dose=1uM, Glipizide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| BD-98-XW77_0.01uM | Dose=0.01uM |
| BD-98-XW77_0.1uM | Dose=0.1uM |
| BD-98-XW77_10uM | Dose=10uM |
| BD-98-XW77_1uM | Dose=1uM |
| BD-99-DU20_0.01uM | Dose=0.01uM, 2-(furan-2-yl)-4H-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1 |
| BD-99-DU20_0.1uM | Dose=0.1uM, 2-(furan-2-yl)-4H-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1 |
| BD-99-DU20_10uM | Dose=10uM, 2-(furan-2-yl)-4H-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1 |
| BD-99-DU20_1uM | Dose=1uM, 2-(furan-2-yl)-4H-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1 |
| BE-03-XC62_0.01uM | Dose=0.01uM, 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, FYN, HCK, SRC, ABL2 |
| BE-03-XC62_0.1uM | Dose=0.1uM, 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, FYN, HCK, SRC, ABL2 |
| BE-03-XC62_10uM | Dose=10uM, 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, FYN, HCK, SRC, ABL2 |
| BE-03-XC62_1uM | Dose=1uM, 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, FYN, HCK, SRC, ABL2 |
| BE-04-AN21_0.01uM | Dose=0.01uM, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| BE-04-AN21_0.1uM | Dose=0.1uM, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| BE-04-AN21_10uM | Dose=10uM, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| BE-04-AN21_1uM | Dose=1uM, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| BE-05-KR03_0.01uM | Dose=0.01uM, 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine, Inhibitors of Signal Transduction Pathways;ALK Inhibitors targeting ALK |
| BE-05-KR03_0.1uM | Dose=0.1uM, 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine, Inhibitors of Signal Transduction Pathways;ALK Inhibitors targeting ALK |
| BE-05-KR03_10uM | Dose=10uM, 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine, Inhibitors of Signal Transduction Pathways;ALK Inhibitors targeting ALK |
| BE-05-KR03_1uM | Dose=1uM, 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)pyrimidine-2,4-diamine, Inhibitors of Signal Transduction Pathways;ALK Inhibitors targeting ALK |
| BE-07-BZ97_0.01uM | Dose=0.01uM, 2-Amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide targeting GHSR |
| BE-07-BZ97_0.1uM | Dose=0.1uM, 2-Amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide targeting GHSR |
| BE-07-BZ97_1uM | Dose=1uM, 2-Amino-N-((2R)-3-(benzyloxy)-1-(2-methyl-1-oxo-4-phenyl-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide targeting GHSR |
| BE-07-IS45_0.01uM | Dose=0.01uM, Antalarmin, CRHR1 antagonist targeting CRHR1 |
| BE-07-IS45_0.1uM | Dose=0.1uM, Antalarmin, CRHR1 antagonist targeting CRHR1 |
| BE-07-IS45_10uM | Dose=10uM, Antalarmin, CRHR1 antagonist targeting CRHR1 |
| BE-07-IS45_1uM | Dose=1uM, Antalarmin, CRHR1 antagonist targeting CRHR1 |
| BE-07-NI91_0.01uM | Dose=0.01uM, Isradipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA2D1, CACNB2, CACNA1H, CACNA2D2 |
| BE-07-NI91_10uM | Dose=10uM, Isradipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA2D1, CACNB2, CACNA1H, CACNA2D2 |
| BE-07-NI91_1uM | Dose=1uM, Isradipine, Calcium Channel Blockers targeting CACNA1C, CACNA1D, CACNA1S, CACNA2D1, CACNB2, CACNA1H, CACNA2D2 |
| BE-07-XF09_0.01uM | Dose=0.01uM, Neurotensin(8-13), Neurotensin Agonists targeting SORT1, NTSR2 |
| BE-07-XF09_0.1uM | Dose=0.1uM, Neurotensin(8-13), Neurotensin Agonists targeting SORT1, NTSR2 |
| BE-07-XF09_10uM | Dose=10uM, Neurotensin(8-13), Neurotensin Agonists targeting SORT1, NTSR2 |
| BE-07-XF09_1uM | Dose=1uM, Neurotensin(8-13), Neurotensin Agonists targeting SORT1, NTSR2 |
| BE-07-XI66_0.01uM | Dose=0.01uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-[1,3,4]-thiadiazol-2-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| BE-07-XI66_0.1uM | Dose=0.1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-[1,3,4]-thiadiazol-2-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| BE-07-XI66_10uM | Dose=10uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-[1,3,4]-thiadiazol-2-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| BE-07-XI66_1uM | Dose=1uM, 1-{(S)-3-[3-(4-Chloro-phenoxy)-azetidin-1-yl]-1-hydroxymethyl-propyl}-3-(5-ethyl-[1,3,4]-thiadiazol-2-yl)-urea, Chemokine CCR3 Antagonists targeting CCR3 |
| BE-09-HN23_0.01uM | Dose=0.01uM, Sligrl-NH2, F2RL1 agonist targeting F2RL1 |
| BE-09-HN23_0.1uM | Dose=0.1uM, Sligrl-NH2, F2RL1 agonist targeting F2RL1 |
| BE-09-HN23_10uM | Dose=10uM, Sligrl-NH2, F2RL1 agonist targeting F2RL1 |
| BE-10-NK39_0.1uM | Dose=0.1uM, Nbi-30775, CRF1 Antagonists targeting CRHR1 |
| BE-10-NK39_10uM | Dose=10uM, Nbi-30775, CRF1 Antagonists targeting CRHR1 |
| BE-10-NK39_1uM | Dose=1uM, Nbi-30775, CRF1 Antagonists targeting CRHR1 |
| BE-13-XC52_0.01uM | Dose=0.01uM, Indolo[1,2-a]quinazolin-5(6H)-one, 7-(1H-tetrazol-5-ylmethyl)-(9CI), NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1 |
| BE-13-XC52_0.1uM | Dose=0.1uM, Indolo[1,2-a]quinazolin-5(6H)-one, 7-(1H-tetrazol-5-ylmethyl)-(9CI), NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1 |
| BE-13-XC52_10uM | Dose=10uM, Indolo[1,2-a]quinazolin-5(6H)-one, 7-(1H-tetrazol-5-ylmethyl)-(9CI), NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1 |
| BE-13-XC52_1uM | Dose=1uM, Indolo[1,2-a]quinazolin-5(6H)-one, 7-(1H-tetrazol-5-ylmethyl)-(9CI), NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase| PARP) Inhibitors targeting PARP1 |
| BE-15-IE57_0.01uM | Dose=0.01uM, 2-(Butane-1-sulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno(2,3-b)pyridin-3-amine, Prostaglandin-degrading enzyme 15-PGDH inhibitor;inhibitor of the prostaglandin-degrading enzyme 15-PGDH targeting HPGD |
| BE-15-IE57_1uM | Dose=1uM, 2-(Butane-1-sulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno(2,3-b)pyridin-3-amine, Prostaglandin-degrading enzyme 15-PGDH inhibitor;inhibitor of the prostaglandin-degrading enzyme 15-PGDH targeting HPGD |
| BE-16-UV45_0.01uM | Dose=0.01uM |
| BE-16-UV45_0.1uM | Dose=0.1uM |
| BE-16-UV45_10uM | Dose=10uM |
| BE-16-UV45_1uM | Dose=1uM |
| BE-16-VM54_0.01uM | Dose=0.01uM, Carbidopa, Dopa decarboxylase inhibitor targeting DDC |
| BE-16-VM54_0.1uM | Dose=0.1uM, Carbidopa, Dopa decarboxylase inhibitor targeting DDC |
| BE-16-VM54_10uM | Dose=10uM, Carbidopa, Dopa decarboxylase inhibitor targeting DDC |
| BE-16-VM54_1uM | Dose=1uM, Carbidopa, Dopa decarboxylase inhibitor targeting DDC |
| BE-17-CS60_0.01uM | Dose=0.01uM, Tanespimycin, CHK1 Expression Inhibitors;Inhibitors of Signal Transduction Pathways;Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| BE-17-CS60_0.1uM | Dose=0.1uM, Tanespimycin, CHK1 Expression Inhibitors;Inhibitors of Signal Transduction Pathways;Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| BE-17-CS60_10uM | Dose=10uM, Tanespimycin, CHK1 Expression Inhibitors;Inhibitors of Signal Transduction Pathways;Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| BE-17-CS60_1uM | Dose=1uM, Tanespimycin, CHK1 Expression Inhibitors;Inhibitors of Signal Transduction Pathways;Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1 |
| BE-18-EM88_0.01uM | Dose=0.01uM, Nimesulide, Cyclooxygenase-2 Inhibitors targeting PTGS2, SC5D |
| BE-18-EM88_0.1uM | Dose=0.1uM, Nimesulide, Cyclooxygenase-2 Inhibitors targeting PTGS2, SC5D |
| BE-18-EM88_10uM | Dose=10uM, Nimesulide, Cyclooxygenase-2 Inhibitors targeting PTGS2, SC5D |
| BE-18-EM88_1uM | Dose=1uM, Nimesulide, Cyclooxygenase-2 Inhibitors targeting PTGS2, SC5D |
| BE-24-LQ28_0.01uM | Dose=0.01uM |
| BE-24-LQ28_0.1uM | Dose=0.1uM |
| BE-24-LQ28_10uM | Dose=10uM |
| BE-24-LQ28_1uM | Dose=1uM |
| BE-25-UR78_0.01uM | Dose=0.01uM, Tpca-1, IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKB |
| BE-25-UR78_0.1uM | Dose=0.1uM, Tpca-1, IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKB |
| BE-25-UR78_10uM | Dose=10uM, Tpca-1, IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKB |
| BE-25-UR78_1uM | Dose=1uM, Tpca-1, IKK-2 (IKK-beta) Inhibitors targeting CHUK, IKBKB |
| BE-27-RQ61_0.01uM | Dose=0.01uM |
| BE-27-RQ61_0.1uM | Dose=0.1uM |
| BE-27-RQ61_10uM | Dose=10uM |
| BE-27-RQ61_1uM | Dose=1uM |
| BE-27-XF09_0.01uM | Dose=0.01uM, (4S,8aR,12S,12aR)-12-hydroxy-4-methyl-4,5,6,7,8,8a,12,12a-octahydro-1H-3-benzoxecine-2,9-dione, bacterial DNA Primase Inhibitors;tat Inhibitors targeting PRIM1 |
| BE-27-XF09_10uM | Dose=10uM, (4S,8aR,12S,12aR)-12-hydroxy-4-methyl-4,5,6,7,8,8a,12,12a-octahydro-1H-3-benzoxecine-2,9-dione, bacterial DNA Primase Inhibitors;tat Inhibitors targeting PRIM1 |
| BE-27-XF09_1uM | Dose=1uM, (4S,8aR,12S,12aR)-12-hydroxy-4-methyl-4,5,6,7,8,8a,12,12a-octahydro-1H-3-benzoxecine-2,9-dione, bacterial DNA Primase Inhibitors;tat Inhibitors targeting PRIM1 |
| BE-28-QT65_0.01uM | Dose=0.01uM, Cgs 26303, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2 |
| BE-28-QT65_0.1uM | Dose=0.1uM, Cgs 26303, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2 |
| BE-28-QT65_10uM | Dose=10uM, Cgs 26303, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2 |
| BE-28-QT65_1uM | Dose=1uM, Cgs 26303, Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ECE1, MME, ECE2 |
| BE-28-WW67_0.01uM | Dose=0.01uM, Pyroxamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BE-28-WW67_0.1uM | Dose=0.1uM, Pyroxamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BE-28-WW67_10uM | Dose=10uM, Pyroxamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BE-28-WW67_1uM | Dose=1uM, Pyroxamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| BE-29-DG26_0.01uM | Dose=0.01uM, Varespladib, Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G1B, PLA2G2A, PLA2G5, PLA2G2D, PLA2G2E, PLA2G7, PLA2G6, PLA2R1, PLA2G3, PLA2G12A, PLA2G12B, PLA2G4F, PLA2G2C |
| BE-29-DG26_0.1uM | Dose=0.1uM, Varespladib, Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G1B, PLA2G2A, PLA2G5, PLA2G2D, PLA2G2E, PLA2G7, PLA2G6, PLA2R1, PLA2G3, PLA2G12A, PLA2G12B, PLA2G4F, PLA2G2C |
| BE-29-DG26_10uM | Dose=10uM, Varespladib, Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G1B, PLA2G2A, PLA2G5, PLA2G2D, PLA2G2E, PLA2G7, PLA2G6, PLA2R1, PLA2G3, PLA2G12A, PLA2G12B, PLA2G4F, PLA2G2C |
| BE-29-DG26_1uM | Dose=1uM, Varespladib, Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G1B, PLA2G2A, PLA2G5, PLA2G2D, PLA2G2E, PLA2G7, PLA2G6, PLA2R1, PLA2G3, PLA2G12A, PLA2G12B, PLA2G4F, PLA2G2C |
| BE-29-HA72_0.01uM | Dose=0.01uM, Ifosfamide |
| BE-29-HA72_0.1uM | Dose=0.1uM, Ifosfamide |
| BE-29-HA72_1uM | Dose=1uM, Ifosfamide |
| BE-31-XV38_0.01uM | Dose=0.01uM, Camptothecin, topoisomerase I targeting TOP1 |
| BE-31-XV38_0.1uM | Dose=0.1uM, Camptothecin, topoisomerase I targeting TOP1 |
| BE-31-XV38_10uM | Dose=10uM, Camptothecin, topoisomerase I targeting TOP1 |
| BE-31-XV38_1uM | Dose=1uM, Camptothecin, topoisomerase I targeting TOP1 |
| BE-33-IM71_0.01uM | Dose=0.01uM, 1-Naphthalenecarboxamide, 6-[(2-amino-4-pyrimidinyl)oxy]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| BE-33-IM71_0.1uM | Dose=0.1uM, 1-Naphthalenecarboxamide, 6-[(2-amino-4-pyrimidinyl)oxy]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| BE-33-IM71_10uM | Dose=10uM, 1-Naphthalenecarboxamide, 6-[(2-amino-4-pyrimidinyl)oxy]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| BE-33-IM71_1uM | Dose=1uM, 1-Naphthalenecarboxamide, 6-[(2-amino-4-pyrimidinyl)oxy]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| BE-34-JO19_0.01uM | Dose=0.01uM, EIF2B4 modulator;Inhibits UPR, reactives translation targeting EIF2B4 |
| BE-34-JO19_10uM | Dose=10uM, EIF2B4 modulator;Inhibits UPR, reactives translation targeting EIF2B4 |
| BE-36-FY37_0.01uM | Dose=0.01uM, N(6)-acetimidoyl-L-lysine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2 |
| BE-36-FY37_0.1uM | Dose=0.1uM, N(6)-acetimidoyl-L-lysine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2 |
| BE-36-FY37_10uM | Dose=10uM, N(6)-acetimidoyl-L-lysine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2 |
| BE-36-FY37_1uM | Dose=1uM, N(6)-acetimidoyl-L-lysine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2 |
| BE-36-XE09_0.01uM | Dose=0.01uM, 7-benzyl-5-morpholino-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine |
| BE-36-XE09_0.1uM | Dose=0.1uM, 7-benzyl-5-morpholino-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine |
| BE-36-XE09_10uM | Dose=10uM, 7-benzyl-5-morpholino-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine |
| BE-36-XE09_1uM | Dose=1uM, 7-benzyl-5-morpholino-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine |
| BE-37-IC77_0.01uM | Dose=0.01uM, Oleanolic Acid, G-Protein Coupled Bile Acid Receptor 1 Agonists;Protein Tyrosine Phosphatase PTP-1B Inhibitors;LDL Antioxidants;Insulin Secretagogues;Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G2A, PTPN1, PTPN2, AKR1B10, GPBAR1 |
| BE-37-IC77_0.1uM | Dose=0.1uM, Oleanolic Acid, G-Protein Coupled Bile Acid Receptor 1 Agonists;Protein Tyrosine Phosphatase PTP-1B Inhibitors;LDL Antioxidants;Insulin Secretagogues;Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G2A, PTPN1, PTPN2, AKR1B10, GPBAR1 |
| BE-37-IC77_10uM | Dose=10uM, Oleanolic Acid, G-Protein Coupled Bile Acid Receptor 1 Agonists;Protein Tyrosine Phosphatase PTP-1B Inhibitors;LDL Antioxidants;Insulin Secretagogues;Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G2A, PTPN1, PTPN2, AKR1B10, GPBAR1 |
| BE-37-IC77_1uM | Dose=1uM, Oleanolic Acid, G-Protein Coupled Bile Acid Receptor 1 Agonists;Protein Tyrosine Phosphatase PTP-1B Inhibitors;LDL Antioxidants;Insulin Secretagogues;Secretory Phospholipase A2 (sPLA2) Inhibitors targeting PLA2G2A, PTPN1, PTPN2, AKR1B10, GPBAR1 |
| BE-37-ZF44_0.01uM | Dose=0.01uM, (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid targeting LTC4S |
| BE-37-ZF44_0.1uM | Dose=0.1uM, (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid targeting LTC4S |
| BE-37-ZF44_10uM | Dose=10uM, (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid targeting LTC4S |
| BE-37-ZF44_1uM | Dose=1uM, (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid targeting LTC4S |
| BE-38-UW72_0.01uM | Dose=0.01uM |
| BE-38-UW72_0.1uM | Dose=0.1uM |
| BE-38-UW72_10uM | Dose=10uM |
| BE-38-UW72_1uM | Dose=1uM |
| BE-41-AV63_0.01uM | Dose=0.01uM, Miglitol, SGLT-3 Activators;alpha-Glucosidase Inhibitors targeting GAA, SLC5A4 |
| BE-41-AV63_0.1uM | Dose=0.1uM, Miglitol, SGLT-3 Activators;alpha-Glucosidase Inhibitors targeting GAA, SLC5A4 |
| BE-41-AV63_10uM | Dose=10uM, Miglitol, SGLT-3 Activators;alpha-Glucosidase Inhibitors targeting GAA, SLC5A4 |
| BE-41-AV63_1uM | Dose=1uM, Miglitol, SGLT-3 Activators;alpha-Glucosidase Inhibitors targeting GAA, SLC5A4 |
| BE-41-UE67_0.01uM | Dose=0.01uM, Piericidin A, Electron transport chain inhibitor;NADH oxidase inhibitors targeting NDUFAB1, NDUFS1, NDUFV1 |
| BE-41-UE67_0.1uM | Dose=0.1uM, Piericidin A, Electron transport chain inhibitor;NADH oxidase inhibitors targeting NDUFAB1, NDUFS1, NDUFV1 |
| BE-41-UE67_10uM | Dose=10uM, Piericidin A, Electron transport chain inhibitor;NADH oxidase inhibitors targeting NDUFAB1, NDUFS1, NDUFV1 |
| BE-41-UE67_1uM | Dose=1uM, Piericidin A, Electron transport chain inhibitor;NADH oxidase inhibitors targeting NDUFAB1, NDUFS1, NDUFV1 |
| BE-42-IC00_0.01uM | Dose=0.01uM, Zygosporin A, actin polymerization targeting ACTA1 |
| BE-42-IC00_0.1uM | Dose=0.1uM, Zygosporin A, actin polymerization targeting ACTA1 |
| BE-42-IC00_10uM | Dose=10uM, Zygosporin A, actin polymerization targeting ACTA1 |
| BE-42-IC00_1uM | Dose=1uM, Zygosporin A, actin polymerization targeting ACTA1 |
| BE-42-WI29_0.01uM | Dose=0.01uM, Flumazenil, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
| BE-42-WI29_0.1uM | Dose=0.1uM, Flumazenil, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
| BE-42-WI29_10uM | Dose=10uM, Flumazenil, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
| BE-42-WI29_1uM | Dose=1uM, Flumazenil, GABA(A) BZ Site Receptor Antagonists targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
| BE-45-UU35_0.01uM | Dose=0.01uM, N-(2-aminoethyl)isoquinoline-5-sulfonamide, Inhibitors of Signal Transduction Pathways;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA |
| BE-45-UU35_0.1uM | Dose=0.1uM, N-(2-aminoethyl)isoquinoline-5-sulfonamide, Inhibitors of Signal Transduction Pathways;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA |
| BE-45-UU35_10uM | Dose=10uM, N-(2-aminoethyl)isoquinoline-5-sulfonamide, Inhibitors of Signal Transduction Pathways;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA |
| BE-45-UU35_1uM | Dose=1uM, N-(2-aminoethyl)isoquinoline-5-sulfonamide, Inhibitors of Signal Transduction Pathways;cAMP-Dependent Protein Kinase (PKA) Inhibitors targeting PRKACA |
| BE-45-VH04_0.01uM | Dose=0.01uM, Ethyl 3-[(phenylmethyl)amino]-4-pyridinecarboxylate |
| BE-45-VH04_0.1uM | Dose=0.1uM, Ethyl 3-[(phenylmethyl)amino]-4-pyridinecarboxylate |
| BE-45-VH04_10uM | Dose=10uM, Ethyl 3-[(phenylmethyl)amino]-4-pyridinecarboxylate |
| BE-45-VH04_1uM | Dose=1uM, Ethyl 3-[(phenylmethyl)amino]-4-pyridinecarboxylate |
| BE-45-XA42_0.01uM | Dose=0.01uM, 4-[[2-[[4-[[[(Adamantane-1-yl)acetyl]amino]acetyl]piperazine-1-yl]methyl]phenoxy]methyl]benzoic acid methyl ester, Niemann-Pick C1 inhibitor targeting NPC1 |
| BE-45-XA42_0.1uM | Dose=0.1uM, 4-[[2-[[4-[[[(Adamantane-1-yl)acetyl]amino]acetyl]piperazine-1-yl]methyl]phenoxy]methyl]benzoic acid methyl ester, Niemann-Pick C1 inhibitor targeting NPC1 |
| BE-45-XA42_10uM | Dose=10uM, 4-[[2-[[4-[[[(Adamantane-1-yl)acetyl]amino]acetyl]piperazine-1-yl]methyl]phenoxy]methyl]benzoic acid methyl ester, Niemann-Pick C1 inhibitor targeting NPC1 |
| BE-45-XA42_1uM | Dose=1uM, 4-[[2-[[4-[[[(Adamantane-1-yl)acetyl]amino]acetyl]piperazine-1-yl]methyl]phenoxy]methyl]benzoic acid methyl ester, Niemann-Pick C1 inhibitor targeting NPC1 |
| BE-46-FY47_0.01uM | Dose=0.01uM, N-Desmethylclozapine, Dopamine D2 Receptor Partial Agonists;Dopamine D3 Partial Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, DRD3, HTR2A |
| BE-46-FY47_0.1uM | Dose=0.1uM, N-Desmethylclozapine, Dopamine D2 Receptor Partial Agonists;Dopamine D3 Partial Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, DRD3, HTR2A |
| BE-46-FY47_10uM | Dose=10uM, N-Desmethylclozapine, Dopamine D2 Receptor Partial Agonists;Dopamine D3 Partial Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, DRD3, HTR2A |
| BE-46-FY47_1uM | Dose=1uM, N-Desmethylclozapine, Dopamine D2 Receptor Partial Agonists;Dopamine D3 Partial Agonists;Muscarinic M1 Agonists;5-HT2A Inverse Agonists targeting CHRM1, DRD2, DRD3, HTR2A |
| BE-47-IP08_0.01uM | Dose=0.01uM, Acifran, GPR109A agonist targeting HCAR2 |
| BE-47-IP08_0.1uM | Dose=0.1uM, Acifran, GPR109A agonist targeting HCAR2 |
| BE-47-IP08_10uM | Dose=10uM, Acifran, GPR109A agonist targeting HCAR2 |
| BE-47-IP08_1uM | Dose=1uM, Acifran, GPR109A agonist targeting HCAR2 |
| BE-48-IT75_0.01uM | Dose=0.01uM |
| BE-48-IT75_0.1uM | Dose=0.1uM |
| BE-48-IT75_10uM | Dose=10uM |
| BE-48-IT75_1uM | Dose=1uM |
| BE-48-TM93_0.01uM | Dose=0.01uM, Seratrodast, Prostanoid TP Antagonists targeting TBXA2R |
| BE-48-TM93_0.1uM | Dose=0.1uM, Seratrodast, Prostanoid TP Antagonists targeting TBXA2R |
| BE-48-TM93_10uM | Dose=10uM, Seratrodast, Prostanoid TP Antagonists targeting TBXA2R |
| BE-48-TM93_1uM | Dose=1uM, Seratrodast, Prostanoid TP Antagonists targeting TBXA2R |
| BE-49-AQ65_0.01uM | Dose=0.01uM, Cgp-37849, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
| BE-49-AQ65_0.1uM | Dose=0.1uM, Cgp-37849, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
| BE-49-AQ65_10uM | Dose=10uM, Cgp-37849, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
| BE-49-AQ65_1uM | Dose=1uM, Cgp-37849, NMDA Antagonists;Glutamate Ionotropic Antagonists targeting GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
| BE-49-XN43_0.01uM | Dose=0.01uM |
| BE-49-XN43_0.1uM | Dose=0.1uM |
| BE-49-XN43_10uM | Dose=10uM |
| BE-49-XN43_1uM | Dose=1uM |
| BE-50-RK99_0.01uM | Dose=0.01uM, N-(4-tert-butylphenyl)-4-(isoquinolin-7-yl)isoquinolin-1-amine |
| BE-50-RK99_0.1uM | Dose=0.1uM, N-(4-tert-butylphenyl)-4-(isoquinolin-7-yl)isoquinolin-1-amine |
| BE-50-RK99_10uM | Dose=10uM, N-(4-tert-butylphenyl)-4-(isoquinolin-7-yl)isoquinolin-1-amine |
| BE-50-RK99_1uM | Dose=1uM, N-(4-tert-butylphenyl)-4-(isoquinolin-7-yl)isoquinolin-1-amine |
| BE-51-FL19_0.01uM | Dose=0.01uM |
| BE-51-FL19_0.1uM | Dose=0.1uM |
| BE-51-FL19_10uM | Dose=10uM |
| BE-51-FL19_1uM | Dose=1uM |
| BE-51-JY70_0.01uM | Dose=0.01uM, Dutacatib, Cathepsin K Inhibitors targeting CTSK |
| BE-51-JY70_0.1uM | Dose=0.1uM, Dutacatib, Cathepsin K Inhibitors targeting CTSK |
| BE-51-JY70_10uM | Dose=10uM, Dutacatib, Cathepsin K Inhibitors targeting CTSK |
| BE-51-JY70_1uM | Dose=1uM, Dutacatib, Cathepsin K Inhibitors targeting CTSK |
| BE-54-BG59_10uM | Dose=10uM, Sgc0946, Dot1L inhibitor targeting DOT1L |
| BE-57-VZ17_0.01uM | Dose=0.01uM |
| BE-57-VZ17_0.1uM | Dose=0.1uM |
| BE-57-VZ17_10uM | Dose=10uM |
| BE-57-VZ17_1uM | Dose=1uM |
| BE-58-FC64_0.01uM | Dose=0.01uM, 1-(8-(3-Cyanophenyl)-1,7-naphthyridin-6-yl)piperidine-4-carboxylic acid, Phosphodiesterase PDE4D Inhibitors targeting PDE4D |
| BE-58-FC64_0.1uM | Dose=0.1uM, 1-(8-(3-Cyanophenyl)-1,7-naphthyridin-6-yl)piperidine-4-carboxylic acid, Phosphodiesterase PDE4D Inhibitors targeting PDE4D |
| BE-58-FC64_10uM | Dose=10uM, 1-(8-(3-Cyanophenyl)-1,7-naphthyridin-6-yl)piperidine-4-carboxylic acid, Phosphodiesterase PDE4D Inhibitors targeting PDE4D |
| BE-58-FC64_1uM | Dose=1uM, 1-(8-(3-Cyanophenyl)-1,7-naphthyridin-6-yl)piperidine-4-carboxylic acid, Phosphodiesterase PDE4D Inhibitors targeting PDE4D |
| BE-59-WG31_0.01uM | Dose=0.01uM, 3-(4-Methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1 |
| BE-59-WG31_0.1uM | Dose=0.1uM, 3-(4-Methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1 |
| BE-59-WG31_10uM | Dose=10uM, 3-(4-Methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1 |
| BE-59-WG31_1uM | Dose=1uM, 3-(4-Methyl-1H-imidazol-1-yl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-5-(trifluoromethyl)benzamide, Abl Kinase Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways targeting ABL1 |
| BE-61-CB85_0.01uM | Dose=0.01uM |
| BE-61-CB85_0.1uM | Dose=0.1uM |
| BE-61-CB85_10uM | Dose=10uM |
| BE-61-CB85_1uM | Dose=1uM |
| BE-61-OB65_0.01uM | Dose=0.01uM, 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;Inhibitors of Signal Transduction Pathways targeting FLT4, KDR |
| BE-61-OB65_0.1uM | Dose=0.1uM, 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;Inhibitors of Signal Transduction Pathways targeting FLT4, KDR |
| BE-61-OB65_10uM | Dose=10uM, 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;Inhibitors of Signal Transduction Pathways targeting FLT4, KDR |
| BE-61-OB65_1uM | Dose=1uM, 2-(Pyridin-4-Ylmethylamino)-~{n}-[3-(Trifluoromethyl)phenyl]benzamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;Inhibitors of Signal Transduction Pathways targeting FLT4, KDR |
| BE-64-ZN31_0.01uM | Dose=0.01uM, Enzalutamide, Androgen Receptor Antagonists targeting AR |
| BE-64-ZN31_0.1uM | Dose=0.1uM, Enzalutamide, Androgen Receptor Antagonists targeting AR |
| BE-64-ZN31_10uM | Dose=10uM, Enzalutamide, Androgen Receptor Antagonists targeting AR |
| BE-64-ZN31_1uM | Dose=1uM, Enzalutamide, Androgen Receptor Antagonists targeting AR |
| BE-65-HV88_0.01uM | Dose=0.01uM, Agomelatine, 5-HT2C Antagonists;Melatonin MT2 Agonists;Melatonin MT1 Agonists;melatonergic antidepressant targeting HTR2C, MTNR1A, MTNR1B |
| BE-65-HV88_0.1uM | Dose=0.1uM, Agomelatine, 5-HT2C Antagonists;Melatonin MT2 Agonists;Melatonin MT1 Agonists;melatonergic antidepressant targeting HTR2C, MTNR1A, MTNR1B |
| BE-65-HV88_10uM | Dose=10uM, Agomelatine, 5-HT2C Antagonists;Melatonin MT2 Agonists;Melatonin MT1 Agonists;melatonergic antidepressant targeting HTR2C, MTNR1A, MTNR1B |
| BE-65-HV88_1uM | Dose=1uM, Agomelatine, 5-HT2C Antagonists;Melatonin MT2 Agonists;Melatonin MT1 Agonists;melatonergic antidepressant targeting HTR2C, MTNR1A, MTNR1B |
| BE-66-GV20_0.01uM | Dose=0.01uM, Pipamperone, 5-HT2 Antagonists;Dopamine D2 Antagonists targeting HTR1E, HTR1F |
| BE-66-GV20_0.1uM | Dose=0.1uM, Pipamperone, 5-HT2 Antagonists;Dopamine D2 Antagonists targeting HTR1E, HTR1F |
| BE-66-GV20_10uM | Dose=10uM, Pipamperone, 5-HT2 Antagonists;Dopamine D2 Antagonists targeting HTR1E, HTR1F |
| BE-66-GV20_1uM | Dose=1uM, Pipamperone, 5-HT2 Antagonists;Dopamine D2 Antagonists targeting HTR1E, HTR1F |
| BE-66-UB12_0.01uM | Dose=0.01uM |
| BE-66-UB12_0.1uM | Dose=0.1uM |
| BE-66-UB12_10uM | Dose=10uM |
| BE-66-UB12_1uM | Dose=1uM |
| BE-67-QZ92_0.01uM | Dose=0.01uM, Hydrochlorothiazide, SLC12A3 gene inhibitor targeting CA1, CA4, SLC12A3, CA5B |
| BE-67-QZ92_0.1uM | Dose=0.1uM, Hydrochlorothiazide, SLC12A3 gene inhibitor targeting CA1, CA4, SLC12A3, CA5B |
| BE-67-QZ92_10uM | Dose=10uM, Hydrochlorothiazide, SLC12A3 gene inhibitor targeting CA1, CA4, SLC12A3, CA5B |
| BE-68-LK29_0.01uM | Dose=0.01uM, Valproic Acid, GABAergic Transmission Enhancers;Histone Deacetylase 1 (HDAC1) Inhibitors targeting ABAT, ACADSB, HDAC1, SCN1A, HDAC9 |
| BE-68-LK29_0.1uM | Dose=0.1uM, Valproic Acid, GABAergic Transmission Enhancers;Histone Deacetylase 1 (HDAC1) Inhibitors targeting ABAT, ACADSB, HDAC1, SCN1A, HDAC9 |
| BE-68-LK29_10uM | Dose=10uM, Valproic Acid, GABAergic Transmission Enhancers;Histone Deacetylase 1 (HDAC1) Inhibitors targeting ABAT, ACADSB, HDAC1, SCN1A, HDAC9 |
| BE-68-PM13_10uM | Dose=10uM, (2R)-3-cyclopentyl-N-(5-methoxy[1,3]thiazolo[5,4-b]pyridin-2-yl)-2-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}propanamide, Glucokinase Activators targeting GCK |
| BE-69-RD44_0.01uM | Dose=0.01uM, 2-[(Cyclopropylsulfonyl)amino]-N-(2-ethoxyphenyl)benzamide, MrgX1 PAM targeting MRGPRX1 |
| BE-69-RD44_0.1uM | Dose=0.1uM, 2-[(Cyclopropylsulfonyl)amino]-N-(2-ethoxyphenyl)benzamide, MrgX1 PAM targeting MRGPRX1 |
| BE-69-RD44_10uM | Dose=10uM, 2-[(Cyclopropylsulfonyl)amino]-N-(2-ethoxyphenyl)benzamide, MrgX1 PAM targeting MRGPRX1 |
| BE-69-RD44_1uM | Dose=1uM, 2-[(Cyclopropylsulfonyl)amino]-N-(2-ethoxyphenyl)benzamide, MrgX1 PAM targeting MRGPRX1 |
| BE-70-CU78_0.01uM | Dose=0.01uM, 8-(2,1,3-Benzoxadiazol-5-yl)-1,7-naphthyridin-6-amine, Phosphodiesterase IV Inhibitors;TNF-alpha Release Inhibitors targeting PDE2A |
| BE-70-CU78_0.1uM | Dose=0.1uM, 8-(2,1,3-Benzoxadiazol-5-yl)-1,7-naphthyridin-6-amine, Phosphodiesterase IV Inhibitors;TNF-alpha Release Inhibitors targeting PDE2A |
| BE-70-CU78_10uM | Dose=10uM, 8-(2,1,3-Benzoxadiazol-5-yl)-1,7-naphthyridin-6-amine, Phosphodiesterase IV Inhibitors;TNF-alpha Release Inhibitors targeting PDE2A |
| BE-70-CU78_1uM | Dose=1uM, 8-(2,1,3-Benzoxadiazol-5-yl)-1,7-naphthyridin-6-amine, Phosphodiesterase IV Inhibitors;TNF-alpha Release Inhibitors targeting PDE2A |
| BE-70-YH17_0.01uM | Dose=0.01uM, LG 100268, Insulin Sensitizers;ABCA1 Expression Enhancers;Antiinflammatory Drugs;Retinoid RXR Agonists;Angiogenesis Inhibitors targeting RXRB, RXRG |
| BE-70-YH17_0.1uM | Dose=0.1uM, LG 100268, Insulin Sensitizers;ABCA1 Expression Enhancers;Antiinflammatory Drugs;Retinoid RXR Agonists;Angiogenesis Inhibitors targeting RXRB, RXRG |
| BE-70-YH17_10uM | Dose=10uM, LG 100268, Insulin Sensitizers;ABCA1 Expression Enhancers;Antiinflammatory Drugs;Retinoid RXR Agonists;Angiogenesis Inhibitors targeting RXRB, RXRG |
| BE-70-YH17_1uM | Dose=1uM, LG 100268, Insulin Sensitizers;ABCA1 Expression Enhancers;Antiinflammatory Drugs;Retinoid RXR Agonists;Angiogenesis Inhibitors targeting RXRB, RXRG |
| BE-71-AV63_0.01uM | Dose=0.01uM, N1-(2-Aminophenyl)-N7-phenylheptanediamide, HDACs targeting HDAC1, HDAC3 |
| BE-71-AV63_0.1uM | Dose=0.1uM, N1-(2-Aminophenyl)-N7-phenylheptanediamide, HDACs targeting HDAC1, HDAC3 |
| BE-71-AV63_10uM | Dose=10uM, N1-(2-Aminophenyl)-N7-phenylheptanediamide, HDACs targeting HDAC1, HDAC3 |
| BE-71-AV63_1uM | Dose=1uM, N1-(2-Aminophenyl)-N7-phenylheptanediamide, HDACs targeting HDAC1, HDAC3 |
| BE-72-EW73_10uM | Dose=10uM, Roscovitine, CDK inhibitors targeting CDK2, CDK5R1, CCNA1, CCNB2, CCNE2, CCNB3 |
| BE-73-EJ14_0.01uM | Dose=0.01uM |
| BE-73-EJ14_0.1uM | Dose=0.1uM |
| BE-73-EJ14_10uM | Dose=10uM |
| BE-73-EJ14_1uM | Dose=1uM |
| BE-73-IJ64_0.01uM | Dose=0.01uM, (1-methylcyclopropyl) 4-[[5-[2-oxo-4-[(3S)-pyrrolidin-3-yl]sulfonylpiperazin-1-yl]pyrazin-2-yl]oxymethyl]piperidine-1-carboxylate |
| BE-73-IJ64_0.1uM | Dose=0.1uM, (1-methylcyclopropyl) 4-[[5-[2-oxo-4-[(3S)-pyrrolidin-3-yl]sulfonylpiperazin-1-yl]pyrazin-2-yl]oxymethyl]piperidine-1-carboxylate |
| BE-73-IJ64_10uM | Dose=10uM, (1-methylcyclopropyl) 4-[[5-[2-oxo-4-[(3S)-pyrrolidin-3-yl]sulfonylpiperazin-1-yl]pyrazin-2-yl]oxymethyl]piperidine-1-carboxylate |
| BE-73-IJ64_1uM | Dose=1uM, (1-methylcyclopropyl) 4-[[5-[2-oxo-4-[(3S)-pyrrolidin-3-yl]sulfonylpiperazin-1-yl]pyrazin-2-yl]oxymethyl]piperidine-1-carboxylate |
| BE-73-KD75_0.01uM | Dose=0.01uM, 6-[(7-Nitro-2,1,3-Benzoxadiazol-4-Yl)sulfanyl]hexan-1-Ol, Glutathione-S-Transferase P1 (GSTP1) Inhibitors targeting GSTM2, GSTP1 |
| BE-73-KD75_0.1uM | Dose=0.1uM, 6-[(7-Nitro-2,1,3-Benzoxadiazol-4-Yl)sulfanyl]hexan-1-Ol, Glutathione-S-Transferase P1 (GSTP1) Inhibitors targeting GSTM2, GSTP1 |
| BE-73-KD75_10uM | Dose=10uM, 6-[(7-Nitro-2,1,3-Benzoxadiazol-4-Yl)sulfanyl]hexan-1-Ol, Glutathione-S-Transferase P1 (GSTP1) Inhibitors targeting GSTM2, GSTP1 |
| BE-73-KD75_1uM | Dose=1uM, 6-[(7-Nitro-2,1,3-Benzoxadiazol-4-Yl)sulfanyl]hexan-1-Ol, Glutathione-S-Transferase P1 (GSTP1) Inhibitors targeting GSTM2, GSTP1 |
| BE-74-SX40_0.01uM | Dose=0.01uM, 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine, HRH3 antagonist targeting HRH3 |
| BE-74-SX40_0.1uM | Dose=0.1uM, 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine, HRH3 antagonist targeting HRH3 |
| BE-74-SX40_10uM | Dose=10uM, 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine, HRH3 antagonist targeting HRH3 |
| BE-74-SX40_1uM | Dose=1uM, 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine, HRH3 antagonist targeting HRH3 |
| BE-76-XL76_0.01uM | Dose=0.01uM, (1-Carbamoyl-3-{[(1R,3S,5R)-3-(3-chloro-2-fluoro-benzylcarbamoyl)-2-aza-bicyclo[3.1.0]hexane-2-carbonyl]-amino}-1H-indol-5-yloxy)-acetic acid, Complement Factor D (CFD) Inhibitor targeting CFD |
| BE-76-XL76_0.1uM | Dose=0.1uM, (1-Carbamoyl-3-{[(1R,3S,5R)-3-(3-chloro-2-fluoro-benzylcarbamoyl)-2-aza-bicyclo[3.1.0]hexane-2-carbonyl]-amino}-1H-indol-5-yloxy)-acetic acid, Complement Factor D (CFD) Inhibitor targeting CFD |
| BE-76-XL76_1uM | Dose=1uM, (1-Carbamoyl-3-{[(1R,3S,5R)-3-(3-chloro-2-fluoro-benzylcarbamoyl)-2-aza-bicyclo[3.1.0]hexane-2-carbonyl]-amino}-1H-indol-5-yloxy)-acetic acid, Complement Factor D (CFD) Inhibitor targeting CFD |
| BE-77-XF69_0.01uM | Dose=0.01uM |
| BE-77-XF69_0.1uM | Dose=0.1uM |
| BE-77-XF69_10uM | Dose=10uM |
| BE-77-XF69_1uM | Dose=1uM |
| BE-79-PQ70_0.01uM | Dose=0.01uM, 1-[3-Amino-6-(3,4,5-Trimethoxyphenyl)pyrazin-2-Yl]piperidine-4-Carboxylic Acid, NEK2 gene inhibitor targeting NEK2 |
| BE-79-PQ70_10uM | Dose=10uM, 1-[3-Amino-6-(3,4,5-Trimethoxyphenyl)pyrazin-2-Yl]piperidine-4-Carboxylic Acid, NEK2 gene inhibitor targeting NEK2 |
| BE-79-PQ70_1uM | Dose=1uM, 1-[3-Amino-6-(3,4,5-Trimethoxyphenyl)pyrazin-2-Yl]piperidine-4-Carboxylic Acid, NEK2 gene inhibitor targeting NEK2 |
| BE-79-QU25_0.01uM | Dose=0.01uM, Emetine, Translation inhibitor targeting RPS14, RPS20 |
| BE-79-QU25_0.1uM | Dose=0.1uM, Emetine, Translation inhibitor targeting RPS14, RPS20 |
| BE-79-QU25_10uM | Dose=10uM, Emetine, Translation inhibitor targeting RPS14, RPS20 |
| BE-79-QU25_1uM | Dose=1uM, Emetine, Translation inhibitor targeting RPS14, RPS20 |
| BE-81-QL64_0.01uM | Dose=0.01uM, Ponatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR |
| BE-81-QL64_0.1uM | Dose=0.1uM, Ponatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR |
| BE-81-QL64_10uM | Dose=10uM, Ponatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR |
| BE-81-QL64_1uM | Dose=1uM, Ponatinib, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR |
| BE-82-MI84_0.01uM | Dose=0.01uM, Pamidronic Acid, Farnesyl Pyrophosphate Synthase Inhibitors targeting FDPS |
| BE-82-MI84_0.1uM | Dose=0.1uM, Pamidronic Acid, Farnesyl Pyrophosphate Synthase Inhibitors targeting FDPS |
| BE-82-MI84_10uM | Dose=10uM, Pamidronic Acid, Farnesyl Pyrophosphate Synthase Inhibitors targeting FDPS |
| BE-82-TS38_0.01uM | Dose=0.01uM, 4-Chlorodiazepam, Peripheral Benzodiazepine Receptor (PBR) Agonists targeting TSPO |
| BE-82-TS38_0.1uM | Dose=0.1uM, 4-Chlorodiazepam, Peripheral Benzodiazepine Receptor (PBR) Agonists targeting TSPO |
| BE-82-TS38_10uM | Dose=10uM, 4-Chlorodiazepam, Peripheral Benzodiazepine Receptor (PBR) Agonists targeting TSPO |
| BE-82-TS38_1uM | Dose=1uM, 4-Chlorodiazepam, Peripheral Benzodiazepine Receptor (PBR) Agonists targeting TSPO |
| BE-85-CH49_0.01uM | Dose=0.01uM, 3-Bromopyruvic acid, HK2 inhibitor targeting HK2 |
| BE-85-CH49_0.1uM | Dose=0.1uM, 3-Bromopyruvic acid, HK2 inhibitor targeting HK2 |
| BE-85-CH49_10uM | Dose=10uM, 3-Bromopyruvic acid, HK2 inhibitor targeting HK2 |
| BE-85-CH49_1uM | Dose=1uM, 3-Bromopyruvic acid, HK2 inhibitor targeting HK2 |
| BE-86-FY67_0.01uM | Dose=0.01uM, Enoxolone, 11-beta-Hydroxysteroid Dehydrogenase Type 2 (11beta-HSD2) Inhibitors;17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1, HSD11B2, HSD17B3 |
| BE-86-FY67_0.1uM | Dose=0.1uM, Enoxolone, 11-beta-Hydroxysteroid Dehydrogenase Type 2 (11beta-HSD2) Inhibitors;17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1, HSD11B2, HSD17B3 |
| BE-86-FY67_10uM | Dose=10uM, Enoxolone, 11-beta-Hydroxysteroid Dehydrogenase Type 2 (11beta-HSD2) Inhibitors;17beta-Hydroxysteroid Dehydrogenase Type 3 (17beta-HSD3) Inhibitors;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors targeting HSD11B1, HSD11B2, HSD17B3 |
| BE-87-TM66_0.01uM | Dose=0.01uM, [4-(5-aminomethyl-2-fluorophenyl)piperidine-1-yl][7-fluoro-1-(2-methoxyethyl)-4-trifluoromethoxy-1H-indol-3-yl]methanone, Known Tryptase inhibitor targeting TPSB2 |
| BE-87-TM66_10uM | Dose=10uM, [4-(5-aminomethyl-2-fluorophenyl)piperidine-1-yl][7-fluoro-1-(2-methoxyethyl)-4-trifluoromethoxy-1H-indol-3-yl]methanone, Known Tryptase inhibitor targeting TPSB2 |
| BE-89-DG86_0.01uM | Dose=0.01uM, 4-methyl-3-[[1-[6-[(4-methylpiperazin-1-yl)amino]pyrimidin-4-yl]imidazol-2-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide |
| BE-89-DG86_0.1uM | Dose=0.1uM, 4-methyl-3-[[1-[6-[(4-methylpiperazin-1-yl)amino]pyrimidin-4-yl]imidazol-2-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide |
| BE-89-DG86_10uM | Dose=10uM, 4-methyl-3-[[1-[6-[(4-methylpiperazin-1-yl)amino]pyrimidin-4-yl]imidazol-2-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide |
| BE-89-DG86_1uM | Dose=1uM, 4-methyl-3-[[1-[6-[(4-methylpiperazin-1-yl)amino]pyrimidin-4-yl]imidazol-2-yl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide |
| BE-90-IY33_0.01uM | Dose=0.01uM, Vamifeport, Ferroportin inhibitor targeting SLC40A1 |
| BE-90-IY33_0.1uM | Dose=0.1uM, Vamifeport, Ferroportin inhibitor targeting SLC40A1 |
| BE-90-IY33_10uM | Dose=10uM, Vamifeport, Ferroportin inhibitor targeting SLC40A1 |
| BE-90-YK54_0.01uM | Dose=0.01uM, 7-Methoxy-2-oxo-8-propyl-2H-chromene-3-carboxylic acid (4-aminomethyl-phenyl)-amide, Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| BE-90-YK54_0.1uM | Dose=0.1uM, 7-Methoxy-2-oxo-8-propyl-2H-chromene-3-carboxylic acid (4-aminomethyl-phenyl)-amide, Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| BE-90-YK54_10uM | Dose=10uM, 7-Methoxy-2-oxo-8-propyl-2H-chromene-3-carboxylic acid (4-aminomethyl-phenyl)-amide, Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| BE-90-YK54_1uM | Dose=1uM, 7-Methoxy-2-oxo-8-propyl-2H-chromene-3-carboxylic acid (4-aminomethyl-phenyl)-amide, Lysophospholipid edg1 (S1P1) Receptor Agonists targeting S1PR1 |
| BE-92-TW08_0.01uM | Dose=0.01uM, 4-[(1E)-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-methylhydrazin-1-ylidene}methyl]-2-methyl-6-oxo-1,4,5,6-tetrahydropyridine-3-carbonitrile, ABCA1 Expression Inhibitors;Cholesterol Absorption Inhibitors;Niemann-Pick C1-like protein 1 (NPC1L1) Inhibitors;HMGCS2 Expression Enhancers targeting ABCA1, NPC1L1 |
| BE-92-TW08_10uM | Dose=10uM, 4-[(1E)-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-methylhydrazin-1-ylidene}methyl]-2-methyl-6-oxo-1,4,5,6-tetrahydropyridine-3-carbonitrile, ABCA1 Expression Inhibitors;Cholesterol Absorption Inhibitors;Niemann-Pick C1-like protein 1 (NPC1L1) Inhibitors;HMGCS2 Expression Enhancers targeting ABCA1, NPC1L1 |
| BE-92-TW08_1uM | Dose=1uM, 4-[(1E)-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-2-methylhydrazin-1-ylidene}methyl]-2-methyl-6-oxo-1,4,5,6-tetrahydropyridine-3-carbonitrile, ABCA1 Expression Inhibitors;Cholesterol Absorption Inhibitors;Niemann-Pick C1-like protein 1 (NPC1L1) Inhibitors;HMGCS2 Expression Enhancers targeting ABCA1, NPC1L1 |
| BE-95-OR23_0.01uM | Dose=0.01uM, (R)-2-Hydroxy-N,N-dimethyl-3-((2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)benzamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists;Angiogenesis Inhibitors;Apoptosis Inducers;Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists targeting CXCR1, CXCR2 |
| BE-95-OR23_10uM | Dose=10uM, (R)-2-Hydroxy-N,N-dimethyl-3-((2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)benzamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists;Angiogenesis Inhibitors;Apoptosis Inducers;Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists targeting CXCR1, CXCR2 |
| BE-95-OR23_1uM | Dose=1uM, (R)-2-Hydroxy-N,N-dimethyl-3-((2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)benzamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists;Angiogenesis Inhibitors;Apoptosis Inducers;Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists targeting CXCR1, CXCR2 |
| BF-00-PE90_0.01uM | Dose=0.01uM, Cambridge id 5572089, Potassium Channel Activators; ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting ABCG2 |
| BF-00-PE90_0.1uM | Dose=0.1uM, Cambridge id 5572089, Potassium Channel Activators; ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting ABCG2 |
| BF-00-PE90_10uM | Dose=10uM, Cambridge id 5572089, Potassium Channel Activators; ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting ABCG2 |
| BF-02-AC35_0.01uM | Dose=0.01uM, 1-Cyclopropyl-3-[4-(1-phenylpyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl]urea |
| BF-02-AC35_0.1uM | Dose=0.1uM, 1-Cyclopropyl-3-[4-(1-phenylpyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl]urea |
| BF-02-AC35_10uM | Dose=10uM, 1-Cyclopropyl-3-[4-(1-phenylpyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl]urea |
| BF-02-AC35_1uM | Dose=1uM, 1-Cyclopropyl-3-[4-(1-phenylpyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl]urea |
| BF-02-AC95_0.01uM | Dose=0.01uM, 3,3'-((Propane-2,2-diylbis(2,6-dibromo-4,1-phenylene))bis(oxy))bis(1-morpholinopropan-2-ol), beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP |
| BF-02-AC95_0.1uM | Dose=0.1uM, 3,3'-((Propane-2,2-diylbis(2,6-dibromo-4,1-phenylene))bis(oxy))bis(1-morpholinopropan-2-ol), beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP |
| BF-02-AC95_10uM | Dose=10uM, 3,3'-((Propane-2,2-diylbis(2,6-dibromo-4,1-phenylene))bis(oxy))bis(1-morpholinopropan-2-ol), beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP |
| BF-02-AC95_1uM | Dose=1uM, 3,3'-((Propane-2,2-diylbis(2,6-dibromo-4,1-phenylene))bis(oxy))bis(1-morpholinopropan-2-ol), beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP |
| BF-02-QT56_0.01uM | Dose=0.01uM, Doxifluridine, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors;Apoptosis Inducers targeting TYMS |
| BF-02-QT56_0.1uM | Dose=0.1uM, Doxifluridine, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors;Apoptosis Inducers targeting TYMS |
| BF-02-QT56_10uM | Dose=10uM, Doxifluridine, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors;Apoptosis Inducers targeting TYMS |
| BF-02-QT56_1uM | Dose=1uM, Doxifluridine, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors;Apoptosis Inducers targeting TYMS |
| BF-03-RM76_0.01uM | Dose=0.01uM, N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)carbamoyl]amino]benzamide, Angiogenesis Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Flt3 (FLK2/STK1) Inhibitors;FGFR3 Inhibitors targeting ABL1, BCR, FGFR3, FLT3, ABL2 |
| BF-03-RM76_0.1uM | Dose=0.1uM, N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)carbamoyl]amino]benzamide, Angiogenesis Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Flt3 (FLK2/STK1) Inhibitors;FGFR3 Inhibitors targeting ABL1, BCR, FGFR3, FLT3, ABL2 |
| BF-03-RM76_10uM | Dose=10uM, N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)carbamoyl]amino]benzamide, Angiogenesis Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Flt3 (FLK2/STK1) Inhibitors;FGFR3 Inhibitors targeting ABL1, BCR, FGFR3, FLT3, ABL2 |
| BF-03-RM76_1uM | Dose=1uM, N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)carbamoyl]amino]benzamide, Angiogenesis Inhibitors;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;Flt3 (FLK2/STK1) Inhibitors;FGFR3 Inhibitors targeting ABL1, BCR, FGFR3, FLT3, ABL2 |
| BF-04-NQ13_0.01uM | Dose=0.01uM, Benzoic acid 6,6-dimethyl-3-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl ester |
| BF-04-NQ13_0.1uM | Dose=0.1uM, Benzoic acid 6,6-dimethyl-3-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl ester |
| BF-04-NQ13_10uM | Dose=10uM, Benzoic acid 6,6-dimethyl-3-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl ester |
| BF-04-NQ13_1uM | Dose=1uM, Benzoic acid 6,6-dimethyl-3-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)-5,6,7,8-tetrahydronaphthalen-2-yl ester |
| BF-05-EV13_0.01uM | Dose=0.01uM, Calpain Inhibitor III, Calpain Inhibitors targeting CAPN1 |
| BF-05-EV13_0.1uM | Dose=0.1uM, Calpain Inhibitor III, Calpain Inhibitors targeting CAPN1 |
| BF-05-EV13_1uM | Dose=1uM, Calpain Inhibitor III, Calpain Inhibitors targeting CAPN1 |
| BF-08-RW47_0.01uM | Dose=0.01uM, N,N-dimethyl-2-(5-phenyl-1H-indol-3-yl)ethanamine, HTR1D agonist;5-HT1D Agonists targeting HTR1D |
| BF-08-RW47_0.1uM | Dose=0.1uM, N,N-dimethyl-2-(5-phenyl-1H-indol-3-yl)ethanamine, HTR1D agonist;5-HT1D Agonists targeting HTR1D |
| BF-08-RW47_10uM | Dose=10uM, N,N-dimethyl-2-(5-phenyl-1H-indol-3-yl)ethanamine, HTR1D agonist;5-HT1D Agonists targeting HTR1D |
| BF-08-RW47_1uM | Dose=1uM, N,N-dimethyl-2-(5-phenyl-1H-indol-3-yl)ethanamine, HTR1D agonist;5-HT1D Agonists targeting HTR1D |
| BF-10-IO69_0.01uM | Dose=0.01uM, Gemcitabine, DNA Damaging Agent;Ribonucleotide Reductase inhibitor targeting SLC29A1, SLC29A2, RRM1, RRM2, TYMS, SLC29A3 |
| BF-10-IO69_0.1uM | Dose=0.1uM, Gemcitabine, DNA Damaging Agent;Ribonucleotide Reductase inhibitor targeting SLC29A1, SLC29A2, RRM1, RRM2, TYMS, SLC29A3 |
| BF-10-IO69_10uM | Dose=10uM, Gemcitabine, DNA Damaging Agent;Ribonucleotide Reductase inhibitor targeting SLC29A1, SLC29A2, RRM1, RRM2, TYMS, SLC29A3 |
| BF-10-IO69_1uM | Dose=1uM, Gemcitabine, DNA Damaging Agent;Ribonucleotide Reductase inhibitor targeting SLC29A1, SLC29A2, RRM1, RRM2, TYMS, SLC29A3 |
| BF-12-AC65_0.01uM | Dose=0.01uM, ACAT Inhibitors |
| BF-12-AC65_1uM | Dose=1uM, ACAT Inhibitors |
| BF-13-HM71_0.01uM | Dose=0.01uM, 5-chloro-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine, ALK Inhibitors targeting ALK |
| BF-13-HM71_0.1uM | Dose=0.1uM, 5-chloro-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine, ALK Inhibitors targeting ALK |
| BF-13-HM71_10uM | Dose=10uM, 5-chloro-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine, ALK Inhibitors targeting ALK |
| BF-13-HM71_1uM | Dose=1uM, 5-chloro-2-N-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-propan-2-yloxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine, ALK Inhibitors targeting ALK |
| BF-18-MJ41_0.01uM | Dose=0.01uM, 2-[(6-Methylpyridin-2-Yl)carbamoyl]-5-(Trifluoromethyl)benzoic Acid, sortilin inhibitor (SORT1) targeting SORT1 |
| BF-18-MJ41_0.1uM | Dose=0.1uM, 2-[(6-Methylpyridin-2-Yl)carbamoyl]-5-(Trifluoromethyl)benzoic Acid, sortilin inhibitor (SORT1) targeting SORT1 |
| BF-18-MJ41_10uM | Dose=10uM, 2-[(6-Methylpyridin-2-Yl)carbamoyl]-5-(Trifluoromethyl)benzoic Acid, sortilin inhibitor (SORT1) targeting SORT1 |
| BF-18-MJ41_1uM | Dose=1uM, 2-[(6-Methylpyridin-2-Yl)carbamoyl]-5-(Trifluoromethyl)benzoic Acid, sortilin inhibitor (SORT1) targeting SORT1 |
| BF-19-KU00_0.01uM | Dose=0.01uM, Carmofur, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors targeting TYMS |
| BF-19-KU00_10uM | Dose=10uM, Carmofur, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors targeting TYMS |
| BF-19-KU00_1uM | Dose=1uM, Carmofur, Pyrimidine Antagonists;Thymidylate Synthase Inhibitors targeting TYMS |
| BF-22-EP86_0.01uM | Dose=0.01uM, Gsk-1059615, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| BF-22-EP86_0.1uM | Dose=0.1uM, Gsk-1059615, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| BF-22-EP86_10uM | Dose=10uM, Gsk-1059615, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| BF-22-EP86_1uM | Dose=1uM, Gsk-1059615, Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA |
| BF-24-JN36_0.01uM | Dose=0.01uM, 6-[(3~{R})-3-oxidanylpyrrolidin-1-yl]-5-pyrimidin-5-yl-~{N}-[4-(trifluoromethyloxy)phenyl]pyridine-3-carboxamide, Allosteric ABL1 inhibitor targeting ABL1, ABL2 |
| BF-24-JN36_0.1uM | Dose=0.1uM, 6-[(3~{R})-3-oxidanylpyrrolidin-1-yl]-5-pyrimidin-5-yl-~{N}-[4-(trifluoromethyloxy)phenyl]pyridine-3-carboxamide, Allosteric ABL1 inhibitor targeting ABL1, ABL2 |
| BF-24-JN36_10uM | Dose=10uM, 6-[(3~{R})-3-oxidanylpyrrolidin-1-yl]-5-pyrimidin-5-yl-~{N}-[4-(trifluoromethyloxy)phenyl]pyridine-3-carboxamide, Allosteric ABL1 inhibitor targeting ABL1, ABL2 |
| BF-24-JN36_1uM | Dose=1uM, 6-[(3~{R})-3-oxidanylpyrrolidin-1-yl]-5-pyrimidin-5-yl-~{N}-[4-(trifluoromethyloxy)phenyl]pyridine-3-carboxamide, Allosteric ABL1 inhibitor targeting ABL1, ABL2 |
| BF-26-MB27_0.01uM | Dose=0.01uM, Izorlisib, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA, PIK3CB, PIK3CG |
| BF-26-MB27_0.1uM | Dose=0.1uM, Izorlisib, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA, PIK3CB, PIK3CG |
| BF-26-MB27_10uM | Dose=10uM, Izorlisib, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA, PIK3CB, PIK3CG |
| BF-26-MB27_1uM | Dose=1uM, Izorlisib, Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3CA, PIK3CB, PIK3CG |
| BF-27-HP68_0.01uM | Dose=0.01uM, Argyrin A, Apoptosis Inducers;Proteasome Inhibitors;GFM1 inhibitor targeting GFM1 |
| BF-27-HP68_0.1uM | Dose=0.1uM, Argyrin A, Apoptosis Inducers;Proteasome Inhibitors;GFM1 inhibitor targeting GFM1 |
| BF-27-HP68_10uM | Dose=10uM, Argyrin A, Apoptosis Inducers;Proteasome Inhibitors;GFM1 inhibitor targeting GFM1 |
| BF-27-HP68_1uM | Dose=1uM, Argyrin A, Apoptosis Inducers;Proteasome Inhibitors;GFM1 inhibitor targeting GFM1 |
| BF-29-LU75_0.01uM | Dose=0.01uM, Voxelotor, Hemoglobin Subunit beta (Sickle Cell Anemia Variant) Polimerization Inhibitors targeting HBB |
| BF-29-LU75_0.1uM | Dose=0.1uM, Voxelotor, Hemoglobin Subunit beta (Sickle Cell Anemia Variant) Polimerization Inhibitors targeting HBB |
| BF-29-LU75_10uM | Dose=10uM, Voxelotor, Hemoglobin Subunit beta (Sickle Cell Anemia Variant) Polimerization Inhibitors targeting HBB |
| BF-29-LU75_1uM | Dose=1uM, Voxelotor, Hemoglobin Subunit beta (Sickle Cell Anemia Variant) Polimerization Inhibitors targeting HBB |
| BF-31-BY55_0.01uM | Dose=0.01uM, 5-[1-Fluoro-3-hydroxy-7-(5-hydroxy-4,4-dimethylpentyl)-naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one |
| BF-31-BY55_0.1uM | Dose=0.1uM, 5-[1-Fluoro-3-hydroxy-7-(5-hydroxy-4,4-dimethylpentyl)-naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one |
| BF-31-BY55_10uM | Dose=10uM, 5-[1-Fluoro-3-hydroxy-7-(5-hydroxy-4,4-dimethylpentyl)-naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one |
| BF-31-BY55_1uM | Dose=1uM, 5-[1-Fluoro-3-hydroxy-7-(5-hydroxy-4,4-dimethylpentyl)-naphthalen-2-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one |
| BF-32-CI54_0.01uM | Dose=0.01uM |
| BF-32-CI54_0.1uM | Dose=0.1uM |
| BF-32-CI54_10uM | Dose=10uM |
| BF-32-CI54_1uM | Dose=1uM |
| BF-34-DG44_0.01uM | Dose=0.01uM, CID 6509858 |
| BF-34-DG44_0.1uM | Dose=0.1uM, CID 6509858 |
| BF-34-DG44_10uM | Dose=10uM, CID 6509858 |
| BF-41-MV83_0.01uM | Dose=0.01uM, Edaravone |
| BF-41-MV83_0.1uM | Dose=0.1uM, Edaravone |
| BF-41-MV83_10uM | Dose=10uM, Edaravone |
| BF-44-HD37_0.01uM | Dose=0.01uM, 3-[5-[[5-(4-Chlorophenyl)-1,2,4-oxadiazol-3-yl]amino]-2-methylphenyl]-1,7-dimethyl-1,6-naphthyridin-2-one, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors targeting KIT, PDGFRA, PDGFRB |
| BF-44-HD37_0.1uM | Dose=0.1uM, 3-[5-[[5-(4-Chlorophenyl)-1,2,4-oxadiazol-3-yl]amino]-2-methylphenyl]-1,7-dimethyl-1,6-naphthyridin-2-one, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors targeting KIT, PDGFRA, PDGFRB |
| BF-44-HD37_10uM | Dose=10uM, 3-[5-[[5-(4-Chlorophenyl)-1,2,4-oxadiazol-3-yl]amino]-2-methylphenyl]-1,7-dimethyl-1,6-naphthyridin-2-one, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors targeting KIT, PDGFRA, PDGFRB |
| BF-44-HD37_1uM | Dose=1uM, 3-[5-[[5-(4-Chlorophenyl)-1,2,4-oxadiazol-3-yl]amino]-2-methylphenyl]-1,7-dimethyl-1,6-naphthyridin-2-one, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors targeting KIT, PDGFRA, PDGFRB |
| BF-44-RX10_0.01uM | Dose=0.01uM, N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor;SMURF1 inhibitor targeting SMURF1 |
| BF-44-RX10_0.1uM | Dose=0.1uM, N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor;SMURF1 inhibitor targeting SMURF1 |
| BF-44-RX10_10uM | Dose=10uM, N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor;SMURF1 inhibitor targeting SMURF1 |
| BF-44-RX10_1uM | Dose=1uM, N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-12-(trifluoromethoxy)-3-oxa-4-azatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide, SMAD-1 inhibitor;SMURF1 inhibitor targeting SMURF1 |
| BF-49-IA57_0.01uM | Dose=0.01uM, N-Hydroxyphthalimide, Ribonucleoside-Diphosphate Reductase Inhibitors targeting RRM1, GABRA1, RRM2 |
| BF-49-IA57_0.1uM | Dose=0.1uM, N-Hydroxyphthalimide, Ribonucleoside-Diphosphate Reductase Inhibitors targeting RRM1, GABRA1, RRM2 |
| BF-49-IA57_10uM | Dose=10uM, N-Hydroxyphthalimide, Ribonucleoside-Diphosphate Reductase Inhibitors targeting RRM1, GABRA1, RRM2 |
| BF-49-IA57_1uM | Dose=1uM, N-Hydroxyphthalimide, Ribonucleoside-Diphosphate Reductase Inhibitors targeting RRM1, GABRA1, RRM2 |
| BF-49-KQ10_0.01uM | Dose=0.01uM, (2S)-1-N-[5-(2-tert-butylpyrimidin-4-yl)-4-methyl-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide, Selective PI3Kalpha inhibitor targeting PIK3CA |
| BF-49-KQ10_0.1uM | Dose=0.1uM, (2S)-1-N-[5-(2-tert-butylpyrimidin-4-yl)-4-methyl-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide, Selective PI3Kalpha inhibitor targeting PIK3CA |
| BF-49-KQ10_10uM | Dose=10uM, (2S)-1-N-[5-(2-tert-butylpyrimidin-4-yl)-4-methyl-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide, Selective PI3Kalpha inhibitor targeting PIK3CA |
| BF-49-KQ10_1uM | Dose=1uM, (2S)-1-N-[5-(2-tert-butylpyrimidin-4-yl)-4-methyl-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide, Selective PI3Kalpha inhibitor targeting PIK3CA |
| BF-49-QA17_10uM | Dose=10uM, Vaf347 |
| BF-49-QA17_1uM | Dose=1uM, Vaf347 |
| BF-51-OI57_0.01uM | Dose=0.01uM, Tolazamide |
| BF-51-OI57_0.1uM | Dose=0.1uM, Tolazamide |
| BF-51-OI57_1uM | Dose=1uM, Tolazamide |
| BF-52-HF07_0.01uM | Dose=0.01uM, APOA1 Expression Enhancers;BRD2/3/4/T BET familiy inhibitor;BRD4 inhibitor targeting BRD4 |
| BF-52-HF07_0.1uM | Dose=0.1uM, APOA1 Expression Enhancers;BRD2/3/4/T BET familiy inhibitor;BRD4 inhibitor targeting BRD4 |
| BF-52-HF07_10uM | Dose=10uM, APOA1 Expression Enhancers;BRD2/3/4/T BET familiy inhibitor;BRD4 inhibitor targeting BRD4 |
| BF-53-AT13_0.01uM | Dose=0.01uM, 8-chloro-N-(4-(methylcarbamoyl)pyridin-2-yl)spiro[chroman-2,4'-piperidine]-1'-carboxamide, scd inhibitor targeting SCD |
| BF-53-AT13_0.1uM | Dose=0.1uM, 8-chloro-N-(4-(methylcarbamoyl)pyridin-2-yl)spiro[chroman-2,4'-piperidine]-1'-carboxamide, scd inhibitor targeting SCD |
| BF-53-AT13_10uM | Dose=10uM, 8-chloro-N-(4-(methylcarbamoyl)pyridin-2-yl)spiro[chroman-2,4'-piperidine]-1'-carboxamide, scd inhibitor targeting SCD |
| BF-53-AT13_1uM | Dose=1uM, 8-chloro-N-(4-(methylcarbamoyl)pyridin-2-yl)spiro[chroman-2,4'-piperidine]-1'-carboxamide, scd inhibitor targeting SCD |
| BF-54-GX35_0.01uM | Dose=0.01uM |
| BF-54-GX35_0.1uM | Dose=0.1uM |
| BF-54-GX35_10uM | Dose=10uM |
| BF-54-GX35_1uM | Dose=1uM |
| BF-55-JR43_0.1uM | Dose=0.1uM, (3R)-1-[[3-[[(1S)-1-(4-chloro-3-methylphenyl)-2,2,2-trifluoroethyl]amino]-2,6-dimethylphenyl]methyl]pyrrolidine-3-carboxylic acid, S1PR1 antagonist targeting S1PR1 |
| BF-55-JR43_1uM | Dose=1uM, (3R)-1-[[3-[[(1S)-1-(4-chloro-3-methylphenyl)-2,2,2-trifluoroethyl]amino]-2,6-dimethylphenyl]methyl]pyrrolidine-3-carboxylic acid, S1PR1 antagonist targeting S1PR1 |
| BF-57-II91_0.01uM | Dose=0.01uM, (E)-3-[4-(3,5-Diisopropyl-2-propoxy-phenyl)-benzo[b]thiophen-2-yl]-but-2-enoic acid, Retinoid RXRalpha Antagonists targeting RXRA |
| BF-57-II91_0.1uM | Dose=0.1uM, (E)-3-[4-(3,5-Diisopropyl-2-propoxy-phenyl)-benzo[b]thiophen-2-yl]-but-2-enoic acid, Retinoid RXRalpha Antagonists targeting RXRA |
| BF-57-II91_1uM | Dose=1uM, (E)-3-[4-(3,5-Diisopropyl-2-propoxy-phenyl)-benzo[b]thiophen-2-yl]-but-2-enoic acid, Retinoid RXRalpha Antagonists targeting RXRA |
| BF-59-OR93_0.01uM | Dose=0.01uM, Liothyronine, Thyroid hormone receptor alpha agonist;Hormone replacement agent targeting THRA, THRB |
| BF-59-OR93_0.1uM | Dose=0.1uM, Liothyronine, Thyroid hormone receptor alpha agonist;Hormone replacement agent targeting THRA, THRB |
| BF-59-OR93_10uM | Dose=10uM, Liothyronine, Thyroid hormone receptor alpha agonist;Hormone replacement agent targeting THRA, THRB |
| BF-59-OR93_1uM | Dose=1uM, Liothyronine, Thyroid hormone receptor alpha agonist;Hormone replacement agent targeting THRA, THRB |
| BF-61-BY15_0.1uM | Dose=0.1uM, 5-[6-[[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1H-indole targeting CHRNA7 |
| BF-61-BY15_10uM | Dose=10uM, 5-[6-[[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1H-indole targeting CHRNA7 |
| BF-61-BY15_1uM | Dose=1uM, 5-[6-[[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1H-indole targeting CHRNA7 |
| BF-61-IO76_0.01uM | Dose=0.01uM, Axitirome, Thyroid Hormone Receptor beta Agonists targeting THRB |
| BF-61-IO76_0.1uM | Dose=0.1uM, Axitirome, Thyroid Hormone Receptor beta Agonists targeting THRB |
| BF-61-IO76_10uM | Dose=10uM, Axitirome, Thyroid Hormone Receptor beta Agonists targeting THRB |
| BF-61-IO76_1uM | Dose=1uM, Axitirome, Thyroid Hormone Receptor beta Agonists targeting THRB |
| BF-63-DQ96_0.01uM | Dose=0.01uM, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL |
| BF-63-DQ96_0.1uM | Dose=0.1uM, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL |
| BF-63-DQ96_10uM | Dose=10uM, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL |
| BF-63-DQ96_1uM | Dose=1uM, Thrombopoietin Receptor (TpoR) Agonists;Signal Transduction Modulators targeting MPL |
| BF-63-NG22_0.1uM | Dose=0.1uM, Tankyrase 2 (TNKS2) Inhibitors;Tankyrase 1 (TNKS1) Inhibitors targeting TNKS, TNKS2 |
| BF-63-NG22_10uM | Dose=10uM, Tankyrase 2 (TNKS2) Inhibitors;Tankyrase 1 (TNKS1) Inhibitors targeting TNKS, TNKS2 |
| BF-63-NG22_1uM | Dose=1uM, Tankyrase 2 (TNKS2) Inhibitors;Tankyrase 1 (TNKS1) Inhibitors targeting TNKS, TNKS2 |
| BF-69-DN58_0.01uM | Dose=0.01uM |
| BF-69-DN58_0.1uM | Dose=0.1uM |
| BF-69-DN58_10uM | Dose=10uM |
| BF-69-DN58_1uM | Dose=1uM |
| BF-69-DX62_0.01uM | Dose=0.01uM, Nibr-1282, Chemokine CCR5 Antagonists targeting CCR5 |
| BF-69-DX62_0.1uM | Dose=0.1uM, Nibr-1282, Chemokine CCR5 Antagonists targeting CCR5 |
| BF-69-DX62_10uM | Dose=10uM, Nibr-1282, Chemokine CCR5 Antagonists targeting CCR5 |
| BF-69-DX62_1uM | Dose=1uM, Nibr-1282, Chemokine CCR5 Antagonists targeting CCR5 |
| BF-72-LI04_0.01uM | Dose=0.01uM, CID 44327160, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| BF-72-LI04_0.1uM | Dose=0.1uM, CID 44327160, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| BF-72-LI04_10uM | Dose=10uM, CID 44327160, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| BF-72-LI04_1uM | Dose=1uM, CID 44327160, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| BF-76-AO03_0.01uM | Dose=0.01uM, ML SA1 |
| BF-76-AO03_0.1uM | Dose=0.1uM, ML SA1 |
| BF-76-AO03_10uM | Dose=10uM, ML SA1 |
| BF-77-FT23_0.01uM | Dose=0.01uM, trans-Ned 19, Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Antagonists targeting TPCN1, TPCN2 |
| BF-77-FT23_0.1uM | Dose=0.1uM, trans-Ned 19, Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Antagonists targeting TPCN1, TPCN2 |
| BF-77-FT23_10uM | Dose=10uM, trans-Ned 19, Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Antagonists targeting TPCN1, TPCN2 |
| BF-77-FT23_1uM | Dose=1uM, trans-Ned 19, Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Antagonists targeting TPCN1, TPCN2 |
| BF-79-GG96_0.01uM | Dose=0.01uM, Idebenone, Antioxidants;Calcium Channel Modulators targeting CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, CACNA2D4 |
| BF-79-GG96_0.1uM | Dose=0.1uM, Idebenone, Antioxidants;Calcium Channel Modulators targeting CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, CACNA2D4 |
| BF-79-GG96_10uM | Dose=10uM, Idebenone, Antioxidants;Calcium Channel Modulators targeting CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, CACNA2D4 |
| BF-79-GG96_1uM | Dose=1uM, Idebenone, Antioxidants;Calcium Channel Modulators targeting CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, CACNA2D4 |
| BF-81-KO31_0.01uM | Dose=0.01uM, (S)-1-(sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2 |
| BF-81-KO31_0.1uM | Dose=0.1uM, (S)-1-(sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2 |
| BF-81-LL19_0.01uM | Dose=0.01uM, Known ACE inhibitor |
| BF-81-LL19_10uM | Dose=10uM, Known ACE inhibitor |
| BF-81-LL19_1uM | Dose=1uM, Known ACE inhibitor |
| BF-89-QD24_0.01uM | Dose=0.01uM |
| BF-89-QD24_0.1uM | Dose=0.1uM |
| BF-89-QD24_10uM | Dose=10uM |
| BF-89-QD24_1uM | Dose=1uM |
| BF-94-CQ58_0.01uM | Dose=0.01uM, 4-bromo-2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylthio)pyridin-3-yl)methyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| BF-94-CQ58_0.1uM | Dose=0.1uM, 4-bromo-2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylthio)pyridin-3-yl)methyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| BF-94-CQ58_10uM | Dose=10uM, 4-bromo-2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylthio)pyridin-3-yl)methyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| BF-94-CQ58_1uM | Dose=1uM, 4-bromo-2-(4-isopropylphenyl)-7-methoxy-1-(2-methoxyethyl)-5-((2-(methylthio)pyridin-3-yl)methyl)-1H-benzo[d]imidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| BF-94-GX05_0.01uM | Dose=0.01uM |
| BF-94-GX05_0.1uM | Dose=0.1uM |
| BF-94-GX05_10uM | Dose=10uM |
| BF-94-GX05_1uM | Dose=1uM |
| BF-94-NX85_0.01uM | Dose=0.01uM, Ipatasertib, AKT inhibitor targeting AKT1, AKT2, AKT3 |
| BF-94-NX85_0.1uM | Dose=0.1uM, Ipatasertib, AKT inhibitor targeting AKT1, AKT2, AKT3 |
| BF-94-NX85_10uM | Dose=10uM, Ipatasertib, AKT inhibitor targeting AKT1, AKT2, AKT3 |
| BF-94-NX85_1uM | Dose=1uM, Ipatasertib, AKT inhibitor targeting AKT1, AKT2, AKT3 |
| BF-95-KA82_0.01uM | Dose=0.01uM, SOAT-1 inhibitor |
| BF-95-KA82_0.1uM | Dose=0.1uM, SOAT-1 inhibitor |
| BF-95-KA82_10uM | Dose=10uM, SOAT-1 inhibitor |
| BF-95-KA82_1uM | Dose=1uM, SOAT-1 inhibitor |
| BF-96-PY22_0.01uM | Dose=0.01uM, trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide |
| BF-96-PY22_0.1uM | Dose=0.1uM, trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide |
| BF-96-PY22_10uM | Dose=10uM, trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide |
| BF-96-PY22_1uM | Dose=1uM, trans-N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-N-(1-benzyl-piperidin-4-yl)-3-phenyl-acrylamide |
| BF-97-LS55_0.01uM | Dose=0.01uM, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| BF-97-LS55_0.1uM | Dose=0.1uM, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| BF-97-LS55_10uM | Dose=10uM, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| BF-97-LS55_1uM | Dose=1uM, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| CA-00-AR16_0.01uM | Dose=0.01uM, (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N'-(5-bromo-2-hydroxybenzylidene)propanehydrazide, soluble adenylyl cyclase inhibitor targeting ADCY10 |
| CA-00-AR16_0.1uM | Dose=0.1uM, (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N'-(5-bromo-2-hydroxybenzylidene)propanehydrazide, soluble adenylyl cyclase inhibitor targeting ADCY10 |
| CA-00-AR16_10uM | Dose=10uM, (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N'-(5-bromo-2-hydroxybenzylidene)propanehydrazide, soluble adenylyl cyclase inhibitor targeting ADCY10 |
| CA-00-AR16_1uM | Dose=1uM, (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N'-(5-bromo-2-hydroxybenzylidene)propanehydrazide, soluble adenylyl cyclase inhibitor targeting ADCY10 |
| CA-06-FY97_0.01uM | Dose=0.01uM, 1-Methylcyclopropyl 4-(((5-(4-((3-(azetidin-1-yl)propyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate, Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Ligands targeting GPR119 |
| CA-06-FY97_0.1uM | Dose=0.1uM, 1-Methylcyclopropyl 4-(((5-(4-((3-(azetidin-1-yl)propyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate, Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Ligands targeting GPR119 |
| CA-06-FY97_10uM | Dose=10uM, 1-Methylcyclopropyl 4-(((5-(4-((3-(azetidin-1-yl)propyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate, Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Ligands targeting GPR119 |
| CA-06-FY97_1uM | Dose=1uM, 1-Methylcyclopropyl 4-(((5-(4-((3-(azetidin-1-yl)propyl)sulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yl)oxy)methyl)piperidine-1-carboxylate, Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Ligands targeting GPR119 |
| CA-07-KS70_0.01uM | Dose=0.01uM, 5-(3-Chlorophenyl)-N-(2-(pyridin-2-yl)ethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, Pim-1 Kinase Inhibitors targeting PIM1 |
| CA-07-KS70_10uM | Dose=10uM, 5-(3-Chlorophenyl)-N-(2-(pyridin-2-yl)ethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, Pim-1 Kinase Inhibitors targeting PIM1 |
| CA-07-KS70_1uM | Dose=1uM, 5-(3-Chlorophenyl)-N-(2-(pyridin-2-yl)ethyl)imidazo[2,1-b][1,3,4]thiadiazol-2-amine, Pim-1 Kinase Inhibitors targeting PIM1 |
| CA-08-ON66_0.01uM | Dose=0.01uM, 3-Cyano-5-(trifluoromethyl)benzyl 4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate, Autotaxin inhibitor targeting ENPP2 |
| CA-08-ON66_0.1uM | Dose=0.1uM, 3-Cyano-5-(trifluoromethyl)benzyl 4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate, Autotaxin inhibitor targeting ENPP2 |
| CA-08-ON66_10uM | Dose=10uM, 3-Cyano-5-(trifluoromethyl)benzyl 4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate, Autotaxin inhibitor targeting ENPP2 |
| CA-08-ON66_1uM | Dose=1uM, 3-Cyano-5-(trifluoromethyl)benzyl 4-(4-(1H-1,2,3-triazol-4-yl)butanamido)piperidine-1-carboxylate, Autotaxin inhibitor targeting ENPP2 |
| CA-10-RU23_0.01uM | Dose=0.01uM, Biphenylindanone A, GRM2 agonist;mgluR2 Positive Allosteric Modulator targeting GRM2 |
| CA-10-RU23_0.1uM | Dose=0.1uM, Biphenylindanone A, GRM2 agonist;mgluR2 Positive Allosteric Modulator targeting GRM2 |
| CA-10-RU23_10uM | Dose=10uM, Biphenylindanone A, GRM2 agonist;mgluR2 Positive Allosteric Modulator targeting GRM2 |
| CA-10-RU23_1uM | Dose=1uM, Biphenylindanone A, GRM2 agonist;mgluR2 Positive Allosteric Modulator targeting GRM2 |
| CA-11-KY95_0.01uM | Dose=0.01uM, P5091, Ubiquitin C-terminal Hydrolase Inhibitors 7 (USP7| HAUSP) Inhibitors targeting USP7 |
| CA-11-KY95_0.1uM | Dose=0.1uM, P5091, Ubiquitin C-terminal Hydrolase Inhibitors 7 (USP7| HAUSP) Inhibitors targeting USP7 |
| CA-11-KY95_10uM | Dose=10uM, P5091, Ubiquitin C-terminal Hydrolase Inhibitors 7 (USP7| HAUSP) Inhibitors targeting USP7 |
| CA-11-KY95_1uM | Dose=1uM, P5091, Ubiquitin C-terminal Hydrolase Inhibitors 7 (USP7| HAUSP) Inhibitors targeting USP7 |
| CA-16-ZL71_0.01uM | Dose=0.01uM, Ceftriaxone, Antibiotic;Antibacterial;organic anion transporter inhibitor targeting SLC15A1, SLC22A6, SLC22A8, SLC22A11, pbp2b |
| CA-16-ZL71_0.1uM | Dose=0.1uM, Ceftriaxone, Antibiotic;Antibacterial;organic anion transporter inhibitor targeting SLC15A1, SLC22A6, SLC22A8, SLC22A11, pbp2b |
| CA-16-ZL71_10uM | Dose=10uM, Ceftriaxone, Antibiotic;Antibacterial;organic anion transporter inhibitor targeting SLC15A1, SLC22A6, SLC22A8, SLC22A11, pbp2b |
| CA-16-ZL71_1uM | Dose=1uM, Ceftriaxone, Antibiotic;Antibacterial;organic anion transporter inhibitor targeting SLC15A1, SLC22A6, SLC22A8, SLC22A11, pbp2b |
| CA-17-QL18_0.01uM | Dose=0.01uM, (2S)-4-cyclohexyl-2-[[1-[(4-nitrophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]butanoic acid, Angiotensin AT2 Antagonists targeting AGTR2 |
| CA-17-QL18_0.1uM | Dose=0.1uM, (2S)-4-cyclohexyl-2-[[1-[(4-nitrophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]butanoic acid, Angiotensin AT2 Antagonists targeting AGTR2 |
| CA-17-QL18_10uM | Dose=10uM, (2S)-4-cyclohexyl-2-[[1-[(4-nitrophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]butanoic acid, Angiotensin AT2 Antagonists targeting AGTR2 |
| CA-17-QL18_1uM | Dose=1uM, (2S)-4-cyclohexyl-2-[[1-[(4-nitrophenyl)methyl]-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]butanoic acid, Angiotensin AT2 Antagonists targeting AGTR2 |
| CA-17-XB39_0.01uM | Dose=0.01uM, Hesperetin, Triglyceride Lowering Agents;TRPM3 Antagonists;Cytochrome P450 CYP1B1 Inhibitors;Lipid Lowering Agents;Antioxidants targeting CYP1B1, TRPM3 |
| CA-17-XB39_0.1uM | Dose=0.1uM, Hesperetin, Triglyceride Lowering Agents;TRPM3 Antagonists;Cytochrome P450 CYP1B1 Inhibitors;Lipid Lowering Agents;Antioxidants targeting CYP1B1, TRPM3 |
| CA-17-XB39_10uM | Dose=10uM, Hesperetin, Triglyceride Lowering Agents;TRPM3 Antagonists;Cytochrome P450 CYP1B1 Inhibitors;Lipid Lowering Agents;Antioxidants targeting CYP1B1, TRPM3 |
| CA-17-XB39_1uM | Dose=1uM, Hesperetin, Triglyceride Lowering Agents;TRPM3 Antagonists;Cytochrome P450 CYP1B1 Inhibitors;Lipid Lowering Agents;Antioxidants targeting CYP1B1, TRPM3 |
| CA-23-BW20_0.01uM | Dose=0.01uM, {1-[(5-Chloro-2,4-dimethoxy-phenylcarbamoyl)-methyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl}-acetic acid, S1PR2 antagonist targeting S1PR2 |
| CA-23-BW20_0.1uM | Dose=0.1uM, {1-[(5-Chloro-2,4-dimethoxy-phenylcarbamoyl)-methyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl}-acetic acid, S1PR2 antagonist targeting S1PR2 |
| CA-23-BW20_10uM | Dose=10uM, {1-[(5-Chloro-2,4-dimethoxy-phenylcarbamoyl)-methyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl}-acetic acid, S1PR2 antagonist targeting S1PR2 |
| CA-23-BW20_1uM | Dose=1uM, {1-[(5-Chloro-2,4-dimethoxy-phenylcarbamoyl)-methyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl}-acetic acid, S1PR2 antagonist targeting S1PR2 |
| CA-23-CC52_0.01uM | Dose=0.01uM, Gsk417651A, TRPC6 Antagonists;TRPC3 Antagonists targeting TRPC3, TRPC6 |
| CA-23-CC52_0.1uM | Dose=0.1uM, Gsk417651A, TRPC6 Antagonists;TRPC3 Antagonists targeting TRPC3, TRPC6 |
| CA-23-CC52_1uM | Dose=1uM, Gsk417651A, TRPC6 Antagonists;TRPC3 Antagonists targeting TRPC3, TRPC6 |
| CA-25-LR28_0.01uM | Dose=0.01uM, Ramipril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| CA-25-LR28_0.1uM | Dose=0.1uM, Ramipril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| CA-25-LR28_10uM | Dose=10uM, Ramipril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| CA-25-LR28_1uM | Dose=1uM, Ramipril, Angiotensin-I Converting Enzyme (ACE) Inhibitors targeting ACE |
| CA-26-BI29_0.01uM | Dose=0.01uM, Lorglumide, CCK1 (CCKA) Antagonists targeting CCKAR |
| CA-26-BI29_0.1uM | Dose=0.1uM, Lorglumide, CCK1 (CCKA) Antagonists targeting CCKAR |
| CA-26-BI29_10uM | Dose=10uM, Lorglumide, CCK1 (CCKA) Antagonists targeting CCKAR |
| CA-26-BI29_1uM | Dose=1uM, Lorglumide, CCK1 (CCKA) Antagonists targeting CCKAR |
| CA-26-UY62_0.01uM | Dose=0.01uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| CA-26-UY62_0.1uM | Dose=0.1uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| CA-26-UY62_10uM | Dose=10uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| CA-26-UY62_1uM | Dose=1uM, 6-(6-aminopyrimidin-4-yl)oxy-N-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| CA-31-EL19_0.01uM | Dose=0.01uM, 1-((2,6-Difluorophenyl)sulfonyl)-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine, Activator of human pyruvate kinase M2 targeting PKLR, PKM |
| CA-31-EL19_0.1uM | Dose=0.1uM, 1-((2,6-Difluorophenyl)sulfonyl)-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine, Activator of human pyruvate kinase M2 targeting PKLR, PKM |
| CA-31-EL19_10uM | Dose=10uM, 1-((2,6-Difluorophenyl)sulfonyl)-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine, Activator of human pyruvate kinase M2 targeting PKLR, PKM |
| CA-31-EL19_1uM | Dose=1uM, 1-((2,6-Difluorophenyl)sulfonyl)-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine, Activator of human pyruvate kinase M2 targeting PKLR, PKM |
| CA-31-EV03_0.01uM | Dose=0.01uM |
| CA-31-EV03_0.1uM | Dose=0.1uM |
| CA-31-EV03_10uM | Dose=10uM |
| CA-31-EV03_1uM | Dose=1uM |
| CA-32-XV05_0.1uM | Dose=0.1uM, Alrestatin, Aldose Reductase Inhibitors targeting AKR1B1 |
| CA-32-XV05_1uM | Dose=1uM, Alrestatin, Aldose Reductase Inhibitors targeting AKR1B1 |
| CA-37-NI01_0.01uM | Dose=0.01uM, 6-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-1-propan-2-ylpyrazolo[3,4-b]pyridine-4-carboxamide, PRC2/EZH2;EZH2 targeting EZH2 |
| CA-37-NI01_0.1uM | Dose=0.1uM, 6-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-1-propan-2-ylpyrazolo[3,4-b]pyridine-4-carboxamide, PRC2/EZH2;EZH2 targeting EZH2 |
| CA-37-NI01_10uM | Dose=10uM, 6-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-1-propan-2-ylpyrazolo[3,4-b]pyridine-4-carboxamide, PRC2/EZH2;EZH2 targeting EZH2 |
| CA-37-NI01_1uM | Dose=1uM, 6-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-1-propan-2-ylpyrazolo[3,4-b]pyridine-4-carboxamide, PRC2/EZH2;EZH2 targeting EZH2 |
| CA-38-JF31_0.01uM | Dose=0.01uM, Novolactone, covalent HSP70 inhibitor targeting HSPA1A, HSPA4, HSPA8 |
| CA-38-JF31_0.1uM | Dose=0.1uM, Novolactone, covalent HSP70 inhibitor targeting HSPA1A, HSPA4, HSPA8 |
| CA-38-JF31_10uM | Dose=10uM, Novolactone, covalent HSP70 inhibitor targeting HSPA1A, HSPA4, HSPA8 |
| CA-38-JF31_1uM | Dose=1uM, Novolactone, covalent HSP70 inhibitor targeting HSPA1A, HSPA4, HSPA8 |
| CA-39-ZJ18_0.01uM | Dose=0.01uM, Aspirin, Non-Steroidal Antiinflammatory Drugs;Nitric Oxide Donors;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;TP53 Expression Enhancers targeting PTGS1, PTGS2, TP53 |
| CA-39-ZJ18_0.1uM | Dose=0.1uM, Aspirin, Non-Steroidal Antiinflammatory Drugs;Nitric Oxide Donors;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;TP53 Expression Enhancers targeting PTGS1, PTGS2, TP53 |
| CA-39-ZJ18_10uM | Dose=10uM, Aspirin, Non-Steroidal Antiinflammatory Drugs;Nitric Oxide Donors;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;TP53 Expression Enhancers targeting PTGS1, PTGS2, TP53 |
| CA-39-ZJ18_1uM | Dose=1uM, Aspirin, Non-Steroidal Antiinflammatory Drugs;Nitric Oxide Donors;Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;TP53 Expression Enhancers targeting PTGS1, PTGS2, TP53 |
| CA-42-YI34_0.01uM | Dose=0.01uM, ZY63TG2Nhl, Deoxycytidine kinase-1 inhibitor;DCK gene inhibitor targeting DCK |
| CA-42-YI34_0.1uM | Dose=0.1uM, ZY63TG2Nhl, Deoxycytidine kinase-1 inhibitor;DCK gene inhibitor targeting DCK |
| CA-42-YI34_10uM | Dose=10uM, ZY63TG2Nhl, Deoxycytidine kinase-1 inhibitor;DCK gene inhibitor targeting DCK |
| CA-42-YI34_1uM | Dose=1uM, ZY63TG2Nhl, Deoxycytidine kinase-1 inhibitor;DCK gene inhibitor targeting DCK |
| CA-43-WF29_0.01uM | Dose=0.01uM, (2R)-1-[2-[hydroxy(phosphonooxy)phosphoryl]oxyacetyl]pyrrolidine-2-carboxylic acid, Cholesterol Biosynthesis Inhibitors targeting MVD |
| CA-43-WF29_0.1uM | Dose=0.1uM, (2R)-1-[2-[hydroxy(phosphonooxy)phosphoryl]oxyacetyl]pyrrolidine-2-carboxylic acid, Cholesterol Biosynthesis Inhibitors targeting MVD |
| CA-43-WF29_10uM | Dose=10uM, (2R)-1-[2-[hydroxy(phosphonooxy)phosphoryl]oxyacetyl]pyrrolidine-2-carboxylic acid, Cholesterol Biosynthesis Inhibitors targeting MVD |
| CA-43-WF29_1uM | Dose=1uM, (2R)-1-[2-[hydroxy(phosphonooxy)phosphoryl]oxyacetyl]pyrrolidine-2-carboxylic acid, Cholesterol Biosynthesis Inhibitors targeting MVD |
| CA-43-YM01_0.01uM | Dose=0.01uM, 2-(4-Naphthalen-1-ylsulfonylpiperazin-1-yl)quinazolin-4-amine, NPY5R antagonist targeting NPY5R |
| CA-43-YM01_10uM | Dose=10uM, 2-(4-Naphthalen-1-ylsulfonylpiperazin-1-yl)quinazolin-4-amine, NPY5R antagonist targeting NPY5R |
| CA-43-YM01_1uM | Dose=1uM, 2-(4-Naphthalen-1-ylsulfonylpiperazin-1-yl)quinazolin-4-amine, NPY5R antagonist targeting NPY5R |
| CA-44-LT45_0.01uM | Dose=0.01uM, 4-(3,4-Dichlorophenyl)-5-(4-pyridinyl)-2-thiazolamine, Adenosine A2B Antagonists;p38 MAPK Inhibitors;Adenosine A1 Antagonists;Phosphodiesterase IV Inhibitors;Adenosine A3 Antagonists targeting ADORA1, ADORA2B, ADORA3, PDE2A, MAPK13 |
| CA-44-LT45_0.1uM | Dose=0.1uM, 4-(3,4-Dichlorophenyl)-5-(4-pyridinyl)-2-thiazolamine, Adenosine A2B Antagonists;p38 MAPK Inhibitors;Adenosine A1 Antagonists;Phosphodiesterase IV Inhibitors;Adenosine A3 Antagonists targeting ADORA1, ADORA2B, ADORA3, PDE2A, MAPK13 |
| CA-44-LT45_10uM | Dose=10uM, 4-(3,4-Dichlorophenyl)-5-(4-pyridinyl)-2-thiazolamine, Adenosine A2B Antagonists;p38 MAPK Inhibitors;Adenosine A1 Antagonists;Phosphodiesterase IV Inhibitors;Adenosine A3 Antagonists targeting ADORA1, ADORA2B, ADORA3, PDE2A, MAPK13 |
| CA-44-LT45_1uM | Dose=1uM, 4-(3,4-Dichlorophenyl)-5-(4-pyridinyl)-2-thiazolamine, Adenosine A2B Antagonists;p38 MAPK Inhibitors;Adenosine A1 Antagonists;Phosphodiesterase IV Inhibitors;Adenosine A3 Antagonists targeting ADORA1, ADORA2B, ADORA3, PDE2A, MAPK13 |
| CA-44-WJ06_0.01uM | Dose=0.01uM, Tnp-470, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Angiogenesis Inhibitors targeting METAP2 |
| CA-44-WJ06_0.1uM | Dose=0.1uM, Tnp-470, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Angiogenesis Inhibitors targeting METAP2 |
| CA-44-WJ06_10uM | Dose=10uM, Tnp-470, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Angiogenesis Inhibitors targeting METAP2 |
| CA-44-WJ06_1uM | Dose=1uM, Tnp-470, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Angiogenesis Inhibitors targeting METAP2 |
| CA-48-CT20_0.01uM | Dose=0.01uM |
| CA-48-CT20_0.1uM | Dose=0.1uM |
| CA-48-CT20_10uM | Dose=10uM |
| CA-48-CT20_1uM | Dose=1uM |
| CA-48-JF51_0.01uM | Dose=0.01uM, 2-Hexynyladenosine, Adenosine A2A Agonists;Adenosine A3 Agonists targeting ADORA2A, ADORA3 |
| CA-48-JF51_0.1uM | Dose=0.1uM, 2-Hexynyladenosine, Adenosine A2A Agonists;Adenosine A3 Agonists targeting ADORA2A, ADORA3 |
| CA-48-JF51_10uM | Dose=10uM, 2-Hexynyladenosine, Adenosine A2A Agonists;Adenosine A3 Agonists targeting ADORA2A, ADORA3 |
| CA-48-JF51_1uM | Dose=1uM, 2-Hexynyladenosine, Adenosine A2A Agonists;Adenosine A3 Agonists targeting ADORA2A, ADORA3 |
| CA-48-SW47_0.01uM | Dose=0.01uM, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| CA-48-SW47_0.1uM | Dose=0.1uM, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| CA-48-SW47_10uM | Dose=10uM, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| CA-48-SW47_1uM | Dose=1uM, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| CA-50-SD02_0.1uM | Dose=0.1uM, Propentofylline, Adenosine Reuptake Inhibitors targeting SLC29A1, SLC29A2, SLC29A3, SLC29A4 |
| CA-50-SD02_10uM | Dose=10uM, Propentofylline, Adenosine Reuptake Inhibitors targeting SLC29A1, SLC29A2, SLC29A3, SLC29A4 |
| CA-53-TT18_0.01uM | Dose=0.01uM, 1-cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]-piperazine, HIF-1 inhibitor;HIF target gene expression suppressor targeting HIF1A |
| CA-53-TT18_0.1uM | Dose=0.1uM, 1-cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]-piperazine, HIF-1 inhibitor;HIF target gene expression suppressor targeting HIF1A |
| CA-53-TT18_10uM | Dose=10uM, 1-cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]-piperazine, HIF-1 inhibitor;HIF target gene expression suppressor targeting HIF1A |
| CA-53-TT18_1uM | Dose=1uM, 1-cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]-piperazine, HIF-1 inhibitor;HIF target gene expression suppressor targeting HIF1A |
| CA-54-WJ96_0.01uM | Dose=0.01uM, (5-Hydroxyindolo(1,2-a)quinazolin-7-yl)acetic acid, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B |
| CA-54-WJ96_0.1uM | Dose=0.1uM, (5-Hydroxyindolo(1,2-a)quinazolin-7-yl)acetic acid, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B |
| CA-54-WJ96_10uM | Dose=10uM, (5-Hydroxyindolo(1,2-a)quinazolin-7-yl)acetic acid, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B |
| CA-54-WJ96_1uM | Dose=1uM, (5-Hydroxyindolo(1,2-a)quinazolin-7-yl)acetic acid, Casein Kinase II (CK2) Inhibitors targeting CSNK2A1, CSNK2A2, CSNK2B |
| CA-56-GE89_0.01uM | Dose=0.01uM, 7-Deaza-2'-C-ethynyladenosine |
| CA-56-GE89_0.1uM | Dose=0.1uM, 7-Deaza-2'-C-ethynyladenosine |
| CA-56-GE89_10uM | Dose=10uM, 7-Deaza-2'-C-ethynyladenosine |
| CA-56-GE89_1uM | Dose=1uM, 7-Deaza-2'-C-ethynyladenosine |
| CA-56-VE74_0.01uM | Dose=0.01uM, Ciprofloxacin |
| CA-56-VE74_0.1uM | Dose=0.1uM, Ciprofloxacin |
| CA-56-VE74_10uM | Dose=10uM, Ciprofloxacin |
| CA-56-VE74_1uM | Dose=1uM, Ciprofloxacin |
| CA-57-TC62_0.01uM | Dose=0.01uM, Montelukast, Leukotriene CysLT1 (LTD4) Antagonists targeting GPR17, CYSLTR1 |
| CA-57-TC62_0.1uM | Dose=0.1uM, Montelukast, Leukotriene CysLT1 (LTD4) Antagonists targeting GPR17, CYSLTR1 |
| CA-57-TC62_10uM | Dose=10uM, Montelukast, Leukotriene CysLT1 (LTD4) Antagonists targeting GPR17, CYSLTR1 |
| CA-57-TC62_1uM | Dose=1uM, Montelukast, Leukotriene CysLT1 (LTD4) Antagonists targeting GPR17, CYSLTR1 |
| CA-60-LK14_0.01uM | Dose=0.01uM, oxan-4-yl N-cyclopropyl-N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]carbamate |
| CA-60-LK14_0.1uM | Dose=0.1uM, oxan-4-yl N-cyclopropyl-N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]carbamate |
| CA-60-LK14_10uM | Dose=10uM, oxan-4-yl N-cyclopropyl-N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]carbamate |
| CA-60-LK14_1uM | Dose=1uM, oxan-4-yl N-cyclopropyl-N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]carbamate |
| CA-60-RU13_0.01uM | Dose=0.01uM |
| CA-60-RU13_0.1uM | Dose=0.1uM |
| CA-60-RU13_10uM | Dose=10uM |
| CA-60-RU13_1uM | Dose=1uM |
| CA-61-VV83_0.01uM | Dose=0.01uM |
| CA-61-VV83_0.1uM | Dose=0.1uM |
| CA-61-VV83_10uM | Dose=10uM |
| CA-61-VV83_1uM | Dose=1uM |
| CA-63-LW25_0.01uM | Dose=0.01uM, 4-(3-Fluoro-4-methoxyphenyl)-5,16-diazatetracyclo[8.6.0.02,7.011,15]hexadeca-1(10),2,4,6,8,11(15)-hexaen-12-one, TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| CA-63-LW25_0.1uM | Dose=0.1uM, 4-(3-Fluoro-4-methoxyphenyl)-5,16-diazatetracyclo[8.6.0.02,7.011,15]hexadeca-1(10),2,4,6,8,11(15)-hexaen-12-one, TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| CA-63-LW25_10uM | Dose=10uM, 4-(3-Fluoro-4-methoxyphenyl)-5,16-diazatetracyclo[8.6.0.02,7.011,15]hexadeca-1(10),2,4,6,8,11(15)-hexaen-12-one, TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| CA-63-LW25_1uM | Dose=1uM, 4-(3-Fluoro-4-methoxyphenyl)-5,16-diazatetracyclo[8.6.0.02,7.011,15]hexadeca-1(10),2,4,6,8,11(15)-hexaen-12-one, TNF-alpha Release Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| CA-64-LT35_0.01uM | Dose=0.01uM, N-(3-bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR |
| CA-64-LT35_0.1uM | Dose=0.1uM, N-(3-bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR |
| CA-64-LT35_10uM | Dose=10uM, N-(3-bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR |
| CA-64-LT35_1uM | Dose=1uM, N-(3-bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting KDR |
| CA-65-MK91_0.01uM | Dose=0.01uM, Tosedostat targeting ANPEP, NPEPPS, LTA4H |
| CA-65-MK91_0.1uM | Dose=0.1uM, Tosedostat targeting ANPEP, NPEPPS, LTA4H |
| CA-65-MK91_10uM | Dose=10uM, Tosedostat targeting ANPEP, NPEPPS, LTA4H |
| CA-65-MK91_1uM | Dose=1uM, Tosedostat targeting ANPEP, NPEPPS, LTA4H |
| CA-66-FY97_0.01uM | Dose=0.01uM, N-[4-chloro-2-[5-[6-fluoro-2-imino-3-(1H-indol-4-ylmethyl)benzimidazol-1-yl]pyridin-2-yl]phenyl]acetamide |
| CA-66-FY97_0.1uM | Dose=0.1uM, N-[4-chloro-2-[5-[6-fluoro-2-imino-3-(1H-indol-4-ylmethyl)benzimidazol-1-yl]pyridin-2-yl]phenyl]acetamide |
| CA-66-FY97_10uM | Dose=10uM, N-[4-chloro-2-[5-[6-fluoro-2-imino-3-(1H-indol-4-ylmethyl)benzimidazol-1-yl]pyridin-2-yl]phenyl]acetamide |
| CA-66-FY97_1uM | Dose=1uM, N-[4-chloro-2-[5-[6-fluoro-2-imino-3-(1H-indol-4-ylmethyl)benzimidazol-1-yl]pyridin-2-yl]phenyl]acetamide |
| CA-66-GI09_0.01uM | Dose=0.01uM, 3-(3,4-Dimethoxyphenyl)-1-prop-2-enyl-7-(trifluoromethyl)indazole, Aryl hydrocarbon receptor modulator targeting AHR |
| CA-66-GI09_0.1uM | Dose=0.1uM, 3-(3,4-Dimethoxyphenyl)-1-prop-2-enyl-7-(trifluoromethyl)indazole, Aryl hydrocarbon receptor modulator targeting AHR |
| CA-66-GI09_10uM | Dose=10uM, 3-(3,4-Dimethoxyphenyl)-1-prop-2-enyl-7-(trifluoromethyl)indazole, Aryl hydrocarbon receptor modulator targeting AHR |
| CA-66-GI09_1uM | Dose=1uM, 3-(3,4-Dimethoxyphenyl)-1-prop-2-enyl-7-(trifluoromethyl)indazole, Aryl hydrocarbon receptor modulator targeting AHR |
| CA-66-YB17_0.01uM | Dose=0.01uM, Flecainide, Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers targeting SCN5A |
| CA-66-YB17_0.1uM | Dose=0.1uM, Flecainide, Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers targeting SCN5A |
| CA-66-YB17_10uM | Dose=10uM, Flecainide, Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers targeting SCN5A |
| CA-66-YB17_1uM | Dose=1uM, Flecainide, Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers targeting SCN5A |
| CA-67-IB54_0.01uM | Dose=0.01uM, (R)-N-(furan-2-ylmethyl)-2-(2-methoxyphenyl)-2-(2-oxo-1,2-dihydroquinoline-6-sulfonamido)-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT |
| CA-67-IB54_10uM | Dose=10uM, (R)-N-(furan-2-ylmethyl)-2-(2-methoxyphenyl)-2-(2-oxo-1,2-dihydroquinoline-6-sulfonamido)-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT |
| CA-67-IB54_1uM | Dose=1uM, (R)-N-(furan-2-ylmethyl)-2-(2-methoxyphenyl)-2-(2-oxo-1,2-dihydroquinoline-6-sulfonamido)-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT |
| CA-67-XI76_0.01uM | Dose=0.01uM, Racepinefrine, (S)- |
| CA-67-XI76_0.1uM | Dose=0.1uM, Racepinefrine, (S)- |
| CA-67-XI76_10uM | Dose=10uM, Racepinefrine, (S)- |
| CA-67-XI76_1uM | Dose=1uM, Racepinefrine, (S)- |
| CA-68-KG29_0.01uM | Dose=0.01uM, 1-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indol-3-yl]hexan-1-one, covalent inhibitor of ALDH1A1 targeting ALDH1A1 |
| CA-68-KG29_0.1uM | Dose=0.1uM, 1-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indol-3-yl]hexan-1-one, covalent inhibitor of ALDH1A1 targeting ALDH1A1 |
| CA-68-KG29_10uM | Dose=10uM, 1-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indol-3-yl]hexan-1-one, covalent inhibitor of ALDH1A1 targeting ALDH1A1 |
| CA-68-KG29_1uM | Dose=1uM, 1-[(1S)-1-(chloromethyl)-5-hydroxy-1,2-dihydrobenzo[e]indol-3-yl]hexan-1-one, covalent inhibitor of ALDH1A1 targeting ALDH1A1 |
| CA-68-SW47_0.01uM | Dose=0.01uM, Sib-1893, mgluR5 Antagonists targeting GRM5 |
| CA-68-SW47_0.1uM | Dose=0.1uM, Sib-1893, mgluR5 Antagonists targeting GRM5 |
| CA-68-SW47_10uM | Dose=10uM, Sib-1893, mgluR5 Antagonists targeting GRM5 |
| CA-68-TC79_0.01uM | Dose=0.01uM, Quinidine, P-Glycoprotein (MDR-1) Inhibitors;Sodium channel inhibitor targeting CYP2D6, CYP3A4, ABCB1, SCN1A, SCN2A |
| CA-68-TC79_0.1uM | Dose=0.1uM, Quinidine, P-Glycoprotein (MDR-1) Inhibitors;Sodium channel inhibitor targeting CYP2D6, CYP3A4, ABCB1, SCN1A, SCN2A |
| CA-68-TC79_10uM | Dose=10uM, Quinidine, P-Glycoprotein (MDR-1) Inhibitors;Sodium channel inhibitor targeting CYP2D6, CYP3A4, ABCB1, SCN1A, SCN2A |
| CA-68-TC79_1uM | Dose=1uM, Quinidine, P-Glycoprotein (MDR-1) Inhibitors;Sodium channel inhibitor targeting CYP2D6, CYP3A4, ABCB1, SCN1A, SCN2A |
| CA-70-EK39_0.01uM | Dose=0.01uM, 4-(4-(5,5-Dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine, Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1 |
| CA-70-EK39_0.1uM | Dose=0.1uM, 4-(4-(5,5-Dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine, Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1 |
| CA-70-EK39_10uM | Dose=10uM, 4-(4-(5,5-Dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine, Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1 |
| CA-70-EK39_1uM | Dose=1uM, 4-(4-(5,5-Dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine, Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1 |
| CA-72-JV60_0.01uM | Dose=0.01uM, Benzamidine targeting PLG |
| CA-72-JV60_0.1uM | Dose=0.1uM, Benzamidine targeting PLG |
| CA-72-JV60_10uM | Dose=10uM, Benzamidine targeting PLG |
| CA-72-JV60_1uM | Dose=1uM, Benzamidine targeting PLG |
| CA-72-UL91_0.01uM | Dose=0.01uM, Z-Asp-CH2-DCB, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| CA-72-UL91_0.1uM | Dose=0.1uM, Z-Asp-CH2-DCB, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| CA-72-UL91_10uM | Dose=10uM, Z-Asp-CH2-DCB, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| CA-72-UL91_1uM | Dose=1uM, Z-Asp-CH2-DCB, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| CA-73-BW50_0.01uM | Dose=0.01uM, TG101209, Jak2 Inhibitors;Apoptosis Inducers targeting JAK2 |
| CA-73-BW50_0.1uM | Dose=0.1uM, TG101209, Jak2 Inhibitors;Apoptosis Inducers targeting JAK2 |
| CA-73-BW50_10uM | Dose=10uM, TG101209, Jak2 Inhibitors;Apoptosis Inducers targeting JAK2 |
| CA-73-TP18_0.01uM | Dose=0.01uM, 3,4-dihydro-6,7-dihydroxy-3-(3,4-dimethoxyphenyl)-2H-1-benzopyran, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX12, ALOX5, ALOX15 |
| CA-73-TP18_10uM | Dose=10uM, 3,4-dihydro-6,7-dihydroxy-3-(3,4-dimethoxyphenyl)-2H-1-benzopyran, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX12, ALOX5, ALOX15 |
| CA-73-TP18_1uM | Dose=1uM, 3,4-dihydro-6,7-dihydroxy-3-(3,4-dimethoxyphenyl)-2H-1-benzopyran, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX12, ALOX5, ALOX15 |
| CA-75-HA22_0.01uM | Dose=0.01uM, Sns-032, CDK9 Inhibitors;CDK2/Cyclin E Inhibitors;CDK7 Inhibitors targeting CCNE1, CDK2, CDK7, CDK9, CCNA1, CCNE2 |
| CA-75-HA22_0.1uM | Dose=0.1uM, Sns-032, CDK9 Inhibitors;CDK2/Cyclin E Inhibitors;CDK7 Inhibitors targeting CCNE1, CDK2, CDK7, CDK9, CCNA1, CCNE2 |
| CA-75-HA22_10uM | Dose=10uM, Sns-032, CDK9 Inhibitors;CDK2/Cyclin E Inhibitors;CDK7 Inhibitors targeting CCNE1, CDK2, CDK7, CDK9, CCNA1, CCNE2 |
| CA-75-HA22_1uM | Dose=1uM, Sns-032, CDK9 Inhibitors;CDK2/Cyclin E Inhibitors;CDK7 Inhibitors targeting CCNE1, CDK2, CDK7, CDK9, CCNA1, CCNE2 |
| CA-84-IJ41_0.01uM | Dose=0.01uM, 3,4-Dichlorophenylbiguanide, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CA-84-IJ41_0.1uM | Dose=0.1uM, 3,4-Dichlorophenylbiguanide, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CA-84-IJ41_10uM | Dose=10uM, 3,4-Dichlorophenylbiguanide, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CA-84-IJ41_1uM | Dose=1uM, 3,4-Dichlorophenylbiguanide, Cell Adhesion Inhibitors;5-HT3 Receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CA-88-FC74_0.01uM | Dose=0.01uM, Pyrrolo[2,3-d]pyrimidine derivative 9, CDK4 Inhibitors targeting CDK4 |
| CA-88-FC74_10uM | Dose=10uM, Pyrrolo[2,3-d]pyrimidine derivative 9, CDK4 Inhibitors targeting CDK4 |
| CA-88-FC74_1uM | Dose=1uM, Pyrrolo[2,3-d]pyrimidine derivative 9, CDK4 Inhibitors targeting CDK4 |
| CA-90-RU33_0.01uM | Dose=0.01uM, 7-Cyclopentyl-2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carbonitrile, CDK4 Inhibitors targeting CDK4 |
| CA-90-RU33_0.1uM | Dose=0.1uM, 7-Cyclopentyl-2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carbonitrile, CDK4 Inhibitors targeting CDK4 |
| CA-90-RU33_10uM | Dose=10uM, 7-Cyclopentyl-2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carbonitrile, CDK4 Inhibitors targeting CDK4 |
| CA-90-RU33_1uM | Dose=1uM, 7-Cyclopentyl-2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carbonitrile, CDK4 Inhibitors targeting CDK4 |
| CA-90-TK74_0.1uM | Dose=0.1uM, Binds to hemoglobin, increases oxygen affinity thereby reducing sickling of cells |
| CA-90-TK74_1uM | Dose=1uM, Binds to hemoglobin, increases oxygen affinity thereby reducing sickling of cells |
| CA-96-KH56_0.01uM | Dose=0.01uM, (5R)-3-methyl-5-phenyl-5H-[1,3]thiazolo[2,3-b]quinazoline |
| CA-96-KH56_0.1uM | Dose=0.1uM, (5R)-3-methyl-5-phenyl-5H-[1,3]thiazolo[2,3-b]quinazoline |
| CA-96-KH56_1uM | Dose=1uM, (5R)-3-methyl-5-phenyl-5H-[1,3]thiazolo[2,3-b]quinazoline |
| CA-96-UO48_0.01uM | Dose=0.01uM, 4,4'-Dimethoxybenzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| CA-96-UO48_0.1uM | Dose=0.1uM, 4,4'-Dimethoxybenzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| CA-96-UO48_10uM | Dose=10uM, 4,4'-Dimethoxybenzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| CA-96-UO48_1uM | Dose=1uM, 4,4'-Dimethoxybenzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| CA-98-SW47_0.01uM | Dose=0.01uM, Cilostazol, Phosphodiesterase III Inhibitors targeting PDE2A |
| CA-98-SW47_0.1uM | Dose=0.1uM, Cilostazol, Phosphodiesterase III Inhibitors targeting PDE2A |
| CA-98-SW47_10uM | Dose=10uM, Cilostazol, Phosphodiesterase III Inhibitors targeting PDE2A |
| CB-00-BH77_0.01uM | Dose=0.01uM, 9-benzyl-8-oxo-2-pyridin-3-yl-7H-purine-6-carboxamide |
| CB-00-BH77_0.1uM | Dose=0.1uM, 9-benzyl-8-oxo-2-pyridin-3-yl-7H-purine-6-carboxamide |
| CB-00-BH77_10uM | Dose=10uM, 9-benzyl-8-oxo-2-pyridin-3-yl-7H-purine-6-carboxamide |
| CB-00-BH77_1uM | Dose=1uM, 9-benzyl-8-oxo-2-pyridin-3-yl-7H-purine-6-carboxamide |
| CB-01-MR53_0.01uM | Dose=0.01uM, Firategrast, Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4 |
| CB-01-MR53_0.1uM | Dose=0.1uM, Firategrast, Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4 |
| CB-01-MR53_10uM | Dose=10uM, Firategrast, Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4 |
| CB-01-MR53_1uM | Dose=1uM, Firategrast, Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin alpha4beta1 (VLA-4) Antagonists targeting ITGA4 |
| CB-02-XL81_0.01uM | Dose=0.01uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| CB-02-XL81_0.1uM | Dose=0.1uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| CB-02-XL81_10uM | Dose=10uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| CB-02-XL81_1uM | Dose=1uM, Deoxypodophyllotoxin, Cyclooxygenase-2 Inhibitors;Angiogenesis Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP3, PTGS2 |
| CB-03-EP53_0.01uM | Dose=0.01uM, 1-(2-Chlorophenyl)biguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CB-03-EP53_10uM | Dose=10uM, 1-(2-Chlorophenyl)biguanide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CB-05-AU50_0.01uM | Dose=0.01uM, N-(3-hydroxy-2,4-dioxo-1H-quinazolin-7-yl)acetamide, Nucleotide Excision Repair Inhibitor targeting ERCC1, ERCC4, FEN1 |
| CB-05-AU50_0.1uM | Dose=0.1uM, N-(3-hydroxy-2,4-dioxo-1H-quinazolin-7-yl)acetamide, Nucleotide Excision Repair Inhibitor targeting ERCC1, ERCC4, FEN1 |
| CB-05-AU50_10uM | Dose=10uM, N-(3-hydroxy-2,4-dioxo-1H-quinazolin-7-yl)acetamide, Nucleotide Excision Repair Inhibitor targeting ERCC1, ERCC4, FEN1 |
| CB-05-AU50_1uM | Dose=1uM, N-(3-hydroxy-2,4-dioxo-1H-quinazolin-7-yl)acetamide, Nucleotide Excision Repair Inhibitor targeting ERCC1, ERCC4, FEN1 |
| CB-05-UD24_0.01uM | Dose=0.01uM, (3R)-3-amino-1-hydroxypyrrolidin-2-one, NMDA Glycine B Receptor Partial Agonists targeting GRIN1 |
| CB-05-UD24_10uM | Dose=10uM, (3R)-3-amino-1-hydroxypyrrolidin-2-one, NMDA Glycine B Receptor Partial Agonists targeting GRIN1 |
| CB-06-FE89_0.01uM | Dose=0.01uM, 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylicacid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, (9S,10R,12R)- |
| CB-06-FE89_0.1uM | Dose=0.1uM, 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylicacid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, (9S,10R,12R)- |
| CB-06-FE89_10uM | Dose=10uM, 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylicacid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, (9S,10R,12R)- |
| CB-06-FE89_1uM | Dose=1uM, 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylicacid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, (9S,10R,12R)- |
| CB-07-WI76_0.01uM | Dose=0.01uM, Pidotimod |
| CB-07-WI76_0.1uM | Dose=0.1uM, Pidotimod |
| CB-07-WI76_1uM | Dose=1uM, Pidotimod |
| CB-10-UX80_0.01uM | Dose=0.01uM |
| CB-10-UX80_0.1uM | Dose=0.1uM |
| CB-10-UX80_1uM | Dose=1uM |
| CB-10-YX20_0.01uM | Dose=0.01uM, 2-(2-Phenylethenyl)-4-(pyridin-3-ylmethylidene)-4,5-dihydro-1,3-oxazol-5-one, DAPK1/3 inhibitor targeting DAPK1 |
| CB-10-YX20_0.1uM | Dose=0.1uM, 2-(2-Phenylethenyl)-4-(pyridin-3-ylmethylidene)-4,5-dihydro-1,3-oxazol-5-one, DAPK1/3 inhibitor targeting DAPK1 |
| CB-10-YX20_10uM | Dose=10uM, 2-(2-Phenylethenyl)-4-(pyridin-3-ylmethylidene)-4,5-dihydro-1,3-oxazol-5-one, DAPK1/3 inhibitor targeting DAPK1 |
| CB-10-YX20_1uM | Dose=1uM, 2-(2-Phenylethenyl)-4-(pyridin-3-ylmethylidene)-4,5-dihydro-1,3-oxazol-5-one, DAPK1/3 inhibitor targeting DAPK1 |
| CB-11-GB40_0.01uM | Dose=0.01uM, Smarca2-IN-6, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| CB-11-GB40_0.1uM | Dose=0.1uM, Smarca2-IN-6, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| CB-11-GB40_10uM | Dose=10uM, Smarca2-IN-6, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| CB-11-GB40_1uM | Dose=1uM, Smarca2-IN-6, ATPase SMARCA2, SMARCA4 Inhibitor targeting SMARCA2, SMARCA4 |
| CB-12-BV05_0.01uM | Dose=0.01uM |
| CB-12-BV05_0.1uM | Dose=0.1uM |
| CB-12-BV05_10uM | Dose=10uM |
| CB-12-BV05_1uM | Dose=1uM |
| CB-12-HC20_0.01uM | Dose=0.01uM, Palmidrol, Cannabinoid CB2 Agonists targeting CNR2, GPR55 |
| CB-12-HC20_0.1uM | Dose=0.1uM, Palmidrol, Cannabinoid CB2 Agonists targeting CNR2, GPR55 |
| CB-12-HC20_10uM | Dose=10uM, Palmidrol, Cannabinoid CB2 Agonists targeting CNR2, GPR55 |
| CB-12-HC20_1uM | Dose=1uM, Palmidrol, Cannabinoid CB2 Agonists targeting CNR2, GPR55 |
| CB-13-OP88_0.01uM | Dose=0.01uM, Benzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| CB-13-OP88_0.1uM | Dose=0.1uM, Benzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| CB-13-OP88_1uM | Dose=1uM, Benzil, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| CB-13-WC72_0.01uM | Dose=0.01uM |
| CB-13-WC72_0.1uM | Dose=0.1uM |
| CB-13-WC72_10uM | Dose=10uM |
| CB-13-WC72_1uM | Dose=1uM |
| CB-13-ZM26_0.01uM | Dose=0.01uM, Arotinoid acid, Retinoid RAR Agonists targeting RARA |
| CB-13-ZM26_0.1uM | Dose=0.1uM, Arotinoid acid, Retinoid RAR Agonists targeting RARA |
| CB-13-ZM26_10uM | Dose=10uM, Arotinoid acid, Retinoid RAR Agonists targeting RARA |
| CB-13-ZM26_1uM | Dose=1uM, Arotinoid acid, Retinoid RAR Agonists targeting RARA |
| CB-13-ZM96_0.01uM | Dose=0.01uM, 5-chloro-N2-(4-(1-cyclopropylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine |
| CB-13-ZM96_0.1uM | Dose=0.1uM, 5-chloro-N2-(4-(1-cyclopropylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine |
| CB-13-ZM96_10uM | Dose=10uM, 5-chloro-N2-(4-(1-cyclopropylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine |
| CB-13-ZM96_1uM | Dose=1uM, 5-chloro-N2-(4-(1-cyclopropylpiperidin-4-yl)-2-fluoro-5-methylphenyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine |
| CB-15-RU50_0.01uM | Dose=0.01uM, 2-[4-(2-{[5-(4-Chlorophenyl)-2-furoyl]amino}ethyl)phenoxy]-2-methylpropanoic acid |
| CB-15-RU50_0.1uM | Dose=0.1uM, 2-[4-(2-{[5-(4-Chlorophenyl)-2-furoyl]amino}ethyl)phenoxy]-2-methylpropanoic acid |
| CB-15-RU50_10uM | Dose=10uM, 2-[4-(2-{[5-(4-Chlorophenyl)-2-furoyl]amino}ethyl)phenoxy]-2-methylpropanoic acid |
| CB-15-RU50_1uM | Dose=1uM, 2-[4-(2-{[5-(4-Chlorophenyl)-2-furoyl]amino}ethyl)phenoxy]-2-methylpropanoic acid |
| CB-16-JO93_0.01uM | Dose=0.01uM |
| CB-16-JO93_0.1uM | Dose=0.1uM |
| CB-16-JO93_10uM | Dose=10uM |
| CB-16-JO93_1uM | Dose=1uM |
| CB-16-SY72_0.01uM | Dose=0.01uM, Halofuginone, glutamyl-prolyl-tRNA synthetase inhibitor targeting EPRS1 |
| CB-16-SY72_0.1uM | Dose=0.1uM, Halofuginone, glutamyl-prolyl-tRNA synthetase inhibitor targeting EPRS1 |
| CB-16-SY72_10uM | Dose=10uM, Halofuginone, glutamyl-prolyl-tRNA synthetase inhibitor targeting EPRS1 |
| CB-16-SY72_1uM | Dose=1uM, Halofuginone, glutamyl-prolyl-tRNA synthetase inhibitor targeting EPRS1 |
| CB-20-ND22_0.01uM | Dose=0.01uM, (2S)-2-[[(2S)-2-[[cyclohexylmethyl(hydroxy)phosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| CB-20-ND22_0.1uM | Dose=0.1uM, (2S)-2-[[(2S)-2-[[cyclohexylmethyl(hydroxy)phosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| CB-20-ND22_10uM | Dose=10uM, (2S)-2-[[(2S)-2-[[cyclohexylmethyl(hydroxy)phosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| CB-20-ND22_1uM | Dose=1uM, (2S)-2-[[(2S)-2-[[cyclohexylmethyl(hydroxy)phosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, Endothelin-Converting Enzyme (ECE) Inhibitors targeting ECE1, ECE2 |
| CB-24-AT90_0.01uM | Dose=0.01uM, Monensin |
| CB-24-AT90_0.1uM | Dose=0.1uM, Monensin |
| CB-24-AT90_10uM | Dose=10uM, Monensin |
| CB-24-AT90_1uM | Dose=1uM, Monensin |
| CB-24-FA25_0.01uM | Dose=0.01uM, Spiperone |
| CB-24-FA25_0.1uM | Dose=0.1uM, Spiperone |
| CB-24-FA25_10uM | Dose=10uM, Spiperone |
| CB-24-FA25_1uM | Dose=1uM, Spiperone |
| CB-25-VR83_0.01uM | Dose=0.01uM |
| CB-25-VR83_0.1uM | Dose=0.1uM |
| CB-25-VR83_10uM | Dose=10uM |
| CB-25-VR83_1uM | Dose=1uM |
| CB-29-AX17_10uM | Dose=10uM, (2R,3S,5R)-5-[[4,6-difluoro-5-(4-phenylphenyl)-1H-benzimidazol-2-yl]oxy]-2-(hydroxymethyl)oxan-3-ol |
| CB-29-AX17_1uM | Dose=1uM, (2R,3S,5R)-5-[[4,6-difluoro-5-(4-phenylphenyl)-1H-benzimidazol-2-yl]oxy]-2-(hydroxymethyl)oxan-3-ol |
| CB-29-KG96_0.01uM | Dose=0.01uM |
| CB-29-KG96_0.1uM | Dose=0.1uM |
| CB-29-KG96_10uM | Dose=10uM |
| CB-29-KG96_1uM | Dose=1uM |
| CB-30-KN11_0.1uM | Dose=0.1uM, Sardomozide, SAMDC inhibitor targeting AMD1 |
| CB-30-KN11_10uM | Dose=10uM, Sardomozide, SAMDC inhibitor targeting AMD1 |
| CB-30-KN11_1uM | Dose=1uM, Sardomozide, SAMDC inhibitor targeting AMD1 |
| CB-31-UO16_0.01uM | Dose=0.01uM, JTC-801 free base, OPRL1 gene inhibitor;OPRM1 gene inhibitor targeting OPRL1, OPRM1 |
| CB-31-UO16_0.1uM | Dose=0.1uM, JTC-801 free base, OPRL1 gene inhibitor;OPRM1 gene inhibitor targeting OPRL1, OPRM1 |
| CB-31-UO16_10uM | Dose=10uM, JTC-801 free base, OPRL1 gene inhibitor;OPRM1 gene inhibitor targeting OPRL1, OPRM1 |
| CB-31-UO16_1uM | Dose=1uM, JTC-801 free base, OPRL1 gene inhibitor;OPRM1 gene inhibitor targeting OPRL1, OPRM1 |
| CB-32-EI69_0.01uM | Dose=0.01uM, Clofarabine, DNA Polymerase Inhibitors;Ribonucleoside-Diphosphate Reductase Inhibitors targeting POLA1, RRM1 |
| CB-32-EI69_0.1uM | Dose=0.1uM, Clofarabine, DNA Polymerase Inhibitors;Ribonucleoside-Diphosphate Reductase Inhibitors targeting POLA1, RRM1 |
| CB-32-EI69_10uM | Dose=10uM, Clofarabine, DNA Polymerase Inhibitors;Ribonucleoside-Diphosphate Reductase Inhibitors targeting POLA1, RRM1 |
| CB-32-EI69_1uM | Dose=1uM, Clofarabine, DNA Polymerase Inhibitors;Ribonucleoside-Diphosphate Reductase Inhibitors targeting POLA1, RRM1 |
| CB-36-QH71_0.01uM | Dose=0.01uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-phenoxyphenoxy]acetic acid |
| CB-36-QH71_0.1uM | Dose=0.1uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-phenoxyphenoxy]acetic acid |
| CB-36-QH71_10uM | Dose=10uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-phenoxyphenoxy]acetic acid |
| CB-36-QH71_1uM | Dose=1uM, 2-[5-[(E)-4-(diethylamino)-4-oxobut-2-en-2-yl]-2-phenoxyphenoxy]acetic acid |
| CB-36-TO28_0.01uM | Dose=0.01uM, [(9Z,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate |
| CB-36-TO28_0.1uM | Dose=0.1uM, [(9Z,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate |
| CB-36-TO28_10uM | Dose=10uM, [(9Z,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate |
| CB-36-TO28_1uM | Dose=1uM, [(9Z,19Z,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate |
| CB-37-NM86_0.01uM | Dose=0.01uM, (4-Hydroxypiperidin-1-yl)(5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)thiophen-2-yl)methanone, Novel and Selective Monoamine Oxidase B Inhibitors targeting MAOB |
| CB-37-NM86_10uM | Dose=10uM, (4-Hydroxypiperidin-1-yl)(5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)thiophen-2-yl)methanone, Novel and Selective Monoamine Oxidase B Inhibitors targeting MAOB |
| CB-37-NM86_1uM | Dose=1uM, (4-Hydroxypiperidin-1-yl)(5-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)thiophen-2-yl)methanone, Novel and Selective Monoamine Oxidase B Inhibitors targeting MAOB |
| CB-38-AW77_0.01uM | Dose=0.01uM, 2-Methyl-7-((3-methylthiophen-2-yl)(pyridin-2-ylamino)methyl)quinolin-8-ol, Apoptosis Inducers;Caspase Activators;Mcl-1 Inhibitors targeting MCL1 |
| CB-38-AW77_0.1uM | Dose=0.1uM, 2-Methyl-7-((3-methylthiophen-2-yl)(pyridin-2-ylamino)methyl)quinolin-8-ol, Apoptosis Inducers;Caspase Activators;Mcl-1 Inhibitors targeting MCL1 |
| CB-38-AW77_10uM | Dose=10uM, 2-Methyl-7-((3-methylthiophen-2-yl)(pyridin-2-ylamino)methyl)quinolin-8-ol, Apoptosis Inducers;Caspase Activators;Mcl-1 Inhibitors targeting MCL1 |
| CB-38-AW77_1uM | Dose=1uM, 2-Methyl-7-((3-methylthiophen-2-yl)(pyridin-2-ylamino)methyl)quinolin-8-ol, Apoptosis Inducers;Caspase Activators;Mcl-1 Inhibitors targeting MCL1 |
| CB-40-DA30_0.01uM | Dose=0.01uM, (5-Chloro-6-((6-methylpyridin-3-yl)amino)pyridin-3-yl)-((2R)-2-ethylpiperidin-1-yl)methanone, mgluR5 Antagonists targeting GRM5 |
| CB-40-DA30_0.1uM | Dose=0.1uM, (5-Chloro-6-((6-methylpyridin-3-yl)amino)pyridin-3-yl)-((2R)-2-ethylpiperidin-1-yl)methanone, mgluR5 Antagonists targeting GRM5 |
| CB-40-DA30_10uM | Dose=10uM, (5-Chloro-6-((6-methylpyridin-3-yl)amino)pyridin-3-yl)-((2R)-2-ethylpiperidin-1-yl)methanone, mgluR5 Antagonists targeting GRM5 |
| CB-40-DA30_1uM | Dose=1uM, (5-Chloro-6-((6-methylpyridin-3-yl)amino)pyridin-3-yl)-((2R)-2-ethylpiperidin-1-yl)methanone, mgluR5 Antagonists targeting GRM5 |
| CB-42-EI79_0.01uM | Dose=0.01uM, Fludarabine Phosphate, Purine Antagonists targeting DCK, POLA1, RRM1 |
| CB-42-EI79_0.1uM | Dose=0.1uM, Fludarabine Phosphate, Purine Antagonists targeting DCK, POLA1, RRM1 |
| CB-42-EI79_10uM | Dose=10uM, Fludarabine Phosphate, Purine Antagonists targeting DCK, POLA1, RRM1 |
| CB-42-EI79_1uM | Dose=1uM, Fludarabine Phosphate, Purine Antagonists targeting DCK, POLA1, RRM1 |
| CB-44-FA25_0.01uM | Dose=0.01uM, N-Tosyl-L-phenylalanyl chloromethyl ketone |
| CB-44-FA25_0.1uM | Dose=0.1uM, N-Tosyl-L-phenylalanyl chloromethyl ketone |
| CB-44-FA25_10uM | Dose=10uM, N-Tosyl-L-phenylalanyl chloromethyl ketone |
| CB-44-FA25_1uM | Dose=1uM, N-Tosyl-L-phenylalanyl chloromethyl ketone |
| CB-44-RT90_0.01uM | Dose=0.01uM, Pivagabine, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| CB-44-RT90_0.1uM | Dose=0.1uM, Pivagabine, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| CB-44-RT90_10uM | Dose=10uM, Pivagabine, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| CB-44-RT90_1uM | Dose=1uM, Pivagabine, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| CB-45-VH79_0.01uM | Dose=0.01uM |
| CB-45-VH79_0.1uM | Dose=0.1uM |
| CB-45-VH79_10uM | Dose=10uM |
| CB-45-VH79_1uM | Dose=1uM |
| CB-46-FO63_0.01uM | Dose=0.01uM, 3,3'-(pyridin-3-ylmethanediyl)bis(1H-indole), MMP-8 (Neutrophil Collagenase) Inhibitors targeting MMP8 |
| CB-46-FO63_0.1uM | Dose=0.1uM, 3,3'-(pyridin-3-ylmethanediyl)bis(1H-indole), MMP-8 (Neutrophil Collagenase) Inhibitors targeting MMP8 |
| CB-46-FO63_10uM | Dose=10uM, 3,3'-(pyridin-3-ylmethanediyl)bis(1H-indole), MMP-8 (Neutrophil Collagenase) Inhibitors targeting MMP8 |
| CB-46-FO63_1uM | Dose=1uM, 3,3'-(pyridin-3-ylmethanediyl)bis(1H-indole), MMP-8 (Neutrophil Collagenase) Inhibitors targeting MMP8 |
| CB-47-SB29_0.1uM | Dose=0.1uM, Opc-21268, Vasopressin (AVP) V1a Antagonists targeting AVPR1A |
| CB-47-SB29_10uM | Dose=10uM, Opc-21268, Vasopressin (AVP) V1a Antagonists targeting AVPR1A |
| CB-47-SB29_1uM | Dose=1uM, Opc-21268, Vasopressin (AVP) V1a Antagonists targeting AVPR1A |
| CB-48-WM43_0.01uM | Dose=0.01uM, Quipazine, 5-HT3 receptor agonist selective against 5-HT1B targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CB-48-WM43_0.1uM | Dose=0.1uM, Quipazine, 5-HT3 receptor agonist selective against 5-HT1B targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CB-48-WM43_10uM | Dose=10uM, Quipazine, 5-HT3 receptor agonist selective against 5-HT1B targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CB-48-WM43_1uM | Dose=1uM, Quipazine, 5-HT3 receptor agonist selective against 5-HT1B targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CB-49-OG36_0.01uM | Dose=0.01uM, N-((1S)-2-Amino-1-(2,4-dichlorobenzyl)ethyl)-5-(2-(methylamino)pyrimidin-4-YL)thiophene-2-carboxamide, PKA and AKT (a.k.a. PKB) targeting AKT1 |
| CB-49-OG36_0.1uM | Dose=0.1uM, N-((1S)-2-Amino-1-(2,4-dichlorobenzyl)ethyl)-5-(2-(methylamino)pyrimidin-4-YL)thiophene-2-carboxamide, PKA and AKT (a.k.a. PKB) targeting AKT1 |
| CB-49-OG36_10uM | Dose=10uM, N-((1S)-2-Amino-1-(2,4-dichlorobenzyl)ethyl)-5-(2-(methylamino)pyrimidin-4-YL)thiophene-2-carboxamide, PKA and AKT (a.k.a. PKB) targeting AKT1 |
| CB-49-OG36_1uM | Dose=1uM, N-((1S)-2-Amino-1-(2,4-dichlorobenzyl)ethyl)-5-(2-(methylamino)pyrimidin-4-YL)thiophene-2-carboxamide, PKA and AKT (a.k.a. PKB) targeting AKT1 |
| CB-52-IL46_0.01uM | Dose=0.01uM, 6-(4-Chloro-benzenesulfonylamino)-5-pyridin-3-yl-hexanoic acid; hydrochloride;0.5hydrate |
| CB-52-IL46_0.1uM | Dose=0.1uM, 6-(4-Chloro-benzenesulfonylamino)-5-pyridin-3-yl-hexanoic acid; hydrochloride;0.5hydrate |
| CB-52-IL46_10uM | Dose=10uM, 6-(4-Chloro-benzenesulfonylamino)-5-pyridin-3-yl-hexanoic acid; hydrochloride;0.5hydrate |
| CB-52-IL46_1uM | Dose=1uM, 6-(4-Chloro-benzenesulfonylamino)-5-pyridin-3-yl-hexanoic acid; hydrochloride;0.5hydrate |
| CB-55-AK76_0.01uM | Dose=0.01uM, Nvs-bet-1, Bromodomain inhibitor targeting BRD2, BRD3, BRD4 |
| CB-55-AK76_0.1uM | Dose=0.1uM, Nvs-bet-1, Bromodomain inhibitor targeting BRD2, BRD3, BRD4 |
| CB-55-AK76_10uM | Dose=10uM, Nvs-bet-1, Bromodomain inhibitor targeting BRD2, BRD3, BRD4 |
| CB-55-AK76_1uM | Dose=1uM, Nvs-bet-1, Bromodomain inhibitor targeting BRD2, BRD3, BRD4 |
| CB-55-GX92_0.01uM | Dose=0.01uM, Lfa703, LFA-1/ICAM-1 Interaction Inhibitors targeting ITGAL, ITGB2 |
| CB-55-GX92_0.1uM | Dose=0.1uM, Lfa703, LFA-1/ICAM-1 Interaction Inhibitors targeting ITGAL, ITGB2 |
| CB-55-GX92_10uM | Dose=10uM, Lfa703, LFA-1/ICAM-1 Interaction Inhibitors targeting ITGAL, ITGB2 |
| CB-55-GX92_1uM | Dose=1uM, Lfa703, LFA-1/ICAM-1 Interaction Inhibitors targeting ITGAL, ITGB2 |
| CB-59-FD39_0.01uM | Dose=0.01uM, NS3763, iGluR5 (GluK5) Antagonists targeting GRIK1 |
| CB-59-FD39_0.1uM | Dose=0.1uM, NS3763, iGluR5 (GluK5) Antagonists targeting GRIK1 |
| CB-59-FD39_10uM | Dose=10uM, NS3763, iGluR5 (GluK5) Antagonists targeting GRIK1 |
| CB-59-FD39_1uM | Dose=1uM, NS3763, iGluR5 (GluK5) Antagonists targeting GRIK1 |
| CB-59-ZX97_0.01uM | Dose=0.01uM |
| CB-59-ZX97_0.1uM | Dose=0.1uM |
| CB-59-ZX97_10uM | Dose=10uM |
| CB-59-ZX97_1uM | Dose=1uM |
| CB-62-TB77_0.01uM | Dose=0.01uM, Methyl mycophenolate, Inosine 5'-Monophosphate Dehydrogenase Type I (IMPDH I) Inhibitors;Inosine 5'-Monophosphate Dehydrogenase Type II (IMPDH II) Inhibitors targeting IMPDH1, IMPDH2 |
| CB-62-TB77_0.1uM | Dose=0.1uM, Methyl mycophenolate, Inosine 5'-Monophosphate Dehydrogenase Type I (IMPDH I) Inhibitors;Inosine 5'-Monophosphate Dehydrogenase Type II (IMPDH II) Inhibitors targeting IMPDH1, IMPDH2 |
| CB-62-TB77_10uM | Dose=10uM, Methyl mycophenolate, Inosine 5'-Monophosphate Dehydrogenase Type I (IMPDH I) Inhibitors;Inosine 5'-Monophosphate Dehydrogenase Type II (IMPDH II) Inhibitors targeting IMPDH1, IMPDH2 |
| CB-62-TB77_1uM | Dose=1uM, Methyl mycophenolate, Inosine 5'-Monophosphate Dehydrogenase Type I (IMPDH I) Inhibitors;Inosine 5'-Monophosphate Dehydrogenase Type II (IMPDH II) Inhibitors targeting IMPDH1, IMPDH2 |
| CB-68-GZ09_0.01uM | Dose=0.01uM, SB-204741, HTR2B antagonist targeting HTR2B |
| CB-68-GZ09_0.1uM | Dose=0.1uM, SB-204741, HTR2B antagonist targeting HTR2B |
| CB-68-GZ09_10uM | Dose=10uM, SB-204741, HTR2B antagonist targeting HTR2B |
| CB-68-GZ09_1uM | Dose=1uM, SB-204741, HTR2B antagonist targeting HTR2B |
| CB-68-HM58_0.01uM | Dose=0.01uM |
| CB-68-HM58_0.1uM | Dose=0.1uM |
| CB-68-HM58_10uM | Dose=10uM |
| CB-68-HM58_1uM | Dose=1uM |
| CB-68-SP90_0.01uM | Dose=0.01uM, Omapatrilat, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| CB-68-SP90_0.1uM | Dose=0.1uM, Omapatrilat, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| CB-68-SP90_10uM | Dose=10uM, Omapatrilat, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| CB-68-SP90_1uM | Dose=1uM, Omapatrilat, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| CB-69-DJ58_0.01uM | Dose=0.01uM, Midafotel, NMDA Antagonists targeting GRIN1 |
| CB-69-DJ58_0.1uM | Dose=0.1uM, Midafotel, NMDA Antagonists targeting GRIN1 |
| CB-69-DJ58_10uM | Dose=10uM, Midafotel, NMDA Antagonists targeting GRIN1 |
| CB-69-DJ58_1uM | Dose=1uM, Midafotel, NMDA Antagonists targeting GRIN1 |
| CB-69-KJ83_0.01uM | Dose=0.01uM |
| CB-69-KJ83_0.1uM | Dose=0.1uM |
| CB-69-KJ83_1uM | Dose=1uM |
| CB-72-CP81_0.01uM | Dose=0.01uM |
| CB-72-CP81_0.1uM | Dose=0.1uM |
| CB-72-CP81_10uM | Dose=10uM |
| CB-72-CP81_1uM | Dose=1uM |
| CB-73-HZ47_0.01uM | Dose=0.01uM, Morpholine-4-carboxylic acid {1-[(benzyloxymethyl-cyano-methyl)-carbamoyl]-3,3-dimethyl-butyl}-amide, Cathepsin S Inhibitors targeting CTSS |
| CB-73-HZ47_0.1uM | Dose=0.1uM, Morpholine-4-carboxylic acid {1-[(benzyloxymethyl-cyano-methyl)-carbamoyl]-3,3-dimethyl-butyl}-amide, Cathepsin S Inhibitors targeting CTSS |
| CB-73-HZ47_10uM | Dose=10uM, Morpholine-4-carboxylic acid {1-[(benzyloxymethyl-cyano-methyl)-carbamoyl]-3,3-dimethyl-butyl}-amide, Cathepsin S Inhibitors targeting CTSS |
| CB-73-HZ47_1uM | Dose=1uM, Morpholine-4-carboxylic acid {1-[(benzyloxymethyl-cyano-methyl)-carbamoyl]-3,3-dimethyl-butyl}-amide, Cathepsin S Inhibitors targeting CTSS |
| CB-73-MJ69_0.01uM | Dose=0.01uM, AC1LA18U, HIF prolyl hydroxylase-1 inhibitor targeting P4HA1, P4HB, P4HA2, EGLN1, P4HA3 |
| CB-73-MJ69_0.1uM | Dose=0.1uM, AC1LA18U, HIF prolyl hydroxylase-1 inhibitor targeting P4HA1, P4HB, P4HA2, EGLN1, P4HA3 |
| CB-73-MJ69_10uM | Dose=10uM, AC1LA18U, HIF prolyl hydroxylase-1 inhibitor targeting P4HA1, P4HB, P4HA2, EGLN1, P4HA3 |
| CB-73-ZP43_1uM | Dose=1uM, 5-tert-butyl-N-[(2S)-1-(cyanomethylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpyrazole-3-carboxamide, cathepsin L (CTSL1) inhibitor targeting CTSL |
| CB-75-PH34_0.01uM | Dose=0.01uM, Eleclazine, Nav1.5 channel inhibitor targeting SCN5A |
| CB-75-PH34_0.1uM | Dose=0.1uM, Eleclazine, Nav1.5 channel inhibitor targeting SCN5A |
| CB-75-PH34_10uM | Dose=10uM, Eleclazine, Nav1.5 channel inhibitor targeting SCN5A |
| CB-75-PH34_1uM | Dose=1uM, Eleclazine, Nav1.5 channel inhibitor targeting SCN5A |
| CB-77-KL88_0.01uM | Dose=0.01uM, 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| CB-77-KL88_0.1uM | Dose=0.1uM, 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| CB-77-KL88_10uM | Dose=10uM, 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| CB-77-KL88_1uM | Dose=1uM, 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| CB-80-CK24_0.01uM | Dose=0.01uM, F1174-1718 |
| CB-80-CK24_0.1uM | Dose=0.1uM, F1174-1718 |
| CB-80-CK24_10uM | Dose=10uM, F1174-1718 |
| CB-80-CK24_1uM | Dose=1uM, F1174-1718 |
| CB-82-BV25_0.01uM | Dose=0.01uM, [4-(2-Acetylamino-2-{1-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-ethyl)-benzyl]-phosphonic acid, Grb2 SH2 Domain Inhibitors targeting GRB2, PTK2B, PTK2, PTK6, PTK7 |
| CB-82-BV25_0.1uM | Dose=0.1uM, [4-(2-Acetylamino-2-{1-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-ethyl)-benzyl]-phosphonic acid, Grb2 SH2 Domain Inhibitors targeting GRB2, PTK2B, PTK2, PTK6, PTK7 |
| CB-82-BV25_10uM | Dose=10uM, [4-(2-Acetylamino-2-{1-[2-carbamoyl-1-(3-naphthalen-1-yl-propylcarbamoyl)-ethylcarbamoyl]-cyclohexylcarbamoyl}-ethyl)-benzyl]-phosphonic acid, Grb2 SH2 Domain Inhibitors targeting GRB2, PTK2B, PTK2, PTK6, PTK7 |
| CB-82-PL01_0.1uM | Dose=0.1uM, N-(4-((6-(Cyclobutylamino)-9H-purin-2-yl)amino)phenyl)-N-methylacetamide, Syk Kinase Inhibitors targeting SYK |
| CB-82-PL01_10uM | Dose=10uM, N-(4-((6-(Cyclobutylamino)-9H-purin-2-yl)amino)phenyl)-N-methylacetamide, Syk Kinase Inhibitors targeting SYK |
| CB-82-PL01_1uM | Dose=1uM, N-(4-((6-(Cyclobutylamino)-9H-purin-2-yl)amino)phenyl)-N-methylacetamide, Syk Kinase Inhibitors targeting SYK |
| CB-83-LF14_0.01uM | Dose=0.01uM, (2S)-1-[2-(3-propan-2-yloxypropylamino)acetyl]pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| CB-83-LF14_0.1uM | Dose=0.1uM, (2S)-1-[2-(3-propan-2-yloxypropylamino)acetyl]pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| CB-83-LF14_10uM | Dose=10uM, (2S)-1-[2-(3-propan-2-yloxypropylamino)acetyl]pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| CB-83-LF14_1uM | Dose=1uM, (2S)-1-[2-(3-propan-2-yloxypropylamino)acetyl]pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| CB-83-SC82_0.01uM | Dose=0.01uM |
| CB-83-SC82_0.1uM | Dose=0.1uM |
| CB-83-SC82_10uM | Dose=10uM |
| CB-83-SC82_1uM | Dose=1uM |
| CB-83-ZW70_0.01uM | Dose=0.01uM, Bumetanide, Inhibits the sodium-potassium ATPase pump targeting CA4, CA5A, GPR35, SLC12A1, SLC12A2, SLC12A4, CA5B, SLC12A5 |
| CB-83-ZW70_0.1uM | Dose=0.1uM, Bumetanide, Inhibits the sodium-potassium ATPase pump targeting CA4, CA5A, GPR35, SLC12A1, SLC12A2, SLC12A4, CA5B, SLC12A5 |
| CB-83-ZW70_10uM | Dose=10uM, Bumetanide, Inhibits the sodium-potassium ATPase pump targeting CA4, CA5A, GPR35, SLC12A1, SLC12A2, SLC12A4, CA5B, SLC12A5 |
| CB-83-ZW70_1uM | Dose=1uM, Bumetanide, Inhibits the sodium-potassium ATPase pump targeting CA4, CA5A, GPR35, SLC12A1, SLC12A2, SLC12A4, CA5B, SLC12A5 |
| CB-84-FA85_0.01uM | Dose=0.01uM |
| CB-84-FA85_0.1uM | Dose=0.1uM |
| CB-84-FA85_10uM | Dose=10uM |
| CB-84-FA85_1uM | Dose=1uM |
| CB-86-ME74_0.01uM | Dose=0.01uM, Sulindac, Non-Steroidal Antiinflammatory Drugs;NF-kappaB (NFKB) Activation Inhibitors;ABCC3 Expression Enhancers;ABCC1 Expression Enhancers targeting PTGS2, TTR, ABCC3 |
| CB-86-ME74_0.1uM | Dose=0.1uM, Sulindac, Non-Steroidal Antiinflammatory Drugs;NF-kappaB (NFKB) Activation Inhibitors;ABCC3 Expression Enhancers;ABCC1 Expression Enhancers targeting PTGS2, TTR, ABCC3 |
| CB-86-ME74_10uM | Dose=10uM, Sulindac, Non-Steroidal Antiinflammatory Drugs;NF-kappaB (NFKB) Activation Inhibitors;ABCC3 Expression Enhancers;ABCC1 Expression Enhancers targeting PTGS2, TTR, ABCC3 |
| CB-86-ME74_1uM | Dose=1uM, Sulindac, Non-Steroidal Antiinflammatory Drugs;NF-kappaB (NFKB) Activation Inhibitors;ABCC3 Expression Enhancers;ABCC1 Expression Enhancers targeting PTGS2, TTR, ABCC3 |
| CB-87-GT98_0.01uM | Dose=0.01uM, Necrosulfonamide, Covalent Necroptosis Inhibitors;Reduces sulfur mustard intoxication targeting GSDMD, MLKL |
| CB-87-GT98_0.1uM | Dose=0.1uM, Necrosulfonamide, Covalent Necroptosis Inhibitors;Reduces sulfur mustard intoxication targeting GSDMD, MLKL |
| CB-87-GT98_10uM | Dose=10uM, Necrosulfonamide, Covalent Necroptosis Inhibitors;Reduces sulfur mustard intoxication targeting GSDMD, MLKL |
| CB-87-GT98_1uM | Dose=1uM, Necrosulfonamide, Covalent Necroptosis Inhibitors;Reduces sulfur mustard intoxication targeting GSDMD, MLKL |
| CB-87-RB49_0.01uM | Dose=0.01uM, MK-0429, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| CB-87-RB49_0.1uM | Dose=0.1uM, MK-0429, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| CB-87-RB49_10uM | Dose=10uM, MK-0429, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| CB-87-RB49_1uM | Dose=1uM, MK-0429, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| CB-88-LG34_0.01uM | Dose=0.01uM, Bix-01294, EHMT1/2;DNA Methyltransferase (DNMT) Inhibitors;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1 |
| CB-88-LG34_0.1uM | Dose=0.1uM, Bix-01294, EHMT1/2;DNA Methyltransferase (DNMT) Inhibitors;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1 |
| CB-88-LG34_10uM | Dose=10uM, Bix-01294, EHMT1/2;DNA Methyltransferase (DNMT) Inhibitors;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1 |
| CB-88-LG34_1uM | Dose=1uM, Bix-01294, EHMT1/2;DNA Methyltransferase (DNMT) Inhibitors;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1 |
| CB-88-OC19_0.01uM | Dose=0.01uM, Prenalterol, beta-Adrenoceptor Agonists targeting ADRB1 |
| CB-88-OC19_0.1uM | Dose=0.1uM, Prenalterol, beta-Adrenoceptor Agonists targeting ADRB1 |
| CB-88-OC19_1uM | Dose=1uM, Prenalterol, beta-Adrenoceptor Agonists targeting ADRB1 |
| CB-92-FS28_0.01uM | Dose=0.01uM |
| CB-92-FS28_0.1uM | Dose=0.1uM |
| CB-92-FS28_10uM | Dose=10uM |
| CB-92-FS28_1uM | Dose=1uM |
| CB-92-VC05_0.01uM | Dose=0.01uM, Betp, covalent positive allosteric modulator of GLP1R targeting GLP1R |
| CB-92-VC05_0.1uM | Dose=0.1uM, Betp, covalent positive allosteric modulator of GLP1R targeting GLP1R |
| CB-92-VC05_10uM | Dose=10uM, Betp, covalent positive allosteric modulator of GLP1R targeting GLP1R |
| CB-92-VC05_1uM | Dose=1uM, Betp, covalent positive allosteric modulator of GLP1R targeting GLP1R |
| CB-93-YZ07_0.01uM | Dose=0.01uM, Sdz-mld-987, TLR8 Receptor Agonists;FKBP12 gene modulator;Calcineurin inhibitor;TLR7 Receptor Agonists targeting PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| CB-93-YZ07_0.1uM | Dose=0.1uM, Sdz-mld-987, TLR8 Receptor Agonists;FKBP12 gene modulator;Calcineurin inhibitor;TLR7 Receptor Agonists targeting PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| CB-93-YZ07_10uM | Dose=10uM, Sdz-mld-987, TLR8 Receptor Agonists;FKBP12 gene modulator;Calcineurin inhibitor;TLR7 Receptor Agonists targeting PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| CB-93-YZ07_1uM | Dose=1uM, Sdz-mld-987, TLR8 Receptor Agonists;FKBP12 gene modulator;Calcineurin inhibitor;TLR7 Receptor Agonists targeting PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| CB-97-LV32_0.01uM | Dose=0.01uM, Piperine, MAO-B Inhibitors;MAO-A Inhibitors;ACAT Inhibitors targeting MAOA, MAOB, ACAT1 |
| CB-97-LV32_0.1uM | Dose=0.1uM, Piperine, MAO-B Inhibitors;MAO-A Inhibitors;ACAT Inhibitors targeting MAOA, MAOB, ACAT1 |
| CB-97-LV32_10uM | Dose=10uM, Piperine, MAO-B Inhibitors;MAO-A Inhibitors;ACAT Inhibitors targeting MAOA, MAOB, ACAT1 |
| CB-97-LV32_1uM | Dose=1uM, Piperine, MAO-B Inhibitors;MAO-A Inhibitors;ACAT Inhibitors targeting MAOA, MAOB, ACAT1 |
| CB-99-NG16_0.01uM | Dose=0.01uM, Duvelisib, lipid kinase inhibitor targeting PIK3CD |
| CB-99-NG16_0.1uM | Dose=0.1uM, Duvelisib, lipid kinase inhibitor targeting PIK3CD |
| CB-99-NG16_10uM | Dose=10uM, Duvelisib, lipid kinase inhibitor targeting PIK3CD |
| CB-99-NG16_1uM | Dose=1uM, Duvelisib, lipid kinase inhibitor targeting PIK3CD |
| CB-99-OG76_0.01uM | Dose=0.01uM |
| CB-99-OG76_0.1uM | Dose=0.1uM |
| CB-99-OG76_10uM | Dose=10uM |
| CB-99-OG76_1uM | Dose=1uM |
| CC-00-ZO24_0.01uM | Dose=0.01uM, Picotamide, Prostanoid TP Antagonists targeting TBXA2R |
| CC-00-ZO24_0.1uM | Dose=0.1uM, Picotamide, Prostanoid TP Antagonists targeting TBXA2R |
| CC-00-ZO24_10uM | Dose=10uM, Picotamide, Prostanoid TP Antagonists targeting TBXA2R |
| CC-00-ZO24_1uM | Dose=1uM, Picotamide, Prostanoid TP Antagonists targeting TBXA2R |
| CC-01-ER18_0.01uM | Dose=0.01uM, Pirodomast |
| CC-01-ER18_0.1uM | Dose=0.1uM, Pirodomast |
| CC-01-ER18_10uM | Dose=10uM, Pirodomast |
| CC-01-ER18_1uM | Dose=1uM, Pirodomast |
| CC-01-PR23_0.01uM | Dose=0.01uM, Saredutant, Tachykinin NK2 Antagonists targeting TACR2 |
| CC-01-PR23_0.1uM | Dose=0.1uM, Saredutant, Tachykinin NK2 Antagonists targeting TACR2 |
| CC-01-PR23_10uM | Dose=10uM, Saredutant, Tachykinin NK2 Antagonists targeting TACR2 |
| CC-03-PW00_0.01uM | Dose=0.01uM, (S)-1-(6-Chloro-1-isobutyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-3-(4,4-difluoropiperidin-1-yl)propan-1-one, Antimicrobial;Inhibitor of pyrimidine biosynthesis targeting DHODH |
| CC-03-PW00_0.1uM | Dose=0.1uM, (S)-1-(6-Chloro-1-isobutyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-3-(4,4-difluoropiperidin-1-yl)propan-1-one, Antimicrobial;Inhibitor of pyrimidine biosynthesis targeting DHODH |
| CC-03-PW00_10uM | Dose=10uM, (S)-1-(6-Chloro-1-isobutyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-3-(4,4-difluoropiperidin-1-yl)propan-1-one, Antimicrobial;Inhibitor of pyrimidine biosynthesis targeting DHODH |
| CC-03-PW00_1uM | Dose=1uM, (S)-1-(6-Chloro-1-isobutyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-3-(4,4-difluoropiperidin-1-yl)propan-1-one, Antimicrobial;Inhibitor of pyrimidine biosynthesis targeting DHODH |
| CC-04-FJ21_10uM | Dose=10uM, ML315, CLK4 inhibitor targeting CLK4 |
| CC-04-WK34_0.01uM | Dose=0.01uM, Brompheniramine, Histamine Receptor Antagonists targeting HRH1 |
| CC-04-WK34_0.1uM | Dose=0.1uM, Brompheniramine, Histamine Receptor Antagonists targeting HRH1 |
| CC-04-WK34_10uM | Dose=10uM, Brompheniramine, Histamine Receptor Antagonists targeting HRH1 |
| CC-04-WK34_1uM | Dose=1uM, Brompheniramine, Histamine Receptor Antagonists targeting HRH1 |
| CC-04-YT10_0.01uM | Dose=0.01uM |
| CC-04-YT10_0.1uM | Dose=0.1uM |
| CC-04-YT10_10uM | Dose=10uM |
| CC-04-YT10_1uM | Dose=1uM |
| CC-05-MK46_0.01uM | Dose=0.01uM, (RS)-4-Carboxy-3-hydroxyphenylglycine |
| CC-05-MK46_0.1uM | Dose=0.1uM, (RS)-4-Carboxy-3-hydroxyphenylglycine |
| CC-05-MK46_10uM | Dose=10uM, (RS)-4-Carboxy-3-hydroxyphenylglycine |
| CC-05-MK46_1uM | Dose=1uM, (RS)-4-Carboxy-3-hydroxyphenylglycine |
| CC-06-WH01_0.01uM | Dose=0.01uM |
| CC-06-WH01_0.1uM | Dose=0.1uM |
| CC-06-WH01_10uM | Dose=10uM |
| CC-06-WH01_1uM | Dose=1uM |
| CC-07-DV77_0.01uM | Dose=0.01uM, 1-Cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin4-one, Phosphodiesterase V (PDE5A) Inhibitors;Phosphodiesterase PDE11A Inhibitors targeting PDE5A, PDE11A |
| CC-07-DV77_0.1uM | Dose=0.1uM, 1-Cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin4-one, Phosphodiesterase V (PDE5A) Inhibitors;Phosphodiesterase PDE11A Inhibitors targeting PDE5A, PDE11A |
| CC-07-DV77_10uM | Dose=10uM, 1-Cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin4-one, Phosphodiesterase V (PDE5A) Inhibitors;Phosphodiesterase PDE11A Inhibitors targeting PDE5A, PDE11A |
| CC-07-DV77_1uM | Dose=1uM, 1-Cyclopentyl-3-ethyl-6-(3-ethoxy-4-pyridyl)-pyrazolo[3,4-d]pyrimidin4-one, Phosphodiesterase V (PDE5A) Inhibitors;Phosphodiesterase PDE11A Inhibitors targeting PDE5A, PDE11A |
| CC-07-LB64_0.01uM | Dose=0.01uM, 3-hydroxy-8,9,10,11-tetrahydrocyclohepta[c]chromen-6(7H)-one |
| CC-07-LB64_0.1uM | Dose=0.1uM, 3-hydroxy-8,9,10,11-tetrahydrocyclohepta[c]chromen-6(7H)-one |
| CC-07-LB64_10uM | Dose=10uM, 3-hydroxy-8,9,10,11-tetrahydrocyclohepta[c]chromen-6(7H)-one |
| CC-07-LB64_1uM | Dose=1uM, 3-hydroxy-8,9,10,11-tetrahydrocyclohepta[c]chromen-6(7H)-one |
| CC-08-JZ09_0.01uM | Dose=0.01uM, Dykellic Acid, Apoptosis Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4 |
| CC-08-JZ09_0.1uM | Dose=0.1uM, Dykellic Acid, Apoptosis Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4 |
| CC-08-JZ09_10uM | Dose=10uM, Dykellic Acid, Apoptosis Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4 |
| CC-08-JZ09_1uM | Dose=1uM, Dykellic Acid, Apoptosis Inhibitors;IL-4 Production Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4 |
| CC-09-YG11_0.01uM | Dose=0.01uM, BPKDi, Protein Kinase D (PKD) Inhibitors targeting PRKD1, PRKD3, PRKD2 |
| CC-09-YG11_0.1uM | Dose=0.1uM, BPKDi, Protein Kinase D (PKD) Inhibitors targeting PRKD1, PRKD3, PRKD2 |
| CC-09-YG11_10uM | Dose=10uM, BPKDi, Protein Kinase D (PKD) Inhibitors targeting PRKD1, PRKD3, PRKD2 |
| CC-09-YG11_1uM | Dose=1uM, BPKDi, Protein Kinase D (PKD) Inhibitors targeting PRKD1, PRKD3, PRKD2 |
| CC-14-WK34_0.01uM | Dose=0.01uM, Nomifensine, Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| CC-14-WK34_0.1uM | Dose=0.1uM, Nomifensine, Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| CC-14-WK34_10uM | Dose=10uM, Nomifensine, Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| CC-14-WK34_1uM | Dose=1uM, Nomifensine, Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| CC-15-HU70_0.01uM | Dose=0.01uM, {3-(3-Bromo-phenyl)-2-[(furan-2-carbonyl)-amino]-acryloylamino}-acetic acid, ADAM12 gene inhibitor targeting ADAM12 |
| CC-15-HU70_0.1uM | Dose=0.1uM, {3-(3-Bromo-phenyl)-2-[(furan-2-carbonyl)-amino]-acryloylamino}-acetic acid, ADAM12 gene inhibitor targeting ADAM12 |
| CC-15-HU70_10uM | Dose=10uM, {3-(3-Bromo-phenyl)-2-[(furan-2-carbonyl)-amino]-acryloylamino}-acetic acid, ADAM12 gene inhibitor targeting ADAM12 |
| CC-15-HU70_1uM | Dose=1uM, {3-(3-Bromo-phenyl)-2-[(furan-2-carbonyl)-amino]-acryloylamino}-acetic acid, ADAM12 gene inhibitor targeting ADAM12 |
| CC-15-MK46_0.01uM | Dose=0.01uM, 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid, PTGER2 antagonist targeting PTGER2 |
| CC-15-MK46_0.1uM | Dose=0.1uM, 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid, PTGER2 antagonist targeting PTGER2 |
| CC-15-MK46_10uM | Dose=10uM, 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid, PTGER2 antagonist targeting PTGER2 |
| CC-15-MK46_1uM | Dose=1uM, 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid, PTGER2 antagonist targeting PTGER2 |
| CC-15-TX17_0.01uM | Dose=0.01uM, Mecamylamine, Nicotinic Receptor Antagonists targeting CHRNA2, CHRNA3, CHRNA5, CHRNB4, CHRNB3, CHRNA6, CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, CHRNA9, CHRNA10 |
| CC-15-TX17_0.1uM | Dose=0.1uM, Mecamylamine, Nicotinic Receptor Antagonists targeting CHRNA2, CHRNA3, CHRNA5, CHRNB4, CHRNB3, CHRNA6, CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, CHRNA9, CHRNA10 |
| CC-15-TX17_10uM | Dose=10uM, Mecamylamine, Nicotinic Receptor Antagonists targeting CHRNA2, CHRNA3, CHRNA5, CHRNB4, CHRNB3, CHRNA6, CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, CHRNA9, CHRNA10 |
| CC-15-TX17_1uM | Dose=1uM, Mecamylamine, Nicotinic Receptor Antagonists targeting CHRNA2, CHRNA3, CHRNA5, CHRNB4, CHRNB3, CHRNA6, CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, CHRNA9, CHRNA10 |
| CC-16-ZE49_0.01uM | Dose=0.01uM, Linopirdine, Acetylcholine Release Enhancers targeting KCNQ1 |
| CC-16-ZE49_0.1uM | Dose=0.1uM, Linopirdine, Acetylcholine Release Enhancers targeting KCNQ1 |
| CC-16-ZE49_1uM | Dose=1uM, Linopirdine, Acetylcholine Release Enhancers targeting KCNQ1 |
| CC-17-HI11_0.01uM | Dose=0.01uM, N-(5-Methyl-isoxazol-3-yl)-3-{3-[4-methyl-5-(4-pyrazol-1-yl-phenyl)-thiazol-2-yl]-ureido}-propionamide, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| CC-17-HI11_0.1uM | Dose=0.1uM, N-(5-Methyl-isoxazol-3-yl)-3-{3-[4-methyl-5-(4-pyrazol-1-yl-phenyl)-thiazol-2-yl]-ureido}-propionamide, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| CC-17-HI11_10uM | Dose=10uM, N-(5-Methyl-isoxazol-3-yl)-3-{3-[4-methyl-5-(4-pyrazol-1-yl-phenyl)-thiazol-2-yl]-ureido}-propionamide, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| CC-17-HI11_1uM | Dose=1uM, N-(5-Methyl-isoxazol-3-yl)-3-{3-[4-methyl-5-(4-pyrazol-1-yl-phenyl)-thiazol-2-yl]-ureido}-propionamide, Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors targeting PIK3CD |
| CC-17-JL38_0.01uM | Dose=0.01uM, Ilk-IN-1 targeting ILK |
| CC-17-JL38_0.1uM | Dose=0.1uM, Ilk-IN-1 targeting ILK |
| CC-17-JL38_10uM | Dose=10uM, Ilk-IN-1 targeting ILK |
| CC-17-JL38_1uM | Dose=1uM, Ilk-IN-1 targeting ILK |
| CC-18-YW57_0.01uM | Dose=0.01uM |
| CC-18-YW57_0.1uM | Dose=0.1uM |
| CC-18-YW57_10uM | Dose=10uM |
| CC-18-YW57_1uM | Dose=1uM |
| CC-20-FN31_0.01uM | Dose=0.01uM, Dnk 333, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1 |
| CC-20-FN31_0.1uM | Dose=0.1uM, Dnk 333, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1 |
| CC-20-FN31_10uM | Dose=10uM, Dnk 333, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1 |
| CC-20-FN31_1uM | Dose=1uM, Dnk 333, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR2, TACR1 |
| CC-20-ZO24_0.01uM | Dose=0.01uM, Neboglamine, NMDA Glycine-Site Modulators;Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| CC-20-ZO24_0.1uM | Dose=0.1uM, Neboglamine, NMDA Glycine-Site Modulators;Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| CC-20-ZO24_10uM | Dose=10uM, Neboglamine, NMDA Glycine-Site Modulators;Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| CC-20-ZO24_1uM | Dose=1uM, Neboglamine, NMDA Glycine-Site Modulators;Norepinephrine Reuptake Inhibitors targeting SLC6A2 |
| CC-21-IE22_0.01uM | Dose=0.01uM, N-[[3a(2)-[[(4-Chloro-2,5-dimethylphenyl)sulfonyl]amino]-3,5-dimethyl[1,1a(2)-biphenyl]-4-yl]carbonyl]-L-alanine, S1PR1 antagonist targeting S1PR1 |
| CC-21-IE22_0.1uM | Dose=0.1uM, N-[[3a(2)-[[(4-Chloro-2,5-dimethylphenyl)sulfonyl]amino]-3,5-dimethyl[1,1a(2)-biphenyl]-4-yl]carbonyl]-L-alanine, S1PR1 antagonist targeting S1PR1 |
| CC-21-IE22_10uM | Dose=10uM, N-[[3a(2)-[[(4-Chloro-2,5-dimethylphenyl)sulfonyl]amino]-3,5-dimethyl[1,1a(2)-biphenyl]-4-yl]carbonyl]-L-alanine, S1PR1 antagonist targeting S1PR1 |
| CC-21-IE22_1uM | Dose=1uM, N-[[3a(2)-[[(4-Chloro-2,5-dimethylphenyl)sulfonyl]amino]-3,5-dimethyl[1,1a(2)-biphenyl]-4-yl]carbonyl]-L-alanine, S1PR1 antagonist targeting S1PR1 |
| CC-25-QN53_0.01uM | Dose=0.01uM, Medetomidine, ADRA2A agonist;ADRA2B agonist;alpha2-Adrenoceptor Agonists;Extracellular-regulated kinase (ERK) Activators;ADRA2C agonist targeting ADRA2B, ADRA2C, MAPK13 |
| CC-25-QN53_0.1uM | Dose=0.1uM, Medetomidine, ADRA2A agonist;ADRA2B agonist;alpha2-Adrenoceptor Agonists;Extracellular-regulated kinase (ERK) Activators;ADRA2C agonist targeting ADRA2B, ADRA2C, MAPK13 |
| CC-25-QN53_10uM | Dose=10uM, Medetomidine, ADRA2A agonist;ADRA2B agonist;alpha2-Adrenoceptor Agonists;Extracellular-regulated kinase (ERK) Activators;ADRA2C agonist targeting ADRA2B, ADRA2C, MAPK13 |
| CC-25-QN53_1uM | Dose=1uM, Medetomidine, ADRA2A agonist;ADRA2B agonist;alpha2-Adrenoceptor Agonists;Extracellular-regulated kinase (ERK) Activators;ADRA2C agonist targeting ADRA2B, ADRA2C, MAPK13 |
| CC-29-RG66_0.01uM | Dose=0.01uM |
| CC-29-RG66_0.1uM | Dose=0.1uM |
| CC-29-RG66_10uM | Dose=10uM |
| CC-29-RG66_1uM | Dose=1uM |
| CC-30-TN36_0.1uM | Dose=0.1uM, Benalfocin, alpha2-Adrenoceptor Antagonists targeting ADRA1B |
| CC-30-TN36_10uM | Dose=10uM, Benalfocin, alpha2-Adrenoceptor Antagonists targeting ADRA1B |
| CC-30-TN36_1uM | Dose=1uM, Benalfocin, alpha2-Adrenoceptor Antagonists targeting ADRA1B |
| CC-31-VS31_0.01uM | Dose=0.01uM, [[4-[4-[2-[[(3R,3aR,6R,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-6-chloro-1H-imidazo[4,5-b]pyridin-5-yl]phenyl]phenyl]-methyl-oxo-lambda6-sulfanylidene]cyanamide, AMP activated protein kinase alpha 1 stimulator targeting PRKAA1, PRKAB1 |
| CC-31-VS31_0.1uM | Dose=0.1uM, [[4-[4-[2-[[(3R,3aR,6R,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-6-chloro-1H-imidazo[4,5-b]pyridin-5-yl]phenyl]phenyl]-methyl-oxo-lambda6-sulfanylidene]cyanamide, AMP activated protein kinase alpha 1 stimulator targeting PRKAA1, PRKAB1 |
| CC-31-VS31_10uM | Dose=10uM, [[4-[4-[2-[[(3R,3aR,6R,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-6-chloro-1H-imidazo[4,5-b]pyridin-5-yl]phenyl]phenyl]-methyl-oxo-lambda6-sulfanylidene]cyanamide, AMP activated protein kinase alpha 1 stimulator targeting PRKAA1, PRKAB1 |
| CC-31-VS31_1uM | Dose=1uM, [[4-[4-[2-[[(3R,3aR,6R,6aR)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-6-chloro-1H-imidazo[4,5-b]pyridin-5-yl]phenyl]phenyl]-methyl-oxo-lambda6-sulfanylidene]cyanamide, AMP activated protein kinase alpha 1 stimulator targeting PRKAA1, PRKAB1 |
| CC-37-QW80_0.01uM | Dose=0.01uM |
| CC-37-QW80_0.1uM | Dose=0.1uM |
| CC-37-QW80_10uM | Dose=10uM |
| CC-37-QW80_1uM | Dose=1uM |
| CC-41-SI77_0.01uM | Dose=0.01uM, 5-(2-chloro-4-cyclopropylphenyl)-N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-4-methyl-1,2-oxazole-3-carboxamide, SMAD-1 inhibitor;SMURF1 inhibitor targeting SMURF1 |
| CC-41-SI77_10uM | Dose=10uM, 5-(2-chloro-4-cyclopropylphenyl)-N-[1-(2-fluorophenyl)-2,3-dimethyl-5-oxopyrazol-4-yl]-4-methyl-1,2-oxazole-3-carboxamide, SMAD-1 inhibitor;SMURF1 inhibitor targeting SMURF1 |
| CC-42-ZV45_0.01uM | Dose=0.01uM, (S)-2-amino-5-phosphonopentanoic acid |
| CC-42-ZV45_0.1uM | Dose=0.1uM, (S)-2-amino-5-phosphonopentanoic acid |
| CC-42-ZV45_10uM | Dose=10uM, (S)-2-amino-5-phosphonopentanoic acid |
| CC-42-ZV45_1uM | Dose=1uM, (S)-2-amino-5-phosphonopentanoic acid |
| CC-44-MG29_0.01uM | Dose=0.01uM, 2'-(2-fluorophenyl)-1-methyl-6',8',9',11'-tetrahydrospiro[azetidine-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinolin]-7'(5'H)-one, MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| CC-44-MG29_0.1uM | Dose=0.1uM, 2'-(2-fluorophenyl)-1-methyl-6',8',9',11'-tetrahydrospiro[azetidine-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinolin]-7'(5'H)-one, MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| CC-44-MG29_10uM | Dose=10uM, 2'-(2-fluorophenyl)-1-methyl-6',8',9',11'-tetrahydrospiro[azetidine-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinolin]-7'(5'H)-one, MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| CC-44-MG29_1uM | Dose=1uM, 2'-(2-fluorophenyl)-1-methyl-6',8',9',11'-tetrahydrospiro[azetidine-3,10'-pyrido[3',4':4,5]pyrrolo[2,3-f]isoquinolin]-7'(5'H)-one, MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| CC-46-CE74_0.01uM | Dose=0.01uM, 4-methyl-N-(naphthalen-1-yl)thiazol-2-amine, Chemokine CCR4 Antagonists targeting CCR4 |
| CC-46-CE74_0.1uM | Dose=0.1uM, 4-methyl-N-(naphthalen-1-yl)thiazol-2-amine, Chemokine CCR4 Antagonists targeting CCR4 |
| CC-46-CE74_10uM | Dose=10uM, 4-methyl-N-(naphthalen-1-yl)thiazol-2-amine, Chemokine CCR4 Antagonists targeting CCR4 |
| CC-46-CE74_1uM | Dose=1uM, 4-methyl-N-(naphthalen-1-yl)thiazol-2-amine, Chemokine CCR4 Antagonists targeting CCR4 |
| CC-47-VS90_0.01uM | Dose=0.01uM, Tgx-221, PI3Kbeta inhibitor targeting PIK3CB |
| CC-47-VS90_0.1uM | Dose=0.1uM, Tgx-221, PI3Kbeta inhibitor targeting PIK3CB |
| CC-47-VS90_10uM | Dose=10uM, Tgx-221, PI3Kbeta inhibitor targeting PIK3CB |
| CC-47-VS90_1uM | Dose=1uM, Tgx-221, PI3Kbeta inhibitor targeting PIK3CB |
| CC-48-OM48_0.01uM | Dose=0.01uM, Gsk343, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2 |
| CC-48-OM48_0.1uM | Dose=0.1uM, Gsk343, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2 |
| CC-48-OM48_10uM | Dose=10uM, Gsk343, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2 |
| CC-48-OM48_1uM | Dose=1uM, Gsk343, PRC2/EZH2;EZH2 gene inhibitor targeting EZH2 |
| CC-48-ZJ56_10uM | Dose=10uM |
| CC-49-CQ25_0.01uM | Dose=0.01uM, (2S)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-N-(2-phenylphenyl)pyrrolidine-2-carboxamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| CC-49-CQ25_0.1uM | Dose=0.1uM, (2S)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-N-(2-phenylphenyl)pyrrolidine-2-carboxamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| CC-49-CQ25_10uM | Dose=10uM, (2S)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-N-(2-phenylphenyl)pyrrolidine-2-carboxamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| CC-49-CQ25_1uM | Dose=1uM, (2S)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-N-(2-phenylphenyl)pyrrolidine-2-carboxamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| CC-50-FK24_0.01uM | Dose=0.01uM, Navitoclax, Apoptosis Inducers;Bcl-2 Inhibitors;Bcl-xl Inhibitors;BCL-2/xL inhibitor;Bcl-w Inhibitors targeting BCL2, BCL2L1, BCL2L2 |
| CC-50-FK24_0.1uM | Dose=0.1uM, Navitoclax, Apoptosis Inducers;Bcl-2 Inhibitors;Bcl-xl Inhibitors;BCL-2/xL inhibitor;Bcl-w Inhibitors targeting BCL2, BCL2L1, BCL2L2 |
| CC-50-FK24_10uM | Dose=10uM, Navitoclax, Apoptosis Inducers;Bcl-2 Inhibitors;Bcl-xl Inhibitors;BCL-2/xL inhibitor;Bcl-w Inhibitors targeting BCL2, BCL2L1, BCL2L2 |
| CC-50-FK24_1uM | Dose=1uM, Navitoclax, Apoptosis Inducers;Bcl-2 Inhibitors;Bcl-xl Inhibitors;BCL-2/xL inhibitor;Bcl-w Inhibitors targeting BCL2, BCL2L1, BCL2L2 |
| CC-51-KS26_0.01uM | Dose=0.01uM, 1-[5-(thiophen-2-ylmethoxy)-1H-indol-3-yl]propan-2-amine, HTR2B agonist targeting HTR2B |
| CC-51-KS26_0.1uM | Dose=0.1uM, 1-[5-(thiophen-2-ylmethoxy)-1H-indol-3-yl]propan-2-amine, HTR2B agonist targeting HTR2B |
| CC-51-KS26_10uM | Dose=10uM, 1-[5-(thiophen-2-ylmethoxy)-1H-indol-3-yl]propan-2-amine, HTR2B agonist targeting HTR2B |
| CC-51-KS26_1uM | Dose=1uM, 1-[5-(thiophen-2-ylmethoxy)-1H-indol-3-yl]propan-2-amine, HTR2B agonist targeting HTR2B |
| CC-55-CD84_0.01uM | Dose=0.01uM, 4-[5-(4-methoxyphenyl)thiophen-2-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-2-amine, Inhibitors of Signal Transduction Pathways;Inhibitory kappaB Kinase (IKK) Inhibitors targeting IKBKB |
| CC-55-CD84_0.1uM | Dose=0.1uM, 4-[5-(4-methoxyphenyl)thiophen-2-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-2-amine, Inhibitors of Signal Transduction Pathways;Inhibitory kappaB Kinase (IKK) Inhibitors targeting IKBKB |
| CC-55-CD84_10uM | Dose=10uM, 4-[5-(4-methoxyphenyl)thiophen-2-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-2-amine, Inhibitors of Signal Transduction Pathways;Inhibitory kappaB Kinase (IKK) Inhibitors targeting IKBKB |
| CC-55-CD84_1uM | Dose=1uM, 4-[5-(4-methoxyphenyl)thiophen-2-yl]-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyrimidin-2-amine, Inhibitors of Signal Transduction Pathways;Inhibitory kappaB Kinase (IKK) Inhibitors targeting IKBKB |
| CC-56-MO03_0.01uM | Dose=0.01uM, 4-(1H-indol-3-yl)pyrimidin-2-amine |
| CC-56-MO03_0.1uM | Dose=0.1uM, 4-(1H-indol-3-yl)pyrimidin-2-amine |
| CC-56-MO03_10uM | Dose=10uM, 4-(1H-indol-3-yl)pyrimidin-2-amine |
| CC-56-MO03_1uM | Dose=1uM, 4-(1H-indol-3-yl)pyrimidin-2-amine |
| CC-58-DF11_0.01uM | Dose=0.01uM, Xanomeline, Muscarinic M1 receptor agonist;Cholinergic Muscarinic 1-4 agonist;Muscarinic M4 receptor agonist;Muscarinic M5 receptor agonist targeting CHRM1, CHRM4, CHRM5 |
| CC-58-DF11_0.1uM | Dose=0.1uM, Xanomeline, Muscarinic M1 receptor agonist;Cholinergic Muscarinic 1-4 agonist;Muscarinic M4 receptor agonist;Muscarinic M5 receptor agonist targeting CHRM1, CHRM4, CHRM5 |
| CC-58-DF11_10uM | Dose=10uM, Xanomeline, Muscarinic M1 receptor agonist;Cholinergic Muscarinic 1-4 agonist;Muscarinic M4 receptor agonist;Muscarinic M5 receptor agonist targeting CHRM1, CHRM4, CHRM5 |
| CC-58-JZ09_0.01uM | Dose=0.01uM, LCK and PI3K dual inhibitor, also targets mTOR |
| CC-58-JZ09_10uM | Dose=10uM, LCK and PI3K dual inhibitor, also targets mTOR |
| CC-58-RP30_0.01uM | Dose=0.01uM, (r)-6-Methyl-4'-trifluoromethylbiphenyl-2-carboxylic acid (2-methoxycarbonylaminoindan-5-yl)-amide, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting APOB, MTTP |
| CC-58-RP30_0.1uM | Dose=0.1uM, (r)-6-Methyl-4'-trifluoromethylbiphenyl-2-carboxylic acid (2-methoxycarbonylaminoindan-5-yl)-amide, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting APOB, MTTP |
| CC-58-RP30_10uM | Dose=10uM, (r)-6-Methyl-4'-trifluoromethylbiphenyl-2-carboxylic acid (2-methoxycarbonylaminoindan-5-yl)-amide, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting APOB, MTTP |
| CC-58-RP30_1uM | Dose=1uM, (r)-6-Methyl-4'-trifluoromethylbiphenyl-2-carboxylic acid (2-methoxycarbonylaminoindan-5-yl)-amide, ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors targeting APOB, MTTP |
| CC-61-HH09_0.01uM | Dose=0.01uM, 6-Chrysenamine targeting HPRT1 |
| CC-61-HH09_10uM | Dose=10uM, 6-Chrysenamine targeting HPRT1 |
| CC-61-HH09_1uM | Dose=1uM, 6-Chrysenamine targeting HPRT1 |
| CC-61-KS26_0.01uM | Dose=0.01uM, PK 11195, Pregnane X Receptor (PXR) Agonists;Peripheral Benzodiazepine Receptor (PBR) Antagonists;Constitutive Androstane Receptor (CAR) Antagonists targeting TSPO, NR1I2, NR1I3 |
| CC-61-KS26_10uM | Dose=10uM, PK 11195, Pregnane X Receptor (PXR) Agonists;Peripheral Benzodiazepine Receptor (PBR) Antagonists;Constitutive Androstane Receptor (CAR) Antagonists targeting TSPO, NR1I2, NR1I3 |
| CC-62-XM29_0.01uM | Dose=0.01uM, Skf-81297, DRD1 agonist targeting DRD1 |
| CC-62-XM29_0.1uM | Dose=0.1uM, Skf-81297, DRD1 agonist targeting DRD1 |
| CC-62-XM29_10uM | Dose=10uM, Skf-81297, DRD1 agonist targeting DRD1 |
| CC-62-XM29_1uM | Dose=1uM, Skf-81297, DRD1 agonist targeting DRD1 |
| CC-67-LI41_0.01uM | Dose=0.01uM, 3-Aminobenzamide, PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| CC-67-LI41_0.1uM | Dose=0.1uM, 3-Aminobenzamide, PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| CC-67-LI41_10uM | Dose=10uM, 3-Aminobenzamide, PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| CC-67-LI41_1uM | Dose=1uM, 3-Aminobenzamide, PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| CC-68-YZ44_0.01uM | Dose=0.01uM, 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CC-68-YZ44_0.1uM | Dose=0.1uM, 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CC-68-YZ44_10uM | Dose=10uM, 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CC-68-YZ44_1uM | Dose=1uM, 4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CC-70-BD07_0.01uM | Dose=0.01uM, Voriconazole Impurity 7 |
| CC-70-BD07_0.1uM | Dose=0.1uM, Voriconazole Impurity 7 |
| CC-70-BD07_10uM | Dose=10uM, Voriconazole Impurity 7 |
| CC-70-BD07_1uM | Dose=1uM, Voriconazole Impurity 7 |
| CC-72-ZV25_0.01uM | Dose=0.01uM, N-(1,2-diphenylethyl)-4,5-dihydrothiazol-2-amine, alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA2A, ADRA2B |
| CC-72-ZV25_0.1uM | Dose=0.1uM, N-(1,2-diphenylethyl)-4,5-dihydrothiazol-2-amine, alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA2A, ADRA2B |
| CC-72-ZV25_1uM | Dose=1uM, N-(1,2-diphenylethyl)-4,5-dihydrothiazol-2-amine, alpha2B-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists targeting ADRA2A, ADRA2B |
| CC-84-JQ48_0.01uM | Dose=0.01uM, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| CC-84-JQ48_0.1uM | Dose=0.1uM, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| CC-84-JQ48_10uM | Dose=10uM, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| CC-84-JQ48_1uM | Dose=1uM, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| CC-84-QJ26_0.01uM | Dose=0.01uM, Fluoxetine, Serotonin Transporter (SERT) Inhibitors;Sodium Channel Blockers targeting SLC6A4 |
| CC-84-QJ26_0.1uM | Dose=0.1uM, Fluoxetine, Serotonin Transporter (SERT) Inhibitors;Sodium Channel Blockers targeting SLC6A4 |
| CC-84-QJ26_10uM | Dose=10uM, Fluoxetine, Serotonin Transporter (SERT) Inhibitors;Sodium Channel Blockers targeting SLC6A4 |
| CC-85-AY05_0.01uM | Dose=0.01uM, Clavulanic Acid, beta-Lactamase Inhibitors targeting LACTB |
| CC-85-AY05_0.1uM | Dose=0.1uM, Clavulanic Acid, beta-Lactamase Inhibitors targeting LACTB |
| CC-85-AY05_10uM | Dose=10uM, Clavulanic Acid, beta-Lactamase Inhibitors targeting LACTB |
| CC-85-AY05_1uM | Dose=1uM, Clavulanic Acid, beta-Lactamase Inhibitors targeting LACTB |
| CC-85-XK71_0.01uM | Dose=0.01uM, GW 4064, Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| CC-85-XK71_0.1uM | Dose=0.1uM, GW 4064, Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| CC-85-XK71_1uM | Dose=1uM, GW 4064, Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| CC-86-IO63_0.01uM | Dose=0.01uM, Mirdametinib, MEK Inhibitor targeting MAP2K3, MAP2K5, MAP2K6 |
| CC-86-IO63_0.1uM | Dose=0.1uM, Mirdametinib, MEK Inhibitor targeting MAP2K3, MAP2K5, MAP2K6 |
| CC-86-IO63_10uM | Dose=10uM, Mirdametinib, MEK Inhibitor targeting MAP2K3, MAP2K5, MAP2K6 |
| CC-86-IO63_1uM | Dose=1uM, Mirdametinib, MEK Inhibitor targeting MAP2K3, MAP2K5, MAP2K6 |
| CC-88-JZ09_0.01uM | Dose=0.01uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(pyrrolidin-1-ylmethyl)benzamide |
| CC-88-JZ09_0.1uM | Dose=0.1uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(pyrrolidin-1-ylmethyl)benzamide |
| CC-88-JZ09_10uM | Dose=10uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(pyrrolidin-1-ylmethyl)benzamide |
| CC-88-JZ09_1uM | Dose=1uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(pyrrolidin-1-ylmethyl)benzamide |
| CC-90-EX35_0.01uM | Dose=0.01uM |
| CC-90-EX35_0.1uM | Dose=0.1uM |
| CC-90-EX35_10uM | Dose=10uM |
| CC-90-EX35_1uM | Dose=1uM |
| CC-90-FE70_0.01uM | Dose=0.01uM, 1,1'-Biphenyl-4-yl-boronic acid, Carbonic Anhydrase Type XII Inhibitors;Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA12 |
| CC-90-FE70_0.1uM | Dose=0.1uM, 1,1'-Biphenyl-4-yl-boronic acid, Carbonic Anhydrase Type XII Inhibitors;Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA12 |
| CC-90-FE70_10uM | Dose=10uM, 1,1'-Biphenyl-4-yl-boronic acid, Carbonic Anhydrase Type XII Inhibitors;Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA12 |
| CC-90-FE70_1uM | Dose=1uM, 1,1'-Biphenyl-4-yl-boronic acid, Carbonic Anhydrase Type XII Inhibitors;Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA12 |
| CC-90-NK44_0.01uM | Dose=0.01uM, Spautin-1, Autophagy Agonist;Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A |
| CC-90-NK44_0.1uM | Dose=0.1uM, Spautin-1, Autophagy Agonist;Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A |
| CC-90-NK44_10uM | Dose=10uM, Spautin-1, Autophagy Agonist;Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A |
| CC-90-NK44_1uM | Dose=1uM, Spautin-1, Autophagy Agonist;Phosphodiesterase V (PDE5A) Inhibitors targeting PDE5A |
| CC-91-RO81_0.01uM | Dose=0.01uM, Mcc950, inhibits NLRP3 inflammasome (exact target/mechanism unknown). Shows reduction of IL-1B in vivo in EAE expt models of MS.;NRLP3 inflammasome inhibitor targeting NLRP3 |
| CC-91-RO81_0.1uM | Dose=0.1uM, Mcc950, inhibits NLRP3 inflammasome (exact target/mechanism unknown). Shows reduction of IL-1B in vivo in EAE expt models of MS.;NRLP3 inflammasome inhibitor targeting NLRP3 |
| CC-91-RO81_10uM | Dose=10uM, Mcc950, inhibits NLRP3 inflammasome (exact target/mechanism unknown). Shows reduction of IL-1B in vivo in EAE expt models of MS.;NRLP3 inflammasome inhibitor targeting NLRP3 |
| CC-91-RO81_1uM | Dose=1uM, Mcc950, inhibits NLRP3 inflammasome (exact target/mechanism unknown). Shows reduction of IL-1B in vivo in EAE expt models of MS.;NRLP3 inflammasome inhibitor targeting NLRP3 |
| CC-91-VE57_0.01uM | Dose=0.01uM, N-[4-chloro-3-(trifluoromethyl)phenyl]-2,4,6-trimethylaniline, RAPGEF4 inhibitor targeting RAPGEF4 |
| CC-91-VE57_0.1uM | Dose=0.1uM, N-[4-chloro-3-(trifluoromethyl)phenyl]-2,4,6-trimethylaniline, RAPGEF4 inhibitor targeting RAPGEF4 |
| CC-91-VE57_10uM | Dose=10uM, N-[4-chloro-3-(trifluoromethyl)phenyl]-2,4,6-trimethylaniline, RAPGEF4 inhibitor targeting RAPGEF4 |
| CC-91-VE57_1uM | Dose=1uM, N-[4-chloro-3-(trifluoromethyl)phenyl]-2,4,6-trimethylaniline, RAPGEF4 inhibitor targeting RAPGEF4 |
| CC-93-RP38_0.01uM | Dose=0.01uM, Teriflunomide, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| CC-93-RP38_0.1uM | Dose=0.1uM, Teriflunomide, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| CC-93-RP38_10uM | Dose=10uM, Teriflunomide, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| CC-93-RP38_1uM | Dose=1uM, Teriflunomide, Dihydroorotate Dehydrogenase (DHODH) Inhibitors targeting DHODH |
| CC-98-YC44_0.01uM | Dose=0.01uM, N-(4,4-Diphenyl-3-butenyl)nipecotic acid, GAT-1 Inhibitors targeting SLC6A1, SLC6A12 |
| CC-98-YC44_0.1uM | Dose=0.1uM, N-(4,4-Diphenyl-3-butenyl)nipecotic acid, GAT-1 Inhibitors targeting SLC6A1, SLC6A12 |
| CC-98-YC44_10uM | Dose=10uM, N-(4,4-Diphenyl-3-butenyl)nipecotic acid, GAT-1 Inhibitors targeting SLC6A1, SLC6A12 |
| CD-01-ZO61_10uM | Dose=10uM, Fatty Acid Amide Hydrolase (FAAH) Inhibitors |
| CD-01-ZO61_1uM | Dose=1uM, Fatty Acid Amide Hydrolase (FAAH) Inhibitors |
| CD-03-QC42_0.01uM | Dose=0.01uM, 3-Aminopropyl(methyl)phosphinic acid, GABA(B) Agonists;GABBR1 agonist targeting GABBR1, GABBR2 |
| CD-03-QC42_10uM | Dose=10uM, 3-Aminopropyl(methyl)phosphinic acid, GABA(B) Agonists;GABBR1 agonist targeting GABBR1, GABBR2 |
| CD-03-QC42_1uM | Dose=1uM, 3-Aminopropyl(methyl)phosphinic acid, GABA(B) Agonists;GABBR1 agonist targeting GABBR1, GABBR2 |
| CD-05-PU90_0.01uM | Dose=0.01uM, 4-(1H-Pyrrolo[2,3-B]pyridin-3-YL)pyrimidin-2-amine, CDK inhibitors targeting CDK2, CDK9, DYRK1A, CCNA1, CCNB2, ROCK2, CCNB3 |
| CD-05-PU90_0.1uM | Dose=0.1uM, 4-(1H-Pyrrolo[2,3-B]pyridin-3-YL)pyrimidin-2-amine, CDK inhibitors targeting CDK2, CDK9, DYRK1A, CCNA1, CCNB2, ROCK2, CCNB3 |
| CD-05-PU90_10uM | Dose=10uM, 4-(1H-Pyrrolo[2,3-B]pyridin-3-YL)pyrimidin-2-amine, CDK inhibitors targeting CDK2, CDK9, DYRK1A, CCNA1, CCNB2, ROCK2, CCNB3 |
| CD-05-PU90_1uM | Dose=1uM, 4-(1H-Pyrrolo[2,3-B]pyridin-3-YL)pyrimidin-2-amine, CDK inhibitors targeting CDK2, CDK9, DYRK1A, CCNA1, CCNB2, ROCK2, CCNB3 |
| CD-07-GB34_0.01uM | Dose=0.01uM, 3-(1-Aminopropan-2-yl)-1H-indol-5-ol targeting HTR1F |
| CD-07-GB34_0.1uM | Dose=0.1uM, 3-(1-Aminopropan-2-yl)-1H-indol-5-ol targeting HTR1F |
| CD-07-GB34_10uM | Dose=10uM, 3-(1-Aminopropan-2-yl)-1H-indol-5-ol targeting HTR1F |
| CD-07-GB34_1uM | Dose=1uM, 3-(1-Aminopropan-2-yl)-1H-indol-5-ol targeting HTR1F |
| CD-08-MF16_0.01uM | Dose=0.01uM, Sulfamic acid, [1,1'-biphenyl]-4-yl ester, Carbonic anhydrase inhibitor targeting CA1 |
| CD-08-MF16_0.1uM | Dose=0.1uM, Sulfamic acid, [1,1'-biphenyl]-4-yl ester, Carbonic anhydrase inhibitor targeting CA1 |
| CD-08-MF16_10uM | Dose=10uM, Sulfamic acid, [1,1'-biphenyl]-4-yl ester, Carbonic anhydrase inhibitor targeting CA1 |
| CD-08-MF16_1uM | Dose=1uM, Sulfamic acid, [1,1'-biphenyl]-4-yl ester, Carbonic anhydrase inhibitor targeting CA1 |
| CD-10-LX95_0.01uM | Dose=0.01uM, (E)-[5-(2-diethylcarbamoyl-1-methyl-vinyl)-2-(2,6-difluorobenzyloxy)-phenyl]-acetic acid, Leukotriene BLT (LTB4) Antagonists targeting LTB4R2 |
| CD-10-LX95_10uM | Dose=10uM, (E)-[5-(2-diethylcarbamoyl-1-methyl-vinyl)-2-(2,6-difluorobenzyloxy)-phenyl]-acetic acid, Leukotriene BLT (LTB4) Antagonists targeting LTB4R2 |
| CD-10-LX95_1uM | Dose=1uM, (E)-[5-(2-diethylcarbamoyl-1-methyl-vinyl)-2-(2,6-difluorobenzyloxy)-phenyl]-acetic acid, Leukotriene BLT (LTB4) Antagonists targeting LTB4R2 |
| CD-12-NI84_0.01uM | Dose=0.01uM, 1-Adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| CD-12-NI84_0.1uM | Dose=0.1uM, 1-Adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| CD-12-NI84_10uM | Dose=10uM, 1-Adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| CD-12-NI84_1uM | Dose=1uM, 1-Adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea, Soluble Epoxide Hydrolase Inhibitors targeting EPHX2 |
| CD-13-QZ32_0.01uM | Dose=0.01uM, N-[6-(hydroxyamino)-6-oxohexyl]-4-phenylmethoxybenzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CD-13-QZ32_0.1uM | Dose=0.1uM, N-[6-(hydroxyamino)-6-oxohexyl]-4-phenylmethoxybenzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CD-13-QZ32_10uM | Dose=10uM, N-[6-(hydroxyamino)-6-oxohexyl]-4-phenylmethoxybenzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CD-13-QZ32_1uM | Dose=1uM, N-[6-(hydroxyamino)-6-oxohexyl]-4-phenylmethoxybenzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CD-16-KY17_0.01uM | Dose=0.01uM, 6-{[4-(2-Chloro-phenyl)-thiazol-2-ylmethyl]-amino}-naphthalene-2-carboxylic acid, G Protein-Coupled Receptor GPR120 Agonists targeting FFAR4 |
| CD-16-KY17_0.1uM | Dose=0.1uM, 6-{[4-(2-Chloro-phenyl)-thiazol-2-ylmethyl]-amino}-naphthalene-2-carboxylic acid, G Protein-Coupled Receptor GPR120 Agonists targeting FFAR4 |
| CD-16-KY17_10uM | Dose=10uM, 6-{[4-(2-Chloro-phenyl)-thiazol-2-ylmethyl]-amino}-naphthalene-2-carboxylic acid, G Protein-Coupled Receptor GPR120 Agonists targeting FFAR4 |
| CD-16-KY17_1uM | Dose=1uM, 6-{[4-(2-Chloro-phenyl)-thiazol-2-ylmethyl]-amino}-naphthalene-2-carboxylic acid, G Protein-Coupled Receptor GPR120 Agonists targeting FFAR4 |
| CD-18-KC24_0.1uM | Dose=0.1uM, Finasteride, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2 |
| CD-18-KC24_10uM | Dose=10uM, Finasteride, Steroid 5alpha-Reductase Inhibitors targeting SRD5A1, SRD5A2 |
| CD-18-RM48_0.01uM | Dose=0.01uM, Rabeprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B |
| CD-18-RM48_0.1uM | Dose=0.1uM, Rabeprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B |
| CD-18-RM48_10uM | Dose=10uM, Rabeprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B |
| CD-18-RM48_1uM | Dose=1uM, Rabeprazole, H+/K+-ATPase Inhibitors targeting ATP4A, ATP4B |
| CD-20-GE75_0.01uM | Dose=0.01uM, Bemcentinib, Axl tyrosine kinase receptor inhibitor targeting AXL |
| CD-20-GE75_0.1uM | Dose=0.1uM, Bemcentinib, Axl tyrosine kinase receptor inhibitor targeting AXL |
| CD-20-GE75_10uM | Dose=10uM, Bemcentinib, Axl tyrosine kinase receptor inhibitor targeting AXL |
| CD-20-GE75_1uM | Dose=1uM, Bemcentinib, Axl tyrosine kinase receptor inhibitor targeting AXL |
| CD-20-MH57_0.01uM | Dose=0.01uM, UF010, HDAC3 gene inhibitor targeting HDAC1, HDAC2, HDAC3 |
| CD-20-MH57_0.1uM | Dose=0.1uM, UF010, HDAC3 gene inhibitor targeting HDAC1, HDAC2, HDAC3 |
| CD-20-MH57_10uM | Dose=10uM, UF010, HDAC3 gene inhibitor targeting HDAC1, HDAC2, HDAC3 |
| CD-20-MH57_1uM | Dose=1uM, UF010, HDAC3 gene inhibitor targeting HDAC1, HDAC2, HDAC3 |
| CD-21-MI27_0.01uM | Dose=0.01uM, Deoxyuridine |
| CD-21-MI27_0.1uM | Dose=0.1uM, Deoxyuridine |
| CD-21-MI27_10uM | Dose=10uM, Deoxyuridine |
| CD-21-MI27_1uM | Dose=1uM, Deoxyuridine |
| CD-25-PY50_10uM | Dose=10uM, Lumacaftor, Specific stabilization of CFTR MSD1, specifically TMD1. targeting CFTR |
| CD-26-MB82_0.01uM | Dose=0.01uM, Zebularine, DNA Methyltransferase (DNMT) Inhibitors;Cytidine Deaminase (CDA) Inhibitors targeting CDA, DNMT1, DNMT3A |
| CD-26-MB82_0.1uM | Dose=0.1uM, Zebularine, DNA Methyltransferase (DNMT) Inhibitors;Cytidine Deaminase (CDA) Inhibitors targeting CDA, DNMT1, DNMT3A |
| CD-26-MB82_10uM | Dose=10uM, Zebularine, DNA Methyltransferase (DNMT) Inhibitors;Cytidine Deaminase (CDA) Inhibitors targeting CDA, DNMT1, DNMT3A |
| CD-26-MB82_1uM | Dose=1uM, Zebularine, DNA Methyltransferase (DNMT) Inhibitors;Cytidine Deaminase (CDA) Inhibitors targeting CDA, DNMT1, DNMT3A |
| CD-29-EG36_0.1uM | Dose=0.1uM, Sparfosic Acid, Aspartate Carbamoyltransferase Inhibitors;Antimetabolites targeting CAD |
| CD-29-EG36_1uM | Dose=1uM, Sparfosic Acid, Aspartate Carbamoyltransferase Inhibitors;Antimetabolites targeting CAD |
| CD-30-AD57_0.01uM | Dose=0.01uM, Dichloroacetic Acid, Pyruvate Dehydrogenase Kinase (PDHK;Apoptosis Inducers;PDK) Inhibitors targeting PDK1 |
| CD-30-AD57_0.1uM | Dose=0.1uM, Dichloroacetic Acid, Pyruvate Dehydrogenase Kinase (PDHK;Apoptosis Inducers;PDK) Inhibitors targeting PDK1 |
| CD-30-AD57_10uM | Dose=10uM, Dichloroacetic Acid, Pyruvate Dehydrogenase Kinase (PDHK;Apoptosis Inducers;PDK) Inhibitors targeting PDK1 |
| CD-30-AD57_1uM | Dose=1uM, Dichloroacetic Acid, Pyruvate Dehydrogenase Kinase (PDHK;Apoptosis Inducers;PDK) Inhibitors targeting PDK1 |
| CD-30-JO39_10uM | Dose=10uM, [2-chloro-3-(trifluoromethyl)phenyl]-[1-(5-fluoropyrimidin-2-yl)-6,7-dihydro-4H-triazolo[4,5-c]pyridin-5-yl]methanone, P2RX7 antagonist targeting P2RX7 |
| CD-35-BD44_0.01uM | Dose=0.01uM, (1S,2R)-2-[[9-ethyl-6-[4-(4-phenylpiperazin-1-yl)sulfonylanilino]purin-2-yl]amino]cyclohexane-1-carboxamide |
| CD-35-BD44_0.1uM | Dose=0.1uM, (1S,2R)-2-[[9-ethyl-6-[4-(4-phenylpiperazin-1-yl)sulfonylanilino]purin-2-yl]amino]cyclohexane-1-carboxamide |
| CD-35-BD44_10uM | Dose=10uM, (1S,2R)-2-[[9-ethyl-6-[4-(4-phenylpiperazin-1-yl)sulfonylanilino]purin-2-yl]amino]cyclohexane-1-carboxamide |
| CD-35-BD44_1uM | Dose=1uM, (1S,2R)-2-[[9-ethyl-6-[4-(4-phenylpiperazin-1-yl)sulfonylanilino]purin-2-yl]amino]cyclohexane-1-carboxamide |
| CD-41-RE87_0.01uM | Dose=0.01uM, (1R,2R)-2-[[6-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxy-1,3-benzothiazol-2-yl]amino]cyclohexan-1-ol, Angiogenesis Inhibitors;CSF1R (c-FMS) Inhibitors targeting CSF1R |
| CD-41-RE87_0.1uM | Dose=0.1uM, (1R,2R)-2-[[6-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxy-1,3-benzothiazol-2-yl]amino]cyclohexan-1-ol, Angiogenesis Inhibitors;CSF1R (c-FMS) Inhibitors targeting CSF1R |
| CD-41-RE87_10uM | Dose=10uM, (1R,2R)-2-[[6-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxy-1,3-benzothiazol-2-yl]amino]cyclohexan-1-ol, Angiogenesis Inhibitors;CSF1R (c-FMS) Inhibitors targeting CSF1R |
| CD-44-XT40_0.01uM | Dose=0.01uM, Glycyrrhizin, Cell Adhesion Inhibitors;Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways;Antioxidants targeting F2 |
| CD-44-XT40_0.1uM | Dose=0.1uM, Glycyrrhizin, Cell Adhesion Inhibitors;Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways;Antioxidants targeting F2 |
| CD-44-XT40_10uM | Dose=10uM, Glycyrrhizin, Cell Adhesion Inhibitors;Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways;Antioxidants targeting F2 |
| CD-44-XT40_1uM | Dose=1uM, Glycyrrhizin, Cell Adhesion Inhibitors;Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways;Antioxidants targeting F2 |
| CD-47-BV87_0.01uM | Dose=0.01uM, Atomoxetine, Norepinephrine Transporter (NET) Inhibitors targeting SLC6A2 |
| CD-47-BV87_0.1uM | Dose=0.1uM, Atomoxetine, Norepinephrine Transporter (NET) Inhibitors targeting SLC6A2 |
| CD-47-BV87_10uM | Dose=10uM, Atomoxetine, Norepinephrine Transporter (NET) Inhibitors targeting SLC6A2 |
| CD-47-YL43_0.01uM | Dose=0.01uM, Cirazoline, ADRA1D agonist;ADRA1B agonist targeting ADRA1D, ADRA1B |
| CD-47-YL43_0.1uM | Dose=0.1uM, Cirazoline, ADRA1D agonist;ADRA1B agonist targeting ADRA1D, ADRA1B |
| CD-47-YL43_10uM | Dose=10uM, Cirazoline, ADRA1D agonist;ADRA1B agonist targeting ADRA1D, ADRA1B |
| CD-47-YL43_1uM | Dose=1uM, Cirazoline, ADRA1D agonist;ADRA1B agonist targeting ADRA1D, ADRA1B |
| CD-49-HJ53_0.01uM | Dose=0.01uM, (Z-LL)2 ketone, SPPL1 inhibitor targeting HM13 |
| CD-49-HJ53_0.1uM | Dose=0.1uM, (Z-LL)2 ketone, SPPL1 inhibitor targeting HM13 |
| CD-49-HJ53_10uM | Dose=10uM, (Z-LL)2 ketone, SPPL1 inhibitor targeting HM13 |
| CD-49-HJ53_1uM | Dose=1uM, (Z-LL)2 ketone, SPPL1 inhibitor targeting HM13 |
| CD-54-FJ31_0.01uM | Dose=0.01uM, (3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium, Fatty acid oxidation;Antioxidants;Lipid Lowering Agents targeting CPT1A, CRAT |
| CD-54-FJ31_0.1uM | Dose=0.1uM, (3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium, Fatty acid oxidation;Antioxidants;Lipid Lowering Agents targeting CPT1A, CRAT |
| CD-54-FJ31_10uM | Dose=10uM, (3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium, Fatty acid oxidation;Antioxidants;Lipid Lowering Agents targeting CPT1A, CRAT |
| CD-54-FJ31_1uM | Dose=1uM, (3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium, Fatty acid oxidation;Antioxidants;Lipid Lowering Agents targeting CPT1A, CRAT |
| CD-55-ZN88_0.01uM | Dose=0.01uM, cyclo(Arg-Gly-Asp-D-Phe-Val), Integrin binder;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5 |
| CD-55-ZN88_10uM | Dose=10uM, cyclo(Arg-Gly-Asp-D-Phe-Val), Integrin binder;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5 |
| CD-55-ZN88_1uM | Dose=1uM, cyclo(Arg-Gly-Asp-D-Phe-Val), Integrin binder;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGAV, ITGB3, ITGB5 |
| CD-59-MG26_0.01uM | Dose=0.01uM, (2R)-3-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-(5-pyridin-4-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)propanamide targeting GCK |
| CD-59-MG26_0.1uM | Dose=0.1uM, (2R)-3-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-(5-pyridin-4-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)propanamide targeting GCK |
| CD-59-MG26_10uM | Dose=10uM, (2R)-3-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-(5-pyridin-4-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)propanamide targeting GCK |
| CD-59-MG26_1uM | Dose=1uM, (2R)-3-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-(5-pyridin-4-yl-[1,3]thiazolo[5,4-b]pyridin-2-yl)propanamide targeting GCK |
| CD-59-PT17_0.01uM | Dose=0.01uM, FK-739 free acid, Angiotensin Receptor Antagonists targeting AGTR1 |
| CD-59-PT17_10uM | Dose=10uM, FK-739 free acid, Angiotensin Receptor Antagonists targeting AGTR1 |
| CD-59-PT17_1uM | Dose=1uM, FK-739 free acid, Angiotensin Receptor Antagonists targeting AGTR1 |
| CD-62-GL56_0.01uM | Dose=0.01uM, Fenesin |
| CD-62-GL56_0.1uM | Dose=0.1uM, Fenesin |
| CD-62-GL56_10uM | Dose=10uM, Fenesin |
| CD-62-GL56_1uM | Dose=1uM, Fenesin |
| CD-63-FZ67_0.01uM | Dose=0.01uM, 4-[1-(1,3-Benzodioxol-5-yl)-2-oxo-2-[(4-propan-2-ylphenyl)sulfonylamino]ethoxy]-3-propylbenzoic acid, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists;Endothelin Receptor Antagonists targeting EDNRA, EDNRB |
| CD-63-FZ67_0.1uM | Dose=0.1uM, 4-[1-(1,3-Benzodioxol-5-yl)-2-oxo-2-[(4-propan-2-ylphenyl)sulfonylamino]ethoxy]-3-propylbenzoic acid, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists;Endothelin Receptor Antagonists targeting EDNRA, EDNRB |
| CD-63-FZ67_10uM | Dose=10uM, 4-[1-(1,3-Benzodioxol-5-yl)-2-oxo-2-[(4-propan-2-ylphenyl)sulfonylamino]ethoxy]-3-propylbenzoic acid, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists;Endothelin Receptor Antagonists targeting EDNRA, EDNRB |
| CD-63-FZ67_1uM | Dose=1uM, 4-[1-(1,3-Benzodioxol-5-yl)-2-oxo-2-[(4-propan-2-ylphenyl)sulfonylamino]ethoxy]-3-propylbenzoic acid, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists;Endothelin Receptor Antagonists targeting EDNRA, EDNRB |
| CD-70-GD72_0.01uM | Dose=0.01uM, MI-3 (Menin-MLL Inhibitor), Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1 |
| CD-70-GD72_0.1uM | Dose=0.1uM, MI-3 (Menin-MLL Inhibitor), Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1 |
| CD-70-GD72_10uM | Dose=10uM, MI-3 (Menin-MLL Inhibitor), Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1 |
| CD-70-GD72_1uM | Dose=1uM, MI-3 (Menin-MLL Inhibitor), Inhibitor of MEN1 (Menin);MEN1 inhibitor targeting MEN1 |
| CD-75-QY45_0.01uM | Dose=0.01uM, 4-fluoro-5-methyl-N'-(phenylsulfonyl)[1,1'-biphenyl]-3-carbohydrazide targeting KAT6A |
| CD-75-QY45_0.1uM | Dose=0.1uM, 4-fluoro-5-methyl-N'-(phenylsulfonyl)[1,1'-biphenyl]-3-carbohydrazide targeting KAT6A |
| CD-75-QY45_10uM | Dose=10uM, 4-fluoro-5-methyl-N'-(phenylsulfonyl)[1,1'-biphenyl]-3-carbohydrazide targeting KAT6A |
| CD-75-QY45_1uM | Dose=1uM, 4-fluoro-5-methyl-N'-(phenylsulfonyl)[1,1'-biphenyl]-3-carbohydrazide targeting KAT6A |
| CD-77-YB29_0.1uM | Dose=0.1uM, NMDA Glycine-Site Antagonists |
| CD-77-YB29_10uM | Dose=10uM, NMDA Glycine-Site Antagonists |
| CD-77-YB29_1uM | Dose=1uM, NMDA Glycine-Site Antagonists |
| CD-80-ZD47_0.01uM | Dose=0.01uM, 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline targeting PNMT |
| CD-80-ZD47_0.1uM | Dose=0.1uM, 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline targeting PNMT |
| CD-80-ZD47_10uM | Dose=10uM, 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline targeting PNMT |
| CD-80-ZD47_1uM | Dose=1uM, 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline targeting PNMT |
| CD-84-BU23_0.01uM | Dose=0.01uM, Oseltamivir |
| CD-84-BU23_0.1uM | Dose=0.1uM, Oseltamivir |
| CD-84-BU23_10uM | Dose=10uM, Oseltamivir |
| CD-84-BU23_1uM | Dose=1uM, Oseltamivir |
| CD-84-ET75_0.1uM | Dose=0.1uM |
| CD-84-ET75_10uM | Dose=10uM |
| CD-84-FJ21_0.01uM | Dose=0.01uM, Dpn 205-734 |
| CD-84-FJ21_0.1uM | Dose=0.1uM, Dpn 205-734 |
| CD-84-FJ21_10uM | Dose=10uM, Dpn 205-734 |
| CD-84-FJ21_1uM | Dose=1uM, Dpn 205-734 |
| CD-88-UF56_0.01uM | Dose=0.01uM, 1-[3-(Trifluoromethyl)-4-chlorophenyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CD-88-UF56_0.1uM | Dose=0.1uM, 1-[3-(Trifluoromethyl)-4-chlorophenyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CD-88-UF56_10uM | Dose=10uM, 1-[3-(Trifluoromethyl)-4-chlorophenyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CD-88-UF56_1uM | Dose=1uM, 1-[3-(Trifluoromethyl)-4-chlorophenyl]guanidine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CD-89-CG91_0.01uM | Dose=0.01uM |
| CD-89-CG91_0.1uM | Dose=0.1uM |
| CD-89-CG91_10uM | Dose=10uM |
| CD-89-CG91_1uM | Dose=1uM |
| CD-90-SN76_0.01uM | Dose=0.01uM, Tazolol, adrenoceptor beta 1 partial agonist;Drugs Acting on Adrenoceptors targeting ADRB1 |
| CD-90-SN76_0.1uM | Dose=0.1uM, Tazolol, adrenoceptor beta 1 partial agonist;Drugs Acting on Adrenoceptors targeting ADRB1 |
| CD-90-SN76_1uM | Dose=1uM, Tazolol, adrenoceptor beta 1 partial agonist;Drugs Acting on Adrenoceptors targeting ADRB1 |
| CD-91-BY60_0.01uM | Dose=0.01uM, N'-(5-chlorobenzofuran-2-carbonyl)-2-(trifluoromethyl)benzenesulfonohydrazide, Branched amino acid aminotransferase 1 inhibitor targeting BCAT1 |
| CD-91-BY60_0.1uM | Dose=0.1uM, N'-(5-chlorobenzofuran-2-carbonyl)-2-(trifluoromethyl)benzenesulfonohydrazide, Branched amino acid aminotransferase 1 inhibitor targeting BCAT1 |
| CD-91-BY60_1uM | Dose=1uM, N'-(5-chlorobenzofuran-2-carbonyl)-2-(trifluoromethyl)benzenesulfonohydrazide, Branched amino acid aminotransferase 1 inhibitor targeting BCAT1 |
| CD-91-MI27_0.01uM | Dose=0.01uM, SB269970, 5-HT7 Antagonists targeting HTR5A, HTR7 |
| CD-91-MI27_0.1uM | Dose=0.1uM, SB269970, 5-HT7 Antagonists targeting HTR5A, HTR7 |
| CD-91-MI27_10uM | Dose=10uM, SB269970, 5-HT7 Antagonists targeting HTR5A, HTR7 |
| CD-91-MI27_1uM | Dose=1uM, SB269970, 5-HT7 Antagonists targeting HTR5A, HTR7 |
| CD-96-HO43_0.01uM | Dose=0.01uM, 1-Propanone, 2-amino-1-((8S)-8-(cyclohexylmethyl)-5,6-dihydro-2-phenylimidazo(1,2-a)pyrazin-7(8H)-yl)-3-mercapto-, (2R)-, Inhibitor;Inhibitor of Gq (GNA11) mediated GPCR signaling;G protein inhibitor - preferentially blocking Gq. targeting GNA11, GNAQ |
| CD-96-HO43_0.1uM | Dose=0.1uM, 1-Propanone, 2-amino-1-((8S)-8-(cyclohexylmethyl)-5,6-dihydro-2-phenylimidazo(1,2-a)pyrazin-7(8H)-yl)-3-mercapto-, (2R)-, Inhibitor;Inhibitor of Gq (GNA11) mediated GPCR signaling;G protein inhibitor - preferentially blocking Gq. targeting GNA11, GNAQ |
| CD-96-HO43_10uM | Dose=10uM, 1-Propanone, 2-amino-1-((8S)-8-(cyclohexylmethyl)-5,6-dihydro-2-phenylimidazo(1,2-a)pyrazin-7(8H)-yl)-3-mercapto-, (2R)-, Inhibitor;Inhibitor of Gq (GNA11) mediated GPCR signaling;G protein inhibitor - preferentially blocking Gq. targeting GNA11, GNAQ |
| CD-96-HO43_1uM | Dose=1uM, 1-Propanone, 2-amino-1-((8S)-8-(cyclohexylmethyl)-5,6-dihydro-2-phenylimidazo(1,2-a)pyrazin-7(8H)-yl)-3-mercapto-, (2R)-, Inhibitor;Inhibitor of Gq (GNA11) mediated GPCR signaling;G protein inhibitor - preferentially blocking Gq. targeting GNA11, GNAQ |
| CD-97-ZV62_0.01uM | Dose=0.01uM, (R)-1-(3-(3-Amino-6-(2-fluoro-5-isopropoxyphenyl)pyrazine-2-carboxamido)pyridin-4-yl)piperidine-3-carboxylic acid, DYRK-1 alpha protein kinase inhibitor targeting DYRK1A, GSK3B |
| CD-97-ZV62_0.1uM | Dose=0.1uM, (R)-1-(3-(3-Amino-6-(2-fluoro-5-isopropoxyphenyl)pyrazine-2-carboxamido)pyridin-4-yl)piperidine-3-carboxylic acid, DYRK-1 alpha protein kinase inhibitor targeting DYRK1A, GSK3B |
| CD-97-ZV62_10uM | Dose=10uM, (R)-1-(3-(3-Amino-6-(2-fluoro-5-isopropoxyphenyl)pyrazine-2-carboxamido)pyridin-4-yl)piperidine-3-carboxylic acid, DYRK-1 alpha protein kinase inhibitor targeting DYRK1A, GSK3B |
| CD-97-ZV62_1uM | Dose=1uM, (R)-1-(3-(3-Amino-6-(2-fluoro-5-isopropoxyphenyl)pyrazine-2-carboxamido)pyridin-4-yl)piperidine-3-carboxylic acid, DYRK-1 alpha protein kinase inhibitor targeting DYRK1A, GSK3B |
| CE-00-EK89_0.01uM | Dose=0.01uM, 4-Chloro-N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-YL)benzene-1-sulfonamide |
| CE-00-EK89_0.1uM | Dose=0.1uM, 4-Chloro-N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-YL)benzene-1-sulfonamide |
| CE-00-EK89_10uM | Dose=10uM, 4-Chloro-N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-YL)benzene-1-sulfonamide |
| CE-00-EK89_1uM | Dose=1uM, 4-Chloro-N-(6-methoxy-1,3-dimethyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-YL)benzene-1-sulfonamide |
| CE-02-FZ80_0.01uM | Dose=0.01uM, 2-Isopropylphenyl (2-(naphthalen-2-yl)ethyl)carbamate, Cytokine Secretion Inhibitor;KIAA1363 inhibitor;NCEH1 inhibitor targeting NCEH1 |
| CE-02-FZ80_0.1uM | Dose=0.1uM, 2-Isopropylphenyl (2-(naphthalen-2-yl)ethyl)carbamate, Cytokine Secretion Inhibitor;KIAA1363 inhibitor;NCEH1 inhibitor targeting NCEH1 |
| CE-02-FZ80_10uM | Dose=10uM, 2-Isopropylphenyl (2-(naphthalen-2-yl)ethyl)carbamate, Cytokine Secretion Inhibitor;KIAA1363 inhibitor;NCEH1 inhibitor targeting NCEH1 |
| CE-02-FZ80_1uM | Dose=1uM, 2-Isopropylphenyl (2-(naphthalen-2-yl)ethyl)carbamate, Cytokine Secretion Inhibitor;KIAA1363 inhibitor;NCEH1 inhibitor targeting NCEH1 |
| CE-03-PW65_0.1uM | Dose=0.1uM, Eglumetad, GRM2 agonist;GRM3 agonist targeting GRM2, GRM3, GRM4, GRM6, GRM8 |
| CE-03-PW65_10uM | Dose=10uM, Eglumetad, GRM2 agonist;GRM3 agonist targeting GRM2, GRM3, GRM4, GRM6, GRM8 |
| CE-03-PW65_1uM | Dose=1uM, Eglumetad, GRM2 agonist;GRM3 agonist targeting GRM2, GRM3, GRM4, GRM6, GRM8 |
| CE-03-YQ91_0.01uM | Dose=0.01uM, 3-pyridin-3-yl-N-(thiophen-2-ylmethyl)imidazo[1,2-b]pyridazin-6-amine |
| CE-03-YQ91_0.1uM | Dose=0.1uM, 3-pyridin-3-yl-N-(thiophen-2-ylmethyl)imidazo[1,2-b]pyridazin-6-amine |
| CE-03-YQ91_10uM | Dose=10uM, 3-pyridin-3-yl-N-(thiophen-2-ylmethyl)imidazo[1,2-b]pyridazin-6-amine |
| CE-03-YQ91_1uM | Dose=1uM, 3-pyridin-3-yl-N-(thiophen-2-ylmethyl)imidazo[1,2-b]pyridazin-6-amine |
| CE-04-HT15_0.01uM | Dose=0.01uM, (S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate, AGTR1 antagonist targeting AGTR1 |
| CE-04-HT15_0.1uM | Dose=0.1uM, (S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate, AGTR1 antagonist targeting AGTR1 |
| CE-04-HT15_10uM | Dose=10uM, (S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate, AGTR1 antagonist targeting AGTR1 |
| CE-04-HT15_1uM | Dose=1uM, (S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate, AGTR1 antagonist targeting AGTR1 |
| CE-04-OJ56_0.01uM | Dose=0.01uM, 2-(2-Aminoethyl)pyridine |
| CE-04-OJ56_0.1uM | Dose=0.1uM, 2-(2-Aminoethyl)pyridine |
| CE-04-OJ56_10uM | Dose=10uM, 2-(2-Aminoethyl)pyridine |
| CE-04-OJ56_1uM | Dose=1uM, 2-(2-Aminoethyl)pyridine |
| CE-04-PX35_0.01uM | Dose=0.01uM, PT2385, HIF2a / Hif-2 alpha inhibitor (gene: EPAS1);HIF2A inhibitor (HIF-2 alpha inhibitor) targeting EPAS1 |
| CE-04-PX35_0.1uM | Dose=0.1uM, PT2385, HIF2a / Hif-2 alpha inhibitor (gene: EPAS1);HIF2A inhibitor (HIF-2 alpha inhibitor) targeting EPAS1 |
| CE-04-PX35_10uM | Dose=10uM, PT2385, HIF2a / Hif-2 alpha inhibitor (gene: EPAS1);HIF2A inhibitor (HIF-2 alpha inhibitor) targeting EPAS1 |
| CE-04-PX35_1uM | Dose=1uM, PT2385, HIF2a / Hif-2 alpha inhibitor (gene: EPAS1);HIF2A inhibitor (HIF-2 alpha inhibitor) targeting EPAS1 |
| CE-09-HG76_0.01uM | Dose=0.01uM, Triprolidine, HRH1 antagonist targeting HRH1 |
| CE-09-HG76_0.1uM | Dose=0.1uM, Triprolidine, HRH1 antagonist targeting HRH1 |
| CE-09-HG76_10uM | Dose=10uM, Triprolidine, HRH1 antagonist targeting HRH1 |
| CE-09-HG76_1uM | Dose=1uM, Triprolidine, HRH1 antagonist targeting HRH1 |
| CE-09-ZT22_0.01uM | Dose=0.01uM, Ethinyl Estradiol, Estrogen Receptor (ER) Agonists targeting CYP2B6, ESR1, ESR2 |
| CE-09-ZT22_0.1uM | Dose=0.1uM, Ethinyl Estradiol, Estrogen Receptor (ER) Agonists targeting CYP2B6, ESR1, ESR2 |
| CE-09-ZT22_10uM | Dose=10uM, Ethinyl Estradiol, Estrogen Receptor (ER) Agonists targeting CYP2B6, ESR1, ESR2 |
| CE-09-ZT22_1uM | Dose=1uM, Ethinyl Estradiol, Estrogen Receptor (ER) Agonists targeting CYP2B6, ESR1, ESR2 |
| CE-10-WA05_0.01uM | Dose=0.01uM, 4-[(7-Methylthieno[3,2-d]pyrimidin-4-yl)amino]-3-(oxolan-3-yloxy)benzamide |
| CE-10-WA05_0.1uM | Dose=0.1uM, 4-[(7-Methylthieno[3,2-d]pyrimidin-4-yl)amino]-3-(oxolan-3-yloxy)benzamide |
| CE-10-WA05_10uM | Dose=10uM, 4-[(7-Methylthieno[3,2-d]pyrimidin-4-yl)amino]-3-(oxolan-3-yloxy)benzamide |
| CE-10-WA05_1uM | Dose=1uM, 4-[(7-Methylthieno[3,2-d]pyrimidin-4-yl)amino]-3-(oxolan-3-yloxy)benzamide |
| CE-14-SQ43_0.01uM | Dose=0.01uM, 2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1H-benzimidazole, Dopamine D4 Agonists targeting DRD4 |
| CE-14-SQ43_10uM | Dose=10uM, 2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1H-benzimidazole, Dopamine D4 Agonists targeting DRD4 |
| CE-15-DU45_0.01uM | Dose=0.01uM, Vanoxerine, Dopamine Reuptake Inhibitors targeting SLC6A3 |
| CE-15-DU45_0.1uM | Dose=0.1uM, Vanoxerine, Dopamine Reuptake Inhibitors targeting SLC6A3 |
| CE-15-DU45_10uM | Dose=10uM, Vanoxerine, Dopamine Reuptake Inhibitors targeting SLC6A3 |
| CE-15-DU45_1uM | Dose=1uM, Vanoxerine, Dopamine Reuptake Inhibitors targeting SLC6A3 |
| CE-15-YU05_0.01uM | Dose=0.01uM, Antimycin A, Electron Transport Chain Inhibitors;Electron transport chain inhibitor;Cytochrome c reductase targeting UQCRC1 |
| CE-15-YU05_0.1uM | Dose=0.1uM, Antimycin A, Electron Transport Chain Inhibitors;Electron transport chain inhibitor;Cytochrome c reductase targeting UQCRC1 |
| CE-15-YU05_10uM | Dose=10uM, Antimycin A, Electron Transport Chain Inhibitors;Electron transport chain inhibitor;Cytochrome c reductase targeting UQCRC1 |
| CE-15-YU05_1uM | Dose=1uM, Antimycin A, Electron Transport Chain Inhibitors;Electron transport chain inhibitor;Cytochrome c reductase targeting UQCRC1 |
| CE-17-FI51_0.01uM | Dose=0.01uM, (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester, CETP inhibitor targeting CETP |
| CE-17-FI51_10uM | Dose=10uM, (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester, CETP inhibitor targeting CETP |
| CE-17-FI51_1uM | Dose=1uM, (2R,4S)-4-{(3,5-Bis-trifluoromethyl-benzyl)-[5-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amino}-2-ethyl-pyrrolidine-1-carboxylic acid isopropyl ester, CETP inhibitor targeting CETP |
| CE-18-AP15_0.01uM | Dose=0.01uM, 4-(Dimethylamino)-N-[6-(hydroxyamino)-6-oxohexyl]-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CE-18-AP15_0.1uM | Dose=0.1uM, 4-(Dimethylamino)-N-[6-(hydroxyamino)-6-oxohexyl]-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CE-18-AP15_10uM | Dose=10uM, 4-(Dimethylamino)-N-[6-(hydroxyamino)-6-oxohexyl]-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CE-18-AP15_1uM | Dose=1uM, 4-(Dimethylamino)-N-[6-(hydroxyamino)-6-oxohexyl]-benzamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CE-18-AP85_0.01uM | Dose=0.01uM |
| CE-18-AP85_0.1uM | Dose=0.1uM |
| CE-18-AP85_10uM | Dose=10uM |
| CE-18-AP85_1uM | Dose=1uM |
| CE-18-CG29_0.01uM | Dose=0.01uM, 5-(N,N-Hexamethylene)Amiloride, GnRH (LHRH) Antagonists;Na+/H+ Exchanger (NHE) Inhibitors targeting GNRHR, SLC9A2, GNRH1 |
| CE-18-CG29_0.1uM | Dose=0.1uM, 5-(N,N-Hexamethylene)Amiloride, GnRH (LHRH) Antagonists;Na+/H+ Exchanger (NHE) Inhibitors targeting GNRHR, SLC9A2, GNRH1 |
| CE-18-CG29_10uM | Dose=10uM, 5-(N,N-Hexamethylene)Amiloride, GnRH (LHRH) Antagonists;Na+/H+ Exchanger (NHE) Inhibitors targeting GNRHR, SLC9A2, GNRH1 |
| CE-18-CG29_1uM | Dose=1uM, 5-(N,N-Hexamethylene)Amiloride, GnRH (LHRH) Antagonists;Na+/H+ Exchanger (NHE) Inhibitors targeting GNRHR, SLC9A2, GNRH1 |
| CE-18-ZM38_0.01uM | Dose=0.01uM, N-[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]-N',N'-diethylpropane-1,3-diamine, IL-2 Production Inhibitors;Protein Kinase PKC theta Inhibitors targeting IL2, PRKCQ |
| CE-18-ZM38_0.1uM | Dose=0.1uM, N-[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]-N',N'-diethylpropane-1,3-diamine, IL-2 Production Inhibitors;Protein Kinase PKC theta Inhibitors targeting IL2, PRKCQ |
| CE-18-ZM38_10uM | Dose=10uM, N-[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]-N',N'-diethylpropane-1,3-diamine, IL-2 Production Inhibitors;Protein Kinase PKC theta Inhibitors targeting IL2, PRKCQ |
| CE-18-ZM38_1uM | Dose=1uM, N-[3-(3-chlorophenyl)imidazo[1,2-b]pyridazin-6-yl]-N',N'-diethylpropane-1,3-diamine, IL-2 Production Inhibitors;Protein Kinase PKC theta Inhibitors targeting IL2, PRKCQ |
| CE-19-PD79_0.01uM | Dose=0.01uM, Tropicamide, CHRM4 Antagonists;Anticholinergics;CHRM4 antagonist targeting CHRM4 |
| CE-19-PD79_0.1uM | Dose=0.1uM, Tropicamide, CHRM4 Antagonists;Anticholinergics;CHRM4 antagonist targeting CHRM4 |
| CE-19-PD79_10uM | Dose=10uM, Tropicamide, CHRM4 Antagonists;Anticholinergics;CHRM4 antagonist targeting CHRM4 |
| CE-19-PD79_1uM | Dose=1uM, Tropicamide, CHRM4 Antagonists;Anticholinergics;CHRM4 antagonist targeting CHRM4 |
| CE-20-VA70_0.01uM | Dose=0.01uM, Cycloheximide, Translation Inhibitor;Glycogen Synthase Kinase 3 beta (GSK-3beta;tau Protein Kinase I) Inhibitors targeting GSK3B, RPL6 |
| CE-20-VA70_0.1uM | Dose=0.1uM, Cycloheximide, Translation Inhibitor;Glycogen Synthase Kinase 3 beta (GSK-3beta;tau Protein Kinase I) Inhibitors targeting GSK3B, RPL6 |
| CE-20-VA70_10uM | Dose=10uM, Cycloheximide, Translation Inhibitor;Glycogen Synthase Kinase 3 beta (GSK-3beta;tau Protein Kinase I) Inhibitors targeting GSK3B, RPL6 |
| CE-20-VA70_1uM | Dose=1uM, Cycloheximide, Translation Inhibitor;Glycogen Synthase Kinase 3 beta (GSK-3beta;tau Protein Kinase I) Inhibitors targeting GSK3B, RPL6 |
| CE-21-AY10_0.1uM | Dose=0.1uM, 1-Piperidinesulfonamide, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors;Carbonic anhydrase inhibitor targeting CA1, CA2, NAMPT |
| CE-21-AY10_1uM | Dose=1uM, 1-Piperidinesulfonamide, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors;Carbonic anhydrase inhibitor targeting CA1, CA2, NAMPT |
| CE-21-UO81_0.01uM | Dose=0.01uM, (S)-N-(4-(4-Fluorophenyl)-3-(N-methyl-1-naphthamido)butyl)picolinamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| CE-21-UO81_0.1uM | Dose=0.1uM, (S)-N-(4-(4-Fluorophenyl)-3-(N-methyl-1-naphthamido)butyl)picolinamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| CE-21-UO81_10uM | Dose=10uM, (S)-N-(4-(4-Fluorophenyl)-3-(N-methyl-1-naphthamido)butyl)picolinamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| CE-21-UO81_1uM | Dose=1uM, (S)-N-(4-(4-Fluorophenyl)-3-(N-methyl-1-naphthamido)butyl)picolinamide, Orexin OX-1 Antagonists;Orexin OX-2 Antagonists targeting HCRTR1, HCRTR2 |
| CE-23-HP88_0.01uM | Dose=0.01uM, 2-(4-Methoxyphenyl)guanidine, 5-HT3 agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CE-23-HP88_0.1uM | Dose=0.1uM, 2-(4-Methoxyphenyl)guanidine, 5-HT3 agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CE-23-HP88_10uM | Dose=10uM, 2-(4-Methoxyphenyl)guanidine, 5-HT3 agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CE-23-HP88_1uM | Dose=1uM, 2-(4-Methoxyphenyl)guanidine, 5-HT3 agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CE-24-LQ98_0.01uM | Dose=0.01uM, N-[3-(1H-imidazol-1-yl)propyl]-5-thien-2-ylisoxazole-3-carboxamide |
| CE-24-LQ98_0.1uM | Dose=0.1uM, N-[3-(1H-imidazol-1-yl)propyl]-5-thien-2-ylisoxazole-3-carboxamide |
| CE-24-LQ98_10uM | Dose=10uM, N-[3-(1H-imidazol-1-yl)propyl]-5-thien-2-ylisoxazole-3-carboxamide |
| CE-24-LQ98_1uM | Dose=1uM, N-[3-(1H-imidazol-1-yl)propyl]-5-thien-2-ylisoxazole-3-carboxamide |
| CE-25-VD54_0.01uM | Dose=0.01uM, (S)-1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3-(2-methoxyphenyl)pyrrolidine, alpha2-Adrenoceptor Antagonists targeting ADRA2A |
| CE-25-VD54_0.1uM | Dose=0.1uM, (S)-1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3-(2-methoxyphenyl)pyrrolidine, alpha2-Adrenoceptor Antagonists targeting ADRA2A |
| CE-25-VD54_10uM | Dose=10uM, (S)-1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3-(2-methoxyphenyl)pyrrolidine, alpha2-Adrenoceptor Antagonists targeting ADRA2A |
| CE-25-VD54_1uM | Dose=1uM, (S)-1-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3-(2-methoxyphenyl)pyrrolidine, alpha2-Adrenoceptor Antagonists targeting ADRA2A |
| CE-35-LA42_0.01uM | Dose=0.01uM, N-(5-phenyl-1H-pyrazol-3-yl)-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide |
| CE-35-LA42_0.1uM | Dose=0.1uM, N-(5-phenyl-1H-pyrazol-3-yl)-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide |
| CE-35-LA42_10uM | Dose=10uM, N-(5-phenyl-1H-pyrazol-3-yl)-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide |
| CE-35-LA42_1uM | Dose=1uM, N-(5-phenyl-1H-pyrazol-3-yl)-5-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide |
| CE-36-HY42_0.01uM | Dose=0.01uM |
| CE-36-HY42_0.1uM | Dose=0.1uM |
| CE-36-HY42_10uM | Dose=10uM |
| CE-36-HY42_1uM | Dose=1uM |
| CE-36-KR60_0.01uM | Dose=0.01uM, Hydroxychloroquine |
| CE-36-KR60_0.1uM | Dose=0.1uM, Hydroxychloroquine |
| CE-36-KR60_10uM | Dose=10uM, Hydroxychloroquine |
| CE-36-KR60_1uM | Dose=1uM, Hydroxychloroquine |
| CE-36-UR55_0.1uM | Dose=0.1uM, 2-Methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid, Thromboxane Synthase Inhibitors targeting TBXAS1 |
| CE-36-UR55_10uM | Dose=10uM, 2-Methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid, Thromboxane Synthase Inhibitors targeting TBXAS1 |
| CE-36-UR55_1uM | Dose=1uM, 2-Methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid, Thromboxane Synthase Inhibitors targeting TBXAS1 |
| CE-37-MS25_0.01uM | Dose=0.01uM, 2-{4-[Butyl(3-chloro-4,5-dimethoxybenzyl)amino]phenyl}-1,1,1,3,3,3-hexafluoropropan-2-ol, Liver X Receptor (LXR) Ligands targeting NR1H2 |
| CE-37-MS25_0.1uM | Dose=0.1uM, 2-{4-[Butyl(3-chloro-4,5-dimethoxybenzyl)amino]phenyl}-1,1,1,3,3,3-hexafluoropropan-2-ol, Liver X Receptor (LXR) Ligands targeting NR1H2 |
| CE-37-MS25_10uM | Dose=10uM, 2-{4-[Butyl(3-chloro-4,5-dimethoxybenzyl)amino]phenyl}-1,1,1,3,3,3-hexafluoropropan-2-ol, Liver X Receptor (LXR) Ligands targeting NR1H2 |
| CE-37-MS25_1uM | Dose=1uM, 2-{4-[Butyl(3-chloro-4,5-dimethoxybenzyl)amino]phenyl}-1,1,1,3,3,3-hexafluoropropan-2-ol, Liver X Receptor (LXR) Ligands targeting NR1H2 |
| CE-37-XI06_0.01uM | Dose=0.01uM, 4-methyl-8-(2,4,6-trimethyl-phenylamino)-2H-phthalazin-1-one, S1PR5 agonist targeting S1PR5 |
| CE-37-XI06_0.1uM | Dose=0.1uM, 4-methyl-8-(2,4,6-trimethyl-phenylamino)-2H-phthalazin-1-one, S1PR5 agonist targeting S1PR5 |
| CE-37-XI06_10uM | Dose=10uM, 4-methyl-8-(2,4,6-trimethyl-phenylamino)-2H-phthalazin-1-one, S1PR5 agonist targeting S1PR5 |
| CE-37-XI06_1uM | Dose=1uM, 4-methyl-8-(2,4,6-trimethyl-phenylamino)-2H-phthalazin-1-one, S1PR5 agonist targeting S1PR5 |
| CE-38-KX20_0.01uM | Dose=0.01uM, Decitabine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors targeting DNMT1, DCK |
| CE-38-KX20_0.1uM | Dose=0.1uM, Decitabine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors targeting DNMT1, DCK |
| CE-38-KX20_10uM | Dose=10uM, Decitabine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors targeting DNMT1, DCK |
| CE-38-KX20_1uM | Dose=1uM, Decitabine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors targeting DNMT1, DCK |
| CE-39-DG56_0.01uM | Dose=0.01uM, 4-{(R)-4-[Benzo[1,3]dioxol-5-ylmethyl-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-4-hydroxycarbamoyl-butyryl}-piperazine-1-carboxylic acid ethyl ester, Procollagen C-Proteinase Inhibitors targeting BMP1 |
| CE-39-DG56_0.1uM | Dose=0.1uM, 4-{(R)-4-[Benzo[1,3]dioxol-5-ylmethyl-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-4-hydroxycarbamoyl-butyryl}-piperazine-1-carboxylic acid ethyl ester, Procollagen C-Proteinase Inhibitors targeting BMP1 |
| CE-39-DG56_10uM | Dose=10uM, 4-{(R)-4-[Benzo[1,3]dioxol-5-ylmethyl-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-4-hydroxycarbamoyl-butyryl}-piperazine-1-carboxylic acid ethyl ester, Procollagen C-Proteinase Inhibitors targeting BMP1 |
| CE-39-DG56_1uM | Dose=1uM, 4-{(R)-4-[Benzo[1,3]dioxol-5-ylmethyl-(4-methoxy-2,3,6-trimethyl-benzenesulfonyl)-amino]-4-hydroxycarbamoyl-butyryl}-piperazine-1-carboxylic acid ethyl ester, Procollagen C-Proteinase Inhibitors targeting BMP1 |
| CE-40-VU73_0.01uM | Dose=0.01uM, Taranabant, Cannabinoid CB1 Inverse Agonists targeting CNR1 |
| CE-40-VU73_0.1uM | Dose=0.1uM, Taranabant, Cannabinoid CB1 Inverse Agonists targeting CNR1 |
| CE-40-VU73_10uM | Dose=10uM, Taranabant, Cannabinoid CB1 Inverse Agonists targeting CNR1 |
| CE-40-VU73_1uM | Dose=1uM, Taranabant, Cannabinoid CB1 Inverse Agonists targeting CNR1 |
| CE-42-GB12_0.01uM | Dose=0.01uM |
| CE-42-GB12_0.1uM | Dose=0.1uM |
| CE-42-GB12_10uM | Dose=10uM |
| CE-42-GB12_1uM | Dose=1uM |
| CE-44-KU68_0.1uM | Dose=0.1uM, Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors;Inhibitors of Signal Transduction Pathways |
| CE-44-KU68_1uM | Dose=1uM, Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors;Inhibitors of Signal Transduction Pathways |
| CE-45-AD14_0.01uM | Dose=0.01uM, Omigapil, Apoptosis Inhibitors;Glyceraldehyde 3-phosphate Dehydrogenase (GAPDH) Inhibitors targeting GAPDH |
| CE-45-AD14_0.1uM | Dose=0.1uM, Omigapil, Apoptosis Inhibitors;Glyceraldehyde 3-phosphate Dehydrogenase (GAPDH) Inhibitors targeting GAPDH |
| CE-45-AD14_1uM | Dose=1uM, Omigapil, Apoptosis Inhibitors;Glyceraldehyde 3-phosphate Dehydrogenase (GAPDH) Inhibitors targeting GAPDH |
| CE-48-TP40_0.01uM | Dose=0.01uM, Benoxathian, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| CE-48-TP40_0.1uM | Dose=0.1uM, Benoxathian, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| CE-48-TP40_10uM | Dose=10uM, Benoxathian, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| CE-48-TP40_1uM | Dose=1uM, Benoxathian, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| CE-52-SB42_10uM | Dose=10uM, 1-Aminobenzotriazole, Cytochrome P450 Inhibitors targeting CYP2W1 |
| CE-52-SB42_1uM | Dose=1uM, 1-Aminobenzotriazole, Cytochrome P450 Inhibitors targeting CYP2W1 |
| CE-52-XV55_0.01uM | Dose=0.01uM, Fananserin, 5-HT2A Antagonists;Dopamine D4 Antagonists targeting DRD4, HTR2A |
| CE-52-XV55_0.1uM | Dose=0.1uM, Fananserin, 5-HT2A Antagonists;Dopamine D4 Antagonists targeting DRD4, HTR2A |
| CE-52-XV55_10uM | Dose=10uM, Fananserin, 5-HT2A Antagonists;Dopamine D4 Antagonists targeting DRD4, HTR2A |
| CE-52-XV55_1uM | Dose=1uM, Fananserin, 5-HT2A Antagonists;Dopamine D4 Antagonists targeting DRD4, HTR2A |
| CE-57-KI16_0.01uM | Dose=0.01uM, CID 134691740, SPPL2A Inhibitor targeting SPPL2A |
| CE-57-KI16_0.1uM | Dose=0.1uM, CID 134691740, SPPL2A Inhibitor targeting SPPL2A |
| CE-57-KI16_10uM | Dose=10uM, CID 134691740, SPPL2A Inhibitor targeting SPPL2A |
| CE-58-XJ66_0.01uM | Dose=0.01uM, Unoprostone Isopropyl |
| CE-58-XJ66_0.1uM | Dose=0.1uM, Unoprostone Isopropyl |
| CE-58-XJ66_10uM | Dose=10uM, Unoprostone Isopropyl |
| CE-58-XJ66_1uM | Dose=1uM, Unoprostone Isopropyl |
| CE-66-GR30_0.01uM | Dose=0.01uM, Halopemide, Dopamine Receptor Antagonists;Phospholipase D2 (PLD2) Inhibitors targeting PLD2 |
| CE-66-GR30_0.1uM | Dose=0.1uM, Halopemide, Dopamine Receptor Antagonists;Phospholipase D2 (PLD2) Inhibitors targeting PLD2 |
| CE-66-GR30_10uM | Dose=10uM, Halopemide, Dopamine Receptor Antagonists;Phospholipase D2 (PLD2) Inhibitors targeting PLD2 |
| CE-66-GR30_1uM | Dose=1uM, Halopemide, Dopamine Receptor Antagonists;Phospholipase D2 (PLD2) Inhibitors targeting PLD2 |
| CE-68-CC69_0.01uM | Dose=0.01uM |
| CE-68-CC69_0.1uM | Dose=0.1uM |
| CE-68-CC69_10uM | Dose=10uM |
| CE-68-CC69_1uM | Dose=1uM |
| CE-69-FD64_0.01uM | Dose=0.01uM, 2,6-Dichloro-4-(2-Piperazin-1-Ylpyridin-4-Yl)-N-(1,3,5-Trimethyl-1h-Pyrazol-4-Yl)benzenesulfonamide, N-Myristoyltransferase Inhibitors targeting NMT1 |
| CE-69-FD64_0.1uM | Dose=0.1uM, 2,6-Dichloro-4-(2-Piperazin-1-Ylpyridin-4-Yl)-N-(1,3,5-Trimethyl-1h-Pyrazol-4-Yl)benzenesulfonamide, N-Myristoyltransferase Inhibitors targeting NMT1 |
| CE-69-FD64_10uM | Dose=10uM, 2,6-Dichloro-4-(2-Piperazin-1-Ylpyridin-4-Yl)-N-(1,3,5-Trimethyl-1h-Pyrazol-4-Yl)benzenesulfonamide, N-Myristoyltransferase Inhibitors targeting NMT1 |
| CE-69-FD64_1uM | Dose=1uM, 2,6-Dichloro-4-(2-Piperazin-1-Ylpyridin-4-Yl)-N-(1,3,5-Trimethyl-1h-Pyrazol-4-Yl)benzenesulfonamide, N-Myristoyltransferase Inhibitors targeting NMT1 |
| CE-69-HJ13_0.01uM | Dose=0.01uM, anthra(1,9-cd)pyrazol-6(2H)-one, Dardarin) Inhibitors;AP-1 Inhibitors;SAPK1a (JNK2) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2;Inhibitors of Signal Transduction Pathways;SAPK1b (JNK3) Inhibitors;SAPK1c (JNK1) Inhibitors targeting MAPK8, MAPK9, MAPK10, MAP2K4, TTK, FLT3, GAK, CDK16, AAK1, BMP2K |
| CE-69-HJ13_0.1uM | Dose=0.1uM, anthra(1,9-cd)pyrazol-6(2H)-one, Dardarin) Inhibitors;AP-1 Inhibitors;SAPK1a (JNK2) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2;Inhibitors of Signal Transduction Pathways;SAPK1b (JNK3) Inhibitors;SAPK1c (JNK1) Inhibitors targeting MAPK8, MAPK9, MAPK10, MAP2K4, TTK, FLT3, GAK, CDK16, AAK1, BMP2K |
| CE-69-HJ13_10uM | Dose=10uM, anthra(1,9-cd)pyrazol-6(2H)-one, Dardarin) Inhibitors;AP-1 Inhibitors;SAPK1a (JNK2) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2;Inhibitors of Signal Transduction Pathways;SAPK1b (JNK3) Inhibitors;SAPK1c (JNK1) Inhibitors targeting MAPK8, MAPK9, MAPK10, MAP2K4, TTK, FLT3, GAK, CDK16, AAK1, BMP2K |
| CE-69-HJ13_1uM | Dose=1uM, anthra(1,9-cd)pyrazol-6(2H)-one, Dardarin) Inhibitors;AP-1 Inhibitors;SAPK1a (JNK2) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2;Inhibitors of Signal Transduction Pathways;SAPK1b (JNK3) Inhibitors;SAPK1c (JNK1) Inhibitors targeting MAPK8, MAPK9, MAPK10, MAP2K4, TTK, FLT3, GAK, CDK16, AAK1, BMP2K |
| CE-69-VJ68_0.01uM | Dose=0.01uM, Gallic Acid, PPARgamma Agonists;Apoptosis Inducers;beta-Amyloid (Abeta) Aggregation Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Antioxidants targeting APP, PPARG |
| CE-69-VJ68_0.1uM | Dose=0.1uM, Gallic Acid, PPARgamma Agonists;Apoptosis Inducers;beta-Amyloid (Abeta) Aggregation Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Antioxidants targeting APP, PPARG |
| CE-69-VJ68_10uM | Dose=10uM, Gallic Acid, PPARgamma Agonists;Apoptosis Inducers;beta-Amyloid (Abeta) Aggregation Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Antioxidants targeting APP, PPARG |
| CE-70-KX45_0.01uM | Dose=0.01uM, Bq-123, Endothelin ETA Receptor Antagonists targeting EDNRA |
| CE-70-KX45_0.1uM | Dose=0.1uM, Bq-123, Endothelin ETA Receptor Antagonists targeting EDNRA |
| CE-70-KX45_1uM | Dose=1uM, Bq-123, Endothelin ETA Receptor Antagonists targeting EDNRA |
| CE-70-RN96_0.01uM | Dose=0.01uM, Phlorizin, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A1, SLC5A2 |
| CE-70-RN96_0.1uM | Dose=0.1uM, Phlorizin, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A1, SLC5A2 |
| CE-70-RN96_1uM | Dose=1uM, Phlorizin, SGLT-1 Inhibitors;SGLT-2 Inhibitors targeting SLC5A1, SLC5A2 |
| CE-72-GF32_0.01uM | Dose=0.01uM, Everolimus, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR;Rotamase (FKBP12) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;mTOR inhibitor targeting FKBP1A, MTOR |
| CE-72-GF32_0.1uM | Dose=0.1uM, Everolimus, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR;Rotamase (FKBP12) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;mTOR inhibitor targeting FKBP1A, MTOR |
| CE-72-GF32_10uM | Dose=10uM, Everolimus, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR;Rotamase (FKBP12) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;mTOR inhibitor targeting FKBP1A, MTOR |
| CE-72-GF32_1uM | Dose=1uM, Everolimus, FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR;Rotamase (FKBP12) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors;mTOR inhibitor targeting FKBP1A, MTOR |
| CE-72-SF92_0.01uM | Dose=0.01uM, 2-(4-Chlorophenyl)imidazo[2,1-b][1,3]benzothiazole, STAT-6 Inhibitors targeting STAT6 |
| CE-72-SF92_0.1uM | Dose=0.1uM, 2-(4-Chlorophenyl)imidazo[2,1-b][1,3]benzothiazole, STAT-6 Inhibitors targeting STAT6 |
| CE-72-SF92_10uM | Dose=10uM, 2-(4-Chlorophenyl)imidazo[2,1-b][1,3]benzothiazole, STAT-6 Inhibitors targeting STAT6 |
| CE-72-SF92_1uM | Dose=1uM, 2-(4-Chlorophenyl)imidazo[2,1-b][1,3]benzothiazole, STAT-6 Inhibitors targeting STAT6 |
| CE-73-JW90_0.01uM | Dose=0.01uM, Cdk-IN-10, Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors targeting CDK2 |
| CE-73-JW90_0.1uM | Dose=0.1uM, Cdk-IN-10, Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors targeting CDK2 |
| CE-73-JW90_10uM | Dose=10uM, Cdk-IN-10, Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors targeting CDK2 |
| CE-73-JW90_1uM | Dose=1uM, Cdk-IN-10, Inhibitors of Signal Transduction Pathways;CDK2 Inhibitors targeting CDK2 |
| CE-73-XC72_0.01uM | Dose=0.01uM, Type 1 deiodinase inhibitor;Thyroid peroxidase inhibitor targeting TPO, DIO1 |
| CE-73-XC72_0.1uM | Dose=0.1uM, Type 1 deiodinase inhibitor;Thyroid peroxidase inhibitor targeting TPO, DIO1 |
| CE-73-XC72_10uM | Dose=10uM, Type 1 deiodinase inhibitor;Thyroid peroxidase inhibitor targeting TPO, DIO1 |
| CE-74-KU68_0.01uM | Dose=0.01uM, Dorzolamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA2, CA4, CA5A, CA12, CA5B, CA3, CA8, CA11, CA10 |
| CE-74-KU68_0.1uM | Dose=0.1uM, Dorzolamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA2, CA4, CA5A, CA12, CA5B, CA3, CA8, CA11, CA10 |
| CE-74-KU68_10uM | Dose=10uM, Dorzolamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA2, CA4, CA5A, CA12, CA5B, CA3, CA8, CA11, CA10 |
| CE-74-KU68_1uM | Dose=1uM, Dorzolamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA2, CA4, CA5A, CA12, CA5B, CA3, CA8, CA11, CA10 |
| CE-77-JB44_0.01uM | Dose=0.01uM, Nvp-saa164, Bradykinin B1 Antagonists targeting BDKRB1 |
| CE-77-JB44_0.1uM | Dose=0.1uM, Nvp-saa164, Bradykinin B1 Antagonists targeting BDKRB1 |
| CE-77-JB44_10uM | Dose=10uM, Nvp-saa164, Bradykinin B1 Antagonists targeting BDKRB1 |
| CE-77-JB44_1uM | Dose=1uM, Nvp-saa164, Bradykinin B1 Antagonists targeting BDKRB1 |
| CE-85-KN13_0.01uM | Dose=0.01uM, 3,3,3-trifluoro-2-hydroxy-N-(2-methoxyphenyl)-2-methylpropanamide |
| CE-85-KN13_0.1uM | Dose=0.1uM, 3,3,3-trifluoro-2-hydroxy-N-(2-methoxyphenyl)-2-methylpropanamide |
| CE-85-KN13_10uM | Dose=10uM, 3,3,3-trifluoro-2-hydroxy-N-(2-methoxyphenyl)-2-methylpropanamide |
| CE-85-KN13_1uM | Dose=1uM, 3,3,3-trifluoro-2-hydroxy-N-(2-methoxyphenyl)-2-methylpropanamide |
| CE-88-RJ81_0.01uM | Dose=0.01uM, 4-(3-(5-Chloro-2-methoxyphenyl)thioureido)-1-ethyl-1H-pyrazole-3-carboxamide |
| CE-88-RJ81_0.1uM | Dose=0.1uM, 4-(3-(5-Chloro-2-methoxyphenyl)thioureido)-1-ethyl-1H-pyrazole-3-carboxamide |
| CE-88-RJ81_10uM | Dose=10uM, 4-(3-(5-Chloro-2-methoxyphenyl)thioureido)-1-ethyl-1H-pyrazole-3-carboxamide |
| CE-88-RJ81_1uM | Dose=1uM, 4-(3-(5-Chloro-2-methoxyphenyl)thioureido)-1-ethyl-1H-pyrazole-3-carboxamide |
| CE-95-YX02_0.01uM | Dose=0.01uM, N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide, Adenosine A3 Antagonists targeting ADORA3 |
| CE-95-YX02_0.1uM | Dose=0.1uM, N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide, Adenosine A3 Antagonists targeting ADORA3 |
| CE-95-YX02_10uM | Dose=10uM, N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide, Adenosine A3 Antagonists targeting ADORA3 |
| CE-95-YX02_1uM | Dose=1uM, N-[4-(3,5-dimethylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]acetamide, Adenosine A3 Antagonists targeting ADORA3 |
| CE-96-CZ90_0.01uM | Dose=0.01uM |
| CE-96-CZ90_10uM | Dose=10uM |
| CE-96-CZ90_1uM | Dose=1uM |
| CE-96-GH46_0.01uM | Dose=0.01uM, (E)-N-hydroxy-3-[4-[[2-(5-methoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CE-96-GH46_0.1uM | Dose=0.1uM, (E)-N-hydroxy-3-[4-[[2-(5-methoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CE-96-GH46_10uM | Dose=10uM, (E)-N-hydroxy-3-[4-[[2-(5-methoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CE-96-GH46_1uM | Dose=1uM, (E)-N-hydroxy-3-[4-[[2-(5-methoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| CE-96-JE44_0.01uM | Dose=0.01uM, A438079, P2X7 Receptor Antagonists targeting P2RX7 |
| CE-96-JE44_0.1uM | Dose=0.1uM, A438079, P2X7 Receptor Antagonists targeting P2RX7 |
| CE-96-JE44_10uM | Dose=10uM, A438079, P2X7 Receptor Antagonists targeting P2RX7 |
| CE-99-NH84_0.1uM | Dose=0.1uM, C3AR1 antagonist |
| CF-01-BY15_0.01uM | Dose=0.01uM |
| CF-01-BY15_10uM | Dose=10uM |
| CF-01-BY15_1uM | Dose=1uM |
| CF-01-IO46_0.1uM | Dose=0.1uM, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, Potassium Channel Blockers;Soluble Guanylyl Cyclase (sGC) Inhibitors targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| CF-01-IO46_10uM | Dose=10uM, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, Potassium Channel Blockers;Soluble Guanylyl Cyclase (sGC) Inhibitors targeting GUCY1A2, GUCY1A1, GUCY1B1 |
| CF-02-MS93_0.01uM | Dose=0.01uM, Agi-6780, Isocitrate Dehydrogenase (NADP+) (IDPm, IDH2) (Arg140Gln Mutant) Inhibitors targeting IDH2 |
| CF-02-MS93_0.1uM | Dose=0.1uM, Agi-6780, Isocitrate Dehydrogenase (NADP+) (IDPm, IDH2) (Arg140Gln Mutant) Inhibitors targeting IDH2 |
| CF-02-MS93_1uM | Dose=1uM, Agi-6780, Isocitrate Dehydrogenase (NADP+) (IDPm, IDH2) (Arg140Gln Mutant) Inhibitors targeting IDH2 |
| CF-03-QN99_0.01uM | Dose=0.01uM, Emricasan, Apoptosis Inhibitors;Caspase Inhibitors targeting CASP1, CASP3, CASP8 |
| CF-03-QN99_0.1uM | Dose=0.1uM, Emricasan, Apoptosis Inhibitors;Caspase Inhibitors targeting CASP1, CASP3, CASP8 |
| CF-03-QN99_10uM | Dose=10uM, Emricasan, Apoptosis Inhibitors;Caspase Inhibitors targeting CASP1, CASP3, CASP8 |
| CF-03-QN99_1uM | Dose=1uM, Emricasan, Apoptosis Inhibitors;Caspase Inhibitors targeting CASP1, CASP3, CASP8 |
| CF-15-FD69_0.01uM | Dose=0.01uM, Irosustat, Carbonic Anhydrase Type II Inhibitors;Steryl Sulfatase Inhibitors targeting STS, CA2, CA12 |
| CF-15-FD69_0.1uM | Dose=0.1uM, Irosustat, Carbonic Anhydrase Type II Inhibitors;Steryl Sulfatase Inhibitors targeting STS, CA2, CA12 |
| CF-15-FD69_10uM | Dose=10uM, Irosustat, Carbonic Anhydrase Type II Inhibitors;Steryl Sulfatase Inhibitors targeting STS, CA2, CA12 |
| CF-15-FD69_1uM | Dose=1uM, Irosustat, Carbonic Anhydrase Type II Inhibitors;Steryl Sulfatase Inhibitors targeting STS, CA2, CA12 |
| CF-15-GU15_0.01uM | Dose=0.01uM |
| CF-15-GU15_0.1uM | Dose=0.1uM |
| CF-15-GU15_1uM | Dose=1uM |
| CF-17-PV42_0.1uM | Dose=0.1uM, Dsp 4, Adrenergic Neuron Blockers targeting SLC22A3, SLC22A2 |
| CF-17-PV42_10uM | Dose=10uM, Dsp 4, Adrenergic Neuron Blockers targeting SLC22A3, SLC22A2 |
| CF-22-IS33_0.01uM | Dose=0.01uM, (3beta,4alpha,5alpha,8alpha,9beta,11alpha)-3,8,11-Trihydroxy-4-methyl-1,6-dioxo-9,19-cycloergost-24(28)-ene-4-carboxylic acid, Cholesterol synthesis inhibitor targeting NSDHL |
| CF-22-IS33_0.1uM | Dose=0.1uM, (3beta,4alpha,5alpha,8alpha,9beta,11alpha)-3,8,11-Trihydroxy-4-methyl-1,6-dioxo-9,19-cycloergost-24(28)-ene-4-carboxylic acid, Cholesterol synthesis inhibitor targeting NSDHL |
| CF-22-IS33_10uM | Dose=10uM, (3beta,4alpha,5alpha,8alpha,9beta,11alpha)-3,8,11-Trihydroxy-4-methyl-1,6-dioxo-9,19-cycloergost-24(28)-ene-4-carboxylic acid, Cholesterol synthesis inhibitor targeting NSDHL |
| CF-22-IS33_1uM | Dose=1uM, (3beta,4alpha,5alpha,8alpha,9beta,11alpha)-3,8,11-Trihydroxy-4-methyl-1,6-dioxo-9,19-cycloergost-24(28)-ene-4-carboxylic acid, Cholesterol synthesis inhibitor targeting NSDHL |
| CF-22-OS28_0.01uM | Dose=0.01uM, [2-(5-Ethyl-imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid, Farnesyl Pyrophosphate Synthase Inhibitors targeting FDPS |
| CF-22-OS28_0.1uM | Dose=0.1uM, [2-(5-Ethyl-imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid, Farnesyl Pyrophosphate Synthase Inhibitors targeting FDPS |
| CF-22-OS28_10uM | Dose=10uM, [2-(5-Ethyl-imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid, Farnesyl Pyrophosphate Synthase Inhibitors targeting FDPS |
| CF-22-OS28_1uM | Dose=1uM, [2-(5-Ethyl-imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid, Farnesyl Pyrophosphate Synthase Inhibitors targeting FDPS |
| CF-24-KQ98_0.01uM | Dose=0.01uM, Ar-67, DNA Topoisomerase I Inhibitors;DNA-Intercalating Drugs targeting TOP1 |
| CF-24-KQ98_0.1uM | Dose=0.1uM, Ar-67, DNA Topoisomerase I Inhibitors;DNA-Intercalating Drugs targeting TOP1 |
| CF-24-KQ98_10uM | Dose=10uM, Ar-67, DNA Topoisomerase I Inhibitors;DNA-Intercalating Drugs targeting TOP1 |
| CF-24-KQ98_1uM | Dose=1uM, Ar-67, DNA Topoisomerase I Inhibitors;DNA-Intercalating Drugs targeting TOP1 |
| CF-24-PH37_0.01uM | Dose=0.01uM, ethyl 2-(1H-imidazol-4-yl)acetate, IL-10 Production Enhancers targeting IL10 |
| CF-24-PH37_0.1uM | Dose=0.1uM, ethyl 2-(1H-imidazol-4-yl)acetate, IL-10 Production Enhancers targeting IL10 |
| CF-24-PH37_10uM | Dose=10uM, ethyl 2-(1H-imidazol-4-yl)acetate, IL-10 Production Enhancers targeting IL10 |
| CF-26-ME34_10uM | Dose=10uM, N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide, 15-Lipoxygenase Inhibitors targeting ALOX15, ALOX15B |
| CF-26-ME34_1uM | Dose=1uM, N-[2-(1H-indol-3-yl)ethyl]benzenesulfonamide, 15-Lipoxygenase Inhibitors targeting ALOX15, ALOX15B |
| CF-31-GE67_0.01uM | Dose=0.01uM, 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine, EHMT1/2;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1 |
| CF-31-GE67_0.1uM | Dose=0.1uM, 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine, EHMT1/2;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1 |
| CF-31-GE67_10uM | Dose=10uM, 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine, EHMT1/2;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1 |
| CF-31-GE67_1uM | Dose=1uM, 2-Cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine, EHMT1/2;Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 (EHMT2| G9a) Inhibitors targeting EHMT2, EHMT1 |
| CF-32-LB77_0.01uM | Dose=0.01uM, SR 144528, Cannabinoid CB2 Inverse Agonists;ACAT Inhibitors targeting CNR2 |
| CF-32-LB77_0.1uM | Dose=0.1uM, SR 144528, Cannabinoid CB2 Inverse Agonists;ACAT Inhibitors targeting CNR2 |
| CF-32-LB77_10uM | Dose=10uM, SR 144528, Cannabinoid CB2 Inverse Agonists;ACAT Inhibitors targeting CNR2 |
| CF-32-LB77_1uM | Dose=1uM, SR 144528, Cannabinoid CB2 Inverse Agonists;ACAT Inhibitors targeting CNR2 |
| CF-35-NN63_0.1uM | Dose=0.1uM, Ro 61-8048, Kynurenine 3-Monooxygenase Inhibitors targeting KMO |
| CF-35-NN63_10uM | Dose=10uM, Ro 61-8048, Kynurenine 3-Monooxygenase Inhibitors targeting KMO |
| CF-35-NN63_1uM | Dose=1uM, Ro 61-8048, Kynurenine 3-Monooxygenase Inhibitors targeting KMO |
| CF-42-OS28_0.01uM | Dose=0.01uM, Paclitaxel, Microtubule stabilizer targeting TUBB1 |
| CF-42-OS28_0.1uM | Dose=0.1uM, Paclitaxel, Microtubule stabilizer targeting TUBB1 |
| CF-42-OS28_10uM | Dose=10uM, Paclitaxel, Microtubule stabilizer targeting TUBB1 |
| CF-42-OS28_1uM | Dose=1uM, Paclitaxel, Microtubule stabilizer targeting TUBB1 |
| CF-44-NQ13_0.01uM | Dose=0.01uM |
| CF-44-NQ13_0.1uM | Dose=0.1uM |
| CF-44-NQ13_10uM | Dose=10uM |
| CF-44-NQ13_1uM | Dose=1uM |
| CF-46-PR45_0.01uM | Dose=0.01uM, Aldo keto reductase 1C1 inhibitor |
| CF-46-PR45_0.1uM | Dose=0.1uM, Aldo keto reductase 1C1 inhibitor |
| CF-46-PR45_1uM | Dose=1uM, Aldo keto reductase 1C1 inhibitor |
| CF-48-QD87_0.01uM | Dose=0.01uM, Abt-737, Bcl-2 Inhibitors;Apoptosis Inducers;Bcl-w Inhibitors;Bcl-xl Inhibitors targeting BCL2, BCL2L1, BCL2L2 |
| CF-48-QD87_0.1uM | Dose=0.1uM, Abt-737, Bcl-2 Inhibitors;Apoptosis Inducers;Bcl-w Inhibitors;Bcl-xl Inhibitors targeting BCL2, BCL2L1, BCL2L2 |
| CF-48-QD87_10uM | Dose=10uM, Abt-737, Bcl-2 Inhibitors;Apoptosis Inducers;Bcl-w Inhibitors;Bcl-xl Inhibitors targeting BCL2, BCL2L1, BCL2L2 |
| CF-48-QD87_1uM | Dose=1uM, Abt-737, Bcl-2 Inhibitors;Apoptosis Inducers;Bcl-w Inhibitors;Bcl-xl Inhibitors targeting BCL2, BCL2L1, BCL2L2 |
| CF-50-MN16_0.01uM | Dose=0.01uM, Cinalukast, CYSLTR1 antagonist targeting CYSLTR1 |
| CF-50-MN16_0.1uM | Dose=0.1uM, Cinalukast, CYSLTR1 antagonist targeting CYSLTR1 |
| CF-50-MN16_10uM | Dose=10uM, Cinalukast, CYSLTR1 antagonist targeting CYSLTR1 |
| CF-50-MN16_1uM | Dose=1uM, Cinalukast, CYSLTR1 antagonist targeting CYSLTR1 |
| CF-50-QK79_0.01uM | Dose=0.01uM, (4s)-4-[(1r)-1-Hydroxy-2-({1-[3-(1-Methylethyl)phenyl]cyclopropyl}amino)ethyl]-19-(Methoxymethyl)-11-Oxa-3,16-Diazatricyclo[15.3.1.1~6,10~]docosa-1(21),6(22),7,9,17,19-Hexaen-2-One, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors;Cathepsin D Inhibitors targeting CTSD, CTSE, BACE1, BACE2 |
| CF-50-QK79_0.1uM | Dose=0.1uM, (4s)-4-[(1r)-1-Hydroxy-2-({1-[3-(1-Methylethyl)phenyl]cyclopropyl}amino)ethyl]-19-(Methoxymethyl)-11-Oxa-3,16-Diazatricyclo[15.3.1.1~6,10~]docosa-1(21),6(22),7,9,17,19-Hexaen-2-One, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors;Cathepsin D Inhibitors targeting CTSD, CTSE, BACE1, BACE2 |
| CF-50-QK79_10uM | Dose=10uM, (4s)-4-[(1r)-1-Hydroxy-2-({1-[3-(1-Methylethyl)phenyl]cyclopropyl}amino)ethyl]-19-(Methoxymethyl)-11-Oxa-3,16-Diazatricyclo[15.3.1.1~6,10~]docosa-1(21),6(22),7,9,17,19-Hexaen-2-One, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors;Cathepsin D Inhibitors targeting CTSD, CTSE, BACE1, BACE2 |
| CF-50-QK79_1uM | Dose=1uM, (4s)-4-[(1r)-1-Hydroxy-2-({1-[3-(1-Methylethyl)phenyl]cyclopropyl}amino)ethyl]-19-(Methoxymethyl)-11-Oxa-3,16-Diazatricyclo[15.3.1.1~6,10~]docosa-1(21),6(22),7,9,17,19-Hexaen-2-One, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin E Inhibitors;beta-Secretase 2 (BACE2) Inhibitors;Cathepsin D Inhibitors targeting CTSD, CTSE, BACE1, BACE2 |
| CF-53-GP28_0.01uM | Dose=0.01uM, Retinol, 1 Epidermal transglutaminase inhibitor targeting TGM1 |
| CF-53-GP28_10uM | Dose=10uM, Retinol, 1 Epidermal transglutaminase inhibitor targeting TGM1 |
| CF-53-HM41_0.01uM | Dose=0.01uM, GRM6 agonist;GRM4 agonist;GRM7 agonist;GRM8 agonist targeting GRM4, GRM6, GRM7, GRM8 |
| CF-53-HM41_10uM | Dose=10uM, GRM6 agonist;GRM4 agonist;GRM7 agonist;GRM8 agonist targeting GRM4, GRM6, GRM7, GRM8 |
| CF-53-HM41_1uM | Dose=1uM, GRM6 agonist;GRM4 agonist;GRM7 agonist;GRM8 agonist targeting GRM4, GRM6, GRM7, GRM8 |
| CF-55-OA12_0.01uM | Dose=0.01uM, AZ505, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2 |
| CF-55-OA12_0.1uM | Dose=0.1uM, AZ505, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2 |
| CF-55-OA12_10uM | Dose=10uM, AZ505, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2 |
| CF-55-OA12_1uM | Dose=1uM, AZ505, SMYD2 / KMT3C;SMYD2 gene inhibitor targeting SMYD2 |
| CF-56-LO98_0.01uM | Dose=0.01uM, Atenolol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| CF-56-LO98_0.1uM | Dose=0.1uM, Atenolol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| CF-56-LO98_10uM | Dose=10uM, Atenolol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| CF-56-LO98_1uM | Dose=1uM, Atenolol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| CF-57-GW25_0.1uM | Dose=0.1uM, Perphenazine, Dopamine Receptor Antagonists targeting DRD2 |
| CF-57-GW25_10uM | Dose=10uM, Perphenazine, Dopamine Receptor Antagonists targeting DRD2 |
| CF-61-EH59_0.01uM | Dose=0.01uM, Asenapine, Dopamine D2 Antagonists;5-HT2 Antagonists;Dopamine D1 Antagonists targeting DRD1, DRD2 |
| CF-61-EH59_0.1uM | Dose=0.1uM, Asenapine, Dopamine D2 Antagonists;5-HT2 Antagonists;Dopamine D1 Antagonists targeting DRD1, DRD2 |
| CF-61-EH59_10uM | Dose=10uM, Asenapine, Dopamine D2 Antagonists;5-HT2 Antagonists;Dopamine D1 Antagonists targeting DRD1, DRD2 |
| CF-61-EH59_1uM | Dose=1uM, Asenapine, Dopamine D2 Antagonists;5-HT2 Antagonists;Dopamine D1 Antagonists targeting DRD1, DRD2 |
| CF-61-OL44_0.01uM | Dose=0.01uM, N-(3-hydroxyphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-2-carboxamide, Phosphodiesterase PDE11A Inhibitors targeting PDE11A |
| CF-61-OL44_10uM | Dose=10uM, N-(3-hydroxyphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-2-carboxamide, Phosphodiesterase PDE11A Inhibitors targeting PDE11A |
| CF-61-OL44_1uM | Dose=1uM, N-(3-hydroxyphenyl)-7-methyl-5-phenylpyrazolo[1,5-a]pyrimidine-2-carboxamide, Phosphodiesterase PDE11A Inhibitors targeting PDE11A |
| CF-65-GU65_0.01uM | Dose=0.01uM, (E)-3-(1H-benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one, Apoptosis Inhibitors;PKB alpha/Akt1 Inhibitors targeting AKT1 |
| CF-65-GU65_0.1uM | Dose=0.1uM, (E)-3-(1H-benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one, Apoptosis Inhibitors;PKB alpha/Akt1 Inhibitors targeting AKT1 |
| CF-65-GU65_10uM | Dose=10uM, (E)-3-(1H-benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one, Apoptosis Inhibitors;PKB alpha/Akt1 Inhibitors targeting AKT1 |
| CF-65-GU65_1uM | Dose=1uM, (E)-3-(1H-benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one, Apoptosis Inhibitors;PKB alpha/Akt1 Inhibitors targeting AKT1 |
| CF-68-DM58_0.01uM | Dose=0.01uM, Acetylsulfapyridine, Anti-inflammatory;tetrahydrobiopterin biosynthesis inhibitor targeting SPR |
| CF-68-DM58_0.1uM | Dose=0.1uM, Acetylsulfapyridine, Anti-inflammatory;tetrahydrobiopterin biosynthesis inhibitor targeting SPR |
| CF-68-DM58_10uM | Dose=10uM, Acetylsulfapyridine, Anti-inflammatory;tetrahydrobiopterin biosynthesis inhibitor targeting SPR |
| CF-68-DM58_1uM | Dose=1uM, Acetylsulfapyridine, Anti-inflammatory;tetrahydrobiopterin biosynthesis inhibitor targeting SPR |
| CF-79-FU20_0.01uM | Dose=0.01uM, Muscimol, GABA A receptor agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| CF-79-FU20_0.1uM | Dose=0.1uM, Muscimol, GABA A receptor agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| CF-79-FU20_10uM | Dose=10uM, Muscimol, GABA A receptor agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| CF-79-FU20_1uM | Dose=1uM, Muscimol, GABA A receptor agonist targeting GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6 |
| CF-81-DS26_0.01uM | Dose=0.01uM, N-[(1S,2S)-2-phenylcyclopentyl]-1-azacyclotridecen-2-amine, Adenylate Cyclase Inhibitors;Calcium Channel Blockers targeting ADCY1, ADCY2, ADCY3, ADCY5, ADCY6, ADCY7, ADCY9, CACNA1C |
| CF-81-DS26_0.1uM | Dose=0.1uM, N-[(1S,2S)-2-phenylcyclopentyl]-1-azacyclotridecen-2-amine, Adenylate Cyclase Inhibitors;Calcium Channel Blockers targeting ADCY1, ADCY2, ADCY3, ADCY5, ADCY6, ADCY7, ADCY9, CACNA1C |
| CF-81-DS26_10uM | Dose=10uM, N-[(1S,2S)-2-phenylcyclopentyl]-1-azacyclotridecen-2-amine, Adenylate Cyclase Inhibitors;Calcium Channel Blockers targeting ADCY1, ADCY2, ADCY3, ADCY5, ADCY6, ADCY7, ADCY9, CACNA1C |
| CF-81-DS26_1uM | Dose=1uM, N-[(1S,2S)-2-phenylcyclopentyl]-1-azacyclotridecen-2-amine, Adenylate Cyclase Inhibitors;Calcium Channel Blockers targeting ADCY1, ADCY2, ADCY3, ADCY5, ADCY6, ADCY7, ADCY9, CACNA1C |
| CF-82-AS63_0.01uM | Dose=0.01uM, Salsalate, inhibition of p300-induced Tau acetylation;NF-kappaB (NFKB) Activation Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| CF-82-AS63_0.1uM | Dose=0.1uM, Salsalate, inhibition of p300-induced Tau acetylation;NF-kappaB (NFKB) Activation Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| CF-82-AS63_10uM | Dose=10uM, Salsalate, inhibition of p300-induced Tau acetylation;NF-kappaB (NFKB) Activation Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| CF-82-AS63_1uM | Dose=1uM, Salsalate, inhibition of p300-induced Tau acetylation;NF-kappaB (NFKB) Activation Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| CF-82-FS38_0.01uM | Dose=0.01uM |
| CF-82-FS38_0.1uM | Dose=0.1uM |
| CF-82-FS38_10uM | Dose=10uM |
| CF-82-FS38_1uM | Dose=1uM |
| CF-82-LL11_0.01uM | Dose=0.01uM, 2,6-Di-tert-butyl-4-(2-(3-pyridinyl)ethenyl)phenol, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2, ALOX5 |
| CF-82-LL11_0.1uM | Dose=0.1uM, 2,6-Di-tert-butyl-4-(2-(3-pyridinyl)ethenyl)phenol, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2, ALOX5 |
| CF-82-LL11_10uM | Dose=10uM, 2,6-Di-tert-butyl-4-(2-(3-pyridinyl)ethenyl)phenol, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2, ALOX5 |
| CF-82-LL11_1uM | Dose=1uM, 2,6-Di-tert-butyl-4-(2-(3-pyridinyl)ethenyl)phenol, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2, ALOX5 |
| CF-83-HM41_0.01uM | Dose=0.01uM, 5,6-Dihydro-2,3-dimethoxy-6,6-dimethylbenz[7,8]indolizino[2,3-B]quinoxaline, IL-5 Receptor Antagonists targeting IL5RA |
| CF-83-HM41_0.1uM | Dose=0.1uM, 5,6-Dihydro-2,3-dimethoxy-6,6-dimethylbenz[7,8]indolizino[2,3-B]quinoxaline, IL-5 Receptor Antagonists targeting IL5RA |
| CF-83-HM41_10uM | Dose=10uM, 5,6-Dihydro-2,3-dimethoxy-6,6-dimethylbenz[7,8]indolizino[2,3-B]quinoxaline, IL-5 Receptor Antagonists targeting IL5RA |
| CF-83-HM41_1uM | Dose=1uM, 5,6-Dihydro-2,3-dimethoxy-6,6-dimethylbenz[7,8]indolizino[2,3-B]quinoxaline, IL-5 Receptor Antagonists targeting IL5RA |
| CF-83-PM81_0.01uM | Dose=0.01uM |
| CF-83-PM81_0.1uM | Dose=0.1uM |
| CF-83-PM81_10uM | Dose=10uM |
| CF-83-PM81_1uM | Dose=1uM |
| CF-87-AS90_0.01uM | Dose=0.01uM, Imidazolo-oxindole PKR inhibitor C16, PKR Inhibitor targeting EIF2AK2 |
| CF-87-AS90_0.1uM | Dose=0.1uM, Imidazolo-oxindole PKR inhibitor C16, PKR Inhibitor targeting EIF2AK2 |
| CF-87-AS90_10uM | Dose=10uM, Imidazolo-oxindole PKR inhibitor C16, PKR Inhibitor targeting EIF2AK2 |
| CF-87-AS90_1uM | Dose=1uM, Imidazolo-oxindole PKR inhibitor C16, PKR Inhibitor targeting EIF2AK2 |
| CF-90-DA50_0.01uM | Dose=0.01uM, 1-((S)-1-((3S)-2-hydroxy-tetrahydrofuran-3-ylamino)-4-methyl-1-oxopentan-2-yl)-3-phenylthiourea, mu-Calpain (Calpain-1) Inhibitors;m-Calpain (Calpain-2) Inhibitors targeting CAPN1 |
| CF-90-DA50_0.1uM | Dose=0.1uM, 1-((S)-1-((3S)-2-hydroxy-tetrahydrofuran-3-ylamino)-4-methyl-1-oxopentan-2-yl)-3-phenylthiourea, mu-Calpain (Calpain-1) Inhibitors;m-Calpain (Calpain-2) Inhibitors targeting CAPN1 |
| CF-90-DA50_10uM | Dose=10uM, 1-((S)-1-((3S)-2-hydroxy-tetrahydrofuran-3-ylamino)-4-methyl-1-oxopentan-2-yl)-3-phenylthiourea, mu-Calpain (Calpain-1) Inhibitors;m-Calpain (Calpain-2) Inhibitors targeting CAPN1 |
| CF-90-DA50_1uM | Dose=1uM, 1-((S)-1-((3S)-2-hydroxy-tetrahydrofuran-3-ylamino)-4-methyl-1-oxopentan-2-yl)-3-phenylthiourea, mu-Calpain (Calpain-1) Inhibitors;m-Calpain (Calpain-2) Inhibitors targeting CAPN1 |
| CF-91-JY05_0.01uM | Dose=0.01uM, 1-(Naphthalen-2-yl)piperazine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CF-91-JY05_0.1uM | Dose=0.1uM, 1-(Naphthalen-2-yl)piperazine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CF-91-JY05_10uM | Dose=10uM, 1-(Naphthalen-2-yl)piperazine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CF-91-JY05_1uM | Dose=1uM, 1-(Naphthalen-2-yl)piperazine, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| CF-92-QS83_0.01uM | Dose=0.01uM, Talniflumate, Mucin Production, Inhibitors;Calcium-activated Chloride Channels 1 Blockers targeting CLCA1, SLC26A3 |
| CF-92-QS83_0.1uM | Dose=0.1uM, Talniflumate, Mucin Production, Inhibitors;Calcium-activated Chloride Channels 1 Blockers targeting CLCA1, SLC26A3 |
| CF-92-QS83_10uM | Dose=10uM, Talniflumate, Mucin Production, Inhibitors;Calcium-activated Chloride Channels 1 Blockers targeting CLCA1, SLC26A3 |
| CF-92-QS83_1uM | Dose=1uM, Talniflumate, Mucin Production, Inhibitors;Calcium-activated Chloride Channels 1 Blockers targeting CLCA1, SLC26A3 |
| CF-97-AV07_0.01uM | Dose=0.01uM, Tianeptine, 5-HT Reuptake Enhancers targeting SLC6A4 |
| CF-97-AV07_0.1uM | Dose=0.1uM, Tianeptine, 5-HT Reuptake Enhancers targeting SLC6A4 |
| CF-97-AV07_10uM | Dose=10uM, Tianeptine, 5-HT Reuptake Enhancers targeting SLC6A4 |
| CF-97-AV07_1uM | Dose=1uM, Tianeptine, 5-HT Reuptake Enhancers targeting SLC6A4 |
| CF-97-KZ12_0.01uM | Dose=0.01uM, 1-((4-Methoxy-3-methylphenyl)sulfonyl)piperidine, Melanopsin Antagonist targeting OPN4 |
| CF-97-KZ12_0.1uM | Dose=0.1uM, 1-((4-Methoxy-3-methylphenyl)sulfonyl)piperidine, Melanopsin Antagonist targeting OPN4 |
| CF-97-KZ12_10uM | Dose=10uM, 1-((4-Methoxy-3-methylphenyl)sulfonyl)piperidine, Melanopsin Antagonist targeting OPN4 |
| CF-97-KZ12_1uM | Dose=1uM, 1-((4-Methoxy-3-methylphenyl)sulfonyl)piperidine, Melanopsin Antagonist targeting OPN4 |
| CF-98-GZ19_0.01uM | Dose=0.01uM, 2-Phenyl-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1 |
| CF-98-GZ19_0.1uM | Dose=0.1uM, 2-Phenyl-3,1-benzoxazin-4-one, Elastase inhibitor targeting CELA1 |
| CF-98-KM73_0.01uM | Dose=0.01uM, Senicapoc, Gardos channel, SK41, IK1) Channel Blockers;Intermediate Conductance K(Ca) 3.1 (IKCa1 targeting KCNN4 |
| CF-98-KM73_10uM | Dose=10uM, Senicapoc, Gardos channel, SK41, IK1) Channel Blockers;Intermediate Conductance K(Ca) 3.1 (IKCa1 targeting KCNN4 |
| CF-98-KM73_1uM | Dose=1uM, Senicapoc, Gardos channel, SK41, IK1) Channel Blockers;Intermediate Conductance K(Ca) 3.1 (IKCa1 targeting KCNN4 |
| DA-01-GV68_0.01uM | Dose=0.01uM, N-[4-[(1R,3R,4R,5S)-3-amino-4-hydroxy-5-methylcyclohexyl]pyridin-3-yl]-6-[4-(ethoxymethyl)-2,6-difluorophenyl]-5-fluoropyridine-2-carboxamide targeting PIM2, MAPK15 |
| DA-01-GV68_0.1uM | Dose=0.1uM, N-[4-[(1R,3R,4R,5S)-3-amino-4-hydroxy-5-methylcyclohexyl]pyridin-3-yl]-6-[4-(ethoxymethyl)-2,6-difluorophenyl]-5-fluoropyridine-2-carboxamide targeting PIM2, MAPK15 |
| DA-01-GV68_10uM | Dose=10uM, N-[4-[(1R,3R,4R,5S)-3-amino-4-hydroxy-5-methylcyclohexyl]pyridin-3-yl]-6-[4-(ethoxymethyl)-2,6-difluorophenyl]-5-fluoropyridine-2-carboxamide targeting PIM2, MAPK15 |
| DA-01-GV68_1uM | Dose=1uM, N-[4-[(1R,3R,4R,5S)-3-amino-4-hydroxy-5-methylcyclohexyl]pyridin-3-yl]-6-[4-(ethoxymethyl)-2,6-difluorophenyl]-5-fluoropyridine-2-carboxamide targeting PIM2, MAPK15 |
| DA-05-NN93_0.01uM | Dose=0.01uM, Sgc707, protein arginine methyltransferase 3 inhibitor;PRMT3 inhibitor targeting PRMT3 |
| DA-05-NN93_0.1uM | Dose=0.1uM, Sgc707, protein arginine methyltransferase 3 inhibitor;PRMT3 inhibitor targeting PRMT3 |
| DA-05-NN93_10uM | Dose=10uM, Sgc707, protein arginine methyltransferase 3 inhibitor;PRMT3 inhibitor targeting PRMT3 |
| DA-05-NN93_1uM | Dose=1uM, Sgc707, protein arginine methyltransferase 3 inhibitor;PRMT3 inhibitor targeting PRMT3 |
| DA-07-LL18_0.01uM | Dose=0.01uM, (2M)-7-[(3R)-3-methylmorpholin-4-yl]-5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridine |
| DA-07-LL18_0.1uM | Dose=0.1uM, (2M)-7-[(3R)-3-methylmorpholin-4-yl]-5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridine |
| DA-07-LL18_10uM | Dose=10uM, (2M)-7-[(3R)-3-methylmorpholin-4-yl]-5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridine |
| DA-07-LL18_1uM | Dose=1uM, (2M)-7-[(3R)-3-methylmorpholin-4-yl]-5-[(3S)-3-methylmorpholin-4-yl]-2-(1H-pyrazol-3-yl)-3H-imidazo[4,5-b]pyridine |
| DA-08-XJ96_0.01uM | Dose=0.01uM, N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide, Apurinic/Apyrimidinic Endonuclease 1 (Apex1) Inhibitors targeting APEX1 |
| DA-08-XJ96_0.1uM | Dose=0.1uM, N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide, Apurinic/Apyrimidinic Endonuclease 1 (Apex1) Inhibitors targeting APEX1 |
| DA-08-XJ96_10uM | Dose=10uM, N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide, Apurinic/Apyrimidinic Endonuclease 1 (Apex1) Inhibitors targeting APEX1 |
| DA-08-XJ96_1uM | Dose=1uM, N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide, Apurinic/Apyrimidinic Endonuclease 1 (Apex1) Inhibitors targeting APEX1 |
| DA-09-XJ53_0.01uM | Dose=0.01uM, (R)-Pfi-2, SET7/9 Inhibitor;Substrate competitive SET7/9 inhibitor targeting SETD7 |
| DA-09-XJ53_0.1uM | Dose=0.1uM, (R)-Pfi-2, SET7/9 Inhibitor;Substrate competitive SET7/9 inhibitor targeting SETD7 |
| DA-09-XJ53_10uM | Dose=10uM, (R)-Pfi-2, SET7/9 Inhibitor;Substrate competitive SET7/9 inhibitor targeting SETD7 |
| DA-09-XJ53_1uM | Dose=1uM, (R)-Pfi-2, SET7/9 Inhibitor;Substrate competitive SET7/9 inhibitor targeting SETD7 |
| DA-10-GX45_0.01uM | Dose=0.01uM, Podofilox targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| DA-10-GX45_0.1uM | Dose=0.1uM, Podofilox targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| DA-10-GX45_10uM | Dose=10uM, Podofilox targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| DA-10-GX45_1uM | Dose=1uM, Podofilox targeting TUBA4A, TUBB2A, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB, TUBB8, TUBB2B, TUBA3C, TUBG1, TUBG2, TUBD1, TUBA8 |
| DA-10-HD17_0.01uM | Dose=0.01uM, N-Phthalylglycine |
| DA-10-HD17_0.1uM | Dose=0.1uM, N-Phthalylglycine |
| DA-10-HD17_10uM | Dose=10uM, N-Phthalylglycine |
| DA-10-HD17_1uM | Dose=1uM, N-Phthalylglycine |
| DA-10-VU83_0.01uM | Dose=0.01uM, PF-8380, Autotaxin) Inhibitors;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2 |
| DA-10-VU83_0.1uM | Dose=0.1uM, PF-8380, Autotaxin) Inhibitors;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2 |
| DA-10-VU83_10uM | Dose=10uM, PF-8380, Autotaxin) Inhibitors;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2 |
| DA-10-VU83_1uM | Dose=1uM, PF-8380, Autotaxin) Inhibitors;Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2 targeting ENPP2 |
| DA-10-ZX00_0.01uM | Dose=0.01uM, 5-chloro-N-[(1S,3S)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]furan-2-carboxamide, mgluR5 Antagonists targeting GRM5 |
| DA-10-ZX00_0.1uM | Dose=0.1uM, 5-chloro-N-[(1S,3S)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]furan-2-carboxamide, mgluR5 Antagonists targeting GRM5 |
| DA-10-ZX00_10uM | Dose=10uM, 5-chloro-N-[(1S,3S)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]furan-2-carboxamide, mgluR5 Antagonists targeting GRM5 |
| DA-10-ZX00_1uM | Dose=1uM, 5-chloro-N-[(1S,3S)-3-[2-(3-chlorophenyl)ethynyl]-3-hydroxycyclohexyl]furan-2-carboxamide, mgluR5 Antagonists targeting GRM5 |
| DA-11-GV88_0.01uM | Dose=0.01uM, PD 128042, ACAT Inhibitors targeting SOAT1 |
| DA-11-GV88_0.1uM | Dose=0.1uM, PD 128042, ACAT Inhibitors targeting SOAT1 |
| DA-11-GV88_10uM | Dose=10uM, PD 128042, ACAT Inhibitors targeting SOAT1 |
| DA-11-GV88_1uM | Dose=1uM, PD 128042, ACAT Inhibitors targeting SOAT1 |
| DA-15-PU65_0.01uM | Dose=0.01uM, Ondansetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E |
| DA-15-PU65_0.1uM | Dose=0.1uM, Ondansetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E |
| DA-15-PU65_10uM | Dose=10uM, Ondansetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E |
| DA-15-PU65_1uM | Dose=1uM, Ondansetron, 5-HT3 receptor antagonist targeting HTR3A, HTR3B, HTR3C, HTR3D, HTR3E |
| DA-17-XI26_0.01uM | Dose=0.01uM, Serdemetan, MDM2 (hdm2) Inhibitors targeting MDM2 |
| DA-17-XI26_0.1uM | Dose=0.1uM, Serdemetan, MDM2 (hdm2) Inhibitors targeting MDM2 |
| DA-17-XI26_10uM | Dose=10uM, Serdemetan, MDM2 (hdm2) Inhibitors targeting MDM2 |
| DA-17-XI26_1uM | Dose=1uM, Serdemetan, MDM2 (hdm2) Inhibitors targeting MDM2 |
| DA-17-YW85_0.01uM | Dose=0.01uM, Tgba01AD |
| DA-17-YW85_0.1uM | Dose=0.1uM, Tgba01AD |
| DA-17-YW85_10uM | Dose=10uM, Tgba01AD |
| DA-17-YW85_1uM | Dose=1uM, Tgba01AD |
| DA-18-QP05_0.01uM | Dose=0.01uM |
| DA-18-QP05_0.1uM | Dose=0.1uM |
| DA-18-QP05_10uM | Dose=10uM |
| DA-18-QP05_1uM | Dose=1uM |
| DA-19-AJ18_0.01uM | Dose=0.01uM, Dicumarol, Anticoagulant;Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors;NADPH Quinone Oxidoreductase 1 (NQO1) Inhibitors targeting NQO1, VKORC1 |
| DA-19-AJ18_0.1uM | Dose=0.1uM, Dicumarol, Anticoagulant;Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors;NADPH Quinone Oxidoreductase 1 (NQO1) Inhibitors targeting NQO1, VKORC1 |
| DA-19-AJ18_10uM | Dose=10uM, Dicumarol, Anticoagulant;Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors;NADPH Quinone Oxidoreductase 1 (NQO1) Inhibitors targeting NQO1, VKORC1 |
| DA-19-JA87_0.01uM | Dose=0.01uM, Doxofylline, Adenosine A1 Antagonists targeting ADORA1 |
| DA-19-JA87_0.1uM | Dose=0.1uM, Doxofylline, Adenosine A1 Antagonists targeting ADORA1 |
| DA-19-JA87_10uM | Dose=10uM, Doxofylline, Adenosine A1 Antagonists targeting ADORA1 |
| DA-19-JA87_1uM | Dose=1uM, Doxofylline, Adenosine A1 Antagonists targeting ADORA1 |
| DA-20-OX15_0.01uM | Dose=0.01uM, Nafamostat, Tryptase Inhibitors targeting C1S, F11, F12, KLK1, PLG, PROC, TPSAB1, KLK8, KLK5, KLK14, TPSB2, KLK2, KLK3, KLK6, KLK10, KLK4, KLK11, KLK13, KLK12, KLK15, KLK9 |
| DA-20-OX15_0.1uM | Dose=0.1uM, Nafamostat, Tryptase Inhibitors targeting C1S, F11, F12, KLK1, PLG, PROC, TPSAB1, KLK8, KLK5, KLK14, TPSB2, KLK2, KLK3, KLK6, KLK10, KLK4, KLK11, KLK13, KLK12, KLK15, KLK9 |
| DA-20-OX15_10uM | Dose=10uM, Nafamostat, Tryptase Inhibitors targeting C1S, F11, F12, KLK1, PLG, PROC, TPSAB1, KLK8, KLK5, KLK14, TPSB2, KLK2, KLK3, KLK6, KLK10, KLK4, KLK11, KLK13, KLK12, KLK15, KLK9 |
| DA-20-OX15_1uM | Dose=1uM, Nafamostat, Tryptase Inhibitors targeting C1S, F11, F12, KLK1, PLG, PROC, TPSAB1, KLK8, KLK5, KLK14, TPSB2, KLK2, KLK3, KLK6, KLK10, KLK4, KLK11, KLK13, KLK12, KLK15, KLK9 |
| DA-20-VR86_0.01uM | Dose=0.01uM, Lamivudine, Reverse Transcriptase Inhibitors targeting POLB, POLG, POLD1, POLD2, POLE, POLE2, POLH, POLD3, POLQ, TENT4A, POLI, POLG2, POLL, POLM, POLK, POLE3, POLE4, POLD4, POLN |
| DA-20-VR86_0.1uM | Dose=0.1uM, Lamivudine, Reverse Transcriptase Inhibitors targeting POLB, POLG, POLD1, POLD2, POLE, POLE2, POLH, POLD3, POLQ, TENT4A, POLI, POLG2, POLL, POLM, POLK, POLE3, POLE4, POLD4, POLN |
| DA-20-VR86_10uM | Dose=10uM, Lamivudine, Reverse Transcriptase Inhibitors targeting POLB, POLG, POLD1, POLD2, POLE, POLE2, POLH, POLD3, POLQ, TENT4A, POLI, POLG2, POLL, POLM, POLK, POLE3, POLE4, POLD4, POLN |
| DA-20-VR86_1uM | Dose=1uM, Lamivudine, Reverse Transcriptase Inhibitors targeting POLB, POLG, POLD1, POLD2, POLE, POLE2, POLH, POLD3, POLQ, TENT4A, POLI, POLG2, POLL, POLM, POLK, POLE3, POLE4, POLD4, POLN |
| DA-21-GV88_0.01uM | Dose=0.01uM, 4-{2-[(7-Amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol, Adenosine A2A Antagonists;Adenosine A2B Antagonists targeting ADORA2A, ADORA2B |
| DA-21-GV88_0.1uM | Dose=0.1uM, 4-{2-[(7-Amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol, Adenosine A2A Antagonists;Adenosine A2B Antagonists targeting ADORA2A, ADORA2B |
| DA-21-GV88_10uM | Dose=10uM, 4-{2-[(7-Amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol, Adenosine A2A Antagonists;Adenosine A2B Antagonists targeting ADORA2A, ADORA2B |
| DA-21-GV88_1uM | Dose=1uM, 4-{2-[(7-Amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol, Adenosine A2A Antagonists;Adenosine A2B Antagonists targeting ADORA2A, ADORA2B |
| DA-23-IF64_0.01uM | Dose=0.01uM, Lufironil, Prolyl 4-Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1 |
| DA-23-IF64_0.1uM | Dose=0.1uM, Lufironil, Prolyl 4-Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1 |
| DA-23-IF64_10uM | Dose=10uM, Lufironil, Prolyl 4-Hydroxylase Inhibitors targeting P4HB, P4HA2, P4HA3, P4HA1 |
| DA-23-TZ42_0.01uM | Dose=0.01uM |
| DA-23-TZ42_0.1uM | Dose=0.1uM |
| DA-23-TZ42_10uM | Dose=10uM |
| DA-23-TZ42_1uM | Dose=1uM |
| DA-27-BW20_0.01uM | Dose=0.01uM, 1-(4-(4-(4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, Inhibitor of Aurora targeting CDK2, AURKA, CCNE2 |
| DA-27-BW20_0.1uM | Dose=0.1uM, 1-(4-(4-(4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, Inhibitor of Aurora targeting CDK2, AURKA, CCNE2 |
| DA-27-BW20_10uM | Dose=10uM, 1-(4-(4-(4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, Inhibitor of Aurora targeting CDK2, AURKA, CCNE2 |
| DA-27-BW20_1uM | Dose=1uM, 1-(4-(4-(4-(4-Methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)phenyl)piperazin-1-yl)ethanone, Inhibitor of Aurora targeting CDK2, AURKA, CCNE2 |
| DA-27-BW40_0.01uM | Dose=0.01uM, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, BET inhibitor BD2 selective targeting BRD2, BRD3, BRD4 |
| DA-27-BW40_0.1uM | Dose=0.1uM, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, BET inhibitor BD2 selective targeting BRD2, BRD3, BRD4 |
| DA-27-BW40_10uM | Dose=10uM, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, BET inhibitor BD2 selective targeting BRD2, BRD3, BRD4 |
| DA-27-BW40_1uM | Dose=1uM, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide, BET inhibitor BD2 selective targeting BRD2, BRD3, BRD4 |
| DA-28-TM43_0.1uM | Dose=0.1uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)benzonitrile, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK4, IRAK2 |
| DA-28-TM43_10uM | Dose=10uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)benzonitrile, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK4, IRAK2 |
| DA-28-TM43_1uM | Dose=1uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)benzonitrile, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK4, IRAK2 |
| DA-29-ZD04_0.1uM | Dose=0.1uM, Losartan, AGTR1 gene inhibitor targeting AGTR1 |
| DA-29-ZD04_10uM | Dose=10uM, Losartan, AGTR1 gene inhibitor targeting AGTR1 |
| DA-29-ZD04_1uM | Dose=1uM, Losartan, AGTR1 gene inhibitor targeting AGTR1 |
| DA-30-HN81_0.1uM | Dose=0.1uM, Peripheral Benzodiazepine Receptor (PBR) Ligands |
| DA-32-QL71_0.01uM | Dose=0.01uM, Namodenoson, Adenosine A3 Agonists targeting ADORA3 |
| DA-32-QL71_0.1uM | Dose=0.1uM, Namodenoson, Adenosine A3 Agonists targeting ADORA3 |
| DA-32-QL71_10uM | Dose=10uM, Namodenoson, Adenosine A3 Agonists targeting ADORA3 |
| DA-32-QL71_1uM | Dose=1uM, Namodenoson, Adenosine A3 Agonists targeting ADORA3 |
| DA-33-BM26_0.01uM | Dose=0.01uM, 6,7-diMethoxy-2-(4-(4-Methylpiperazin-1-yl)phenyl)-N-(2-Morpholinoethyl)quinazolin-4-aMine, TLR9 Receptor Antagonists;TLR7 Receptor Antagonists;TLR8 Receptor Antagonists targeting TLR7, TLR8, TLR9 |
| DA-33-BM26_0.1uM | Dose=0.1uM, 6,7-diMethoxy-2-(4-(4-Methylpiperazin-1-yl)phenyl)-N-(2-Morpholinoethyl)quinazolin-4-aMine, TLR9 Receptor Antagonists;TLR7 Receptor Antagonists;TLR8 Receptor Antagonists targeting TLR7, TLR8, TLR9 |
| DA-33-BM26_10uM | Dose=10uM, 6,7-diMethoxy-2-(4-(4-Methylpiperazin-1-yl)phenyl)-N-(2-Morpholinoethyl)quinazolin-4-aMine, TLR9 Receptor Antagonists;TLR7 Receptor Antagonists;TLR8 Receptor Antagonists targeting TLR7, TLR8, TLR9 |
| DA-33-BM26_1uM | Dose=1uM, 6,7-diMethoxy-2-(4-(4-Methylpiperazin-1-yl)phenyl)-N-(2-Morpholinoethyl)quinazolin-4-aMine, TLR9 Receptor Antagonists;TLR7 Receptor Antagonists;TLR8 Receptor Antagonists targeting TLR7, TLR8, TLR9 |
| DA-33-CW45_0.01uM | Dose=0.01uM, N2-Isopropyl-N4,6-diphenyl-1,3,5-triazine-2,4-diamine, IDH2 mutant inhibitor targeting IDH2 |
| DA-33-CW45_0.1uM | Dose=0.1uM, N2-Isopropyl-N4,6-diphenyl-1,3,5-triazine-2,4-diamine, IDH2 mutant inhibitor targeting IDH2 |
| DA-33-CW45_10uM | Dose=10uM, N2-Isopropyl-N4,6-diphenyl-1,3,5-triazine-2,4-diamine, IDH2 mutant inhibitor targeting IDH2 |
| DA-33-CW45_1uM | Dose=1uM, N2-Isopropyl-N4,6-diphenyl-1,3,5-triazine-2,4-diamine, IDH2 mutant inhibitor targeting IDH2 |
| DA-33-CX68_0.01uM | Dose=0.01uM, AZ-Dyrk1B-33, Dyrk1 inhibitor targeting DYRK1B |
| DA-33-CX68_0.1uM | Dose=0.1uM, AZ-Dyrk1B-33, Dyrk1 inhibitor targeting DYRK1B |
| DA-33-CX68_10uM | Dose=10uM, AZ-Dyrk1B-33, Dyrk1 inhibitor targeting DYRK1B |
| DA-33-CX68_1uM | Dose=1uM, AZ-Dyrk1B-33, Dyrk1 inhibitor targeting DYRK1B |
| DA-33-IZ67_0.01uM | Dose=0.01uM, (2S)-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-1-(4-oxo-3H-quinazolin-2-yl)pyrrolidine-2-carboxamide, Tachykinin Antagonists targeting TACR1 |
| DA-33-IZ67_0.1uM | Dose=0.1uM, (2S)-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-1-(4-oxo-3H-quinazolin-2-yl)pyrrolidine-2-carboxamide, Tachykinin Antagonists targeting TACR1 |
| DA-33-IZ67_10uM | Dose=10uM, (2S)-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-1-(4-oxo-3H-quinazolin-2-yl)pyrrolidine-2-carboxamide, Tachykinin Antagonists targeting TACR1 |
| DA-33-IZ67_1uM | Dose=1uM, (2S)-N-[(2S)-1-[benzyl(methyl)amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-1-(4-oxo-3H-quinazolin-2-yl)pyrrolidine-2-carboxamide, Tachykinin Antagonists targeting TACR1 |
| DA-33-NF79_0.01uM | Dose=0.01uM, Brofaromine, MAO-A Inhibitors targeting MAOA |
| DA-33-NF79_0.1uM | Dose=0.1uM, Brofaromine, MAO-A Inhibitors targeting MAOA |
| DA-33-NF79_10uM | Dose=10uM, Brofaromine, MAO-A Inhibitors targeting MAOA |
| DA-33-NF79_1uM | Dose=1uM, Brofaromine, MAO-A Inhibitors targeting MAOA |
| DA-35-DU85_0.01uM | Dose=0.01uM, (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide, Immunoproteasome Inhibitors targeting PSMB8 |
| DA-35-DU85_0.1uM | Dose=0.1uM, (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide, Immunoproteasome Inhibitors targeting PSMB8 |
| DA-35-DU85_10uM | Dose=10uM, (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide, Immunoproteasome Inhibitors targeting PSMB8 |
| DA-35-DU85_1uM | Dose=1uM, (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide, Immunoproteasome Inhibitors targeting PSMB8 |
| DA-35-ZK21_0.01uM | Dose=0.01uM, 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine, CDK Inhibitors targeting CCND2, CCND3 |
| DA-35-ZK21_0.1uM | Dose=0.1uM, 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine, CDK Inhibitors targeting CCND2, CCND3 |
| DA-35-ZK21_10uM | Dose=10uM, 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine, CDK Inhibitors targeting CCND2, CCND3 |
| DA-35-ZK21_1uM | Dose=1uM, 1-(4-aminophenyl)-N,N-dimethylpiperidin-4-amine, CDK Inhibitors targeting CCND2, CCND3 |
| DA-39-AJ98_0.01uM | Dose=0.01uM, Metylperon, DRD2 antagonist targeting DRD2 |
| DA-39-AJ98_0.1uM | Dose=0.1uM, Metylperon, DRD2 antagonist targeting DRD2 |
| DA-39-AJ98_10uM | Dose=10uM, Metylperon, DRD2 antagonist targeting DRD2 |
| DA-39-AJ98_1uM | Dose=1uM, Metylperon, DRD2 antagonist targeting DRD2 |
| DA-40-HO94_0.01uM | Dose=0.01uM, (6R)-5-(6-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-methyl-3-(1-methylsulfonylpiperidin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine, ATR gene inhibitor targeting ATR |
| DA-40-HO94_0.1uM | Dose=0.1uM, (6R)-5-(6-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-methyl-3-(1-methylsulfonylpiperidin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine, ATR gene inhibitor targeting ATR |
| DA-40-HO94_10uM | Dose=10uM, (6R)-5-(6-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-methyl-3-(1-methylsulfonylpiperidin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine, ATR gene inhibitor targeting ATR |
| DA-40-HO94_1uM | Dose=1uM, (6R)-5-(6-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-6-methyl-3-(1-methylsulfonylpiperidin-4-yl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine, ATR gene inhibitor targeting ATR |
| DA-42-BI19_0.01uM | Dose=0.01uM, (2S)-2-(4-chlorophenyl)-N-[5-[3-(2-hydroxyethylsulfonyl)-4-methoxy-phenyl]-4-methyl-1H-imidazol-2-yl]propanamide, PI4Kb inhibitor targeting PI4KB |
| DA-42-BI19_0.1uM | Dose=0.1uM, (2S)-2-(4-chlorophenyl)-N-[5-[3-(2-hydroxyethylsulfonyl)-4-methoxy-phenyl]-4-methyl-1H-imidazol-2-yl]propanamide, PI4Kb inhibitor targeting PI4KB |
| DA-42-BI19_10uM | Dose=10uM, (2S)-2-(4-chlorophenyl)-N-[5-[3-(2-hydroxyethylsulfonyl)-4-methoxy-phenyl]-4-methyl-1H-imidazol-2-yl]propanamide, PI4Kb inhibitor targeting PI4KB |
| DA-42-BI19_1uM | Dose=1uM, (2S)-2-(4-chlorophenyl)-N-[5-[3-(2-hydroxyethylsulfonyl)-4-methoxy-phenyl]-4-methyl-1H-imidazol-2-yl]propanamide, PI4Kb inhibitor targeting PI4KB |
| DA-45-PU65_0.01uM | Dose=0.01uM, Torsemide, Drugs Acting on Potassium Channels targeting SLC12A1, SLC12A2 |
| DA-45-PU65_0.1uM | Dose=0.1uM, Torsemide, Drugs Acting on Potassium Channels targeting SLC12A1, SLC12A2 |
| DA-46-KH36_0.01uM | Dose=0.01uM, 1,2,3,4-Tetrahydroisoquinoline |
| DA-46-KH36_0.1uM | Dose=0.1uM, 1,2,3,4-Tetrahydroisoquinoline |
| DA-46-KH36_10uM | Dose=10uM, 1,2,3,4-Tetrahydroisoquinoline |
| DA-46-KH36_1uM | Dose=1uM, 1,2,3,4-Tetrahydroisoquinoline |
| DA-48-IP75_0.01uM | Dose=0.01uM, Camostat, Known Trypsin inhibitor targeting PRSS1, KLKB1, PLG |
| DA-48-IP75_0.1uM | Dose=0.1uM, Camostat, Known Trypsin inhibitor targeting PRSS1, KLKB1, PLG |
| DA-48-IP75_10uM | Dose=10uM, Camostat, Known Trypsin inhibitor targeting PRSS1, KLKB1, PLG |
| DA-48-IP75_1uM | Dose=1uM, Camostat, Known Trypsin inhibitor targeting PRSS1, KLKB1, PLG |
| DA-48-NC44_0.01uM | Dose=0.01uM |
| DA-48-NC44_0.1uM | Dose=0.1uM |
| DA-48-NC44_10uM | Dose=10uM |
| DA-48-NC44_1uM | Dose=1uM |
| DA-49-ZD74_0.01uM | Dose=0.01uM, Latanoprost, Prostaglandin F agonists targeting PTGFR |
| DA-49-ZD74_0.1uM | Dose=0.1uM, Latanoprost, Prostaglandin F agonists targeting PTGFR |
| DA-49-ZD74_10uM | Dose=10uM, Latanoprost, Prostaglandin F agonists targeting PTGFR |
| DA-49-ZD74_1uM | Dose=1uM, Latanoprost, Prostaglandin F agonists targeting PTGFR |
| DA-54-NN76_0.01uM | Dose=0.01uM, (1R,2R)-N-((S)-1-(4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-phenylcyclopropanecarboxamide, PLD1 Inhibitor targeting PLD1 |
| DA-54-NN76_0.1uM | Dose=0.1uM, (1R,2R)-N-((S)-1-(4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-phenylcyclopropanecarboxamide, PLD1 Inhibitor targeting PLD1 |
| DA-54-NN76_10uM | Dose=10uM, (1R,2R)-N-((S)-1-(4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-phenylcyclopropanecarboxamide, PLD1 Inhibitor targeting PLD1 |
| DA-54-NN76_1uM | Dose=1uM, (1R,2R)-N-((S)-1-(4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-phenylcyclopropanecarboxamide, PLD1 Inhibitor targeting PLD1 |
| DA-56-CH26_0.1uM | Dose=0.1uM, N-(1-(3-hydroxypropyl)-1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2 |
| DA-56-CH26_10uM | Dose=10uM, N-(1-(3-hydroxypropyl)-1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2 |
| DA-56-CH26_1uM | Dose=1uM, N-(1-(3-hydroxypropyl)-1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2 |
| DA-58-LZ09_0.01uM | Dose=0.01uM, 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7, MAPK13 |
| DA-58-LZ09_0.1uM | Dose=0.1uM, 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7, MAPK13 |
| DA-58-LZ09_10uM | Dose=10uM, 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7, MAPK13 |
| DA-58-LZ09_1uM | Dose=1uM, 2-(2-Chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide, Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K7, MAPK13 |
| DA-59-ZD74_0.01uM | Dose=0.01uM, Bosentan, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB |
| DA-59-ZD74_0.1uM | Dose=0.1uM, Bosentan, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB |
| DA-59-ZD74_10uM | Dose=10uM, Bosentan, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB |
| DA-59-ZD74_1uM | Dose=1uM, Bosentan, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB |
| DA-60-KU38_0.01uM | Dose=0.01uM, N-acetyl-N-[7-ethyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide |
| DA-60-KU38_0.1uM | Dose=0.1uM, N-acetyl-N-[7-ethyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide |
| DA-60-KU38_10uM | Dose=10uM, N-acetyl-N-[7-ethyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide |
| DA-60-KU38_1uM | Dose=1uM, N-acetyl-N-[7-ethyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide |
| DA-62-QB27_0.01uM | Dose=0.01uM, (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| DA-62-QB27_0.1uM | Dose=0.1uM, (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| DA-62-QB27_10uM | Dose=10uM, (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| DA-62-QB27_1uM | Dose=1uM, (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| DA-62-XV25_0.01uM | Dose=0.01uM, (4S,5R)-4-[5-(1H-indol-5-yl)pyrimidin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane, Nicotinic alpha7 Agonists targeting CHRNA7 |
| DA-62-XV25_0.1uM | Dose=0.1uM, (4S,5R)-4-[5-(1H-indol-5-yl)pyrimidin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane, Nicotinic alpha7 Agonists targeting CHRNA7 |
| DA-62-XV25_10uM | Dose=10uM, (4S,5R)-4-[5-(1H-indol-5-yl)pyrimidin-2-yloxy]-1-aza-bicyclo[3.3.1]nonane, Nicotinic alpha7 Agonists targeting CHRNA7 |
| DA-63-NP63_0.01uM | Dose=0.01uM, (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-[(2R)-1-[4-(2-methoxyethyl)piperazin-1-yl]propan-2-yl]-1,4,7,10,12,15,19,25,27,28-decamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone, Cyclophilin inhibitor targeting PPIA, PPIB, PPID |
| DA-63-NP63_0.1uM | Dose=0.1uM, (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-[(2R)-1-[4-(2-methoxyethyl)piperazin-1-yl]propan-2-yl]-1,4,7,10,12,15,19,25,27,28-decamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone, Cyclophilin inhibitor targeting PPIA, PPIB, PPID |
| DA-63-NP63_10uM | Dose=10uM, (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-[(2R)-1-[4-(2-methoxyethyl)piperazin-1-yl]propan-2-yl]-1,4,7,10,12,15,19,25,27,28-decamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone, Cyclophilin inhibitor targeting PPIA, PPIB, PPID |
| DA-63-NP63_1uM | Dose=1uM, (3S,6S,9S,12R,15S,18S,21S,24S,27R,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-24-[(2R)-1-[4-(2-methoxyethyl)piperazin-1-yl]propan-2-yl]-1,4,7,10,12,15,19,25,27,28-decamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone, Cyclophilin inhibitor targeting PPIA, PPIB, PPID |
| DA-66-OE69_0.01uM | Dose=0.01uM, Gliotoxin, NF-kappaB (NFKB) Activation Inhibitors targeting SUV39H1 |
| DA-66-OE69_0.1uM | Dose=0.1uM, Gliotoxin, NF-kappaB (NFKB) Activation Inhibitors targeting SUV39H1 |
| DA-66-OE69_10uM | Dose=10uM, Gliotoxin, NF-kappaB (NFKB) Activation Inhibitors targeting SUV39H1 |
| DA-66-OE69_1uM | Dose=1uM, Gliotoxin, NF-kappaB (NFKB) Activation Inhibitors targeting SUV39H1 |
| DA-67-HS65_0.01uM | Dose=0.01uM, 4-(Aminomethyl)-N-benzylpicolinamide, LOXL2 inhibitor targeting LOXL2 |
| DA-67-HS65_0.1uM | Dose=0.1uM, 4-(Aminomethyl)-N-benzylpicolinamide, LOXL2 inhibitor targeting LOXL2 |
| DA-67-HS65_10uM | Dose=10uM, 4-(Aminomethyl)-N-benzylpicolinamide, LOXL2 inhibitor targeting LOXL2 |
| DA-67-HS65_1uM | Dose=1uM, 4-(Aminomethyl)-N-benzylpicolinamide, LOXL2 inhibitor targeting LOXL2 |
| DA-69-UN88_0.01uM | Dose=0.01uM, 2-[(6-Methoxy-1,3-benzothiazol-2-yl)amino]-2-oxoethyl 3-(benzoylamino)-3-phenylpropanoate targeting TAOK2, TAOK3, TAOK1 |
| DA-69-UN88_0.1uM | Dose=0.1uM, 2-[(6-Methoxy-1,3-benzothiazol-2-yl)amino]-2-oxoethyl 3-(benzoylamino)-3-phenylpropanoate targeting TAOK2, TAOK3, TAOK1 |
| DA-69-UN88_10uM | Dose=10uM, 2-[(6-Methoxy-1,3-benzothiazol-2-yl)amino]-2-oxoethyl 3-(benzoylamino)-3-phenylpropanoate targeting TAOK2, TAOK3, TAOK1 |
| DA-69-UN88_1uM | Dose=1uM, 2-[(6-Methoxy-1,3-benzothiazol-2-yl)amino]-2-oxoethyl 3-(benzoylamino)-3-phenylpropanoate targeting TAOK2, TAOK3, TAOK1 |
| DA-75-KD59_0.01uM | Dose=0.01uM, (2S,3R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-3-(hydroxymethyl)-2-p-tolylsuccinamide, MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP9, MMP13, ADAM17 |
| DA-75-KD59_0.1uM | Dose=0.1uM, (2S,3R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-3-(hydroxymethyl)-2-p-tolylsuccinamide, MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP9, MMP13, ADAM17 |
| DA-75-KD59_10uM | Dose=10uM, (2S,3R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-3-(hydroxymethyl)-2-p-tolylsuccinamide, MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP9, MMP13, ADAM17 |
| DA-75-KD59_1uM | Dose=1uM, (2S,3R)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4-hydroxy-3-(hydroxymethyl)-2-p-tolylsuccinamide, MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP9, MMP13, ADAM17 |
| DA-75-NX57_0.01uM | Dose=0.01uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-acetylamino-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1 |
| DA-75-NX57_1uM | Dose=1uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-acetylamino-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1 |
| DA-76-NE84_0.01uM | Dose=0.01uM, 2-[(E)-1-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]ethylideneamino]oxyethanol, c-Met) Inhibitors;HGFR (MET targeting MET |
| DA-76-NE84_0.1uM | Dose=0.1uM, 2-[(E)-1-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]ethylideneamino]oxyethanol, c-Met) Inhibitors;HGFR (MET targeting MET |
| DA-76-NE84_10uM | Dose=10uM, 2-[(E)-1-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]ethylideneamino]oxyethanol, c-Met) Inhibitors;HGFR (MET targeting MET |
| DA-76-NE84_1uM | Dose=1uM, 2-[(E)-1-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]ethylideneamino]oxyethanol, c-Met) Inhibitors;HGFR (MET targeting MET |
| DA-77-II31_0.01uM | Dose=0.01uM, Adenosine, 5'-S-[2-[[(ethylamino)carbonyl]amino]ethyl]-5'-thio-, Dual PRMT5 and PRMT7 inhibitor targeting PRMT5, PRMT7 |
| DA-77-II31_0.1uM | Dose=0.1uM, Adenosine, 5'-S-[2-[[(ethylamino)carbonyl]amino]ethyl]-5'-thio-, Dual PRMT5 and PRMT7 inhibitor targeting PRMT5, PRMT7 |
| DA-77-II31_10uM | Dose=10uM, Adenosine, 5'-S-[2-[[(ethylamino)carbonyl]amino]ethyl]-5'-thio-, Dual PRMT5 and PRMT7 inhibitor targeting PRMT5, PRMT7 |
| DA-77-II31_1uM | Dose=1uM, Adenosine, 5'-S-[2-[[(ethylamino)carbonyl]amino]ethyl]-5'-thio-, Dual PRMT5 and PRMT7 inhibitor targeting PRMT5, PRMT7 |
| DA-78-WW87_0.01uM | Dose=0.01uM, 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| DA-78-WW87_0.1uM | Dose=0.1uM, 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| DA-78-WW87_10uM | Dose=10uM, 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| DA-78-WW87_1uM | Dose=1uM, 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| DA-79-ZD74_0.01uM | Dose=0.01uM, Acacetin, Melanin Inhibitors;Xanthine Oxidase Inhibitors targeting XDH |
| DA-79-ZD74_0.1uM | Dose=0.1uM, Acacetin, Melanin Inhibitors;Xanthine Oxidase Inhibitors targeting XDH |
| DA-79-ZD74_10uM | Dose=10uM, Acacetin, Melanin Inhibitors;Xanthine Oxidase Inhibitors targeting XDH |
| DA-79-ZD74_1uM | Dose=1uM, Acacetin, Melanin Inhibitors;Xanthine Oxidase Inhibitors targeting XDH |
| DA-80-IV36_0.01uM | Dose=0.01uM, Lapatinib, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2 |
| DA-80-IV36_0.1uM | Dose=0.1uM, Lapatinib, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2 |
| DA-80-IV36_10uM | Dose=10uM, Lapatinib, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2 |
| DA-80-IV36_1uM | Dose=1uM, Lapatinib, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2 |
| DA-80-IY83_0.01uM | Dose=0.01uM, Doxazosin, alpha1-Adrenoceptor Antagonists;Apoptosis Inducers targeting ADRA1D, ADRA1B, ADRA1A |
| DA-80-IY83_0.1uM | Dose=0.1uM, Doxazosin, alpha1-Adrenoceptor Antagonists;Apoptosis Inducers targeting ADRA1D, ADRA1B, ADRA1A |
| DA-80-IY83_10uM | Dose=10uM, Doxazosin, alpha1-Adrenoceptor Antagonists;Apoptosis Inducers targeting ADRA1D, ADRA1B, ADRA1A |
| DA-80-IY83_1uM | Dose=1uM, Doxazosin, alpha1-Adrenoceptor Antagonists;Apoptosis Inducers targeting ADRA1D, ADRA1B, ADRA1A |
| DA-81-VY50_0.1uM | Dose=0.1uM, 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-(5-isopropoxy-pyridin-3-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG |
| DA-81-VY50_10uM | Dose=10uM, 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-(5-isopropoxy-pyridin-3-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG |
| DA-81-VY50_1uM | Dose=1uM, 1-(1,3-Dimethyl-1H-pyrazol-4-yl)-8-(5-isopropoxy-pyridin-3-yl)-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG |
| DA-83-IZ87_0.01uM | Dose=0.01uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| DA-83-IZ87_0.1uM | Dose=0.1uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| DA-83-IZ87_10uM | Dose=10uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| DA-83-IZ87_1uM | Dose=1uM, Chemokine CCR2 (MCP-1 Receptor) Antagonists;Chemokine CCR5 Antagonists targeting CCR5, CCR2 |
| DA-83-VJ09_0.01uM | Dose=0.01uM, 1,1'-Binaphthalene-2,2'-dicarboxylic acid, CDC-Like Kinase 4 (CLK4) Inhibitors targeting CLK4 |
| DA-83-VJ09_0.1uM | Dose=0.1uM, 1,1'-Binaphthalene-2,2'-dicarboxylic acid, CDC-Like Kinase 4 (CLK4) Inhibitors targeting CLK4 |
| DA-83-VJ09_10uM | Dose=10uM, 1,1'-Binaphthalene-2,2'-dicarboxylic acid, CDC-Like Kinase 4 (CLK4) Inhibitors targeting CLK4 |
| DA-83-VJ09_1uM | Dose=1uM, 1,1'-Binaphthalene-2,2'-dicarboxylic acid, CDC-Like Kinase 4 (CLK4) Inhibitors targeting CLK4 |
| DA-85-SU90_0.01uM | Dose=0.01uM, 4'-Chloro-3-hydroxy-2-naphthanilide, Cyclic AMP Response Element-Binding Protein (CREB) Inhibitors targeting CREB1 |
| DA-85-SU90_0.1uM | Dose=0.1uM, 4'-Chloro-3-hydroxy-2-naphthanilide, Cyclic AMP Response Element-Binding Protein (CREB) Inhibitors targeting CREB1 |
| DA-85-SU90_10uM | Dose=10uM, 4'-Chloro-3-hydroxy-2-naphthanilide, Cyclic AMP Response Element-Binding Protein (CREB) Inhibitors targeting CREB1 |
| DA-85-SU90_1uM | Dose=1uM, 4'-Chloro-3-hydroxy-2-naphthanilide, Cyclic AMP Response Element-Binding Protein (CREB) Inhibitors targeting CREB1 |
| DA-86-GO43_0.01uM | Dose=0.01uM, LY 393558, 5-HT2B Antagonists;5-HT Reuptake Inhibitors;5-HT1B Antagonists;5-HT2A Antagonists;5-HT1D Antagonists targeting HTR1B, HTR1D, HTR2A, HTR2B |
| DA-86-GO43_0.1uM | Dose=0.1uM, LY 393558, 5-HT2B Antagonists;5-HT Reuptake Inhibitors;5-HT1B Antagonists;5-HT2A Antagonists;5-HT1D Antagonists targeting HTR1B, HTR1D, HTR2A, HTR2B |
| DA-86-GO43_10uM | Dose=10uM, LY 393558, 5-HT2B Antagonists;5-HT Reuptake Inhibitors;5-HT1B Antagonists;5-HT2A Antagonists;5-HT1D Antagonists targeting HTR1B, HTR1D, HTR2A, HTR2B |
| DA-86-GO43_1uM | Dose=1uM, LY 393558, 5-HT2B Antagonists;5-HT Reuptake Inhibitors;5-HT1B Antagonists;5-HT2A Antagonists;5-HT1D Antagonists targeting HTR1B, HTR1D, HTR2A, HTR2B |
| DA-87-JB14_0.1uM | Dose=0.1uM, Protoporphyrinogen oxidase inhibitor |
| DA-87-JB14_10uM | Dose=10uM, Protoporphyrinogen oxidase inhibitor |
| DA-88-JF21_0.01uM | Dose=0.01uM, FG-9041 targeting GRIA4 |
| DA-88-JF21_0.1uM | Dose=0.1uM, FG-9041 targeting GRIA4 |
| DA-88-JF21_10uM | Dose=10uM, FG-9041 targeting GRIA4 |
| DA-88-JF21_1uM | Dose=1uM, FG-9041 targeting GRIA4 |
| DA-91-NR73_0.01uM | Dose=0.01uM, [4-(3-Chloro-phenyl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-carbamic acid 2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl ester |
| DA-91-NR73_0.1uM | Dose=0.1uM, [4-(3-Chloro-phenyl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-carbamic acid 2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl ester |
| DA-91-NR73_10uM | Dose=10uM, [4-(3-Chloro-phenyl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-carbamic acid 2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl ester |
| DA-91-NR73_1uM | Dose=1uM, [4-(3-Chloro-phenyl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-carbamic acid 2-[(2-hydroxy-ethyl)-methyl-amino]-ethyl ester |
| DA-91-RR73_0.01uM | Dose=0.01uM, Drugs Acting on 5-Hydroxytryptamine Receptors |
| DA-91-RR73_0.1uM | Dose=0.1uM, Drugs Acting on 5-Hydroxytryptamine Receptors |
| DA-91-RR73_10uM | Dose=10uM, Drugs Acting on 5-Hydroxytryptamine Receptors |
| DA-91-RR73_1uM | Dose=1uM, Drugs Acting on 5-Hydroxytryptamine Receptors |
| DA-97-MT18_10uM | Dose=10uM |
| DB-00-QN66_0.01uM | Dose=0.01uM |
| DB-00-QN66_0.1uM | Dose=0.1uM |
| DB-00-QN66_10uM | Dose=10uM |
| DB-00-QN66_1uM | Dose=1uM |
| DB-01-BR68_0.01uM | Dose=0.01uM, Guaifenesin |
| DB-01-BR68_0.1uM | Dose=0.1uM, Guaifenesin |
| DB-01-BR68_10uM | Dose=10uM, Guaifenesin |
| DB-01-BR68_1uM | Dose=1uM, Guaifenesin |
| DB-05-UK61_0.01uM | Dose=0.01uM, Ibutamoren, Growth Hormone Secretagogues targeting GH1 |
| DB-05-UK61_10uM | Dose=10uM, Ibutamoren, Growth Hormone Secretagogues targeting GH1 |
| DB-05-UK61_1uM | Dose=1uM, Ibutamoren, Growth Hormone Secretagogues targeting GH1 |
| DB-06-HE04_0.1uM | Dose=0.1uM, Methyl 3-[[1-[2-(4-fluoroanilino)pyrimidin-4-yl]pyrrolidin-3-yl]carbamoylamino]benzoate, BPTF gene inhibitor targeting BPTF |
| DB-06-HE04_10uM | Dose=10uM, Methyl 3-[[1-[2-(4-fluoroanilino)pyrimidin-4-yl]pyrrolidin-3-yl]carbamoylamino]benzoate, BPTF gene inhibitor targeting BPTF |
| DB-06-HE04_1uM | Dose=1uM, Methyl 3-[[1-[2-(4-fluoroanilino)pyrimidin-4-yl]pyrrolidin-3-yl]carbamoylamino]benzoate, BPTF gene inhibitor targeting BPTF |
| DB-07-WB29_0.01uM | Dose=0.01uM, Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]-, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK |
| DB-07-WB29_0.1uM | Dose=0.1uM, Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]-, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK |
| DB-07-WB29_10uM | Dose=10uM, Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]-, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK |
| DB-07-WB29_1uM | Dose=1uM, Benzamide, N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]-, Angiogenesis Inhibitors;VEGFR Inhibitors targeting MUSK |
| DB-11-SS01_0.01uM | Dose=0.01uM, Thal-sns-032 targeting CDK9 |
| DB-11-SS01_0.1uM | Dose=0.1uM, Thal-sns-032 targeting CDK9 |
| DB-11-SS01_10uM | Dose=10uM, Thal-sns-032 targeting CDK9 |
| DB-18-IF31_0.01uM | Dose=0.01uM, (4bS,7R,8aR)-4b-benzyl-7-hydroxy-7-(prop-1-ynyl)-N-(pyridin-4-ylmethyl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carboxamide, Glucocorticoid Receptor (GR) Modulators targeting NR3C1 |
| DB-18-IF31_0.1uM | Dose=0.1uM, (4bS,7R,8aR)-4b-benzyl-7-hydroxy-7-(prop-1-ynyl)-N-(pyridin-4-ylmethyl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carboxamide, Glucocorticoid Receptor (GR) Modulators targeting NR3C1 |
| DB-18-IF31_10uM | Dose=10uM, (4bS,7R,8aR)-4b-benzyl-7-hydroxy-7-(prop-1-ynyl)-N-(pyridin-4-ylmethyl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carboxamide, Glucocorticoid Receptor (GR) Modulators targeting NR3C1 |
| DB-18-IF31_1uM | Dose=1uM, (4bS,7R,8aR)-4b-benzyl-7-hydroxy-7-(prop-1-ynyl)-N-(pyridin-4-ylmethyl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carboxamide, Glucocorticoid Receptor (GR) Modulators targeting NR3C1 |
| DB-18-UF01_0.01uM | Dose=0.01uM, N-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide, TRPV4 gene stimulator targeting TRPV4 |
| DB-18-UF01_0.1uM | Dose=0.1uM, N-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide, TRPV4 gene stimulator targeting TRPV4 |
| DB-18-UF01_10uM | Dose=10uM, N-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide, TRPV4 gene stimulator targeting TRPV4 |
| DB-18-UF01_1uM | Dose=1uM, N-[(2S)-1-[4-[(2S)-2-[(2,4-dichlorophenyl)sulfonylamino]-3-hydroxypropanoyl]piperazin-1-yl]-4-methyl-1-oxopentan-2-yl]-1-benzothiophene-2-carboxamide, TRPV4 gene stimulator targeting TRPV4 |
| DB-20-QK39_0.01uM | Dose=0.01uM, (2S,4S)-1-[4-(aminomethyl)-3-methoxybenzoyl]-4-(4-cyclopropyltriazol-1-yl)-N-(2,2-diphenylethyl)pyrrolidine-2-carboxamide, Trypsin Inhibitor targeting PRSS1 |
| DB-20-QK39_0.1uM | Dose=0.1uM, (2S,4S)-1-[4-(aminomethyl)-3-methoxybenzoyl]-4-(4-cyclopropyltriazol-1-yl)-N-(2,2-diphenylethyl)pyrrolidine-2-carboxamide, Trypsin Inhibitor targeting PRSS1 |
| DB-20-QK39_10uM | Dose=10uM, (2S,4S)-1-[4-(aminomethyl)-3-methoxybenzoyl]-4-(4-cyclopropyltriazol-1-yl)-N-(2,2-diphenylethyl)pyrrolidine-2-carboxamide, Trypsin Inhibitor targeting PRSS1 |
| DB-20-QK39_1uM | Dose=1uM, (2S,4S)-1-[4-(aminomethyl)-3-methoxybenzoyl]-4-(4-cyclopropyltriazol-1-yl)-N-(2,2-diphenylethyl)pyrrolidine-2-carboxamide, Trypsin Inhibitor targeting PRSS1 |
| DB-21-FY25_0.01uM | Dose=0.01uM, Avagacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| DB-21-FY25_0.1uM | Dose=0.1uM, Avagacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| DB-21-FY25_10uM | Dose=10uM, Avagacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| DB-21-FY25_1uM | Dose=1uM, Avagacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| DB-21-FY75_0.01uM | Dose=0.01uM, CID 67042933, CDK9 inhibitor targeting CDK9 |
| DB-21-FY75_0.1uM | Dose=0.1uM, CID 67042933, CDK9 inhibitor targeting CDK9 |
| DB-21-FY75_10uM | Dose=10uM, CID 67042933, CDK9 inhibitor targeting CDK9 |
| DB-21-FY75_1uM | Dose=1uM, CID 67042933, CDK9 inhibitor targeting CDK9 |
| DB-24-CQ08_0.01uM | Dose=0.01uM, [1-(Pyridin-3-ylmethyl)indol-3-yl]methanol |
| DB-24-CQ08_0.1uM | Dose=0.1uM, [1-(Pyridin-3-ylmethyl)indol-3-yl]methanol |
| DB-24-CQ08_10uM | Dose=10uM, [1-(Pyridin-3-ylmethyl)indol-3-yl]methanol |
| DB-24-CQ08_1uM | Dose=1uM, [1-(Pyridin-3-ylmethyl)indol-3-yl]methanol |
| DB-28-SP20_0.1uM | Dose=0.1uM, (2Z)-6-hydroxy-2-(2,4,5-trimethoxybenzylidene)-1-benzofuran-3(2H)-one, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B4 |
| DB-28-SP20_10uM | Dose=10uM, (2Z)-6-hydroxy-2-(2,4,5-trimethoxybenzylidene)-1-benzofuran-3(2H)-one, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B4 |
| DB-28-SP20_1uM | Dose=1uM, (2Z)-6-hydroxy-2-(2,4,5-trimethoxybenzylidene)-1-benzofuran-3(2H)-one, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B4 |
| DB-28-ZJ81_0.01uM | Dose=0.01uM, Tanomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP3, MMP9 |
| DB-28-ZJ81_0.1uM | Dose=0.1uM, Tanomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP3, MMP9 |
| DB-28-ZJ81_10uM | Dose=10uM, Tanomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP3, MMP9 |
| DB-28-ZJ81_1uM | Dose=1uM, Tanomastat, Angiogenesis Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP2, MMP3, MMP9 |
| DB-29-HQ45_0.01uM | Dose=0.01uM |
| DB-29-HQ45_0.1uM | Dose=0.1uM |
| DB-29-HQ45_10uM | Dose=10uM |
| DB-29-HQ45_1uM | Dose=1uM |
| DB-32-FS68_0.01uM | Dose=0.01uM, Becampanel, AMPA Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| DB-32-FS68_0.1uM | Dose=0.1uM, Becampanel, AMPA Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| DB-32-FS68_10uM | Dose=10uM, Becampanel, AMPA Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| DB-32-FS68_1uM | Dose=1uM, Becampanel, AMPA Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| DB-33-HZ87_0.01uM | Dose=0.01uM, Vgx-1027, Cytokine Modulators targeting TLR4 |
| DB-33-HZ87_10uM | Dose=10uM, Vgx-1027, Cytokine Modulators targeting TLR4 |
| DB-33-HZ87_1uM | Dose=1uM, Vgx-1027, Cytokine Modulators targeting TLR4 |
| DB-33-TM61_0.01uM | Dose=0.01uM, Profenamine, NMDA Antagonists;Butyrylcholinesterase Inhibitors targeting BCHE |
| DB-33-TM61_10uM | Dose=10uM, Profenamine, NMDA Antagonists;Butyrylcholinesterase Inhibitors targeting BCHE |
| DB-33-TM61_1uM | Dose=1uM, Profenamine, NMDA Antagonists;Butyrylcholinesterase Inhibitors targeting BCHE |
| DB-34-KT45_0.01uM | Dose=0.01uM, [4,7']Biisoquinolinyl-1-yl-(2-tert-butyl-pyrimidin-5-yl)-amine, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF |
| DB-34-KT45_0.1uM | Dose=0.1uM, [4,7']Biisoquinolinyl-1-yl-(2-tert-butyl-pyrimidin-5-yl)-amine, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF |
| DB-34-KT45_10uM | Dose=10uM, [4,7']Biisoquinolinyl-1-yl-(2-tert-butyl-pyrimidin-5-yl)-amine, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF |
| DB-34-KT45_1uM | Dose=1uM, [4,7']Biisoquinolinyl-1-yl-(2-tert-butyl-pyrimidin-5-yl)-amine, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF |
| DB-34-QA60_0.01uM | Dose=0.01uM, Reversine, Differentiation Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs;Adenosine A3 Antagonists targeting ADORA3, AURKA, AURKB |
| DB-34-QA60_0.1uM | Dose=0.1uM, Reversine, Differentiation Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs;Adenosine A3 Antagonists targeting ADORA3, AURKA, AURKB |
| DB-34-QA60_10uM | Dose=10uM, Reversine, Differentiation Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs;Adenosine A3 Antagonists targeting ADORA3, AURKA, AURKB |
| DB-34-QA60_1uM | Dose=1uM, Reversine, Differentiation Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Antimitotic Drugs;Adenosine A3 Antagonists targeting ADORA3, AURKA, AURKB |
| DB-36-TR95_0.01uM | Dose=0.01uM, Ramatroban, PTGDR antagonist;Prostanoid TP Antagonists;CCL2 Expression Inhibitors;CRTH2 Receptor Antagonists;GPR44 antagonist targeting PTGDR, CCL2, TBXA2R, PTGDR2 |
| DB-36-TR95_0.1uM | Dose=0.1uM, Ramatroban, PTGDR antagonist;Prostanoid TP Antagonists;CCL2 Expression Inhibitors;CRTH2 Receptor Antagonists;GPR44 antagonist targeting PTGDR, CCL2, TBXA2R, PTGDR2 |
| DB-36-TR95_10uM | Dose=10uM, Ramatroban, PTGDR antagonist;Prostanoid TP Antagonists;CCL2 Expression Inhibitors;CRTH2 Receptor Antagonists;GPR44 antagonist targeting PTGDR, CCL2, TBXA2R, PTGDR2 |
| DB-40-GN91_0.01uM | Dose=0.01uM, (2S,4R)-1-((R)-3-Cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(pyrazin-2-yl)pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DB-40-GN91_0.1uM | Dose=0.1uM, (2S,4R)-1-((R)-3-Cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(pyrazin-2-yl)pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DB-40-GN91_10uM | Dose=10uM, (2S,4R)-1-((R)-3-Cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(pyrazin-2-yl)pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DB-40-GN91_1uM | Dose=1uM, (2S,4R)-1-((R)-3-Cyclopentyl-2-((N-hydroxyformamido)methyl)propanoyl)-4-fluoro-N-(pyrazin-2-yl)pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DB-40-HA40_0.01uM | Dose=0.01uM, 6-(1-benzothiophen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| DB-40-HA40_0.1uM | Dose=0.1uM, 6-(1-benzothiophen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| DB-40-HA40_10uM | Dose=10uM, 6-(1-benzothiophen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| DB-40-HA40_1uM | Dose=1uM, 6-(1-benzothiophen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine, Splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| DB-41-IH69_0.01uM | Dose=0.01uM |
| DB-41-IH69_0.1uM | Dose=0.1uM |
| DB-41-IH69_10uM | Dose=10uM |
| DB-41-IH69_1uM | Dose=1uM |
| DB-41-OE47_0.01uM | Dose=0.01uM |
| DB-41-OE47_10uM | Dose=10uM |
| DB-41-OE47_1uM | Dose=1uM |
| DB-41-SH04_0.01uM | Dose=0.01uM, (R)-3-(cyclopentylmethyl)-4-(cyclopropyl(4-(2-(6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)phenyl)thiazol-2-yl)amino)-4-oxobutanoic acid, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Ligands;FFAR2 agonist targeting FFAR2, FFAR3 |
| DB-41-SH04_0.1uM | Dose=0.1uM, (R)-3-(cyclopentylmethyl)-4-(cyclopropyl(4-(2-(6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)phenyl)thiazol-2-yl)amino)-4-oxobutanoic acid, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Ligands;FFAR2 agonist targeting FFAR2, FFAR3 |
| DB-41-SH04_10uM | Dose=10uM, (R)-3-(cyclopentylmethyl)-4-(cyclopropyl(4-(2-(6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)phenyl)thiazol-2-yl)amino)-4-oxobutanoic acid, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Ligands;FFAR2 agonist targeting FFAR2, FFAR3 |
| DB-41-SH04_1uM | Dose=1uM, (R)-3-(cyclopentylmethyl)-4-(cyclopropyl(4-(2-(6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)phenyl)thiazol-2-yl)amino)-4-oxobutanoic acid, Free Fatty Acid Receptor 2 (FFAR2| GPR43) Ligands;FFAR2 agonist targeting FFAR2, FFAR3 |
| DB-42-FS68_0.01uM | Dose=0.01uM, Valspodar |
| DB-42-FS68_0.1uM | Dose=0.1uM, Valspodar |
| DB-42-FS68_10uM | Dose=10uM, Valspodar |
| DB-42-FS68_1uM | Dose=1uM, Valspodar |
| DB-42-PI54_0.01uM | Dose=0.01uM |
| DB-42-PI54_0.1uM | Dose=0.1uM |
| DB-42-PI54_10uM | Dose=10uM |
| DB-42-PI54_1uM | Dose=1uM |
| DB-45-EH09_0.1uM | Dose=0.1uM, [[5-Cyano-2-prop-2-ynylsulfanyl-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]amino]thiourea, LSD1 inhibitor targeting KDM1A |
| DB-45-EH09_10uM | Dose=10uM, [[5-Cyano-2-prop-2-ynylsulfanyl-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]amino]thiourea, LSD1 inhibitor targeting KDM1A |
| DB-45-EH09_1uM | Dose=1uM, [[5-Cyano-2-prop-2-ynylsulfanyl-6-(3,4,5-trimethoxyphenyl)pyrimidin-4-yl]amino]thiourea, LSD1 inhibitor targeting KDM1A |
| DB-47-EV77_0.01uM | Dose=0.01uM, Rofecoxib targeting SC5D |
| DB-47-EV77_0.1uM | Dose=0.1uM, Rofecoxib targeting SC5D |
| DB-47-EV77_10uM | Dose=10uM, Rofecoxib targeting SC5D |
| DB-47-QB24_1uM | Dose=1uM, Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Ligands |
| DB-51-UO66_0.01uM | Dose=0.01uM, Pioglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARG, ADIPOR2 |
| DB-51-UO66_0.1uM | Dose=0.1uM, Pioglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARG, ADIPOR2 |
| DB-51-UO66_10uM | Dose=10uM, Pioglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARG, ADIPOR2 |
| DB-51-UO66_1uM | Dose=1uM, Pioglitazone, PPARgamma Agonists;Insulin Sensitizers targeting PPARG, ADIPOR2 |
| DB-54-GQ68_0.01uM | Dose=0.01uM, Itk antagonist, IL-4 Production Inhibitors;ITK (EMT) Kinase Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, ITK |
| DB-54-GQ68_0.1uM | Dose=0.1uM, Itk antagonist, IL-4 Production Inhibitors;ITK (EMT) Kinase Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, ITK |
| DB-54-GQ68_10uM | Dose=10uM, Itk antagonist, IL-4 Production Inhibitors;ITK (EMT) Kinase Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, ITK |
| DB-54-GQ68_1uM | Dose=1uM, Itk antagonist, IL-4 Production Inhibitors;ITK (EMT) Kinase Inhibitors;IL-2 Production Inhibitors targeting IL2, IL4, ITK |
| DB-54-ZQ73_0.01uM | Dose=0.01uM |
| DB-54-ZQ73_0.1uM | Dose=0.1uM |
| DB-54-ZQ73_10uM | Dose=10uM |
| DB-54-ZQ73_1uM | Dose=1uM |
| DB-55-UX87_0.01uM | Dose=0.01uM, 8-(4-Fluoro-phenylethynyl)-4-(3-imidazol-1-yl-phenyl)-1,3-dihydro-benzo[b][1,4]diazepin-2-one, mgluR2 Antagonists targeting GRM2 |
| DB-55-UX87_0.1uM | Dose=0.1uM, 8-(4-Fluoro-phenylethynyl)-4-(3-imidazol-1-yl-phenyl)-1,3-dihydro-benzo[b][1,4]diazepin-2-one, mgluR2 Antagonists targeting GRM2 |
| DB-55-UX87_10uM | Dose=10uM, 8-(4-Fluoro-phenylethynyl)-4-(3-imidazol-1-yl-phenyl)-1,3-dihydro-benzo[b][1,4]diazepin-2-one, mgluR2 Antagonists targeting GRM2 |
| DB-55-UX87_1uM | Dose=1uM, 8-(4-Fluoro-phenylethynyl)-4-(3-imidazol-1-yl-phenyl)-1,3-dihydro-benzo[b][1,4]diazepin-2-one, mgluR2 Antagonists targeting GRM2 |
| DB-56-XL71_0.01uM | Dose=0.01uM, Vinorelbine, Tubulin polymerization inhibitors;Antimitotic Drugs targeting TUBB |
| DB-56-XL71_0.1uM | Dose=0.1uM, Vinorelbine, Tubulin polymerization inhibitors;Antimitotic Drugs targeting TUBB |
| DB-56-XL71_10uM | Dose=10uM, Vinorelbine, Tubulin polymerization inhibitors;Antimitotic Drugs targeting TUBB |
| DB-56-XL71_1uM | Dose=1uM, Vinorelbine, Tubulin polymerization inhibitors;Antimitotic Drugs targeting TUBB |
| DB-58-ZC04_0.01uM | Dose=0.01uM, 6-Cyano-N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-1-(1-ethylpropyl)-1H-indole-4-carboxamide, PRC2/EZH2 targeting EZH2 |
| DB-58-ZC04_0.1uM | Dose=0.1uM, 6-Cyano-N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-1-(1-ethylpropyl)-1H-indole-4-carboxamide, PRC2/EZH2 targeting EZH2 |
| DB-58-ZC04_10uM | Dose=10uM, 6-Cyano-N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-1-(1-ethylpropyl)-1H-indole-4-carboxamide, PRC2/EZH2 targeting EZH2 |
| DB-58-ZC04_1uM | Dose=1uM, 6-Cyano-N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-1-(1-ethylpropyl)-1H-indole-4-carboxamide, PRC2/EZH2 targeting EZH2 |
| DB-62-ES23_0.01uM | Dose=0.01uM, 2-amino-5-oxo-7-phenyl-4-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile |
| DB-62-ES23_0.1uM | Dose=0.1uM, 2-amino-5-oxo-7-phenyl-4-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile |
| DB-62-ES23_10uM | Dose=10uM, 2-amino-5-oxo-7-phenyl-4-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile |
| DB-62-ES23_1uM | Dose=1uM, 2-amino-5-oxo-7-phenyl-4-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile |
| DB-63-TM61_0.01uM | Dose=0.01uM, Zatebradine, HCN [I(f)] Blockers targeting HCN2, HCN4, HCN3, HCN1 |
| DB-63-TM61_0.1uM | Dose=0.1uM, Zatebradine, HCN [I(f)] Blockers targeting HCN2, HCN4, HCN3, HCN1 |
| DB-63-TM61_10uM | Dose=10uM, Zatebradine, HCN [I(f)] Blockers targeting HCN2, HCN4, HCN3, HCN1 |
| DB-63-TM61_1uM | Dose=1uM, Zatebradine, HCN [I(f)] Blockers targeting HCN2, HCN4, HCN3, HCN1 |
| DB-67-IP73_0.01uM | Dose=0.01uM, Zileuton, 5-Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;5-Lipoxygenase inhibitor targeting ALOX5 |
| DB-67-IP73_0.1uM | Dose=0.1uM, Zileuton, 5-Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;5-Lipoxygenase inhibitor targeting ALOX5 |
| DB-67-IP73_10uM | Dose=10uM, Zileuton, 5-Lipoxygenase Inhibitors;Leukotriene Synthesis Inhibitors;5-Lipoxygenase inhibitor targeting ALOX5 |
| DB-68-AC34_0.01uM | Dose=0.01uM, (3R)-N-[2-(4-cyanophenyl)ethyl]-1-[6-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl]piperidine-3-carboxamide, GPBAR1 agonist targeting GPBAR1 |
| DB-68-AC34_0.1uM | Dose=0.1uM, (3R)-N-[2-(4-cyanophenyl)ethyl]-1-[6-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl]piperidine-3-carboxamide, GPBAR1 agonist targeting GPBAR1 |
| DB-68-AC34_1uM | Dose=1uM, (3R)-N-[2-(4-cyanophenyl)ethyl]-1-[6-(4-methylpiperazin-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl]piperidine-3-carboxamide, GPBAR1 agonist targeting GPBAR1 |
| DB-69-JG66_0.01uM | Dose=0.01uM, N-[3-(diethylamino)propyl]-2-(12-methyl-9-oxidanylidene-5-thia-1,10,11-triazatricyclo[6.4.0.0^2,6]dodeca-2(6),3,7,11-tetraen-10-yl)ethanamide |
| DB-69-JG66_0.1uM | Dose=0.1uM, N-[3-(diethylamino)propyl]-2-(12-methyl-9-oxidanylidene-5-thia-1,10,11-triazatricyclo[6.4.0.0^2,6]dodeca-2(6),3,7,11-tetraen-10-yl)ethanamide |
| DB-69-JG66_10uM | Dose=10uM, N-[3-(diethylamino)propyl]-2-(12-methyl-9-oxidanylidene-5-thia-1,10,11-triazatricyclo[6.4.0.0^2,6]dodeca-2(6),3,7,11-tetraen-10-yl)ethanamide |
| DB-69-JG66_1uM | Dose=1uM, N-[3-(diethylamino)propyl]-2-(12-methyl-9-oxidanylidene-5-thia-1,10,11-triazatricyclo[6.4.0.0^2,6]dodeca-2(6),3,7,11-tetraen-10-yl)ethanamide |
| DB-73-BC12_0.01uM | Dose=0.01uM, 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole, GPR4 antagonist targeting GPR4 |
| DB-73-BC12_0.1uM | Dose=0.1uM, 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole, GPR4 antagonist targeting GPR4 |
| DB-73-BC12_10uM | Dose=10uM, 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole, GPR4 antagonist targeting GPR4 |
| DB-73-BC12_1uM | Dose=1uM, 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole, GPR4 antagonist targeting GPR4 |
| DB-73-KP48_0.01uM | Dose=0.01uM, N-[[(3S,4S)-4-[[[2-(1-acetylpiperidin-4-yl)acetyl]-cyclopropylamino]methyl]pyrrolidin-3-yl]methyl]-4-ethyl-3-(3-methoxypropoxy)-N-propan-2-ylbenzamide, renin (REN) inhibitor targeting REN |
| DB-73-KP48_0.1uM | Dose=0.1uM, N-[[(3S,4S)-4-[[[2-(1-acetylpiperidin-4-yl)acetyl]-cyclopropylamino]methyl]pyrrolidin-3-yl]methyl]-4-ethyl-3-(3-methoxypropoxy)-N-propan-2-ylbenzamide, renin (REN) inhibitor targeting REN |
| DB-73-KP48_10uM | Dose=10uM, N-[[(3S,4S)-4-[[[2-(1-acetylpiperidin-4-yl)acetyl]-cyclopropylamino]methyl]pyrrolidin-3-yl]methyl]-4-ethyl-3-(3-methoxypropoxy)-N-propan-2-ylbenzamide, renin (REN) inhibitor targeting REN |
| DB-73-KP48_1uM | Dose=1uM, N-[[(3S,4S)-4-[[[2-(1-acetylpiperidin-4-yl)acetyl]-cyclopropylamino]methyl]pyrrolidin-3-yl]methyl]-4-ethyl-3-(3-methoxypropoxy)-N-propan-2-ylbenzamide, renin (REN) inhibitor targeting REN |
| DB-74-HJ91_0.01uM | Dose=0.01uM, Dazoxiben, Thromboxane Synthase Inhibitors targeting TBXAS1 |
| DB-74-HJ91_0.1uM | Dose=0.1uM, Dazoxiben, Thromboxane Synthase Inhibitors targeting TBXAS1 |
| DB-74-HJ91_10uM | Dose=10uM, Dazoxiben, Thromboxane Synthase Inhibitors targeting TBXAS1 |
| DB-77-AV67_0.01uM | Dose=0.01uM, 2-(4-Phenylpiperidin-1-yl)cyclohexyl benzoate |
| DB-77-AV67_0.1uM | Dose=0.1uM, 2-(4-Phenylpiperidin-1-yl)cyclohexyl benzoate |
| DB-77-AV67_10uM | Dose=10uM, 2-(4-Phenylpiperidin-1-yl)cyclohexyl benzoate |
| DB-77-AV67_1uM | Dose=1uM, 2-(4-Phenylpiperidin-1-yl)cyclohexyl benzoate |
| DB-78-NM13_0.01uM | Dose=0.01uM, Telenzepine, CHRM1 antagonist targeting CHRM1 |
| DB-78-NM13_0.1uM | Dose=0.1uM, Telenzepine, CHRM1 antagonist targeting CHRM1 |
| DB-78-NM13_10uM | Dose=10uM, Telenzepine, CHRM1 antagonist targeting CHRM1 |
| DB-78-NM13_1uM | Dose=1uM, Telenzepine, CHRM1 antagonist targeting CHRM1 |
| DB-80-CD47_0.01uM | Dose=0.01uM, Methylene blue cation, Tau Aggregation Inhibitors;Nitric Oxide Production Inhibitors targeting MAPT |
| DB-80-CD47_0.1uM | Dose=0.1uM, Methylene blue cation, Tau Aggregation Inhibitors;Nitric Oxide Production Inhibitors targeting MAPT |
| DB-80-CD47_10uM | Dose=10uM, Methylene blue cation, Tau Aggregation Inhibitors;Nitric Oxide Production Inhibitors targeting MAPT |
| DB-80-CD47_1uM | Dose=1uM, Methylene blue cation, Tau Aggregation Inhibitors;Nitric Oxide Production Inhibitors targeting MAPT |
| DB-80-QN16_0.01uM | Dose=0.01uM, Valpromide |
| DB-80-QN16_0.1uM | Dose=0.1uM, Valpromide |
| DB-80-QN16_10uM | Dose=10uM, Valpromide |
| DB-80-QN16_1uM | Dose=1uM, Valpromide |
| DB-82-PI34_0.01uM | Dose=0.01uM, 2-Aminonaphthiazole, Small Conductance SK(Ca) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1| Gardos channel, SK41, IK1) Channel Activators targeting KCNN4 |
| DB-82-PI34_0.1uM | Dose=0.1uM, 2-Aminonaphthiazole, Small Conductance SK(Ca) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1| Gardos channel, SK41, IK1) Channel Activators targeting KCNN4 |
| DB-82-PI34_10uM | Dose=10uM, 2-Aminonaphthiazole, Small Conductance SK(Ca) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1| Gardos channel, SK41, IK1) Channel Activators targeting KCNN4 |
| DB-82-PI34_1uM | Dose=1uM, 2-Aminonaphthiazole, Small Conductance SK(Ca) Channel Activators;Intermediate Conductance K(Ca) 3.1 (IKCa1| Gardos channel, SK41, IK1) Channel Activators targeting KCNN4 |
| DB-83-LM41_0.01uM | Dose=0.01uM, N-(5-cyclopropyl-1,2-oxazol-3-yl)-5-(6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| DB-83-LM41_0.1uM | Dose=0.1uM, N-(5-cyclopropyl-1,2-oxazol-3-yl)-5-(6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| DB-83-LM41_10uM | Dose=10uM, N-(5-cyclopropyl-1,2-oxazol-3-yl)-5-(6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| DB-83-LM41_1uM | Dose=1uM, N-(5-cyclopropyl-1,2-oxazol-3-yl)-5-(6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yloxy)indole-1-carboxamide, VEGFR-2 (FLK-1/KDR) Inhibitors targeting KDR |
| DB-84-EQ63_0.01uM | Dose=0.01uM, Oleoyl Ethanolamide, K(V)4.3 Channel Blockers;Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Agonists targeting KCND3, GPR55, GPR119 |
| DB-84-EQ63_0.1uM | Dose=0.1uM, Oleoyl Ethanolamide, K(V)4.3 Channel Blockers;Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Agonists targeting KCND3, GPR55, GPR119 |
| DB-84-EQ63_10uM | Dose=10uM, Oleoyl Ethanolamide, K(V)4.3 Channel Blockers;Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Agonists targeting KCND3, GPR55, GPR119 |
| DB-84-EQ63_1uM | Dose=1uM, Oleoyl Ethanolamide, K(V)4.3 Channel Blockers;Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Agonists targeting KCND3, GPR55, GPR119 |
| DB-86-XL71_0.01uM | Dose=0.01uM, Tryptanthrine, Cyclooxygenase-2 Inhibitors;5-Lipoxygenase Inhibitors;Hepatocyte Growth Factor (HGF) Antagonists targeting ALOX5, HGF, PTGS2 |
| DB-86-XL71_0.1uM | Dose=0.1uM, Tryptanthrine, Cyclooxygenase-2 Inhibitors;5-Lipoxygenase Inhibitors;Hepatocyte Growth Factor (HGF) Antagonists targeting ALOX5, HGF, PTGS2 |
| DB-86-XL71_10uM | Dose=10uM, Tryptanthrine, Cyclooxygenase-2 Inhibitors;5-Lipoxygenase Inhibitors;Hepatocyte Growth Factor (HGF) Antagonists targeting ALOX5, HGF, PTGS2 |
| DB-86-XL71_1uM | Dose=1uM, Tryptanthrine, Cyclooxygenase-2 Inhibitors;5-Lipoxygenase Inhibitors;Hepatocyte Growth Factor (HGF) Antagonists targeting ALOX5, HGF, PTGS2 |
| DB-87-WL13_0.01uM | Dose=0.01uM, (S)-6-Amino-2-[(R)-2-[(1-benzenesulfonyl-piperidine-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester, Somatostatin SRIF1A (sst2) Antagonists targeting SSTR2 |
| DB-87-WL13_0.1uM | Dose=0.1uM, (S)-6-Amino-2-[(R)-2-[(1-benzenesulfonyl-piperidine-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester, Somatostatin SRIF1A (sst2) Antagonists targeting SSTR2 |
| DB-87-WL13_10uM | Dose=10uM, (S)-6-Amino-2-[(R)-2-[(1-benzenesulfonyl-piperidine-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester, Somatostatin SRIF1A (sst2) Antagonists targeting SSTR2 |
| DB-87-WL13_1uM | Dose=1uM, (S)-6-Amino-2-[(R)-2-[(1-benzenesulfonyl-piperidine-4-carbonyl)-amino]-3-(1H-indol-3-yl)-propionylamino]-hexanoic acid tert-butyl ester, Somatostatin SRIF1A (sst2) Antagonists targeting SSTR2 |
| DB-88-VW47_0.01uM | Dose=0.01uM, 2-[(E)-{2-[(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene}methyl]-6-(prop-2-en-1-yl)phenolate, Apoptosis Inducers;Procaspase 3 Activators targeting CASP3 |
| DB-88-VW47_0.1uM | Dose=0.1uM, 2-[(E)-{2-[(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene}methyl]-6-(prop-2-en-1-yl)phenolate, Apoptosis Inducers;Procaspase 3 Activators targeting CASP3 |
| DB-88-VW47_10uM | Dose=10uM, 2-[(E)-{2-[(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene}methyl]-6-(prop-2-en-1-yl)phenolate, Apoptosis Inducers;Procaspase 3 Activators targeting CASP3 |
| DB-88-VW47_1uM | Dose=1uM, 2-[(E)-{2-[(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene}methyl]-6-(prop-2-en-1-yl)phenolate, Apoptosis Inducers;Procaspase 3 Activators targeting CASP3 |
| DB-89-DT62_1uM | Dose=1uM |
| DB-89-PT22_0.01uM | Dose=0.01uM, 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione, Muscarinic Agonists targeting CHRM1 |
| DB-89-PT22_0.1uM | Dose=0.1uM, 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione, Muscarinic Agonists targeting CHRM1 |
| DB-89-PT22_10uM | Dose=10uM, 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione, Muscarinic Agonists targeting CHRM1 |
| DB-89-PT22_1uM | Dose=1uM, 2-Ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione, Muscarinic Agonists targeting CHRM1 |
| DB-92-FB02_0.01uM | Dose=0.01uM, 6-[[4-(2,4-Dimethoxyphenyl)piperazin-1-yl]methyl]-7-(2,2-dimethylpropyl)pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors targeting CTSK |
| DB-92-FB02_10uM | Dose=10uM, 6-[[4-(2,4-Dimethoxyphenyl)piperazin-1-yl]methyl]-7-(2,2-dimethylpropyl)pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors targeting CTSK |
| DB-92-FB02_1uM | Dose=1uM, 6-[[4-(2,4-Dimethoxyphenyl)piperazin-1-yl]methyl]-7-(2,2-dimethylpropyl)pyrrolo[2,3-d]pyrimidine-2-carbonitrile, Cathepsin K Inhibitors targeting CTSK |
| DB-93-SW55_0.01uM | Dose=0.01uM, N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide, porcupine inhibitor targeting PORCN |
| DB-93-SW55_0.1uM | Dose=0.1uM, N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide, porcupine inhibitor targeting PORCN |
| DB-93-SW55_10uM | Dose=10uM, N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide, porcupine inhibitor targeting PORCN |
| DB-93-SW55_1uM | Dose=1uM, N-(6-Methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide, porcupine inhibitor targeting PORCN |
| DB-98-LQ88_0.01uM | Dose=0.01uM, Vemurafenib, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF |
| DB-98-LQ88_0.1uM | Dose=0.1uM, Vemurafenib, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF |
| DB-98-LQ88_10uM | Dose=10uM, Vemurafenib, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF |
| DB-98-LQ88_1uM | Dose=1uM, Vemurafenib, Raf kinase B Inhibitors;Inhibitors of Signal Transduction Pathways targeting BRAF |
| DC-01-WE57_0.01uM | Dose=0.01uM |
| DC-01-WE57_0.1uM | Dose=0.1uM |
| DC-01-WE57_10uM | Dose=10uM |
| DC-01-WE57_1uM | Dose=1uM |
| DC-02-OP01_0.01uM | Dose=0.01uM, Docebenone, Lipoxygenase Inhibitors targeting ALOX5 |
| DC-02-OP01_0.1uM | Dose=0.1uM, Docebenone, Lipoxygenase Inhibitors targeting ALOX5 |
| DC-02-OP01_10uM | Dose=10uM, Docebenone, Lipoxygenase Inhibitors targeting ALOX5 |
| DC-02-OP01_1uM | Dose=1uM, Docebenone, Lipoxygenase Inhibitors targeting ALOX5 |
| DC-04-FQ48_0.01uM | Dose=0.01uM, (S)-4-(3-(1-(5,7-Difluoroquinolin-6-yl)ethyl)imidazo[1,2-b]pyridazin-6-yl)piperazin-2-one, c-Met) Inhibitors;HGFR (MET targeting MET |
| DC-04-FQ48_0.1uM | Dose=0.1uM, (S)-4-(3-(1-(5,7-Difluoroquinolin-6-yl)ethyl)imidazo[1,2-b]pyridazin-6-yl)piperazin-2-one, c-Met) Inhibitors;HGFR (MET targeting MET |
| DC-04-FQ48_10uM | Dose=10uM, (S)-4-(3-(1-(5,7-Difluoroquinolin-6-yl)ethyl)imidazo[1,2-b]pyridazin-6-yl)piperazin-2-one, c-Met) Inhibitors;HGFR (MET targeting MET |
| DC-04-FQ48_1uM | Dose=1uM, (S)-4-(3-(1-(5,7-Difluoroquinolin-6-yl)ethyl)imidazo[1,2-b]pyridazin-6-yl)piperazin-2-one, c-Met) Inhibitors;HGFR (MET targeting MET |
| DC-05-LU10_0.01uM | Dose=0.01uM, (S)-3-{[1-(2-Fluoro-Phenyl)-5-Hydroxy-1h-Pyrazole-3-Carbonyl]-Amino}-3-O-Tolyl-Propionic Acid targeting CTSA |
| DC-05-LU10_0.1uM | Dose=0.1uM, (S)-3-{[1-(2-Fluoro-Phenyl)-5-Hydroxy-1h-Pyrazole-3-Carbonyl]-Amino}-3-O-Tolyl-Propionic Acid targeting CTSA |
| DC-05-LU10_10uM | Dose=10uM, (S)-3-{[1-(2-Fluoro-Phenyl)-5-Hydroxy-1h-Pyrazole-3-Carbonyl]-Amino}-3-O-Tolyl-Propionic Acid targeting CTSA |
| DC-08-CM08_0.01uM | Dose=0.01uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylpyrido[3,4-d]pyrimidine, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| DC-08-CM08_0.1uM | Dose=0.1uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylpyrido[3,4-d]pyrimidine, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| DC-08-CM08_10uM | Dose=10uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylpyrido[3,4-d]pyrimidine, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| DC-08-CM08_1uM | Dose=1uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylpyrido[3,4-d]pyrimidine, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| DC-08-KP05_0.01uM | Dose=0.01uM, 5-O-[10-[4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-2-cyano-1H-indol-7-yl]decyl] 3-O-methyl (4R)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, beta-Adrenoceptor Antagonists;Calcium Channel Blockers targeting ADRB3, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, ORAI1, MCU, CACNA2D4 |
| DC-08-KP05_0.1uM | Dose=0.1uM, 5-O-[10-[4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-2-cyano-1H-indol-7-yl]decyl] 3-O-methyl (4R)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, beta-Adrenoceptor Antagonists;Calcium Channel Blockers targeting ADRB3, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, ORAI1, MCU, CACNA2D4 |
| DC-08-KP05_10uM | Dose=10uM, 5-O-[10-[4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-2-cyano-1H-indol-7-yl]decyl] 3-O-methyl (4R)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, beta-Adrenoceptor Antagonists;Calcium Channel Blockers targeting ADRB3, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, ORAI1, MCU, CACNA2D4 |
| DC-08-KP05_1uM | Dose=1uM, 5-O-[10-[4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-2-cyano-1H-indol-7-yl]decyl] 3-O-methyl (4R)-4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, beta-Adrenoceptor Antagonists;Calcium Channel Blockers targeting ADRB3, CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1E, CACNA1F, CACNA1S, CACNB2, CACNB4, CACNG1, CACNA1I, CACNA1H, CACNA1G, CACNA2D2, CACNG3, CACNG2, CACNG5, CACNA2D3, CACNG8, ORAI1, MCU, CACNA2D4 |
| DC-11-AR68_0.01uM | Dose=0.01uM, (S)-2-[(R)-2-[(3,5-Dimethyl-benzoyl)-methyl-amino]-3-(4-isoxazol-5-yl-phenyl)-propionylamino]-3-(1H-indol-3-yl)-propionic acid, EDNRB gene inhibitor targeting EDNRB |
| DC-11-AR68_0.1uM | Dose=0.1uM, (S)-2-[(R)-2-[(3,5-Dimethyl-benzoyl)-methyl-amino]-3-(4-isoxazol-5-yl-phenyl)-propionylamino]-3-(1H-indol-3-yl)-propionic acid, EDNRB gene inhibitor targeting EDNRB |
| DC-11-AR68_10uM | Dose=10uM, (S)-2-[(R)-2-[(3,5-Dimethyl-benzoyl)-methyl-amino]-3-(4-isoxazol-5-yl-phenyl)-propionylamino]-3-(1H-indol-3-yl)-propionic acid, EDNRB gene inhibitor targeting EDNRB |
| DC-11-AR68_1uM | Dose=1uM, (S)-2-[(R)-2-[(3,5-Dimethyl-benzoyl)-methyl-amino]-3-(4-isoxazol-5-yl-phenyl)-propionylamino]-3-(1H-indol-3-yl)-propionic acid, EDNRB gene inhibitor targeting EDNRB |
| DC-13-RZ62_0.01uM | Dose=0.01uM, Ubidecarenone |
| DC-13-RZ62_0.1uM | Dose=0.1uM, Ubidecarenone |
| DC-13-RZ62_10uM | Dose=10uM, Ubidecarenone |
| DC-13-RZ62_1uM | Dose=1uM, Ubidecarenone |
| DC-17-EL33_0.01uM | Dose=0.01uM, 10-Methoxy-2,2,4-trimethyl-5-prop-2-enyl-1,5-dihydrochromeno[3,4-f]quinoline, Glucocorticoid Receptor (GR) Modulators targeting NR3C1 |
| DC-17-EL33_0.1uM | Dose=0.1uM, 10-Methoxy-2,2,4-trimethyl-5-prop-2-enyl-1,5-dihydrochromeno[3,4-f]quinoline, Glucocorticoid Receptor (GR) Modulators targeting NR3C1 |
| DC-17-EL33_10uM | Dose=10uM, 10-Methoxy-2,2,4-trimethyl-5-prop-2-enyl-1,5-dihydrochromeno[3,4-f]quinoline, Glucocorticoid Receptor (GR) Modulators targeting NR3C1 |
| DC-17-ZB19_0.01uM | Dose=0.01uM, 2-Chloro-5-(3-(2-(3-methoxypropyl)pyridin-4-yl)-1H-indole-6-carbonyl)benzenesulfonamide, MMP-2 (Gelatinase A) Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP2, MMP13 |
| DC-17-ZB19_0.1uM | Dose=0.1uM, 2-Chloro-5-(3-(2-(3-methoxypropyl)pyridin-4-yl)-1H-indole-6-carbonyl)benzenesulfonamide, MMP-2 (Gelatinase A) Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP2, MMP13 |
| DC-17-ZB19_10uM | Dose=10uM, 2-Chloro-5-(3-(2-(3-methoxypropyl)pyridin-4-yl)-1H-indole-6-carbonyl)benzenesulfonamide, MMP-2 (Gelatinase A) Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP2, MMP13 |
| DC-17-ZB19_1uM | Dose=1uM, 2-Chloro-5-(3-(2-(3-methoxypropyl)pyridin-4-yl)-1H-indole-6-carbonyl)benzenesulfonamide, MMP-2 (Gelatinase A) Inhibitors;MMP-13 (Collagenase 3) Inhibitors targeting MMP2, MMP13 |
| DC-22-HS83_0.01uM | Dose=0.01uM, 4-[(5r)-5,6,7,8-Tetrahydroimidazo[1,5-A]pyridin-5-Yl]benzonitrile, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| DC-22-HS83_0.1uM | Dose=0.1uM, 4-[(5r)-5,6,7,8-Tetrahydroimidazo[1,5-A]pyridin-5-Yl]benzonitrile, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| DC-22-HS83_10uM | Dose=10uM, 4-[(5r)-5,6,7,8-Tetrahydroimidazo[1,5-A]pyridin-5-Yl]benzonitrile, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| DC-22-HS83_1uM | Dose=1uM, 4-[(5r)-5,6,7,8-Tetrahydroimidazo[1,5-A]pyridin-5-Yl]benzonitrile, Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors targeting CYP11B2 |
| DC-22-OP01_0.01uM | Dose=0.01uM, Afatinib, Irreversible EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2, ERBB4 |
| DC-22-OP01_0.1uM | Dose=0.1uM, Afatinib, Irreversible EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2, ERBB4 |
| DC-22-OP01_10uM | Dose=10uM, Afatinib, Irreversible EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2, ERBB4 |
| DC-22-OP01_1uM | Dose=1uM, Afatinib, Irreversible EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2, ERBB4 |
| DC-23-UM36_0.01uM | Dose=0.01uM, 1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-methyl-5-(propan-2-yloxy)pyridin-3-yl)-1H,2H,3H-imidazo(4,5-c)quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| DC-23-UM36_0.1uM | Dose=0.1uM, 1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-methyl-5-(propan-2-yloxy)pyridin-3-yl)-1H,2H,3H-imidazo(4,5-c)quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| DC-23-UM36_10uM | Dose=10uM, 1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-methyl-5-(propan-2-yloxy)pyridin-3-yl)-1H,2H,3H-imidazo(4,5-c)quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| DC-23-UM36_1uM | Dose=1uM, 1-(1,3-dimethyl-1H-pyrazol-4-yl)-3-methyl-8-(6-methyl-5-(propan-2-yloxy)pyridin-3-yl)-1H,2H,3H-imidazo(4,5-c)quinolin-2-one, PI3K inhibitors;FRAP1) Inhibitors;Mammalian Target of Rapamycin (mTOR targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| DC-28-NF06_0.01uM | Dose=0.01uM, Nefazodone, 5-HT Reuptake Inhibitors;ADRA1B gene modulator;5-HT2A Antagonists targeting ADRA1B, HTR2A |
| DC-28-NF06_0.1uM | Dose=0.1uM, Nefazodone, 5-HT Reuptake Inhibitors;ADRA1B gene modulator;5-HT2A Antagonists targeting ADRA1B, HTR2A |
| DC-28-NF06_10uM | Dose=10uM, Nefazodone, 5-HT Reuptake Inhibitors;ADRA1B gene modulator;5-HT2A Antagonists targeting ADRA1B, HTR2A |
| DC-28-NF06_1uM | Dose=1uM, Nefazodone, 5-HT Reuptake Inhibitors;ADRA1B gene modulator;5-HT2A Antagonists targeting ADRA1B, HTR2A |
| DC-31-WP64_0.01uM | Dose=0.01uM, 2-(4-ethylsulfonylphenyl)-~{N}-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]ethanamide |
| DC-31-WP64_0.1uM | Dose=0.1uM, 2-(4-ethylsulfonylphenyl)-~{N}-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]ethanamide |
| DC-31-WP64_10uM | Dose=10uM, 2-(4-ethylsulfonylphenyl)-~{N}-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]ethanamide |
| DC-31-WP64_1uM | Dose=1uM, 2-(4-ethylsulfonylphenyl)-~{N}-[4-phenyl-5-(phenylcarbonyl)-1,3-thiazol-2-yl]ethanamide |
| DC-39-CT52_0.01uM | Dose=0.01uM |
| DC-39-CT52_0.1uM | Dose=0.1uM |
| DC-39-CT52_10uM | Dose=10uM |
| DC-39-CT52_1uM | Dose=1uM |
| DC-43-KF54_0.01uM | Dose=0.01uM, 2-(Naphthalene-2-sulfonamido)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1 |
| DC-43-KF54_0.1uM | Dose=0.1uM, 2-(Naphthalene-2-sulfonamido)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1 |
| DC-43-KF54_10uM | Dose=10uM, 2-(Naphthalene-2-sulfonamido)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1 |
| DC-43-KF54_1uM | Dose=1uM, 2-(Naphthalene-2-sulfonamido)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1 |
| DC-45-WU45_0.01uM | Dose=0.01uM, Refametinib, MEK1 Inhibitors;MEK2 Inhibitors targeting MAP2K1, MAP2K2 |
| DC-45-WU45_0.1uM | Dose=0.1uM, Refametinib, MEK1 Inhibitors;MEK2 Inhibitors targeting MAP2K1, MAP2K2 |
| DC-45-WU45_10uM | Dose=10uM, Refametinib, MEK1 Inhibitors;MEK2 Inhibitors targeting MAP2K1, MAP2K2 |
| DC-45-WU45_1uM | Dose=1uM, Refametinib, MEK1 Inhibitors;MEK2 Inhibitors targeting MAP2K1, MAP2K2 |
| DC-47-KV62_0.01uM | Dose=0.01uM, Topotecan, DNA Topoisomerase I Inhibitors targeting TOP1 |
| DC-47-KV62_0.1uM | Dose=0.1uM, Topotecan, DNA Topoisomerase I Inhibitors targeting TOP1 |
| DC-47-KV62_10uM | Dose=10uM, Topotecan, DNA Topoisomerase I Inhibitors targeting TOP1 |
| DC-47-KV62_1uM | Dose=1uM, Topotecan, DNA Topoisomerase I Inhibitors targeting TOP1 |
| DC-49-EJ23_0.01uM | Dose=0.01uM, Sar7334, TRPC6 ion channel inhibitor targeting TRPC6 |
| DC-49-EJ23_0.1uM | Dose=0.1uM, Sar7334, TRPC6 ion channel inhibitor targeting TRPC6 |
| DC-49-EJ23_10uM | Dose=10uM, Sar7334, TRPC6 ion channel inhibitor targeting TRPC6 |
| DC-49-EJ23_1uM | Dose=1uM, Sar7334, TRPC6 ion channel inhibitor targeting TRPC6 |
| DC-50-QD52_0.01uM | Dose=0.01uM, Cts-1027, MMP-14 (Membrane-Type Matrix Metalloproteinase 1) Inhibitors;MMP-12 (Macrophage Elastase) Inhibitors;MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| DC-50-QD52_0.1uM | Dose=0.1uM, Cts-1027, MMP-14 (Membrane-Type Matrix Metalloproteinase 1) Inhibitors;MMP-12 (Macrophage Elastase) Inhibitors;MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| DC-50-QD52_10uM | Dose=10uM, Cts-1027, MMP-14 (Membrane-Type Matrix Metalloproteinase 1) Inhibitors;MMP-12 (Macrophage Elastase) Inhibitors;MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| DC-50-QD52_1uM | Dose=1uM, Cts-1027, MMP-14 (Membrane-Type Matrix Metalloproteinase 1) Inhibitors;MMP-12 (Macrophage Elastase) Inhibitors;MMP-13 (Collagenase 3) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP14, MMP11, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| DC-51-WE27_0.01uM | Dose=0.01uM, CDK9 inhibitor;Transcription inhibitor targeting CDK9 |
| DC-51-WE27_0.1uM | Dose=0.1uM, CDK9 inhibitor;Transcription inhibitor targeting CDK9 |
| DC-51-WE27_10uM | Dose=10uM, CDK9 inhibitor;Transcription inhibitor targeting CDK9 |
| DC-51-WE27_1uM | Dose=1uM, CDK9 inhibitor;Transcription inhibitor targeting CDK9 |
| DC-59-NQ20_0.01uM | Dose=0.01uM, Vx-702, P38a kinase inhibitor targeting MAPK14 |
| DC-59-NQ20_0.1uM | Dose=0.1uM, Vx-702, P38a kinase inhibitor targeting MAPK14 |
| DC-59-NQ20_10uM | Dose=10uM, Vx-702, P38a kinase inhibitor targeting MAPK14 |
| DC-59-NQ20_1uM | Dose=1uM, Vx-702, P38a kinase inhibitor targeting MAPK14 |
| DC-61-QV78_0.01uM | Dose=0.01uM, 3-ethyl-2-[(1Z,3E)-3-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)prop-1-en-1-yl]-1,3-benzothiazol-3-ium, SIRT2 inhibitor targeting SIRT2 |
| DC-61-QV78_0.1uM | Dose=0.1uM, 3-ethyl-2-[(1Z,3E)-3-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)prop-1-en-1-yl]-1,3-benzothiazol-3-ium, SIRT2 inhibitor targeting SIRT2 |
| DC-61-QV78_10uM | Dose=10uM, 3-ethyl-2-[(1Z,3E)-3-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)prop-1-en-1-yl]-1,3-benzothiazol-3-ium, SIRT2 inhibitor targeting SIRT2 |
| DC-61-QV78_1uM | Dose=1uM, 3-ethyl-2-[(1Z,3E)-3-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)prop-1-en-1-yl]-1,3-benzothiazol-3-ium, SIRT2 inhibitor targeting SIRT2 |
| DC-63-KC77_0.01uM | Dose=0.01uM, 1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene, Jak2 Inhibitors;Apoptosis Inducers;Extracellular-Regulated Kinase (ERK) Inhibitors;Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors targeting JAK2, MAP2K7, MAPK13 |
| DC-63-KC77_0.1uM | Dose=0.1uM, 1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene, Jak2 Inhibitors;Apoptosis Inducers;Extracellular-Regulated Kinase (ERK) Inhibitors;Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors targeting JAK2, MAP2K7, MAPK13 |
| DC-63-KC77_10uM | Dose=10uM, 1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene, Jak2 Inhibitors;Apoptosis Inducers;Extracellular-Regulated Kinase (ERK) Inhibitors;Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors targeting JAK2, MAP2K7, MAPK13 |
| DC-63-KC77_1uM | Dose=1uM, 1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene, Jak2 Inhibitors;Apoptosis Inducers;Extracellular-Regulated Kinase (ERK) Inhibitors;Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors targeting JAK2, MAP2K7, MAPK13 |
| DC-70-EK34_0.01uM | Dose=0.01uM, BF-844, CLRN stabilizer targeting CLRN1 |
| DC-70-EK34_0.1uM | Dose=0.1uM, BF-844, CLRN stabilizer targeting CLRN1 |
| DC-70-EK34_10uM | Dose=10uM, BF-844, CLRN stabilizer targeting CLRN1 |
| DC-70-EK34_1uM | Dose=1uM, BF-844, CLRN stabilizer targeting CLRN1 |
| DC-72-IB32_0.01uM | Dose=0.01uM, Trimazosin, alpha-Adrenoceptor Antagonists targeting ADRA1A |
| DC-72-IB32_0.1uM | Dose=0.1uM, Trimazosin, alpha-Adrenoceptor Antagonists targeting ADRA1A |
| DC-72-IB32_10uM | Dose=10uM, Trimazosin, alpha-Adrenoceptor Antagonists targeting ADRA1A |
| DC-72-IB32_1uM | Dose=1uM, Trimazosin, alpha-Adrenoceptor Antagonists targeting ADRA1A |
| DC-78-CM38_0.01uM | Dose=0.01uM, IKK-3 Inhibitor, IKBKE (IKK-epsilon;TBK1 gene inhibitor;IKK-i) Inhibitors targeting IKBKE, TBK1 |
| DC-78-CM38_0.1uM | Dose=0.1uM, IKK-3 Inhibitor, IKBKE (IKK-epsilon;TBK1 gene inhibitor;IKK-i) Inhibitors targeting IKBKE, TBK1 |
| DC-78-CM38_10uM | Dose=10uM, IKK-3 Inhibitor, IKBKE (IKK-epsilon;TBK1 gene inhibitor;IKK-i) Inhibitors targeting IKBKE, TBK1 |
| DC-78-CM38_1uM | Dose=1uM, IKK-3 Inhibitor, IKBKE (IKK-epsilon;TBK1 gene inhibitor;IKK-i) Inhibitors targeting IKBKE, TBK1 |
| DC-81-PH69_0.01uM | Dose=0.01uM, Saracatinib, Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, ABL2, CSK, SRC, YES1 |
| DC-81-PH69_0.1uM | Dose=0.1uM, Saracatinib, Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, ABL2, CSK, SRC, YES1 |
| DC-81-PH69_10uM | Dose=10uM, Saracatinib, Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, ABL2, CSK, SRC, YES1 |
| DC-81-PH69_1uM | Dose=1uM, Saracatinib, Inhibitors of Signal Transduction Pathways;Abl Kinase Inhibitors;Src Kinase Inhibitors targeting ABL1, ABL2, CSK, SRC, YES1 |
| DC-82-AV25_0.01uM | Dose=0.01uM, 3-[[[3,5-bis(trifluoromethyl)benzoyl]-methylamino]-[(3,4-dichlorophenyl)methyl]amino]-N-[(3R)-2-oxoazepan-3-yl]propanamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR1 |
| DC-82-AV25_0.1uM | Dose=0.1uM, 3-[[[3,5-bis(trifluoromethyl)benzoyl]-methylamino]-[(3,4-dichlorophenyl)methyl]amino]-N-[(3R)-2-oxoazepan-3-yl]propanamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR1 |
| DC-82-AV25_10uM | Dose=10uM, 3-[[[3,5-bis(trifluoromethyl)benzoyl]-methylamino]-[(3,4-dichlorophenyl)methyl]amino]-N-[(3R)-2-oxoazepan-3-yl]propanamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR1 |
| DC-82-AV25_1uM | Dose=1uM, 3-[[[3,5-bis(trifluoromethyl)benzoyl]-methylamino]-[(3,4-dichlorophenyl)methyl]amino]-N-[(3R)-2-oxoazepan-3-yl]propanamide, Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists targeting TACR1 |
| DC-84-CJ21_0.01uM | Dose=0.01uM, N-(9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide, ADORA3 antagonist targeting ADORA3 |
| DC-84-CJ21_0.1uM | Dose=0.1uM, N-(9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide, ADORA3 antagonist targeting ADORA3 |
| DC-84-CJ21_10uM | Dose=10uM, N-(9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide, ADORA3 antagonist targeting ADORA3 |
| DC-84-CJ21_1uM | Dose=1uM, N-(9-chloro-2-(furan-2-yl)-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide, ADORA3 antagonist targeting ADORA3 |
| DC-84-GJ21_0.01uM | Dose=0.01uM, Angiogenesis Inhibitors;Tie2 Receptor Inhibitors;Inhibitors of Signal Transduction Pathways targeting TEK |
| DC-84-GJ21_10uM | Dose=10uM, Angiogenesis Inhibitors;Tie2 Receptor Inhibitors;Inhibitors of Signal Transduction Pathways targeting TEK |
| DC-84-GJ21_1uM | Dose=1uM, Angiogenesis Inhibitors;Tie2 Receptor Inhibitors;Inhibitors of Signal Transduction Pathways targeting TEK |
| DC-87-HI21_0.01uM | Dose=0.01uM, Cc-401, SAPK1 (JNK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK9 |
| DC-87-HI21_0.1uM | Dose=0.1uM, Cc-401, SAPK1 (JNK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK9 |
| DC-87-HI21_10uM | Dose=10uM, Cc-401, SAPK1 (JNK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK9 |
| DC-87-HI21_1uM | Dose=1uM, Cc-401, SAPK1 (JNK) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK9 |
| DC-91-ME12_0.01uM | Dose=0.01uM, 30S Ribosomal Protein Inhibitors;Protein Arginine Deiminase Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PADI6 |
| DC-91-ME12_0.1uM | Dose=0.1uM, 30S Ribosomal Protein Inhibitors;Protein Arginine Deiminase Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PADI6 |
| DC-91-ME12_10uM | Dose=10uM, 30S Ribosomal Protein Inhibitors;Protein Arginine Deiminase Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PADI6 |
| DC-91-ME12_1uM | Dose=1uM, 30S Ribosomal Protein Inhibitors;Protein Arginine Deiminase Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PADI6 |
| DC-93-NP78_0.01uM | Dose=0.01uM, K252A, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors targeting CAMK2G, PRKCG, PRKCH, PRKCI, PRKCZ, PRKD3, LRRK2, CAMK2B, FYN |
| DC-93-NP78_0.1uM | Dose=0.1uM, K252A, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors targeting CAMK2G, PRKCG, PRKCH, PRKCI, PRKCZ, PRKD3, LRRK2, CAMK2B, FYN |
| DC-93-NP78_10uM | Dose=10uM, K252A, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors targeting CAMK2G, PRKCG, PRKCH, PRKCI, PRKCZ, PRKD3, LRRK2, CAMK2B, FYN |
| DC-93-NP78_1uM | Dose=1uM, K252A, Leucine-Rich Repeat Kinase 2 (LRRK2;Dardarin) Inhibitors targeting CAMK2G, PRKCG, PRKCH, PRKCI, PRKCZ, PRKD3, LRRK2, CAMK2B, FYN |
| DC-93-RZ62_0.01uM | Dose=0.01uM |
| DC-93-RZ62_0.1uM | Dose=0.1uM |
| DC-93-RZ62_10uM | Dose=10uM |
| DC-93-RZ62_1uM | Dose=1uM |
| DC-93-WC67_0.01uM | Dose=0.01uM, Cyclothiazide, AMPA Receptor Modulators targeting GRIA2 |
| DC-93-WC67_0.1uM | Dose=0.1uM, Cyclothiazide, AMPA Receptor Modulators targeting GRIA2 |
| DC-93-WC67_10uM | Dose=10uM, Cyclothiazide, AMPA Receptor Modulators targeting GRIA2 |
| DC-93-WC67_1uM | Dose=1uM, Cyclothiazide, AMPA Receptor Modulators targeting GRIA2 |
| DC-96-HY67_0.01uM | Dose=0.01uM, Dimethyl Fumarate, NF-kappaB (NFKB) Activation Inhibitors;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Kelch-like ECH-Associated Protein 1 (Keap1, INrf2) Ligands targeting NFE2L2, KEAP1 |
| DC-96-HY67_0.1uM | Dose=0.1uM, Dimethyl Fumarate, NF-kappaB (NFKB) Activation Inhibitors;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Kelch-like ECH-Associated Protein 1 (Keap1, INrf2) Ligands targeting NFE2L2, KEAP1 |
| DC-96-HY67_10uM | Dose=10uM, Dimethyl Fumarate, NF-kappaB (NFKB) Activation Inhibitors;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Kelch-like ECH-Associated Protein 1 (Keap1, INrf2) Ligands targeting NFE2L2, KEAP1 |
| DC-96-HY67_1uM | Dose=1uM, Dimethyl Fumarate, NF-kappaB (NFKB) Activation Inhibitors;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Kelch-like ECH-Associated Protein 1 (Keap1, INrf2) Ligands targeting NFE2L2, KEAP1 |
| DC-97-ZB69_0.01uM | Dose=0.01uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP |
| DC-97-ZB69_0.1uM | Dose=0.1uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP |
| DC-97-ZB69_1uM | Dose=1uM, Purine-Nucleoside Phosphorylase Inhibitors targeting PNP |
| DC-98-CP35_0.01uM | Dose=0.01uM, UL78GH28WX, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin D Inhibitors targeting CTSD, BACE1 |
| DC-98-CP35_0.1uM | Dose=0.1uM, UL78GH28WX, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin D Inhibitors targeting CTSD, BACE1 |
| DC-98-CP35_10uM | Dose=10uM, UL78GH28WX, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin D Inhibitors targeting CTSD, BACE1 |
| DC-98-CP35_1uM | Dose=1uM, UL78GH28WX, beta-Secretase 1 (BACE1) Inhibitors;Cathepsin D Inhibitors targeting CTSD, BACE1 |
| DC-98-HC94_0.01uM | Dose=0.01uM, 7-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-6-oxopiperidin-1-yl]heptanoic acid, Prostanoid EP4 agonist targeting PTGER4 |
| DC-98-HC94_0.1uM | Dose=0.1uM, 7-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-6-oxopiperidin-1-yl]heptanoic acid, Prostanoid EP4 agonist targeting PTGER4 |
| DC-98-HC94_10uM | Dose=10uM, 7-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-6-oxopiperidin-1-yl]heptanoic acid, Prostanoid EP4 agonist targeting PTGER4 |
| DC-98-HC94_1uM | Dose=1uM, 7-[(2R)-2-[(E,3S)-3-hydroxy-4-phenylbut-1-enyl]-6-oxopiperidin-1-yl]heptanoic acid, Prostanoid EP4 agonist targeting PTGER4 |
| DC-98-RF46_0.01uM | Dose=0.01uM, 4-[8-(3-Cyano-phenyl)-[1,7]naphthyridin-6-yl]-cyclohexanecarboxylic acid |
| DC-98-RF46_0.1uM | Dose=0.1uM, 4-[8-(3-Cyano-phenyl)-[1,7]naphthyridin-6-yl]-cyclohexanecarboxylic acid |
| DC-98-RF46_10uM | Dose=10uM, 4-[8-(3-Cyano-phenyl)-[1,7]naphthyridin-6-yl]-cyclohexanecarboxylic acid |
| DC-99-NQ50_0.01uM | Dose=0.01uM, 4-methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| DC-99-NQ50_0.1uM | Dose=0.1uM, 4-methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| DC-99-NQ50_10uM | Dose=10uM, 4-methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| DC-99-NQ50_1uM | Dose=1uM, 4-methyl-2-(2-oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-3-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| DD-01-VE87_0.01uM | Dose=0.01uM |
| DD-01-VE87_0.1uM | Dose=0.1uM |
| DD-01-VE87_10uM | Dose=10uM |
| DD-01-VE87_1uM | Dose=1uM |
| DD-08-BT45_0.01uM | Dose=0.01uM, Moxonidine, Imidazoline I1 Receptor Agonists targeting NISCH |
| DD-08-BT45_0.1uM | Dose=0.1uM, Moxonidine, Imidazoline I1 Receptor Agonists targeting NISCH |
| DD-08-BT45_10uM | Dose=10uM, Moxonidine, Imidazoline I1 Receptor Agonists targeting NISCH |
| DD-08-BT45_1uM | Dose=1uM, Moxonidine, Imidazoline I1 Receptor Agonists targeting NISCH |
| DD-08-NW42_0.01uM | Dose=0.01uM, Ras/Rac Transformation Blocker, SCH 51344, NUDT1 inhibitor;Ras/Rac transformation blocker targeting NUDT1 |
| DD-08-NW42_10uM | Dose=10uM, Ras/Rac Transformation Blocker, SCH 51344, NUDT1 inhibitor;Ras/Rac transformation blocker targeting NUDT1 |
| DD-08-NW42_1uM | Dose=1uM, Ras/Rac Transformation Blocker, SCH 51344, NUDT1 inhibitor;Ras/Rac transformation blocker targeting NUDT1 |
| DD-10-NA60_0.01uM | Dose=0.01uM |
| DD-10-NA60_0.1uM | Dose=0.1uM |
| DD-10-NA60_10uM | Dose=10uM |
| DD-10-NA60_1uM | Dose=1uM |
| DD-12-RF07_0.01uM | Dose=0.01uM, Ivacaftor, CFTR Channel Activators targeting CFTR |
| DD-12-RF07_0.1uM | Dose=0.1uM, Ivacaftor, CFTR Channel Activators targeting CFTR |
| DD-12-RF07_10uM | Dose=10uM, Ivacaftor, CFTR Channel Activators targeting CFTR |
| DD-12-RF07_1uM | Dose=1uM, Ivacaftor, CFTR Channel Activators targeting CFTR |
| DD-15-VH74_0.01uM | Dose=0.01uM, Terazosin, PGK1 activator;alpha1-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A, PGK1 |
| DD-15-VH74_0.1uM | Dose=0.1uM, Terazosin, PGK1 activator;alpha1-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A, PGK1 |
| DD-15-VH74_10uM | Dose=10uM, Terazosin, PGK1 activator;alpha1-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A, PGK1 |
| DD-15-VH74_1uM | Dose=1uM, Terazosin, PGK1 activator;alpha1-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A, PGK1 |
| DD-16-GL76_0.01uM | Dose=0.01uM, Memantine, NMDA Antagonists targeting GRIN2A, GRIN2B |
| DD-16-GL76_0.1uM | Dose=0.1uM, Memantine, NMDA Antagonists targeting GRIN2A, GRIN2B |
| DD-16-GL76_1uM | Dose=1uM, Memantine, NMDA Antagonists targeting GRIN2A, GRIN2B |
| DD-16-RV85_0.01uM | Dose=0.01uM, Methyl 2-{[(2-imino-4-oxo-1,3-thiazolidin-5-yl)acetyl]amino}-4,5-dimethylthiophene-3-carboxylate, Secreted Frizzled-related Protein-1 (SFRP-1) Inhibitors targeting SFRP1 |
| DD-16-RV85_0.1uM | Dose=0.1uM, Methyl 2-{[(2-imino-4-oxo-1,3-thiazolidin-5-yl)acetyl]amino}-4,5-dimethylthiophene-3-carboxylate, Secreted Frizzled-related Protein-1 (SFRP-1) Inhibitors targeting SFRP1 |
| DD-16-RV85_10uM | Dose=10uM, Methyl 2-{[(2-imino-4-oxo-1,3-thiazolidin-5-yl)acetyl]amino}-4,5-dimethylthiophene-3-carboxylate, Secreted Frizzled-related Protein-1 (SFRP-1) Inhibitors targeting SFRP1 |
| DD-16-RV85_1uM | Dose=1uM, Methyl 2-{[(2-imino-4-oxo-1,3-thiazolidin-5-yl)acetyl]amino}-4,5-dimethylthiophene-3-carboxylate, Secreted Frizzled-related Protein-1 (SFRP-1) Inhibitors targeting SFRP1 |
| DD-17-HS50_0.1uM | Dose=0.1uM, N-[(2-fluoro-6-methoxyphenyl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED |
| DD-17-HS50_10uM | Dose=10uM, N-[(2-fluoro-6-methoxyphenyl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED |
| DD-17-HS50_1uM | Dose=1uM, N-[(2-fluoro-6-methoxyphenyl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridin-5-amine, EED gene inhibitor targeting EED |
| DD-23-QZ62_0.01uM | Dose=0.01uM, Carbonic Anhydrase Type VII Inhibitors |
| DD-23-QZ62_10uM | Dose=10uM, Carbonic Anhydrase Type VII Inhibitors |
| DD-23-ZC57_0.01uM | Dose=0.01uM, [(2R,3R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate, P2RY13 agonist;P2RY1 agonist;P2RY12 agonist targeting P2RY1, P2RY13, P2RY12 |
| DD-23-ZC57_0.1uM | Dose=0.1uM, [(2R,3R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate, P2RY13 agonist;P2RY1 agonist;P2RY12 agonist targeting P2RY1, P2RY13, P2RY12 |
| DD-23-ZC57_10uM | Dose=10uM, [(2R,3R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate, P2RY13 agonist;P2RY1 agonist;P2RY12 agonist targeting P2RY1, P2RY13, P2RY12 |
| DD-23-ZC57_1uM | Dose=1uM, [(2R,3R,5R)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate, P2RY13 agonist;P2RY1 agonist;P2RY12 agonist targeting P2RY1, P2RY13, P2RY12 |
| DD-24-TT70_0.01uM | Dose=0.01uM, Talampanel, AMPA Non-Competitive Antagonists;Kainate Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| DD-24-TT70_0.1uM | Dose=0.1uM, Talampanel, AMPA Non-Competitive Antagonists;Kainate Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| DD-24-TT70_10uM | Dose=10uM, Talampanel, AMPA Non-Competitive Antagonists;Kainate Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| DD-24-TT70_1uM | Dose=1uM, Talampanel, AMPA Non-Competitive Antagonists;Kainate Antagonists targeting GRIA1, GRIA2, GRIA3, GRIA4 |
| DD-26-RY82_0.01uM | Dose=0.01uM, Enobosarm, Selective Androgen Receptor Modulator targeting AR |
| DD-26-RY82_0.1uM | Dose=0.1uM, Enobosarm, Selective Androgen Receptor Modulator targeting AR |
| DD-26-RY82_10uM | Dose=10uM, Enobosarm, Selective Androgen Receptor Modulator targeting AR |
| DD-26-RY82_1uM | Dose=1uM, Enobosarm, Selective Androgen Receptor Modulator targeting AR |
| DD-26-VR55_10uM | Dose=10uM, 6-[[2-(3-Methoxyanilino)pyrimidin-4-yl]amino]-2,3-dihydro-1,4-benzodioxine-5-sulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ALK, ZAP70 |
| DD-26-VR55_1uM | Dose=1uM, 6-[[2-(3-Methoxyanilino)pyrimidin-4-yl]amino]-2,3-dihydro-1,4-benzodioxine-5-sulfonamide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ALK, ZAP70 |
| DD-28-MZ39_0.01uM | Dose=0.01uM, 2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide, Peripheral Benzodiazepine Receptor (PBR) Ligands targeting TSPO |
| DD-28-MZ39_0.1uM | Dose=0.1uM, 2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide, Peripheral Benzodiazepine Receptor (PBR) Ligands targeting TSPO |
| DD-28-MZ39_10uM | Dose=10uM, 2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide, Peripheral Benzodiazepine Receptor (PBR) Ligands targeting TSPO |
| DD-28-MZ39_1uM | Dose=1uM, 2-(7-Chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide, Peripheral Benzodiazepine Receptor (PBR) Ligands targeting TSPO |
| DD-30-NA60_0.01uM | Dose=0.01uM, N,N-dimethyl-2-[3-(4-phenylphenyl)-1-[3-(trifluoromethyl)phenyl]pyrazol-4-yl]acetamide |
| DD-30-NA60_0.1uM | Dose=0.1uM, N,N-dimethyl-2-[3-(4-phenylphenyl)-1-[3-(trifluoromethyl)phenyl]pyrazol-4-yl]acetamide |
| DD-30-NA60_10uM | Dose=10uM, N,N-dimethyl-2-[3-(4-phenylphenyl)-1-[3-(trifluoromethyl)phenyl]pyrazol-4-yl]acetamide |
| DD-30-NA60_1uM | Dose=1uM, N,N-dimethyl-2-[3-(4-phenylphenyl)-1-[3-(trifluoromethyl)phenyl]pyrazol-4-yl]acetamide |
| DD-30-SX80_0.01uM | Dose=0.01uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)phenol, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2 |
| DD-30-SX80_0.1uM | Dose=0.1uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)phenol, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2 |
| DD-30-SX80_10uM | Dose=10uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)phenol, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2 |
| DD-30-SX80_1uM | Dose=1uM, 4-(6-(Cyclohexylamino)imidazo[1,2-b]pyridazin-3-yl)phenol, Interleukin-1 Receptor-Associated Kinase (IRAK) Inhibitors targeting IRAK1, IRAK2 |
| DD-31-LY65_0.01uM | Dose=0.01uM, Menatetrenone |
| DD-31-LY65_0.1uM | Dose=0.1uM, Menatetrenone |
| DD-31-LY65_10uM | Dose=10uM, Menatetrenone |
| DD-31-LY65_1uM | Dose=1uM, Menatetrenone |
| DD-33-XP23_0.01uM | Dose=0.01uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-thione, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| DD-33-XP23_0.1uM | Dose=0.1uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-thione, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| DD-33-XP23_10uM | Dose=10uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-thione, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| DD-33-XP23_1uM | Dose=1uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-thione, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| DD-34-AN51_0.01uM | Dose=0.01uM, Polydatin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Xanthine Oxidase Inhibitors targeting XDH |
| DD-34-AN51_0.1uM | Dose=0.1uM, Polydatin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Xanthine Oxidase Inhibitors targeting XDH |
| DD-34-AN51_10uM | Dose=10uM, Polydatin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Xanthine Oxidase Inhibitors targeting XDH |
| DD-34-AN51_1uM | Dose=1uM, Polydatin, VCAM1 Expression Inhibitors;ICAM1 Expression Inhibitors;Xanthine Oxidase Inhibitors targeting XDH |
| DD-34-TT70_0.01uM | Dose=0.01uM, 2-amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1 |
| DD-34-TT70_0.1uM | Dose=0.1uM, 2-amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1 |
| DD-34-TT70_1uM | Dose=1uM, 2-amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile, Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators targeting KCNMA1 |
| DD-36-YH76_0.01uM | Dose=0.01uM, Ast-487, Flt3 (FLK2/STK1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK14, FLT3, KIT, PDGFRB, MAPK8, MAPK10 |
| DD-36-YH76_0.1uM | Dose=0.1uM, Ast-487, Flt3 (FLK2/STK1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK14, FLT3, KIT, PDGFRB, MAPK8, MAPK10 |
| DD-36-YH76_10uM | Dose=10uM, Ast-487, Flt3 (FLK2/STK1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK14, FLT3, KIT, PDGFRB, MAPK8, MAPK10 |
| DD-36-YH76_1uM | Dose=1uM, Ast-487, Flt3 (FLK2/STK1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK14, FLT3, KIT, PDGFRB, MAPK8, MAPK10 |
| DD-38-BM78_0.01uM | Dose=0.01uM, 4-(2-(5-(4-Hydroxy-3-methoxystyryl)isoxazol-3-yl)vinyl)-2-methoxyphenol, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;Free Radical Scavengers;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP, PTGS1, PTGS2 |
| DD-38-BM78_0.1uM | Dose=0.1uM, 4-(2-(5-(4-Hydroxy-3-methoxystyryl)isoxazol-3-yl)vinyl)-2-methoxyphenol, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;Free Radical Scavengers;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP, PTGS1, PTGS2 |
| DD-38-BM78_10uM | Dose=10uM, 4-(2-(5-(4-Hydroxy-3-methoxystyryl)isoxazol-3-yl)vinyl)-2-methoxyphenol, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;Free Radical Scavengers;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP, PTGS1, PTGS2 |
| DD-38-BM78_1uM | Dose=1uM, 4-(2-(5-(4-Hydroxy-3-methoxystyryl)isoxazol-3-yl)vinyl)-2-methoxyphenol, Cyclooxygenase-1 Inhibitors;Cyclooxygenase-2 Inhibitors;Free Radical Scavengers;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP, PTGS1, PTGS2 |
| DD-38-MZ39_0.01uM | Dose=0.01uM, N-(4-tert-butylphenyl)-4-(quinazolin-6-yl)isoquinolin-1-amine |
| DD-38-MZ39_0.1uM | Dose=0.1uM, N-(4-tert-butylphenyl)-4-(quinazolin-6-yl)isoquinolin-1-amine |
| DD-38-MZ39_10uM | Dose=10uM, N-(4-tert-butylphenyl)-4-(quinazolin-6-yl)isoquinolin-1-amine |
| DD-38-MZ39_1uM | Dose=1uM, N-(4-tert-butylphenyl)-4-(quinazolin-6-yl)isoquinolin-1-amine |
| DD-41-AE67_0.01uM | Dose=0.01uM, Zanamivir, inhibitor of neuraminidase and Sialidase targeting NEU1, NEU2, NEU3 |
| DD-41-AE67_0.1uM | Dose=0.1uM, Zanamivir, inhibitor of neuraminidase and Sialidase targeting NEU1, NEU2, NEU3 |
| DD-41-AE67_10uM | Dose=10uM, Zanamivir, inhibitor of neuraminidase and Sialidase targeting NEU1, NEU2, NEU3 |
| DD-41-AE67_1uM | Dose=1uM, Zanamivir, inhibitor of neuraminidase and Sialidase targeting NEU1, NEU2, NEU3 |
| DD-42-DB72_0.01uM | Dose=0.01uM, (S)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, CHRM1 agonist targeting CHRM1 |
| DD-42-DB72_0.1uM | Dose=0.1uM, (S)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, CHRM1 agonist targeting CHRM1 |
| DD-42-DB72_10uM | Dose=10uM, (S)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, CHRM1 agonist targeting CHRM1 |
| DD-42-DB72_1uM | Dose=1uM, (S)-2,8-Dimethyl-1,3-dioxa-8-aza-spiro[4.5]decane, CHRM1 agonist targeting CHRM1 |
| DD-42-PC65_0.01uM | Dose=0.01uM, 4-[3-[[ethyl(propan-2-yl)amino]methyl]phenyl]-N-(3-nitrophenyl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 beta (GSK-3beta| tau Protein Kinase I) Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Cyclin-Dependent Kinase Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting GSK3B, AURKA, CDKL5 |
| DD-42-PC65_0.1uM | Dose=0.1uM, 4-[3-[[ethyl(propan-2-yl)amino]methyl]phenyl]-N-(3-nitrophenyl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 beta (GSK-3beta| tau Protein Kinase I) Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Cyclin-Dependent Kinase Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting GSK3B, AURKA, CDKL5 |
| DD-42-PC65_10uM | Dose=10uM, 4-[3-[[ethyl(propan-2-yl)amino]methyl]phenyl]-N-(3-nitrophenyl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 beta (GSK-3beta| tau Protein Kinase I) Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Cyclin-Dependent Kinase Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting GSK3B, AURKA, CDKL5 |
| DD-42-PC65_1uM | Dose=1uM, 4-[3-[[ethyl(propan-2-yl)amino]methyl]phenyl]-N-(3-nitrophenyl)pyrimidin-2-amine, Glycogen Synthase Kinase 3 beta (GSK-3beta| tau Protein Kinase I) Inhibitors;Aurora-A (ARK1) Kinase Inhibitors;Cyclin-Dependent Kinase Inhibitors;Antimitotic Drugs;Inhibitors of Signal Transduction Pathways targeting GSK3B, AURKA, CDKL5 |
| DD-43-WW40_0.01uM | Dose=0.01uM, MS023, Type I PRMT inhibitor targeting PRMT1, PRMT6, PRMT8 |
| DD-43-WW40_0.1uM | Dose=0.1uM, MS023, Type I PRMT inhibitor targeting PRMT1, PRMT6, PRMT8 |
| DD-43-WW40_10uM | Dose=10uM, MS023, Type I PRMT inhibitor targeting PRMT1, PRMT6, PRMT8 |
| DD-43-WW40_1uM | Dose=1uM, MS023, Type I PRMT inhibitor targeting PRMT1, PRMT6, PRMT8 |
| DD-44-OX00_0.01uM | Dose=0.01uM, 2-(3,4-dichlorophenyl)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]acetamide |
| DD-44-OX00_0.1uM | Dose=0.1uM, 2-(3,4-dichlorophenyl)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]acetamide |
| DD-44-OX00_10uM | Dose=10uM, 2-(3,4-dichlorophenyl)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]acetamide |
| DD-44-OX00_1uM | Dose=1uM, 2-(3,4-dichlorophenyl)-N-[2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl]acetamide |
| DD-47-GB64_0.01uM | Dose=0.01uM, (2,4-Dimethylpyridin-3-yl)(4-methyl-4-(4-(phenyl(pyridin-3-yl)amino)piperidin-1-yl)piperidin-1-yl)methanone, CCR5 antagonist targeting CCR5 |
| DD-47-GB64_0.1uM | Dose=0.1uM, (2,4-Dimethylpyridin-3-yl)(4-methyl-4-(4-(phenyl(pyridin-3-yl)amino)piperidin-1-yl)piperidin-1-yl)methanone, CCR5 antagonist targeting CCR5 |
| DD-47-GB64_10uM | Dose=10uM, (2,4-Dimethylpyridin-3-yl)(4-methyl-4-(4-(phenyl(pyridin-3-yl)amino)piperidin-1-yl)piperidin-1-yl)methanone, CCR5 antagonist targeting CCR5 |
| DD-47-GB64_1uM | Dose=1uM, (2,4-Dimethylpyridin-3-yl)(4-methyl-4-(4-(phenyl(pyridin-3-yl)amino)piperidin-1-yl)piperidin-1-yl)methanone, CCR5 antagonist targeting CCR5 |
| DD-48-MZ39_0.01uM | Dose=0.01uM, 3-[(3,4-Dichlorobenzyl)sulfanyl]-2-thiophenecarboxylic acid |
| DD-48-MZ39_0.1uM | Dose=0.1uM, 3-[(3,4-Dichlorobenzyl)sulfanyl]-2-thiophenecarboxylic acid |
| DD-48-MZ39_10uM | Dose=10uM, 3-[(3,4-Dichlorobenzyl)sulfanyl]-2-thiophenecarboxylic acid |
| DD-49-YG96_0.01uM | Dose=0.01uM, Tacrolimus, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| DD-49-YG96_0.1uM | Dose=0.1uM, Tacrolimus, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| DD-49-YG96_10uM | Dose=10uM, Tacrolimus, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| DD-49-YG96_1uM | Dose=1uM, Tacrolimus, FKBP12 gene modulator;Calcineurin inhibitor targeting FKBP1A, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
| DD-54-MA35_0.01uM | Dose=0.01uM, N-(5-((2-(2,2-Dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide, PDGFR kinase inhibitor targeting PDGFRA, PDGFRB |
| DD-54-MA35_10uM | Dose=10uM, N-(5-((2-(2,2-Dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide, PDGFR kinase inhibitor targeting PDGFRA, PDGFRB |
| DD-54-MA35_1uM | Dose=1uM, N-(5-((2-(2,2-Dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide, PDGFR kinase inhibitor targeting PDGFRA, PDGFRB |
| DD-55-AU25_0.01uM | Dose=0.01uM, Eflornithine, Ornithine Decarboxylase Inhibitors targeting ODC1 |
| DD-55-AU25_0.1uM | Dose=0.1uM, Eflornithine, Ornithine Decarboxylase Inhibitors targeting ODC1 |
| DD-55-AU25_10uM | Dose=10uM, Eflornithine, Ornithine Decarboxylase Inhibitors targeting ODC1 |
| DD-55-AU25_1uM | Dose=1uM, Eflornithine, Ornithine Decarboxylase Inhibitors targeting ODC1 |
| DD-55-SD64_0.01uM | Dose=0.01uM, 4-(8-(3-Nitrophenyl)-1,7-naphthyridin-6-yl)benzoic acid, Phosphodiesterase IV Inhibitors targeting PDE4C |
| DD-55-SD64_0.1uM | Dose=0.1uM, 4-(8-(3-Nitrophenyl)-1,7-naphthyridin-6-yl)benzoic acid, Phosphodiesterase IV Inhibitors targeting PDE4C |
| DD-55-SD64_10uM | Dose=10uM, 4-(8-(3-Nitrophenyl)-1,7-naphthyridin-6-yl)benzoic acid, Phosphodiesterase IV Inhibitors targeting PDE4C |
| DD-55-SD64_1uM | Dose=1uM, 4-(8-(3-Nitrophenyl)-1,7-naphthyridin-6-yl)benzoic acid, Phosphodiesterase IV Inhibitors targeting PDE4C |
| DD-58-HC29_0.01uM | Dose=0.01uM |
| DD-58-HC29_0.1uM | Dose=0.1uM |
| DD-58-HC29_10uM | Dose=10uM |
| DD-58-HC29_1uM | Dose=1uM |
| DD-61-DY35_0.01uM | Dose=0.01uM |
| DD-61-DY35_0.1uM | Dose=0.1uM |
| DD-61-DY35_10uM | Dose=10uM |
| DD-61-DY35_1uM | Dose=1uM |
| DD-64-ET45_0.01uM | Dose=0.01uM, 4-Cyclobutylmethoxy-1H-indole-2-carboxylic acid {1-[(S)-2-((3S,4S)-4-hydroxy-3-methyl-piperidin-1-yl)-propyl]-piperidin-4-yl}-amide, Chemokine CCR2 (MCP-1 Receptor) Antagonists targeting CCR2 |
| DD-64-ET45_0.1uM | Dose=0.1uM, 4-Cyclobutylmethoxy-1H-indole-2-carboxylic acid {1-[(S)-2-((3S,4S)-4-hydroxy-3-methyl-piperidin-1-yl)-propyl]-piperidin-4-yl}-amide, Chemokine CCR2 (MCP-1 Receptor) Antagonists targeting CCR2 |
| DD-64-ET45_10uM | Dose=10uM, 4-Cyclobutylmethoxy-1H-indole-2-carboxylic acid {1-[(S)-2-((3S,4S)-4-hydroxy-3-methyl-piperidin-1-yl)-propyl]-piperidin-4-yl}-amide, Chemokine CCR2 (MCP-1 Receptor) Antagonists targeting CCR2 |
| DD-64-ET45_1uM | Dose=1uM, 4-Cyclobutylmethoxy-1H-indole-2-carboxylic acid {1-[(S)-2-((3S,4S)-4-hydroxy-3-methyl-piperidin-1-yl)-propyl]-piperidin-4-yl}-amide, Chemokine CCR2 (MCP-1 Receptor) Antagonists targeting CCR2 |
| DD-65-SA37_0.01uM | Dose=0.01uM, 3-Pyridinecarboxamide, 6-chloro-N-[4-[[[2-(methylamino)-4-quinazolinyl]amino]methyl]phenyl]-, beta-Catenin Inhibitors targeting CTNNB1, TCF4 |
| DD-65-SA37_0.1uM | Dose=0.1uM, 3-Pyridinecarboxamide, 6-chloro-N-[4-[[[2-(methylamino)-4-quinazolinyl]amino]methyl]phenyl]-, beta-Catenin Inhibitors targeting CTNNB1, TCF4 |
| DD-65-SA37_10uM | Dose=10uM, 3-Pyridinecarboxamide, 6-chloro-N-[4-[[[2-(methylamino)-4-quinazolinyl]amino]methyl]phenyl]-, beta-Catenin Inhibitors targeting CTNNB1, TCF4 |
| DD-65-SA37_1uM | Dose=1uM, 3-Pyridinecarboxamide, 6-chloro-N-[4-[[[2-(methylamino)-4-quinazolinyl]amino]methyl]phenyl]-, beta-Catenin Inhibitors targeting CTNNB1, TCF4 |
| DD-66-VY52_0.01uM | Dose=0.01uM, SB 218795, Tachykinin NK3 Antagonists targeting TACR3 |
| DD-66-VY52_0.1uM | Dose=0.1uM, SB 218795, Tachykinin NK3 Antagonists targeting TACR3 |
| DD-66-VY52_1uM | Dose=1uM, SB 218795, Tachykinin NK3 Antagonists targeting TACR3 |
| DD-67-EC82_0.1uM | Dose=0.1uM, Quetiapine, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F |
| DD-67-EC82_10uM | Dose=10uM, Quetiapine, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F |
| DD-67-EC82_1uM | Dose=1uM, Quetiapine, alpha1-Adrenoceptor Antagonists targeting ADRA1B, HTR1E, HTR1F |
| DD-68-ZP95_0.01uM | Dose=0.01uM, US11160797, Example 1, Kinase inhibitors;Ossification inhibitor;Inhibitor of bone morphogenetic protein kinases targeting ACVR1, ACVRL1, BMPR1A |
| DD-68-ZP95_0.1uM | Dose=0.1uM, US11160797, Example 1, Kinase inhibitors;Ossification inhibitor;Inhibitor of bone morphogenetic protein kinases targeting ACVR1, ACVRL1, BMPR1A |
| DD-68-ZP95_10uM | Dose=10uM, US11160797, Example 1, Kinase inhibitors;Ossification inhibitor;Inhibitor of bone morphogenetic protein kinases targeting ACVR1, ACVRL1, BMPR1A |
| DD-68-ZP95_1uM | Dose=1uM, US11160797, Example 1, Kinase inhibitors;Ossification inhibitor;Inhibitor of bone morphogenetic protein kinases targeting ACVR1, ACVRL1, BMPR1A |
| DD-71-LY65_0.01uM | Dose=0.01uM, Trimetrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| DD-71-LY65_0.1uM | Dose=0.1uM, Trimetrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| DD-71-LY65_10uM | Dose=10uM, Trimetrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| DD-71-LY65_1uM | Dose=1uM, Trimetrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| DD-73-IP88_0.01uM | Dose=0.01uM, Pki166, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2 |
| DD-73-IP88_0.1uM | Dose=0.1uM, Pki166, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2 |
| DD-73-IP88_10uM | Dose=10uM, Pki166, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2 |
| DD-73-IP88_1uM | Dose=1uM, Pki166, EGFR (HER1;HER2 (erbB2) Inhibitors;Inhibitors of Signal Transduction Pathways;erbB1) Inhibitors targeting EGFR, ERBB2 |
| DD-74-PJ26_0.01uM | Dose=0.01uM, Amn082, mgluR7 Agonists targeting GRM7 |
| DD-74-PJ26_0.1uM | Dose=0.1uM, Amn082, mgluR7 Agonists targeting GRM7 |
| DD-74-PJ26_10uM | Dose=10uM, Amn082, mgluR7 Agonists targeting GRM7 |
| DD-74-PJ26_1uM | Dose=1uM, Amn082, mgluR7 Agonists targeting GRM7 |
| DD-75-HY40_0.01uM | Dose=0.01uM, Celastrol |
| DD-75-HY40_0.1uM | Dose=0.1uM, Celastrol |
| DD-75-HY40_10uM | Dose=10uM, Celastrol |
| DD-75-HY40_1uM | Dose=1uM, Celastrol |
| DD-77-GV27_0.01uM | Dose=0.01uM, Fluspirilene, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F |
| DD-77-GV27_10uM | Dose=10uM, Fluspirilene, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F |
| DD-77-GV27_1uM | Dose=1uM, Fluspirilene, Dopamine D2 Antagonists targeting DRD2, HTR1E, HTR1F |
| DD-77-OI11_0.01uM | Dose=0.01uM, PARP5B) Inhibitors;Tankyrase 1 (TNKS1;Tankyrase 2 (TNKS2;PARP5A) Inhibitors targeting TNKS, TNKS2 |
| DD-77-OI11_0.1uM | Dose=0.1uM, PARP5B) Inhibitors;Tankyrase 1 (TNKS1;Tankyrase 2 (TNKS2;PARP5A) Inhibitors targeting TNKS, TNKS2 |
| DD-77-OI11_10uM | Dose=10uM, PARP5B) Inhibitors;Tankyrase 1 (TNKS1;Tankyrase 2 (TNKS2;PARP5A) Inhibitors targeting TNKS, TNKS2 |
| DD-77-OI11_1uM | Dose=1uM, PARP5B) Inhibitors;Tankyrase 1 (TNKS1;Tankyrase 2 (TNKS2;PARP5A) Inhibitors targeting TNKS, TNKS2 |
| DD-82-GV50_0.01uM | Dose=0.01uM, (2S,4R)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DD-82-GV50_0.1uM | Dose=0.1uM, (2S,4R)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DD-82-GV50_10uM | Dose=10uM, (2S,4R)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DD-82-GV50_1uM | Dose=1uM, (2S,4R)-1-[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DD-82-HB82_0.1uM | Dose=0.1uM, Prodipine targeting CYP2D6 |
| DD-82-HB82_10uM | Dose=10uM, Prodipine targeting CYP2D6 |
| DD-82-HB82_1uM | Dose=1uM, Prodipine targeting CYP2D6 |
| DD-85-AN28_0.01uM | Dose=0.01uM, (S)-2-(2-(3,5-Difluorophenyl)acetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting APH1A, PSENEN, APH1B |
| DD-85-AN28_0.1uM | Dose=0.1uM, (S)-2-(2-(3,5-Difluorophenyl)acetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting APH1A, PSENEN, APH1B |
| DD-85-AN28_10uM | Dose=10uM, (S)-2-(2-(3,5-Difluorophenyl)acetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting APH1A, PSENEN, APH1B |
| DD-85-AN28_1uM | Dose=1uM, (S)-2-(2-(3,5-Difluorophenyl)acetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)propanamide, Antiamyloidogenic Agents;Notch Signaling Inhibitors;gamma-Secretase Inhibitors targeting APH1A, PSENEN, APH1B |
| DD-85-KU00_0.01uM | Dose=0.01uM, 2-[4-(5-heptanoyl-1-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]-2-methylpropanoic acid, Serine Palmitoyl Transferase inhibitor targeting SPTLC1 |
| DD-85-KU00_0.1uM | Dose=0.1uM, 2-[4-(5-heptanoyl-1-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]-2-methylpropanoic acid, Serine Palmitoyl Transferase inhibitor targeting SPTLC1 |
| DD-85-KU00_10uM | Dose=10uM, 2-[4-(5-heptanoyl-1-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]-2-methylpropanoic acid, Serine Palmitoyl Transferase inhibitor targeting SPTLC1 |
| DD-85-KU00_1uM | Dose=1uM, 2-[4-(5-heptanoyl-1-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl)phenyl]-2-methylpropanoic acid, Serine Palmitoyl Transferase inhibitor targeting SPTLC1 |
| DD-85-WO51_0.01uM | Dose=0.01uM |
| DD-85-WO51_0.1uM | Dose=0.1uM |
| DD-85-WO51_10uM | Dose=10uM |
| DD-85-WO51_1uM | Dose=1uM |
| DD-89-HG56_0.01uM | Dose=0.01uM, eIF4A3-IN-1 targeting EIF4A3 |
| DD-89-HG56_10uM | Dose=10uM, eIF4A3-IN-1 targeting EIF4A3 |
| DD-89-MJ03_0.01uM | Dose=0.01uM, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DD-89-MJ03_10uM | Dose=10uM, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DD-89-MJ03_1uM | Dose=1uM, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DD-89-WQ95_0.01uM | Dose=0.01uM |
| DD-89-WQ95_0.1uM | Dose=0.1uM |
| DD-89-WQ95_10uM | Dose=10uM |
| DD-89-WQ95_1uM | Dose=1uM |
| DD-91-OY40_0.01uM | Dose=0.01uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB |
| DD-91-OY40_0.1uM | Dose=0.1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB |
| DD-91-OY40_10uM | Dose=10uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB |
| DD-91-OY40_1uM | Dose=1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB |
| DD-93-NF74_0.01uM | Dose=0.01uM, N-[2-[(2R)-2-amino-3-(2,4-dichlorophenyl)propanoyl]-1,3-dihydroisoindol-5-yl]benzamide |
| DD-93-NF74_0.1uM | Dose=0.1uM, N-[2-[(2R)-2-amino-3-(2,4-dichlorophenyl)propanoyl]-1,3-dihydroisoindol-5-yl]benzamide |
| DD-93-NF74_10uM | Dose=10uM, N-[2-[(2R)-2-amino-3-(2,4-dichlorophenyl)propanoyl]-1,3-dihydroisoindol-5-yl]benzamide |
| DD-93-NF74_1uM | Dose=1uM, N-[2-[(2R)-2-amino-3-(2,4-dichlorophenyl)propanoyl]-1,3-dihydroisoindol-5-yl]benzamide |
| DD-95-TY80_0.01uM | Dose=0.01uM, Tolvaptan, antagonist of AVPR2 targeting AVPR2 |
| DD-95-TY80_0.1uM | Dose=0.1uM, Tolvaptan, antagonist of AVPR2 targeting AVPR2 |
| DD-95-TY80_10uM | Dose=10uM, Tolvaptan, antagonist of AVPR2 targeting AVPR2 |
| DD-95-TY80_1uM | Dose=1uM, Tolvaptan, antagonist of AVPR2 targeting AVPR2 |
| DD-96-DE39_0.01uM | Dose=0.01uM, 6-[(2R)-4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide |
| DD-96-DE39_0.1uM | Dose=0.1uM, 6-[(2R)-4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide |
| DD-96-DE39_10uM | Dose=10uM, 6-[(2R)-4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide |
| DD-96-DE39_1uM | Dose=1uM, 6-[(2R)-4,4-difluoro-2-(3-fluorophenyl)pyrrolidin-1-yl]imidazo[1,2-b]pyridazine-3-carboxamide |
| DD-96-VY72_0.01uM | Dose=0.01uM |
| DD-96-VY72_0.1uM | Dose=0.1uM |
| DD-96-VY72_10uM | Dose=10uM |
| DD-96-VY72_1uM | Dose=1uM |
| DD-99-WQ55_0.01uM | Dose=0.01uM, Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one,5-chloro-6',7'-difluoro-2',3',4',9'-tetrahydro-3'-methyl-,(1'R,3'S)- |
| DD-99-WQ55_0.1uM | Dose=0.1uM, Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one,5-chloro-6',7'-difluoro-2',3',4',9'-tetrahydro-3'-methyl-,(1'R,3'S)- |
| DD-99-WQ55_10uM | Dose=10uM, Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one,5-chloro-6',7'-difluoro-2',3',4',9'-tetrahydro-3'-methyl-,(1'R,3'S)- |
| DD-99-WQ55_1uM | Dose=1uM, Spiro[3H-indole-3,1'-[1H]pyrido[3,4-b]indol]-2(1H)-one,5-chloro-6',7'-difluoro-2',3',4',9'-tetrahydro-3'-methyl-,(1'R,3'S)- |
| DE-00-JU18_0.01uM | Dose=0.01uM, Rho Kinase 2 (ROCK 2| ROCKalpha) Inhibitors;Calcium Sensitizers;Leucine-Rich Repeat Kinase 2 (LRRK2| Dardarin) Inhibitors;Rho Kinase 1 (ROCK 1| p160-ROCK) Inhibitors targeting ROCK1, ROCK2, LRRK2 |
| DE-00-JU18_0.1uM | Dose=0.1uM, Rho Kinase 2 (ROCK 2| ROCKalpha) Inhibitors;Calcium Sensitizers;Leucine-Rich Repeat Kinase 2 (LRRK2| Dardarin) Inhibitors;Rho Kinase 1 (ROCK 1| p160-ROCK) Inhibitors targeting ROCK1, ROCK2, LRRK2 |
| DE-00-JU18_10uM | Dose=10uM, Rho Kinase 2 (ROCK 2| ROCKalpha) Inhibitors;Calcium Sensitizers;Leucine-Rich Repeat Kinase 2 (LRRK2| Dardarin) Inhibitors;Rho Kinase 1 (ROCK 1| p160-ROCK) Inhibitors targeting ROCK1, ROCK2, LRRK2 |
| DE-00-JU18_1uM | Dose=1uM, Rho Kinase 2 (ROCK 2| ROCKalpha) Inhibitors;Calcium Sensitizers;Leucine-Rich Repeat Kinase 2 (LRRK2| Dardarin) Inhibitors;Rho Kinase 1 (ROCK 1| p160-ROCK) Inhibitors targeting ROCK1, ROCK2, LRRK2 |
| DE-01-HO61_0.01uM | Dose=0.01uM, Ataluren, modulator of translational readthrough;Nonsense Mutation Suppressors;Putative translational readthrough (TRT) molecule targeting CFTR |
| DE-01-HO61_0.1uM | Dose=0.1uM, Ataluren, modulator of translational readthrough;Nonsense Mutation Suppressors;Putative translational readthrough (TRT) molecule targeting CFTR |
| DE-01-HO61_10uM | Dose=10uM, Ataluren, modulator of translational readthrough;Nonsense Mutation Suppressors;Putative translational readthrough (TRT) molecule targeting CFTR |
| DE-01-HO61_1uM | Dose=1uM, Ataluren, modulator of translational readthrough;Nonsense Mutation Suppressors;Putative translational readthrough (TRT) molecule targeting CFTR |
| DE-02-BL66_0.01uM | Dose=0.01uM, N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine, 7-dehydrocholesterol reductase inhibitor;Hedgehog pathway inhibitor targeting DHCR7 |
| DE-02-BL66_0.1uM | Dose=0.1uM, N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine, 7-dehydrocholesterol reductase inhibitor;Hedgehog pathway inhibitor targeting DHCR7 |
| DE-02-BL66_10uM | Dose=10uM, N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine, 7-dehydrocholesterol reductase inhibitor;Hedgehog pathway inhibitor targeting DHCR7 |
| DE-02-BL66_1uM | Dose=1uM, N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine, 7-dehydrocholesterol reductase inhibitor;Hedgehog pathway inhibitor targeting DHCR7 |
| DE-03-BW70_0.01uM | Dose=0.01uM, 1-(6-Fluoro-2-methyl-3,4-dihydroquinolin-1(2h)-yl)-2-(isoquinolin-5-yloxy)ethanone, Bile Acid Responsive TGR5 Receptors (GPBAR1, AXOR 109, GPCR19) Agonists targeting GPBAR1 |
| DE-03-BW70_10uM | Dose=10uM, 1-(6-Fluoro-2-methyl-3,4-dihydroquinolin-1(2h)-yl)-2-(isoquinolin-5-yloxy)ethanone, Bile Acid Responsive TGR5 Receptors (GPBAR1, AXOR 109, GPCR19) Agonists targeting GPBAR1 |
| DE-03-BW70_1uM | Dose=1uM, 1-(6-Fluoro-2-methyl-3,4-dihydroquinolin-1(2h)-yl)-2-(isoquinolin-5-yloxy)ethanone, Bile Acid Responsive TGR5 Receptors (GPBAR1, AXOR 109, GPCR19) Agonists targeting GPBAR1 |
| DE-03-NP53_0.01uM | Dose=0.01uM, [(1S,2R,5R,6R,7S,8R,10R)-1,5-dimethyl-7-[(E)-3-phenylprop-2-enoyl]oxy-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-10-yl] (2S)-2-hydroxypropanoate |
| DE-03-NP53_0.1uM | Dose=0.1uM, [(1S,2R,5R,6R,7S,8R,10R)-1,5-dimethyl-7-[(E)-3-phenylprop-2-enoyl]oxy-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-10-yl] (2S)-2-hydroxypropanoate |
| DE-03-NP53_10uM | Dose=10uM, [(1S,2R,5R,6R,7S,8R,10R)-1,5-dimethyl-7-[(E)-3-phenylprop-2-enoyl]oxy-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-10-yl] (2S)-2-hydroxypropanoate |
| DE-03-NP53_1uM | Dose=1uM, [(1S,2R,5R,6R,7S,8R,10R)-1,5-dimethyl-7-[(E)-3-phenylprop-2-enoyl]oxy-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-10-yl] (2S)-2-hydroxypropanoate |
| DE-05-NX87_0.01uM | Dose=0.01uM, 8-Phenylimidazo[1,5-a]pyridine, Glutaminyl Cyclase Inhibitors targeting QPCT |
| DE-05-NX87_0.1uM | Dose=0.1uM, 8-Phenylimidazo[1,5-a]pyridine, Glutaminyl Cyclase Inhibitors targeting QPCT |
| DE-05-NX87_10uM | Dose=10uM, 8-Phenylimidazo[1,5-a]pyridine, Glutaminyl Cyclase Inhibitors targeting QPCT |
| DE-05-NX87_1uM | Dose=1uM, 8-Phenylimidazo[1,5-a]pyridine, Glutaminyl Cyclase Inhibitors targeting QPCT |
| DE-09-HJ53_0.01uM | Dose=0.01uM, (3S,10R,13R)-17-[(2R)-5-hydroxy-5-propan-2-ylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
| DE-09-HJ53_0.1uM | Dose=0.1uM, (3S,10R,13R)-17-[(2R)-5-hydroxy-5-propan-2-ylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
| DE-09-HJ53_10uM | Dose=10uM, (3S,10R,13R)-17-[(2R)-5-hydroxy-5-propan-2-ylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
| DE-09-HJ53_1uM | Dose=1uM, (3S,10R,13R)-17-[(2R)-5-hydroxy-5-propan-2-ylhept-6-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol |
| DE-10-AU63_0.01uM | Dose=0.01uM, Pentostatin, Antimetabolites;Adenosine Deaminase Inhibitors targeting ADA, ADAR |
| DE-10-AU63_0.1uM | Dose=0.1uM, Pentostatin, Antimetabolites;Adenosine Deaminase Inhibitors targeting ADA, ADAR |
| DE-10-AU63_1uM | Dose=1uM, Pentostatin, Antimetabolites;Adenosine Deaminase Inhibitors targeting ADA, ADAR |
| DE-11-PO61_0.01uM | Dose=0.01uM, (S)-N-(8-((2-Amino-4-methylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)cyclopropanecarboxamide, AP2-Associated Protein Kinase 1 (AAK1) Inhibitors targeting AAK1 |
| DE-11-PO61_0.1uM | Dose=0.1uM, (S)-N-(8-((2-Amino-4-methylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)cyclopropanecarboxamide, AP2-Associated Protein Kinase 1 (AAK1) Inhibitors targeting AAK1 |
| DE-11-PO61_10uM | Dose=10uM, (S)-N-(8-((2-Amino-4-methylpentyl)oxy)-5H-chromeno[3,4-c]pyridin-2-yl)cyclopropanecarboxamide, AP2-Associated Protein Kinase 1 (AAK1) Inhibitors targeting AAK1 |
| DE-14-EG14_0.01uM | Dose=0.01uM, N-acetyl-N-[7-isopropyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide |
| DE-14-EG14_0.1uM | Dose=0.1uM, N-acetyl-N-[7-isopropyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide |
| DE-14-EG14_10uM | Dose=10uM, N-acetyl-N-[7-isopropyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide |
| DE-14-EG14_1uM | Dose=1uM, N-acetyl-N-[7-isopropyl-6-(2-methyl-2H-pyrazol-3-yl)-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl]-methanesulfonamide |
| DE-15-GD59_0.01uM | Dose=0.01uM |
| DE-15-GD59_0.1uM | Dose=0.1uM |
| DE-15-GD59_10uM | Dose=10uM |
| DE-15-GD59_1uM | Dose=1uM |
| DE-17-IZ77_0.01uM | Dose=0.01uM, Bupivacaine, Sodium Channel Blocker; anaesthetic targeting SCN2A, SCN2B, SCN1A, SCN3A, SCN1B, SCN7A, SCN8A, SCN3B |
| DE-17-IZ77_0.1uM | Dose=0.1uM, Bupivacaine, Sodium Channel Blocker; anaesthetic targeting SCN2A, SCN2B, SCN1A, SCN3A, SCN1B, SCN7A, SCN8A, SCN3B |
| DE-17-IZ77_10uM | Dose=10uM, Bupivacaine, Sodium Channel Blocker; anaesthetic targeting SCN2A, SCN2B, SCN1A, SCN3A, SCN1B, SCN7A, SCN8A, SCN3B |
| DE-17-IZ77_1uM | Dose=1uM, Bupivacaine, Sodium Channel Blocker; anaesthetic targeting SCN2A, SCN2B, SCN1A, SCN3A, SCN1B, SCN7A, SCN8A, SCN3B |
| DE-18-BC44_0.01uM | Dose=0.01uM |
| DE-18-BC44_0.1uM | Dose=0.1uM |
| DE-18-BC44_10uM | Dose=10uM |
| DE-18-BC44_1uM | Dose=1uM |
| DE-20-VX20_0.01uM | Dose=0.01uM |
| DE-20-VX20_0.1uM | Dose=0.1uM |
| DE-20-VX20_10uM | Dose=10uM |
| DE-20-VX20_1uM | Dose=1uM |
| DE-22-JV30_0.01uM | Dose=0.01uM, Isotretinoin, Retinoid RAR Agonists targeting RARA, RARB, RARG |
| DE-22-JV30_10uM | Dose=10uM, Isotretinoin, Retinoid RAR Agonists targeting RARA, RARB, RARG |
| DE-23-IF54_0.1uM | Dose=0.1uM, (3R)-1,1-bis(ethoxymethyl)-3-(5-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydropyrido[3,4-b]indole, Somatostatin srif1C (sst3) Antagonists targeting SSTR3 |
| DE-23-IF54_1uM | Dose=1uM, (3R)-1,1-bis(ethoxymethyl)-3-(5-phenyl-1H-imidazol-2-yl)-2,3,4,9-tetrahydropyrido[3,4-b]indole, Somatostatin srif1C (sst3) Antagonists targeting SSTR3 |
| DE-24-AX80_0.01uM | Dose=0.01uM, 2-(2,4-Dimethylphenethyl)benzo[f][1,7]naphthyridin-5-amine, TLR8 Receptor Agonists;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| DE-24-AX80_0.1uM | Dose=0.1uM, 2-(2,4-Dimethylphenethyl)benzo[f][1,7]naphthyridin-5-amine, TLR8 Receptor Agonists;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| DE-24-AX80_10uM | Dose=10uM, 2-(2,4-Dimethylphenethyl)benzo[f][1,7]naphthyridin-5-amine, TLR8 Receptor Agonists;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| DE-24-AX80_1uM | Dose=1uM, 2-(2,4-Dimethylphenethyl)benzo[f][1,7]naphthyridin-5-amine, TLR8 Receptor Agonists;TLR7 Receptor Agonists targeting TLR7, TLR8 |
| DE-27-WV67_0.01uM | Dose=0.01uM |
| DE-27-WV67_0.1uM | Dose=0.1uM |
| DE-27-WV67_10uM | Dose=10uM |
| DE-27-WV67_1uM | Dose=1uM |
| DE-27-WV87_0.01uM | Dose=0.01uM, (4S,7S)-4-Methyl-octahydro-[1]pyrindin-(2E)-ylideneamine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2 |
| DE-27-WV87_0.1uM | Dose=0.1uM, (4S,7S)-4-Methyl-octahydro-[1]pyrindin-(2E)-ylideneamine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2 |
| DE-27-WV87_10uM | Dose=10uM, (4S,7S)-4-Methyl-octahydro-[1]pyrindin-(2E)-ylideneamine, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors targeting NOS2 |
| DE-28-BW67_0.01uM | Dose=0.01uM, 2-[[4-(cyclopropylmethoxy)phenyl]sulfonyl-[[4-(dimethylamino)phenyl]methyl]amino]-N-hydroxyacetamide |
| DE-28-BW67_0.1uM | Dose=0.1uM, 2-[[4-(cyclopropylmethoxy)phenyl]sulfonyl-[[4-(dimethylamino)phenyl]methyl]amino]-N-hydroxyacetamide |
| DE-28-BW67_10uM | Dose=10uM, 2-[[4-(cyclopropylmethoxy)phenyl]sulfonyl-[[4-(dimethylamino)phenyl]methyl]amino]-N-hydroxyacetamide |
| DE-28-BW67_1uM | Dose=1uM, 2-[[4-(cyclopropylmethoxy)phenyl]sulfonyl-[[4-(dimethylamino)phenyl]methyl]amino]-N-hydroxyacetamide |
| DE-28-XP50_0.01uM | Dose=0.01uM, Gsk2801, Dual BAZ2A/BAZ2B inhibitor;BAZ2A/B dual inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B |
| DE-28-XP50_0.1uM | Dose=0.1uM, Gsk2801, Dual BAZ2A/BAZ2B inhibitor;BAZ2A/B dual inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B |
| DE-28-XP50_10uM | Dose=10uM, Gsk2801, Dual BAZ2A/BAZ2B inhibitor;BAZ2A/B dual inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B |
| DE-28-XP50_1uM | Dose=1uM, Gsk2801, Dual BAZ2A/BAZ2B inhibitor;BAZ2A/B dual inhibitor;BAZ2A, BAZ2B dual inhibitor targeting BAZ2A, BAZ2B |
| DE-28-ZP75_0.01uM | Dose=0.01uM, Deserpidine |
| DE-28-ZP75_0.1uM | Dose=0.1uM, Deserpidine |
| DE-28-ZP75_10uM | Dose=10uM, Deserpidine |
| DE-28-ZP75_1uM | Dose=1uM, Deserpidine |
| DE-29-MT22_0.01uM | Dose=0.01uM, Abiraterone Acetate, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Biosynthesis Inhibitors targeting CYP17A1 |
| DE-29-MT22_0.1uM | Dose=0.1uM, Abiraterone Acetate, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Biosynthesis Inhibitors targeting CYP17A1 |
| DE-29-MT22_10uM | Dose=10uM, Abiraterone Acetate, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Biosynthesis Inhibitors targeting CYP17A1 |
| DE-29-MT22_1uM | Dose=1uM, Abiraterone Acetate, Cytochrome P450 CYP17 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Androgen Biosynthesis Inhibitors targeting CYP17A1 |
| DE-30-EA70_0.01uM | Dose=0.01uM, Tiplasinin, Plasminogen Activator Inhibitor (PAI-1) Inhibitors targeting SERPINE1 |
| DE-30-EA70_0.1uM | Dose=0.1uM, Tiplasinin, Plasminogen Activator Inhibitor (PAI-1) Inhibitors targeting SERPINE1 |
| DE-30-EA70_1uM | Dose=1uM, Tiplasinin, Plasminogen Activator Inhibitor (PAI-1) Inhibitors targeting SERPINE1 |
| DE-30-UR76_0.01uM | Dose=0.01uM, Phorbol 12-myristate 13-acetate, Protein kinase C alpha stimulator targeting PRKCA |
| DE-30-UR76_0.1uM | Dose=0.1uM, Phorbol 12-myristate 13-acetate, Protein kinase C alpha stimulator targeting PRKCA |
| DE-30-UR76_10uM | Dose=10uM, Phorbol 12-myristate 13-acetate, Protein kinase C alpha stimulator targeting PRKCA |
| DE-30-UR76_1uM | Dose=1uM, Phorbol 12-myristate 13-acetate, Protein kinase C alpha stimulator targeting PRKCA |
| DE-34-DT75_0.1uM | Dose=0.1uM, NG5DD6UA5D, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers;Caspase 8 Activators;Caspase 3 Activators;Angiogenesis Inhibitors;Caspase 9 Activators targeting BIRC2, XIAP |
| DE-34-DT75_10uM | Dose=10uM, NG5DD6UA5D, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers;Caspase 8 Activators;Caspase 3 Activators;Angiogenesis Inhibitors;Caspase 9 Activators targeting BIRC2, XIAP |
| DE-34-DT75_1uM | Dose=1uM, NG5DD6UA5D, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers;Caspase 8 Activators;Caspase 3 Activators;Angiogenesis Inhibitors;Caspase 9 Activators targeting BIRC2, XIAP |
| DE-37-JV37_0.01uM | Dose=0.01uM, [5-[5-[5-(Hydroxymethyl)thiophen-2-yl]furan-2-yl]thiophen-2-yl]methanol, SULT1A1 prodrug;Antiinflammatory Drugs;Cytokine Production Inhibitors;Chemical crosslinker targeting MDM2, TXNRD1, TXNRD2 |
| DE-37-JV37_0.1uM | Dose=0.1uM, [5-[5-[5-(Hydroxymethyl)thiophen-2-yl]furan-2-yl]thiophen-2-yl]methanol, SULT1A1 prodrug;Antiinflammatory Drugs;Cytokine Production Inhibitors;Chemical crosslinker targeting MDM2, TXNRD1, TXNRD2 |
| DE-37-JV37_10uM | Dose=10uM, [5-[5-[5-(Hydroxymethyl)thiophen-2-yl]furan-2-yl]thiophen-2-yl]methanol, SULT1A1 prodrug;Antiinflammatory Drugs;Cytokine Production Inhibitors;Chemical crosslinker targeting MDM2, TXNRD1, TXNRD2 |
| DE-37-JV37_1uM | Dose=1uM, [5-[5-[5-(Hydroxymethyl)thiophen-2-yl]furan-2-yl]thiophen-2-yl]methanol, SULT1A1 prodrug;Antiinflammatory Drugs;Cytokine Production Inhibitors;Chemical crosslinker targeting MDM2, TXNRD1, TXNRD2 |
| DE-40-RX20_0.01uM | Dose=0.01uM, Pyridinium, 3-((2-(methylsulfonyl)hydrazinyl)carbonyl)-1-(2-oxo-2-(2-thienyl)ethyl)- |
| DE-40-RX20_0.1uM | Dose=0.1uM, Pyridinium, 3-((2-(methylsulfonyl)hydrazinyl)carbonyl)-1-(2-oxo-2-(2-thienyl)ethyl)- |
| DE-40-RX20_10uM | Dose=10uM, Pyridinium, 3-((2-(methylsulfonyl)hydrazinyl)carbonyl)-1-(2-oxo-2-(2-thienyl)ethyl)- |
| DE-40-RX20_1uM | Dose=1uM, Pyridinium, 3-((2-(methylsulfonyl)hydrazinyl)carbonyl)-1-(2-oxo-2-(2-thienyl)ethyl)- |
| DE-42-QB97_0.01uM | Dose=0.01uM, N-Acetylserotonin |
| DE-42-QB97_0.1uM | Dose=0.1uM, N-Acetylserotonin |
| DE-42-QB97_10uM | Dose=10uM, N-Acetylserotonin |
| DE-42-QB97_1uM | Dose=1uM, N-Acetylserotonin |
| DE-46-NH51_0.01uM | Dose=0.01uM, 3-(3-Cyclopentyloxy-4-methoxyphenyl)cyclopentan-1-one |
| DE-46-NH51_0.1uM | Dose=0.1uM, 3-(3-Cyclopentyloxy-4-methoxyphenyl)cyclopentan-1-one |
| DE-46-NH51_10uM | Dose=10uM, 3-(3-Cyclopentyloxy-4-methoxyphenyl)cyclopentan-1-one |
| DE-46-NH51_1uM | Dose=1uM, 3-(3-Cyclopentyloxy-4-methoxyphenyl)cyclopentan-1-one |
| DE-48-FF01_0.01uM | Dose=0.01uM, N-cyclopropyl-4-{8-[(2-methylpropyl)amino]imidazo[1,2-a]pyrazin-3-yl}benzamide, TTK gene inhibitor targeting TTK |
| DE-48-FF01_0.1uM | Dose=0.1uM, N-cyclopropyl-4-{8-[(2-methylpropyl)amino]imidazo[1,2-a]pyrazin-3-yl}benzamide, TTK gene inhibitor targeting TTK |
| DE-48-FF01_10uM | Dose=10uM, N-cyclopropyl-4-{8-[(2-methylpropyl)amino]imidazo[1,2-a]pyrazin-3-yl}benzamide, TTK gene inhibitor targeting TTK |
| DE-48-FF01_1uM | Dose=1uM, N-cyclopropyl-4-{8-[(2-methylpropyl)amino]imidazo[1,2-a]pyrazin-3-yl}benzamide, TTK gene inhibitor targeting TTK |
| DE-48-HZ49_0.01uM | Dose=0.01uM, BX-912, PKB beta/Akt2 Inhibitors targeting AKT2 |
| DE-48-HZ49_0.1uM | Dose=0.1uM, BX-912, PKB beta/Akt2 Inhibitors targeting AKT2 |
| DE-48-HZ49_10uM | Dose=10uM, BX-912, PKB beta/Akt2 Inhibitors targeting AKT2 |
| DE-48-HZ49_1uM | Dose=1uM, BX-912, PKB beta/Akt2 Inhibitors targeting AKT2 |
| DE-48-PP80_0.01uM | Dose=0.01uM, Apafant, Platelet-Activating Factor Receptor (PAFR) Antagonists;PTAFR antagonist targeting PTAFR |
| DE-48-PP80_0.1uM | Dose=0.1uM, Apafant, Platelet-Activating Factor Receptor (PAFR) Antagonists;PTAFR antagonist targeting PTAFR |
| DE-48-PP80_10uM | Dose=10uM, Apafant, Platelet-Activating Factor Receptor (PAFR) Antagonists;PTAFR antagonist targeting PTAFR |
| DE-48-PP80_1uM | Dose=1uM, Apafant, Platelet-Activating Factor Receptor (PAFR) Antagonists;PTAFR antagonist targeting PTAFR |
| DE-52-BS63_0.01uM | Dose=0.01uM, PAK1 gene inhibitor targeting PAK1 |
| DE-52-BS63_0.1uM | Dose=0.1uM, PAK1 gene inhibitor targeting PAK1 |
| DE-52-BS63_10uM | Dose=10uM, PAK1 gene inhibitor targeting PAK1 |
| DE-52-BS63_1uM | Dose=1uM, PAK1 gene inhibitor targeting PAK1 |
| DE-57-JI61_0.01uM | Dose=0.01uM, (E)-3-(4-((Z)-1-(4-Hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid, Selective Estrogen Receptor Downregulators (SERDs) targeting ESR1, ESR2 |
| DE-57-JI61_0.1uM | Dose=0.1uM, (E)-3-(4-((Z)-1-(4-Hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid, Selective Estrogen Receptor Downregulators (SERDs) targeting ESR1, ESR2 |
| DE-57-JI61_10uM | Dose=10uM, (E)-3-(4-((Z)-1-(4-Hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid, Selective Estrogen Receptor Downregulators (SERDs) targeting ESR1, ESR2 |
| DE-57-JI61_1uM | Dose=1uM, (E)-3-(4-((Z)-1-(4-Hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid, Selective Estrogen Receptor Downregulators (SERDs) targeting ESR1, ESR2 |
| DE-57-XI06_0.01uM | Dose=0.01uM, Dihydro-beta-erythroidine, Nicotinic alpha4beta2 Antagonists targeting CHRNA4, CHRNB2 |
| DE-57-XI06_0.1uM | Dose=0.1uM, Dihydro-beta-erythroidine, Nicotinic alpha4beta2 Antagonists targeting CHRNA4, CHRNB2 |
| DE-57-XI06_10uM | Dose=10uM, Dihydro-beta-erythroidine, Nicotinic alpha4beta2 Antagonists targeting CHRNA4, CHRNB2 |
| DE-57-XI06_1uM | Dose=1uM, Dihydro-beta-erythroidine, Nicotinic alpha4beta2 Antagonists targeting CHRNA4, CHRNB2 |
| DE-58-OW37_0.01uM | Dose=0.01uM, Cytarabine, DNA Polymerase Inhibitors;Antimetabolites targeting POLB, REV3L |
| DE-58-OW37_0.1uM | Dose=0.1uM, Cytarabine, DNA Polymerase Inhibitors;Antimetabolites targeting POLB, REV3L |
| DE-58-OW37_10uM | Dose=10uM, Cytarabine, DNA Polymerase Inhibitors;Antimetabolites targeting POLB, REV3L |
| DE-58-OW37_1uM | Dose=1uM, Cytarabine, DNA Polymerase Inhibitors;Antimetabolites targeting POLB, REV3L |
| DE-59-HQ30_0.01uM | Dose=0.01uM, (2S,4R)-1-N-(1-carbamoylindol-3-yl)-4-fluoro-2-N-[2-fluoro-3-(trifluoromethoxy)phenyl]pyrrolidine-1,2-dicarboxamide, Complement Factor D (CFD) Inhibitor targeting CFD |
| DE-59-HQ30_0.1uM | Dose=0.1uM, (2S,4R)-1-N-(1-carbamoylindol-3-yl)-4-fluoro-2-N-[2-fluoro-3-(trifluoromethoxy)phenyl]pyrrolidine-1,2-dicarboxamide, Complement Factor D (CFD) Inhibitor targeting CFD |
| DE-59-HQ30_10uM | Dose=10uM, (2S,4R)-1-N-(1-carbamoylindol-3-yl)-4-fluoro-2-N-[2-fluoro-3-(trifluoromethoxy)phenyl]pyrrolidine-1,2-dicarboxamide, Complement Factor D (CFD) Inhibitor targeting CFD |
| DE-59-OT87_0.01uM | Dose=0.01uM, N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluoromethoxy)phenyl]acetamide, Chemokine CXCR3 Antagonists targeting CXCR3 |
| DE-59-OT87_0.1uM | Dose=0.1uM, N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluoromethoxy)phenyl]acetamide, Chemokine CXCR3 Antagonists targeting CXCR3 |
| DE-59-OT87_1uM | Dose=1uM, N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluoromethoxy)phenyl]acetamide, Chemokine CXCR3 Antagonists targeting CXCR3 |
| DE-60-SD92_0.01uM | Dose=0.01uM, Lamotrigine |
| DE-60-SD92_0.1uM | Dose=0.1uM, Lamotrigine |
| DE-60-SD92_10uM | Dose=10uM, Lamotrigine |
| DE-60-SD92_1uM | Dose=1uM, Lamotrigine |
| DE-62-FI29_0.01uM | Dose=0.01uM, Fedratinib, Jak2 Inhibitors;Flt3 (FLK2/STK1) Inhibitors targeting FLT3, JAK2, BRD4 |
| DE-62-FI29_0.1uM | Dose=0.1uM, Fedratinib, Jak2 Inhibitors;Flt3 (FLK2/STK1) Inhibitors targeting FLT3, JAK2, BRD4 |
| DE-62-FI29_10uM | Dose=10uM, Fedratinib, Jak2 Inhibitors;Flt3 (FLK2/STK1) Inhibitors targeting FLT3, JAK2, BRD4 |
| DE-62-FI29_1uM | Dose=1uM, Fedratinib, Jak2 Inhibitors;Flt3 (FLK2/STK1) Inhibitors targeting FLT3, JAK2, BRD4 |
| DE-62-MB57_0.01uM | Dose=0.01uM, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors |
| DE-65-KO26_0.01uM | Dose=0.01uM, 2-Chloro-5-nitro-N-4-pyridinylbenzamide, PPARgamma antagonist targeting PPARG |
| DE-65-KO26_0.1uM | Dose=0.1uM, 2-Chloro-5-nitro-N-4-pyridinylbenzamide, PPARgamma antagonist targeting PPARG |
| DE-65-KO26_10uM | Dose=10uM, 2-Chloro-5-nitro-N-4-pyridinylbenzamide, PPARgamma antagonist targeting PPARG |
| DE-65-KO26_1uM | Dose=1uM, 2-Chloro-5-nitro-N-4-pyridinylbenzamide, PPARgamma antagonist targeting PPARG |
| DE-65-KO66_0.01uM | Dose=0.01uM |
| DE-65-KO66_0.1uM | Dose=0.1uM |
| DE-65-KO66_10uM | Dose=10uM |
| DE-65-KO66_1uM | Dose=1uM |
| DE-69-QQ25_0.01uM | Dose=0.01uM, 3,7-Dihydro-3,7-bis[(4-methoxyphenyl)methyl]-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one, DDX3X gene inhibitor targeting DDX3X |
| DE-69-QQ25_0.1uM | Dose=0.1uM, 3,7-Dihydro-3,7-bis[(4-methoxyphenyl)methyl]-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one, DDX3X gene inhibitor targeting DDX3X |
| DE-69-QQ25_10uM | Dose=10uM, 3,7-Dihydro-3,7-bis[(4-methoxyphenyl)methyl]-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one, DDX3X gene inhibitor targeting DDX3X |
| DE-69-QQ25_1uM | Dose=1uM, 3,7-Dihydro-3,7-bis[(4-methoxyphenyl)methyl]-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one, DDX3X gene inhibitor targeting DDX3X |
| DE-73-EF24_0.01uM | Dose=0.01uM, Reduced Feeding in mice;NPY5R antagonist;Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R |
| DE-73-EF24_0.1uM | Dose=0.1uM, Reduced Feeding in mice;NPY5R antagonist;Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R |
| DE-73-EF24_10uM | Dose=10uM, Reduced Feeding in mice;NPY5R antagonist;Neuropeptide Y5 (NPY Y5) Antagonists targeting NPY5R |
| DE-73-JX23_0.01uM | Dose=0.01uM, (2-(Phenylamino)-1,4-phenylene)bis((4-(pyrrolidin-1-yl)piperidin-1-yl)methanone), L3MBTL3 inhibitor;L3MBTL3 reader domain inhibitor targeting L3MBTL3, L3MBTL1 |
| DE-73-JX23_0.1uM | Dose=0.1uM, (2-(Phenylamino)-1,4-phenylene)bis((4-(pyrrolidin-1-yl)piperidin-1-yl)methanone), L3MBTL3 inhibitor;L3MBTL3 reader domain inhibitor targeting L3MBTL3, L3MBTL1 |
| DE-73-JX23_10uM | Dose=10uM, (2-(Phenylamino)-1,4-phenylene)bis((4-(pyrrolidin-1-yl)piperidin-1-yl)methanone), L3MBTL3 inhibitor;L3MBTL3 reader domain inhibitor targeting L3MBTL3, L3MBTL1 |
| DE-73-JX23_1uM | Dose=1uM, (2-(Phenylamino)-1,4-phenylene)bis((4-(pyrrolidin-1-yl)piperidin-1-yl)methanone), L3MBTL3 inhibitor;L3MBTL3 reader domain inhibitor targeting L3MBTL3, L3MBTL1 |
| DE-79-FD94_0.01uM | Dose=0.01uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB |
| DE-79-FD94_0.1uM | Dose=0.1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB |
| DE-79-FD94_10uM | Dose=10uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB |
| DE-79-FD94_1uM | Dose=1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACB |
| DE-80-BU08_0.01uM | Dose=0.01uM, DC_AC50, ATOX1 inhibitor targeting ATOX1 |
| DE-80-BU08_0.1uM | Dose=0.1uM, DC_AC50, ATOX1 inhibitor targeting ATOX1 |
| DE-80-BU08_10uM | Dose=10uM, DC_AC50, ATOX1 inhibitor targeting ATOX1 |
| DE-80-BU08_1uM | Dose=1uM, DC_AC50, ATOX1 inhibitor targeting ATOX1 |
| DE-81-OY65_10uM | Dose=10uM, Erlotinib, EGFR (HER1 or erbB1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting EGFR |
| DE-81-OY65_1uM | Dose=1uM, Erlotinib, EGFR (HER1 or erbB1) Inhibitors;Inhibitors of Signal Transduction Pathways targeting EGFR |
| DE-81-PO11_0.01uM | Dose=0.01uM, PF-Cbp1, N-Ac Lysine competitive CREBBP/EP300 inhibitor targeting CREBBP, EP300 |
| DE-81-PO11_0.1uM | Dose=0.1uM, PF-Cbp1, N-Ac Lysine competitive CREBBP/EP300 inhibitor targeting CREBBP, EP300 |
| DE-81-PO11_10uM | Dose=10uM, PF-Cbp1, N-Ac Lysine competitive CREBBP/EP300 inhibitor targeting CREBBP, EP300 |
| DE-81-PO11_1uM | Dose=1uM, PF-Cbp1, N-Ac Lysine competitive CREBBP/EP300 inhibitor targeting CREBBP, EP300 |
| DE-81-UE07_0.01uM | Dose=0.01uM, Creatine, ADP to ATP Phosphate donor;Creatine Kinase substrate targeting CKB, CKBE, CKM, CKMT1B, CKMT2, CKMT1A |
| DE-81-UE07_0.1uM | Dose=0.1uM, Creatine, ADP to ATP Phosphate donor;Creatine Kinase substrate targeting CKB, CKBE, CKM, CKMT1B, CKMT2, CKMT1A |
| DE-81-UE07_10uM | Dose=10uM, Creatine, ADP to ATP Phosphate donor;Creatine Kinase substrate targeting CKB, CKBE, CKM, CKMT1B, CKMT2, CKMT1A |
| DE-81-UE07_1uM | Dose=1uM, Creatine, ADP to ATP Phosphate donor;Creatine Kinase substrate targeting CKB, CKBE, CKM, CKMT1B, CKMT2, CKMT1A |
| DE-82-SC55_0.01uM | Dose=0.01uM, 3-[3-Tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid, Leukotriene Synthesis Inhibitors;5-Lipoxygenase-Activating Protein (FLAP) Inhibitors;PPAR Modulators targeting ALOX5AP |
| DE-82-SC55_0.1uM | Dose=0.1uM, 3-[3-Tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid, Leukotriene Synthesis Inhibitors;5-Lipoxygenase-Activating Protein (FLAP) Inhibitors;PPAR Modulators targeting ALOX5AP |
| DE-82-SC55_10uM | Dose=10uM, 3-[3-Tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid, Leukotriene Synthesis Inhibitors;5-Lipoxygenase-Activating Protein (FLAP) Inhibitors;PPAR Modulators targeting ALOX5AP |
| DE-82-SC55_1uM | Dose=1uM, 3-[3-Tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-ylindol-2-yl]-2,2-dimethylpropanoic acid, Leukotriene Synthesis Inhibitors;5-Lipoxygenase-Activating Protein (FLAP) Inhibitors;PPAR Modulators targeting ALOX5AP |
| DE-85-DO61_0.01uM | Dose=0.01uM, S-(2-boronoethyl)-L-cysteine, Arginase, Inhibitors targeting ARG1, ARG2 |
| DE-85-DO61_0.1uM | Dose=0.1uM, S-(2-boronoethyl)-L-cysteine, Arginase, Inhibitors targeting ARG1, ARG2 |
| DE-85-DO61_10uM | Dose=10uM, S-(2-boronoethyl)-L-cysteine, Arginase, Inhibitors targeting ARG1, ARG2 |
| DE-85-FR73_0.01uM | Dose=0.01uM, Azd1208, PIM1, PIM2 and PIM3 inhibitor targeting PIM1, PIM2, PIM3 |
| DE-85-FR73_0.1uM | Dose=0.1uM, Azd1208, PIM1, PIM2 and PIM3 inhibitor targeting PIM1, PIM2, PIM3 |
| DE-85-FR73_10uM | Dose=10uM, Azd1208, PIM1, PIM2 and PIM3 inhibitor targeting PIM1, PIM2, PIM3 |
| DE-85-FR73_1uM | Dose=1uM, Azd1208, PIM1, PIM2 and PIM3 inhibitor targeting PIM1, PIM2, PIM3 |
| DE-85-LX22_0.01uM | Dose=0.01uM, (2S,4R)-1-[(2R)-2-(cyclobutylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DE-85-LX22_0.1uM | Dose=0.1uM, (2S,4R)-1-[(2R)-2-(cyclobutylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DE-85-LX22_10uM | Dose=10uM, (2S,4R)-1-[(2R)-2-(cyclobutylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DE-85-LX22_1uM | Dose=1uM, (2S,4R)-1-[(2R)-2-(cyclobutylmethyl)-3-[formyl(hydroxy)amino]propanoyl]-4-fluoro-N-pyridazin-3-ylpyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DE-86-XV75_0.01uM | Dose=0.01uM, Griseofulvin, Keratin 12 modulator targeting KRT12 |
| DE-86-XV75_0.1uM | Dose=0.1uM, Griseofulvin, Keratin 12 modulator targeting KRT12 |
| DE-86-XV75_10uM | Dose=10uM, Griseofulvin, Keratin 12 modulator targeting KRT12 |
| DE-86-XV75_1uM | Dose=1uM, Griseofulvin, Keratin 12 modulator targeting KRT12 |
| DE-90-RU43_0.01uM | Dose=0.01uM, 7-Amino-1-bromo-8,9-dihydro-5H-benzo[7]annulen-6(7H)-one, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP |
| DE-90-RU43_0.1uM | Dose=0.1uM, 7-Amino-1-bromo-8,9-dihydro-5H-benzo[7]annulen-6(7H)-one, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP |
| DE-90-RU43_10uM | Dose=10uM, 7-Amino-1-bromo-8,9-dihydro-5H-benzo[7]annulen-6(7H)-one, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP |
| DE-90-RU43_1uM | Dose=1uM, 7-Amino-1-bromo-8,9-dihydro-5H-benzo[7]annulen-6(7H)-one, Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors targeting ANPEP |
| DE-91-FH69_0.01uM | Dose=0.01uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| DE-91-FH69_0.1uM | Dose=0.1uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| DE-91-FH69_10uM | Dose=10uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| DE-91-FH69_1uM | Dose=1uM, 1-[3-(2-Hydroxy-ethoxy)-benzyl]-4-(4-isopropyl-phenyl)-6-propargyloxy-1H-quinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| DE-93-IC37_0.01uM | Dose=0.01uM, Protein Tyrosine Phosphatase PTP-1C Inhibitors;Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors;Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1, PTPN6, PTPN11 |
| DE-93-IC37_0.1uM | Dose=0.1uM, Protein Tyrosine Phosphatase PTP-1C Inhibitors;Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors;Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1, PTPN6, PTPN11 |
| DE-93-IC37_1uM | Dose=1uM, Protein Tyrosine Phosphatase PTP-1C Inhibitors;Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors;Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1, PTPN6, PTPN11 |
| DE-97-IV02_0.1uM | Dose=0.1uM, 2-amino-4-(2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl)-N-ethylthieno(2,3-d)pyrimidine-6-carboxamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1, HSP90B1 |
| DE-97-IV02_10uM | Dose=10uM, 2-amino-4-(2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl)-N-ethylthieno(2,3-d)pyrimidine-6-carboxamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1, HSP90B1 |
| DE-97-IV02_1uM | Dose=1uM, 2-amino-4-(2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl)-N-ethylthieno(2,3-d)pyrimidine-6-carboxamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90AA1, HSP90B1 |
| DE-98-FC24_0.01uM | Dose=0.01uM |
| DE-98-FC24_0.1uM | Dose=0.1uM |
| DE-98-FC24_10uM | Dose=10uM |
| DE-98-FC24_1uM | Dose=1uM |
| DE-99-OT37_0.01uM | Dose=0.01uM, Melevodopa, Dopamine Precursors targeting DRD1, DRD3, DRD2, DRD4, DRD5 |
| DE-99-OT37_0.1uM | Dose=0.1uM, Melevodopa, Dopamine Precursors targeting DRD1, DRD3, DRD2, DRD4, DRD5 |
| DE-99-OT37_10uM | Dose=10uM, Melevodopa, Dopamine Precursors targeting DRD1, DRD3, DRD2, DRD4, DRD5 |
| DE-99-OT37_1uM | Dose=1uM, Melevodopa, Dopamine Precursors targeting DRD1, DRD3, DRD2, DRD4, DRD5 |
| DF-00-BU08_0.01uM | Dose=0.01uM, Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester, PAK4 gene inhibitor targeting PAK4 |
| DF-00-BU08_0.1uM | Dose=0.1uM, Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester, PAK4 gene inhibitor targeting PAK4 |
| DF-00-BU08_10uM | Dose=10uM, Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester, PAK4 gene inhibitor targeting PAK4 |
| DF-00-BU08_1uM | Dose=1uM, Pyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-4,6-dihydro-6,6-dimethyl-, (1S)-2-(dimethylamino)-1-phenylethyl ester, PAK4 gene inhibitor targeting PAK4 |
| DF-00-BX35_0.01uM | Dose=0.01uM, N-[5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methyl-phenyl]methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1 |
| DF-00-BX35_0.1uM | Dose=0.1uM, N-[5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methyl-phenyl]methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1 |
| DF-00-BX35_10uM | Dose=10uM, N-[5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methyl-phenyl]methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1 |
| DF-00-BX35_1uM | Dose=1uM, N-[5-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]-2-methyl-phenyl]methanesulfonamide, CDK inhibitor targeting CDK2, CCNA1 |
| DF-00-DK69_0.01uM | Dose=0.01uM, Azacitidine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors;Apoptosis Inducers targeting DNMT1, DTYMK, UHRF1 |
| DF-00-DK69_0.1uM | Dose=0.1uM, Azacitidine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors;Apoptosis Inducers targeting DNMT1, DTYMK, UHRF1 |
| DF-00-DK69_10uM | Dose=10uM, Azacitidine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors;Apoptosis Inducers targeting DNMT1, DTYMK, UHRF1 |
| DF-00-DK69_1uM | Dose=1uM, Azacitidine, Antimetabolites;DNMT1;DNA Methyltransferase (DNMT) Inhibitors;Apoptosis Inducers targeting DNMT1, DTYMK, UHRF1 |
| DF-00-NA25_0.01uM | Dose=0.01uM, 2-(2-Chloro-6-fluorophenyl)-5-(6-(phenylethynyl)pyridin-3-yl)-1H-imidazole-4-carbonitrile, Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors targeting PTGES |
| DF-00-NA25_10uM | Dose=10uM, 2-(2-Chloro-6-fluorophenyl)-5-(6-(phenylethynyl)pyridin-3-yl)-1H-imidazole-4-carbonitrile, Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors targeting PTGES |
| DF-00-NA25_1uM | Dose=1uM, 2-(2-Chloro-6-fluorophenyl)-5-(6-(phenylethynyl)pyridin-3-yl)-1H-imidazole-4-carbonitrile, Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors targeting PTGES |
| DF-03-OP38_0.01uM | Dose=0.01uM |
| DF-03-OP38_10uM | Dose=10uM |
| DF-03-OP38_1uM | Dose=1uM |
| DF-11-IL69_0.01uM | Dose=0.01uM, Antimetabolites;DHFR inhibitor;de novo synthesis inhibitor targeting DHFR, GART, TYMS |
| DF-11-IL69_0.1uM | Dose=0.1uM, Antimetabolites;DHFR inhibitor;de novo synthesis inhibitor targeting DHFR, GART, TYMS |
| DF-11-IL69_10uM | Dose=10uM, Antimetabolites;DHFR inhibitor;de novo synthesis inhibitor targeting DHFR, GART, TYMS |
| DF-11-IL69_1uM | Dose=1uM, Antimetabolites;DHFR inhibitor;de novo synthesis inhibitor targeting DHFR, GART, TYMS |
| DF-13-OP48_0.01uM | Dose=0.01uM, (2R)-2-amino-2-methyl-4-(4-pentoxyphenyl)butan-1-ol |
| DF-13-OP48_0.1uM | Dose=0.1uM, (2R)-2-amino-2-methyl-4-(4-pentoxyphenyl)butan-1-ol |
| DF-13-OP48_10uM | Dose=10uM, (2R)-2-amino-2-methyl-4-(4-pentoxyphenyl)butan-1-ol |
| DF-13-OP48_1uM | Dose=1uM, (2R)-2-amino-2-methyl-4-(4-pentoxyphenyl)butan-1-ol |
| DF-26-EY87_0.01uM | Dose=0.01uM |
| DF-26-EY87_0.1uM | Dose=0.1uM |
| DF-26-EY87_10uM | Dose=10uM |
| DF-26-EY87_1uM | Dose=1uM |
| DF-32-EL16_0.01uM | Dose=0.01uM, SB-334867, HCRTR1 antagonist;Orexin OX-1 Antagonists targeting HCRTR1 |
| DF-32-EL16_0.1uM | Dose=0.1uM, SB-334867, HCRTR1 antagonist;Orexin OX-1 Antagonists targeting HCRTR1 |
| DF-32-EL16_10uM | Dose=10uM, SB-334867, HCRTR1 antagonist;Orexin OX-1 Antagonists targeting HCRTR1 |
| DF-32-EL16_1uM | Dose=1uM, SB-334867, HCRTR1 antagonist;Orexin OX-1 Antagonists targeting HCRTR1 |
| DF-32-MM89_10uM | Dose=10uM, Dihydropyrimidine Dehydrogenase Inhibitors targeting DPYD |
| DF-32-MM89_1uM | Dose=1uM, Dihydropyrimidine Dehydrogenase Inhibitors targeting DPYD |
| DF-37-AV77_0.01uM | Dose=0.01uM, Chlorthalidone, Carbonic Anhydrase Type VII Inhibitors targeting CA1, CA4, CA5A, CA7, CA12, CA5B |
| DF-37-AV77_10uM | Dose=10uM, Chlorthalidone, Carbonic Anhydrase Type VII Inhibitors targeting CA1, CA4, CA5A, CA7, CA12, CA5B |
| DF-37-AV77_1uM | Dose=1uM, Chlorthalidone, Carbonic Anhydrase Type VII Inhibitors targeting CA1, CA4, CA5A, CA7, CA12, CA5B |
| DF-40-CD57_0.01uM | Dose=0.01uM, ((R)-1-Phenyl-ethyl)-[6-(4-piperazin-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine, EGFR (HER1;Angiogenesis Inhibitors;VEGFR Inhibitors;erbB1) Inhibitors targeting EGFR, ERBB2, ABL1 |
| DF-40-CD57_0.1uM | Dose=0.1uM, ((R)-1-Phenyl-ethyl)-[6-(4-piperazin-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine, EGFR (HER1;Angiogenesis Inhibitors;VEGFR Inhibitors;erbB1) Inhibitors targeting EGFR, ERBB2, ABL1 |
| DF-40-CD57_10uM | Dose=10uM, ((R)-1-Phenyl-ethyl)-[6-(4-piperazin-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine, EGFR (HER1;Angiogenesis Inhibitors;VEGFR Inhibitors;erbB1) Inhibitors targeting EGFR, ERBB2, ABL1 |
| DF-40-CD57_1uM | Dose=1uM, ((R)-1-Phenyl-ethyl)-[6-(4-piperazin-1-ylmethyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amine, EGFR (HER1;Angiogenesis Inhibitors;VEGFR Inhibitors;erbB1) Inhibitors targeting EGFR, ERBB2, ABL1 |
| DF-41-HL79_0.01uM | Dose=0.01uM, D-Methionine |
| DF-41-HL79_0.1uM | Dose=0.1uM, D-Methionine |
| DF-41-HL79_10uM | Dose=10uM, D-Methionine |
| DF-45-GA42_0.01uM | Dose=0.01uM, SB 224289, HTR1B antagonist targeting HTR1B |
| DF-45-GA42_0.1uM | Dose=0.1uM, SB 224289, HTR1B antagonist targeting HTR1B |
| DF-45-GA42_10uM | Dose=10uM, SB 224289, HTR1B antagonist targeting HTR1B |
| DF-45-GA42_1uM | Dose=1uM, SB 224289, HTR1B antagonist targeting HTR1B |
| DF-46-QE34_0.01uM | Dose=0.01uM, [(3S,4R,5R)-4-[4-[[(2S)-3-methoxy-2-methylpropoxy]methyl]phenyl]-5-[[4-(3-methoxypropyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methoxy]piperidin-3-yl]methanol, beta-Secretase (BACE) Inhibitors;Plasmepsin II Inhibitors;Cathepsin D Inhibitors;HIV Protease Inhibitors targeting CTSD, BACE1 |
| DF-46-QE34_0.1uM | Dose=0.1uM, [(3S,4R,5R)-4-[4-[[(2S)-3-methoxy-2-methylpropoxy]methyl]phenyl]-5-[[4-(3-methoxypropyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methoxy]piperidin-3-yl]methanol, beta-Secretase (BACE) Inhibitors;Plasmepsin II Inhibitors;Cathepsin D Inhibitors;HIV Protease Inhibitors targeting CTSD, BACE1 |
| DF-46-QE34_10uM | Dose=10uM, [(3S,4R,5R)-4-[4-[[(2S)-3-methoxy-2-methylpropoxy]methyl]phenyl]-5-[[4-(3-methoxypropyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methoxy]piperidin-3-yl]methanol, beta-Secretase (BACE) Inhibitors;Plasmepsin II Inhibitors;Cathepsin D Inhibitors;HIV Protease Inhibitors targeting CTSD, BACE1 |
| DF-46-QE34_1uM | Dose=1uM, [(3S,4R,5R)-4-[4-[[(2S)-3-methoxy-2-methylpropoxy]methyl]phenyl]-5-[[4-(3-methoxypropyl)-2,3-dihydro-1,4-benzoxazin-6-yl]methoxy]piperidin-3-yl]methanol, beta-Secretase (BACE) Inhibitors;Plasmepsin II Inhibitors;Cathepsin D Inhibitors;HIV Protease Inhibitors targeting CTSD, BACE1 |
| DF-53-QT23_0.01uM | Dose=0.01uM, 4-(4-((Dimethylamino)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one, BRD9 gene inhibitor;BRD7/9 inhibitor targeting BRD7, BRD9 |
| DF-53-QT23_0.1uM | Dose=0.1uM, 4-(4-((Dimethylamino)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one, BRD9 gene inhibitor;BRD7/9 inhibitor targeting BRD7, BRD9 |
| DF-53-QT23_10uM | Dose=10uM, 4-(4-((Dimethylamino)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one, BRD9 gene inhibitor;BRD7/9 inhibitor targeting BRD7, BRD9 |
| DF-53-QT23_1uM | Dose=1uM, 4-(4-((Dimethylamino)methyl)-2,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one, BRD9 gene inhibitor;BRD7/9 inhibitor targeting BRD7, BRD9 |
| DF-56-GR45_0.01uM | Dose=0.01uM, 3-Butenoic acid, 4-phenyl-, (3E)-, Peptidyl-Glycine alpha-Amidating Monooxygenase (PAM) Inhibitors targeting PAM |
| DF-56-GR45_0.1uM | Dose=0.1uM, 3-Butenoic acid, 4-phenyl-, (3E)-, Peptidyl-Glycine alpha-Amidating Monooxygenase (PAM) Inhibitors targeting PAM |
| DF-56-GR45_10uM | Dose=10uM, 3-Butenoic acid, 4-phenyl-, (3E)-, Peptidyl-Glycine alpha-Amidating Monooxygenase (PAM) Inhibitors targeting PAM |
| DF-56-GR45_1uM | Dose=1uM, 3-Butenoic acid, 4-phenyl-, (3E)-, Peptidyl-Glycine alpha-Amidating Monooxygenase (PAM) Inhibitors targeting PAM |
| DF-57-BL63_0.01uM | Dose=0.01uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-[(3-carbamoylpropionyl)amino]-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1 |
| DF-57-BL63_0.1uM | Dose=0.1uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-[(3-carbamoylpropionyl)amino]-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1 |
| DF-57-BL63_10uM | Dose=10uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-[(3-carbamoylpropionyl)amino]-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1 |
| DF-57-BL63_1uM | Dose=1uM, (5S,7S)-5-(4-Cyanobenzyl)-3-(3,5-dichlorophenyl)-7-[(3-carbamoylpropionyl)amino]-1,3-diazabicyclo[3.3.0]octane-2,4-dione, Cell Adhesion Inhibitors;Tachykinin NK1 Antagonists;Integrin alphaLbeta2 (LFA-1) Antagonists targeting TACR1 |
| DF-57-FI46_0.01uM | Dose=0.01uM, Nimodipine, Calcium channel inhibitor L-type targeting CACNA1C, CACNA1D, CACNA1S, CACNB1, CACNB4, CACNA1A, CACNA1E, CACNG1 |
| DF-57-FI46_0.1uM | Dose=0.1uM, Nimodipine, Calcium channel inhibitor L-type targeting CACNA1C, CACNA1D, CACNA1S, CACNB1, CACNB4, CACNA1A, CACNA1E, CACNG1 |
| DF-57-FI46_10uM | Dose=10uM, Nimodipine, Calcium channel inhibitor L-type targeting CACNA1C, CACNA1D, CACNA1S, CACNB1, CACNB4, CACNA1A, CACNA1E, CACNG1 |
| DF-57-FI46_1uM | Dose=1uM, Nimodipine, Calcium channel inhibitor L-type targeting CACNA1C, CACNA1D, CACNA1S, CACNB1, CACNB4, CACNA1A, CACNA1E, CACNG1 |
| DF-70-CD57_0.01uM | Dose=0.01uM, 2H-[1]Benzopyrano[3,4-b]pyridin-7-ol, 1,3,4,4a,5,10b-hexahydro-4-propyl-, trans-, Dopamine Autoreceptor Agonists targeting DRD2 |
| DF-70-CD57_0.1uM | Dose=0.1uM, 2H-[1]Benzopyrano[3,4-b]pyridin-7-ol, 1,3,4,4a,5,10b-hexahydro-4-propyl-, trans-, Dopamine Autoreceptor Agonists targeting DRD2 |
| DF-70-CD57_10uM | Dose=10uM, 2H-[1]Benzopyrano[3,4-b]pyridin-7-ol, 1,3,4,4a,5,10b-hexahydro-4-propyl-, trans-, Dopamine Autoreceptor Agonists targeting DRD2 |
| DF-70-CD57_1uM | Dose=1uM, 2H-[1]Benzopyrano[3,4-b]pyridin-7-ol, 1,3,4,4a,5,10b-hexahydro-4-propyl-, trans-, Dopamine Autoreceptor Agonists targeting DRD2 |
| DF-74-MG39_0.01uM | Dose=0.01uM, N-(2-Methyl-2-(2-phenyloxazol-4-yl)propyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide targeting HDAC9, HDAC4, HDAC5, HDAC7 |
| DF-74-MG39_10uM | Dose=10uM, N-(2-Methyl-2-(2-phenyloxazol-4-yl)propyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide targeting HDAC9, HDAC4, HDAC5, HDAC7 |
| DF-74-MG39_1uM | Dose=1uM, N-(2-Methyl-2-(2-phenyloxazol-4-yl)propyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide targeting HDAC9, HDAC4, HDAC5, HDAC7 |
| DF-75-JD89_0.01uM | Dose=0.01uM, (2S)-N-(4-ethylpyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DF-75-JD89_0.1uM | Dose=0.1uM, (2S)-N-(4-ethylpyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DF-75-JD89_10uM | Dose=10uM, (2S)-N-(4-ethylpyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DF-75-JD89_1uM | Dose=1uM, (2S)-N-(4-ethylpyridin-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]pyrrolidine-2-carboxamide, Peptide Deformylase (PDF) Inhibitors targeting PDF |
| DF-75-MR73_0.01uM | Dose=0.01uM, Denbufylline, Phosphodiesterase IV Inhibitors targeting ENPP4 |
| DF-75-MR73_0.1uM | Dose=0.1uM, Denbufylline, Phosphodiesterase IV Inhibitors targeting ENPP4 |
| DF-75-MR73_10uM | Dose=10uM, Denbufylline, Phosphodiesterase IV Inhibitors targeting ENPP4 |
| DF-75-OU25_0.1uM | Dose=0.1uM, Dot1L-IN-4 |
| DF-75-OU25_10uM | Dose=10uM, Dot1L-IN-4 |
| DF-75-OU25_1uM | Dose=1uM, Dot1L-IN-4 |
| DF-80-BU28_0.01uM | Dose=0.01uM, Nvs-crf38, CRF1 Antagonists;CRF-1 receptor antagonist targeting CRHR1 |
| DF-80-BU28_0.1uM | Dose=0.1uM, Nvs-crf38, CRF1 Antagonists;CRF-1 receptor antagonist targeting CRHR1 |
| DF-80-BU28_1uM | Dose=1uM, Nvs-crf38, CRF1 Antagonists;CRF-1 receptor antagonist targeting CRHR1 |
| DF-80-HY53_0.1uM | Dose=0.1uM, Baicalein |
| DF-80-HY53_10uM | Dose=10uM, Baicalein |
| DF-84-RT50_0.01uM | Dose=0.01uM |
| DF-84-RT50_0.1uM | Dose=0.1uM |
| DF-84-RT50_10uM | Dose=10uM |
| DF-84-RT50_1uM | Dose=1uM |
| DF-85-QA87_0.01uM | Dose=0.01uM, Htfmt, HRH1 agonist targeting HRH1 |
| DF-85-QA87_0.1uM | Dose=0.1uM, Htfmt, HRH1 agonist targeting HRH1 |
| DF-85-QA87_10uM | Dose=10uM, Htfmt, HRH1 agonist targeting HRH1 |
| DF-85-QA87_1uM | Dose=1uM, Htfmt, HRH1 agonist targeting HRH1 |
| DF-92-CF17_0.01uM | Dose=0.01uM, Carbonyl cyanide p-trifluoromethoxyphenylhydrazone |
| DF-92-CF17_10uM | Dose=10uM, Carbonyl cyanide p-trifluoromethoxyphenylhydrazone |
| DF-92-CF17_1uM | Dose=1uM, Carbonyl cyanide p-trifluoromethoxyphenylhydrazone |
| DF-93-BT88_0.01uM | Dose=0.01uM, N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide, KDM4C inhibitor targeting KDM4C |
| DF-93-BT88_10uM | Dose=10uM, N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide, KDM4C inhibitor targeting KDM4C |
| DF-93-BT88_1uM | Dose=1uM, N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide, KDM4C inhibitor targeting KDM4C |
| DF-95-CY55_0.01uM | Dose=0.01uM |
| DF-95-CY55_0.1uM | Dose=0.1uM |
| DF-95-CY55_10uM | Dose=10uM |
| DF-95-CY55_1uM | Dose=1uM |
| EA-00-QR36_0.01uM | Dose=0.01uM, MLL1-WDR5 blocker DDO-2117, MLL1-WDR5 Protein-protein interaction inhibitor targeting KMT2A |
| EA-00-QR36_0.1uM | Dose=0.1uM, MLL1-WDR5 blocker DDO-2117, MLL1-WDR5 Protein-protein interaction inhibitor targeting KMT2A |
| EA-00-QR36_10uM | Dose=10uM, MLL1-WDR5 blocker DDO-2117, MLL1-WDR5 Protein-protein interaction inhibitor targeting KMT2A |
| EA-00-QR36_1uM | Dose=1uM, MLL1-WDR5 blocker DDO-2117, MLL1-WDR5 Protein-protein interaction inhibitor targeting KMT2A |
| EA-00-RN06_0.01uM | Dose=0.01uM, N-(3-nitrophenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| EA-00-RN06_0.1uM | Dose=0.1uM, N-(3-nitrophenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| EA-00-RN06_10uM | Dose=10uM, N-(3-nitrophenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| EA-00-RN06_1uM | Dose=1uM, N-(3-nitrophenyl)imidodicarbonimidic diamide, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| EA-02-ZO63_0.01uM | Dose=0.01uM, Gilteritinib, FLT3/AXL inhibitor targeting ALK, AXL, FLT3 |
| EA-02-ZO63_0.1uM | Dose=0.1uM, Gilteritinib, FLT3/AXL inhibitor targeting ALK, AXL, FLT3 |
| EA-02-ZO63_10uM | Dose=10uM, Gilteritinib, FLT3/AXL inhibitor targeting ALK, AXL, FLT3 |
| EA-02-ZO63_1uM | Dose=1uM, Gilteritinib, FLT3/AXL inhibitor targeting ALK, AXL, FLT3 |
| EA-06-CH36_0.01uM | Dose=0.01uM, 2-(1-{4-[3-(3,5-Dimethyl-isoxazol-4-yl)-ureido]-2-fluoro-phenyl}-piperidin-4-yl)-N,N-diethyl-2-phenyl-acetamide, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R |
| EA-06-CH36_0.1uM | Dose=0.1uM, 2-(1-{4-[3-(3,5-Dimethyl-isoxazol-4-yl)-ureido]-2-fluoro-phenyl}-piperidin-4-yl)-N,N-diethyl-2-phenyl-acetamide, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R |
| EA-06-CH36_10uM | Dose=10uM, 2-(1-{4-[3-(3,5-Dimethyl-isoxazol-4-yl)-ureido]-2-fluoro-phenyl}-piperidin-4-yl)-N,N-diethyl-2-phenyl-acetamide, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R |
| EA-06-CH36_1uM | Dose=1uM, 2-(1-{4-[3-(3,5-Dimethyl-isoxazol-4-yl)-ureido]-2-fluoro-phenyl}-piperidin-4-yl)-N,N-diethyl-2-phenyl-acetamide, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R |
| EA-07-RB34_0.01uM | Dose=0.01uM |
| EA-07-RB34_0.1uM | Dose=0.1uM |
| EA-07-RB34_10uM | Dose=10uM |
| EA-07-RB34_1uM | Dose=1uM |
| EA-09-HM95_0.01uM | Dose=0.01uM |
| EA-09-HM95_0.1uM | Dose=0.1uM |
| EA-09-HM95_10uM | Dose=10uM |
| EA-09-HM95_1uM | Dose=1uM |
| EA-12-SS08_0.01uM | Dose=0.01uM, Tenogenic;Nerve Growth Factor (NGF) Enhancers targeting NGF, CDK8 |
| EA-12-SS08_0.1uM | Dose=0.1uM, Tenogenic;Nerve Growth Factor (NGF) Enhancers targeting NGF, CDK8 |
| EA-12-SS08_10uM | Dose=10uM, Tenogenic;Nerve Growth Factor (NGF) Enhancers targeting NGF, CDK8 |
| EA-12-SS08_1uM | Dose=1uM, Tenogenic;Nerve Growth Factor (NGF) Enhancers targeting NGF, CDK8 |
| EA-17-BY69_0.01uM | Dose=0.01uM |
| EA-17-BY69_0.1uM | Dose=0.1uM |
| EA-17-BY69_10uM | Dose=10uM |
| EA-17-BY69_1uM | Dose=1uM |
| EA-18-FP00_0.01uM | Dose=0.01uM, Omacetaxine Mepesuccinate, Elongation inhibitor;Translation inhibitor;Treatment of orphan leukemia;treatment of orphan leukemia targeting EIF4E |
| EA-18-FP00_0.1uM | Dose=0.1uM, Omacetaxine Mepesuccinate, Elongation inhibitor;Translation inhibitor;Treatment of orphan leukemia;treatment of orphan leukemia targeting EIF4E |
| EA-18-FP00_10uM | Dose=10uM, Omacetaxine Mepesuccinate, Elongation inhibitor;Translation inhibitor;Treatment of orphan leukemia;treatment of orphan leukemia targeting EIF4E |
| EA-18-FP00_1uM | Dose=1uM, Omacetaxine Mepesuccinate, Elongation inhibitor;Translation inhibitor;Treatment of orphan leukemia;treatment of orphan leukemia targeting EIF4E |
| EA-22-SB72_0.01uM | Dose=0.01uM, 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone, IGF-1R Inhibitors targeting IGF1R |
| EA-22-SB72_0.1uM | Dose=0.1uM, 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone, IGF-1R Inhibitors targeting IGF1R |
| EA-22-SB72_10uM | Dose=10uM, 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone, IGF-1R Inhibitors targeting IGF1R |
| EA-22-SB72_1uM | Dose=1uM, 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone, IGF-1R Inhibitors targeting IGF1R |
| EA-25-VD74_0.01uM | Dose=0.01uM, Tramiprosate, Antiamyloidogenic Agents;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP |
| EA-25-VD74_0.1uM | Dose=0.1uM, Tramiprosate, Antiamyloidogenic Agents;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP |
| EA-25-VD74_10uM | Dose=10uM, Tramiprosate, Antiamyloidogenic Agents;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP |
| EA-25-VD74_1uM | Dose=1uM, Tramiprosate, Antiamyloidogenic Agents;beta-Amyloid (Abeta) Aggregation Inhibitors targeting APP |
| EA-30-DG14_0.01uM | Dose=0.01uM, Lanepitant, Growth Hormone Secretagogues;Tachykinin NK1 Antagonists targeting GH1, TACR1 |
| EA-30-DG14_10uM | Dose=10uM, Lanepitant, Growth Hormone Secretagogues;Tachykinin NK1 Antagonists targeting GH1, TACR1 |
| EA-30-ZX90_0.01uM | Dose=0.01uM, 6-Chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| EA-30-ZX90_0.1uM | Dose=0.1uM, 6-Chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| EA-30-ZX90_10uM | Dose=10uM, 6-Chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| EA-30-ZX90_1uM | Dose=1uM, 6-Chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-enylamino]-2-hydroxy-N-methoxy-N-methyl-benzenesulfonamide, Chemokine CXCR2 (IL-8 beta Receptor) Antagonists targeting CXCR2 |
| EA-32-CY22_0.01uM | Dose=0.01uM, 2-[(4S)-4-[(3,3-dimethyl-2,4-dihydro-1H-quinolin-8-yl)sulfonylamino]-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-oxopentyl]guanidine, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2 |
| EA-32-CY22_0.1uM | Dose=0.1uM, 2-[(4S)-4-[(3,3-dimethyl-2,4-dihydro-1H-quinolin-8-yl)sulfonylamino]-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-oxopentyl]guanidine, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2 |
| EA-32-CY22_10uM | Dose=10uM, 2-[(4S)-4-[(3,3-dimethyl-2,4-dihydro-1H-quinolin-8-yl)sulfonylamino]-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-oxopentyl]guanidine, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2 |
| EA-32-CY22_1uM | Dose=1uM, 2-[(4S)-4-[(3,3-dimethyl-2,4-dihydro-1H-quinolin-8-yl)sulfonylamino]-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-oxopentyl]guanidine, Thrombin Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F2 |
| EA-33-QC97_0.01uM | Dose=0.01uM |
| EA-33-QC97_0.1uM | Dose=0.1uM |
| EA-33-QC97_10uM | Dose=10uM |
| EA-33-QC97_1uM | Dose=1uM |
| EA-39-WW34_0.01uM | Dose=0.01uM, 5-Phosphono-D-norvaline, NMDA Antagonists targeting GRIN1 |
| EA-39-WW34_10uM | Dose=10uM, 5-Phosphono-D-norvaline, NMDA Antagonists targeting GRIN1 |
| EA-39-YN88_0.01uM | Dose=0.01uM |
| EA-39-YN88_0.1uM | Dose=0.1uM |
| EA-39-YN88_10uM | Dose=10uM |
| EA-39-YN88_1uM | Dose=1uM |
| EA-40-GQ08_0.01uM | Dose=0.01uM, N-[N-[N-[(2,6-dimethyl-1-piperidinyl)carbonyl]-4-methyl-l-leucyl]-1-(methoxycarbonyl)-d-tryptophyl]-d-norleucine, Endothelin ETB Receptor Antagonists targeting EDNRB |
| EA-40-GQ08_10uM | Dose=10uM, N-[N-[N-[(2,6-dimethyl-1-piperidinyl)carbonyl]-4-methyl-l-leucyl]-1-(methoxycarbonyl)-d-tryptophyl]-d-norleucine, Endothelin ETB Receptor Antagonists targeting EDNRB |
| EA-40-GQ08_1uM | Dose=1uM, N-[N-[N-[(2,6-dimethyl-1-piperidinyl)carbonyl]-4-methyl-l-leucyl]-1-(methoxycarbonyl)-d-tryptophyl]-d-norleucine, Endothelin ETB Receptor Antagonists targeting EDNRB |
| EA-40-KQ08_0.01uM | Dose=0.01uM, Kco-912, K(ATP) Channel Activators targeting KCNJ8, KCNJ11, ABCC8, ABCC9 |
| EA-40-KQ08_0.1uM | Dose=0.1uM, Kco-912, K(ATP) Channel Activators targeting KCNJ8, KCNJ11, ABCC8, ABCC9 |
| EA-40-KQ08_10uM | Dose=10uM, Kco-912, K(ATP) Channel Activators targeting KCNJ8, KCNJ11, ABCC8, ABCC9 |
| EA-40-KQ08_1uM | Dose=1uM, Kco-912, K(ATP) Channel Activators targeting KCNJ8, KCNJ11, ABCC8, ABCC9 |
| EA-41-GV68_0.01uM | Dose=0.01uM, Firibastat, Known aminopeptidase A inhibitor targeting ENPEP |
| EA-41-GV68_0.1uM | Dose=0.1uM, Firibastat, Known aminopeptidase A inhibitor targeting ENPEP |
| EA-41-GV68_10uM | Dose=10uM, Firibastat, Known aminopeptidase A inhibitor targeting ENPEP |
| EA-41-GV68_1uM | Dose=1uM, Firibastat, Known aminopeptidase A inhibitor targeting ENPEP |
| EA-43-FS10_0.01uM | Dose=0.01uM, (E)-1-(3-hydroxy-4-methoxyphenyl)-7-phenylhept-1-en-3-one |
| EA-43-FS10_0.1uM | Dose=0.1uM, (E)-1-(3-hydroxy-4-methoxyphenyl)-7-phenylhept-1-en-3-one |
| EA-43-FS10_10uM | Dose=10uM, (E)-1-(3-hydroxy-4-methoxyphenyl)-7-phenylhept-1-en-3-one |
| EA-43-FS10_1uM | Dose=1uM, (E)-1-(3-hydroxy-4-methoxyphenyl)-7-phenylhept-1-en-3-one |
| EA-43-XP68_0.01uM | Dose=0.01uM, 3-[[4-[(2R)-1-[(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-3-cyclopentyl-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid |
| EA-43-XP68_0.1uM | Dose=0.1uM, 3-[[4-[(2R)-1-[(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-3-cyclopentyl-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid |
| EA-43-XP68_10uM | Dose=10uM, 3-[[4-[(2R)-1-[(5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-3-cyclopentyl-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid |
| EA-50-GQ38_0.01uM | Dose=0.01uM, Gentisic Acid |
| EA-50-GQ38_10uM | Dose=10uM, Gentisic Acid |
| EA-60-LN91_0.01uM | Dose=0.01uM, N-(1,3-dimethyl-2-oxo-6-piperidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide, BRPF1 inhibitor;BRPF1 inhbitor targeting BRPF1 |
| EA-60-LN91_0.1uM | Dose=0.1uM, N-(1,3-dimethyl-2-oxo-6-piperidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide, BRPF1 inhibitor;BRPF1 inhbitor targeting BRPF1 |
| EA-60-LN91_10uM | Dose=10uM, N-(1,3-dimethyl-2-oxo-6-piperidin-1-ylbenzimidazol-5-yl)-2-methoxybenzamide, BRPF1 inhibitor;BRPF1 inhbitor targeting BRPF1 |
| EA-61-RR63_0.01uM | Dose=0.01uM, 3-(3,5-dichloro-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenyl)-propionic acid, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| EA-61-RR63_0.1uM | Dose=0.1uM, 3-(3,5-dichloro-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenyl)-propionic acid, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| EA-61-RR63_10uM | Dose=10uM, 3-(3,5-dichloro-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenyl)-propionic acid, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| EA-61-RR63_1uM | Dose=1uM, 3-(3,5-dichloro-4-[6-(quinolin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-phenyl)-propionic acid, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| EA-62-MI89_0.01uM | Dose=0.01uM, (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide, Apoptosis Inducers;Wnt Signaling Inhibitors;CREBBP - beta-catenin interaction inhibitor targeting CREBBP, CTNNB1 |
| EA-62-MI89_0.1uM | Dose=0.1uM, (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide, Apoptosis Inducers;Wnt Signaling Inhibitors;CREBBP - beta-catenin interaction inhibitor targeting CREBBP, CTNNB1 |
| EA-62-MI89_10uM | Dose=10uM, (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide, Apoptosis Inducers;Wnt Signaling Inhibitors;CREBBP - beta-catenin interaction inhibitor targeting CREBBP, CTNNB1 |
| EA-67-CO00_0.01uM | Dose=0.01uM, Flupirtine, Voltage-Gated K(V) 7 (KCNQ) Channel Activators targeting KCNQ2, KCNQ3, KCNQ4 |
| EA-67-CO00_0.1uM | Dose=0.1uM, Flupirtine, Voltage-Gated K(V) 7 (KCNQ) Channel Activators targeting KCNQ2, KCNQ3, KCNQ4 |
| EA-67-CO00_1uM | Dose=1uM, Flupirtine, Voltage-Gated K(V) 7 (KCNQ) Channel Activators targeting KCNQ2, KCNQ3, KCNQ4 |
| EA-67-FY34_0.01uM | Dose=0.01uM, (-)-Gallocatechin gallate, PPARalpha Agonists;Antioxidants;Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors targeting PPARA |
| EA-67-FY34_0.1uM | Dose=0.1uM, (-)-Gallocatechin gallate, PPARalpha Agonists;Antioxidants;Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors targeting PPARA |
| EA-67-FY34_10uM | Dose=10uM, (-)-Gallocatechin gallate, PPARalpha Agonists;Antioxidants;Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors targeting PPARA |
| EA-67-FY34_1uM | Dose=1uM, (-)-Gallocatechin gallate, PPARalpha Agonists;Antioxidants;Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors targeting PPARA |
| EA-67-SE76_0.01uM | Dose=0.01uM |
| EA-67-SE76_0.1uM | Dose=0.1uM |
| EA-67-SE76_10uM | Dose=10uM |
| EA-67-SE76_1uM | Dose=1uM |
| EA-69-VJ68_0.01uM | Dose=0.01uM |
| EA-69-VJ68_0.1uM | Dose=0.1uM |
| EA-69-VJ68_10uM | Dose=10uM |
| EA-69-VJ68_1uM | Dose=1uM |
| EA-73-MI41_0.01uM | Dose=0.01uM, Tetracaine targeting SCN1A, SCN3A, SCN8A, SCN1B, SCN7A, SCN3B |
| EA-73-MI41_0.1uM | Dose=0.1uM, Tetracaine targeting SCN1A, SCN3A, SCN8A, SCN1B, SCN7A, SCN3B |
| EA-73-MI41_10uM | Dose=10uM, Tetracaine targeting SCN1A, SCN3A, SCN8A, SCN1B, SCN7A, SCN3B |
| EA-73-MI41_1uM | Dose=1uM, Tetracaine targeting SCN1A, SCN3A, SCN8A, SCN1B, SCN7A, SCN3B |
| EA-73-UC67_0.01uM | Dose=0.01uM |
| EA-73-UC67_0.1uM | Dose=0.1uM |
| EA-73-UC67_10uM | Dose=10uM |
| EA-73-UC67_1uM | Dose=1uM |
| EA-73-WI86_0.01uM | Dose=0.01uM, Epinephrine, Adrenergic Agonists targeting ADRA1B, ADRA1A, ADRA2B, ADRB1, ADRB2, CA1 |
| EA-73-WI86_0.1uM | Dose=0.1uM, Epinephrine, Adrenergic Agonists targeting ADRA1B, ADRA1A, ADRA2B, ADRB1, ADRB2, CA1 |
| EA-73-WI86_10uM | Dose=10uM, Epinephrine, Adrenergic Agonists targeting ADRA1B, ADRA1A, ADRA2B, ADRB1, ADRB2, CA1 |
| EA-73-WI86_1uM | Dose=1uM, Epinephrine, Adrenergic Agonists targeting ADRA1B, ADRA1A, ADRA2B, ADRB1, ADRB2, CA1 |
| EA-81-CR68_0.01uM | Dose=0.01uM |
| EA-81-CR68_0.1uM | Dose=0.1uM |
| EA-81-CR68_10uM | Dose=10uM |
| EA-81-CR68_1uM | Dose=1uM |
| EA-84-SC49_10uM | Dose=10uM, (3-Amino-phenyl)-(4-amino-2-phenylamino-thiazol-5-yl)-methanone, CDK inhibitor targeting CDK2, CDK4, CCNA1 |
| EA-84-SC49_1uM | Dose=1uM, (3-Amino-phenyl)-(4-amino-2-phenylamino-thiazol-5-yl)-methanone, CDK inhibitor targeting CDK2, CDK4, CCNA1 |
| EA-86-QK08_0.01uM | Dose=0.01uM, N-{{3-{3-[4-Acetyl-3-hydroxy-2-(3,3,3-trifluoropropyl)-phenoxy]-propoxy}-4-bromo-6-methyl-phenyl}}-oxamic acid, Non-Steroidal Antiinflammatory Drugs;Phospholipase A2 (PLA2) Inhibitors;Platelet-Activating Factor Receptor (PAFR) Antagonists;Leukotriene Antagonists targeting PTAFR, PLA2G10 |
| EA-86-QK08_0.1uM | Dose=0.1uM, N-{{3-{3-[4-Acetyl-3-hydroxy-2-(3,3,3-trifluoropropyl)-phenoxy]-propoxy}-4-bromo-6-methyl-phenyl}}-oxamic acid, Non-Steroidal Antiinflammatory Drugs;Phospholipase A2 (PLA2) Inhibitors;Platelet-Activating Factor Receptor (PAFR) Antagonists;Leukotriene Antagonists targeting PTAFR, PLA2G10 |
| EA-86-QK08_10uM | Dose=10uM, N-{{3-{3-[4-Acetyl-3-hydroxy-2-(3,3,3-trifluoropropyl)-phenoxy]-propoxy}-4-bromo-6-methyl-phenyl}}-oxamic acid, Non-Steroidal Antiinflammatory Drugs;Phospholipase A2 (PLA2) Inhibitors;Platelet-Activating Factor Receptor (PAFR) Antagonists;Leukotriene Antagonists targeting PTAFR, PLA2G10 |
| EA-86-YK48_0.01uM | Dose=0.01uM, (S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid, Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin binder targeting ITGB1 |
| EA-86-YK48_0.1uM | Dose=0.1uM, (S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid, Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin binder targeting ITGB1 |
| EA-86-YK48_10uM | Dose=10uM, (S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid, Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin binder targeting ITGB1 |
| EA-86-YK48_1uM | Dose=1uM, (S)-2-(2,6-Dichlorobenzamido)-3-(2',6'-dimethoxy-[1,1'-biphenyl]-4-yl)propanoic acid, Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Integrin binder targeting ITGB1 |
| EA-90-PK44_0.01uM | Dose=0.01uM, N-2-naphthylimidodicarbonimidic diamide, 5-HT3 receptoe agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| EA-90-PK44_0.1uM | Dose=0.1uM, N-2-naphthylimidodicarbonimidic diamide, 5-HT3 receptoe agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| EA-90-PK44_10uM | Dose=10uM, N-2-naphthylimidodicarbonimidic diamide, 5-HT3 receptoe agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| EA-90-PK44_1uM | Dose=1uM, N-2-naphthylimidodicarbonimidic diamide, 5-HT3 receptoe agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| EA-92-CV45_0.01uM | Dose=0.01uM, Nan 190, ADRA2A antagonist;5-HT1A Receptor Antagonists targeting HTR1A, ADRA2A |
| EA-92-CV45_0.1uM | Dose=0.1uM, Nan 190, ADRA2A antagonist;5-HT1A Receptor Antagonists targeting HTR1A, ADRA2A |
| EA-92-CV45_10uM | Dose=10uM, Nan 190, ADRA2A antagonist;5-HT1A Receptor Antagonists targeting HTR1A, ADRA2A |
| EA-92-CV45_1uM | Dose=1uM, Nan 190, ADRA2A antagonist;5-HT1A Receptor Antagonists targeting HTR1A, ADRA2A |
| EA-93-KT88_0.01uM | Dose=0.01uM |
| EA-93-KT88_0.1uM | Dose=0.1uM |
| EA-93-KT88_10uM | Dose=10uM |
| EA-93-KT88_1uM | Dose=1uM |
| EA-95-OQ30_0.01uM | Dose=0.01uM, Azinphos-methyl |
| EA-95-OQ30_0.1uM | Dose=0.1uM, Azinphos-methyl |
| EA-95-OQ30_10uM | Dose=10uM, Azinphos-methyl |
| EA-95-OQ30_1uM | Dose=1uM, Azinphos-methyl |
| EA-95-YN88_0.1uM | Dose=0.1uM, rel-(3R,4S)-3-((4-Chlorophenyl)sulfonyl)-4-(isobutylamino)tetrahydrothiophene 1,1-dioxide targeting PGK1 |
| EA-95-YN88_10uM | Dose=10uM, rel-(3R,4S)-3-((4-Chlorophenyl)sulfonyl)-4-(isobutylamino)tetrahydrothiophene 1,1-dioxide targeting PGK1 |
| EA-95-YN88_1uM | Dose=1uM, rel-(3R,4S)-3-((4-Chlorophenyl)sulfonyl)-4-(isobutylamino)tetrahydrothiophene 1,1-dioxide targeting PGK1 |
| EA-95-YQ95_0.01uM | Dose=0.01uM, Protopine, Inhibits LPS induced cytokine secretion;Acetylcholinesterase Inhibitors;Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting ACHE, SLC6A2, SLC6A4, HDAC6 |
| EA-95-YQ95_0.1uM | Dose=0.1uM, Protopine, Inhibits LPS induced cytokine secretion;Acetylcholinesterase Inhibitors;Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting ACHE, SLC6A2, SLC6A4, HDAC6 |
| EA-95-YQ95_10uM | Dose=10uM, Protopine, Inhibits LPS induced cytokine secretion;Acetylcholinesterase Inhibitors;Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting ACHE, SLC6A2, SLC6A4, HDAC6 |
| EA-95-YQ95_1uM | Dose=1uM, Protopine, Inhibits LPS induced cytokine secretion;Acetylcholinesterase Inhibitors;Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors targeting ACHE, SLC6A2, SLC6A4, HDAC6 |
| EA-96-QK68_0.01uM | Dose=0.01uM, 4-Amino-6-chloro-1,3-benzenedisulfonamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| EA-96-QK68_0.1uM | Dose=0.1uM, 4-Amino-6-chloro-1,3-benzenedisulfonamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| EA-96-QK68_10uM | Dose=10uM, 4-Amino-6-chloro-1,3-benzenedisulfonamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| EA-96-QK68_1uM | Dose=1uM, 4-Amino-6-chloro-1,3-benzenedisulfonamide, Carbonic Anhydrase Type II Inhibitors targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| EA-98-NW07_0.01uM | Dose=0.01uM, GW-3965, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting NR1H2, NR1H3 |
| EA-98-NW07_0.1uM | Dose=0.1uM, GW-3965, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting NR1H2, NR1H3 |
| EA-98-NW07_10uM | Dose=10uM, GW-3965, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting NR1H2, NR1H3 |
| EA-98-NW07_1uM | Dose=1uM, GW-3965, ABCA1 Expression Enhancers;Liver X Receptor (LXR) Agonists targeting NR1H2, NR1H3 |
| EB-00-JQ48_0.01uM | Dose=0.01uM, Tandamine, Drugs Acting on Adrenergic Transmission;norepinephrine reuptake inhibitor targeting SLC6A2 |
| EB-00-JQ48_0.1uM | Dose=0.1uM, Tandamine, Drugs Acting on Adrenergic Transmission;norepinephrine reuptake inhibitor targeting SLC6A2 |
| EB-00-JQ48_1uM | Dose=1uM, Tandamine, Drugs Acting on Adrenergic Transmission;norepinephrine reuptake inhibitor targeting SLC6A2 |
| EB-07-JB09_0.01uM | Dose=0.01uM |
| EB-07-JB09_0.1uM | Dose=0.1uM |
| EB-07-JB09_10uM | Dose=10uM |
| EB-07-JB09_1uM | Dose=1uM |
| EB-08-WP80_0.01uM | Dose=0.01uM |
| EB-08-WP80_0.1uM | Dose=0.1uM |
| EB-08-WP80_10uM | Dose=10uM |
| EB-08-WP80_1uM | Dose=1uM |
| EB-09-GW59_0.01uM | Dose=0.01uM, 3-[1-Hydroxy-2-(methylamino)ethyl]phenol, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| EB-09-GW59_0.1uM | Dose=0.1uM, 3-[1-Hydroxy-2-(methylamino)ethyl]phenol, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| EB-09-GW59_10uM | Dose=10uM, 3-[1-Hydroxy-2-(methylamino)ethyl]phenol, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| EB-09-GW59_1uM | Dose=1uM, 3-[1-Hydroxy-2-(methylamino)ethyl]phenol, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| EB-09-JJ93_0.01uM | Dose=0.01uM, Vinpocetine, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Phosphodiesterase I Inhibitors targeting SCN10A |
| EB-09-JJ93_0.1uM | Dose=0.1uM, Vinpocetine, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Phosphodiesterase I Inhibitors targeting SCN10A |
| EB-09-JJ93_10uM | Dose=10uM, Vinpocetine, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Phosphodiesterase I Inhibitors targeting SCN10A |
| EB-09-JJ93_1uM | Dose=1uM, Vinpocetine, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Phosphodiesterase I Inhibitors targeting SCN10A |
| EB-09-LQ45_0.01uM | Dose=0.01uM, 2,4-Pyrimidinediamine, 5-[5-iodo-4-methoxy-2-(1-methylethyl)phenoxy]-, P2RX2 and P2RX3 Purinergic Receptor Antagonist targeting P2RX2 |
| EB-09-LQ45_0.1uM | Dose=0.1uM, 2,4-Pyrimidinediamine, 5-[5-iodo-4-methoxy-2-(1-methylethyl)phenoxy]-, P2RX2 and P2RX3 Purinergic Receptor Antagonist targeting P2RX2 |
| EB-09-LQ45_10uM | Dose=10uM, 2,4-Pyrimidinediamine, 5-[5-iodo-4-methoxy-2-(1-methylethyl)phenoxy]-, P2RX2 and P2RX3 Purinergic Receptor Antagonist targeting P2RX2 |
| EB-09-LQ45_1uM | Dose=1uM, 2,4-Pyrimidinediamine, 5-[5-iodo-4-methoxy-2-(1-methylethyl)phenoxy]-, P2RX2 and P2RX3 Purinergic Receptor Antagonist targeting P2RX2 |
| EB-09-OC36_0.01uM | Dose=0.01uM, Benzyl Cinnamate, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B2, HSD17B7, HSD17B10, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| EB-09-OC36_0.1uM | Dose=0.1uM, Benzyl Cinnamate, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B2, HSD17B7, HSD17B10, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| EB-09-OC36_10uM | Dose=10uM, Benzyl Cinnamate, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B2, HSD17B7, HSD17B10, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| EB-09-OC36_1uM | Dose=1uM, Benzyl Cinnamate, 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) Inhibitors targeting HSD17B1, HSD17B2, HSD17B7, HSD17B10, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| EB-11-MR93_0.01uM | Dose=0.01uM, 7beta,25-Dihydroxycholesterol |
| EB-11-MR93_0.1uM | Dose=0.1uM, 7beta,25-Dihydroxycholesterol |
| EB-11-MR93_10uM | Dose=10uM, 7beta,25-Dihydroxycholesterol |
| EB-11-MR93_1uM | Dose=1uM, 7beta,25-Dihydroxycholesterol |
| EB-18-PP65_0.01uM | Dose=0.01uM, 6-Chloro-9H-beta-carbolin-8-amine targeting CHUK |
| EB-18-PP65_0.1uM | Dose=0.1uM, 6-Chloro-9H-beta-carbolin-8-amine targeting CHUK |
| EB-18-PP65_10uM | Dose=10uM, 6-Chloro-9H-beta-carbolin-8-amine targeting CHUK |
| EB-18-PP65_1uM | Dose=1uM, 6-Chloro-9H-beta-carbolin-8-amine targeting CHUK |
| EB-19-SM10_0.01uM | Dose=0.01uM, N-hydroxy-3-(naphthalen-1-yl)acrylamide, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8 |
| EB-19-SM10_0.1uM | Dose=0.1uM, N-hydroxy-3-(naphthalen-1-yl)acrylamide, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8 |
| EB-19-SM10_10uM | Dose=10uM, N-hydroxy-3-(naphthalen-1-yl)acrylamide, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8 |
| EB-19-SM10_1uM | Dose=1uM, N-hydroxy-3-(naphthalen-1-yl)acrylamide, Histone Deacetylase 8 (HDAC8) Inhibitors targeting HDAC8 |
| EB-28-HP05_0.01uM | Dose=0.01uM, Cyclopamine, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH |
| EB-28-HP05_0.1uM | Dose=0.1uM, Cyclopamine, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH |
| EB-28-HP05_10uM | Dose=10uM, Cyclopamine, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH |
| EB-28-HP05_1uM | Dose=1uM, Cyclopamine, Smo Receptor Antagonists;Hedgehog Signaling Inhibitors targeting PTCH1, SHH, SMO, IHH, DHH |
| EB-28-ZJ41_0.01uM | Dose=0.01uM, Cidofovir |
| EB-28-ZJ41_0.1uM | Dose=0.1uM, Cidofovir |
| EB-28-ZJ41_10uM | Dose=10uM, Cidofovir |
| EB-28-ZJ41_1uM | Dose=1uM, Cidofovir |
| EB-30-VD02_0.01uM | Dose=0.01uM, Selumetinib, MEK1 Inhibitors;MEK2 Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K1, MAP2K2 |
| EB-30-VD02_0.1uM | Dose=0.1uM, Selumetinib, MEK1 Inhibitors;MEK2 Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K1, MAP2K2 |
| EB-30-VD02_10uM | Dose=10uM, Selumetinib, MEK1 Inhibitors;MEK2 Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K1, MAP2K2 |
| EB-30-VD02_1uM | Dose=1uM, Selumetinib, MEK1 Inhibitors;MEK2 Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAP2K1, MAP2K2 |
| EB-33-ZP53_0.01uM | Dose=0.01uM, 3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione, Jak3 tyrosine kinase inhibitor targeting GSK3B, JAK3, PRKCA |
| EB-33-ZP53_0.1uM | Dose=0.1uM, 3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione, Jak3 tyrosine kinase inhibitor targeting GSK3B, JAK3, PRKCA |
| EB-33-ZP53_10uM | Dose=10uM, 3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione, Jak3 tyrosine kinase inhibitor targeting GSK3B, JAK3, PRKCA |
| EB-33-ZP53_1uM | Dose=1uM, 3-[5-[4-(2-Hydroxy-2-methyl-1-oxopropyl)-1-piperazinyl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione, Jak3 tyrosine kinase inhibitor targeting GSK3B, JAK3, PRKCA |
| EB-34-KW22_0.01uM | Dose=0.01uM, Mifobate, PPARgamma Antagonists targeting PPARG |
| EB-34-KW22_0.1uM | Dose=0.1uM, Mifobate, PPARgamma Antagonists targeting PPARG |
| EB-34-KW22_10uM | Dose=10uM, Mifobate, PPARgamma Antagonists targeting PPARG |
| EB-34-KW22_1uM | Dose=1uM, Mifobate, PPARgamma Antagonists targeting PPARG |
| EB-44-GM58_0.01uM | Dose=0.01uM, Abanoquil, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| EB-44-GM58_0.1uM | Dose=0.1uM, Abanoquil, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| EB-44-GM58_10uM | Dose=10uM, Abanoquil, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| EB-44-GM58_1uM | Dose=1uM, Abanoquil, alpha1-Adrenoceptor Antagonists targeting ADRA1B |
| EB-44-OW82_0.01uM | Dose=0.01uM, Pitrazepin, Glycine Receptor Antagonists;GABA(A) Receptor Antagonists targeting GABRA1, GLRA1 |
| EB-44-OW82_0.1uM | Dose=0.1uM, Pitrazepin, Glycine Receptor Antagonists;GABA(A) Receptor Antagonists targeting GABRA1, GLRA1 |
| EB-44-OW82_10uM | Dose=10uM, Pitrazepin, Glycine Receptor Antagonists;GABA(A) Receptor Antagonists targeting GABRA1, GLRA1 |
| EB-44-OW82_1uM | Dose=1uM, Pitrazepin, Glycine Receptor Antagonists;GABA(A) Receptor Antagonists targeting GABRA1, GLRA1 |
| EB-47-BB89_0.01uM | Dose=0.01uM, Pik-III, Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 (PIK3C3;Vps34) Inhibitors targeting PIK3C3 |
| EB-47-BB89_0.1uM | Dose=0.1uM, Pik-III, Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 (PIK3C3;Vps34) Inhibitors targeting PIK3C3 |
| EB-47-BB89_10uM | Dose=10uM, Pik-III, Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 (PIK3C3;Vps34) Inhibitors targeting PIK3C3 |
| EB-47-BB89_1uM | Dose=1uM, Pik-III, Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 (PIK3C3;Vps34) Inhibitors targeting PIK3C3 |
| EB-52-HZ20_0.01uM | Dose=0.01uM, Dexchlorpheniramine, Histamine Receptor Antagonists targeting HRH1 |
| EB-52-HZ20_0.1uM | Dose=0.1uM, Dexchlorpheniramine, Histamine Receptor Antagonists targeting HRH1 |
| EB-52-HZ20_10uM | Dose=10uM, Dexchlorpheniramine, Histamine Receptor Antagonists targeting HRH1 |
| EB-52-HZ20_1uM | Dose=1uM, Dexchlorpheniramine, Histamine Receptor Antagonists targeting HRH1 |
| EB-55-VD69_0.01uM | Dose=0.01uM, (1S,2S,3R,4R)-N-(3,4-dichlorophenyl)-3-pyridin-4-yl-7-oxabicyclo[2.2.1]heptane-2-carboxamide |
| EB-55-VD69_10uM | Dose=10uM, (1S,2S,3R,4R)-N-(3,4-dichlorophenyl)-3-pyridin-4-yl-7-oxabicyclo[2.2.1]heptane-2-carboxamide |
| EB-55-VD69_1uM | Dose=1uM, (1S,2S,3R,4R)-N-(3,4-dichlorophenyl)-3-pyridin-4-yl-7-oxabicyclo[2.2.1]heptane-2-carboxamide |
| EB-56-HU77_0.01uM | Dose=0.01uM, (4-Morpholin-4-yl-1,2,5-thiadiazol-3-yl) N-cyclooctyl-N-methylcarbamate, ABHD6 Inhibitor targeting ABHD6 |
| EB-56-HU77_0.1uM | Dose=0.1uM, (4-Morpholin-4-yl-1,2,5-thiadiazol-3-yl) N-cyclooctyl-N-methylcarbamate, ABHD6 Inhibitor targeting ABHD6 |
| EB-56-HU77_10uM | Dose=10uM, (4-Morpholin-4-yl-1,2,5-thiadiazol-3-yl) N-cyclooctyl-N-methylcarbamate, ABHD6 Inhibitor targeting ABHD6 |
| EB-56-HU77_1uM | Dose=1uM, (4-Morpholin-4-yl-1,2,5-thiadiazol-3-yl) N-cyclooctyl-N-methylcarbamate, ABHD6 Inhibitor targeting ABHD6 |
| EB-61-FU05_0.01uM | Dose=0.01uM, Way 100135, 5-HT1A Receptor Antagonists;ADRA1B gene modulator targeting ADRA1B, HTR1A |
| EB-61-FU05_0.1uM | Dose=0.1uM, Way 100135, 5-HT1A Receptor Antagonists;ADRA1B gene modulator targeting ADRA1B, HTR1A |
| EB-61-FU05_10uM | Dose=10uM, Way 100135, 5-HT1A Receptor Antagonists;ADRA1B gene modulator targeting ADRA1B, HTR1A |
| EB-61-FU05_1uM | Dose=1uM, Way 100135, 5-HT1A Receptor Antagonists;ADRA1B gene modulator targeting ADRA1B, HTR1A |
| EB-66-IH06_0.01uM | Dose=0.01uM, 4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine, Wnt pathway activator;AXIN auto-inhibition inhibitor targeting AXIN1, AXIN2 |
| EB-66-IH06_0.1uM | Dose=0.1uM, 4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine, Wnt pathway activator;AXIN auto-inhibition inhibitor targeting AXIN1, AXIN2 |
| EB-66-IH06_10uM | Dose=10uM, 4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine, Wnt pathway activator;AXIN auto-inhibition inhibitor targeting AXIN1, AXIN2 |
| EB-66-IH06_1uM | Dose=1uM, 4-Ethyl-5-methyl-5,6-dihydro-[1,3]dioxolo[4,5-j]phenanthridine, Wnt pathway activator;AXIN auto-inhibition inhibitor targeting AXIN1, AXIN2 |
| EB-66-TU32_10uM | Dose=10uM, CID 9940118 targeting GRB2 |
| EB-66-TU32_1uM | Dose=1uM, CID 9940118 targeting GRB2 |
| EB-67-WB79_0.01uM | Dose=0.01uM |
| EB-67-WB79_0.1uM | Dose=0.1uM |
| EB-67-WB79_10uM | Dose=10uM |
| EB-67-WB79_1uM | Dose=1uM |
| EB-70-JQ38_0.01uM | Dose=0.01uM, Z-Phe-DL-Ala-fluoromethylketone |
| EB-70-JQ38_0.1uM | Dose=0.1uM, Z-Phe-DL-Ala-fluoromethylketone |
| EB-70-JQ38_10uM | Dose=10uM, Z-Phe-DL-Ala-fluoromethylketone |
| EB-70-JQ38_1uM | Dose=1uM, Z-Phe-DL-Ala-fluoromethylketone |
| EB-72-SO78_0.01uM | Dose=0.01uM, N,N-dimethyl-1-(3-pyridin-3-yl-1H-inden-2-yl)methanamine, 5-HT Reuptake Inhibitors;mu-Opioid Receptor Ligands;Norepinephrine Reuptake Inhibitors targeting OPRM1, SLC6A2, SLC6A4 |
| EB-72-SO78_10uM | Dose=10uM, N,N-dimethyl-1-(3-pyridin-3-yl-1H-inden-2-yl)methanamine, 5-HT Reuptake Inhibitors;mu-Opioid Receptor Ligands;Norepinephrine Reuptake Inhibitors targeting OPRM1, SLC6A2, SLC6A4 |
| EB-82-HZ30_0.1uM | Dose=0.1uM |
| EB-82-HZ30_10uM | Dose=10uM |
| EB-82-HZ30_1uM | Dose=1uM |
| EB-82-QI99_0.01uM | Dose=0.01uM, Hjc 0350, Guanine Nucleotide Exchange Factors (GEFs) Inhibitors targeting RAPGEF4 |
| EB-82-QI99_0.1uM | Dose=0.1uM, Hjc 0350, Guanine Nucleotide Exchange Factors (GEFs) Inhibitors targeting RAPGEF4 |
| EB-82-QI99_10uM | Dose=10uM, Hjc 0350, Guanine Nucleotide Exchange Factors (GEFs) Inhibitors targeting RAPGEF4 |
| EB-82-QI99_1uM | Dose=1uM, Hjc 0350, Guanine Nucleotide Exchange Factors (GEFs) Inhibitors targeting RAPGEF4 |
| EB-83-IM06_0.01uM | Dose=0.01uM, 5-fluoro-2-(2-morpholino-5-(morpholinosulfonyl)phenyl)benzo[d]isothiazol-3(2H)-one, Insulin degrading enzyme inhibitor targeting IDE |
| EB-83-IM06_0.1uM | Dose=0.1uM, 5-fluoro-2-(2-morpholino-5-(morpholinosulfonyl)phenyl)benzo[d]isothiazol-3(2H)-one, Insulin degrading enzyme inhibitor targeting IDE |
| EB-83-IM06_10uM | Dose=10uM, 5-fluoro-2-(2-morpholino-5-(morpholinosulfonyl)phenyl)benzo[d]isothiazol-3(2H)-one, Insulin degrading enzyme inhibitor targeting IDE |
| EB-83-IM06_1uM | Dose=1uM, 5-fluoro-2-(2-morpholino-5-(morpholinosulfonyl)phenyl)benzo[d]isothiazol-3(2H)-one, Insulin degrading enzyme inhibitor targeting IDE |
| EB-85-DG91_0.01uM | Dose=0.01uM, 3-(2-(5-Guanidinopentanamido)acetamido)-3-(pyridin-3-yl)propanoic acid, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGA5, ITGB3 |
| EB-85-DG91_0.1uM | Dose=0.1uM, 3-(2-(5-Guanidinopentanamido)acetamido)-3-(pyridin-3-yl)propanoic acid, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGA5, ITGB3 |
| EB-85-DG91_10uM | Dose=10uM, 3-(2-(5-Guanidinopentanamido)acetamido)-3-(pyridin-3-yl)propanoic acid, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGA5, ITGB3 |
| EB-85-DG91_1uM | Dose=1uM, 3-(2-(5-Guanidinopentanamido)acetamido)-3-(pyridin-3-yl)propanoic acid, Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Inhibitors of Blood Coagulation Pathways;Integrin alphavbeta3 (Vitronectin) Antagonists targeting ITGA5, ITGB3 |
| EB-85-JN83_0.01uM | Dose=0.01uM, 4-[[(1R)-3-(4-Morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide |
| EB-85-JN83_0.1uM | Dose=0.1uM, 4-[[(1R)-3-(4-Morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide |
| EB-85-JN83_10uM | Dose=10uM, 4-[[(1R)-3-(4-Morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide |
| EB-85-JN83_1uM | Dose=1uM, 4-[[(1R)-3-(4-Morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]benzenesulfonamide |
| EB-89-KM10_0.01uM | Dose=0.01uM, 2-(Phenylmethyl)-1-naphthol, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5 |
| EB-89-KM10_0.1uM | Dose=0.1uM, 2-(Phenylmethyl)-1-naphthol, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5 |
| EB-89-KM10_10uM | Dose=10uM, 2-(Phenylmethyl)-1-naphthol, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5 |
| EB-89-KM10_1uM | Dose=1uM, 2-(Phenylmethyl)-1-naphthol, Lipoxygenase Inhibitors;Antiinflammatory Drugs targeting ALOX5 |
| EB-90-BR21_0.01uM | Dose=0.01uM, Gliclazide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| EB-90-BR21_0.1uM | Dose=0.1uM, Gliclazide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| EB-90-BR21_10uM | Dose=10uM, Gliclazide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| EB-90-BR21_1uM | Dose=1uM, Gliclazide, K(ATP) Channel Blockers targeting KCNJ11, ABCC8, ABCC9 |
| EB-92-TL51_0.01uM | Dose=0.01uM, N-(5-chloro-2-hydroxyphenyl)-2-methoxybenzamide |
| EB-92-TL51_0.1uM | Dose=0.1uM, N-(5-chloro-2-hydroxyphenyl)-2-methoxybenzamide |
| EB-92-TL51_10uM | Dose=10uM, N-(5-chloro-2-hydroxyphenyl)-2-methoxybenzamide |
| EB-92-TL51_1uM | Dose=1uM, N-(5-chloro-2-hydroxyphenyl)-2-methoxybenzamide |
| EB-97-AV17_0.01uM | Dose=0.01uM, Diphenylamine-2,2'-dicarboxylic acid |
| EB-97-AV17_0.1uM | Dose=0.1uM, Diphenylamine-2,2'-dicarboxylic acid |
| EB-97-AV17_10uM | Dose=10uM, Diphenylamine-2,2'-dicarboxylic acid |
| EB-97-AV17_1uM | Dose=1uM, Diphenylamine-2,2'-dicarboxylic acid |
| EB-98-LS52_0.01uM | Dose=0.01uM, (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium, Muscarinic receptor agonist targeting CHRM1, CHRM4, CHRM5, CHRM2, CHRM3 |
| EB-98-LS52_0.1uM | Dose=0.1uM, (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium, Muscarinic receptor agonist targeting CHRM1, CHRM4, CHRM5, CHRM2, CHRM3 |
| EB-98-LS52_10uM | Dose=10uM, (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium, Muscarinic receptor agonist targeting CHRM1, CHRM4, CHRM5, CHRM2, CHRM3 |
| EB-98-OI08_0.01uM | Dose=0.01uM |
| EB-98-OI08_0.1uM | Dose=0.1uM |
| EB-98-OI08_10uM | Dose=10uM |
| EB-98-OI08_1uM | Dose=1uM |
| EC-00-KR26_0.01uM | Dose=0.01uM, Dexibuprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| EC-00-KR26_0.1uM | Dose=0.1uM, Dexibuprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| EC-00-KR26_1uM | Dose=1uM, Dexibuprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| EC-01-PH79_0.01uM | Dose=0.01uM, Apilimod, IL-12 Production Inhibitor;PIKFYVE enzyme inhibitor;PIKFYVE inhibitor targeting PIKFYVE |
| EC-01-PH79_0.1uM | Dose=0.1uM, Apilimod, IL-12 Production Inhibitor;PIKFYVE enzyme inhibitor;PIKFYVE inhibitor targeting PIKFYVE |
| EC-01-PH79_10uM | Dose=10uM, Apilimod, IL-12 Production Inhibitor;PIKFYVE enzyme inhibitor;PIKFYVE inhibitor targeting PIKFYVE |
| EC-01-PH79_1uM | Dose=1uM, Apilimod, IL-12 Production Inhibitor;PIKFYVE enzyme inhibitor;PIKFYVE inhibitor targeting PIKFYVE |
| EC-07-AO30_0.01uM | Dose=0.01uM, Sdz 216-525, ADRA1B gene modulator;5-HT1A Receptor Antagonists targeting ADRA1B, HTR1A |
| EC-07-AO30_0.1uM | Dose=0.1uM, Sdz 216-525, ADRA1B gene modulator;5-HT1A Receptor Antagonists targeting ADRA1B, HTR1A |
| EC-07-AO30_10uM | Dose=10uM, Sdz 216-525, ADRA1B gene modulator;5-HT1A Receptor Antagonists targeting ADRA1B, HTR1A |
| EC-07-AO30_1uM | Dose=1uM, Sdz 216-525, ADRA1B gene modulator;5-HT1A Receptor Antagonists targeting ADRA1B, HTR1A |
| EC-07-OP38_0.01uM | Dose=0.01uM, 2-(4-Chlorophenyl)-5-(4-methylpiperazin-1-yl)-4-(4-phenylphenoxy)pyridazin-3-one, Protein-Lysine 6-Oxidase Inhibitors targeting LOX |
| EC-07-OP38_0.1uM | Dose=0.1uM, 2-(4-Chlorophenyl)-5-(4-methylpiperazin-1-yl)-4-(4-phenylphenoxy)pyridazin-3-one, Protein-Lysine 6-Oxidase Inhibitors targeting LOX |
| EC-07-OP38_10uM | Dose=10uM, 2-(4-Chlorophenyl)-5-(4-methylpiperazin-1-yl)-4-(4-phenylphenoxy)pyridazin-3-one, Protein-Lysine 6-Oxidase Inhibitors targeting LOX |
| EC-07-ZB49_0.01uM | Dose=0.01uM, ML-9 free base |
| EC-07-ZB49_0.1uM | Dose=0.1uM, ML-9 free base |
| EC-07-ZB49_10uM | Dose=10uM, ML-9 free base |
| EC-07-ZB49_1uM | Dose=1uM, ML-9 free base |
| EC-08-AP40_0.01uM | Dose=0.01uM, Xevinapant, Apoptosis Inducers;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Inhibitor of Apoptosis Protein 2 (IAP2) Inhibitors;Inhibitor of Apoptosis Protein 1 (IAP1) Inhibitors;Signal Transduction Modulators targeting BIRC2, BIRC3, XIAP |
| EC-08-AP40_0.1uM | Dose=0.1uM, Xevinapant, Apoptosis Inducers;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Inhibitor of Apoptosis Protein 2 (IAP2) Inhibitors;Inhibitor of Apoptosis Protein 1 (IAP1) Inhibitors;Signal Transduction Modulators targeting BIRC2, BIRC3, XIAP |
| EC-08-AP40_10uM | Dose=10uM, Xevinapant, Apoptosis Inducers;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Inhibitor of Apoptosis Protein 2 (IAP2) Inhibitors;Inhibitor of Apoptosis Protein 1 (IAP1) Inhibitors;Signal Transduction Modulators targeting BIRC2, BIRC3, XIAP |
| EC-08-AP40_1uM | Dose=1uM, Xevinapant, Apoptosis Inducers;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Inhibitor of Apoptosis Protein 2 (IAP2) Inhibitors;Inhibitor of Apoptosis Protein 1 (IAP1) Inhibitors;Signal Transduction Modulators targeting BIRC2, BIRC3, XIAP |
| EC-08-KS82_0.01uM | Dose=0.01uM, PDE3A inhibitor targeting PDE3A, PDE3B, PDE4C |
| EC-08-KS82_0.1uM | Dose=0.1uM, PDE3A inhibitor targeting PDE3A, PDE3B, PDE4C |
| EC-08-KS82_10uM | Dose=10uM, PDE3A inhibitor targeting PDE3A, PDE3B, PDE4C |
| EC-08-KS82_1uM | Dose=1uM, PDE3A inhibitor targeting PDE3A, PDE3B, PDE4C |
| EC-09-DC91_0.01uM | Dose=0.01uM, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT |
| EC-09-DC91_0.1uM | Dose=0.1uM, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT |
| EC-09-DC91_10uM | Dose=10uM, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT |
| EC-09-DC91_1uM | Dose=1uM, DNA-Directed RNA Polymerase Inhibitors targeting POLRMT |
| EC-12-AY12_0.01uM | Dose=0.01uM, Lisofylline |
| EC-12-AY12_0.1uM | Dose=0.1uM, Lisofylline |
| EC-12-AY12_10uM | Dose=10uM, Lisofylline |
| EC-12-AY12_1uM | Dose=1uM, Lisofylline |
| EC-14-UM93_0.01uM | Dose=0.01uM, 1-(4-Nitrophenyl)-2-phenylethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| EC-14-UM93_0.1uM | Dose=0.1uM, 1-(4-Nitrophenyl)-2-phenylethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| EC-14-UM93_10uM | Dose=10uM, 1-(4-Nitrophenyl)-2-phenylethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| EC-14-UM93_1uM | Dose=1uM, 1-(4-Nitrophenyl)-2-phenylethane-1,2-dione, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| EC-17-MF19_0.01uM | Dose=0.01uM, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, SIRT1;Histone Deacetylase SIRT1 Inhibitors targeting SIRT1 |
| EC-17-MF19_0.1uM | Dose=0.1uM, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, SIRT1;Histone Deacetylase SIRT1 Inhibitors targeting SIRT1 |
| EC-17-MF19_10uM | Dose=10uM, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, SIRT1;Histone Deacetylase SIRT1 Inhibitors targeting SIRT1 |
| EC-17-MF19_1uM | Dose=1uM, 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, SIRT1;Histone Deacetylase SIRT1 Inhibitors targeting SIRT1 |
| EC-17-VB09_0.01uM | Dose=0.01uM, Pyridazine, 4,6-diphenyl-3-(4-(2-pyrimidinyl)-1-piperazinyl)- |
| EC-17-VB09_10uM | Dose=10uM, Pyridazine, 4,6-diphenyl-3-(4-(2-pyrimidinyl)-1-piperazinyl)- |
| EC-17-VB09_1uM | Dose=1uM, Pyridazine, 4,6-diphenyl-3-(4-(2-pyrimidinyl)-1-piperazinyl)- |
| EC-18-TF61_0.01uM | Dose=0.01uM, PF-429242, Site-1 Protease (S1P) Inhibitors targeting MBTPS1 |
| EC-18-TF61_0.1uM | Dose=0.1uM, PF-429242, Site-1 Protease (S1P) Inhibitors targeting MBTPS1 |
| EC-18-TF61_10uM | Dose=10uM, PF-429242, Site-1 Protease (S1P) Inhibitors targeting MBTPS1 |
| EC-18-TF61_1uM | Dose=1uM, PF-429242, Site-1 Protease (S1P) Inhibitors targeting MBTPS1 |
| EC-22-ZY92_0.01uM | Dose=0.01uM |
| EC-22-ZY92_0.1uM | Dose=0.1uM |
| EC-22-ZY92_10uM | Dose=10uM |
| EC-22-ZY92_1uM | Dose=1uM |
| EC-26-KB37_0.1uM | Dose=0.1uM, Isopregnanolone, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors;GABA(A) Receptor Antagonists targeting HSD11B1 |
| EC-26-KB37_10uM | Dose=10uM, Isopregnanolone, 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors;GABA(A) Receptor Antagonists targeting HSD11B1 |
| EC-31-MR88_0.01uM | Dose=0.01uM, 2-[4-[5-tert-butyl-3-[(2,3-dichlorophenyl)carbamoylamino]thiophene-2-carbonyl]-3,3-dimethyl-2-oxopiperazin-1-yl]-N-[2-(dimethylamino)ethyl]acetamide, p38alpha MAPK Inhibitors targeting MAPK14 |
| EC-31-MR88_0.1uM | Dose=0.1uM, 2-[4-[5-tert-butyl-3-[(2,3-dichlorophenyl)carbamoylamino]thiophene-2-carbonyl]-3,3-dimethyl-2-oxopiperazin-1-yl]-N-[2-(dimethylamino)ethyl]acetamide, p38alpha MAPK Inhibitors targeting MAPK14 |
| EC-31-MR88_10uM | Dose=10uM, 2-[4-[5-tert-butyl-3-[(2,3-dichlorophenyl)carbamoylamino]thiophene-2-carbonyl]-3,3-dimethyl-2-oxopiperazin-1-yl]-N-[2-(dimethylamino)ethyl]acetamide, p38alpha MAPK Inhibitors targeting MAPK14 |
| EC-31-MR88_1uM | Dose=1uM, 2-[4-[5-tert-butyl-3-[(2,3-dichlorophenyl)carbamoylamino]thiophene-2-carbonyl]-3,3-dimethyl-2-oxopiperazin-1-yl]-N-[2-(dimethylamino)ethyl]acetamide, p38alpha MAPK Inhibitors targeting MAPK14 |
| EC-34-FT85_0.01uM | Dose=0.01uM, Nibr-0213 targeting S1PR1 |
| EC-34-FT85_0.1uM | Dose=0.1uM, Nibr-0213 targeting S1PR1 |
| EC-34-FT85_10uM | Dose=10uM, Nibr-0213 targeting S1PR1 |
| EC-34-FT85_1uM | Dose=1uM, Nibr-0213 targeting S1PR1 |
| EC-37-MB09_0.01uM | Dose=0.01uM, MK6-83, Mucolipin agonist targeting MCOLN1 |
| EC-37-MB09_0.1uM | Dose=0.1uM, MK6-83, Mucolipin agonist targeting MCOLN1 |
| EC-37-MB09_10uM | Dose=10uM, MK6-83, Mucolipin agonist targeting MCOLN1 |
| EC-37-MB09_1uM | Dose=1uM, MK6-83, Mucolipin agonist targeting MCOLN1 |
| EC-40-DQ58_0.01uM | Dose=0.01uM, Fexaramine, Farnesoid X-receptor agonist targeting NR1H4 |
| EC-40-DQ58_0.1uM | Dose=0.1uM, Fexaramine, Farnesoid X-receptor agonist targeting NR1H4 |
| EC-40-DQ58_10uM | Dose=10uM, Fexaramine, Farnesoid X-receptor agonist targeting NR1H4 |
| EC-40-DQ58_1uM | Dose=1uM, Fexaramine, Farnesoid X-receptor agonist targeting NR1H4 |
| EC-41-PH99_0.01uM | Dose=0.01uM, 2-[4-[4-[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]amino]-5-fluoro-2-(trifluoromethyl)phenyl]piperidin-1-yl]acetamide |
| EC-41-PH99_0.1uM | Dose=0.1uM, 2-[4-[4-[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]amino]-5-fluoro-2-(trifluoromethyl)phenyl]piperidin-1-yl]acetamide |
| EC-41-PH99_10uM | Dose=10uM, 2-[4-[4-[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]amino]-5-fluoro-2-(trifluoromethyl)phenyl]piperidin-1-yl]acetamide |
| EC-41-PH99_1uM | Dose=1uM, 2-[4-[4-[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]amino]-5-fluoro-2-(trifluoromethyl)phenyl]piperidin-1-yl]acetamide |
| EC-42-DO33_0.01uM | Dose=0.01uM, 1-Propyl-2,3,4,4a,10,10a-hexahydro-1H-9-oxa-1-aza-phenanthren-6-ol, Dopamine Autoreceptor Agonists;Prolactin Secretion Inhibitors targeting PRL |
| EC-42-DO33_10uM | Dose=10uM, 1-Propyl-2,3,4,4a,10,10a-hexahydro-1H-9-oxa-1-aza-phenanthren-6-ol, Dopamine Autoreceptor Agonists;Prolactin Secretion Inhibitors targeting PRL |
| EC-42-WE14_0.01uM | Dose=0.01uM, 2-Iminobiotin, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors targeting NOS1, NOS2 |
| EC-42-WE14_0.1uM | Dose=0.1uM, 2-Iminobiotin, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors targeting NOS1, NOS2 |
| EC-42-WE14_10uM | Dose=10uM, 2-Iminobiotin, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors targeting NOS1, NOS2 |
| EC-42-WE14_1uM | Dose=1uM, 2-Iminobiotin, Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors targeting NOS1, NOS2 |
| EC-47-EO60_0.01uM | Dose=0.01uM, 2-[4-(Morpholin-4-ylsulfonyl)phenyl]benzo[c]azolidine-1,3-dione, Phosphodiesterase IV Inhibitors;Phosphodiesterase V (PDE5A) Inhibitors;TNF-alpha Production Inhibitors targeting PDE5A, PDE2A |
| EC-47-EO60_10uM | Dose=10uM, 2-[4-(Morpholin-4-ylsulfonyl)phenyl]benzo[c]azolidine-1,3-dione, Phosphodiesterase IV Inhibitors;Phosphodiesterase V (PDE5A) Inhibitors;TNF-alpha Production Inhibitors targeting PDE5A, PDE2A |
| EC-47-EO60_1uM | Dose=1uM, 2-[4-(Morpholin-4-ylsulfonyl)phenyl]benzo[c]azolidine-1,3-dione, Phosphodiesterase IV Inhibitors;Phosphodiesterase V (PDE5A) Inhibitors;TNF-alpha Production Inhibitors targeting PDE5A, PDE2A |
| EC-49-OQ85_0.01uM | Dose=0.01uM |
| EC-49-OQ85_0.1uM | Dose=0.1uM |
| EC-49-OQ85_10uM | Dose=10uM |
| EC-49-OQ85_1uM | Dose=1uM |
| EC-50-TX10_0.01uM | Dose=0.01uM, [7-(Aminomethyl)-6-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-morpholin-4-ylmethanone, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| EC-50-TX10_10uM | Dose=10uM, [7-(Aminomethyl)-6-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-morpholin-4-ylmethanone, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| EC-55-XG31_0.01uM | Dose=0.01uM, Idoxifene, Selective Estrogen Receptor Modulators (SERM) targeting ESR1, ESR2 |
| EC-55-XG31_0.1uM | Dose=0.1uM, Idoxifene, Selective Estrogen Receptor Modulators (SERM) targeting ESR1, ESR2 |
| EC-55-XG31_10uM | Dose=10uM, Idoxifene, Selective Estrogen Receptor Modulators (SERM) targeting ESR1, ESR2 |
| EC-55-XG31_1uM | Dose=1uM, Idoxifene, Selective Estrogen Receptor Modulators (SERM) targeting ESR1, ESR2 |
| EC-56-YK73_0.01uM | Dose=0.01uM, Cordycepin, PAPOLA gene inhibitor targeting POLA1, POLB, POLG, PAPOLA, POLA2 |
| EC-56-YK73_0.1uM | Dose=0.1uM, Cordycepin, PAPOLA gene inhibitor targeting POLA1, POLB, POLG, PAPOLA, POLA2 |
| EC-56-YK73_10uM | Dose=10uM, Cordycepin, PAPOLA gene inhibitor targeting POLA1, POLB, POLG, PAPOLA, POLA2 |
| EC-56-YK73_1uM | Dose=1uM, Cordycepin, PAPOLA gene inhibitor targeting POLA1, POLB, POLG, PAPOLA, POLA2 |
| EC-60-CX20_0.01uM | Dose=0.01uM, (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl)benzonitrile targeting KDM1A |
| EC-60-CX20_0.1uM | Dose=0.1uM, (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl)benzonitrile targeting KDM1A |
| EC-60-CX20_10uM | Dose=10uM, (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl)benzonitrile targeting KDM1A |
| EC-60-CX20_1uM | Dose=1uM, (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl)benzonitrile targeting KDM1A |
| EC-60-IX15_0.01uM | Dose=0.01uM, 3',4',7-Trihydroxyisoflavone, Tyrosinase Inhibitors;Melanin Inhibitors;Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF, TYR |
| EC-60-IX15_10uM | Dose=10uM, 3',4',7-Trihydroxyisoflavone, Tyrosinase Inhibitors;Melanin Inhibitors;Macrophage Migration Inhibitory Factor (MIF) Inhibitors targeting MIF, TYR |
| EC-62-HO43_0.01uM | Dose=0.01uM, Cyclazocine, Opioid agonist-antagonists targeting OPRD1, OPRK1, OPRM1 |
| EC-62-HO43_0.1uM | Dose=0.1uM, Cyclazocine, Opioid agonist-antagonists targeting OPRD1, OPRK1, OPRM1 |
| EC-62-HO43_10uM | Dose=10uM, Cyclazocine, Opioid agonist-antagonists targeting OPRD1, OPRK1, OPRM1 |
| EC-62-HO43_1uM | Dose=1uM, Cyclazocine, Opioid agonist-antagonists targeting OPRD1, OPRK1, OPRM1 |
| EC-62-NP61_0.01uM | Dose=0.01uM, 4'-(3,6,9,12-Tetraoxapentadec-14-yn-1-yloxy)-[1,1'-biphenyl]-4-yl sulfurofluoridate, CRABP2 inhibitor targeting CRABP2 |
| EC-62-NP61_0.1uM | Dose=0.1uM, 4'-(3,6,9,12-Tetraoxapentadec-14-yn-1-yloxy)-[1,1'-biphenyl]-4-yl sulfurofluoridate, CRABP2 inhibitor targeting CRABP2 |
| EC-62-NP61_10uM | Dose=10uM, 4'-(3,6,9,12-Tetraoxapentadec-14-yn-1-yloxy)-[1,1'-biphenyl]-4-yl sulfurofluoridate, CRABP2 inhibitor targeting CRABP2 |
| EC-62-OE64_0.01uM | Dose=0.01uM, (E)-N-Hydroxy-3-[4-({[2-(1H-indol-3-yl)-ethyl]-isopropyl-amino}-methyl)-phenyl]-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| EC-62-OE64_0.1uM | Dose=0.1uM, (E)-N-Hydroxy-3-[4-({[2-(1H-indol-3-yl)-ethyl]-isopropyl-amino}-methyl)-phenyl]-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| EC-62-OE64_10uM | Dose=10uM, (E)-N-Hydroxy-3-[4-({[2-(1H-indol-3-yl)-ethyl]-isopropyl-amino}-methyl)-phenyl]-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| EC-62-OE64_1uM | Dose=1uM, (E)-N-Hydroxy-3-[4-({[2-(1H-indol-3-yl)-ethyl]-isopropyl-amino}-methyl)-phenyl]-acrylamide, Histone Deacetylase (HDAC) Inhibitors targeting HDAC9, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10 |
| EC-67-PV87_0.01uM | Dose=0.01uM, 6-chloro-N-pyrimidin-5-yl-3-((3-(trifluoromethyl)phenyl)amino)-1,2-benzisoxazole-7-carboxamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors targeting KIT, PDGFRA |
| EC-67-PV87_0.1uM | Dose=0.1uM, 6-chloro-N-pyrimidin-5-yl-3-((3-(trifluoromethyl)phenyl)amino)-1,2-benzisoxazole-7-carboxamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors targeting KIT, PDGFRA |
| EC-67-PV87_10uM | Dose=10uM, 6-chloro-N-pyrimidin-5-yl-3-((3-(trifluoromethyl)phenyl)amino)-1,2-benzisoxazole-7-carboxamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors targeting KIT, PDGFRA |
| EC-67-PV87_1uM | Dose=1uM, 6-chloro-N-pyrimidin-5-yl-3-((3-(trifluoromethyl)phenyl)amino)-1,2-benzisoxazole-7-carboxamide, Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors targeting KIT, PDGFRA |
| EC-70-XX20_0.01uM | Dose=0.01uM, [5-(7-Chloro-1-propyl-1H-benzoimidazol-2-yl)-pyrimidin-2-yl]-(6-methyl-pyridin-3-yl)-amine, mgluR5 Antagonists targeting GRM5 |
| EC-70-XX20_0.1uM | Dose=0.1uM, [5-(7-Chloro-1-propyl-1H-benzoimidazol-2-yl)-pyrimidin-2-yl]-(6-methyl-pyridin-3-yl)-amine, mgluR5 Antagonists targeting GRM5 |
| EC-70-XX20_10uM | Dose=10uM, [5-(7-Chloro-1-propyl-1H-benzoimidazol-2-yl)-pyrimidin-2-yl]-(6-methyl-pyridin-3-yl)-amine, mgluR5 Antagonists targeting GRM5 |
| EC-71-PH39_0.01uM | Dose=0.01uM, (4S)-3-[2-(1-phenylethylamino)pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one, mutant selective IDH1 inhibitor targeting IDH1 |
| EC-71-PH39_0.1uM | Dose=0.1uM, (4S)-3-[2-(1-phenylethylamino)pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one, mutant selective IDH1 inhibitor targeting IDH1 |
| EC-71-PH39_10uM | Dose=10uM, (4S)-3-[2-(1-phenylethylamino)pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one, mutant selective IDH1 inhibitor targeting IDH1 |
| EC-71-PH39_1uM | Dose=1uM, (4S)-3-[2-(1-phenylethylamino)pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one, mutant selective IDH1 inhibitor targeting IDH1 |
| EC-72-RE74_0.01uM | Dose=0.01uM, 1-(3-((((2R,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea, Dot1L / KMT4;Histone methyltransferase inhibitors targeting DOT1L |
| EC-72-RE74_0.1uM | Dose=0.1uM, 1-(3-((((2R,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea, Dot1L / KMT4;Histone methyltransferase inhibitors targeting DOT1L |
| EC-72-RE74_10uM | Dose=10uM, 1-(3-((((2R,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea, Dot1L / KMT4;Histone methyltransferase inhibitors targeting DOT1L |
| EC-72-RE74_1uM | Dose=1uM, 1-(3-((((2R,3S,4R,5R)-5-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea, Dot1L / KMT4;Histone methyltransferase inhibitors targeting DOT1L |
| EC-81-BA87_0.01uM | Dose=0.01uM, [(6,7-Dichloro-2-cyclopentyl-2-methyl-1-oxo-2,3-dihydro-1h-inden-5-yl)oxy]acetic acid, Chloride Channel Blockers targeting CLCN3 |
| EC-81-BA87_0.1uM | Dose=0.1uM, [(6,7-Dichloro-2-cyclopentyl-2-methyl-1-oxo-2,3-dihydro-1h-inden-5-yl)oxy]acetic acid, Chloride Channel Blockers targeting CLCN3 |
| EC-81-BA87_10uM | Dose=10uM, [(6,7-Dichloro-2-cyclopentyl-2-methyl-1-oxo-2,3-dihydro-1h-inden-5-yl)oxy]acetic acid, Chloride Channel Blockers targeting CLCN3 |
| EC-81-BA87_1uM | Dose=1uM, [(6,7-Dichloro-2-cyclopentyl-2-methyl-1-oxo-2,3-dihydro-1h-inden-5-yl)oxy]acetic acid, Chloride Channel Blockers targeting CLCN3 |
| EC-82-LV30_0.01uM | Dose=0.01uM, PI-103, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| EC-82-LV30_0.1uM | Dose=0.1uM, PI-103, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| EC-82-LV30_10uM | Dose=10uM, PI-103, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| EC-82-LV30_1uM | Dose=1uM, PI-103, FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Mammalian Target of Rapamycin (mTOR;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors targeting PIK3C2B |
| EC-84-CC24_0.1uM | Dose=0.1uM, Lfm-A13, Inhibitors of Signal Transduction Pathways;Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK |
| EC-84-CC24_10uM | Dose=10uM, Lfm-A13, Inhibitors of Signal Transduction Pathways;Bruton's Tyrosine Kinase (BTK) Inhibitors targeting BTK |
| EC-85-CG61_0.01uM | Dose=0.01uM, N-[(R)-1-[(S)-1-(Butane-1-sulfonylaminocarbonyl)-2-methyl-propylcarbamoyl]-2-(4-isoxazol-5-yl-phenyl)-ethyl]-3,5,N-trimethyl-benzamide, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB |
| EC-85-CG61_0.1uM | Dose=0.1uM, N-[(R)-1-[(S)-1-(Butane-1-sulfonylaminocarbonyl)-2-methyl-propylcarbamoyl]-2-(4-isoxazol-5-yl-phenyl)-ethyl]-3,5,N-trimethyl-benzamide, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB |
| EC-85-CG61_10uM | Dose=10uM, N-[(R)-1-[(S)-1-(Butane-1-sulfonylaminocarbonyl)-2-methyl-propylcarbamoyl]-2-(4-isoxazol-5-yl-phenyl)-ethyl]-3,5,N-trimethyl-benzamide, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB |
| EC-85-CG61_1uM | Dose=1uM, N-[(R)-1-[(S)-1-(Butane-1-sulfonylaminocarbonyl)-2-methyl-propylcarbamoyl]-2-(4-isoxazol-5-yl-phenyl)-ethyl]-3,5,N-trimethyl-benzamide, Endothelin ETB Receptor Antagonists;Endothelin ETA Receptor Antagonists targeting EDNRA, EDNRB |
| EC-86-EK93_0.01uM | Dose=0.01uM, 1-Amino-4-((4-((4-chloro-6-((4-sulfophenyl)amino)-1,3,5-triazin-2-yl)amino)-3-sulfophenyl)amino)-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, P2Y2 Antagonists;P2Y4 Receptor Ligands targeting P2RY2, P2RY4 |
| EC-86-EK93_0.1uM | Dose=0.1uM, 1-Amino-4-((4-((4-chloro-6-((4-sulfophenyl)amino)-1,3,5-triazin-2-yl)amino)-3-sulfophenyl)amino)-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, P2Y2 Antagonists;P2Y4 Receptor Ligands targeting P2RY2, P2RY4 |
| EC-86-EK93_10uM | Dose=10uM, 1-Amino-4-((4-((4-chloro-6-((4-sulfophenyl)amino)-1,3,5-triazin-2-yl)amino)-3-sulfophenyl)amino)-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, P2Y2 Antagonists;P2Y4 Receptor Ligands targeting P2RY2, P2RY4 |
| EC-86-EK93_1uM | Dose=1uM, 1-Amino-4-((4-((4-chloro-6-((4-sulfophenyl)amino)-1,3,5-triazin-2-yl)amino)-3-sulfophenyl)amino)-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, P2Y2 Antagonists;P2Y4 Receptor Ligands targeting P2RY2, P2RY4 |
| EC-87-ZB49_0.01uM | Dose=0.01uM, Sto609, calcium/calmodulin-dependent protein kinase inhibitor targeting CAMKK2, CAMKK1 |
| EC-87-ZB49_0.1uM | Dose=0.1uM, Sto609, calcium/calmodulin-dependent protein kinase inhibitor targeting CAMKK2, CAMKK1 |
| EC-87-ZB49_10uM | Dose=10uM, Sto609, calcium/calmodulin-dependent protein kinase inhibitor targeting CAMKK2, CAMKK1 |
| EC-87-ZB49_1uM | Dose=1uM, Sto609, calcium/calmodulin-dependent protein kinase inhibitor targeting CAMKK2, CAMKK1 |
| EC-87-ZE76_0.01uM | Dose=0.01uM, 6-Carbamimidoylnaphthalen-2-yl benzoate, Factor XIa Inhibitor;Complement C1s subcomponent inhibitor targeting C1S, CFD, F10 |
| EC-87-ZE76_0.1uM | Dose=0.1uM, 6-Carbamimidoylnaphthalen-2-yl benzoate, Factor XIa Inhibitor;Complement C1s subcomponent inhibitor targeting C1S, CFD, F10 |
| EC-87-ZE76_10uM | Dose=10uM, 6-Carbamimidoylnaphthalen-2-yl benzoate, Factor XIa Inhibitor;Complement C1s subcomponent inhibitor targeting C1S, CFD, F10 |
| EC-87-ZE76_1uM | Dose=1uM, 6-Carbamimidoylnaphthalen-2-yl benzoate, Factor XIa Inhibitor;Complement C1s subcomponent inhibitor targeting C1S, CFD, F10 |
| EC-89-AJ93_0.01uM | Dose=0.01uM, Valinomycin |
| EC-89-AJ93_0.1uM | Dose=0.1uM, Valinomycin |
| EC-89-AJ93_10uM | Dose=10uM, Valinomycin |
| EC-89-AJ93_1uM | Dose=1uM, Valinomycin |
| EC-90-QX75_0.01uM | Dose=0.01uM, N-[5-cyano-4-[(2S)-2-methoxypropoxy]pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, FGFR4 gene inhibitor targeting FGFR4 |
| EC-90-QX75_10uM | Dose=10uM, N-[5-cyano-4-[(2S)-2-methoxypropoxy]pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, FGFR4 gene inhibitor targeting FGFR4 |
| EC-90-QX75_1uM | Dose=1uM, N-[5-cyano-4-[(2S)-2-methoxypropoxy]pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, FGFR4 gene inhibitor targeting FGFR4 |
| EC-95-BQ25_0.01uM | Dose=0.01uM, 2-(5-Oxo-5,11-dihydro-10-thia-dibenzo[a,d]cyclohepten-7-yl)-propionic acid, DNA Polymerase Inhibitors;ATPase Inhibitors targeting REV3L |
| EC-95-BQ25_0.1uM | Dose=0.1uM, 2-(5-Oxo-5,11-dihydro-10-thia-dibenzo[a,d]cyclohepten-7-yl)-propionic acid, DNA Polymerase Inhibitors;ATPase Inhibitors targeting REV3L |
| EC-95-BQ25_10uM | Dose=10uM, 2-(5-Oxo-5,11-dihydro-10-thia-dibenzo[a,d]cyclohepten-7-yl)-propionic acid, DNA Polymerase Inhibitors;ATPase Inhibitors targeting REV3L |
| EC-96-KI84_0.01uM | Dose=0.01uM |
| EC-96-KI84_0.1uM | Dose=0.1uM |
| EC-96-KI84_10uM | Dose=10uM |
| EC-96-KI84_1uM | Dose=1uM |
| EC-96-OH91_0.01uM | Dose=0.01uM, CID 90656831, NR1H4 gene inhibitor targeting NR1H4 |
| EC-96-OH91_0.1uM | Dose=0.1uM, CID 90656831, NR1H4 gene inhibitor targeting NR1H4 |
| EC-96-OH91_10uM | Dose=10uM, CID 90656831, NR1H4 gene inhibitor targeting NR1H4 |
| EC-96-OH91_1uM | Dose=1uM, CID 90656831, NR1H4 gene inhibitor targeting NR1H4 |
| EC-98-KI28_0.01uM | Dose=0.01uM, CID 196804 |
| EC-98-KI28_0.1uM | Dose=0.1uM, CID 196804 |
| EC-98-KI28_10uM | Dose=10uM, CID 196804 |
| EC-98-KI28_1uM | Dose=1uM, CID 196804 |
| EC-98-YS67_0.01uM | Dose=0.01uM, Aacocf3, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A |
| EC-98-YS67_0.1uM | Dose=0.1uM, Aacocf3, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A |
| EC-98-YS67_10uM | Dose=10uM, Aacocf3, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A |
| EC-98-YS67_1uM | Dose=1uM, Aacocf3, Cytosolic Phospholipase A2 (cPLA2) Inhibitors targeting PLA2G4A |
| ED-00-OH22_0.01uM | Dose=0.01uM, O(6)-Benzylguanine, O6-Alkylguanine-DNA Alkyltransferase (MGMT) Inhibitors targeting MGMT |
| ED-00-OH22_0.1uM | Dose=0.1uM, O(6)-Benzylguanine, O6-Alkylguanine-DNA Alkyltransferase (MGMT) Inhibitors targeting MGMT |
| ED-00-OH22_10uM | Dose=10uM, O(6)-Benzylguanine, O6-Alkylguanine-DNA Alkyltransferase (MGMT) Inhibitors targeting MGMT |
| ED-00-OH22_1uM | Dose=1uM, O(6)-Benzylguanine, O6-Alkylguanine-DNA Alkyltransferase (MGMT) Inhibitors targeting MGMT |
| ED-02-CL76_0.1uM | Dose=0.1uM, Purine Antagonists;Immunosuppressive targeting HPRT1, IMPDH1, IMPDH2, PPAT |
| ED-02-CL76_10uM | Dose=10uM, Purine Antagonists;Immunosuppressive targeting HPRT1, IMPDH1, IMPDH2, PPAT |
| ED-02-CL76_1uM | Dose=1uM, Purine Antagonists;Immunosuppressive targeting HPRT1, IMPDH1, IMPDH2, PPAT |
| ED-03-IP48_0.01uM | Dose=0.01uM, N-{5-[2-chloro-5-(trifluoromethyl)phenyl]pyrazin-2-yl}-2,6-difluorobenzamide, IL-2 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers targeting ORAI1 |
| ED-03-IP48_0.1uM | Dose=0.1uM, N-{5-[2-chloro-5-(trifluoromethyl)phenyl]pyrazin-2-yl}-2,6-difluorobenzamide, IL-2 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers targeting ORAI1 |
| ED-03-IP48_10uM | Dose=10uM, N-{5-[2-chloro-5-(trifluoromethyl)phenyl]pyrazin-2-yl}-2,6-difluorobenzamide, IL-2 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers targeting ORAI1 |
| ED-03-IP48_1uM | Dose=1uM, N-{5-[2-chloro-5-(trifluoromethyl)phenyl]pyrazin-2-yl}-2,6-difluorobenzamide, IL-2 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers targeting ORAI1 |
| ED-05-KX67_0.01uM | Dose=0.01uM, 4-[(E)-(dibenzylhydrazinylidene)methyl]phenol, Glucose-6-phosphatase Inhibitors targeting G6PC |
| ED-05-KX67_0.1uM | Dose=0.1uM, 4-[(E)-(dibenzylhydrazinylidene)methyl]phenol, Glucose-6-phosphatase Inhibitors targeting G6PC |
| ED-05-KX67_10uM | Dose=10uM, 4-[(E)-(dibenzylhydrazinylidene)methyl]phenol, Glucose-6-phosphatase Inhibitors targeting G6PC |
| ED-05-KX67_1uM | Dose=1uM, 4-[(E)-(dibenzylhydrazinylidene)methyl]phenol, Glucose-6-phosphatase Inhibitors targeting G6PC |
| ED-05-LQ40_0.01uM | Dose=0.01uM, N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine |
| ED-05-LQ40_10uM | Dose=10uM, N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine |
| ED-05-LQ40_1uM | Dose=1uM, N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine |
| ED-10-ED67_0.01uM | Dose=0.01uM, Dcebio |
| ED-10-ED67_0.1uM | Dose=0.1uM, Dcebio |
| ED-10-ED67_10uM | Dose=10uM, Dcebio |
| ED-10-ED67_1uM | Dose=1uM, Dcebio |
| ED-11-BL19_0.01uM | Dose=0.01uM, N-[(1-Methyl-1h-Pyrazol-4-Yl)methyl]-5-{[(1s,2s)-2-(Pyridin-2-Yl)cyclopropyl]methoxy}pyrazolo[1,5-A]pyrimidin-7-Amine, PDE10A gene inhibitor targeting PDE10A |
| ED-11-BL19_0.1uM | Dose=0.1uM, N-[(1-Methyl-1h-Pyrazol-4-Yl)methyl]-5-{[(1s,2s)-2-(Pyridin-2-Yl)cyclopropyl]methoxy}pyrazolo[1,5-A]pyrimidin-7-Amine, PDE10A gene inhibitor targeting PDE10A |
| ED-11-BL19_10uM | Dose=10uM, N-[(1-Methyl-1h-Pyrazol-4-Yl)methyl]-5-{[(1s,2s)-2-(Pyridin-2-Yl)cyclopropyl]methoxy}pyrazolo[1,5-A]pyrimidin-7-Amine, PDE10A gene inhibitor targeting PDE10A |
| ED-11-BL19_1uM | Dose=1uM, N-[(1-Methyl-1h-Pyrazol-4-Yl)methyl]-5-{[(1s,2s)-2-(Pyridin-2-Yl)cyclopropyl]methoxy}pyrazolo[1,5-A]pyrimidin-7-Amine, PDE10A gene inhibitor targeting PDE10A |
| ED-11-KK36_0.01uM | Dose=0.01uM, 4-({2-[(Thiophene-2-carbonyl)-amino]-acetyl}-hydrazonomethyl)-benzoic acid, Methionyl-tRNA Synthetase Inhibitors targeting MARS1 |
| ED-11-KK36_0.1uM | Dose=0.1uM, 4-({2-[(Thiophene-2-carbonyl)-amino]-acetyl}-hydrazonomethyl)-benzoic acid, Methionyl-tRNA Synthetase Inhibitors targeting MARS1 |
| ED-11-KK36_10uM | Dose=10uM, 4-({2-[(Thiophene-2-carbonyl)-amino]-acetyl}-hydrazonomethyl)-benzoic acid, Methionyl-tRNA Synthetase Inhibitors targeting MARS1 |
| ED-11-KK36_1uM | Dose=1uM, 4-({2-[(Thiophene-2-carbonyl)-amino]-acetyl}-hydrazonomethyl)-benzoic acid, Methionyl-tRNA Synthetase Inhibitors targeting MARS1 |
| ED-12-PB22_0.01uM | Dose=0.01uM, Daporinad, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting NAMPT |
| ED-12-PB22_0.1uM | Dose=0.1uM, Daporinad, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting NAMPT |
| ED-12-PB22_10uM | Dose=10uM, Daporinad, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting NAMPT |
| ED-12-PB22_1uM | Dose=1uM, Daporinad, Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinamide Phosphoribosyltransferase (NMPRTase) Inhibitors targeting NAMPT |
| ED-14-GQ53_0.01uM | Dose=0.01uM, 2-(4-Methylphenoxy)benzoic acid |
| ED-14-GQ53_0.1uM | Dose=0.1uM, 2-(4-Methylphenoxy)benzoic acid |
| ED-14-GQ53_10uM | Dose=10uM, 2-(4-Methylphenoxy)benzoic acid |
| ED-14-GQ53_1uM | Dose=1uM, 2-(4-Methylphenoxy)benzoic acid |
| ED-15-OX47_0.01uM | Dose=0.01uM, Dimaprit, HRH2 agonist targeting HRH2 |
| ED-15-OX47_0.1uM | Dose=0.1uM, Dimaprit, HRH2 agonist targeting HRH2 |
| ED-15-OX47_10uM | Dose=10uM, Dimaprit, HRH2 agonist targeting HRH2 |
| ED-15-OX47_1uM | Dose=1uM, Dimaprit, HRH2 agonist targeting HRH2 |
| ED-22-QV85_0.01uM | Dose=0.01uM, 4-Methyl-4'-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-1,2,3-thiadiazole-5-carboxanilide, IL-4 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers;IL-2 Production Inhibitors;IL-5 Production Inhibitors;TRPM4 Agonists;Calcium channel inhibitor;TRPM4 agonist targeting IL2, IL4, IL5, TRPM4, ORAI2, ORAI1, ORAI3 |
| ED-22-QV85_0.1uM | Dose=0.1uM, 4-Methyl-4'-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-1,2,3-thiadiazole-5-carboxanilide, IL-4 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers;IL-2 Production Inhibitors;IL-5 Production Inhibitors;TRPM4 Agonists;Calcium channel inhibitor;TRPM4 agonist targeting IL2, IL4, IL5, TRPM4, ORAI2, ORAI1, ORAI3 |
| ED-22-QV85_10uM | Dose=10uM, 4-Methyl-4'-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-1,2,3-thiadiazole-5-carboxanilide, IL-4 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers;IL-2 Production Inhibitors;IL-5 Production Inhibitors;TRPM4 Agonists;Calcium channel inhibitor;TRPM4 agonist targeting IL2, IL4, IL5, TRPM4, ORAI2, ORAI1, ORAI3 |
| ED-22-QV85_1uM | Dose=1uM, 4-Methyl-4'-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-1,2,3-thiadiazole-5-carboxanilide, IL-4 Production Inhibitors;Calcium Release-Activated Channels (CRAC) Blockers;IL-2 Production Inhibitors;IL-5 Production Inhibitors;TRPM4 Agonists;Calcium channel inhibitor;TRPM4 agonist targeting IL2, IL4, IL5, TRPM4, ORAI2, ORAI1, ORAI3 |
| ED-25-BD54_0.01uM | Dose=0.01uM, 2-(2-(2-Fluorophenyl)pyridin-4-YL)-1,5,6,7-tetrahydro-4H-pyrrolo(3,2-C)pyridin-4-one, TNF-alpha Production Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| ED-25-BD54_0.1uM | Dose=0.1uM, 2-(2-(2-Fluorophenyl)pyridin-4-YL)-1,5,6,7-tetrahydro-4H-pyrrolo(3,2-C)pyridin-4-one, TNF-alpha Production Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| ED-25-BD54_10uM | Dose=10uM, 2-(2-(2-Fluorophenyl)pyridin-4-YL)-1,5,6,7-tetrahydro-4H-pyrrolo(3,2-C)pyridin-4-one, TNF-alpha Production Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| ED-25-BD54_1uM | Dose=1uM, 2-(2-(2-Fluorophenyl)pyridin-4-YL)-1,5,6,7-tetrahydro-4H-pyrrolo(3,2-C)pyridin-4-one, TNF-alpha Production Inhibitors;MAPKAP-K2 (MK2) Inhibitors targeting MAPKAPK2 |
| ED-26-RU42_0.01uM | Dose=0.01uM, Ridogrel, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1 |
| ED-26-RU42_0.1uM | Dose=0.1uM, Ridogrel, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1 |
| ED-26-RU42_10uM | Dose=10uM, Ridogrel, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1 |
| ED-26-RU42_1uM | Dose=1uM, Ridogrel, Thromboxane Synthase Inhibitors;Prostanoid TP Antagonists targeting TBXA2R, TBXAS1 |
| ED-27-OE11_0.01uM | Dose=0.01uM, Dimorpholinethiuram disulfide, PDK1 gene inhibitor targeting PDK1 |
| ED-27-OE11_0.1uM | Dose=0.1uM, Dimorpholinethiuram disulfide, PDK1 gene inhibitor targeting PDK1 |
| ED-27-OE11_10uM | Dose=10uM, Dimorpholinethiuram disulfide, PDK1 gene inhibitor targeting PDK1 |
| ED-27-OE11_1uM | Dose=1uM, Dimorpholinethiuram disulfide, PDK1 gene inhibitor targeting PDK1 |
| ED-28-RW52_0.01uM | Dose=0.01uM, 8-(2-Fluorophenyl)-5-(furan-2-ylmethylamino)-[1,2,4]triazolo[4,3-a]pyridine-6-carbonitrile, EED gene inhibitor;PRC2/EED targeting EED |
| ED-28-RW52_1uM | Dose=1uM, 8-(2-Fluorophenyl)-5-(furan-2-ylmethylamino)-[1,2,4]triazolo[4,3-a]pyridine-6-carbonitrile, EED gene inhibitor;PRC2/EED targeting EED |
| ED-31-AA47_0.01uM | Dose=0.01uM, N-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,3-dimethoxy-benzamide, DRD2 antagonist targeting DRD2 |
| ED-31-AA47_0.1uM | Dose=0.1uM, N-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,3-dimethoxy-benzamide, DRD2 antagonist targeting DRD2 |
| ED-31-AA47_10uM | Dose=10uM, N-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,3-dimethoxy-benzamide, DRD2 antagonist targeting DRD2 |
| ED-31-AA47_1uM | Dose=1uM, N-(8-Benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,3-dimethoxy-benzamide, DRD2 antagonist targeting DRD2 |
| ED-32-JY57_0.01uM | Dose=0.01uM, N-((4,5-Dihydro-1H-imidazol-2-yl)methyl)-2-methylaniline, α2-Adrenoceptors targeting ADRA2A |
| ED-32-JY57_0.1uM | Dose=0.1uM, N-((4,5-Dihydro-1H-imidazol-2-yl)methyl)-2-methylaniline, α2-Adrenoceptors targeting ADRA2A |
| ED-32-JY57_10uM | Dose=10uM, N-((4,5-Dihydro-1H-imidazol-2-yl)methyl)-2-methylaniline, α2-Adrenoceptors targeting ADRA2A |
| ED-32-JY57_1uM | Dose=1uM, N-((4,5-Dihydro-1H-imidazol-2-yl)methyl)-2-methylaniline, α2-Adrenoceptors targeting ADRA2A |
| ED-32-VE54_0.01uM | Dose=0.01uM, Thiosalicylic Acid |
| ED-32-VE54_0.1uM | Dose=0.1uM, Thiosalicylic Acid |
| ED-32-VE54_10uM | Dose=10uM, Thiosalicylic Acid |
| ED-32-VE54_1uM | Dose=1uM, Thiosalicylic Acid |
| ED-33-YZ72_0.01uM | Dose=0.01uM, Sgc-cbp30, N-Ac Lysine competitive CREBBP inhibitor;CREBBP / CBP / KAT3A targeting CREBBP, EP300 |
| ED-33-YZ72_0.1uM | Dose=0.1uM, Sgc-cbp30, N-Ac Lysine competitive CREBBP inhibitor;CREBBP / CBP / KAT3A targeting CREBBP, EP300 |
| ED-33-YZ72_10uM | Dose=10uM, Sgc-cbp30, N-Ac Lysine competitive CREBBP inhibitor;CREBBP / CBP / KAT3A targeting CREBBP, EP300 |
| ED-33-YZ72_1uM | Dose=1uM, Sgc-cbp30, N-Ac Lysine competitive CREBBP inhibitor;CREBBP / CBP / KAT3A targeting CREBBP, EP300 |
| ED-35-EX82_0.01uM | Dose=0.01uM, N-[4-chloro-3-(5-phenyl-1H-imidazol-2-yl)phenyl]-2-[(2R)-2-methylmorpholin-4-yl]-1,6-naphthyridin-5-amine, Smoothened Antagonist targeting SMO |
| ED-35-EX82_0.1uM | Dose=0.1uM, N-[4-chloro-3-(5-phenyl-1H-imidazol-2-yl)phenyl]-2-[(2R)-2-methylmorpholin-4-yl]-1,6-naphthyridin-5-amine, Smoothened Antagonist targeting SMO |
| ED-35-EX82_10uM | Dose=10uM, N-[4-chloro-3-(5-phenyl-1H-imidazol-2-yl)phenyl]-2-[(2R)-2-methylmorpholin-4-yl]-1,6-naphthyridin-5-amine, Smoothened Antagonist targeting SMO |
| ED-35-ZX52_0.01uM | Dose=0.01uM, Bergenin, Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1 |
| ED-35-ZX52_10uM | Dose=10uM, Bergenin, Protein Tyrosine Phosphatase PTP-1B Inhibitors targeting PTPN1 |
| ED-39-VX22_0.01uM | Dose=0.01uM, Ursodiol, AKR1C3 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Antioxidants targeting NFE2L2, AKR1C3, GPBAR1 |
| ED-39-VX22_0.1uM | Dose=0.1uM, Ursodiol, AKR1C3 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Antioxidants targeting NFE2L2, AKR1C3, GPBAR1 |
| ED-39-VX22_10uM | Dose=10uM, Ursodiol, AKR1C3 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Antioxidants targeting NFE2L2, AKR1C3, GPBAR1 |
| ED-39-VX22_1uM | Dose=1uM, Ursodiol, AKR1C3 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Antioxidants targeting NFE2L2, AKR1C3, GPBAR1 |
| ED-43-XF39_0.01uM | Dose=0.01uM, 9-(tetrahydro-2-furanyl)-9H-purin-6-amine, Adenylate Cyclase Inhibitors targeting ADCY5 |
| ED-43-XF39_10uM | Dose=10uM, 9-(tetrahydro-2-furanyl)-9H-purin-6-amine, Adenylate Cyclase Inhibitors targeting ADCY5 |
| ED-43-XF39_1uM | Dose=1uM, 9-(tetrahydro-2-furanyl)-9H-purin-6-amine, Adenylate Cyclase Inhibitors targeting ADCY5 |
| ED-62-DB62_0.01uM | Dose=0.01uM |
| ED-62-DB62_0.1uM | Dose=0.1uM |
| ED-62-DB62_10uM | Dose=10uM |
| ED-62-DB62_1uM | Dose=1uM |
| ED-62-GS43_0.01uM | Dose=0.01uM, APLNR agonist targeting APLNR |
| ED-62-GS43_0.1uM | Dose=0.1uM, APLNR agonist targeting APLNR |
| ED-62-GS43_10uM | Dose=10uM, APLNR agonist targeting APLNR |
| ED-62-GS43_1uM | Dose=1uM, APLNR agonist targeting APLNR |
| ED-71-GA72_0.01uM | Dose=0.01uM, Sgi-1027, DNA Methyltransferase I Inhibitors targeting DNMT1 |
| ED-71-GA72_0.1uM | Dose=0.1uM, Sgi-1027, DNA Methyltransferase I Inhibitors targeting DNMT1 |
| ED-71-GA72_10uM | Dose=10uM, Sgi-1027, DNA Methyltransferase I Inhibitors targeting DNMT1 |
| ED-71-GA72_1uM | Dose=1uM, Sgi-1027, DNA Methyltransferase I Inhibitors targeting DNMT1 |
| ED-79-EW79_0.01uM | Dose=0.01uM, mgluR5 Antagonists;GRM5 antagonist targeting GRM5 |
| ED-79-EW79_0.1uM | Dose=0.1uM, mgluR5 Antagonists;GRM5 antagonist targeting GRM5 |
| ED-79-EW79_10uM | Dose=10uM, mgluR5 Antagonists;GRM5 antagonist targeting GRM5 |
| ED-79-EW79_1uM | Dose=1uM, mgluR5 Antagonists;GRM5 antagonist targeting GRM5 |
| ED-80-NA90_0.01uM | Dose=0.01uM, 1-(4-Nitrophenyl)-4-piperidinol, CDK Inhibitors targeting CCND2, CCND3 |
| ED-80-NA90_0.1uM | Dose=0.1uM, 1-(4-Nitrophenyl)-4-piperidinol, CDK Inhibitors targeting CCND2, CCND3 |
| ED-80-NA90_10uM | Dose=10uM, 1-(4-Nitrophenyl)-4-piperidinol, CDK Inhibitors targeting CCND2, CCND3 |
| ED-80-NA90_1uM | Dose=1uM, 1-(4-Nitrophenyl)-4-piperidinol, CDK Inhibitors targeting CCND2, CCND3 |
| ED-81-ZH14_0.01uM | Dose=0.01uM, 4-(tert-Butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide targeting BTK |
| ED-81-ZH14_0.1uM | Dose=0.1uM, 4-(tert-Butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide targeting BTK |
| ED-81-ZH14_10uM | Dose=10uM, 4-(tert-Butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide targeting BTK |
| ED-81-ZH14_1uM | Dose=1uM, 4-(tert-Butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide targeting BTK |
| ED-83-GF49_0.01uM | Dose=0.01uM, 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide |
| ED-83-GF49_0.1uM | Dose=0.1uM, 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide |
| ED-83-GF49_10uM | Dose=10uM, 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide |
| ED-83-GF49_1uM | Dose=1uM, 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide |
| ED-84-WW97_0.01uM | Dose=0.01uM, (2R)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid, GRM5 agonist;GRM1 agonist targeting GRIA1, GRM1, GRM5 |
| ED-84-WW97_0.1uM | Dose=0.1uM, (2R)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid, GRM5 agonist;GRM1 agonist targeting GRIA1, GRM1, GRM5 |
| ED-84-WW97_10uM | Dose=10uM, (2R)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid, GRM5 agonist;GRM1 agonist targeting GRIA1, GRM1, GRM5 |
| ED-84-WW97_1uM | Dose=1uM, (2R)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid, GRM5 agonist;GRM1 agonist targeting GRIA1, GRM1, GRM5 |
| ED-87-UE76_0.01uM | Dose=0.01uM, CP-122721, Neurokinin 1 receptor antagonist;Tachykinin NK1 Antagonists targeting CYP2D6 |
| ED-87-UE76_0.1uM | Dose=0.1uM, CP-122721, Neurokinin 1 receptor antagonist;Tachykinin NK1 Antagonists targeting CYP2D6 |
| ED-87-UE76_10uM | Dose=10uM, CP-122721, Neurokinin 1 receptor antagonist;Tachykinin NK1 Antagonists targeting CYP2D6 |
| ED-90-AH37_0.01uM | Dose=0.01uM |
| ED-90-AH37_10uM | Dose=10uM |
| ED-90-AH37_1uM | Dose=1uM |
| ED-91-LA02_0.01uM | Dose=0.01uM, 5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine, HTR1B agonist targeting HTR1B |
| ED-91-LA02_0.1uM | Dose=0.1uM, 5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine, HTR1B agonist targeting HTR1B |
| ED-91-LA02_10uM | Dose=10uM, 5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine, HTR1B agonist targeting HTR1B |
| ED-91-LA02_1uM | Dose=1uM, 5-propoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[3,2-b]pyridine, HTR1B agonist targeting HTR1B |
| ED-91-LY45_0.01uM | Dose=0.01uM, Tideglusib, GSK3B gene inhibitor targeting GSK3B |
| ED-91-LY45_10uM | Dose=10uM, Tideglusib, GSK3B gene inhibitor targeting GSK3B |
| ED-91-LY45_1uM | Dose=1uM, Tideglusib, GSK3B gene inhibitor targeting GSK3B |
| ED-92-AL11_0.01uM | Dose=0.01uM, Cholic Acid, Cholesterol-7-alpha-hydroxylase product and feedback inhibitor targeting GPBAR1, NR1H4, CYP7A1 |
| ED-92-AL11_0.1uM | Dose=0.1uM, Cholic Acid, Cholesterol-7-alpha-hydroxylase product and feedback inhibitor targeting GPBAR1, NR1H4, CYP7A1 |
| ED-92-AL11_10uM | Dose=10uM, Cholic Acid, Cholesterol-7-alpha-hydroxylase product and feedback inhibitor targeting GPBAR1, NR1H4, CYP7A1 |
| ED-92-AL11_1uM | Dose=1uM, Cholic Acid, Cholesterol-7-alpha-hydroxylase product and feedback inhibitor targeting GPBAR1, NR1H4, CYP7A1 |
| ED-93-KF69_0.01uM | Dose=0.01uM, 3-(2-Aminoethyl)adamantan-1-ol |
| ED-93-KF69_0.1uM | Dose=0.1uM, 3-(2-Aminoethyl)adamantan-1-ol |
| ED-93-KF69_10uM | Dose=10uM, 3-(2-Aminoethyl)adamantan-1-ol |
| ED-93-KF69_1uM | Dose=1uM, 3-(2-Aminoethyl)adamantan-1-ol |
| ED-98-UI13_0.01uM | Dose=0.01uM, Yohimbine, alpha2-Adrenoceptor Antagonists targeting ADRA2A, ADRA2C, HTR1E |
| ED-98-UI13_0.1uM | Dose=0.1uM, Yohimbine, alpha2-Adrenoceptor Antagonists targeting ADRA2A, ADRA2C, HTR1E |
| ED-98-UI13_10uM | Dose=10uM, Yohimbine, alpha2-Adrenoceptor Antagonists targeting ADRA2A, ADRA2C, HTR1E |
| ED-99-XG61_0.01uM | Dose=0.01uM, Kartogenin, Chondrogenesis activator targeting FLNA |
| ED-99-XG61_0.1uM | Dose=0.1uM, Kartogenin, Chondrogenesis activator targeting FLNA |
| ED-99-XG61_10uM | Dose=10uM, Kartogenin, Chondrogenesis activator targeting FLNA |
| ED-99-XG61_1uM | Dose=1uM, Kartogenin, Chondrogenesis activator targeting FLNA |
| EE-01-DO31_0.01uM | Dose=0.01uM, 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile, Caspase 3 Inhibitors;Cathepsin B Inhibitors;Ubiquitin Carboxyl-terminal Hydrolase Inhibitors targeting CASP3, CTSB, USP8 |
| EE-01-DO31_0.1uM | Dose=0.1uM, 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile, Caspase 3 Inhibitors;Cathepsin B Inhibitors;Ubiquitin Carboxyl-terminal Hydrolase Inhibitors targeting CASP3, CTSB, USP8 |
| EE-01-DO31_10uM | Dose=10uM, 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile, Caspase 3 Inhibitors;Cathepsin B Inhibitors;Ubiquitin Carboxyl-terminal Hydrolase Inhibitors targeting CASP3, CTSB, USP8 |
| EE-01-DO31_1uM | Dose=1uM, 9-Oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile, Caspase 3 Inhibitors;Cathepsin B Inhibitors;Ubiquitin Carboxyl-terminal Hydrolase Inhibitors targeting CASP3, CTSB, USP8 |
| EE-01-FB85_0.01uM | Dose=0.01uM, Indolactam V, PKC agonist targeting PRKCA |
| EE-01-FB85_0.1uM | Dose=0.1uM, Indolactam V, PKC agonist targeting PRKCA |
| EE-01-FB85_10uM | Dose=10uM, Indolactam V, PKC agonist targeting PRKCA |
| EE-01-FB85_1uM | Dose=1uM, Indolactam V, PKC agonist targeting PRKCA |
| EE-02-BO83_0.01uM | Dose=0.01uM, Sdz-lap-977, Tubulin Polymerization Inhibitors;Cytoskeleton inhibitors targeting TUBA4A, TUBA3C, TUBB2A, TUBG1, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBG2, TUBD1, TUBA8, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B |
| EE-02-BO83_0.1uM | Dose=0.1uM, Sdz-lap-977, Tubulin Polymerization Inhibitors;Cytoskeleton inhibitors targeting TUBA4A, TUBA3C, TUBB2A, TUBG1, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBG2, TUBD1, TUBA8, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B |
| EE-02-BO83_10uM | Dose=10uM, Sdz-lap-977, Tubulin Polymerization Inhibitors;Cytoskeleton inhibitors targeting TUBA4A, TUBA3C, TUBB2A, TUBG1, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBG2, TUBD1, TUBA8, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B |
| EE-02-BO83_1uM | Dose=1uM, Sdz-lap-977, Tubulin Polymerization Inhibitors;Cytoskeleton inhibitors targeting TUBA4A, TUBA3C, TUBB2A, TUBG1, TUBA1A, TUBA1B, TUBB3, TUBB4A, TUBB4B, TUBG2, TUBD1, TUBA8, TUBB1, TUBB6, TUBA1C, TUBA3E, TUBA3D, TUBB8, TUBB2B |
| EE-03-SG02_0.01uM | Dose=0.01uM, (E)-N-hydroxy-3-[4-[(2S)-1-[2-(1,3,5-trimethylpyrazol-4-yl)ethyl]pyrrolidin-2-yl]phenyl]prop-2-enamide |
| EE-03-SG02_0.1uM | Dose=0.1uM, (E)-N-hydroxy-3-[4-[(2S)-1-[2-(1,3,5-trimethylpyrazol-4-yl)ethyl]pyrrolidin-2-yl]phenyl]prop-2-enamide |
| EE-03-SG02_10uM | Dose=10uM, (E)-N-hydroxy-3-[4-[(2S)-1-[2-(1,3,5-trimethylpyrazol-4-yl)ethyl]pyrrolidin-2-yl]phenyl]prop-2-enamide |
| EE-03-SG02_1uM | Dose=1uM, (E)-N-hydroxy-3-[4-[(2S)-1-[2-(1,3,5-trimethylpyrazol-4-yl)ethyl]pyrrolidin-2-yl]phenyl]prop-2-enamide |
| EE-04-QG34_0.01uM | Dose=0.01uM, Laccaic acid A, Direct competitive inhibitor of DNMT1 targeting DNMT1 |
| EE-04-QG34_0.1uM | Dose=0.1uM, Laccaic acid A, Direct competitive inhibitor of DNMT1 targeting DNMT1 |
| EE-04-QG34_10uM | Dose=10uM, Laccaic acid A, Direct competitive inhibitor of DNMT1 targeting DNMT1 |
| EE-04-QG34_1uM | Dose=1uM, Laccaic acid A, Direct competitive inhibitor of DNMT1 targeting DNMT1 |
| EE-08-FF71_0.01uM | Dose=0.01uM, Levofloxacin |
| EE-08-FF71_0.1uM | Dose=0.1uM, Levofloxacin |
| EE-08-FF71_10uM | Dose=10uM, Levofloxacin |
| EE-08-SZ54_0.01uM | Dose=0.01uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amide, Angiogenesis Inhibitors;FGFR3 Inhibitors targeting FGFR3 |
| EE-08-SZ54_0.1uM | Dose=0.1uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amide, Angiogenesis Inhibitors;FGFR3 Inhibitors targeting FGFR3 |
| EE-08-SZ54_10uM | Dose=10uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amide, Angiogenesis Inhibitors;FGFR3 Inhibitors targeting FGFR3 |
| EE-08-SZ54_1uM | Dose=1uM, 8-(2-Chloro-6-fluoro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid [5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amide, Angiogenesis Inhibitors;FGFR3 Inhibitors targeting FGFR3 |
| EE-13-PS05_0.01uM | Dose=0.01uM, 3-{(R)-2-Cyano-2-[(S)-2-(1,1-dimethyl-3-oxo-1,3-dihydro-isobenzofuran-5-ylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin L Inhibitors targeting CTSV, CTSL3P |
| EE-13-PS05_0.1uM | Dose=0.1uM, 3-{(R)-2-Cyano-2-[(S)-2-(1,1-dimethyl-3-oxo-1,3-dihydro-isobenzofuran-5-ylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin L Inhibitors targeting CTSV, CTSL3P |
| EE-13-PS05_10uM | Dose=10uM, 3-{(R)-2-Cyano-2-[(S)-2-(1,1-dimethyl-3-oxo-1,3-dihydro-isobenzofuran-5-ylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin L Inhibitors targeting CTSV, CTSL3P |
| EE-13-PS05_1uM | Dose=1uM, 3-{(R)-2-Cyano-2-[(S)-2-(1,1-dimethyl-3-oxo-1,3-dihydro-isobenzofuran-5-ylamino)-3-m-tolyl-propionylamino]-ethoxymethyl}-benzoic acid, Cathepsin L Inhibitors targeting CTSV, CTSL3P |
| EE-16-RH01_0.01uM | Dose=0.01uM, Pomaglumetad methionil free base, mgluR2 Agonists;mgluR3 Agonists targeting GRM2, GRM3 |
| EE-16-RH01_0.1uM | Dose=0.1uM, Pomaglumetad methionil free base, mgluR2 Agonists;mgluR3 Agonists targeting GRM2, GRM3 |
| EE-16-RH01_10uM | Dose=10uM, Pomaglumetad methionil free base, mgluR2 Agonists;mgluR3 Agonists targeting GRM2, GRM3 |
| EE-16-RH01_1uM | Dose=1uM, Pomaglumetad methionil free base, mgluR2 Agonists;mgluR3 Agonists targeting GRM2, GRM3 |
| EE-18-HW72_0.01uM | Dose=0.01uM, Dofetilide, K(V)11.1 (erg1) Channel Blockers targeting KCNH2, KCNJ12, KCNK2 |
| EE-18-HW72_0.1uM | Dose=0.1uM, Dofetilide, K(V)11.1 (erg1) Channel Blockers targeting KCNH2, KCNJ12, KCNK2 |
| EE-18-HW72_10uM | Dose=10uM, Dofetilide, K(V)11.1 (erg1) Channel Blockers targeting KCNH2, KCNJ12, KCNK2 |
| EE-18-HW72_1uM | Dose=1uM, Dofetilide, K(V)11.1 (erg1) Channel Blockers targeting KCNH2, KCNJ12, KCNK2 |
| EE-23-MF14_0.01uM | Dose=0.01uM, 3-[[4-[(2R)-3-cyclopentyl-1-[(5-ethyl-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid |
| EE-23-MF14_0.1uM | Dose=0.1uM, 3-[[4-[(2R)-3-cyclopentyl-1-[(5-ethyl-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid |
| EE-23-MF14_10uM | Dose=10uM, 3-[[4-[(2R)-3-cyclopentyl-1-[(5-ethyl-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid |
| EE-23-MF14_1uM | Dose=1uM, 3-[[4-[(2R)-3-cyclopentyl-1-[(5-ethyl-[1,3]thiazolo[5,4-b]pyridin-2-yl)amino]-1-oxopropan-2-yl]phenyl]sulfonyl-(2-methoxyethyl)amino]propanoic acid |
| EE-26-UK38_0.01uM | Dose=0.01uM, BE 2254, ADRA1B antagonist;ADRA1D antagonist;ADRA1A antagonist;alpha-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A |
| EE-26-UK38_0.1uM | Dose=0.1uM, BE 2254, ADRA1B antagonist;ADRA1D antagonist;ADRA1A antagonist;alpha-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A |
| EE-26-UK38_10uM | Dose=10uM, BE 2254, ADRA1B antagonist;ADRA1D antagonist;ADRA1A antagonist;alpha-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A |
| EE-26-UK38_1uM | Dose=1uM, BE 2254, ADRA1B antagonist;ADRA1D antagonist;ADRA1A antagonist;alpha-Adrenoceptor Antagonists targeting ADRA1D, ADRA1B, ADRA1A |
| EE-32-EY37_0.01uM | Dose=0.01uM, Phenidone, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants targeting ALOX5, PTGS1, PTGS2 |
| EE-32-EY37_0.1uM | Dose=0.1uM, Phenidone, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants targeting ALOX5, PTGS1, PTGS2 |
| EE-32-EY37_10uM | Dose=10uM, Phenidone, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants targeting ALOX5, PTGS1, PTGS2 |
| EE-32-EY37_1uM | Dose=1uM, Phenidone, Lipoxygenase Inhibitors;Cyclooxygenase (COX) Inhibitors;Antioxidants targeting ALOX5, PTGS1, PTGS2 |
| EE-35-XA42_0.01uM | Dose=0.01uM, 4-Methoxy-N-(2-methyl-8-quinolinyl)benzenepropanamide |
| EE-35-XA42_0.1uM | Dose=0.1uM, 4-Methoxy-N-(2-methyl-8-quinolinyl)benzenepropanamide |
| EE-35-XA42_10uM | Dose=10uM, 4-Methoxy-N-(2-methyl-8-quinolinyl)benzenepropanamide |
| EE-35-XA42_1uM | Dose=1uM, 4-Methoxy-N-(2-methyl-8-quinolinyl)benzenepropanamide |
| EE-45-VG61_0.01uM | Dose=0.01uM, (2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, EDNRB gene inhibitor targeting EDNRB |
| EE-45-VG61_0.1uM | Dose=0.1uM, (2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, EDNRB gene inhibitor targeting EDNRB |
| EE-45-VG61_10uM | Dose=10uM, (2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, EDNRB gene inhibitor targeting EDNRB |
| EE-45-VG61_1uM | Dose=1uM, (2S)-2-[[(2R)-2-[(3,5-dimethylbenzoyl)-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoic acid, EDNRB gene inhibitor targeting EDNRB |
| EE-45-YQ15_0.01uM | Dose=0.01uM, (2S)-1-[(2S,3S)-2-(4-chlorophenyl)-3-(hydroxycarbamoyl)pentanoyl]-N-propan-2-ylpiperidine-2-carboxamide, MMP-7 (Matrilysin) Inhibitors targeting MMP7 |
| EE-45-YQ15_0.1uM | Dose=0.1uM, (2S)-1-[(2S,3S)-2-(4-chlorophenyl)-3-(hydroxycarbamoyl)pentanoyl]-N-propan-2-ylpiperidine-2-carboxamide, MMP-7 (Matrilysin) Inhibitors targeting MMP7 |
| EE-45-YQ15_10uM | Dose=10uM, (2S)-1-[(2S,3S)-2-(4-chlorophenyl)-3-(hydroxycarbamoyl)pentanoyl]-N-propan-2-ylpiperidine-2-carboxamide, MMP-7 (Matrilysin) Inhibitors targeting MMP7 |
| EE-47-TB79_0.01uM | Dose=0.01uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-[2-(4-methoxyphenyl)ethyl]-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein 7 Inhibitors targeting KLK7 |
| EE-47-TB79_0.1uM | Dose=0.1uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-[2-(4-methoxyphenyl)ethyl]-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein 7 Inhibitors targeting KLK7 |
| EE-47-TB79_10uM | Dose=10uM, (1S,2S,5R)-3-N-[(7-chloronaphthalen-1-yl)methyl]-2-N-[2-(4-methoxyphenyl)ethyl]-3-azabicyclo[3.1.0]hexane-2,3-dicarboxamide, Kallikrein 7 Inhibitors targeting KLK7 |
| EE-49-CD29_0.01uM | Dose=0.01uM, D-Serine, NMDA Glycine-Site Agonists targeting GRIN1 |
| EE-49-CD29_0.1uM | Dose=0.1uM, D-Serine, NMDA Glycine-Site Agonists targeting GRIN1 |
| EE-49-CD29_10uM | Dose=10uM, D-Serine, NMDA Glycine-Site Agonists targeting GRIN1 |
| EE-49-CD29_1uM | Dose=1uM, D-Serine, NMDA Glycine-Site Agonists targeting GRIN1 |
| EE-57-RZ27_0.01uM | Dose=0.01uM, Naproxen, Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| EE-57-RZ27_10uM | Dose=10uM, Naproxen, Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| EE-57-RZ27_1uM | Dose=1uM, Naproxen, Non-Steroidal Antiinflammatory Drugs targeting PTGS1, PTGS2 |
| EE-59-HC06_0.01uM | Dose=0.01uM, 1,2,3,4-Tetrahydroisoquinoline-2-sulfonamide, Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type XIV Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA14 |
| EE-59-HC06_0.1uM | Dose=0.1uM, 1,2,3,4-Tetrahydroisoquinoline-2-sulfonamide, Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type XIV Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA14 |
| EE-59-HC06_10uM | Dose=10uM, 1,2,3,4-Tetrahydroisoquinoline-2-sulfonamide, Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type XIV Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9, CA14 |
| EE-60-CG74_0.01uM | Dose=0.01uM, 3,6-Dibromo-alpha-[(phenylamino)methyl]-9H-carbazole-9-ethanol, Nicotinamide Phosphoribosyltransferase (NAmPRTase;Neuroprotectant;Neuroprotective;Nampt) Activators targeting NAMPT |
| EE-60-CG74_0.1uM | Dose=0.1uM, 3,6-Dibromo-alpha-[(phenylamino)methyl]-9H-carbazole-9-ethanol, Nicotinamide Phosphoribosyltransferase (NAmPRTase;Neuroprotectant;Neuroprotective;Nampt) Activators targeting NAMPT |
| EE-60-CG74_10uM | Dose=10uM, 3,6-Dibromo-alpha-[(phenylamino)methyl]-9H-carbazole-9-ethanol, Nicotinamide Phosphoribosyltransferase (NAmPRTase;Neuroprotectant;Neuroprotective;Nampt) Activators targeting NAMPT |
| EE-60-CG74_1uM | Dose=1uM, 3,6-Dibromo-alpha-[(phenylamino)methyl]-9H-carbazole-9-ethanol, Nicotinamide Phosphoribosyltransferase (NAmPRTase;Neuroprotectant;Neuroprotective;Nampt) Activators targeting NAMPT |
| EE-61-NU30_0.01uM | Dose=0.01uM, 2-[3-[2-(4-Fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1,3-dihydroisoindole, 5-HT7 Antagonists targeting HTR7 |
| EE-61-NU30_0.1uM | Dose=0.1uM, 2-[3-[2-(4-Fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1,3-dihydroisoindole, 5-HT7 Antagonists targeting HTR7 |
| EE-61-NU30_10uM | Dose=10uM, 2-[3-[2-(4-Fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1,3-dihydroisoindole, 5-HT7 Antagonists targeting HTR7 |
| EE-61-NU30_1uM | Dose=1uM, 2-[3-[2-(4-Fluorophenyl)-1,3-dioxolan-2-yl]propyl]-1,3-dihydroisoindole, 5-HT7 Antagonists targeting HTR7 |
| EE-62-XB72_0.01uM | Dose=0.01uM, Isosorbide Dinitrate, Natriuretic peptide receptor A agonist targeting NPR1 |
| EE-62-XB72_0.1uM | Dose=0.1uM, Isosorbide Dinitrate, Natriuretic peptide receptor A agonist targeting NPR1 |
| EE-62-XB72_10uM | Dose=10uM, Isosorbide Dinitrate, Natriuretic peptide receptor A agonist targeting NPR1 |
| EE-62-XB72_1uM | Dose=1uM, Isosorbide Dinitrate, Natriuretic peptide receptor A agonist targeting NPR1 |
| EE-64-WM03_0.01uM | Dose=0.01uM, 6-(6-Carbamimidoylpyridin-2-yl)pyridine-2-carboximidamide, Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| EE-64-WM03_0.1uM | Dose=0.1uM, 6-(6-Carbamimidoylpyridin-2-yl)pyridine-2-carboximidamide, Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| EE-64-WM03_10uM | Dose=10uM, 6-(6-Carbamimidoylpyridin-2-yl)pyridine-2-carboximidamide, Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| EE-64-WM03_1uM | Dose=1uM, 6-(6-Carbamimidoylpyridin-2-yl)pyridine-2-carboximidamide, Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1 |
| EE-66-CK83_0.01uM | Dose=0.01uM, 3-(1H-indol-3-yl)-4-[2-(4-propan-2-ylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH |
| EE-66-CK83_0.1uM | Dose=0.1uM, 3-(1H-indol-3-yl)-4-[2-(4-propan-2-ylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH |
| EE-66-CK83_10uM | Dose=10uM, 3-(1H-indol-3-yl)-4-[2-(4-propan-2-ylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH |
| EE-66-CK83_1uM | Dose=1uM, 3-(1H-indol-3-yl)-4-[2-(4-propan-2-ylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH |
| EE-66-OE89_0.01uM | Dose=0.01uM, Tirofiban, Integrin binder;Integrin alpha-2/beta-3 antagonist targeting ITGA2B, ITGB3 |
| EE-66-OE89_0.1uM | Dose=0.1uM, Tirofiban, Integrin binder;Integrin alpha-2/beta-3 antagonist targeting ITGA2B, ITGB3 |
| EE-66-OE89_10uM | Dose=10uM, Tirofiban, Integrin binder;Integrin alpha-2/beta-3 antagonist targeting ITGA2B, ITGB3 |
| EE-66-OE89_1uM | Dose=1uM, Tirofiban, Integrin binder;Integrin alpha-2/beta-3 antagonist targeting ITGA2B, ITGB3 |
| EE-77-XO60_0.01uM | Dose=0.01uM, (4aS,10aR)-1-methyl-3-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfanylmethyl)-4a,5,10,10a-tetrahydro-2H-benzo[g]quinolin-6-ol |
| EE-77-XO60_0.1uM | Dose=0.1uM, (4aS,10aR)-1-methyl-3-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfanylmethyl)-4a,5,10,10a-tetrahydro-2H-benzo[g]quinolin-6-ol |
| EE-77-XO60_10uM | Dose=10uM, (4aS,10aR)-1-methyl-3-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfanylmethyl)-4a,5,10,10a-tetrahydro-2H-benzo[g]quinolin-6-ol |
| EE-77-XO60_1uM | Dose=1uM, (4aS,10aR)-1-methyl-3-([1,3]thiazolo[5,4-b]pyridin-2-ylsulfanylmethyl)-4a,5,10,10a-tetrahydro-2H-benzo[g]quinolin-6-ol |
| EE-78-ES92_0.01uM | Dose=0.01uM, 5-[[2-(2-Naphthalenyloxy)ethyl]oxy]-alpha-oxo-2-thiopheneacetic acid, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1B, CPT1A |
| EE-78-ES92_0.1uM | Dose=0.1uM, 5-[[2-(2-Naphthalenyloxy)ethyl]oxy]-alpha-oxo-2-thiopheneacetic acid, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1B, CPT1A |
| EE-78-ES92_10uM | Dose=10uM, 5-[[2-(2-Naphthalenyloxy)ethyl]oxy]-alpha-oxo-2-thiopheneacetic acid, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1B, CPT1A |
| EE-78-ES92_1uM | Dose=1uM, 5-[[2-(2-Naphthalenyloxy)ethyl]oxy]-alpha-oxo-2-thiopheneacetic acid, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1B, CPT1A |
| EE-83-RW10_0.01uM | Dose=0.01uM, Ethyl 1-benzyl-4-(propionylanilino)-4-piperidinecarboxylate, Neuromedin U Receptor Modulators targeting NMUR1 |
| EE-83-RW10_0.1uM | Dose=0.1uM, Ethyl 1-benzyl-4-(propionylanilino)-4-piperidinecarboxylate, Neuromedin U Receptor Modulators targeting NMUR1 |
| EE-83-RW10_10uM | Dose=10uM, Ethyl 1-benzyl-4-(propionylanilino)-4-piperidinecarboxylate, Neuromedin U Receptor Modulators targeting NMUR1 |
| EE-83-RW10_1uM | Dose=1uM, Ethyl 1-benzyl-4-(propionylanilino)-4-piperidinecarboxylate, Neuromedin U Receptor Modulators targeting NMUR1 |
| EE-83-WF69_0.01uM | Dose=0.01uM, Nvp-dpp728, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| EE-83-WF69_0.1uM | Dose=0.1uM, Nvp-dpp728, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| EE-83-WF69_1uM | Dose=1uM, Nvp-dpp728, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| EE-85-SK26_0.01uM | Dose=0.01uM, 7-Hydroxy-1,3-dimethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinazoline-2,4(1H, 3H)-dione, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| EE-85-SK26_0.1uM | Dose=0.1uM, 7-Hydroxy-1,3-dimethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinazoline-2,4(1H, 3H)-dione, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| EE-85-SK26_10uM | Dose=10uM, 7-Hydroxy-1,3-dimethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinazoline-2,4(1H, 3H)-dione, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| EE-85-SK26_1uM | Dose=1uM, 7-Hydroxy-1,3-dimethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinazoline-2,4(1H, 3H)-dione, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| EE-98-PF86_0.01uM | Dose=0.01uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylquinazoline, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| EE-98-PF86_0.1uM | Dose=0.1uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylquinazoline, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| EE-98-PF86_10uM | Dose=10uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylquinazoline, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| EE-98-PF86_1uM | Dose=1uM, 2-(1H-indazol-5-yl)-4-piperazin-1-ylquinazoline, Rho Kinase Inhibitors targeting ROCK1, ROCK2 |
| EE-99-ZM45_0.01uM | Dose=0.01uM, Tesmilifene, Histamine Receptor Antagonists;Estrogen Receptor (ER) Antagonists targeting ESR1, LTA4H |
| EE-99-ZM45_0.1uM | Dose=0.1uM, Tesmilifene, Histamine Receptor Antagonists;Estrogen Receptor (ER) Antagonists targeting ESR1, LTA4H |
| EE-99-ZM45_10uM | Dose=10uM, Tesmilifene, Histamine Receptor Antagonists;Estrogen Receptor (ER) Antagonists targeting ESR1, LTA4H |
| EE-99-ZM45_1uM | Dose=1uM, Tesmilifene, Histamine Receptor Antagonists;Estrogen Receptor (ER) Antagonists targeting ESR1, LTA4H |
| EF-01-LB20_0.01uM | Dose=0.01uM, Amantadine, M2 Channel Inhibitors;Dopamine Receptor Agonists;NMDA Antagonists targeting DRD2, GRIN3A |
| EF-01-LB20_0.1uM | Dose=0.1uM, Amantadine, M2 Channel Inhibitors;Dopamine Receptor Agonists;NMDA Antagonists targeting DRD2, GRIN3A |
| EF-01-LB20_10uM | Dose=10uM, Amantadine, M2 Channel Inhibitors;Dopamine Receptor Agonists;NMDA Antagonists targeting DRD2, GRIN3A |
| EF-01-LB20_1uM | Dose=1uM, Amantadine, M2 Channel Inhibitors;Dopamine Receptor Agonists;NMDA Antagonists targeting DRD2, GRIN3A |
| EF-14-GN61_0.01uM | Dose=0.01uM, Talabostat, DPP7) Inhibitors;DPP2;Fibroblast Activation Protein-alpha (FAPalpha) Inhibitors;Dipeptidyl Peptidase IV (CD26;Dipeptidyl Peptidase VIII (DPP8) Inhibitors;DPRP2) Inhibitors;DPP-IV;Dipeptidyl Peptidase IX (DPP9;DP-IV) Inhibitors;Dipeptidyl Peptidase II (DPPII targeting DPP7, DPP8, DPP9 |
| EF-14-GN61_0.1uM | Dose=0.1uM, Talabostat, DPP7) Inhibitors;DPP2;Fibroblast Activation Protein-alpha (FAPalpha) Inhibitors;Dipeptidyl Peptidase IV (CD26;Dipeptidyl Peptidase VIII (DPP8) Inhibitors;DPRP2) Inhibitors;DPP-IV;Dipeptidyl Peptidase IX (DPP9;DP-IV) Inhibitors;Dipeptidyl Peptidase II (DPPII targeting DPP7, DPP8, DPP9 |
| EF-14-GN61_10uM | Dose=10uM, Talabostat, DPP7) Inhibitors;DPP2;Fibroblast Activation Protein-alpha (FAPalpha) Inhibitors;Dipeptidyl Peptidase IV (CD26;Dipeptidyl Peptidase VIII (DPP8) Inhibitors;DPRP2) Inhibitors;DPP-IV;Dipeptidyl Peptidase IX (DPP9;DP-IV) Inhibitors;Dipeptidyl Peptidase II (DPPII targeting DPP7, DPP8, DPP9 |
| EF-14-GN61_1uM | Dose=1uM, Talabostat, DPP7) Inhibitors;DPP2;Fibroblast Activation Protein-alpha (FAPalpha) Inhibitors;Dipeptidyl Peptidase IV (CD26;Dipeptidyl Peptidase VIII (DPP8) Inhibitors;DPRP2) Inhibitors;DPP-IV;Dipeptidyl Peptidase IX (DPP9;DP-IV) Inhibitors;Dipeptidyl Peptidase II (DPPII targeting DPP7, DPP8, DPP9 |
| EF-16-GV25_0.1uM | Dose=0.1uM, Trimethyl-(3-naphthalen-1-yl-3-oxopropyl)azanium, ChAT inhibitor;Chemokine-like Receptor 1 (CMKLR1, CHEMR23) Antagonists;Aldehyde dehydrogenase 1 inhibitor targeting ALDH1A1, CHAT, CMKLR1 |
| EF-16-GV25_10uM | Dose=10uM, Trimethyl-(3-naphthalen-1-yl-3-oxopropyl)azanium, ChAT inhibitor;Chemokine-like Receptor 1 (CMKLR1, CHEMR23) Antagonists;Aldehyde dehydrogenase 1 inhibitor targeting ALDH1A1, CHAT, CMKLR1 |
| EF-16-GV25_1uM | Dose=1uM, Trimethyl-(3-naphthalen-1-yl-3-oxopropyl)azanium, ChAT inhibitor;Chemokine-like Receptor 1 (CMKLR1, CHEMR23) Antagonists;Aldehyde dehydrogenase 1 inhibitor targeting ALDH1A1, CHAT, CMKLR1 |
| EF-19-KJ63_0.01uM | Dose=0.01uM, Tamsulosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A |
| EF-19-KJ63_0.1uM | Dose=0.1uM, Tamsulosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A |
| EF-19-KJ63_10uM | Dose=10uM, Tamsulosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A |
| EF-19-KJ63_1uM | Dose=1uM, Tamsulosin, alpha1-Adrenoceptor Antagonists targeting ADRA1B, ADRA1A |
| EF-20-MG69_0.01uM | Dose=0.01uM, 7,8-Dihydroxyflavone, TRKB Activators targeting NTRK2 |
| EF-20-MG69_10uM | Dose=10uM, 7,8-Dihydroxyflavone, TRKB Activators targeting NTRK2 |
| EF-20-MG69_1uM | Dose=1uM, 7,8-Dihydroxyflavone, TRKB Activators targeting NTRK2 |
| EF-22-PB37_0.01uM | Dose=0.01uM, Acetamide, N-(2-amino-2-oxoethyl)-2-methoxy-N-(9-methyl-6-(((4-(trifluoromethyl)phenyl)methyl)amino)-9H-purin-2-yl)-, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A |
| EF-22-PB37_0.1uM | Dose=0.1uM, Acetamide, N-(2-amino-2-oxoethyl)-2-methoxy-N-(9-methyl-6-(((4-(trifluoromethyl)phenyl)methyl)amino)-9H-purin-2-yl)-, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A |
| EF-22-PB37_10uM | Dose=10uM, Acetamide, N-(2-amino-2-oxoethyl)-2-methoxy-N-(9-methyl-6-(((4-(trifluoromethyl)phenyl)methyl)amino)-9H-purin-2-yl)-, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A |
| EF-22-PB37_1uM | Dose=1uM, Acetamide, N-(2-amino-2-oxoethyl)-2-methoxy-N-(9-methyl-6-(((4-(trifluoromethyl)phenyl)methyl)amino)-9H-purin-2-yl)-, Glycogen Synthase Kinase 3 (GSK-3) Inhibitors targeting GSK3A |
| EF-30-GD67_0.1uM | Dose=0.1uM, N-(1-Benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine, EGLN1 gene inhibitor;EGLN1 inhibitor targeting EGLN1, EGLN2 |
| EF-30-GD67_10uM | Dose=10uM, N-(1-Benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine, EGLN1 gene inhibitor;EGLN1 inhibitor targeting EGLN1, EGLN2 |
| EF-30-GD67_1uM | Dose=1uM, N-(1-Benzyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine, EGLN1 gene inhibitor;EGLN1 inhibitor targeting EGLN1, EGLN2 |
| EF-33-IW50_0.01uM | Dose=0.01uM, 3-(azepan-1-ylsulfonyl)-N-(3-bromophenyl)benzamide, SIRT2;SIRT2 gene inhibitor targeting SIRT2 |
| EF-33-IW50_0.1uM | Dose=0.1uM, 3-(azepan-1-ylsulfonyl)-N-(3-bromophenyl)benzamide, SIRT2;SIRT2 gene inhibitor targeting SIRT2 |
| EF-33-IW50_10uM | Dose=10uM, 3-(azepan-1-ylsulfonyl)-N-(3-bromophenyl)benzamide, SIRT2;SIRT2 gene inhibitor targeting SIRT2 |
| EF-33-IW50_1uM | Dose=1uM, 3-(azepan-1-ylsulfonyl)-N-(3-bromophenyl)benzamide, SIRT2;SIRT2 gene inhibitor targeting SIRT2 |
| EF-33-QP63_0.01uM | Dose=0.01uM, 3-[(6-Methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino]benzoic acid, Protein kinase CK2 inhibition targeting CSNK2A2 |
| EF-33-QP63_0.1uM | Dose=0.1uM, 3-[(6-Methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino]benzoic acid, Protein kinase CK2 inhibition targeting CSNK2A2 |
| EF-33-QP63_10uM | Dose=10uM, 3-[(6-Methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino]benzoic acid, Protein kinase CK2 inhibition targeting CSNK2A2 |
| EF-33-QP63_1uM | Dose=1uM, 3-[(6-Methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)amino]benzoic acid, Protein kinase CK2 inhibition targeting CSNK2A2 |
| EF-43-OP88_0.01uM | Dose=0.01uM, 2-(2-Oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-2-ylmethyl)isonicotinamide, SCD inhibitor targeting SCD |
| EF-43-OP88_0.1uM | Dose=0.1uM, 2-(2-Oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-2-ylmethyl)isonicotinamide, SCD inhibitor targeting SCD |
| EF-43-OP88_10uM | Dose=10uM, 2-(2-Oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-2-ylmethyl)isonicotinamide, SCD inhibitor targeting SCD |
| EF-43-OP88_1uM | Dose=1uM, 2-(2-Oxo-3-(4-(trifluoromethyl)benzyl)imidazolidin-1-yl)-N-(pyridin-2-ylmethyl)isonicotinamide, SCD inhibitor targeting SCD |
| EF-46-LK88_0.01uM | Dose=0.01uM, ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate |
| EF-46-LK88_0.1uM | Dose=0.1uM, ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate |
| EF-46-LK88_10uM | Dose=10uM, ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate |
| EF-46-LK88_1uM | Dose=1uM, ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate |
| EF-52-ML96_0.01uM | Dose=0.01uM, 1H-Benzimidazol-2-amine, N-((1R)-1,2,3,4-tetrahydro-1-naphthalenyl)- targeting KCNN2 |
| EF-52-ML96_0.1uM | Dose=0.1uM, 1H-Benzimidazol-2-amine, N-((1R)-1,2,3,4-tetrahydro-1-naphthalenyl)- targeting KCNN2 |
| EF-52-ML96_10uM | Dose=10uM, 1H-Benzimidazol-2-amine, N-((1R)-1,2,3,4-tetrahydro-1-naphthalenyl)- targeting KCNN2 |
| EF-52-ML96_1uM | Dose=1uM, 1H-Benzimidazol-2-amine, N-((1R)-1,2,3,4-tetrahydro-1-naphthalenyl)- targeting KCNN2 |
| EF-61-NY75_0.01uM | Dose=0.01uM, US9580437, Example 229, PRC2/EED targeting EED |
| EF-61-NY75_0.1uM | Dose=0.1uM, US9580437, Example 229, PRC2/EED targeting EED |
| EF-61-NY75_10uM | Dose=10uM, US9580437, Example 229, PRC2/EED targeting EED |
| EF-61-NY75_1uM | Dose=1uM, US9580437, Example 229, PRC2/EED targeting EED |
| EF-62-IO23_0.01uM | Dose=0.01uM |
| EF-62-IO23_0.1uM | Dose=0.1uM |
| EF-62-IO23_10uM | Dose=10uM |
| EF-62-IO23_1uM | Dose=1uM |
| EF-64-HJ41_0.1uM | Dose=0.1uM, LY 255283, LTB4R2 antagonist targeting LTB4R2 |
| EF-64-HJ41_10uM | Dose=10uM, LY 255283, LTB4R2 antagonist targeting LTB4R2 |
| EF-64-HJ41_1uM | Dose=1uM, LY 255283, LTB4R2 antagonist targeting LTB4R2 |
| EF-73-IP33_0.01uM | Dose=0.01uM, Molibresib, BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| EF-73-IP33_0.1uM | Dose=0.1uM, Molibresib, BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| EF-73-IP33_10uM | Dose=10uM, Molibresib, BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| EF-73-IP33_1uM | Dose=1uM, Molibresib, BRD2/3/4/T BET familiy inhibitor targeting BRD4 |
| EF-74-KW12_0.01uM | Dose=0.01uM, Digitoxigenin, Cardiac glycoside targeting ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3 |
| EF-74-KW12_0.1uM | Dose=0.1uM, Digitoxigenin, Cardiac glycoside targeting ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3 |
| EF-74-KW12_10uM | Dose=10uM, Digitoxigenin, Cardiac glycoside targeting ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3 |
| EF-74-KW12_1uM | Dose=1uM, Digitoxigenin, Cardiac glycoside targeting ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3 |
| EF-75-CQ05_0.01uM | Dose=0.01uM, Tolterodine, Muscarinic M3 Antagonists targeting CHRM3, CHRM4, CHRM5 |
| EF-75-CQ05_0.1uM | Dose=0.1uM, Tolterodine, Muscarinic M3 Antagonists targeting CHRM3, CHRM4, CHRM5 |
| EF-75-CQ05_10uM | Dose=10uM, Tolterodine, Muscarinic M3 Antagonists targeting CHRM3, CHRM4, CHRM5 |
| EF-75-CQ05_1uM | Dose=1uM, Tolterodine, Muscarinic M3 Antagonists targeting CHRM3, CHRM4, CHRM5 |
| EF-75-JG46_0.01uM | Dose=0.01uM, 1-(1-Naphthyl)piperazine targeting HTR1E, HTR1F |
| EF-75-JG46_0.1uM | Dose=0.1uM, 1-(1-Naphthyl)piperazine targeting HTR1E, HTR1F |
| EF-75-JG46_10uM | Dose=10uM, 1-(1-Naphthyl)piperazine targeting HTR1E, HTR1F |
| EF-75-JG46_1uM | Dose=1uM, 1-(1-Naphthyl)piperazine targeting HTR1E, HTR1F |
| EF-80-OD07_0.01uM | Dose=0.01uM, 3,4-difluoro-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-5-(1H-pyrazol-4-yl)phenol, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| EF-80-OD07_0.1uM | Dose=0.1uM, 3,4-difluoro-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-5-(1H-pyrazol-4-yl)phenol, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| EF-80-OD07_10uM | Dose=10uM, 3,4-difluoro-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-5-(1H-pyrazol-4-yl)phenol, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| EF-80-OD07_1uM | Dose=1uM, 3,4-difluoro-2-[5-[methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-5-(1H-pyrazol-4-yl)phenol, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| EF-82-OV15_0.01uM | Dose=0.01uM |
| EF-82-OV15_0.1uM | Dose=0.1uM |
| EF-82-OV15_10uM | Dose=10uM |
| EF-82-OV15_1uM | Dose=1uM |
| EF-83-OP68_0.1uM | Dose=0.1uM, StemRegenin 1, Aryl hydrocarbon receptor antagonist;Stem cell expansion targeting AHR |
| EF-83-OP68_10uM | Dose=10uM, StemRegenin 1, Aryl hydrocarbon receptor antagonist;Stem cell expansion targeting AHR |
| EF-83-OP68_1uM | Dose=1uM, StemRegenin 1, Aryl hydrocarbon receptor antagonist;Stem cell expansion targeting AHR |
| EF-84-QW37_0.01uM | Dose=0.01uM, Skyrin, Glucagon Receptor (GCGR) Antagonists targeting GCGR |
| EF-84-QW37_0.1uM | Dose=0.1uM, Skyrin, Glucagon Receptor (GCGR) Antagonists targeting GCGR |
| EF-84-QW37_10uM | Dose=10uM, Skyrin, Glucagon Receptor (GCGR) Antagonists targeting GCGR |
| EF-84-QW37_1uM | Dose=1uM, Skyrin, Glucagon Receptor (GCGR) Antagonists targeting GCGR |
| EF-85-DA07_0.01uM | Dose=0.01uM |
| EF-85-DA07_0.1uM | Dose=0.1uM |
| EF-85-DA07_10uM | Dose=10uM |
| EF-85-DA07_1uM | Dose=1uM |
| EF-89-OM00_0.01uM | Dose=0.01uM, Paraquat |
| EF-89-OM00_0.1uM | Dose=0.1uM, Paraquat |
| EF-89-OM00_10uM | Dose=10uM, Paraquat |
| EF-89-OM00_1uM | Dose=1uM, Paraquat |
| EF-92-OO68_0.01uM | Dose=0.01uM, (4-(Methylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3 |
| EF-92-OO68_0.1uM | Dose=0.1uM, (4-(Methylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3 |
| EF-92-OO68_10uM | Dose=10uM, (4-(Methylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3 |
| EF-92-OO68_1uM | Dose=1uM, (4-(Methylamino)-2-(methylthio)pyrimidin-5-yl)methanol, CDK Inhibitors targeting CCND2, CCND3 |
| EF-99-HJ48_0.01uM | Dose=0.01uM, 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone targeting USP7 |
| EF-99-HJ48_0.1uM | Dose=0.1uM, 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone targeting USP7 |
| EF-99-HJ48_10uM | Dose=10uM, 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone targeting USP7 |
| EF-99-HJ48_1uM | Dose=1uM, 1-[5-(2,4-Difluoro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone targeting USP7 |
| FA-02-RV60_0.01uM | Dose=0.01uM, 2-((E)-5-((E)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1 |
| FA-02-RV60_0.1uM | Dose=0.1uM, 2-((E)-5-((E)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1 |
| FA-02-RV60_10uM | Dose=10uM, 2-((E)-5-((E)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1 |
| FA-02-RV60_1uM | Dose=1uM, 2-((E)-5-((E)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, Aldose Reductase Inhibitors targeting AKR1A1 |
| FA-03-CZ62_0.1uM | Dose=0.1uM, Desloratadine, Histamine H1 Receptor Antagonists targeting HRH1 |
| FA-03-CZ62_10uM | Dose=10uM, Desloratadine, Histamine H1 Receptor Antagonists targeting HRH1 |
| FA-03-CZ62_1uM | Dose=1uM, Desloratadine, Histamine H1 Receptor Antagonists targeting HRH1 |
| FA-06-GA39_0.01uM | Dose=0.01uM, 2-N-cyclohexyl-6-N-(3,4-dichlorophenyl)-3-[2-(diethylamino)ethyl]-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-2,6-dicarboxamide, GHSR antagonist targeting GHSR |
| FA-06-GA39_0.1uM | Dose=0.1uM, 2-N-cyclohexyl-6-N-(3,4-dichlorophenyl)-3-[2-(diethylamino)ethyl]-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-2,6-dicarboxamide, GHSR antagonist targeting GHSR |
| FA-06-GA39_10uM | Dose=10uM, 2-N-cyclohexyl-6-N-(3,4-dichlorophenyl)-3-[2-(diethylamino)ethyl]-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-2,6-dicarboxamide, GHSR antagonist targeting GHSR |
| FA-06-GA39_1uM | Dose=1uM, 2-N-cyclohexyl-6-N-(3,4-dichlorophenyl)-3-[2-(diethylamino)ethyl]-4-oxo-10-oxa-3-azatricyclo[5.2.1.01,5]dec-8-ene-2,6-dicarboxamide, GHSR antagonist targeting GHSR |
| FA-10-DN36_0.01uM | Dose=0.01uM, Luzindole, Melatonin MT2 Antagonists targeting MTNR1B |
| FA-10-DN36_0.1uM | Dose=0.1uM, Luzindole, Melatonin MT2 Antagonists targeting MTNR1B |
| FA-10-DN36_10uM | Dose=10uM, Luzindole, Melatonin MT2 Antagonists targeting MTNR1B |
| FA-10-DN36_1uM | Dose=1uM, Luzindole, Melatonin MT2 Antagonists targeting MTNR1B |
| FA-10-KQ78_0.01uM | Dose=0.01uM, Loxapine, Dopamine D2 Antagonists;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;5-HT2 Antagonists;Dopamine D4 Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| FA-10-KQ78_0.1uM | Dose=0.1uM, Loxapine, Dopamine D2 Antagonists;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;5-HT2 Antagonists;Dopamine D4 Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| FA-10-KQ78_10uM | Dose=10uM, Loxapine, Dopamine D2 Antagonists;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;5-HT2 Antagonists;Dopamine D4 Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| FA-10-KQ78_1uM | Dose=1uM, Loxapine, Dopamine D2 Antagonists;Dopamine D1 Receptor Ligands;Dopamine D3 Receptor Ligands;5-HT2 Antagonists;Dopamine D4 Receptor Ligands targeting DRD1, DRD2, DRD3, DRD4, HTR2A |
| FA-10-SN61_0.01uM | Dose=0.01uM, Bosutinib, Apoptosis Inducers;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;STAT-5 Inhibitors;Src Kinase Inhibitors;Abl Kinase Inhibitors targeting FYN |
| FA-10-SN61_0.1uM | Dose=0.1uM, Bosutinib, Apoptosis Inducers;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;STAT-5 Inhibitors;Src Kinase Inhibitors;Abl Kinase Inhibitors targeting FYN |
| FA-10-SN61_10uM | Dose=10uM, Bosutinib, Apoptosis Inducers;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;STAT-5 Inhibitors;Src Kinase Inhibitors;Abl Kinase Inhibitors targeting FYN |
| FA-10-SN61_1uM | Dose=1uM, Bosutinib, Apoptosis Inducers;Bcr-Abl Kinase Inhibitors;Inhibitors of Signal Transduction Pathways;STAT-5 Inhibitors;Src Kinase Inhibitors;Abl Kinase Inhibitors targeting FYN |
| FA-12-QB17_0.01uM | Dose=0.01uM, WZ4003, inhibitor of NUAK1 and NUAK2 targeting NUAK1, NUAK2 |
| FA-12-QB17_0.1uM | Dose=0.1uM, WZ4003, inhibitor of NUAK1 and NUAK2 targeting NUAK1, NUAK2 |
| FA-12-QB17_10uM | Dose=10uM, WZ4003, inhibitor of NUAK1 and NUAK2 targeting NUAK1, NUAK2 |
| FA-12-QB17_1uM | Dose=1uM, WZ4003, inhibitor of NUAK1 and NUAK2 targeting NUAK1, NUAK2 |
| FA-14-WC79_0.01uM | Dose=0.01uM, [Phosphoric acid tetradecyl(R)-1-carboxymethyl-2-(trimethylaminio)ethyl]dianion, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1A, CPT1B |
| FA-14-WC79_0.1uM | Dose=0.1uM, [Phosphoric acid tetradecyl(R)-1-carboxymethyl-2-(trimethylaminio)ethyl]dianion, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1A, CPT1B |
| FA-14-WC79_10uM | Dose=10uM, [Phosphoric acid tetradecyl(R)-1-carboxymethyl-2-(trimethylaminio)ethyl]dianion, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1A, CPT1B |
| FA-14-WC79_1uM | Dose=1uM, [Phosphoric acid tetradecyl(R)-1-carboxymethyl-2-(trimethylaminio)ethyl]dianion, Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors targeting CPT1A, CPT1B |
| FA-16-HR75_0.01uM | Dose=0.01uM, Mefloquine, Pannexin 1 (PANX1) Inhibitors;Antimalarial targeting GJA8, PANX1, GJD2 |
| FA-16-HR75_0.1uM | Dose=0.1uM, Mefloquine, Pannexin 1 (PANX1) Inhibitors;Antimalarial targeting GJA8, PANX1, GJD2 |
| FA-16-HR75_10uM | Dose=10uM, Mefloquine, Pannexin 1 (PANX1) Inhibitors;Antimalarial targeting GJA8, PANX1, GJD2 |
| FA-16-HR75_1uM | Dose=1uM, Mefloquine, Pannexin 1 (PANX1) Inhibitors;Antimalarial targeting GJA8, PANX1, GJD2 |
| FA-16-KA99_0.01uM | Dose=0.01uM, N-[4-(6-Methylamino-pyrimidin-4-yloxy)-phenyl]-N'-[3-(4-isopropylpiperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-urea |
| FA-16-KA99_0.1uM | Dose=0.1uM, N-[4-(6-Methylamino-pyrimidin-4-yloxy)-phenyl]-N'-[3-(4-isopropylpiperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-urea |
| FA-16-KA99_10uM | Dose=10uM, N-[4-(6-Methylamino-pyrimidin-4-yloxy)-phenyl]-N'-[3-(4-isopropylpiperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-urea |
| FA-16-KA99_1uM | Dose=1uM, N-[4-(6-Methylamino-pyrimidin-4-yloxy)-phenyl]-N'-[3-(4-isopropylpiperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-urea |
| FA-17-JZ87_0.01uM | Dose=0.01uM, Valdecoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| FA-17-JZ87_0.1uM | Dose=0.1uM, Valdecoxib, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| FA-20-GU88_0.01uM | Dose=0.01uM, N-(4-Cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy)-acetamide, Adenosine A2B Antagonists targeting ADORA2B |
| FA-20-GU88_0.1uM | Dose=0.1uM, N-(4-Cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy)-acetamide, Adenosine A2B Antagonists targeting ADORA2B |
| FA-20-GU88_1uM | Dose=1uM, N-(4-Cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy)-acetamide, Adenosine A2B Antagonists targeting ADORA2B |
| FA-23-LP18_0.01uM | Dose=0.01uM, 4-Quinolinamine, 2-phenyl-, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B |
| FA-23-LP18_0.1uM | Dose=0.1uM, 4-Quinolinamine, 2-phenyl-, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B |
| FA-23-LP18_10uM | Dose=10uM, 4-Quinolinamine, 2-phenyl-, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B |
| FA-23-LP18_1uM | Dose=1uM, 4-Quinolinamine, 2-phenyl-, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1B |
| FA-28-MT45_0.1uM | Dose=0.1uM, Cloprostenol, PTGFR agonist targeting PTGFR |
| FA-28-MT45_1uM | Dose=1uM, Cloprostenol, PTGFR agonist targeting PTGFR |
| FA-30-KQ38_0.1uM | Dose=0.1uM, Nilotinib, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR, PDGFRB |
| FA-30-KQ38_10uM | Dose=10uM, Nilotinib, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR, PDGFRB |
| FA-30-KQ38_1uM | Dose=1uM, Nilotinib, Apoptosis Inducers;Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2, BCR, PDGFRB |
| FA-31-XR78_0.01uM | Dose=0.01uM |
| FA-31-XR78_0.1uM | Dose=0.1uM |
| FA-31-XR78_10uM | Dose=10uM |
| FA-31-XR78_1uM | Dose=1uM |
| FA-36-VA24_0.01uM | Dose=0.01uM, 1-[4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[2-(methylamino)pyrimidin-4-yl]oxyphenyl]urea |
| FA-36-VA24_0.1uM | Dose=0.1uM, 1-[4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[2-(methylamino)pyrimidin-4-yl]oxyphenyl]urea |
| FA-36-VA24_10uM | Dose=10uM, 1-[4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[2-(methylamino)pyrimidin-4-yl]oxyphenyl]urea |
| FA-36-VA24_1uM | Dose=1uM, 1-[4-[(4-Ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[2-(methylamino)pyrimidin-4-yl]oxyphenyl]urea |
| FA-39-KG56_0.01uM | Dose=0.01uM, (3,7-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-yl)-acetic acid ethyl ester |
| FA-39-KG56_0.1uM | Dose=0.1uM, (3,7-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-yl)-acetic acid ethyl ester |
| FA-39-KG56_10uM | Dose=10uM, (3,7-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-yl)-acetic acid ethyl ester |
| FA-39-KG56_1uM | Dose=1uM, (3,7-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-purin-1-yl)-acetic acid ethyl ester |
| FA-39-ZT32_0.01uM | Dose=0.01uM, (7s)-2-[(3,5-Difluoro-4-Hydroxyphenyl)amino]-5,7-Dimethyl-8-(3-Methylbutyl)-7,8-Dihydropteridin-6(5h)-One, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA6 |
| FA-39-ZT32_0.1uM | Dose=0.1uM, (7s)-2-[(3,5-Difluoro-4-Hydroxyphenyl)amino]-5,7-Dimethyl-8-(3-Methylbutyl)-7,8-Dihydropteridin-6(5h)-One, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA6 |
| FA-39-ZT32_10uM | Dose=10uM, (7s)-2-[(3,5-Difluoro-4-Hydroxyphenyl)amino]-5,7-Dimethyl-8-(3-Methylbutyl)-7,8-Dihydropteridin-6(5h)-One, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA6 |
| FA-39-ZT32_1uM | Dose=1uM, (7s)-2-[(3,5-Difluoro-4-Hydroxyphenyl)amino]-5,7-Dimethyl-8-(3-Methylbutyl)-7,8-Dihydropteridin-6(5h)-One, Ribosomal protein S6 kinase inhibitor targeting RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA4, RPS6KA6 |
| FA-43-TP28_0.1uM | Dose=0.1uM, Doxapram targeting KCNK3, KCNK9 |
| FA-43-TP28_10uM | Dose=10uM, Doxapram targeting KCNK3, KCNK9 |
| FA-43-TP28_1uM | Dose=1uM, Doxapram targeting KCNK3, KCNK9 |
| FA-43-XS35_0.01uM | Dose=0.01uM, 2,2,2-Trifluoro-1-(5-(3-(methylsulfonylmethyl)-1,2,4-oxadiazol-5-yl)thiophen-2-yl)ethanone, Histone Deacetylase 4 (HDAC4) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors targeting HDAC4, HDAC6 |
| FA-43-XS35_0.1uM | Dose=0.1uM, 2,2,2-Trifluoro-1-(5-(3-(methylsulfonylmethyl)-1,2,4-oxadiazol-5-yl)thiophen-2-yl)ethanone, Histone Deacetylase 4 (HDAC4) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors targeting HDAC4, HDAC6 |
| FA-43-XS35_10uM | Dose=10uM, 2,2,2-Trifluoro-1-(5-(3-(methylsulfonylmethyl)-1,2,4-oxadiazol-5-yl)thiophen-2-yl)ethanone, Histone Deacetylase 4 (HDAC4) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors targeting HDAC4, HDAC6 |
| FA-43-XS35_1uM | Dose=1uM, 2,2,2-Trifluoro-1-(5-(3-(methylsulfonylmethyl)-1,2,4-oxadiazol-5-yl)thiophen-2-yl)ethanone, Histone Deacetylase 4 (HDAC4) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors targeting HDAC4, HDAC6 |
| FA-45-PN48_0.01uM | Dose=0.01uM |
| FA-45-PN48_10uM | Dose=10uM |
| FA-45-PN48_1uM | Dose=1uM |
| FA-45-XX32_0.01uM | Dose=0.01uM, Fursultiamin, Hepcidin antagonist targeting SLC40A1 |
| FA-45-XX32_0.1uM | Dose=0.1uM, Fursultiamin, Hepcidin antagonist targeting SLC40A1 |
| FA-45-XX32_10uM | Dose=10uM, Fursultiamin, Hepcidin antagonist targeting SLC40A1 |
| FA-45-XX32_1uM | Dose=1uM, Fursultiamin, Hepcidin antagonist targeting SLC40A1 |
| FA-47-IB34_0.01uM | Dose=0.01uM |
| FA-47-IB34_0.1uM | Dose=0.1uM |
| FA-47-IB34_10uM | Dose=10uM |
| FA-47-IB34_1uM | Dose=1uM |
| FA-47-JB44_0.01uM | Dose=0.01uM, (E)-3-(4-bromophenyl)-1-[4-(4-methoxybenzoyl)piperazin-1-yl]prop-2-en-1-one, GPR183 antagonist targeting GPR183 |
| FA-47-JB44_0.1uM | Dose=0.1uM, (E)-3-(4-bromophenyl)-1-[4-(4-methoxybenzoyl)piperazin-1-yl]prop-2-en-1-one, GPR183 antagonist targeting GPR183 |
| FA-47-JB44_10uM | Dose=10uM, (E)-3-(4-bromophenyl)-1-[4-(4-methoxybenzoyl)piperazin-1-yl]prop-2-en-1-one, GPR183 antagonist targeting GPR183 |
| FA-47-JB44_1uM | Dose=1uM, (E)-3-(4-bromophenyl)-1-[4-(4-methoxybenzoyl)piperazin-1-yl]prop-2-en-1-one, GPR183 antagonist targeting GPR183 |
| FA-48-FF91_0.1uM | Dose=0.1uM, 8-Hydroxyquinoline-4-carboxylic acid |
| FA-48-FF91_10uM | Dose=10uM, 8-Hydroxyquinoline-4-carboxylic acid |
| FA-52-OO58_0.01uM | Dose=0.01uM, Bitopertin, glycine reuptake inhibitor targeting SLC6A9 |
| FA-52-OO58_0.1uM | Dose=0.1uM, Bitopertin, glycine reuptake inhibitor targeting SLC6A9 |
| FA-52-OO58_10uM | Dose=10uM, Bitopertin, glycine reuptake inhibitor targeting SLC6A9 |
| FA-52-OO58_1uM | Dose=1uM, Bitopertin, glycine reuptake inhibitor targeting SLC6A9 |
| FA-56-WH26_0.01uM | Dose=0.01uM, Venglustat targeting UGCG |
| FA-56-WH26_0.1uM | Dose=0.1uM, Venglustat targeting UGCG |
| FA-56-WH26_10uM | Dose=10uM, Venglustat targeting UGCG |
| FA-56-WH26_1uM | Dose=1uM, Venglustat targeting UGCG |
| FA-57-CO50_0.01uM | Dose=0.01uM, 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide, HTR1D antagonist targeting HTR1D |
| FA-57-CO50_0.1uM | Dose=0.1uM, 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide, HTR1D antagonist targeting HTR1D |
| FA-57-CO50_10uM | Dose=10uM, 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide, HTR1D antagonist targeting HTR1D |
| FA-57-CO50_1uM | Dose=1uM, 2'-Methyl-4'-(5-methyl-(1,2,4)-oxadiazol-3-yl)biphenyl-4-carboxylic acid (4-methoxy-3-(4-methylpiperazin-1-yl)phenyl)amide, HTR1D antagonist targeting HTR1D |
| FA-57-OP23_0.01uM | Dose=0.01uM |
| FA-57-OP23_0.1uM | Dose=0.1uM |
| FA-57-OP23_10uM | Dose=10uM |
| FA-57-OP23_1uM | Dose=1uM |
| FA-62-JE09_0.01uM | Dose=0.01uM |
| FA-62-JE09_0.1uM | Dose=0.1uM |
| FA-62-JE09_10uM | Dose=10uM |
| FA-62-JE09_1uM | Dose=1uM |
| FA-63-WI26_0.01uM | Dose=0.01uM |
| FA-63-WI26_0.1uM | Dose=0.1uM |
| FA-63-WI26_10uM | Dose=10uM |
| FA-63-WI26_1uM | Dose=1uM |
| FA-65-UA27_0.01uM | Dose=0.01uM, 2-((2-Amino-5-cyano-6-(methylthio)pyrimidin-4-yl)thio)-N-(benzo[d]thiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| FA-65-UA27_0.1uM | Dose=0.1uM, 2-((2-Amino-5-cyano-6-(methylthio)pyrimidin-4-yl)thio)-N-(benzo[d]thiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| FA-65-UA27_10uM | Dose=10uM, 2-((2-Amino-5-cyano-6-(methylthio)pyrimidin-4-yl)thio)-N-(benzo[d]thiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| FA-65-UA27_1uM | Dose=1uM, 2-((2-Amino-5-cyano-6-(methylthio)pyrimidin-4-yl)thio)-N-(benzo[d]thiazol-2-yl)acetamide targeting RPS6KB1, RPS6KB2, RPS6KB3 |
| FA-66-LB92_0.01uM | Dose=0.01uM, Atorvastatin, HMG-CoA Reductase Inhibitors targeting HMGCR |
| FA-66-LB92_0.1uM | Dose=0.1uM, Atorvastatin, HMG-CoA Reductase Inhibitors targeting HMGCR |
| FA-66-LB92_10uM | Dose=10uM, Atorvastatin, HMG-CoA Reductase Inhibitors targeting HMGCR |
| FA-66-LB92_1uM | Dose=1uM, Atorvastatin, HMG-CoA Reductase Inhibitors targeting HMGCR |
| FA-67-MV22_0.01uM | Dose=0.01uM, 4-((3,5-Dichloro-N-(4-fluorobenzyl)-2-hydroxyphenylsulfonamido)methyl)-N-(3,5-dichlorobenzyl)-N-(4-fluorobenzyl)benzamide, Bcl-2 Inhibitors;Apoptosis Inducers;Mcl-1 Inhibitors targeting BCL2, MCL1 |
| FA-67-MV22_0.1uM | Dose=0.1uM, 4-((3,5-Dichloro-N-(4-fluorobenzyl)-2-hydroxyphenylsulfonamido)methyl)-N-(3,5-dichlorobenzyl)-N-(4-fluorobenzyl)benzamide, Bcl-2 Inhibitors;Apoptosis Inducers;Mcl-1 Inhibitors targeting BCL2, MCL1 |
| FA-67-MV22_10uM | Dose=10uM, 4-((3,5-Dichloro-N-(4-fluorobenzyl)-2-hydroxyphenylsulfonamido)methyl)-N-(3,5-dichlorobenzyl)-N-(4-fluorobenzyl)benzamide, Bcl-2 Inhibitors;Apoptosis Inducers;Mcl-1 Inhibitors targeting BCL2, MCL1 |
| FA-70-ZG69_0.01uM | Dose=0.01uM, Olaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PARP2, PARP3 |
| FA-70-ZG69_0.1uM | Dose=0.1uM, Olaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PARP2, PARP3 |
| FA-70-ZG69_10uM | Dose=10uM, Olaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PARP2, PARP3 |
| FA-70-ZG69_1uM | Dose=1uM, Olaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors targeting PARP1, PARP2, PARP3 |
| FA-71-QH69_0.01uM | Dose=0.01uM, (E)-3-(2-(1H-Tetrazol-5-YL)vinyl)-6-fluoro-1H-indole, Immunosuppressant;Tryptophan 2,3 dioxygenase inhibitor targeting TDO2 |
| FA-71-QH69_10uM | Dose=10uM, (E)-3-(2-(1H-Tetrazol-5-YL)vinyl)-6-fluoro-1H-indole, Immunosuppressant;Tryptophan 2,3 dioxygenase inhibitor targeting TDO2 |
| FA-71-UB40_0.01uM | Dose=0.01uM, (R)-4-(1-(3'-chlorobiphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylamino)-4-oxobutanoic acid |
| FA-71-UB40_0.1uM | Dose=0.1uM, (R)-4-(1-(3'-chlorobiphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylamino)-4-oxobutanoic acid |
| FA-71-UB40_10uM | Dose=10uM, (R)-4-(1-(3'-chlorobiphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylamino)-4-oxobutanoic acid |
| FA-71-UB40_1uM | Dose=1uM, (R)-4-(1-(3'-chlorobiphenyl-4-yl)-4-ethoxy-4-oxobutan-2-ylamino)-4-oxobutanoic acid |
| FA-72-JL16_0.01uM | Dose=0.01uM, Nramp2) Inhibitors; DCT1;Divalent Metal Transporter 1 (DMT1 targeting SLC11A2 |
| FA-72-JL16_0.1uM | Dose=0.1uM, Nramp2) Inhibitors; DCT1;Divalent Metal Transporter 1 (DMT1 targeting SLC11A2 |
| FA-72-JL16_10uM | Dose=10uM, Nramp2) Inhibitors; DCT1;Divalent Metal Transporter 1 (DMT1 targeting SLC11A2 |
| FA-72-JL16_1uM | Dose=1uM, Nramp2) Inhibitors; DCT1;Divalent Metal Transporter 1 (DMT1 targeting SLC11A2 |
| FA-73-WF99_0.01uM | Dose=0.01uM, 9-Benzyl-5-[(furan-2-ylmethyl)amino]-7,8,9,10-tetrahydro[1,2,4]triazolo[3,4-a][2,7]naphthyridine-6-carbonitrile, PRC2/EED;EED targeting EED |
| FA-73-WF99_10uM | Dose=10uM, 9-Benzyl-5-[(furan-2-ylmethyl)amino]-7,8,9,10-tetrahydro[1,2,4]triazolo[3,4-a][2,7]naphthyridine-6-carbonitrile, PRC2/EED;EED targeting EED |
| FA-73-WF99_1uM | Dose=1uM, 9-Benzyl-5-[(furan-2-ylmethyl)amino]-7,8,9,10-tetrahydro[1,2,4]triazolo[3,4-a][2,7]naphthyridine-6-carbonitrile, PRC2/EED;EED targeting EED |
| FA-77-LS25_0.01uM | Dose=0.01uM, 6,6-dimethyl-3-(methylthio)-1-(1H-pyrazol-3-yl)-6,7-dihydrobenzo[c]thiophen-4(5H)-one, Ligand of the GABAA alpha5 receptor subtype targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRB3, GABRG2 |
| FA-77-LS25_0.1uM | Dose=0.1uM, 6,6-dimethyl-3-(methylthio)-1-(1H-pyrazol-3-yl)-6,7-dihydrobenzo[c]thiophen-4(5H)-one, Ligand of the GABAA alpha5 receptor subtype targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRB3, GABRG2 |
| FA-77-LS25_10uM | Dose=10uM, 6,6-dimethyl-3-(methylthio)-1-(1H-pyrazol-3-yl)-6,7-dihydrobenzo[c]thiophen-4(5H)-one, Ligand of the GABAA alpha5 receptor subtype targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRB3, GABRG2 |
| FA-77-LS25_1uM | Dose=1uM, 6,6-dimethyl-3-(methylthio)-1-(1H-pyrazol-3-yl)-6,7-dihydrobenzo[c]thiophen-4(5H)-one, Ligand of the GABAA alpha5 receptor subtype targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRB3, GABRG2 |
| FA-77-YL98_0.01uM | Dose=0.01uM, (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine, SHP2 allosteric inhibitor targeting PTPN11 |
| FA-77-YL98_0.1uM | Dose=0.1uM, (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine, SHP2 allosteric inhibitor targeting PTPN11 |
| FA-77-YL98_10uM | Dose=10uM, (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine, SHP2 allosteric inhibitor targeting PTPN11 |
| FA-77-YL98_1uM | Dose=1uM, (4R)-8-[5-(2-amino-3-chloropyridin-4-yl)sulfanylpyrazin-2-yl]-8-azaspiro[4.5]decan-4-amine, SHP2 allosteric inhibitor targeting PTPN11 |
| FA-79-WC91_0.01uM | Dose=0.01uM, 3-[2-(4,7-Diazaspiro[2.5]octan-7-yl)quinazolin-4-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCA, PRKCQ |
| FA-79-WC91_0.1uM | Dose=0.1uM, 3-[2-(4,7-Diazaspiro[2.5]octan-7-yl)quinazolin-4-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCA, PRKCQ |
| FA-79-WC91_10uM | Dose=10uM, 3-[2-(4,7-Diazaspiro[2.5]octan-7-yl)quinazolin-4-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCA, PRKCQ |
| FA-80-DR66_0.01uM | Dose=0.01uM, Bardoxolone Methyl, PPARgamma Agonists;Apoptosis Inducers;Glutathione Reductase (NADPH) Activators;Heme Oxygenase Activators;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Bcl-2 Inhibitors;Angiogenesis Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Nitric Oxide Production Inhibitors;IKK-1 (IKK-alpha) Inhibitors targeting KEAP1, IKBKB |
| FA-80-DR66_0.1uM | Dose=0.1uM, Bardoxolone Methyl, PPARgamma Agonists;Apoptosis Inducers;Glutathione Reductase (NADPH) Activators;Heme Oxygenase Activators;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Bcl-2 Inhibitors;Angiogenesis Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Nitric Oxide Production Inhibitors;IKK-1 (IKK-alpha) Inhibitors targeting KEAP1, IKBKB |
| FA-80-DR66_10uM | Dose=10uM, Bardoxolone Methyl, PPARgamma Agonists;Apoptosis Inducers;Glutathione Reductase (NADPH) Activators;Heme Oxygenase Activators;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Bcl-2 Inhibitors;Angiogenesis Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Nitric Oxide Production Inhibitors;IKK-1 (IKK-alpha) Inhibitors targeting KEAP1, IKBKB |
| FA-80-DR66_1uM | Dose=1uM, Bardoxolone Methyl, PPARgamma Agonists;Apoptosis Inducers;Glutathione Reductase (NADPH) Activators;Heme Oxygenase Activators;Antiinflammatory Drugs;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;Bcl-2 Inhibitors;Angiogenesis Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Nitric Oxide Production Inhibitors;IKK-1 (IKK-alpha) Inhibitors targeting KEAP1, IKBKB |
| FA-88-II68_0.01uM | Dose=0.01uM |
| FA-88-II68_0.1uM | Dose=0.1uM |
| FA-88-II68_10uM | Dose=10uM |
| FA-88-II68_1uM | Dose=1uM |
| FA-88-PW92_0.01uM | Dose=0.01uM |
| FA-88-PW92_10uM | Dose=10uM |
| FA-88-PW92_1uM | Dose=1uM |
| FA-89-PW29_0.01uM | Dose=0.01uM, P505-15 targeting SYK |
| FA-89-PW29_0.1uM | Dose=0.1uM, P505-15 targeting SYK |
| FA-89-PW29_10uM | Dose=10uM, P505-15 targeting SYK |
| FA-89-PW29_1uM | Dose=1uM, P505-15 targeting SYK |
| FA-90-DR66_0.01uM | Dose=0.01uM, Cisapride, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| FA-90-DR66_0.1uM | Dose=0.1uM, Cisapride, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| FA-90-DR66_10uM | Dose=10uM, Cisapride, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| FA-90-DR66_1uM | Dose=1uM, Cisapride, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| FA-91-OA82_0.01uM | Dose=0.01uM, 2-[(2-bromophenyl)methylamino]-N,N-diphenylacetamide, GRM7 agonist targeting GRM7 |
| FA-91-OA82_0.1uM | Dose=0.1uM, 2-[(2-bromophenyl)methylamino]-N,N-diphenylacetamide, GRM7 agonist targeting GRM7 |
| FA-91-OA82_10uM | Dose=10uM, 2-[(2-bromophenyl)methylamino]-N,N-diphenylacetamide, GRM7 agonist targeting GRM7 |
| FA-91-OA82_1uM | Dose=1uM, 2-[(2-bromophenyl)methylamino]-N,N-diphenylacetamide, GRM7 agonist targeting GRM7 |
| FA-92-JL46_0.01uM | Dose=0.01uM, PD-118057, Antiamyloidogenic Agents;Voltage-Gated K(V)11.1 (erg1) Channel Activators targeting KCNH2 |
| FA-92-JL46_0.1uM | Dose=0.1uM, PD-118057, Antiamyloidogenic Agents;Voltage-Gated K(V)11.1 (erg1) Channel Activators targeting KCNH2 |
| FA-92-JL46_10uM | Dose=10uM, PD-118057, Antiamyloidogenic Agents;Voltage-Gated K(V)11.1 (erg1) Channel Activators targeting KCNH2 |
| FA-92-JL46_1uM | Dose=1uM, PD-118057, Antiamyloidogenic Agents;Voltage-Gated K(V)11.1 (erg1) Channel Activators targeting KCNH2 |
| FA-94-QJ71_0.01uM | Dose=0.01uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]thiophene-2-sulfonamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1 |
| FA-94-QJ71_0.1uM | Dose=0.1uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]thiophene-2-sulfonamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1 |
| FA-94-QJ71_10uM | Dose=10uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]thiophene-2-sulfonamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1 |
| FA-94-QJ71_1uM | Dose=1uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]thiophene-2-sulfonamide, Heat Shock Protein 90 (hsp90) Inhibitors targeting HSP90B1 |
| FA-95-HA77_0.01uM | Dose=0.01uM, Gossypol, Apoptosis Inducers;Steroid 5alpha-Reductase Inhibitors;Bcl-xl Inhibitors;Antimitotic Drugs;11beta-Hydroxysteroid Dehydrogenase (11beta-HSD) Inhibitors targeting BCL2L1, AKR1A1, HSD11B1, SRD5A1, SRD5A2 |
| FA-95-HA77_0.1uM | Dose=0.1uM, Gossypol, Apoptosis Inducers;Steroid 5alpha-Reductase Inhibitors;Bcl-xl Inhibitors;Antimitotic Drugs;11beta-Hydroxysteroid Dehydrogenase (11beta-HSD) Inhibitors targeting BCL2L1, AKR1A1, HSD11B1, SRD5A1, SRD5A2 |
| FA-95-HA77_10uM | Dose=10uM, Gossypol, Apoptosis Inducers;Steroid 5alpha-Reductase Inhibitors;Bcl-xl Inhibitors;Antimitotic Drugs;11beta-Hydroxysteroid Dehydrogenase (11beta-HSD) Inhibitors targeting BCL2L1, AKR1A1, HSD11B1, SRD5A1, SRD5A2 |
| FA-95-HA77_1uM | Dose=1uM, Gossypol, Apoptosis Inducers;Steroid 5alpha-Reductase Inhibitors;Bcl-xl Inhibitors;Antimitotic Drugs;11beta-Hydroxysteroid Dehydrogenase (11beta-HSD) Inhibitors targeting BCL2L1, AKR1A1, HSD11B1, SRD5A1, SRD5A2 |
| FB-02-OL41_0.01uM | Dose=0.01uM, Mgat2-IN-2, MOGAT2 inhibitor targeting MOGAT2 |
| FB-02-OL41_0.1uM | Dose=0.1uM, Mgat2-IN-2, MOGAT2 inhibitor targeting MOGAT2 |
| FB-02-OL41_10uM | Dose=10uM, Mgat2-IN-2, MOGAT2 inhibitor targeting MOGAT2 |
| FB-02-OL41_1uM | Dose=1uM, Mgat2-IN-2, MOGAT2 inhibitor targeting MOGAT2 |
| FB-06-IU47_0.01uM | Dose=0.01uM, Methyl 3-[2-(2-thienyl)acetamido]thiophene-2-carboxylate, SAPK1a (JNK2) Inhibitors;SAPK1c (JNK1) Inhibitors;SAPK1b (JNK3) Inhibitors targeting MAPK8, MAPK9, MAPK10 |
| FB-06-IU47_0.1uM | Dose=0.1uM, Methyl 3-[2-(2-thienyl)acetamido]thiophene-2-carboxylate, SAPK1a (JNK2) Inhibitors;SAPK1c (JNK1) Inhibitors;SAPK1b (JNK3) Inhibitors targeting MAPK8, MAPK9, MAPK10 |
| FB-06-IU47_10uM | Dose=10uM, Methyl 3-[2-(2-thienyl)acetamido]thiophene-2-carboxylate, SAPK1a (JNK2) Inhibitors;SAPK1c (JNK1) Inhibitors;SAPK1b (JNK3) Inhibitors targeting MAPK8, MAPK9, MAPK10 |
| FB-12-UL66_0.01uM | Dose=0.01uM, Biperiden, Anticholinergics targeting CHRM1, CHRNA2 |
| FB-12-UL66_0.1uM | Dose=0.1uM, Biperiden, Anticholinergics targeting CHRM1, CHRNA2 |
| FB-12-UL66_10uM | Dose=10uM, Biperiden, Anticholinergics targeting CHRM1, CHRNA2 |
| FB-12-UL66_1uM | Dose=1uM, Biperiden, Anticholinergics targeting CHRM1, CHRNA2 |
| FB-13-ES60_0.01uM | Dose=0.01uM, IL-12 Production Inhibitors;Phosphodiesterase IV Inhibitors;TNF-alpha Production Inhibitors;IL-1beta Production Inhibitors |
| FB-16-FK53_0.1uM | Dose=0.1uM, Phosphodiesterase IV Inhibitors;TNF-alpha Production Inhibitors |
| FB-19-ZG81_0.01uM | Dose=0.01uM, 5-Chloro-2-(((4-chloro-3-nitrophenyl)sulfonyl)amino)-N-(4-chlorophenyl)benzamide, Phosphopantetheine Adenylyltransferase (PPAT) Inhibitors targeting COASY |
| FB-19-ZG81_0.1uM | Dose=0.1uM, 5-Chloro-2-(((4-chloro-3-nitrophenyl)sulfonyl)amino)-N-(4-chlorophenyl)benzamide, Phosphopantetheine Adenylyltransferase (PPAT) Inhibitors targeting COASY |
| FB-19-ZG81_10uM | Dose=10uM, 5-Chloro-2-(((4-chloro-3-nitrophenyl)sulfonyl)amino)-N-(4-chlorophenyl)benzamide, Phosphopantetheine Adenylyltransferase (PPAT) Inhibitors targeting COASY |
| FB-19-ZG81_1uM | Dose=1uM, 5-Chloro-2-(((4-chloro-3-nitrophenyl)sulfonyl)amino)-N-(4-chlorophenyl)benzamide, Phosphopantetheine Adenylyltransferase (PPAT) Inhibitors targeting COASY |
| FB-20-YQ23_0.01uM | Dose=0.01uM, Thiq, Melanocortin MC4 Receptor Agonists targeting MC3R, MC4R, MC5R |
| FB-20-YQ23_0.1uM | Dose=0.1uM, Thiq, Melanocortin MC4 Receptor Agonists targeting MC3R, MC4R, MC5R |
| FB-20-YQ23_10uM | Dose=10uM, Thiq, Melanocortin MC4 Receptor Agonists targeting MC3R, MC4R, MC5R |
| FB-20-YQ23_1uM | Dose=1uM, Thiq, Melanocortin MC4 Receptor Agonists targeting MC3R, MC4R, MC5R |
| FB-24-UT80_0.01uM | Dose=0.01uM, Momelotinib, Jak2 Inhibitors;Jak1 Inhibitors;Tyk2 Inhibitors targeting JAK1, JAK2, TYK2 |
| FB-24-UT80_0.1uM | Dose=0.1uM, Momelotinib, Jak2 Inhibitors;Jak1 Inhibitors;Tyk2 Inhibitors targeting JAK1, JAK2, TYK2 |
| FB-24-UT80_10uM | Dose=10uM, Momelotinib, Jak2 Inhibitors;Jak1 Inhibitors;Tyk2 Inhibitors targeting JAK1, JAK2, TYK2 |
| FB-24-UT80_1uM | Dose=1uM, Momelotinib, Jak2 Inhibitors;Jak1 Inhibitors;Tyk2 Inhibitors targeting JAK1, JAK2, TYK2 |
| FB-29-KC76_0.01uM | Dose=0.01uM, Methoctramine, Muscarinic M2 Antagonists targeting CHRM5 |
| FB-29-KC76_0.1uM | Dose=0.1uM, Methoctramine, Muscarinic M2 Antagonists targeting CHRM5 |
| FB-29-KC76_10uM | Dose=10uM, Methoctramine, Muscarinic M2 Antagonists targeting CHRM5 |
| FB-29-KC76_1uM | Dose=1uM, Methoctramine, Muscarinic M2 Antagonists targeting CHRM5 |
| FB-30-CD67_0.01uM | Dose=0.01uM |
| FB-30-CD67_0.1uM | Dose=0.1uM |
| FB-30-CD67_10uM | Dose=10uM |
| FB-31-TA57_0.01uM | Dose=0.01uM, Pap-1, K(V)1.3 Channel Blockers targeting KCNA1, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7 |
| FB-31-TA57_0.1uM | Dose=0.1uM, Pap-1, K(V)1.3 Channel Blockers targeting KCNA1, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7 |
| FB-31-TA57_10uM | Dose=10uM, Pap-1, K(V)1.3 Channel Blockers targeting KCNA1, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7 |
| FB-31-TA57_1uM | Dose=1uM, Pap-1, K(V)1.3 Channel Blockers targeting KCNA1, KCNA2, KCNA3, KCNA4, KCNA5, KCNA6, KCNA7 |
| FB-32-PY27_0.01uM | Dose=0.01uM, 4-{1-[(2,4-dichlorophenyl)methyl]-1H-pyrazol-4-yl}pyridine, Cytochrome P450 CYP3A4 Inhibitors;Cytochrome P450 CYP2C9 Inhibitors targeting CYP2C9, CYP3A4 |
| FB-32-PY27_0.1uM | Dose=0.1uM, 4-{1-[(2,4-dichlorophenyl)methyl]-1H-pyrazol-4-yl}pyridine, Cytochrome P450 CYP3A4 Inhibitors;Cytochrome P450 CYP2C9 Inhibitors targeting CYP2C9, CYP3A4 |
| FB-32-PY27_10uM | Dose=10uM, 4-{1-[(2,4-dichlorophenyl)methyl]-1H-pyrazol-4-yl}pyridine, Cytochrome P450 CYP3A4 Inhibitors;Cytochrome P450 CYP2C9 Inhibitors targeting CYP2C9, CYP3A4 |
| FB-32-PY27_1uM | Dose=1uM, 4-{1-[(2,4-dichlorophenyl)methyl]-1H-pyrazol-4-yl}pyridine, Cytochrome P450 CYP3A4 Inhibitors;Cytochrome P450 CYP2C9 Inhibitors targeting CYP2C9, CYP3A4 |
| FB-32-TL51_0.01uM | Dose=0.01uM, (R)-N-(1-(Dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide, HDAC4/5 targeting HDAC4 |
| FB-32-TL51_0.1uM | Dose=0.1uM, (R)-N-(1-(Dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide, HDAC4/5 targeting HDAC4 |
| FB-32-TL51_10uM | Dose=10uM, (R)-N-(1-(Dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide, HDAC4/5 targeting HDAC4 |
| FB-32-TL51_1uM | Dose=1uM, (R)-N-(1-(Dimethylamino)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide, HDAC4/5 targeting HDAC4 |
| FB-33-LI31_0.01uM | Dose=0.01uM, 2-amino-7-(dimethylamino)-4-(7-methoxy-1,3-benzodioxol-5-yl)-4H-chromene-3-carbonitrile |
| FB-33-LI31_0.1uM | Dose=0.1uM, 2-amino-7-(dimethylamino)-4-(7-methoxy-1,3-benzodioxol-5-yl)-4H-chromene-3-carbonitrile |
| FB-33-LI31_10uM | Dose=10uM, 2-amino-7-(dimethylamino)-4-(7-methoxy-1,3-benzodioxol-5-yl)-4H-chromene-3-carbonitrile |
| FB-33-LI31_1uM | Dose=1uM, 2-amino-7-(dimethylamino)-4-(7-methoxy-1,3-benzodioxol-5-yl)-4H-chromene-3-carbonitrile |
| FB-39-CW59_0.01uM | Dose=0.01uM, 5-chloro-2-N-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)phenyl]-4-N-(2-propylsulfonylphenyl)pyrimidine-2,4-diamine, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| FB-39-CW59_0.1uM | Dose=0.1uM, 5-chloro-2-N-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)phenyl]-4-N-(2-propylsulfonylphenyl)pyrimidine-2,4-diamine, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| FB-39-CW59_10uM | Dose=10uM, 5-chloro-2-N-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)phenyl]-4-N-(2-propylsulfonylphenyl)pyrimidine-2,4-diamine, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| FB-39-CW59_1uM | Dose=1uM, 5-chloro-2-N-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)phenyl]-4-N-(2-propylsulfonylphenyl)pyrimidine-2,4-diamine, Focal Adhesion Kinase (FAK) Inhibitors targeting PTK2 |
| FB-39-VW14_0.01uM | Dose=0.01uM, 5-Chloro-6-methyl-N-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine, Plasmodium falciparum Methionine Aminopeptidase-1b (PfMetAP1b) Inhibitors;MetAPN inhibitor targeting METAP1 |
| FB-39-VW14_0.1uM | Dose=0.1uM, 5-Chloro-6-methyl-N-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine, Plasmodium falciparum Methionine Aminopeptidase-1b (PfMetAP1b) Inhibitors;MetAPN inhibitor targeting METAP1 |
| FB-39-VW14_10uM | Dose=10uM, 5-Chloro-6-methyl-N-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine, Plasmodium falciparum Methionine Aminopeptidase-1b (PfMetAP1b) Inhibitors;MetAPN inhibitor targeting METAP1 |
| FB-39-VW14_1uM | Dose=1uM, 5-Chloro-6-methyl-N-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine, Plasmodium falciparum Methionine Aminopeptidase-1b (PfMetAP1b) Inhibitors;MetAPN inhibitor targeting METAP1 |
| FB-42-IV40_0.01uM | Dose=0.01uM, 3,4-diMethoxy-N-(4-(3-nitrophenyl)-5-(piperidin-1-ylmethyl)thiazol-2-yl)benzenesulfonaMide |
| FB-42-IV40_0.1uM | Dose=0.1uM, 3,4-diMethoxy-N-(4-(3-nitrophenyl)-5-(piperidin-1-ylmethyl)thiazol-2-yl)benzenesulfonaMide |
| FB-42-IV40_10uM | Dose=10uM, 3,4-diMethoxy-N-(4-(3-nitrophenyl)-5-(piperidin-1-ylmethyl)thiazol-2-yl)benzenesulfonaMide |
| FB-42-IV40_1uM | Dose=1uM, 3,4-diMethoxy-N-(4-(3-nitrophenyl)-5-(piperidin-1-ylmethyl)thiazol-2-yl)benzenesulfonaMide |
| FB-43-LF24_0.01uM | Dose=0.01uM |
| FB-43-LF24_0.1uM | Dose=0.1uM |
| FB-43-LF24_10uM | Dose=10uM |
| FB-43-LF24_1uM | Dose=1uM |
| FB-49-NW04_0.01uM | Dose=0.01uM, CID 11477833, Flt3 (FLK2/STK1) Inhibitors targeting FLT3 |
| FB-49-NW04_0.1uM | Dose=0.1uM, CID 11477833, Flt3 (FLK2/STK1) Inhibitors targeting FLT3 |
| FB-49-NW04_10uM | Dose=10uM, CID 11477833, Flt3 (FLK2/STK1) Inhibitors targeting FLT3 |
| FB-49-NW04_1uM | Dose=1uM, CID 11477833, Flt3 (FLK2/STK1) Inhibitors targeting FLT3 |
| FB-51-DL49_0.01uM | Dose=0.01uM, 6-Fluoro-4-[4-(6-methylpyridin-3-yl)oxypiperidin-1-yl]quinazoline, Positive allosteric modulators (PAMs) of the muscarinic acetylcholine targeting CHRM4 |
| FB-51-DL49_0.1uM | Dose=0.1uM, 6-Fluoro-4-[4-(6-methylpyridin-3-yl)oxypiperidin-1-yl]quinazoline, Positive allosteric modulators (PAMs) of the muscarinic acetylcholine targeting CHRM4 |
| FB-51-DL49_10uM | Dose=10uM, 6-Fluoro-4-[4-(6-methylpyridin-3-yl)oxypiperidin-1-yl]quinazoline, Positive allosteric modulators (PAMs) of the muscarinic acetylcholine targeting CHRM4 |
| FB-51-DL49_1uM | Dose=1uM, 6-Fluoro-4-[4-(6-methylpyridin-3-yl)oxypiperidin-1-yl]quinazoline, Positive allosteric modulators (PAMs) of the muscarinic acetylcholine targeting CHRM4 |
| FB-52-MO63_0.01uM | Dose=0.01uM, Mes-D-Abu(4-piperidyl)-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14 |
| FB-52-MO63_0.1uM | Dose=0.1uM, Mes-D-Abu(4-piperidyl)-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14 |
| FB-52-MO63_10uM | Dose=10uM, Mes-D-Abu(4-piperidyl)-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14 |
| FB-52-MO63_1uM | Dose=1uM, Mes-D-Abu(4-piperidyl)-Hyp(Bn(4-Cl))-Lys-benzoxazol-2-yl, trypsin inhibitor;Plasma Kallikrein (KLKB1) inhibitor;Prostasin (PRSS8) Inhibitor;Matriptase (ST14) inhibitor targeting PRSS8, ST14 |
| FB-56-IR20_0.01uM | Dose=0.01uM, MC1568, Histone Deacetylase 2 (HDAC2) Inhibitors targeting HDAC2 |
| FB-56-IR20_0.1uM | Dose=0.1uM, MC1568, Histone Deacetylase 2 (HDAC2) Inhibitors targeting HDAC2 |
| FB-56-IR20_10uM | Dose=10uM, MC1568, Histone Deacetylase 2 (HDAC2) Inhibitors targeting HDAC2 |
| FB-56-IR20_1uM | Dose=1uM, MC1568, Histone Deacetylase 2 (HDAC2) Inhibitors targeting HDAC2 |
| FB-56-SR65_0.01uM | Dose=0.01uM, Arginine |
| FB-56-SR65_0.1uM | Dose=0.1uM, Arginine |
| FB-56-SR65_10uM | Dose=10uM, Arginine |
| FB-56-SR65_1uM | Dose=1uM, Arginine |
| FB-60-JQ38_0.01uM | Dose=0.01uM, BD 1008, sigma Receptor Antagonists targeting SIGMAR1 |
| FB-60-JQ38_0.1uM | Dose=0.1uM, BD 1008, sigma Receptor Antagonists targeting SIGMAR1 |
| FB-60-JQ38_10uM | Dose=10uM, BD 1008, sigma Receptor Antagonists targeting SIGMAR1 |
| FB-60-JQ38_1uM | Dose=1uM, BD 1008, sigma Receptor Antagonists targeting SIGMAR1 |
| FB-62-GL41_0.01uM | Dose=0.01uM, 3-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]benzoic acid, Nurr1 Receptor Activators targeting NR4A2 |
| FB-62-GL41_0.1uM | Dose=0.1uM, 3-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]benzoic acid, Nurr1 Receptor Activators targeting NR4A2 |
| FB-62-GL41_10uM | Dose=10uM, 3-[3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl]benzoic acid, Nurr1 Receptor Activators targeting NR4A2 |
| FB-62-JY52_0.01uM | Dose=0.01uM, Azd-5904, Myeloperoxidase Inhibitors targeting MPO |
| FB-62-JY52_0.1uM | Dose=0.1uM, Azd-5904, Myeloperoxidase Inhibitors targeting MPO |
| FB-62-JY52_10uM | Dose=10uM, Azd-5904, Myeloperoxidase Inhibitors targeting MPO |
| FB-62-JY52_1uM | Dose=1uM, Azd-5904, Myeloperoxidase Inhibitors targeting MPO |
| FB-62-KB87_0.01uM | Dose=0.01uM |
| FB-62-KB87_0.1uM | Dose=0.1uM |
| FB-62-KB87_10uM | Dose=10uM |
| FB-62-KB87_1uM | Dose=1uM |
| FB-66-UU47_0.01uM | Dose=0.01uM, Didemnin B, binding to EF-1_ mediates inhibition of translocation targeting EEF1A1 |
| FB-66-UU47_0.1uM | Dose=0.1uM, Didemnin B, binding to EF-1_ mediates inhibition of translocation targeting EEF1A1 |
| FB-66-UU47_10uM | Dose=10uM, Didemnin B, binding to EF-1_ mediates inhibition of translocation targeting EEF1A1 |
| FB-66-UU47_1uM | Dose=1uM, Didemnin B, binding to EF-1_ mediates inhibition of translocation targeting EEF1A1 |
| FB-67-OY39_0.01uM | Dose=0.01uM, Galnon, GALR2 agonist targeting GALR2 |
| FB-67-OY39_0.1uM | Dose=0.1uM, Galnon, GALR2 agonist targeting GALR2 |
| FB-67-OY39_10uM | Dose=10uM, Galnon, GALR2 agonist targeting GALR2 |
| FB-67-OY39_1uM | Dose=1uM, Galnon, GALR2 agonist targeting GALR2 |
| FB-67-PL18_0.01uM | Dose=0.01uM, Pitolisant, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| FB-67-PL18_0.1uM | Dose=0.1uM, Pitolisant, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| FB-67-PL18_10uM | Dose=10uM, Pitolisant, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| FB-67-PL18_1uM | Dose=1uM, Pitolisant, Histamine H3 Receptor Inverse Agonists;Histamine H3 Receptor Antagonists targeting HRH3 |
| FB-68-SI43_0.01uM | Dose=0.01uM, N-(2-(4-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-1H-indole-2-carboxamide |
| FB-68-SI43_0.1uM | Dose=0.1uM, N-(2-(4-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-1H-indole-2-carboxamide |
| FB-68-SI43_10uM | Dose=10uM, N-(2-(4-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-1H-indole-2-carboxamide |
| FB-68-SI43_1uM | Dose=1uM, N-(2-(4-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-1H-indole-2-carboxamide |
| FB-75-YG01_0.01uM | Dose=0.01uM, 4-Phenoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin inhibitor targeting CTSV, CTSZ, CTSF |
| FB-75-YG01_0.1uM | Dose=0.1uM, 4-Phenoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin inhibitor targeting CTSV, CTSZ, CTSF |
| FB-75-YG01_10uM | Dose=10uM, 4-Phenoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin inhibitor targeting CTSV, CTSZ, CTSF |
| FB-75-YG01_1uM | Dose=1uM, 4-Phenoxy-6-oxa-1-azabicyclo[3.2.1]octan-7-one, Cathepsin inhibitor targeting CTSV, CTSZ, CTSF |
| FB-84-TJ61_0.1uM | Dose=0.1uM, Rizatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D |
| FB-84-TJ61_10uM | Dose=10uM, Rizatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D |
| FB-84-TJ61_1uM | Dose=1uM, Rizatriptan, 5-HT1B Agonists;5-HT1D Agonists targeting HTR1B, HTR1D |
| FB-85-ND09_0.01uM | Dose=0.01uM |
| FB-85-ND09_0.1uM | Dose=0.1uM |
| FB-85-ND09_10uM | Dose=10uM |
| FB-85-ND09_1uM | Dose=1uM |
| FB-86-FA19_0.01uM | Dose=0.01uM |
| FB-86-FA19_0.1uM | Dose=0.1uM |
| FB-86-FA19_1uM | Dose=1uM |
| FB-86-IO73_0.01uM | Dose=0.01uM, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl N-(2,2,2-trichloro-1-((pyrimidin-2-yl)amino)ethyl)carbamate, CDC20 inhibitor targeting CDC20 |
| FB-86-IO73_0.1uM | Dose=0.1uM, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl N-(2,2,2-trichloro-1-((pyrimidin-2-yl)amino)ethyl)carbamate, CDC20 inhibitor targeting CDC20 |
| FB-86-IO73_10uM | Dose=10uM, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl N-(2,2,2-trichloro-1-((pyrimidin-2-yl)amino)ethyl)carbamate, CDC20 inhibitor targeting CDC20 |
| FB-86-IO73_1uM | Dose=1uM, 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl N-(2,2,2-trichloro-1-((pyrimidin-2-yl)amino)ethyl)carbamate, CDC20 inhibitor targeting CDC20 |
| FB-88-FZ09_0.01uM | Dose=0.01uM, Mjn228, phenocopies NUCB1 shRNA. Compound is likely a NUCB1 inhibitor. targeting NUCB1 |
| FB-88-FZ09_0.1uM | Dose=0.1uM, Mjn228, phenocopies NUCB1 shRNA. Compound is likely a NUCB1 inhibitor. targeting NUCB1 |
| FB-88-FZ09_10uM | Dose=10uM, Mjn228, phenocopies NUCB1 shRNA. Compound is likely a NUCB1 inhibitor. targeting NUCB1 |
| FB-88-FZ09_1uM | Dose=1uM, Mjn228, phenocopies NUCB1 shRNA. Compound is likely a NUCB1 inhibitor. targeting NUCB1 |
| FB-91-BU05_0.01uM | Dose=0.01uM, 5-(Tetradecyloxy)-2-furoic acid, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB |
| FB-91-BU05_0.1uM | Dose=0.1uM, 5-(Tetradecyloxy)-2-furoic acid, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB |
| FB-91-BU05_10uM | Dose=10uM, 5-(Tetradecyloxy)-2-furoic acid, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB |
| FB-91-BU05_1uM | Dose=1uM, 5-(Tetradecyloxy)-2-furoic acid, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors targeting ACACA, ACACB |
| FB-94-TJ61_0.01uM | Dose=0.01uM |
| FB-94-TJ61_0.1uM | Dose=0.1uM |
| FB-94-TJ61_10uM | Dose=10uM |
| FB-94-TJ61_1uM | Dose=1uM |
| FB-95-JD99_0.01uM | Dose=0.01uM, [6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-5-methoxy-2,3-dihydroindol-1-yl]-[4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methanone, 5-HT1B Antagonists targeting HTR1B |
| FB-95-JD99_0.1uM | Dose=0.1uM, [6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-5-methoxy-2,3-dihydroindol-1-yl]-[4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methanone, 5-HT1B Antagonists targeting HTR1B |
| FB-95-JD99_10uM | Dose=10uM, [6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-5-methoxy-2,3-dihydroindol-1-yl]-[4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methanone, 5-HT1B Antagonists targeting HTR1B |
| FB-95-JD99_1uM | Dose=1uM, [6-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-5-methoxy-2,3-dihydroindol-1-yl]-[4-[2-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methanone, 5-HT1B Antagonists targeting HTR1B |
| FB-97-DI91_0.01uM | Dose=0.01uM, 4-[4-[(3,4-dichlorophenyl)methyl]piperazin-1-yl]-1H-indole |
| FB-97-DI91_0.1uM | Dose=0.1uM, 4-[4-[(3,4-dichlorophenyl)methyl]piperazin-1-yl]-1H-indole |
| FB-97-DI91_1uM | Dose=1uM, 4-[4-[(3,4-dichlorophenyl)methyl]piperazin-1-yl]-1H-indole |
| FB-98-HM88_0.1uM | Dose=0.1uM, N-(1-morpholin-4-ylpropan-2-yl)-6-(8-pyridin-4-ylimidazo[4,5-c][1,7]naphthyridin-1-yl)quinolin-2-amine, Cot kinase inhibitor targeting MAP3K8, FLT3 |
| FB-98-HM88_10uM | Dose=10uM, N-(1-morpholin-4-ylpropan-2-yl)-6-(8-pyridin-4-ylimidazo[4,5-c][1,7]naphthyridin-1-yl)quinolin-2-amine, Cot kinase inhibitor targeting MAP3K8, FLT3 |
| FB-99-SM50_0.01uM | Dose=0.01uM, 4-[3-[[4-(Aminomethyl)phenyl]methoxy]phenoxy]pyrimidine-2-carbonitrile |
| FB-99-SM50_0.1uM | Dose=0.1uM, 4-[3-[[4-(Aminomethyl)phenyl]methoxy]phenoxy]pyrimidine-2-carbonitrile |
| FB-99-SM50_10uM | Dose=10uM, 4-[3-[[4-(Aminomethyl)phenyl]methoxy]phenoxy]pyrimidine-2-carbonitrile |
| FB-99-SM50_1uM | Dose=1uM, 4-[3-[[4-(Aminomethyl)phenyl]methoxy]phenoxy]pyrimidine-2-carbonitrile |
| FC-03-PM86_0.01uM | Dose=0.01uM, Oxytocin, OXTR agonist targeting OXTR |
| FC-03-PM86_0.1uM | Dose=0.1uM, Oxytocin, OXTR agonist targeting OXTR |
| FC-03-PM86_10uM | Dose=10uM, Oxytocin, OXTR agonist targeting OXTR |
| FC-03-PM86_1uM | Dose=1uM, Oxytocin, OXTR agonist targeting OXTR |
| FC-05-ID99_0.01uM | Dose=0.01uM, Tivozanib, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting ABL1, FLT1, FLT4, KDR, RET |
| FC-05-ID99_0.1uM | Dose=0.1uM, Tivozanib, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting ABL1, FLT1, FLT4, KDR, RET |
| FC-05-ID99_10uM | Dose=10uM, Tivozanib, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting ABL1, FLT1, FLT4, KDR, RET |
| FC-05-ID99_1uM | Dose=1uM, Tivozanib, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;VEGFR-1 (Flt-1) Inhibitors targeting ABL1, FLT1, FLT4, KDR, RET |
| FC-05-LX47_0.01uM | Dose=0.01uM, Turofexorate Isopropyl, Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| FC-05-LX47_0.1uM | Dose=0.1uM, Turofexorate Isopropyl, Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| FC-05-LX47_10uM | Dose=10uM, Turofexorate Isopropyl, Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| FC-05-LX47_1uM | Dose=1uM, Turofexorate Isopropyl, Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| FC-08-PZ84_0.01uM | Dose=0.01uM, 5-{3-[(Furan-2-carbonyl)-amino]-benzoylamino}-2-hydroxy-benzoic acid, SIRT6 inhibitor targeting SIRT6 |
| FC-08-PZ84_10uM | Dose=10uM, 5-{3-[(Furan-2-carbonyl)-amino]-benzoylamino}-2-hydroxy-benzoic acid, SIRT6 inhibitor targeting SIRT6 |
| FC-08-PZ84_1uM | Dose=1uM, 5-{3-[(Furan-2-carbonyl)-amino]-benzoylamino}-2-hydroxy-benzoic acid, SIRT6 inhibitor targeting SIRT6 |
| FC-11-WH14_0.01uM | Dose=0.01uM, Pivanex, Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Angiogenesis Inhibitors targeting HDAC3 |
| FC-11-WH14_10uM | Dose=10uM, Pivanex, Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Angiogenesis Inhibitors targeting HDAC3 |
| FC-11-WH14_1uM | Dose=1uM, Pivanex, Histone Deacetylase (HDAC) Inhibitors;Apoptosis Inducers;Angiogenesis Inhibitors targeting HDAC3 |
| FC-11-YA62_0.1uM | Dose=0.1uM, Candesartan Cilexetil, Angiotensin AT1 Antagonists targeting AGTR1 |
| FC-13-UF39_0.01uM | Dose=0.01uM |
| FC-13-UF39_0.1uM | Dose=0.1uM |
| FC-13-UF39_10uM | Dose=10uM |
| FC-13-UF39_1uM | Dose=1uM |
| FC-13-VS25_0.01uM | Dose=0.01uM, Topiramate, Carbonic Anhydrase Type II Inhibitors;AMPA Receptor Antagonists;Kainate Receptor Antagonists targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10, GRIA1, GRIA2, GRIA3, GRIA4 |
| FC-13-VS25_0.1uM | Dose=0.1uM, Topiramate, Carbonic Anhydrase Type II Inhibitors;AMPA Receptor Antagonists;Kainate Receptor Antagonists targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10, GRIA1, GRIA2, GRIA3, GRIA4 |
| FC-13-VS25_10uM | Dose=10uM, Topiramate, Carbonic Anhydrase Type II Inhibitors;AMPA Receptor Antagonists;Kainate Receptor Antagonists targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10, GRIA1, GRIA2, GRIA3, GRIA4 |
| FC-13-VS25_1uM | Dose=1uM, Topiramate, Carbonic Anhydrase Type II Inhibitors;AMPA Receptor Antagonists;Kainate Receptor Antagonists targeting CA1, CA2, CA3, CA4, CA5A, CA8, CA11, CA12, CA5B, CA10, GRIA1, GRIA2, GRIA3, GRIA4 |
| FC-15-XG61_0.01uM | Dose=0.01uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| FC-15-XG61_0.1uM | Dose=0.1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| FC-15-XG61_10uM | Dose=10uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| FC-15-XG61_1uM | Dose=1uM, [(3R)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate, Muscarinic M3 Antagonists;Muscarinic M1 Antagonists;Muscarinic M2 Antagonists targeting CHRM3 |
| FC-19-RM40_0.01uM | Dose=0.01uM, Cediranib, VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting FLT1, FLT4, KDR |
| FC-19-RM40_0.1uM | Dose=0.1uM, Cediranib, VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting FLT1, FLT4, KDR |
| FC-19-RM40_10uM | Dose=10uM, Cediranib, VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting FLT1, FLT4, KDR |
| FC-19-RM40_1uM | Dose=1uM, Cediranib, VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-1 (Flt-1) Inhibitors;Inhibitors of Signal Transduction Pathways;Angiogenesis Inhibitors targeting FLT1, FLT4, KDR |
| FC-20-EQ58_0.01uM | Dose=0.01uM, Trichostatin A (racemate), HDAC inhibitor targeting HDAC1, HDAC3, HDAC4, HDAC6, HDAC10 |
| FC-20-EQ58_0.1uM | Dose=0.1uM, Trichostatin A (racemate), HDAC inhibitor targeting HDAC1, HDAC3, HDAC4, HDAC6, HDAC10 |
| FC-20-EQ58_10uM | Dose=10uM, Trichostatin A (racemate), HDAC inhibitor targeting HDAC1, HDAC3, HDAC4, HDAC6, HDAC10 |
| FC-20-EQ58_1uM | Dose=1uM, Trichostatin A (racemate), HDAC inhibitor targeting HDAC1, HDAC3, HDAC4, HDAC6, HDAC10 |
| FC-22-VC55_0.01uM | Dose=0.01uM, 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[4-(methylsulfonyl)tetrahydro-2H-pyran-4-yl]pyrimidin-2-yl}-1H-indole, ATR gene inhibitor;DNA damage reversal pathway modulator;Chemosensitizer targeting ATR |
| FC-22-VC55_0.1uM | Dose=0.1uM, 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[4-(methylsulfonyl)tetrahydro-2H-pyran-4-yl]pyrimidin-2-yl}-1H-indole, ATR gene inhibitor;DNA damage reversal pathway modulator;Chemosensitizer targeting ATR |
| FC-22-VC55_10uM | Dose=10uM, 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[4-(methylsulfonyl)tetrahydro-2H-pyran-4-yl]pyrimidin-2-yl}-1H-indole, ATR gene inhibitor;DNA damage reversal pathway modulator;Chemosensitizer targeting ATR |
| FC-22-VC55_1uM | Dose=1uM, 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[4-(methylsulfonyl)tetrahydro-2H-pyran-4-yl]pyrimidin-2-yl}-1H-indole, ATR gene inhibitor;DNA damage reversal pathway modulator;Chemosensitizer targeting ATR |
| FC-22-ZV65_0.01uM | Dose=0.01uM, Cystamine, Tissue Transglutaminase (TGM2) Inhibitors targeting TGM2 |
| FC-22-ZV65_0.1uM | Dose=0.1uM, Cystamine, Tissue Transglutaminase (TGM2) Inhibitors targeting TGM2 |
| FC-22-ZV65_10uM | Dose=10uM, Cystamine, Tissue Transglutaminase (TGM2) Inhibitors targeting TGM2 |
| FC-22-ZV65_1uM | Dose=1uM, Cystamine, Tissue Transglutaminase (TGM2) Inhibitors targeting TGM2 |
| FC-31-HE22_0.01uM | Dose=0.01uM, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-1H-benzimidazole, Aldehyde dehydrogenase 3 inhibitor targeting ALDH3A1 |
| FC-31-HE22_10uM | Dose=10uM, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-1H-benzimidazole, Aldehyde dehydrogenase 3 inhibitor targeting ALDH3A1 |
| FC-31-HE22_1uM | Dose=1uM, 1-[(4-fluorophenyl)sulfonyl]-2-methyl-1H-benzimidazole, Aldehyde dehydrogenase 3 inhibitor targeting ALDH3A1 |
| FC-35-BX82_0.01uM | Dose=0.01uM, Cyclosporin V |
| FC-35-BX82_0.1uM | Dose=0.1uM, Cyclosporin V |
| FC-35-BX82_10uM | Dose=10uM, Cyclosporin V |
| FC-35-BX82_1uM | Dose=1uM, Cyclosporin V |
| FC-36-SU62_0.01uM | Dose=0.01uM, (2R)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid |
| FC-36-SU62_0.1uM | Dose=0.1uM, (2R)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid |
| FC-36-SU62_10uM | Dose=10uM, (2R)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid |
| FC-36-SU62_1uM | Dose=1uM, (2R)-1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid |
| FC-40-QD52_0.01uM | Dose=0.01uM, 3-Isoquinolinecarboxylic acid, 6-(((2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl)methyl)decahydro-, (3S,4aR,6S,8aR)-, iGluR5 (GluK5) Antagonists targeting GRIK1 |
| FC-40-QD52_0.1uM | Dose=0.1uM, 3-Isoquinolinecarboxylic acid, 6-(((2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl)methyl)decahydro-, (3S,4aR,6S,8aR)-, iGluR5 (GluK5) Antagonists targeting GRIK1 |
| FC-40-QD52_10uM | Dose=10uM, 3-Isoquinolinecarboxylic acid, 6-(((2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl)methyl)decahydro-, (3S,4aR,6S,8aR)-, iGluR5 (GluK5) Antagonists targeting GRIK1 |
| FC-40-QD52_1uM | Dose=1uM, 3-Isoquinolinecarboxylic acid, 6-(((2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl)methyl)decahydro-, (3S,4aR,6S,8aR)-, iGluR5 (GluK5) Antagonists targeting GRIK1 |
| FC-52-RL51_0.1uM | Dose=0.1uM, [1-[(2-Chlorophenyl)methyl]-3-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-5-(trifluoromethoxy)indol-2-yl]methanol, PAR4 antagonist targeting F2RL3 |
| FC-52-RL51_10uM | Dose=10uM, [1-[(2-Chlorophenyl)methyl]-3-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-5-(trifluoromethoxy)indol-2-yl]methanol, PAR4 antagonist targeting F2RL3 |
| FC-52-RL51_1uM | Dose=1uM, [1-[(2-Chlorophenyl)methyl]-3-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-5-(trifluoromethoxy)indol-2-yl]methanol, PAR4 antagonist targeting F2RL3 |
| FC-55-IG96_0.01uM | Dose=0.01uM, 3-(2-Methoxybenzylamino)-2-phenylpiperidine, Tachykinin NK1 Antagonists targeting CYP2D6 |
| FC-55-IG96_0.1uM | Dose=0.1uM, 3-(2-Methoxybenzylamino)-2-phenylpiperidine, Tachykinin NK1 Antagonists targeting CYP2D6 |
| FC-55-IG96_10uM | Dose=10uM, 3-(2-Methoxybenzylamino)-2-phenylpiperidine, Tachykinin NK1 Antagonists targeting CYP2D6 |
| FC-56-ZH16_0.01uM | Dose=0.01uM, 8-Hydroxy-5-quinolinecarboxylic acid, broad-spectrum inhibitor of 2OG oxygenases targeting KDM2A |
| FC-56-ZH16_0.1uM | Dose=0.1uM, 8-Hydroxy-5-quinolinecarboxylic acid, broad-spectrum inhibitor of 2OG oxygenases targeting KDM2A |
| FC-56-ZH16_10uM | Dose=10uM, 8-Hydroxy-5-quinolinecarboxylic acid, broad-spectrum inhibitor of 2OG oxygenases targeting KDM2A |
| FC-56-ZH16_1uM | Dose=1uM, 8-Hydroxy-5-quinolinecarboxylic acid, broad-spectrum inhibitor of 2OG oxygenases targeting KDM2A |
| FC-58-KP35_0.01uM | Dose=0.01uM, AM-966, LPAR1 antagonist targeting LPAR1 |
| FC-58-KP35_0.1uM | Dose=0.1uM, AM-966, LPAR1 antagonist targeting LPAR1 |
| FC-58-KP35_10uM | Dose=10uM, AM-966, LPAR1 antagonist targeting LPAR1 |
| FC-58-KP35_1uM | Dose=1uM, AM-966, LPAR1 antagonist targeting LPAR1 |
| FC-58-QS77_0.01uM | Dose=0.01uM, N-(5-Bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide, CCR4 antagonist targeting CCR4 |
| FC-58-QS77_0.1uM | Dose=0.1uM, N-(5-Bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide, CCR4 antagonist targeting CCR4 |
| FC-58-QS77_10uM | Dose=10uM, N-(5-Bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide, CCR4 antagonist targeting CCR4 |
| FC-58-QS77_1uM | Dose=1uM, N-(5-Bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide, CCR4 antagonist targeting CCR4 |
| FC-61-BK21_0.01uM | Dose=0.01uM, Cinnamaldehyde, Aldose Reductase Inhibitors;TRPA1 Agonists targeting AKR1B1, TRPA1 |
| FC-61-BK21_10uM | Dose=10uM, Cinnamaldehyde, Aldose Reductase Inhibitors;TRPA1 Agonists targeting AKR1B1, TRPA1 |
| FC-61-BK21_1uM | Dose=1uM, Cinnamaldehyde, Aldose Reductase Inhibitors;TRPA1 Agonists targeting AKR1B1, TRPA1 |
| FC-62-AI14_0.01uM | Dose=0.01uM, (R)-2-((S)-4-(3-chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)-3-methylbutan-2-ol, Protein kinase C theta inhibitor targeting PRKCQ |
| FC-62-AI14_0.1uM | Dose=0.1uM, (R)-2-((S)-4-(3-chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)-3-methylbutan-2-ol, Protein kinase C theta inhibitor targeting PRKCQ |
| FC-62-AI14_10uM | Dose=10uM, (R)-2-((S)-4-(3-chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)-3-methylbutan-2-ol, Protein kinase C theta inhibitor targeting PRKCQ |
| FC-62-AI14_1uM | Dose=1uM, (R)-2-((S)-4-(3-chloro-5-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyridin-2-yl)piperazin-2-yl)-3-methylbutan-2-ol, Protein kinase C theta inhibitor targeting PRKCQ |
| FC-64-QJ96_0.01uM | Dose=0.01uM, Jnj-dgat1-A, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| FC-64-QJ96_0.1uM | Dose=0.1uM, Jnj-dgat1-A, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| FC-64-QJ96_1uM | Dose=1uM, Jnj-dgat1-A, Diacylglycerol Acyltransferase type 1 (DGAT-1) Inhibitors targeting DGAT1 |
| FC-67-SZ42_0.01uM | Dose=0.01uM, 3-(((3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Synthesis Inhibitors targeting ABCC4, CYSLTR1 |
| FC-67-SZ42_0.1uM | Dose=0.1uM, 3-(((3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Synthesis Inhibitors targeting ABCC4, CYSLTR1 |
| FC-67-SZ42_10uM | Dose=10uM, 3-(((3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Synthesis Inhibitors targeting ABCC4, CYSLTR1 |
| FC-67-SZ42_1uM | Dose=1uM, 3-(((3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Synthesis Inhibitors targeting ABCC4, CYSLTR1 |
| FC-68-LJ11_0.01uM | Dose=0.01uM |
| FC-68-LJ11_0.1uM | Dose=0.1uM |
| FC-68-LJ11_10uM | Dose=10uM |
| FC-68-LJ11_1uM | Dose=1uM |
| FC-71-PK06_10uM | Dose=10uM, 1-[4-(Diphenylmethyl)-1-piperazinyl]-3,3-diphenyl-1-propanone, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1A, CACNA1B, CACNA1C, CACNA1S |
| FC-71-PK06_1uM | Dose=1uM, 1-[4-(Diphenylmethyl)-1-piperazinyl]-3,3-diphenyl-1-propanone, N-Type Calcium Channel (Ca(v) 2.2) Blockers targeting CACNA1A, CACNA1B, CACNA1C, CACNA1S |
| FC-82-WB67_0.01uM | Dose=0.01uM, Lycopene |
| FC-82-WB67_0.1uM | Dose=0.1uM, Lycopene |
| FC-82-WB67_10uM | Dose=10uM, Lycopene |
| FC-82-WB67_1uM | Dose=1uM, Lycopene |
| FC-85-OX77_0.01uM | Dose=0.01uM, N-[[3-[(1R)-1-amino-2,2,2-trifluoroethyl]-4-fluorophenyl]methyl]-6-fluoro-4-hydroxy-1-methylspiro[3,4-dihydroquinoline-2,4'-piperidine]-1'-carboxamide |
| FC-85-OX77_0.1uM | Dose=0.1uM, N-[[3-[(1R)-1-amino-2,2,2-trifluoroethyl]-4-fluorophenyl]methyl]-6-fluoro-4-hydroxy-1-methylspiro[3,4-dihydroquinoline-2,4'-piperidine]-1'-carboxamide |
| FC-85-OX77_10uM | Dose=10uM, N-[[3-[(1R)-1-amino-2,2,2-trifluoroethyl]-4-fluorophenyl]methyl]-6-fluoro-4-hydroxy-1-methylspiro[3,4-dihydroquinoline-2,4'-piperidine]-1'-carboxamide |
| FC-85-OX77_1uM | Dose=1uM, N-[[3-[(1R)-1-amino-2,2,2-trifluoroethyl]-4-fluorophenyl]methyl]-6-fluoro-4-hydroxy-1-methylspiro[3,4-dihydroquinoline-2,4'-piperidine]-1'-carboxamide |
| FC-88-AJ86_0.01uM | Dose=0.01uM, (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one |
| FC-88-AJ86_0.1uM | Dose=0.1uM, (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one |
| FC-88-AJ86_10uM | Dose=10uM, (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one |
| FC-88-AJ86_1uM | Dose=1uM, (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one |
| FC-96-WR45_0.01uM | Dose=0.01uM, (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid, Leukotriene Synthesis Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting LTA4H |
| FC-96-WR45_0.1uM | Dose=0.1uM, (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid, Leukotriene Synthesis Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting LTA4H |
| FC-96-WR45_10uM | Dose=10uM, (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid, Leukotriene Synthesis Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting LTA4H |
| FC-96-WR45_1uM | Dose=1uM, (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid, Leukotriene Synthesis Inhibitors;Leukotriene A4 Hydrolase Inhibitors targeting LTA4H |
| FC-97-EO10_0.01uM | Dose=0.01uM, N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]-N-methyl-2,3-dihydro-1H-indene-2-carboxamide |
| FC-97-EO10_0.1uM | Dose=0.1uM, N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]-N-methyl-2,3-dihydro-1H-indene-2-carboxamide |
| FC-97-EO10_10uM | Dose=10uM, N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]-N-methyl-2,3-dihydro-1H-indene-2-carboxamide |
| FC-97-EO10_1uM | Dose=1uM, N-[[(3S,4S)-4-[[[4-methoxy-3-(3-methoxypropoxy)benzoyl]-propan-2-ylamino]methyl]pyrrolidin-3-yl]methyl]-N-methyl-2,3-dihydro-1H-indene-2-carboxamide |
| FC-98-AJ86_0.01uM | Dose=0.01uM, Trimebutine |
| FC-98-AJ86_0.1uM | Dose=0.1uM, Trimebutine |
| FC-98-AJ86_10uM | Dose=10uM, Trimebutine |
| FD-00-QG34_0.01uM | Dose=0.01uM, PF-4800567, Casein Kinase CK1epsilon Inhibitors targeting CSNK1E |
| FD-00-QG34_0.1uM | Dose=0.1uM, PF-4800567, Casein Kinase CK1epsilon Inhibitors targeting CSNK1E |
| FD-00-QG34_10uM | Dose=10uM, PF-4800567, Casein Kinase CK1epsilon Inhibitors targeting CSNK1E |
| FD-00-QG34_1uM | Dose=1uM, PF-4800567, Casein Kinase CK1epsilon Inhibitors targeting CSNK1E |
| FD-05-QX72_0.01uM | Dose=0.01uM, (2R,4R)-4-amino-8-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-2-ol, SHP2 inhibitor targeting PTPN11 |
| FD-05-QX72_0.1uM | Dose=0.1uM, (2R,4R)-4-amino-8-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-2-ol, SHP2 inhibitor targeting PTPN11 |
| FD-05-QX72_10uM | Dose=10uM, (2R,4R)-4-amino-8-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-2-ol, SHP2 inhibitor targeting PTPN11 |
| FD-05-QX72_1uM | Dose=1uM, (2R,4R)-4-amino-8-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-8-azaspiro[4.5]decan-2-ol, SHP2 inhibitor targeting PTPN11 |
| FD-06-CV80_0.01uM | Dose=0.01uM, (2R)-2-[(9,10-dioxoanthracene-2-carbonyl)amino]-3-phenylpropanoic acid targeting XDH |
| FD-06-CV80_0.1uM | Dose=0.1uM, (2R)-2-[(9,10-dioxoanthracene-2-carbonyl)amino]-3-phenylpropanoic acid targeting XDH |
| FD-06-CV80_10uM | Dose=10uM, (2R)-2-[(9,10-dioxoanthracene-2-carbonyl)amino]-3-phenylpropanoic acid targeting XDH |
| FD-06-CV80_1uM | Dose=1uM, (2R)-2-[(9,10-dioxoanthracene-2-carbonyl)amino]-3-phenylpropanoic acid targeting XDH |
| FD-09-BQ45_0.01uM | Dose=0.01uM, Nifekalant, K(V)11.1 (erg1) Channel Blockers;Potassium Channel Blockers targeting KCNH2 |
| FD-09-BQ45_0.1uM | Dose=0.1uM, Nifekalant, K(V)11.1 (erg1) Channel Blockers;Potassium Channel Blockers targeting KCNH2 |
| FD-09-BQ45_10uM | Dose=10uM, Nifekalant, K(V)11.1 (erg1) Channel Blockers;Potassium Channel Blockers targeting KCNH2 |
| FD-09-BQ45_1uM | Dose=1uM, Nifekalant, K(V)11.1 (erg1) Channel Blockers;Potassium Channel Blockers targeting KCNH2 |
| FD-13-TF49_0.01uM | Dose=0.01uM |
| FD-13-TF49_0.1uM | Dose=0.1uM |
| FD-13-TF49_10uM | Dose=10uM |
| FD-13-TF49_1uM | Dose=1uM |
| FD-15-HD09_0.01uM | Dose=0.01uM, WX-671/Mesupron, Urokinase (u-PA) Inhibitors targeting PLAU |
| FD-15-HD09_0.1uM | Dose=0.1uM, WX-671/Mesupron, Urokinase (u-PA) Inhibitors targeting PLAU |
| FD-15-HD09_10uM | Dose=10uM, WX-671/Mesupron, Urokinase (u-PA) Inhibitors targeting PLAU |
| FD-15-HD09_1uM | Dose=1uM, WX-671/Mesupron, Urokinase (u-PA) Inhibitors targeting PLAU |
| FD-19-TD14_0.01uM | Dose=0.01uM |
| FD-19-TD14_0.1uM | Dose=0.1uM |
| FD-19-TD14_10uM | Dose=10uM |
| FD-19-TD14_1uM | Dose=1uM |
| FD-20-DQ38_0.01uM | Dose=0.01uM, 1-[[6-(2-Methoxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| FD-20-DQ38_0.1uM | Dose=0.1uM, 1-[[6-(2-Methoxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| FD-20-DQ38_10uM | Dose=10uM, 1-[[6-(2-Methoxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| FD-20-DQ38_1uM | Dose=1uM, 1-[[6-(2-Methoxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| FD-20-OG99_0.01uM | Dose=0.01uM, (2E,10E,12E,16Z,18E)-6-hydroxy-3,5,7,9,11,15,17-heptamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid, Exportin 1 inhibitor targeting XPO1 |
| FD-20-OG99_0.1uM | Dose=0.1uM, (2E,10E,12E,16Z,18E)-6-hydroxy-3,5,7,9,11,15,17-heptamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid, Exportin 1 inhibitor targeting XPO1 |
| FD-20-OG99_10uM | Dose=10uM, (2E,10E,12E,16Z,18E)-6-hydroxy-3,5,7,9,11,15,17-heptamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid, Exportin 1 inhibitor targeting XPO1 |
| FD-20-OG99_1uM | Dose=1uM, (2E,10E,12E,16Z,18E)-6-hydroxy-3,5,7,9,11,15,17-heptamethyl-19-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid, Exportin 1 inhibitor targeting XPO1 |
| FD-25-KX07_0.01uM | Dose=0.01uM |
| FD-25-KX07_0.1uM | Dose=0.1uM |
| FD-25-KX07_10uM | Dose=10uM |
| FD-25-KX07_1uM | Dose=1uM |
| FD-28-EZ19_0.01uM | Dose=0.01uM, Selexipag, Prostanoid IP Agonists targeting PTGIR |
| FD-28-EZ19_1uM | Dose=1uM, Selexipag, Prostanoid IP Agonists targeting PTGIR |
| FD-29-MM50_0.01uM | Dose=0.01uM, (s)-n-((s)-1-Cyclohexyl-2-((s)-2-(5-(4-fluorobenzoyl)pyridin-3-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| FD-29-MM50_0.1uM | Dose=0.1uM, (s)-n-((s)-1-Cyclohexyl-2-((s)-2-(5-(4-fluorobenzoyl)pyridin-3-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| FD-29-MM50_10uM | Dose=10uM, (s)-n-((s)-1-Cyclohexyl-2-((s)-2-(5-(4-fluorobenzoyl)pyridin-3-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| FD-29-MM50_1uM | Dose=1uM, (s)-n-((s)-1-Cyclohexyl-2-((s)-2-(5-(4-fluorobenzoyl)pyridin-3-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| FD-35-PQ00_0.01uM | Dose=0.01uM, Phytonadione, Cytochrome P450 CYP4F2 Inhibitors;Vitamin K analogs targeting BGLAP, GGCX, CYP4F2 |
| FD-35-PQ00_0.1uM | Dose=0.1uM, Phytonadione, Cytochrome P450 CYP4F2 Inhibitors;Vitamin K analogs targeting BGLAP, GGCX, CYP4F2 |
| FD-35-PQ00_10uM | Dose=10uM, Phytonadione, Cytochrome P450 CYP4F2 Inhibitors;Vitamin K analogs targeting BGLAP, GGCX, CYP4F2 |
| FD-35-PQ00_1uM | Dose=1uM, Phytonadione, Cytochrome P450 CYP4F2 Inhibitors;Vitamin K analogs targeting BGLAP, GGCX, CYP4F2 |
| FD-37-GE41_0.01uM | Dose=0.01uM, Torcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP |
| FD-37-GE41_10uM | Dose=10uM, Torcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP |
| FD-37-GE41_1uM | Dose=1uM, Torcetrapib, Cholesteryl Ester Transfer Protein (CETP) Inhibitors targeting CETP |
| FD-43-EF54_0.01uM | Dose=0.01uM, 2-Hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, IRE1 protein kinase inhibitor targeting ERN1 |
| FD-43-EF54_0.1uM | Dose=0.1uM, 2-Hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, IRE1 protein kinase inhibitor targeting ERN1 |
| FD-43-EF54_10uM | Dose=10uM, 2-Hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, IRE1 protein kinase inhibitor targeting ERN1 |
| FD-43-EF54_1uM | Dose=1uM, 2-Hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, IRE1 protein kinase inhibitor targeting ERN1 |
| FD-44-AD67_0.1uM | Dose=0.1uM, 3-(2,3-Difluoro-4-methoxyphenyl)-2,5-dimethyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine targeting GRM7, GRM8 |
| FD-44-AD67_10uM | Dose=10uM, 3-(2,3-Difluoro-4-methoxyphenyl)-2,5-dimethyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine targeting GRM7, GRM8 |
| FD-46-HV00_0.01uM | Dose=0.01uM, (1S,2R,4aS,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid |
| FD-46-HV00_0.1uM | Dose=0.1uM, (1S,2R,4aS,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid |
| FD-46-HV00_10uM | Dose=10uM, (1S,2R,4aS,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid |
| FD-46-HV00_1uM | Dose=1uM, (1S,2R,4aS,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid |
| FD-48-HZ39_0.01uM | Dose=0.01uM |
| FD-48-HZ39_0.1uM | Dose=0.1uM |
| FD-48-HZ39_10uM | Dose=10uM |
| FD-48-HZ39_1uM | Dose=1uM |
| FD-48-ZP65_10uM | Dose=10uM, 5-Fluoro-2-phenyl-1,2-benzothiazol-3-one, PMI Inhibitor targeting MPI |
| FD-48-ZP65_1uM | Dose=1uM, 5-Fluoro-2-phenyl-1,2-benzothiazol-3-one, PMI Inhibitor targeting MPI |
| FD-49-XC21_0.01uM | Dose=0.01uM, 3-[3-(4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2 |
| FD-49-XC21_0.1uM | Dose=0.1uM, 3-[3-(4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2 |
| FD-49-XC21_10uM | Dose=10uM, 3-[3-(4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2 |
| FD-49-XC21_1uM | Dose=1uM, 3-[3-(4,7-diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)pyrrole-2,5-dione, IL-2 Production Inhibitors;Protein Kinase C (PKC) Inhibitors targeting IL2 |
| FD-55-XG26_0.01uM | Dose=0.01uM |
| FD-55-XG26_0.1uM | Dose=0.1uM |
| FD-55-XG26_10uM | Dose=10uM |
| FD-55-XG26_1uM | Dose=1uM |
| FD-59-TC81_0.1uM | Dose=0.1uM, nocardimicin B, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands targeting CHRM3, CHRM4 |
| FD-59-TC81_10uM | Dose=10uM, nocardimicin B, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands targeting CHRM3, CHRM4 |
| FD-59-TC81_1uM | Dose=1uM, nocardimicin B, Muscarinic M3 Receptor Ligands;Muscarinic M4 Receptor Ligands targeting CHRM3, CHRM4 |
| FD-62-ZB67_0.01uM | Dose=0.01uM, Edatrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| FD-62-ZB67_0.1uM | Dose=0.1uM, Edatrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| FD-62-ZB67_10uM | Dose=10uM, Edatrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| FD-62-ZB67_1uM | Dose=1uM, Edatrexate, Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors targeting DHFR |
| FD-63-JF34_0.01uM | Dose=0.01uM |
| FD-63-JF34_0.1uM | Dose=0.1uM |
| FD-63-JF34_10uM | Dose=10uM |
| FD-63-JF34_1uM | Dose=1uM |
| FD-65-VN78_0.1uM | Dose=0.1uM, N-(3-Methylbenzyl)-1H-benzo[d][1,2,3]triazole-1-carboxamide, Endothelial Lipase (EL) Inhibitors targeting LIPG |
| FD-65-VN78_1uM | Dose=1uM, N-(3-Methylbenzyl)-1H-benzo[d][1,2,3]triazole-1-carboxamide, Endothelial Lipase (EL) Inhibitors targeting LIPG |
| FD-67-GI76_0.01uM | Dose=0.01uM, Canrenone, Mineralocorticoid Receptor (MR) Antagonists targeting NR3C2 |
| FD-67-GI76_0.1uM | Dose=0.1uM, Canrenone, Mineralocorticoid Receptor (MR) Antagonists targeting NR3C2 |
| FD-67-GI76_10uM | Dose=10uM, Canrenone, Mineralocorticoid Receptor (MR) Antagonists targeting NR3C2 |
| FD-67-GI76_1uM | Dose=1uM, Canrenone, Mineralocorticoid Receptor (MR) Antagonists targeting NR3C2 |
| FD-69-CC31_0.01uM | Dose=0.01uM, 1,2-Dimethyl-4-[ethyl(phenyl)amino]-6-(methylamino)-1-pyrimidinium, HCN [I(h)] Blockers targeting HCN2, HCN4, HCN3, HCN1 |
| FD-69-CC31_0.1uM | Dose=0.1uM, 1,2-Dimethyl-4-[ethyl(phenyl)amino]-6-(methylamino)-1-pyrimidinium, HCN [I(h)] Blockers targeting HCN2, HCN4, HCN3, HCN1 |
| FD-69-CC31_10uM | Dose=10uM, 1,2-Dimethyl-4-[ethyl(phenyl)amino]-6-(methylamino)-1-pyrimidinium, HCN [I(h)] Blockers targeting HCN2, HCN4, HCN3, HCN1 |
| FD-69-CC31_1uM | Dose=1uM, 1,2-Dimethyl-4-[ethyl(phenyl)amino]-6-(methylamino)-1-pyrimidinium, HCN [I(h)] Blockers targeting HCN2, HCN4, HCN3, HCN1 |
| FD-72-CE19_0.01uM | Dose=0.01uM, Zaldaride, Calmodulin Antagonists targeting CALM1 |
| FD-72-CE19_0.1uM | Dose=0.1uM, Zaldaride, Calmodulin Antagonists targeting CALM1 |
| FD-72-CE19_10uM | Dose=10uM, Zaldaride, Calmodulin Antagonists targeting CALM1 |
| FD-72-CE19_1uM | Dose=1uM, Zaldaride, Calmodulin Antagonists targeting CALM1 |
| FD-74-LD52_0.01uM | Dose=0.01uM, 6-Fluoro-2-(1-methylindol-5-yl)-1,3-benzothiazole targeting MAOB |
| FD-74-LD52_0.1uM | Dose=0.1uM, 6-Fluoro-2-(1-methylindol-5-yl)-1,3-benzothiazole targeting MAOB |
| FD-74-LD52_10uM | Dose=10uM, 6-Fluoro-2-(1-methylindol-5-yl)-1,3-benzothiazole targeting MAOB |
| FD-74-LD52_1uM | Dose=1uM, 6-Fluoro-2-(1-methylindol-5-yl)-1,3-benzothiazole targeting MAOB |
| FD-74-XT10_0.01uM | Dose=0.01uM |
| FD-74-XT10_0.1uM | Dose=0.1uM |
| FD-74-XT10_10uM | Dose=10uM |
| FD-74-XT10_1uM | Dose=1uM |
| FD-75-PQ00_0.01uM | Dose=0.01uM, methyl 3-(4,4-dimethyl-2,3-dihydro-1H-naphthalen-1-yl)imidazole-4-carboxylate |
| FD-75-PQ00_0.1uM | Dose=0.1uM, methyl 3-(4,4-dimethyl-2,3-dihydro-1H-naphthalen-1-yl)imidazole-4-carboxylate |
| FD-75-PQ00_10uM | Dose=10uM, methyl 3-(4,4-dimethyl-2,3-dihydro-1H-naphthalen-1-yl)imidazole-4-carboxylate |
| FD-75-PQ00_1uM | Dose=1uM, methyl 3-(4,4-dimethyl-2,3-dihydro-1H-naphthalen-1-yl)imidazole-4-carboxylate |
| FD-77-DL33_0.01uM | Dose=0.01uM, Imidapril |
| FD-77-DL33_0.1uM | Dose=0.1uM, Imidapril |
| FD-77-DL33_10uM | Dose=10uM, Imidapril |
| FD-77-DL33_1uM | Dose=1uM, Imidapril |
| FD-77-ZV22_0.01uM | Dose=0.01uM, n-(2-(1h-Indol-3-yl)ethyl)-9-isopropyl-2-(5-methylpyridin-3-yl)-9h-purin-6-amine, Aryl hydrocarbon receptor antagonist targeting AHR |
| FD-77-ZV22_10uM | Dose=10uM, n-(2-(1h-Indol-3-yl)ethyl)-9-isopropyl-2-(5-methylpyridin-3-yl)-9h-purin-6-amine, Aryl hydrocarbon receptor antagonist targeting AHR |
| FD-77-ZV22_1uM | Dose=1uM, n-(2-(1h-Indol-3-yl)ethyl)-9-isopropyl-2-(5-methylpyridin-3-yl)-9h-purin-6-amine, Aryl hydrocarbon receptor antagonist targeting AHR |
| FD-79-KT27_0.01uM | Dose=0.01uM, Medermycin, Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1 |
| FD-79-KT27_0.1uM | Dose=0.1uM, Medermycin, Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1 |
| FD-79-KT27_10uM | Dose=10uM, Medermycin, Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1 |
| FD-79-KT27_1uM | Dose=1uM, Medermycin, Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1 |
| FD-79-TC61_0.01uM | Dose=0.01uM, 6-[2-(4-Methyl-3-methylamino-phenylamino)-pyrimidin-4-ylamino]-2,3-dihydro-benzo[1,4]dioxine-5-sulfonic acid amide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70 |
| FD-79-TC61_0.1uM | Dose=0.1uM, 6-[2-(4-Methyl-3-methylamino-phenylamino)-pyrimidin-4-ylamino]-2,3-dihydro-benzo[1,4]dioxine-5-sulfonic acid amide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70 |
| FD-79-TC61_10uM | Dose=10uM, 6-[2-(4-Methyl-3-methylamino-phenylamino)-pyrimidin-4-ylamino]-2,3-dihydro-benzo[1,4]dioxine-5-sulfonic acid amide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70 |
| FD-79-TC61_1uM | Dose=1uM, 6-[2-(4-Methyl-3-methylamino-phenylamino)-pyrimidin-4-ylamino]-2,3-dihydro-benzo[1,4]dioxine-5-sulfonic acid amide, ZAP70 Kinase Inhibitors;ALK Inhibitors targeting ZAP70 |
| FD-80-EG54_0.01uM | Dose=0.01uM, Acumapimod, p38 MAPK Inhibitors targeting MAPK14 |
| FD-80-EG54_0.1uM | Dose=0.1uM, Acumapimod, p38 MAPK Inhibitors targeting MAPK14 |
| FD-80-EG54_10uM | Dose=10uM, Acumapimod, p38 MAPK Inhibitors targeting MAPK14 |
| FD-80-EG54_1uM | Dose=1uM, Acumapimod, p38 MAPK Inhibitors targeting MAPK14 |
| FD-81-SU40_0.01uM | Dose=0.01uM, Methoxyamine |
| FD-81-SU40_0.1uM | Dose=0.1uM, Methoxyamine |
| FD-81-SU40_10uM | Dose=10uM, Methoxyamine |
| FD-81-SU40_1uM | Dose=1uM, Methoxyamine |
| FD-85-SX37_0.01uM | Dose=0.01uM, 4-[[(2r,3s,4r,5r)-5-[6-Amino-8-[(3,4-Dichlorophenyl)methylamino]purin-9-Yl]-3,4-Dihydroxy-Oxolan-2-Yl]methoxymethyl]benzonitrile, Heat Shock Protein 70 (hsp70) Inhibitors targeting HSPA2 |
| FD-85-SX37_0.1uM | Dose=0.1uM, 4-[[(2r,3s,4r,5r)-5-[6-Amino-8-[(3,4-Dichlorophenyl)methylamino]purin-9-Yl]-3,4-Dihydroxy-Oxolan-2-Yl]methoxymethyl]benzonitrile, Heat Shock Protein 70 (hsp70) Inhibitors targeting HSPA2 |
| FD-85-SX37_10uM | Dose=10uM, 4-[[(2r,3s,4r,5r)-5-[6-Amino-8-[(3,4-Dichlorophenyl)methylamino]purin-9-Yl]-3,4-Dihydroxy-Oxolan-2-Yl]methoxymethyl]benzonitrile, Heat Shock Protein 70 (hsp70) Inhibitors targeting HSPA2 |
| FD-85-SX37_1uM | Dose=1uM, 4-[[(2r,3s,4r,5r)-5-[6-Amino-8-[(3,4-Dichlorophenyl)methylamino]purin-9-Yl]-3,4-Dihydroxy-Oxolan-2-Yl]methoxymethyl]benzonitrile, Heat Shock Protein 70 (hsp70) Inhibitors targeting HSPA2 |
| FD-86-NE74_0.01uM | Dose=0.01uM, N-(4-Fluorobenzyl)-2-((R)-5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide, CREBBP/ EP300 KAT inhibitor targeting CREBBP, EP300 |
| FD-86-NE74_0.1uM | Dose=0.1uM, N-(4-Fluorobenzyl)-2-((R)-5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide, CREBBP/ EP300 KAT inhibitor targeting CREBBP, EP300 |
| FD-86-NE74_10uM | Dose=10uM, N-(4-Fluorobenzyl)-2-((R)-5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide, CREBBP/ EP300 KAT inhibitor targeting CREBBP, EP300 |
| FD-86-NE74_1uM | Dose=1uM, N-(4-Fluorobenzyl)-2-((R)-5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide, CREBBP/ EP300 KAT inhibitor targeting CREBBP, EP300 |
| FD-88-CF51_0.01uM | Dose=0.01uM, Obeticholic Acid, activates FXR directly in the liver and increases FGF19 hormone levels via intestinal FXR activation;Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| FD-88-CF51_0.1uM | Dose=0.1uM, Obeticholic Acid, activates FXR directly in the liver and increases FGF19 hormone levels via intestinal FXR activation;Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| FD-88-CF51_10uM | Dose=10uM, Obeticholic Acid, activates FXR directly in the liver and increases FGF19 hormone levels via intestinal FXR activation;Farnesoid X Receptor (FXR) Agonists targeting NR1H4 |
| FD-91-OK66_0.01uM | Dose=0.01uM, 2-Amino-5-thio-substituted thiazole 25, CDK2/Cyclin E Inhibitors targeting CCNE1, CDK2, CCNB2, CCNE2 |
| FD-91-OK66_0.1uM | Dose=0.1uM, 2-Amino-5-thio-substituted thiazole 25, CDK2/Cyclin E Inhibitors targeting CCNE1, CDK2, CCNB2, CCNE2 |
| FD-91-OK66_10uM | Dose=10uM, 2-Amino-5-thio-substituted thiazole 25, CDK2/Cyclin E Inhibitors targeting CCNE1, CDK2, CCNB2, CCNE2 |
| FD-91-OK66_1uM | Dose=1uM, 2-Amino-5-thio-substituted thiazole 25, CDK2/Cyclin E Inhibitors targeting CCNE1, CDK2, CCNB2, CCNE2 |
| FE-03-MI11_0.01uM | Dose=0.01uM, 1-[(4-fluorophenyl)sulfonyl]-1H-benzimidazole |
| FE-03-MI11_0.1uM | Dose=0.1uM, 1-[(4-fluorophenyl)sulfonyl]-1H-benzimidazole |
| FE-03-MI11_10uM | Dose=10uM, 1-[(4-fluorophenyl)sulfonyl]-1H-benzimidazole |
| FE-03-MI11_1uM | Dose=1uM, 1-[(4-fluorophenyl)sulfonyl]-1H-benzimidazole |
| FE-06-GR60_0.01uM | Dose=0.01uM, 1-benzyl-4-[(3R)-4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl]phthalazine-6-carbonitrile, S1P lyase inhibitor targeting SGPL1 |
| FE-06-GR60_0.1uM | Dose=0.1uM, 1-benzyl-4-[(3R)-4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl]phthalazine-6-carbonitrile, S1P lyase inhibitor targeting SGPL1 |
| FE-06-GR60_10uM | Dose=10uM, 1-benzyl-4-[(3R)-4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl]phthalazine-6-carbonitrile, S1P lyase inhibitor targeting SGPL1 |
| FE-06-GR60_1uM | Dose=1uM, 1-benzyl-4-[(3R)-4-(5-cyanopyridin-2-yl)-3-methylpiperazin-1-yl]phthalazine-6-carbonitrile, S1P lyase inhibitor targeting SGPL1 |
| FE-09-JD34_0.01uM | Dose=0.01uM, Dot1L-IN-5 |
| FE-09-JD34_0.1uM | Dose=0.1uM, Dot1L-IN-5 |
| FE-09-JD34_10uM | Dose=10uM, Dot1L-IN-5 |
| FE-09-JD34_1uM | Dose=1uM, Dot1L-IN-5 |
| FE-10-KQ78_0.01uM | Dose=0.01uM, Borrelidin G, angiogenesis inhibitor;Translation inhibitor;TARS inhibitor targeting TARS1 |
| FE-10-KQ78_0.1uM | Dose=0.1uM, Borrelidin G, angiogenesis inhibitor;Translation inhibitor;TARS inhibitor targeting TARS1 |
| FE-10-KQ78_10uM | Dose=10uM, Borrelidin G, angiogenesis inhibitor;Translation inhibitor;TARS inhibitor targeting TARS1 |
| FE-10-KQ78_1uM | Dose=1uM, Borrelidin G, angiogenesis inhibitor;Translation inhibitor;TARS inhibitor targeting TARS1 |
| FE-12-TO68_0.01uM | Dose=0.01uM |
| FE-12-TO68_0.1uM | Dose=0.1uM |
| FE-12-TO68_10uM | Dose=10uM |
| FE-12-TO68_1uM | Dose=1uM |
| FE-16-UK58_0.01uM | Dose=0.01uM, 1-(6-Methylergolin-8beta-ylmethyl)-1,2,4-triazole, Dopamine D2 Agonists;Dopamine D1 Agonists targeting DRD1, DRD2 |
| FE-16-UK58_0.1uM | Dose=0.1uM, 1-(6-Methylergolin-8beta-ylmethyl)-1,2,4-triazole, Dopamine D2 Agonists;Dopamine D1 Agonists targeting DRD1, DRD2 |
| FE-16-UK58_10uM | Dose=10uM, 1-(6-Methylergolin-8beta-ylmethyl)-1,2,4-triazole, Dopamine D2 Agonists;Dopamine D1 Agonists targeting DRD1, DRD2 |
| FE-16-UK58_1uM | Dose=1uM, 1-(6-Methylergolin-8beta-ylmethyl)-1,2,4-triazole, Dopamine D2 Agonists;Dopamine D1 Agonists targeting DRD1, DRD2 |
| FE-18-SS57_0.01uM | Dose=0.01uM, CID 6993119, Calpain Inhibitors targeting CAPN1 |
| FE-18-SS57_0.1uM | Dose=0.1uM, CID 6993119, Calpain Inhibitors targeting CAPN1 |
| FE-18-SS57_1uM | Dose=1uM, CID 6993119, Calpain Inhibitors targeting CAPN1 |
| FE-19-OW54_0.01uM | Dose=0.01uM, Fenofibric Acid |
| FE-19-OW54_0.1uM | Dose=0.1uM, Fenofibric Acid |
| FE-19-OW54_10uM | Dose=10uM, Fenofibric Acid |
| FE-19-OW54_1uM | Dose=1uM, Fenofibric Acid |
| FE-19-SC91_0.01uM | Dose=0.01uM, 1-Benzenesulfonyl-5-(4-methylpiperazin-1-yl-methyl)-1H-indole, 5-HT6 Receptor Ligands targeting HTR6 |
| FE-19-SC91_0.1uM | Dose=0.1uM, 1-Benzenesulfonyl-5-(4-methylpiperazin-1-yl-methyl)-1H-indole, 5-HT6 Receptor Ligands targeting HTR6 |
| FE-19-SC91_1uM | Dose=1uM, 1-Benzenesulfonyl-5-(4-methylpiperazin-1-yl-methyl)-1H-indole, 5-HT6 Receptor Ligands targeting HTR6 |
| FE-21-KA32_0.01uM | Dose=0.01uM, Brl 55834 |
| FE-21-KA32_0.1uM | Dose=0.1uM, Brl 55834 |
| FE-21-KA32_1uM | Dose=1uM, Brl 55834 |
| FE-21-KA82_0.01uM | Dose=0.01uM, (2R)-N~4~-hydroxy-2-(3-hydroxybenzyl)-N~1~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide, Aggrecanase Inhibitors targeting ADAMTS4, ADAMTS5 |
| FE-21-KA82_0.1uM | Dose=0.1uM, (2R)-N~4~-hydroxy-2-(3-hydroxybenzyl)-N~1~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide, Aggrecanase Inhibitors targeting ADAMTS4, ADAMTS5 |
| FE-21-KA82_10uM | Dose=10uM, (2R)-N~4~-hydroxy-2-(3-hydroxybenzyl)-N~1~-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide, Aggrecanase Inhibitors targeting ADAMTS4, ADAMTS5 |
| FE-22-JV50_0.01uM | Dose=0.01uM, (1R,3S,5R)-2-[2-(1-acetylimidazo[1,5-a]pyridin-3-yl)acetyl]-N-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide, Known FactorD inhibitor targeting CFD |
| FE-22-JV50_0.1uM | Dose=0.1uM, (1R,3S,5R)-2-[2-(1-acetylimidazo[1,5-a]pyridin-3-yl)acetyl]-N-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide, Known FactorD inhibitor targeting CFD |
| FE-22-JV50_10uM | Dose=10uM, (1R,3S,5R)-2-[2-(1-acetylimidazo[1,5-a]pyridin-3-yl)acetyl]-N-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide, Known FactorD inhibitor targeting CFD |
| FE-22-JV50_1uM | Dose=1uM, (1R,3S,5R)-2-[2-(1-acetylimidazo[1,5-a]pyridin-3-yl)acetyl]-N-[(3-chloro-2-fluorophenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide, Known FactorD inhibitor targeting CFD |
| FE-23-WP33_0.01uM | Dose=0.01uM, (2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-(2,3-dihydro-1H-inden-2-yl)-N-[(2-fluoro-3-hydroxyphenyl)methyl]propanamide, C5AR1 antagonist targeting C5AR1 |
| FE-23-WP33_0.1uM | Dose=0.1uM, (2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-(2,3-dihydro-1H-inden-2-yl)-N-[(2-fluoro-3-hydroxyphenyl)methyl]propanamide, C5AR1 antagonist targeting C5AR1 |
| FE-23-WP33_10uM | Dose=10uM, (2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-(2,3-dihydro-1H-inden-2-yl)-N-[(2-fluoro-3-hydroxyphenyl)methyl]propanamide, C5AR1 antagonist targeting C5AR1 |
| FE-23-WP33_1uM | Dose=1uM, (2S)-2-[(1R)-1-(2-chlorophenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-(2,3-dihydro-1H-inden-2-yl)-N-[(2-fluoro-3-hydroxyphenyl)methyl]propanamide, C5AR1 antagonist targeting C5AR1 |
| FE-25-GD89_0.01uM | Dose=0.01uM |
| FE-25-GD89_0.1uM | Dose=0.1uM |
| FE-25-GD89_10uM | Dose=10uM |
| FE-25-GD89_1uM | Dose=1uM |
| FE-26-GO83_0.1uM | Dose=0.1uM, methyl 2-[5-[(Z)-(3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]benzoate |
| FE-26-GO83_10uM | Dose=10uM, methyl 2-[5-[(Z)-(3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]benzoate |
| FE-26-GO83_1uM | Dose=1uM, methyl 2-[5-[(Z)-(3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]benzoate |
| FE-27-XB49_0.1uM | Dose=0.1uM, Telcagepant, CGRP antagonist;Calcitonin gene peptide ligand inhibitor targeting CALCA, CALCB, CALCRL, RAMP1, CRCP |
| FE-27-XB49_10uM | Dose=10uM, Telcagepant, CGRP antagonist;Calcitonin gene peptide ligand inhibitor targeting CALCA, CALCB, CALCRL, RAMP1, CRCP |
| FE-27-XB49_1uM | Dose=1uM, Telcagepant, CGRP antagonist;Calcitonin gene peptide ligand inhibitor targeting CALCA, CALCB, CALCRL, RAMP1, CRCP |
| FE-29-HC66_0.01uM | Dose=0.01uM, Pkf-242-484, MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP3, MMP9, MMP13, ADAM17 |
| FE-29-HC66_0.1uM | Dose=0.1uM, Pkf-242-484, MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP3, MMP9, MMP13, ADAM17 |
| FE-29-HC66_10uM | Dose=10uM, Pkf-242-484, MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP3, MMP9, MMP13, ADAM17 |
| FE-29-HC66_1uM | Dose=1uM, Pkf-242-484, MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting MMP1, MMP2, MMP3, MMP9, MMP13, ADAM17 |
| FE-29-XM40_0.01uM | Dose=0.01uM, N-Tert-Butyl-1-(1-{5-[5-(Trifluoromethyl)-1,3,4-Oxadiazol-2-Yl]pyridin-2-Yl}piperidin-4-Yl)-1h-Imidazole-5-Carboxamide, WNK1/2/3/4 inhibitor;WNK1 gene inhibitor targeting WNK1, WNK4, WNK3, WNK2 |
| FE-29-XM40_0.1uM | Dose=0.1uM, N-Tert-Butyl-1-(1-{5-[5-(Trifluoromethyl)-1,3,4-Oxadiazol-2-Yl]pyridin-2-Yl}piperidin-4-Yl)-1h-Imidazole-5-Carboxamide, WNK1/2/3/4 inhibitor;WNK1 gene inhibitor targeting WNK1, WNK4, WNK3, WNK2 |
| FE-29-XM40_10uM | Dose=10uM, N-Tert-Butyl-1-(1-{5-[5-(Trifluoromethyl)-1,3,4-Oxadiazol-2-Yl]pyridin-2-Yl}piperidin-4-Yl)-1h-Imidazole-5-Carboxamide, WNK1/2/3/4 inhibitor;WNK1 gene inhibitor targeting WNK1, WNK4, WNK3, WNK2 |
| FE-29-XM40_1uM | Dose=1uM, N-Tert-Butyl-1-(1-{5-[5-(Trifluoromethyl)-1,3,4-Oxadiazol-2-Yl]pyridin-2-Yl}piperidin-4-Yl)-1h-Imidazole-5-Carboxamide, WNK1/2/3/4 inhibitor;WNK1 gene inhibitor targeting WNK1, WNK4, WNK3, WNK2 |
| FE-31-JU80_0.01uM | Dose=0.01uM, alpha-Amino-2-(2-phosphonoethyl)cyclohexanepropanoic acid |
| FE-31-JU80_0.1uM | Dose=0.1uM, alpha-Amino-2-(2-phosphonoethyl)cyclohexanepropanoic acid |
| FE-31-JU80_10uM | Dose=10uM, alpha-Amino-2-(2-phosphonoethyl)cyclohexanepropanoic acid |
| FE-31-JU80_1uM | Dose=1uM, alpha-Amino-2-(2-phosphonoethyl)cyclohexanepropanoic acid |
| FE-36-JU27_0.01uM | Dose=0.01uM, 4-ethyl-3-(3-methoxypropoxy)-N-[[(3S,4S)-4-[[methyl-(2-phenylacetyl)amino]methyl]pyrrolidin-3-yl]methyl]-N-propan-2-ylbenzamide, Renin Inhibitors targeting REN |
| FE-36-JU27_10uM | Dose=10uM, 4-ethyl-3-(3-methoxypropoxy)-N-[[(3S,4S)-4-[[methyl-(2-phenylacetyl)amino]methyl]pyrrolidin-3-yl]methyl]-N-propan-2-ylbenzamide, Renin Inhibitors targeting REN |
| FE-36-JU27_1uM | Dose=1uM, 4-ethyl-3-(3-methoxypropoxy)-N-[[(3S,4S)-4-[[methyl-(2-phenylacetyl)amino]methyl]pyrrolidin-3-yl]methyl]-N-propan-2-ylbenzamide, Renin Inhibitors targeting REN |
| FE-36-XA09_0.01uM | Dose=0.01uM, 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine, BRS3 agonist;MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting BRS3 |
| FE-36-XA09_0.1uM | Dose=0.1uM, 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine, BRS3 agonist;MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting BRS3 |
| FE-36-XA09_10uM | Dose=10uM, 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine, BRS3 agonist;MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting BRS3 |
| FE-36-XA09_1uM | Dose=1uM, 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-amine, BRS3 agonist;MMP-13 (Collagenase 3) Inhibitors;MMP-1 (Interstitial Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;ADAM17 (TNF-alpha-Converting Enzyme (TACE) Inhibitors);MMP-3 (Stromelysin 1) Inhibitors;MMP-2 (Gelatinase A) Inhibitors targeting BRS3 |
| FE-37-OL13_0.01uM | Dose=0.01uM, Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes;Pharmacological Chaperones targeting GLA |
| FE-37-OL13_0.1uM | Dose=0.1uM, Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes;Pharmacological Chaperones targeting GLA |
| FE-37-OL13_10uM | Dose=10uM, Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes;Pharmacological Chaperones targeting GLA |
| FE-37-OL13_1uM | Dose=1uM, Migalastat, an oral pharmacologic chaperone, stabilizes specific mutant forms of α-galactosidase, increasing enzyme trafficking to lysosomes;Pharmacological Chaperones targeting GLA |
| FE-37-OS90_0.01uM | Dose=0.01uM, 6-[(3-Aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5h-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one, Pyruvate kinase 2 stimulator targeting PKM |
| FE-37-OS90_0.1uM | Dose=0.1uM, 6-[(3-Aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5h-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one, Pyruvate kinase 2 stimulator targeting PKM |
| FE-37-OS90_10uM | Dose=10uM, 6-[(3-Aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5h-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one, Pyruvate kinase 2 stimulator targeting PKM |
| FE-37-OS90_1uM | Dose=1uM, 6-[(3-Aminophenyl)methyl]-4,6-dihydro-4-methyl-2-(methylsulfinyl)-5h-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one, Pyruvate kinase 2 stimulator targeting PKM |
| FE-39-LJ73_0.01uM | Dose=0.01uM |
| FE-39-LJ73_0.1uM | Dose=0.1uM |
| FE-39-LJ73_1uM | Dose=1uM |
| FE-48-QP65_0.01uM | Dose=0.01uM, Iralukast, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Antagonists targeting CYSLTR1 |
| FE-48-QP65_10uM | Dose=10uM, Iralukast, Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Antagonists targeting CYSLTR1 |
| FE-49-VJ28_0.01uM | Dose=0.01uM, Tandospirone, 5-HT1A Receptor Agonists targeting HTR1A |
| FE-49-VJ28_0.1uM | Dose=0.1uM, Tandospirone, 5-HT1A Receptor Agonists targeting HTR1A |
| FE-49-VJ28_10uM | Dose=10uM, Tandospirone, 5-HT1A Receptor Agonists targeting HTR1A |
| FE-49-VJ28_1uM | Dose=1uM, Tandospirone, 5-HT1A Receptor Agonists targeting HTR1A |
| FE-49-ZJ78_0.01uM | Dose=0.01uM |
| FE-49-ZJ78_0.1uM | Dose=0.1uM |
| FE-49-ZJ78_10uM | Dose=10uM |
| FE-49-ZJ78_1uM | Dose=1uM |
| FE-56-PV35_0.01uM | Dose=0.01uM, 4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline, Activin Receptor Like Kinase 3 (ALK3 BMPR-IA) Inhibitors;Activin Receptor Like Kinase 2 (ALK2 ActR-IA) Inhibitors targeting ACVR1, BMPR1A, BMPR1B |
| FE-56-PV35_0.1uM | Dose=0.1uM, 4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline, Activin Receptor Like Kinase 3 (ALK3 BMPR-IA) Inhibitors;Activin Receptor Like Kinase 2 (ALK2 ActR-IA) Inhibitors targeting ACVR1, BMPR1A, BMPR1B |
| FE-56-PV35_10uM | Dose=10uM, 4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline, Activin Receptor Like Kinase 3 (ALK3 BMPR-IA) Inhibitors;Activin Receptor Like Kinase 2 (ALK2 ActR-IA) Inhibitors targeting ACVR1, BMPR1A, BMPR1B |
| FE-56-PV35_1uM | Dose=1uM, 4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline, Activin Receptor Like Kinase 3 (ALK3 BMPR-IA) Inhibitors;Activin Receptor Like Kinase 2 (ALK2 ActR-IA) Inhibitors targeting ACVR1, BMPR1A, BMPR1B |
| FE-58-ES32_0.01uM | Dose=0.01uM, N-(4-Fluorophenyl)-4-phenyl-1,3-thiazol-2-amine |
| FE-58-ES32_0.1uM | Dose=0.1uM, N-(4-Fluorophenyl)-4-phenyl-1,3-thiazol-2-amine |
| FE-58-ES32_10uM | Dose=10uM, N-(4-Fluorophenyl)-4-phenyl-1,3-thiazol-2-amine |
| FE-58-ES32_1uM | Dose=1uM, N-(4-Fluorophenyl)-4-phenyl-1,3-thiazol-2-amine |
| FE-59-BC81_0.01uM | Dose=0.01uM, L-365260, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR |
| FE-59-BC81_0.1uM | Dose=0.1uM, L-365260, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR |
| FE-59-BC81_10uM | Dose=10uM, L-365260, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR |
| FE-59-BC81_1uM | Dose=1uM, L-365260, CCK2 (CCKB/Gastrin) Antagonists targeting CCKBR |
| FE-61-DL94_0.01uM | Dose=0.01uM |
| FE-61-DL94_0.1uM | Dose=0.1uM |
| FE-61-DL94_10uM | Dose=10uM |
| FE-61-DL94_1uM | Dose=1uM |
| FE-64-KC49_0.01uM | Dose=0.01uM, Carvedilol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| FE-64-KC49_0.1uM | Dose=0.1uM, Carvedilol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| FE-64-KC49_10uM | Dose=10uM, Carvedilol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| FE-64-KC49_1uM | Dose=1uM, Carvedilol, beta1-Adrenoceptor Antagonists targeting ADRB1 |
| FE-67-IO55_0.01uM | Dose=0.01uM, 3-[3-(4,7-Diazaspiro[2.5]octan-7-yl)isoquinolin-1-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione targeting PRKCQ |
| FE-68-DZ79_0.01uM | Dose=0.01uM, N-benzylaminosulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2 |
| FE-68-DZ79_0.1uM | Dose=0.1uM, N-benzylaminosulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2 |
| FE-68-DZ79_1uM | Dose=1uM, N-benzylaminosulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2 |
| FE-69-HJ93_0.01uM | Dose=0.01uM, 2-((6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino)ethan-1-ol, CDC42 Rho GTPase inhibitor targeting CDC42 |
| FE-69-HJ93_0.1uM | Dose=0.1uM, 2-((6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino)ethan-1-ol, CDC42 Rho GTPase inhibitor targeting CDC42 |
| FE-69-HJ93_10uM | Dose=10uM, 2-((6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino)ethan-1-ol, CDC42 Rho GTPase inhibitor targeting CDC42 |
| FE-69-HJ93_1uM | Dose=1uM, 2-((6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino)ethan-1-ol, CDC42 Rho GTPase inhibitor targeting CDC42 |
| FE-72-KZ75_0.01uM | Dose=0.01uM, ethyl 4-(5-acrylamido-2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate, irreversible covalent inhibitor of JAK3 targeting JAK3 |
| FE-72-KZ75_0.1uM | Dose=0.1uM, ethyl 4-(5-acrylamido-2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate, irreversible covalent inhibitor of JAK3 targeting JAK3 |
| FE-72-KZ75_10uM | Dose=10uM, ethyl 4-(5-acrylamido-2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate, irreversible covalent inhibitor of JAK3 targeting JAK3 |
| FE-72-KZ75_1uM | Dose=1uM, ethyl 4-(5-acrylamido-2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxylate, irreversible covalent inhibitor of JAK3 targeting JAK3 |
| FE-73-PS05_0.01uM | Dose=0.01uM, N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-benzodioxole-5-carboxamide, TAS1R1 gene antagonist targeting TAS1R1 |
| FE-73-PS05_0.1uM | Dose=0.1uM, N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-benzodioxole-5-carboxamide, TAS1R1 gene antagonist targeting TAS1R1 |
| FE-73-PS05_10uM | Dose=10uM, N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-benzodioxole-5-carboxamide, TAS1R1 gene antagonist targeting TAS1R1 |
| FE-73-PS05_1uM | Dose=1uM, N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,3-benzodioxole-5-carboxamide, TAS1R1 gene antagonist targeting TAS1R1 |
| FE-75-VG41_0.01uM | Dose=0.01uM, Muscarinic M3 Antagonists targeting CHRM3 |
| FE-75-VG41_0.1uM | Dose=0.1uM, Muscarinic M3 Antagonists targeting CHRM3 |
| FE-75-VG41_10uM | Dose=10uM, Muscarinic M3 Antagonists targeting CHRM3 |
| FE-75-VG41_1uM | Dose=1uM, Muscarinic M3 Antagonists targeting CHRM3 |
| FE-76-CA29_0.01uM | Dose=0.01uM, Gnf-2, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2 |
| FE-76-CA29_0.1uM | Dose=0.1uM, Gnf-2, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2 |
| FE-76-CA29_10uM | Dose=10uM, Gnf-2, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2 |
| FE-76-CA29_1uM | Dose=1uM, Gnf-2, Inhibitors of Signal Transduction Pathways;Bcr-Abl Kinase Inhibitors targeting ABL1, ABL2 |
| FE-82-JV20_0.01uM | Dose=0.01uM, 3-(4-Chlorophenyl)-1-(1-methyl-3-oxo-2-phenyl-5-propan-2-ylpyrazol-4-yl)urea, FPR1 agonist;FPR2 agonist targeting FPR1, FPR2 |
| FE-82-JV20_0.1uM | Dose=0.1uM, 3-(4-Chlorophenyl)-1-(1-methyl-3-oxo-2-phenyl-5-propan-2-ylpyrazol-4-yl)urea, FPR1 agonist;FPR2 agonist targeting FPR1, FPR2 |
| FE-82-JV20_10uM | Dose=10uM, 3-(4-Chlorophenyl)-1-(1-methyl-3-oxo-2-phenyl-5-propan-2-ylpyrazol-4-yl)urea, FPR1 agonist;FPR2 agonist targeting FPR1, FPR2 |
| FE-82-JV20_1uM | Dose=1uM, 3-(4-Chlorophenyl)-1-(1-methyl-3-oxo-2-phenyl-5-propan-2-ylpyrazol-4-yl)urea, FPR1 agonist;FPR2 agonist targeting FPR1, FPR2 |
| FE-82-MY37_0.01uM | Dose=0.01uM, 1-Isopropyl-1H-benzoimidazole-5-carboxylic acid |
| FE-82-MY37_0.1uM | Dose=0.1uM, 1-Isopropyl-1H-benzoimidazole-5-carboxylic acid |
| FE-82-MY37_10uM | Dose=10uM, 1-Isopropyl-1H-benzoimidazole-5-carboxylic acid |
| FE-82-MY37_1uM | Dose=1uM, 1-Isopropyl-1H-benzoimidazole-5-carboxylic acid |
| FE-82-WB22_0.01uM | Dose=0.01uM, MRT67307 HCl targeting ULK1 |
| FE-82-WB22_0.1uM | Dose=0.1uM, MRT67307 HCl targeting ULK1 |
| FE-82-WB22_10uM | Dose=10uM, MRT67307 HCl targeting ULK1 |
| FE-82-WB22_1uM | Dose=1uM, MRT67307 HCl targeting ULK1 |
| FE-92-ZL16_0.01uM | Dose=0.01uM, Unc3866, CBX and CDY Kme inhibitor;CDX4 gene inhibitor targeting CBX4, CBX7, CDYL2 |
| FE-92-ZL16_0.1uM | Dose=0.1uM, Unc3866, CBX and CDY Kme inhibitor;CDX4 gene inhibitor targeting CBX4, CBX7, CDYL2 |
| FE-92-ZL16_10uM | Dose=10uM, Unc3866, CBX and CDY Kme inhibitor;CDX4 gene inhibitor targeting CBX4, CBX7, CDYL2 |
| FE-92-ZL16_1uM | Dose=1uM, Unc3866, CBX and CDY Kme inhibitor;CDX4 gene inhibitor targeting CBX4, CBX7, CDYL2 |
| FE-94-NQ13_0.01uM | Dose=0.01uM, Tirasemtiv targeting TNNI2, TNNT3 |
| FE-94-NQ13_0.1uM | Dose=0.1uM, Tirasemtiv targeting TNNI2, TNNT3 |
| FE-94-NQ13_1uM | Dose=1uM, Tirasemtiv targeting TNNI2, TNNT3 |
| FE-94-WT30_0.01uM | Dose=0.01uM, Denufosol, Mucin Production, Enhancers;P2Y2 Agonists targeting P2RY2 |
| FE-94-WT30_0.1uM | Dose=0.1uM, Denufosol, Mucin Production, Enhancers;P2Y2 Agonists targeting P2RY2 |
| FE-94-WT30_10uM | Dose=10uM, Denufosol, Mucin Production, Enhancers;P2Y2 Agonists targeting P2RY2 |
| FE-94-WT30_1uM | Dose=1uM, Denufosol, Mucin Production, Enhancers;P2Y2 Agonists targeting P2RY2 |
| FE-95-PU35_0.01uM | Dose=0.01uM, 4-(2-(4-Chlorophenyl)-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-amine |
| FE-95-PU35_0.1uM | Dose=0.1uM, 4-(2-(4-Chlorophenyl)-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-amine |
| FE-95-PU35_10uM | Dose=10uM, 4-(2-(4-Chlorophenyl)-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-amine |
| FE-95-PU35_1uM | Dose=1uM, 4-(2-(4-Chlorophenyl)-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-amine |
| FE-99-RJ28_0.01uM | Dose=0.01uM, (S)-2-amino-N-(3-(5-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)propanamide, CARM1 inhibitor;CARM1 / PRMT4 inhbitor targeting CARM1 |
| FE-99-RJ28_0.1uM | Dose=0.1uM, (S)-2-amino-N-(3-(5-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)propanamide, CARM1 inhibitor;CARM1 / PRMT4 inhbitor targeting CARM1 |
| FE-99-RJ28_10uM | Dose=10uM, (S)-2-amino-N-(3-(5-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)propanamide, CARM1 inhibitor;CARM1 / PRMT4 inhbitor targeting CARM1 |
| FE-99-RJ28_1uM | Dose=1uM, (S)-2-amino-N-(3-(5-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)propanamide, CARM1 inhibitor;CARM1 / PRMT4 inhbitor targeting CARM1 |
| FF-01-OH44_0.01uM | Dose=0.01uM, 2-Methyl-4-[(2,3,6-trichlorophenyl)methylamino]quinoline-8-carboxamide, CD38 inhibitor targeting CD38 |
| FF-01-OH44_0.1uM | Dose=0.1uM, 2-Methyl-4-[(2,3,6-trichlorophenyl)methylamino]quinoline-8-carboxamide, CD38 inhibitor targeting CD38 |
| FF-01-OH44_10uM | Dose=10uM, 2-Methyl-4-[(2,3,6-trichlorophenyl)methylamino]quinoline-8-carboxamide, CD38 inhibitor targeting CD38 |
| FF-01-OH44_1uM | Dose=1uM, 2-Methyl-4-[(2,3,6-trichlorophenyl)methylamino]quinoline-8-carboxamide, CD38 inhibitor targeting CD38 |
| FF-06-MA64_0.01uM | Dose=0.01uM, Cgp 37157, SERCA Inhibitors;Na+/Ca2+ Exchanger (NCX) Inhibitors targeting ATP2A1, SLC8A2, SLC8A1 |
| FF-06-MA64_0.1uM | Dose=0.1uM, Cgp 37157, SERCA Inhibitors;Na+/Ca2+ Exchanger (NCX) Inhibitors targeting ATP2A1, SLC8A2, SLC8A1 |
| FF-06-MA64_10uM | Dose=10uM, Cgp 37157, SERCA Inhibitors;Na+/Ca2+ Exchanger (NCX) Inhibitors targeting ATP2A1, SLC8A2, SLC8A1 |
| FF-06-MA64_1uM | Dose=1uM, Cgp 37157, SERCA Inhibitors;Na+/Ca2+ Exchanger (NCX) Inhibitors targeting ATP2A1, SLC8A2, SLC8A1 |
| FF-06-MO73_0.01uM | Dose=0.01uM, Vorinostat, Apoptosis Inducers;Histone Deacetylase 3 (HDAC3) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10, STAT3 |
| FF-06-MO73_0.1uM | Dose=0.1uM, Vorinostat, Apoptosis Inducers;Histone Deacetylase 3 (HDAC3) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10, STAT3 |
| FF-06-MO73_10uM | Dose=10uM, Vorinostat, Apoptosis Inducers;Histone Deacetylase 3 (HDAC3) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10, STAT3 |
| FF-06-MO73_1uM | Dose=1uM, Vorinostat, Apoptosis Inducers;Histone Deacetylase 3 (HDAC3) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors;HDACs;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Inhibitor targeting HDAC1, HDAC2, HDAC3, HDAC9, HDAC6, HDAC5, HDAC7, HDAC8, HDAC11, HDAC10, STAT3 |
| FF-07-FL63_0.01uM | Dose=0.01uM, Clopidogrel, P2Y12 (P2T) Antagonists targeting P2RY12 |
| FF-07-FL63_0.1uM | Dose=0.1uM, Clopidogrel, P2Y12 (P2T) Antagonists targeting P2RY12 |
| FF-07-FL63_10uM | Dose=10uM, Clopidogrel, P2Y12 (P2T) Antagonists targeting P2RY12 |
| FF-07-FL63_1uM | Dose=1uM, Clopidogrel, P2Y12 (P2T) Antagonists targeting P2RY12 |
| FF-08-DP35_0.01uM | Dose=0.01uM, Filorexant, Orexin 1 receptor antagonist, Orexin 2 receptor antagonist targeting HCRTR1, HCRTR2 |
| FF-08-DP35_0.1uM | Dose=0.1uM, Filorexant, Orexin 1 receptor antagonist, Orexin 2 receptor antagonist targeting HCRTR1, HCRTR2 |
| FF-08-DP35_10uM | Dose=10uM, Filorexant, Orexin 1 receptor antagonist, Orexin 2 receptor antagonist targeting HCRTR1, HCRTR2 |
| FF-08-DP35_1uM | Dose=1uM, Filorexant, Orexin 1 receptor antagonist, Orexin 2 receptor antagonist targeting HCRTR1, HCRTR2 |
| FF-10-JX55_0.01uM | Dose=0.01uM |
| FF-10-JX55_0.1uM | Dose=0.1uM |
| FF-10-JX55_10uM | Dose=10uM |
| FF-10-JX55_1uM | Dose=1uM |
| FF-14-JG89_0.01uM | Dose=0.01uM, LY 181984, Tumor NADH Oxidase (tNOX) Inhibitors targeting ENOX2 |
| FF-14-JG89_0.1uM | Dose=0.1uM, LY 181984, Tumor NADH Oxidase (tNOX) Inhibitors targeting ENOX2 |
| FF-14-JG89_10uM | Dose=10uM, LY 181984, Tumor NADH Oxidase (tNOX) Inhibitors targeting ENOX2 |
| FF-14-JG89_1uM | Dose=1uM, LY 181984, Tumor NADH Oxidase (tNOX) Inhibitors targeting ENOX2 |
| FF-22-NB12_0.01uM | Dose=0.01uM, 4-(1,3-Benzothiazol-2-yl)-2-methylaniline, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR |
| FF-22-NB12_0.1uM | Dose=0.1uM, 4-(1,3-Benzothiazol-2-yl)-2-methylaniline, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR |
| FF-22-NB12_10uM | Dose=10uM, 4-(1,3-Benzothiazol-2-yl)-2-methylaniline, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR |
| FF-22-NB12_1uM | Dose=1uM, 4-(1,3-Benzothiazol-2-yl)-2-methylaniline, Aryl Hydrocarbon Receptor (AhR) Agonists targeting AHR |
| FF-28-ES17_0.01uM | Dose=0.01uM, (1R,2R,3E,7S,11Z,13S,15S)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-one |
| FF-28-ES17_0.1uM | Dose=0.1uM, (1R,2R,3E,7S,11Z,13S,15S)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-one |
| FF-28-ES17_10uM | Dose=10uM, (1R,2R,3E,7S,11Z,13S,15S)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-one |
| FF-28-ES17_1uM | Dose=1uM, (1R,2R,3E,7S,11Z,13S,15S)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-one |
| FF-31-BR08_0.01uM | Dose=0.01uM, 4-(4-Chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)thiazole, Histone N-Acetyltransferase (HAT) Inhibitors targeting KAT2A, HAT1 |
| FF-31-BR08_0.1uM | Dose=0.1uM, 4-(4-Chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)thiazole, Histone N-Acetyltransferase (HAT) Inhibitors targeting KAT2A, HAT1 |
| FF-31-BR08_10uM | Dose=10uM, 4-(4-Chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)thiazole, Histone N-Acetyltransferase (HAT) Inhibitors targeting KAT2A, HAT1 |
| FF-31-BR08_1uM | Dose=1uM, 4-(4-Chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)thiazole, Histone N-Acetyltransferase (HAT) Inhibitors targeting KAT2A, HAT1 |
| FF-32-LL81_0.01uM | Dose=0.01uM, 1-benzyl-1 H-pyrazole-4-carboxylic acid 4-carbamimidoyl-benzylamide, KLKB1) Inhibitors;Kallikrein B (Plasma Kallikrein targeting KLKB1 |
| FF-32-LL81_0.1uM | Dose=0.1uM, 1-benzyl-1 H-pyrazole-4-carboxylic acid 4-carbamimidoyl-benzylamide, KLKB1) Inhibitors;Kallikrein B (Plasma Kallikrein targeting KLKB1 |
| FF-32-LL81_10uM | Dose=10uM, 1-benzyl-1 H-pyrazole-4-carboxylic acid 4-carbamimidoyl-benzylamide, KLKB1) Inhibitors;Kallikrein B (Plasma Kallikrein targeting KLKB1 |
| FF-34-KW62_0.01uM | Dose=0.01uM, 6-(3-Chlorophenyl)-3-[3-[4-(diethylamino)piperidin-1-yl]phenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine |
| FF-34-KW62_0.1uM | Dose=0.1uM, 6-(3-Chlorophenyl)-3-[3-[4-(diethylamino)piperidin-1-yl]phenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine |
| FF-34-KW62_10uM | Dose=10uM, 6-(3-Chlorophenyl)-3-[3-[4-(diethylamino)piperidin-1-yl]phenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine |
| FF-34-KW62_1uM | Dose=1uM, 6-(3-Chlorophenyl)-3-[3-[4-(diethylamino)piperidin-1-yl]phenyl]-5-methylpyrazolo[1,5-a]pyrimidin-7-amine |
| FF-35-JG06_0.01uM | Dose=0.01uM, Tirilazad, Nitric Oxide Synthase Inhibitors;Lipid Peroxidation Inhibitors targeting NOS1 |
| FF-35-JG06_0.1uM | Dose=0.1uM, Tirilazad, Nitric Oxide Synthase Inhibitors;Lipid Peroxidation Inhibitors targeting NOS1 |
| FF-35-JG06_10uM | Dose=10uM, Tirilazad, Nitric Oxide Synthase Inhibitors;Lipid Peroxidation Inhibitors targeting NOS1 |
| FF-35-JG06_1uM | Dose=1uM, Tirilazad, Nitric Oxide Synthase Inhibitors;Lipid Peroxidation Inhibitors targeting NOS1 |
| FF-46-CU92_0.01uM | Dose=0.01uM |
| FF-46-CU92_0.1uM | Dose=0.1uM |
| FF-46-CU92_10uM | Dose=10uM |
| FF-46-CU92_1uM | Dose=1uM |
| FF-46-IE04_0.01uM | Dose=0.01uM, 4-nitrophenyl 4-[bis(2H-1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-carboxylate, Monoglyceride lipase inhibitor;Monoacylglycerol Lipase Inhibitors targeting MGLL |
| FF-46-IE04_10uM | Dose=10uM, 4-nitrophenyl 4-[bis(2H-1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-carboxylate, Monoglyceride lipase inhibitor;Monoacylglycerol Lipase Inhibitors targeting MGLL |
| FF-46-IE04_1uM | Dose=1uM, 4-nitrophenyl 4-[bis(2H-1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-carboxylate, Monoglyceride lipase inhibitor;Monoacylglycerol Lipase Inhibitors targeting MGLL |
| FF-46-OR35_0.01uM | Dose=0.01uM, (S)-3-(2-Methoxy-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| FF-46-OR35_0.1uM | Dose=0.1uM, (S)-3-(2-Methoxy-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| FF-46-OR35_10uM | Dose=10uM, (S)-3-(2-Methoxy-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| FF-46-OR35_1uM | Dose=1uM, (S)-3-(2-Methoxy-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid, Integrin alpha-V/beta-3 antagonist, Integrin alpha-V/beta-5 antagonist targeting ITGAV, ITGB3, ITGB5 |
| FF-54-JC89_0.01uM | Dose=0.01uM, 2-[2-(3,4-dichlorophenyl)ethyl]-1-[(E)-(5-hydroxy-1H-indol-3-yl)methylideneamino]guanidine |
| FF-54-JC89_0.1uM | Dose=0.1uM, 2-[2-(3,4-dichlorophenyl)ethyl]-1-[(E)-(5-hydroxy-1H-indol-3-yl)methylideneamino]guanidine |
| FF-54-JC89_10uM | Dose=10uM, 2-[2-(3,4-dichlorophenyl)ethyl]-1-[(E)-(5-hydroxy-1H-indol-3-yl)methylideneamino]guanidine |
| FF-54-JC89_1uM | Dose=1uM, 2-[2-(3,4-dichlorophenyl)ethyl]-1-[(E)-(5-hydroxy-1H-indol-3-yl)methylideneamino]guanidine |
| FF-55-AD09_0.01uM | Dose=0.01uM, 7alpha,25-Dihydroxycholesterol, GPR183 agonist;GPR183 activator;GPR183 Agonist targeting GPR183 |
| FF-55-AD09_0.1uM | Dose=0.1uM, 7alpha,25-Dihydroxycholesterol, GPR183 agonist;GPR183 activator;GPR183 Agonist targeting GPR183 |
| FF-55-AD09_10uM | Dose=10uM, 7alpha,25-Dihydroxycholesterol, GPR183 agonist;GPR183 activator;GPR183 Agonist targeting GPR183 |
| FF-55-AD09_1uM | Dose=1uM, 7alpha,25-Dihydroxycholesterol, GPR183 agonist;GPR183 activator;GPR183 Agonist targeting GPR183 |
| FF-59-KC06_0.01uM | Dose=0.01uM, 4-Methyl-1-{2-[1-(toluene-3-sulfonyl)-pyrrolidin-2-yl]-ethyl}-piperidine, 5-HT7 Antagonists;ADRA1B gene modulator targeting HTR7, ADRA1B |
| FF-59-KC06_0.1uM | Dose=0.1uM, 4-Methyl-1-{2-[1-(toluene-3-sulfonyl)-pyrrolidin-2-yl]-ethyl}-piperidine, 5-HT7 Antagonists;ADRA1B gene modulator targeting HTR7, ADRA1B |
| FF-59-KC06_10uM | Dose=10uM, 4-Methyl-1-{2-[1-(toluene-3-sulfonyl)-pyrrolidin-2-yl]-ethyl}-piperidine, 5-HT7 Antagonists;ADRA1B gene modulator targeting HTR7, ADRA1B |
| FF-59-KC06_1uM | Dose=1uM, 4-Methyl-1-{2-[1-(toluene-3-sulfonyl)-pyrrolidin-2-yl]-ethyl}-piperidine, 5-HT7 Antagonists;ADRA1B gene modulator targeting HTR7, ADRA1B |
| FF-60-FQ28_0.01uM | Dose=0.01uM |
| FF-60-FQ28_0.1uM | Dose=0.1uM |
| FF-60-FQ28_1uM | Dose=1uM |
| FF-61-BU95_0.1uM | Dose=0.1uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide, Angiogenesis Inhibitors;PDGFR Inhibitors targeting PDGFRA, PDGFRB |
| FF-61-BU95_10uM | Dose=10uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide, Angiogenesis Inhibitors;PDGFR Inhibitors targeting PDGFRA, PDGFRB |
| FF-61-BU95_1uM | Dose=1uM, N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide, Angiogenesis Inhibitors;PDGFR Inhibitors targeting PDGFRA, PDGFRB |
| FF-61-PA27_0.01uM | Dose=0.01uM, Pentetic Acid, Nitric Oxide Scavengers targeting PGD |
| FF-61-PA27_0.1uM | Dose=0.1uM, Pentetic Acid, Nitric Oxide Scavengers targeting PGD |
| FF-61-PA27_10uM | Dose=10uM, Pentetic Acid, Nitric Oxide Scavengers targeting PGD |
| FF-61-PA27_1uM | Dose=1uM, Pentetic Acid, Nitric Oxide Scavengers targeting PGD |
| FF-76-LK08_0.01uM | Dose=0.01uM |
| FF-76-LK08_0.1uM | Dose=0.1uM |
| FF-76-LK08_10uM | Dose=10uM |
| FF-76-LK08_1uM | Dose=1uM |
| FF-86-NH56_0.01uM | Dose=0.01uM, Thailandepsin A, HDAC inhibitor (no hydroxamic acid) targeting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 |
| FF-86-NH56_0.1uM | Dose=0.1uM, Thailandepsin A, HDAC inhibitor (no hydroxamic acid) targeting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 |
| FF-86-NH56_10uM | Dose=10uM, Thailandepsin A, HDAC inhibitor (no hydroxamic acid) targeting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 |
| FF-86-NH56_1uM | Dose=1uM, Thailandepsin A, HDAC inhibitor (no hydroxamic acid) targeting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 |
| FF-89-KK36_0.01uM | Dose=0.01uM, rac-tert-Butyl (R,E)-3-(3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)acrylamido)-3-(5-(4-((methoxycarbonyl)amino)phenyl)-6-oxo-1,6-dihydropyridazin-3-yl)propanoate, Known FactorXI inhibitor targeting F11 |
| FF-89-KK36_0.1uM | Dose=0.1uM, rac-tert-Butyl (R,E)-3-(3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)acrylamido)-3-(5-(4-((methoxycarbonyl)amino)phenyl)-6-oxo-1,6-dihydropyridazin-3-yl)propanoate, Known FactorXI inhibitor targeting F11 |
| FF-89-KK36_10uM | Dose=10uM, rac-tert-Butyl (R,E)-3-(3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)acrylamido)-3-(5-(4-((methoxycarbonyl)amino)phenyl)-6-oxo-1,6-dihydropyridazin-3-yl)propanoate, Known FactorXI inhibitor targeting F11 |
| FF-89-KK36_1uM | Dose=1uM, rac-tert-Butyl (R,E)-3-(3-(5-chloro-2-(1H-tetrazol-1-yl)phenyl)acrylamido)-3-(5-(4-((methoxycarbonyl)amino)phenyl)-6-oxo-1,6-dihydropyridazin-3-yl)propanoate, Known FactorXI inhibitor targeting F11 |
| FF-90-JK74_0.01uM | Dose=0.01uM, Guanfacine, alpha2-Adrenoceptor Agonists targeting ADRA2A |
| FF-90-JK74_0.1uM | Dose=0.1uM, Guanfacine, alpha2-Adrenoceptor Agonists targeting ADRA2A |
| FF-90-JK74_10uM | Dose=10uM, Guanfacine, alpha2-Adrenoceptor Agonists targeting ADRA2A |
| FF-90-JK74_1uM | Dose=1uM, Guanfacine, alpha2-Adrenoceptor Agonists targeting ADRA2A |
| FF-96-HL81_0.01uM | Dose=0.01uM |
| FF-96-HL81_0.1uM | Dose=0.1uM |
| FF-96-HL81_10uM | Dose=10uM |
| FF-96-HL81_1uM | Dose=1uM |
| GA-01-EO66_0.1uM | Dose=0.1uM, Glucocorticoid receptor agonist, Glucocorticoid Receptor (GR) Ligands;TNF-alpha Production Inhibitors targeting NR3C1 |
| GA-01-EO66_10uM | Dose=10uM, Glucocorticoid receptor agonist, Glucocorticoid Receptor (GR) Ligands;TNF-alpha Production Inhibitors targeting NR3C1 |
| GA-01-EO66_1uM | Dose=1uM, Glucocorticoid receptor agonist, Glucocorticoid Receptor (GR) Ligands;TNF-alpha Production Inhibitors targeting NR3C1 |
| GA-04-JM33_0.01uM | Dose=0.01uM, Ils-920, Neurotrophic Agents;L-Type Calcium Channel Blockers;Signal Transduction Modulators;FK506-Binding Protein 52 (FKBP52) Inhibitors targeting FKBP4 |
| GA-04-JM33_0.1uM | Dose=0.1uM, Ils-920, Neurotrophic Agents;L-Type Calcium Channel Blockers;Signal Transduction Modulators;FK506-Binding Protein 52 (FKBP52) Inhibitors targeting FKBP4 |
| GA-04-JM33_10uM | Dose=10uM, Ils-920, Neurotrophic Agents;L-Type Calcium Channel Blockers;Signal Transduction Modulators;FK506-Binding Protein 52 (FKBP52) Inhibitors targeting FKBP4 |
| GA-04-JM33_1uM | Dose=1uM, Ils-920, Neurotrophic Agents;L-Type Calcium Channel Blockers;Signal Transduction Modulators;FK506-Binding Protein 52 (FKBP52) Inhibitors targeting FKBP4 |
| GA-04-SF76_0.01uM | Dose=0.01uM, Lumiracoxib, Cyclooxygenase-2 Inhibitors targeting PTGS2 |
| GA-04-SF76_0.1uM | Dose=0.1uM, Lumiracoxib, Cyclooxygenase-2 Inhibitors targeting PTGS2 |
| GA-04-SF76_10uM | Dose=10uM, Lumiracoxib, Cyclooxygenase-2 Inhibitors targeting PTGS2 |
| GA-04-SF76_1uM | Dose=1uM, Lumiracoxib, Cyclooxygenase-2 Inhibitors targeting PTGS2 |
| GA-06-UU42_0.01uM | Dose=0.01uM, alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID targeting GRIA4 |
| GA-06-UU42_0.1uM | Dose=0.1uM, alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID targeting GRIA4 |
| GA-06-UU42_10uM | Dose=10uM, alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID targeting GRIA4 |
| GA-06-UU42_1uM | Dose=1uM, alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID targeting GRIA4 |
| GA-07-NB64_0.01uM | Dose=0.01uM, (1,1-Dimethylpiperidin-1-ium-4-yl) octadecyl hydrogen phosphate, Apoptosis Inducers;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1 |
| GA-07-NB64_0.1uM | Dose=0.1uM, (1,1-Dimethylpiperidin-1-ium-4-yl) octadecyl hydrogen phosphate, Apoptosis Inducers;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1 |
| GA-07-NB64_1uM | Dose=1uM, (1,1-Dimethylpiperidin-1-ium-4-yl) octadecyl hydrogen phosphate, Apoptosis Inducers;Protein Kinase B (PKB/Akt) Inhibitors targeting AKT1 |
| GA-09-TM90_0.01uM | Dose=0.01uM, Bms-509744, ITK (EMT) Kinase Inhibitors targeting ITK |
| GA-09-TM90_0.1uM | Dose=0.1uM, Bms-509744, ITK (EMT) Kinase Inhibitors targeting ITK |
| GA-09-TM90_10uM | Dose=10uM, Bms-509744, ITK (EMT) Kinase Inhibitors targeting ITK |
| GA-09-TM90_1uM | Dose=1uM, Bms-509744, ITK (EMT) Kinase Inhibitors targeting ITK |
| GA-10-WX15_0.01uM | Dose=0.01uM |
| GA-10-WX15_0.1uM | Dose=0.1uM |
| GA-10-WX15_10uM | Dose=10uM |
| GA-10-WX15_1uM | Dose=1uM |
| GA-13-WB79_0.01uM | Dose=0.01uM, p-t-butyl-N-[6-chloro-5-(m-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide |
| GA-13-WB79_0.1uM | Dose=0.1uM, p-t-butyl-N-[6-chloro-5-(m-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide |
| GA-13-WB79_10uM | Dose=10uM, p-t-butyl-N-[6-chloro-5-(m-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide |
| GA-13-WB79_1uM | Dose=1uM, p-t-butyl-N-[6-chloro-5-(m-methoxyphenoxy)-4-pyrimidinyl]benzenesulfonamide |
| GA-16-IU17_0.01uM | Dose=0.01uM, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol, Hsp90 inhibitor targeting HSP90AA1, HSP90AB1 |
| GA-16-IU17_0.1uM | Dose=0.1uM, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol, Hsp90 inhibitor targeting HSP90AA1, HSP90AB1 |
| GA-16-IU17_10uM | Dose=10uM, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol, Hsp90 inhibitor targeting HSP90AA1, HSP90AB1 |
| GA-16-IU17_1uM | Dose=1uM, 5-(2-amino-4-chloro-7-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylpent-4-yn-2-ol, Hsp90 inhibitor targeting HSP90AA1, HSP90AB1 |
| GA-18-KF56_0.01uM | Dose=0.01uM |
| GA-18-KF56_0.1uM | Dose=0.1uM |
| GA-18-KF56_10uM | Dose=10uM |
| GA-18-KF56_1uM | Dose=1uM |
| GA-18-PV59_0.01uM | Dose=0.01uM, (2Z)-2-(2-hydroxy-5-nitrobenzylidene)-1-benzothiophen-3(2H)-one, Palmitoyl Acyltransferase Inhibitors targeting ZDHHC17 |
| GA-18-PV59_0.1uM | Dose=0.1uM, (2Z)-2-(2-hydroxy-5-nitrobenzylidene)-1-benzothiophen-3(2H)-one, Palmitoyl Acyltransferase Inhibitors targeting ZDHHC17 |
| GA-18-PV59_10uM | Dose=10uM, (2Z)-2-(2-hydroxy-5-nitrobenzylidene)-1-benzothiophen-3(2H)-one, Palmitoyl Acyltransferase Inhibitors targeting ZDHHC17 |
| GA-18-PV59_1uM | Dose=1uM, (2Z)-2-(2-hydroxy-5-nitrobenzylidene)-1-benzothiophen-3(2H)-one, Palmitoyl Acyltransferase Inhibitors targeting ZDHHC17 |
| GA-23-VF89_0.01uM | Dose=0.01uM, N-{3-[(4-Ethylphenyl)sulfonyl]thieno[2,3-E][1,2,3]triazolo[1,5-A]pyrimidin-5-YL}-N-isopropylamine |
| GA-23-VF89_0.1uM | Dose=0.1uM, N-{3-[(4-Ethylphenyl)sulfonyl]thieno[2,3-E][1,2,3]triazolo[1,5-A]pyrimidin-5-YL}-N-isopropylamine |
| GA-23-VF89_10uM | Dose=10uM, N-{3-[(4-Ethylphenyl)sulfonyl]thieno[2,3-E][1,2,3]triazolo[1,5-A]pyrimidin-5-YL}-N-isopropylamine |
| GA-23-VF89_1uM | Dose=1uM, N-{3-[(4-Ethylphenyl)sulfonyl]thieno[2,3-E][1,2,3]triazolo[1,5-A]pyrimidin-5-YL}-N-isopropylamine |
| GA-27-MH98_0.01uM | Dose=0.01uM, Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-ethyl-2-(methylsulfinyl)-, CDK Inhibitors targeting CCND2, CCND3 |
| GA-27-MH98_0.1uM | Dose=0.1uM, Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-ethyl-2-(methylsulfinyl)-, CDK Inhibitors targeting CCND2, CCND3 |
| GA-27-MH98_10uM | Dose=10uM, Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-ethyl-2-(methylsulfinyl)-, CDK Inhibitors targeting CCND2, CCND3 |
| GA-27-MH98_1uM | Dose=1uM, Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-ethyl-2-(methylsulfinyl)-, CDK Inhibitors targeting CCND2, CCND3 |
| GA-28-SS67_0.01uM | Dose=0.01uM, Methyl 5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate, Inhibitor of pyrimidine biosynthesis targeting DHODH |
| GA-28-SS67_0.1uM | Dose=0.1uM, Methyl 5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate, Inhibitor of pyrimidine biosynthesis targeting DHODH |
| GA-28-SS67_10uM | Dose=10uM, Methyl 5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate, Inhibitor of pyrimidine biosynthesis targeting DHODH |
| GA-28-SS67_1uM | Dose=1uM, Methyl 5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate, Inhibitor of pyrimidine biosynthesis targeting DHODH |
| GA-30-HJ41_0.01uM | Dose=0.01uM, 11-{3-[4-(4-Fluorophenyl)-4-hydroxy-1-piperidinyl]propyl}-6,11-dihydrodibenzo[b,e]thiepine-11-carbonitrile, Antiinflammatory Drugs;Chemokine CCR1 Antagonists targeting CCR6, CCR7, CCR8, CCR10, CX3CR1 |
| GA-30-HJ41_0.1uM | Dose=0.1uM, 11-{3-[4-(4-Fluorophenyl)-4-hydroxy-1-piperidinyl]propyl}-6,11-dihydrodibenzo[b,e]thiepine-11-carbonitrile, Antiinflammatory Drugs;Chemokine CCR1 Antagonists targeting CCR6, CCR7, CCR8, CCR10, CX3CR1 |
| GA-30-HJ41_10uM | Dose=10uM, 11-{3-[4-(4-Fluorophenyl)-4-hydroxy-1-piperidinyl]propyl}-6,11-dihydrodibenzo[b,e]thiepine-11-carbonitrile, Antiinflammatory Drugs;Chemokine CCR1 Antagonists targeting CCR6, CCR7, CCR8, CCR10, CX3CR1 |
| GA-30-HJ41_1uM | Dose=1uM, 11-{3-[4-(4-Fluorophenyl)-4-hydroxy-1-piperidinyl]propyl}-6,11-dihydrodibenzo[b,e]thiepine-11-carbonitrile, Antiinflammatory Drugs;Chemokine CCR1 Antagonists targeting CCR6, CCR7, CCR8, CCR10, CX3CR1 |
| GA-32-TO88_0.01uM | Dose=0.01uM, 2-morpholin-4-yl-N-(4-sulfamoylphenyl)acetamide, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9 |
| GA-32-TO88_0.1uM | Dose=0.1uM, 2-morpholin-4-yl-N-(4-sulfamoylphenyl)acetamide, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9 |
| GA-32-TO88_1uM | Dose=1uM, 2-morpholin-4-yl-N-(4-sulfamoylphenyl)acetamide, Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors targeting CA2, CA9 |
| GA-41-JD09_0.01uM | Dose=0.01uM, 4-[(2R)-2-methyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazine-1-carbonyl]benzonitrile, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| GA-41-JD09_0.1uM | Dose=0.1uM, 4-[(2R)-2-methyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazine-1-carbonyl]benzonitrile, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| GA-41-JD09_10uM | Dose=10uM, 4-[(2R)-2-methyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazine-1-carbonyl]benzonitrile, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| GA-41-JD09_1uM | Dose=1uM, 4-[(2R)-2-methyl-4-[(2R)-3,3,3-trifluoro-2-hydroxy-2-methylpropanoyl]piperazine-1-carbonyl]benzonitrile, Pyruvate Dehydrogenase Kinase (PDHK;PDK) Inhibitors targeting PDK2, PDK3, PDK4 |
| GA-43-FL03_0.01uM | Dose=0.01uM, Aliskiren, Renin Inhibitors targeting REN |
| GA-43-FL03_0.1uM | Dose=0.1uM, Aliskiren, Renin Inhibitors targeting REN |
| GA-43-FL03_10uM | Dose=10uM, Aliskiren, Renin Inhibitors targeting REN |
| GA-43-FL03_1uM | Dose=1uM, Aliskiren, Renin Inhibitors targeting REN |
| GA-47-CH23_0.1uM | Dose=0.1uM, N-[3-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]propanamide, EGFR (HER1;erbB1) Inhibitors targeting EGFR |
| GA-47-CH23_10uM | Dose=10uM, N-[3-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]propanamide, EGFR (HER1;erbB1) Inhibitors targeting EGFR |
| GA-47-CH23_1uM | Dose=1uM, N-[3-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]propanamide, EGFR (HER1;erbB1) Inhibitors targeting EGFR |
| GA-47-MH68_0.01uM | Dose=0.01uM, [(3R,6S)-7-oxo-6-[[(E,2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enoyl]amino]azepan-3-yl] cyclohexanecarboxylate, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Methionine Aminopeptidase-1 (MetAP1) Inhibitors targeting METAP2, METAP1 |
| GA-47-MH68_0.1uM | Dose=0.1uM, [(3R,6S)-7-oxo-6-[[(E,2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enoyl]amino]azepan-3-yl] cyclohexanecarboxylate, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Methionine Aminopeptidase-1 (MetAP1) Inhibitors targeting METAP2, METAP1 |
| GA-47-MH68_10uM | Dose=10uM, [(3R,6S)-7-oxo-6-[[(E,2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enoyl]amino]azepan-3-yl] cyclohexanecarboxylate, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Methionine Aminopeptidase-1 (MetAP1) Inhibitors targeting METAP2, METAP1 |
| GA-47-MH68_1uM | Dose=1uM, [(3R,6S)-7-oxo-6-[[(E,2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enoyl]amino]azepan-3-yl] cyclohexanecarboxylate, Methionine Aminopeptidase-2 (MetAP2) Inhibitors;Methionine Aminopeptidase-1 (MetAP1) Inhibitors targeting METAP2, METAP1 |
| GA-48-JB51_0.01uM | Dose=0.01uM, Adci, NMDA Antagonists;Sodium Channel Blockers targeting GRIN2A, GRIN2B |
| GA-48-JB51_0.1uM | Dose=0.1uM, Adci, NMDA Antagonists;Sodium Channel Blockers targeting GRIN2A, GRIN2B |
| GA-48-JB51_10uM | Dose=10uM, Adci, NMDA Antagonists;Sodium Channel Blockers targeting GRIN2A, GRIN2B |
| GA-48-JB51_1uM | Dose=1uM, Adci, NMDA Antagonists;Sodium Channel Blockers targeting GRIN2A, GRIN2B |
| GA-48-QI68_0.01uM | Dose=0.01uM |
| GA-48-QI68_0.1uM | Dose=0.1uM |
| GA-48-QI68_10uM | Dose=10uM |
| GA-48-QI68_1uM | Dose=1uM |
| GA-49-SZ11_0.01uM | Dose=0.01uM, (2S)-2-amino-2-cyclohexyl-1-(pyrrolidin-1-yl)ethan-1-one, Dipeptidyl Peptidase VIII (DPP8) Inhibitors;Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors;Dipeptidyl Peptidase IV (CD26| DPP-IV| DP-IV) Inhibitors targeting DPP8 |
| GA-49-SZ11_0.1uM | Dose=0.1uM, (2S)-2-amino-2-cyclohexyl-1-(pyrrolidin-1-yl)ethan-1-one, Dipeptidyl Peptidase VIII (DPP8) Inhibitors;Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors;Dipeptidyl Peptidase IV (CD26| DPP-IV| DP-IV) Inhibitors targeting DPP8 |
| GA-49-SZ11_10uM | Dose=10uM, (2S)-2-amino-2-cyclohexyl-1-(pyrrolidin-1-yl)ethan-1-one, Dipeptidyl Peptidase VIII (DPP8) Inhibitors;Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors;Dipeptidyl Peptidase IV (CD26| DPP-IV| DP-IV) Inhibitors targeting DPP8 |
| GA-51-DD14_0.01uM | Dose=0.01uM, N-Acenaphthen-5-yl-N''-(4-methoxy-naphthalen-1-yl)-guanidine |
| GA-51-DD14_0.1uM | Dose=0.1uM, N-Acenaphthen-5-yl-N''-(4-methoxy-naphthalen-1-yl)-guanidine |
| GA-51-DD14_10uM | Dose=10uM, N-Acenaphthen-5-yl-N''-(4-methoxy-naphthalen-1-yl)-guanidine |
| GA-51-DD14_1uM | Dose=1uM, N-Acenaphthen-5-yl-N''-(4-methoxy-naphthalen-1-yl)-guanidine |
| GA-53-SC22_0.01uM | Dose=0.01uM, 8-(3-Chlorostyryl)caffeine, Adenosine A2A Antagonists;MAO-B Inhibitors targeting ADORA2A, MAOB |
| GA-53-SC22_0.1uM | Dose=0.1uM, 8-(3-Chlorostyryl)caffeine, Adenosine A2A Antagonists;MAO-B Inhibitors targeting ADORA2A, MAOB |
| GA-53-SC22_10uM | Dose=10uM, 8-(3-Chlorostyryl)caffeine, Adenosine A2A Antagonists;MAO-B Inhibitors targeting ADORA2A, MAOB |
| GA-53-SC22_1uM | Dose=1uM, 8-(3-Chlorostyryl)caffeine, Adenosine A2A Antagonists;MAO-B Inhibitors targeting ADORA2A, MAOB |
| GA-56-IU17_0.01uM | Dose=0.01uM, Mavorixafor, CXCR4 antagonist, HIV attachment inhibitor targeting CXCR4 |
| GA-56-IU17_0.1uM | Dose=0.1uM, Mavorixafor, CXCR4 antagonist, HIV attachment inhibitor targeting CXCR4 |
| GA-56-IU17_10uM | Dose=10uM, Mavorixafor, CXCR4 antagonist, HIV attachment inhibitor targeting CXCR4 |
| GA-56-IU17_1uM | Dose=1uM, Mavorixafor, CXCR4 antagonist, HIV attachment inhibitor targeting CXCR4 |
| GA-59-RW04_0.01uM | Dose=0.01uM, Cb-5083, p97 AAA ATPase inhibitor targeting VCP |
| GA-59-RW04_0.1uM | Dose=0.1uM, Cb-5083, p97 AAA ATPase inhibitor targeting VCP |
| GA-59-RW04_10uM | Dose=10uM, Cb-5083, p97 AAA ATPase inhibitor targeting VCP |
| GA-59-RW04_1uM | Dose=1uM, Cb-5083, p97 AAA ATPase inhibitor targeting VCP |
| GA-61-GX82_0.01uM | Dose=0.01uM, Abeorphine |
| GA-61-GX82_0.1uM | Dose=0.1uM, Abeorphine |
| GA-61-GX82_10uM | Dose=10uM, Abeorphine |
| GA-61-GX82_1uM | Dose=1uM, Abeorphine |
| GA-66-IX54_0.01uM | Dose=0.01uM, (2R)-N-(furan-2-ylmethyl)-2-[(2-oxo-1H-quinolin-6-yl)sulfonylamino]-2-phenyl-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT |
| GA-66-IX54_0.1uM | Dose=0.1uM, (2R)-N-(furan-2-ylmethyl)-2-[(2-oxo-1H-quinolin-6-yl)sulfonylamino]-2-phenyl-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT |
| GA-66-IX54_10uM | Dose=10uM, (2R)-N-(furan-2-ylmethyl)-2-[(2-oxo-1H-quinolin-6-yl)sulfonylamino]-2-phenyl-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT |
| GA-66-IX54_1uM | Dose=1uM, (2R)-N-(furan-2-ylmethyl)-2-[(2-oxo-1H-quinolin-6-yl)sulfonylamino]-2-phenyl-N-(thiophen-2-ylmethyl)acetamide, OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) inhibitor targeting OGT |
| GA-66-XX49_0.01uM | Dose=0.01uM |
| GA-66-XX49_0.1uM | Dose=0.1uM |
| GA-66-XX49_10uM | Dose=10uM |
| GA-66-XX49_1uM | Dose=1uM |
| GA-68-KC29_0.01uM | Dose=0.01uM, 3-phenacyl-UDP, P2Y6 Receptors targeting P2RY6 |
| GA-68-KC29_0.1uM | Dose=0.1uM, 3-phenacyl-UDP, P2Y6 Receptors targeting P2RY6 |
| GA-68-KC29_10uM | Dose=10uM, 3-phenacyl-UDP, P2Y6 Receptors targeting P2RY6 |
| GA-68-KC29_1uM | Dose=1uM, 3-phenacyl-UDP, P2Y6 Receptors targeting P2RY6 |
| GA-68-SS47_0.01uM | Dose=0.01uM, ERK1 Inhibitors;MEK1 Inhibitors;MEK2 Inhibitors;MKK4 Inhibitors |
| GA-68-SS47_0.1uM | Dose=0.1uM, ERK1 Inhibitors;MEK1 Inhibitors;MEK2 Inhibitors;MKK4 Inhibitors |
| GA-68-SS47_10uM | Dose=10uM, ERK1 Inhibitors;MEK1 Inhibitors;MEK2 Inhibitors;MKK4 Inhibitors |
| GA-77-FY14_0.01uM | Dose=0.01uM |
| GA-77-FY14_0.1uM | Dose=0.1uM |
| GA-77-FY14_10uM | Dose=10uM |
| GA-77-FY14_1uM | Dose=1uM |
| GA-77-MH38_0.01uM | Dose=0.01uM |
| GA-77-MH38_0.1uM | Dose=0.1uM |
| GA-77-MH38_10uM | Dose=10uM |
| GA-77-MH38_1uM | Dose=1uM |
| GA-79-DW49_0.01uM | Dose=0.01uM, Benzoic acid, p-hydroxy-, (p-(diethylamino)benzylidene)hydrazide, Estrogen-Related Receptor gamma (ERRgamma) Agonists;Estrogen-Related Receptor beta (ERRbeta, ERR2) Agonists targeting ESRRG |
| GA-79-DW49_0.1uM | Dose=0.1uM, Benzoic acid, p-hydroxy-, (p-(diethylamino)benzylidene)hydrazide, Estrogen-Related Receptor gamma (ERRgamma) Agonists;Estrogen-Related Receptor beta (ERRbeta, ERR2) Agonists targeting ESRRG |
| GA-79-DW49_10uM | Dose=10uM, Benzoic acid, p-hydroxy-, (p-(diethylamino)benzylidene)hydrazide, Estrogen-Related Receptor gamma (ERRgamma) Agonists;Estrogen-Related Receptor beta (ERRbeta, ERR2) Agonists targeting ESRRG |
| GA-79-DW49_1uM | Dose=1uM, Benzoic acid, p-hydroxy-, (p-(diethylamino)benzylidene)hydrazide, Estrogen-Related Receptor gamma (ERRgamma) Agonists;Estrogen-Related Receptor beta (ERRbeta, ERR2) Agonists targeting ESRRG |
| GA-79-ZF28_0.01uM | Dose=0.01uM, 5-{[(4-Methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2, CA4 |
| GA-79-ZF28_10uM | Dose=10uM, 5-{[(4-Methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2, CA4 |
| GA-79-ZF28_1uM | Dose=1uM, 5-{[(4-Methylphenyl)sulfonyl]amino}-1,3,4-thiadiazole-2-sulfonamide, Carbonic anhydrase inhibitor targeting CA1, CA2, CA4 |
| GA-81-DL34_0.01uM | Dose=0.01uM, Nvs-ZP7-4, ZIP7 modulator;Notch Pathway Antagonist;ER Stress Inducer targeting SLC39A7 |
| GA-81-DL34_0.1uM | Dose=0.1uM, Nvs-ZP7-4, ZIP7 modulator;Notch Pathway Antagonist;ER Stress Inducer targeting SLC39A7 |
| GA-81-DL34_10uM | Dose=10uM, Nvs-ZP7-4, ZIP7 modulator;Notch Pathway Antagonist;ER Stress Inducer targeting SLC39A7 |
| GA-81-DL34_1uM | Dose=1uM, Nvs-ZP7-4, ZIP7 modulator;Notch Pathway Antagonist;ER Stress Inducer targeting SLC39A7 |
| GA-85-SJ43_0.01uM | Dose=0.01uM, DRD1 antagonist |
| GA-85-SJ43_0.1uM | Dose=0.1uM, DRD1 antagonist |
| GA-85-SJ43_10uM | Dose=10uM, DRD1 antagonist |
| GA-87-BR97_0.01uM | Dose=0.01uM |
| GA-87-BR97_0.1uM | Dose=0.1uM |
| GA-87-BR97_10uM | Dose=10uM |
| GA-87-BR97_1uM | Dose=1uM |
| GA-88-CF36_0.01uM | Dose=0.01uM, Brusatol |
| GA-88-CF36_0.1uM | Dose=0.1uM, Brusatol |
| GA-88-CF36_10uM | Dose=10uM, Brusatol |
| GA-88-CF36_1uM | Dose=1uM, Brusatol |
| GA-88-PV69_0.01uM | Dose=0.01uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate, Glucocorticoid Receptor (GR) Ligands targeting NR3C1 |
| GA-88-PV69_0.1uM | Dose=0.1uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate, Glucocorticoid Receptor (GR) Ligands targeting NR3C1 |
| GA-88-PV69_10uM | Dose=10uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate, Glucocorticoid Receptor (GR) Ligands targeting NR3C1 |
| GA-88-PV69_1uM | Dose=1uM, [(6S,9R,10S,11S,13S,16R,17R)-9-chloro-6-fluoro-11-hydroxy-17-methoxycarbonyl-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate, Glucocorticoid Receptor (GR) Ligands targeting NR3C1 |
| GA-89-ZT62_0.01uM | Dose=0.01uM, 2-(7-Aminoheptyl)guanidine, DHPS inhibitor targeting DHPS |
| GA-89-ZT62_0.1uM | Dose=0.1uM, 2-(7-Aminoheptyl)guanidine, DHPS inhibitor targeting DHPS |
| GA-89-ZT62_10uM | Dose=10uM, 2-(7-Aminoheptyl)guanidine, DHPS inhibitor targeting DHPS |
| GA-89-ZT62_1uM | Dose=1uM, 2-(7-Aminoheptyl)guanidine, DHPS inhibitor targeting DHPS |
| GA-94-KZ19_0.01uM | Dose=0.01uM, (6S)-1-[4-(dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid, AGTR2 antagonist targeting AGTR2 |
| GA-94-KZ19_0.1uM | Dose=0.1uM, (6S)-1-[4-(dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid, AGTR2 antagonist targeting AGTR2 |
| GA-94-KZ19_1uM | Dose=1uM, (6S)-1-[4-(dimethylamino)-3-methylbenzyl]-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid, AGTR2 antagonist targeting AGTR2 |
| GA-94-MC54_0.01uM | Dose=0.01uM, 6-(1,4-Diazepan-1-yl)-5-(3,3-dichloroprop-2-enyl)-3-(isoquinolin-1-ylmethyl)-4-oxopyrrolo[3,2-d]pyrimidine-7-carbonitrile, Autophagy agonist targeting DPP4 |
| GA-94-MC54_10uM | Dose=10uM, 6-(1,4-Diazepan-1-yl)-5-(3,3-dichloroprop-2-enyl)-3-(isoquinolin-1-ylmethyl)-4-oxopyrrolo[3,2-d]pyrimidine-7-carbonitrile, Autophagy agonist targeting DPP4 |
| GA-94-MC54_1uM | Dose=1uM, 6-(1,4-Diazepan-1-yl)-5-(3,3-dichloroprop-2-enyl)-3-(isoquinolin-1-ylmethyl)-4-oxopyrrolo[3,2-d]pyrimidine-7-carbonitrile, Autophagy agonist targeting DPP4 |
| GA-97-UL18_0.01uM | Dose=0.01uM, RXFP3/4 agonist 1, RXFP3 agonist targeting RXFP3 |
| GA-97-UL18_0.1uM | Dose=0.1uM, RXFP3/4 agonist 1, RXFP3 agonist targeting RXFP3 |
| GA-97-UL18_10uM | Dose=10uM, RXFP3/4 agonist 1, RXFP3 agonist targeting RXFP3 |
| GA-97-UL18_1uM | Dose=1uM, RXFP3/4 agonist 1, RXFP3 agonist targeting RXFP3 |
| GB-01-UN23_0.01uM | Dose=0.01uM, (3R,4aR,10aR)-1-methyl-3-[(1-methylimidazol-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol |
| GB-01-UN23_0.1uM | Dose=0.1uM, (3R,4aR,10aR)-1-methyl-3-[(1-methylimidazol-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol |
| GB-01-UN23_10uM | Dose=10uM, (3R,4aR,10aR)-1-methyl-3-[(1-methylimidazol-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol |
| GB-01-UN23_1uM | Dose=1uM, (3R,4aR,10aR)-1-methyl-3-[(1-methylimidazol-2-yl)sulfanylmethyl]-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-6-ol |
| GB-05-QT17_10uM | Dose=10uM, 4-Nitro-N-(4-sulfamoylphenyl)benzene-1-sulfonamide, Carbonic anhydrase inhibitor targeting CA1 |
| GB-06-BA49_0.01uM | Dose=0.01uM, 1-[4-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]ethanamine, Activin receptor antagonist targeting TGFBR1 |
| GB-06-BA49_0.1uM | Dose=0.1uM, 1-[4-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]ethanamine, Activin receptor antagonist targeting TGFBR1 |
| GB-06-BA49_10uM | Dose=10uM, 1-[4-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]ethanamine, Activin receptor antagonist targeting TGFBR1 |
| GB-06-BA49_1uM | Dose=1uM, 1-[4-[5-[6-(6-methylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]pyridin-3-yl]phenyl]ethanamine, Activin receptor antagonist targeting TGFBR1 |
| GB-10-QG19_0.01uM | Dose=0.01uM, 2-(4-Isopropyl-phenyl)-5-(2-methanesulfonyl-pyridin-3-ylmethyl)-7-methoxy-1-(2-methoxy-ethyl)-4-trifluoromethyl-1H-benzoimidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| GB-10-QG19_0.1uM | Dose=0.1uM, 2-(4-Isopropyl-phenyl)-5-(2-methanesulfonyl-pyridin-3-ylmethyl)-7-methoxy-1-(2-methoxy-ethyl)-4-trifluoromethyl-1H-benzoimidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| GB-10-QG19_10uM | Dose=10uM, 2-(4-Isopropyl-phenyl)-5-(2-methanesulfonyl-pyridin-3-ylmethyl)-7-methoxy-1-(2-methoxy-ethyl)-4-trifluoromethyl-1H-benzoimidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| GB-10-QG19_1uM | Dose=1uM, 2-(4-Isopropyl-phenyl)-5-(2-methanesulfonyl-pyridin-3-ylmethyl)-7-methoxy-1-(2-methoxy-ethyl)-4-trifluoromethyl-1H-benzoimidazole, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| GB-11-PX47_0.01uM | Dose=0.01uM, 4-Diphenylacetoxy-1,1-dimethylpiperidinium, CHRM3 antagonist targeting CHRM3 |
| GB-11-PX47_0.1uM | Dose=0.1uM, 4-Diphenylacetoxy-1,1-dimethylpiperidinium, CHRM3 antagonist targeting CHRM3 |
| GB-11-PX47_10uM | Dose=10uM, 4-Diphenylacetoxy-1,1-dimethylpiperidinium, CHRM3 antagonist targeting CHRM3 |
| GB-11-TA37_0.01uM | Dose=0.01uM, Abt-107, Nicotinic alpha7 Agonists targeting CHRNA7 |
| GB-11-TA37_0.1uM | Dose=0.1uM, Abt-107, Nicotinic alpha7 Agonists targeting CHRNA7 |
| GB-11-TA37_10uM | Dose=10uM, Abt-107, Nicotinic alpha7 Agonists targeting CHRNA7 |
| GB-11-TA37_1uM | Dose=1uM, Abt-107, Nicotinic alpha7 Agonists targeting CHRNA7 |
| GB-14-AJ76_0.01uM | Dose=0.01uM |
| GB-14-AJ76_0.1uM | Dose=0.1uM |
| GB-14-AJ76_10uM | Dose=10uM |
| GB-14-AJ76_1uM | Dose=1uM |
| GB-16-NN30_0.01uM | Dose=0.01uM, Ethyl 8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate, Negative allosteric modulator of GABAA;Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB3, GABRG2 |
| GB-16-NN30_0.1uM | Dose=0.1uM, Ethyl 8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate, Negative allosteric modulator of GABAA;Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB3, GABRG2 |
| GB-16-NN30_10uM | Dose=10uM, Ethyl 8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate, Negative allosteric modulator of GABAA;Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB3, GABRG2 |
| GB-16-NN30_1uM | Dose=1uM, Ethyl 8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate, Negative allosteric modulator of GABAA;Ligand of the GABAA receptor subtypes targeting GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB3, GABRG2 |
| GB-16-SU72_0.01uM | Dose=0.01uM, Fasiglifam, GPR40) Agonists;Free Fatty Acid Receptor 1 (FFAR1 targeting FFAR1 |
| GB-16-SU72_0.1uM | Dose=0.1uM, Fasiglifam, GPR40) Agonists;Free Fatty Acid Receptor 1 (FFAR1 targeting FFAR1 |
| GB-16-SU72_10uM | Dose=10uM, Fasiglifam, GPR40) Agonists;Free Fatty Acid Receptor 1 (FFAR1 targeting FFAR1 |
| GB-16-SU72_1uM | Dose=1uM, Fasiglifam, GPR40) Agonists;Free Fatty Acid Receptor 1 (FFAR1 targeting FFAR1 |
| GB-19-AP57_0.01uM | Dose=0.01uM, 2,6-Ditert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol |
| GB-19-AP57_0.1uM | Dose=0.1uM, 2,6-Ditert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol |
| GB-19-AP57_10uM | Dose=10uM, 2,6-Ditert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol |
| GB-19-AP57_1uM | Dose=1uM, 2,6-Ditert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol |
| GB-21-FN58_0.01uM | Dose=0.01uM, ({3-[(Carboxymethyl)sulfanyl]-1,2,4-thiadiazol-5-yl}sulfanyl)acetic acid, Lck Kinase SH2 domain Inhibitors targeting LCK |
| GB-21-FN58_0.1uM | Dose=0.1uM, ({3-[(Carboxymethyl)sulfanyl]-1,2,4-thiadiazol-5-yl}sulfanyl)acetic acid, Lck Kinase SH2 domain Inhibitors targeting LCK |
| GB-21-FN58_10uM | Dose=10uM, ({3-[(Carboxymethyl)sulfanyl]-1,2,4-thiadiazol-5-yl}sulfanyl)acetic acid, Lck Kinase SH2 domain Inhibitors targeting LCK |
| GB-21-FN58_1uM | Dose=1uM, ({3-[(Carboxymethyl)sulfanyl]-1,2,4-thiadiazol-5-yl}sulfanyl)acetic acid, Lck Kinase SH2 domain Inhibitors targeting LCK |
| GB-27-AY54_0.01uM | Dose=0.01uM, 5H-Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| GB-27-AY54_0.1uM | Dose=0.1uM, 5H-Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| GB-27-AY54_10uM | Dose=10uM, 5H-Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| GB-27-AY54_1uM | Dose=1uM, 5H-Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-8-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6,7-dihydro-2-methyl-, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| GB-31-HY20_0.01uM | Dose=0.01uM, Spermidine, Protein tyrosine phophatase N-like stimulator;Drugs Acting on NMDA Receptors targeting GRIN2A, GRIN2B, PTPN2 |
| GB-31-HY20_0.1uM | Dose=0.1uM, Spermidine, Protein tyrosine phophatase N-like stimulator;Drugs Acting on NMDA Receptors targeting GRIN2A, GRIN2B, PTPN2 |
| GB-31-HY20_10uM | Dose=10uM, Spermidine, Protein tyrosine phophatase N-like stimulator;Drugs Acting on NMDA Receptors targeting GRIN2A, GRIN2B, PTPN2 |
| GB-31-HY20_1uM | Dose=1uM, Spermidine, Protein tyrosine phophatase N-like stimulator;Drugs Acting on NMDA Receptors targeting GRIN2A, GRIN2B, PTPN2 |
| GB-33-FW25_0.01uM | Dose=0.01uM, Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting PLAT |
| GB-33-FW25_0.1uM | Dose=0.1uM, Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting PLAT |
| GB-33-FW25_10uM | Dose=10uM, Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting PLAT |
| GB-33-FW25_1uM | Dose=1uM, Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting PLAT |
| GB-33-SS25_0.01uM | Dose=0.01uM, 5-Hydroxyflavone targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| GB-33-SS25_0.1uM | Dose=0.1uM, 5-Hydroxyflavone targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| GB-33-SS25_1uM | Dose=1uM, 5-Hydroxyflavone targeting CYP1A1, HSD17B7, HSD17B10, HSD17B2, HSD17B8, HSD17B6, HSD17B12, HSD17B11, HSD17B14, HSD17B13 |
| GB-35-DG61_0.01uM | Dose=0.01uM, Ataciguat, Guanylate Cyclase Activators targeting GUCY1A2 |
| GB-35-DG61_0.1uM | Dose=0.1uM, Ataciguat, Guanylate Cyclase Activators targeting GUCY1A2 |
| GB-35-DG61_10uM | Dose=10uM, Ataciguat, Guanylate Cyclase Activators targeting GUCY1A2 |
| GB-35-DG61_1uM | Dose=1uM, Ataciguat, Guanylate Cyclase Activators targeting GUCY1A2 |
| GB-37-WI36_0.01uM | Dose=0.01uM, Nirogacestat, Apoptosis Inducers;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| GB-37-WI36_0.1uM | Dose=0.1uM, Nirogacestat, Apoptosis Inducers;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| GB-37-WI36_10uM | Dose=10uM, Nirogacestat, Apoptosis Inducers;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| GB-37-WI36_1uM | Dose=1uM, Nirogacestat, Apoptosis Inducers;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| GB-39-OF03_0.01uM | Dose=0.01uM, 2,3-Dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl thiocyanate, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| GB-39-OF03_0.1uM | Dose=0.1uM, 2,3-Dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl thiocyanate, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| GB-39-OF03_10uM | Dose=10uM, 2,3-Dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl thiocyanate, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| GB-39-OF03_1uM | Dose=1uM, 2,3-Dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl thiocyanate, CRF Receptor Antagonists targeting CRHR1, CRHR2 |
| GB-45-CJ58_0.01uM | Dose=0.01uM, 7-Chloro-2,3,4,5-tetrahydro-1H-3-benzazepine, 5-HT2C Agonists targeting HTR2C |
| GB-45-CJ58_0.1uM | Dose=0.1uM, 7-Chloro-2,3,4,5-tetrahydro-1H-3-benzazepine, 5-HT2C Agonists targeting HTR2C |
| GB-45-CJ58_10uM | Dose=10uM, 7-Chloro-2,3,4,5-tetrahydro-1H-3-benzazepine, 5-HT2C Agonists targeting HTR2C |
| GB-45-YG91_0.01uM | Dose=0.01uM, Zaltoprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| GB-45-YG91_0.1uM | Dose=0.1uM, Zaltoprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| GB-45-YG91_10uM | Dose=10uM, Zaltoprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| GB-45-YG91_1uM | Dose=1uM, Zaltoprofen, Cyclooxygenase (COX) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PTGS2 |
| GB-46-CK08_0.01uM | Dose=0.01uM |
| GB-46-CK08_0.1uM | Dose=0.1uM |
| GB-46-CK08_10uM | Dose=10uM |
| GB-46-CK08_1uM | Dose=1uM |
| GB-48-YF11_0.01uM | Dose=0.01uM, Nicaraven, Lipid Peroxidation Inhibitors;PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| GB-48-YF11_0.1uM | Dose=0.1uM, Nicaraven, Lipid Peroxidation Inhibitors;PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| GB-48-YF11_10uM | Dose=10uM, Nicaraven, Lipid Peroxidation Inhibitors;PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| GB-48-YF11_1uM | Dose=1uM, Nicaraven, Lipid Peroxidation Inhibitors;PARP) Inhibitors;Free Radical Scavengers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| GB-50-PK29_0.01uM | Dose=0.01uM, Azapropazone, Xanthine Oxidase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting XDH |
| GB-50-PK29_10uM | Dose=10uM, Azapropazone, Xanthine Oxidase Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting XDH |
| GB-51-MD79_0.01uM | Dose=0.01uM, Gemcabene, HDL-Cholesterol Increasing Agents;PPAR Agonists targeting PPARA, PPARG |
| GB-51-MD79_0.1uM | Dose=0.1uM, Gemcabene, HDL-Cholesterol Increasing Agents;PPAR Agonists targeting PPARA, PPARG |
| GB-51-MD79_10uM | Dose=10uM, Gemcabene, HDL-Cholesterol Increasing Agents;PPAR Agonists targeting PPARA, PPARG |
| GB-51-MD79_1uM | Dose=1uM, Gemcabene, HDL-Cholesterol Increasing Agents;PPAR Agonists targeting PPARA, PPARG |
| GB-56-TN25_0.01uM | Dose=0.01uM |
| GB-56-TN25_0.1uM | Dose=0.1uM |
| GB-56-TN25_10uM | Dose=10uM |
| GB-56-TN25_1uM | Dose=1uM |
| GB-57-XV52_0.01uM | Dose=0.01uM, Brefeldin A, Autophagy inducer;Apoptosis Inducers;Caspase 3 Activators targeting ARF1, GBF1, CYTH2, ARFGEF2, ARFGEF1, CYTH1 |
| GB-57-XV52_0.1uM | Dose=0.1uM, Brefeldin A, Autophagy inducer;Apoptosis Inducers;Caspase 3 Activators targeting ARF1, GBF1, CYTH2, ARFGEF2, ARFGEF1, CYTH1 |
| GB-57-XV52_10uM | Dose=10uM, Brefeldin A, Autophagy inducer;Apoptosis Inducers;Caspase 3 Activators targeting ARF1, GBF1, CYTH2, ARFGEF2, ARFGEF1, CYTH1 |
| GB-57-XV52_1uM | Dose=1uM, Brefeldin A, Autophagy inducer;Apoptosis Inducers;Caspase 3 Activators targeting ARF1, GBF1, CYTH2, ARFGEF2, ARFGEF1, CYTH1 |
| GB-62-IH36_0.01uM | Dose=0.01uM, 4-(4-Methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline, 5-HT1B Agonists targeting HTR1B |
| GB-62-IH36_0.1uM | Dose=0.1uM, 4-(4-Methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline, 5-HT1B Agonists targeting HTR1B |
| GB-62-IH36_10uM | Dose=10uM, 4-(4-Methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline, 5-HT1B Agonists targeting HTR1B |
| GB-62-IH36_1uM | Dose=1uM, 4-(4-Methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline, 5-HT1B Agonists targeting HTR1B |
| GB-64-HC34_0.01uM | Dose=0.01uM, Icofungipen, Isoleucyl-tRNA Synthetase Inhibitors targeting IARS1 |
| GB-64-HC34_0.1uM | Dose=0.1uM, Icofungipen, Isoleucyl-tRNA Synthetase Inhibitors targeting IARS1 |
| GB-64-HC34_10uM | Dose=10uM, Icofungipen, Isoleucyl-tRNA Synthetase Inhibitors targeting IARS1 |
| GB-64-HC34_1uM | Dose=1uM, Icofungipen, Isoleucyl-tRNA Synthetase Inhibitors targeting IARS1 |
| GB-69-YC71_0.01uM | Dose=0.01uM, Citco, Constitutive Androstane Receptor (CAR) Agonists targeting NR1I3 |
| GB-69-YC71_0.1uM | Dose=0.1uM, Citco, Constitutive Androstane Receptor (CAR) Agonists targeting NR1I3 |
| GB-69-YC71_10uM | Dose=10uM, Citco, Constitutive Androstane Receptor (CAR) Agonists targeting NR1I3 |
| GB-69-YC71_1uM | Dose=1uM, Citco, Constitutive Androstane Receptor (CAR) Agonists targeting NR1I3 |
| GB-72-BR65_0.01uM | Dose=0.01uM, Opc 14117 |
| GB-72-BR65_0.1uM | Dose=0.1uM, Opc 14117 |
| GB-72-BR65_10uM | Dose=10uM, Opc 14117 |
| GB-72-BR65_1uM | Dose=1uM, Opc 14117 |
| GB-73-QS80_0.01uM | Dose=0.01uM, 4-tert-butyl-N-(3-sulfamoylphenyl)benzamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| GB-73-QS80_0.1uM | Dose=0.1uM, 4-tert-butyl-N-(3-sulfamoylphenyl)benzamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| GB-73-QS80_10uM | Dose=10uM, 4-tert-butyl-N-(3-sulfamoylphenyl)benzamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| GB-73-QS80_1uM | Dose=1uM, 4-tert-butyl-N-(3-sulfamoylphenyl)benzamide, Carbonic anhydrase inhibitor targeting CA1, CA3, CA4, CA5A, CA8, CA11, CA5B, CA10 |
| GB-76-TN05_0.01uM | Dose=0.01uM, SB 258719, 5-HT7 Antagonists targeting HTR7 |
| GB-76-TN05_10uM | Dose=10uM, SB 258719, 5-HT7 Antagonists targeting HTR7 |
| GB-81-GK41_0.01uM | Dose=0.01uM, QX-314, BLMH gene inhibitor targeting BLM |
| GB-81-GK41_0.1uM | Dose=0.1uM, QX-314, BLMH gene inhibitor targeting BLM |
| GB-81-GK41_10uM | Dose=10uM, QX-314, BLMH gene inhibitor targeting BLM |
| GB-81-GK41_1uM | Dose=1uM, QX-314, BLMH gene inhibitor targeting BLM |
| GB-81-UN03_0.01uM | Dose=0.01uM, 4-Quinolinamine, 2-(2-thienyl)- |
| GB-81-UN03_0.1uM | Dose=0.1uM, 4-Quinolinamine, 2-(2-thienyl)- |
| GB-81-UN03_10uM | Dose=10uM, 4-Quinolinamine, 2-(2-thienyl)- |
| GB-81-UN03_1uM | Dose=1uM, 4-Quinolinamine, 2-(2-thienyl)- |
| GB-84-KP45_0.01uM | Dose=0.01uM, (RS)-Ppg, mgluR8 Agonists targeting GRM8 |
| GB-84-KP45_0.1uM | Dose=0.1uM, (RS)-Ppg, mgluR8 Agonists targeting GRM8 |
| GB-84-KP45_10uM | Dose=10uM, (RS)-Ppg, mgluR8 Agonists targeting GRM8 |
| GB-84-KP45_1uM | Dose=1uM, (RS)-Ppg, mgluR8 Agonists targeting GRM8 |
| GB-86-PE04_0.01uM | Dose=0.01uM, N-(tert-Butyl)-6,7-dichloro-3-(methylsulfonyl)quinoxalin-2-amine, GLP-1 Receptor Agonists;positive allosteric modulator of GLP1R targeting GLP1R |
| GB-86-PE04_0.1uM | Dose=0.1uM, N-(tert-Butyl)-6,7-dichloro-3-(methylsulfonyl)quinoxalin-2-amine, GLP-1 Receptor Agonists;positive allosteric modulator of GLP1R targeting GLP1R |
| GB-86-PE04_10uM | Dose=10uM, N-(tert-Butyl)-6,7-dichloro-3-(methylsulfonyl)quinoxalin-2-amine, GLP-1 Receptor Agonists;positive allosteric modulator of GLP1R targeting GLP1R |
| GB-88-ZP20_0.1uM | Dose=0.1uM, Gemilukast, Dual CysLT1 and CysLT2 antagonist targeting CYSLTR1, CYSLTR2 |
| GB-88-ZP20_10uM | Dose=10uM, Gemilukast, Dual CysLT1 and CysLT2 antagonist targeting CYSLTR1, CYSLTR2 |
| GB-90-UG49_0.01uM | Dose=0.01uM, Bmy-14802, NMDA Antagonists;sigma Receptor Antagonists targeting SIGMAR1, GRIN2A, GRIN2B |
| GB-90-UG49_0.1uM | Dose=0.1uM, Bmy-14802, NMDA Antagonists;sigma Receptor Antagonists targeting SIGMAR1, GRIN2A, GRIN2B |
| GB-90-UG49_10uM | Dose=10uM, Bmy-14802, NMDA Antagonists;sigma Receptor Antagonists targeting SIGMAR1, GRIN2A, GRIN2B |
| GB-90-UG49_1uM | Dose=1uM, Bmy-14802, NMDA Antagonists;sigma Receptor Antagonists targeting SIGMAR1, GRIN2A, GRIN2B |
| GB-90-VQ08_0.1uM | Dose=0.1uM, PH 797804, P38a inhibitor targeting MAPK14 |
| GB-90-VQ08_10uM | Dose=10uM, PH 797804, P38a inhibitor targeting MAPK14 |
| GB-90-VQ08_1uM | Dose=1uM, PH 797804, P38a inhibitor targeting MAPK14 |
| GB-92-JY12_0.01uM | Dose=0.01uM, Batefenterol, Muscarinic M3 receptor antagonist, Beta 2 adrenoceptor agonist targeting ADRB2, CHRM3 |
| GB-92-JY12_0.1uM | Dose=0.1uM, Batefenterol, Muscarinic M3 receptor antagonist, Beta 2 adrenoceptor agonist targeting ADRB2, CHRM3 |
| GB-92-JY12_10uM | Dose=10uM, Batefenterol, Muscarinic M3 receptor antagonist, Beta 2 adrenoceptor agonist targeting ADRB2, CHRM3 |
| GB-92-JY12_1uM | Dose=1uM, Batefenterol, Muscarinic M3 receptor antagonist, Beta 2 adrenoceptor agonist targeting ADRB2, CHRM3 |
| GB-92-MH66_0.01uM | Dose=0.01uM, Ureidosuccinic acid |
| GB-92-MH66_0.1uM | Dose=0.1uM, Ureidosuccinic acid |
| GB-92-MH66_10uM | Dose=10uM, Ureidosuccinic acid |
| GB-92-MH66_1uM | Dose=1uM, Ureidosuccinic acid |
| GB-93-CC27_0.01uM | Dose=0.01uM, (S)-3-(4-(5-Guanidinopentanamido)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carboxamido)propanoic acid, alpha-v Beta1 integrin inhibitor targeting ITGAV, ITGA6 |
| GB-93-CC27_0.1uM | Dose=0.1uM, (S)-3-(4-(5-Guanidinopentanamido)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carboxamido)propanoic acid, alpha-v Beta1 integrin inhibitor targeting ITGAV, ITGA6 |
| GB-93-CC27_10uM | Dose=10uM, (S)-3-(4-(5-Guanidinopentanamido)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carboxamido)propanoic acid, alpha-v Beta1 integrin inhibitor targeting ITGAV, ITGA6 |
| GB-93-CC27_1uM | Dose=1uM, (S)-3-(4-(5-Guanidinopentanamido)phenyl)-2-((S)-1-(phenylsulfonyl)pyrrolidine-2-carboxamido)propanoic acid, alpha-v Beta1 integrin inhibitor targeting ITGAV, ITGA6 |
| GB-94-XG34_0.01uM | Dose=0.01uM, 1-(6-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, NF-kappaB (NFKB) Activation Inhibitors;Cytokine Production Inhibitors;AP-1 Inhibitors targeting JUN |
| GB-94-XG34_0.1uM | Dose=0.1uM, 1-(6-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, NF-kappaB (NFKB) Activation Inhibitors;Cytokine Production Inhibitors;AP-1 Inhibitors targeting JUN |
| GB-94-XG34_10uM | Dose=10uM, 1-(6-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, NF-kappaB (NFKB) Activation Inhibitors;Cytokine Production Inhibitors;AP-1 Inhibitors targeting JUN |
| GB-94-XG34_1uM | Dose=1uM, 1-(6-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione, NF-kappaB (NFKB) Activation Inhibitors;Cytokine Production Inhibitors;AP-1 Inhibitors targeting JUN |
| GB-96-WX99_0.01uM | Dose=0.01uM, 2-(5,6,7,8-tetrahydro-4H-cyclohepta[d][1,3]thiazol-2-yl)guanidine, NPFFR1 antagonist targeting NPFFR1 |
| GB-96-WX99_0.1uM | Dose=0.1uM, 2-(5,6,7,8-tetrahydro-4H-cyclohepta[d][1,3]thiazol-2-yl)guanidine, NPFFR1 antagonist targeting NPFFR1 |
| GB-96-WX99_10uM | Dose=10uM, 2-(5,6,7,8-tetrahydro-4H-cyclohepta[d][1,3]thiazol-2-yl)guanidine, NPFFR1 antagonist targeting NPFFR1 |
| GB-96-WX99_1uM | Dose=1uM, 2-(5,6,7,8-tetrahydro-4H-cyclohepta[d][1,3]thiazol-2-yl)guanidine, NPFFR1 antagonist targeting NPFFR1 |
| GB-98-IZ84_0.01uM | Dose=0.01uM, Complement C5-IN-1, C5 complement protein inhibitor targeting C5 |
| GB-98-IZ84_0.1uM | Dose=0.1uM, Complement C5-IN-1, C5 complement protein inhibitor targeting C5 |
| GB-98-IZ84_10uM | Dose=10uM, Complement C5-IN-1, C5 complement protein inhibitor targeting C5 |
| GB-98-IZ84_1uM | Dose=1uM, Complement C5-IN-1, C5 complement protein inhibitor targeting C5 |
| GC-02-TV70_0.01uM | Dose=0.01uM, Mk-3207, CGRP antagonist;highly potent calcitonin gene-related peptide (CGRP) receptor antagonist targeting CALCA, CALCRL, RAMP1, CRCP |
| GC-02-TV70_0.1uM | Dose=0.1uM, Mk-3207, CGRP antagonist;highly potent calcitonin gene-related peptide (CGRP) receptor antagonist targeting CALCA, CALCRL, RAMP1, CRCP |
| GC-02-TV70_10uM | Dose=10uM, Mk-3207, CGRP antagonist;highly potent calcitonin gene-related peptide (CGRP) receptor antagonist targeting CALCA, CALCRL, RAMP1, CRCP |
| GC-02-TV70_1uM | Dose=1uM, Mk-3207, CGRP antagonist;highly potent calcitonin gene-related peptide (CGRP) receptor antagonist targeting CALCA, CALCRL, RAMP1, CRCP |
| GC-03-VV12_0.01uM | Dose=0.01uM, Vanillin |
| GC-03-VV12_0.1uM | Dose=0.1uM, Vanillin |
| GC-03-VV12_1uM | Dose=1uM, Vanillin |
| GC-04-UF36_0.01uM | Dose=0.01uM, Diacetoxyscirpenol, Translation inhibitor;Apoptosis Inducers;SGLT-1 expression Inhibitors targeting SLC5A1 |
| GC-04-UF36_0.1uM | Dose=0.1uM, Diacetoxyscirpenol, Translation inhibitor;Apoptosis Inducers;SGLT-1 expression Inhibitors targeting SLC5A1 |
| GC-04-UF36_10uM | Dose=10uM, Diacetoxyscirpenol, Translation inhibitor;Apoptosis Inducers;SGLT-1 expression Inhibitors targeting SLC5A1 |
| GC-04-UF36_1uM | Dose=1uM, Diacetoxyscirpenol, Translation inhibitor;Apoptosis Inducers;SGLT-1 expression Inhibitors targeting SLC5A1 |
| GC-06-BU42_0.01uM | Dose=0.01uM, N-benzyl-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide, SCD inhibitor targeting SCD |
| GC-06-BU42_0.1uM | Dose=0.1uM, N-benzyl-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide, SCD inhibitor targeting SCD |
| GC-06-BU42_10uM | Dose=10uM, N-benzyl-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide, SCD inhibitor targeting SCD |
| GC-06-BU42_1uM | Dose=1uM, N-benzyl-2-(4-hydroxy-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-carboxamide, SCD inhibitor targeting SCD |
| GC-07-KH68_0.01uM | Dose=0.01uM, Oxotremorine, Muscarinic receptor agonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| GC-07-KH68_0.1uM | Dose=0.1uM, Oxotremorine, Muscarinic receptor agonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| GC-07-KH68_10uM | Dose=10uM, Oxotremorine, Muscarinic receptor agonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| GC-07-KH68_1uM | Dose=1uM, Oxotremorine, Muscarinic receptor agonist targeting CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| GC-07-UO80_0.01uM | Dose=0.01uM, Ogerin, positive allosteric modulator of GPR68 targeting GPR68 |
| GC-07-UO80_0.1uM | Dose=0.1uM, Ogerin, positive allosteric modulator of GPR68 targeting GPR68 |
| GC-07-UO80_10uM | Dose=10uM, Ogerin, positive allosteric modulator of GPR68 targeting GPR68 |
| GC-07-UO80_1uM | Dose=1uM, Ogerin, positive allosteric modulator of GPR68 targeting GPR68 |
| GC-08-VP20_0.01uM | Dose=0.01uM, Benzamil, ;PKD2L2 gene inhibitor;Sodium calcium exchanger 1 inhibitor targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G, PKD2L2 |
| GC-08-VP20_0.1uM | Dose=0.1uM, Benzamil, ;PKD2L2 gene inhibitor;Sodium calcium exchanger 1 inhibitor targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G, PKD2L2 |
| GC-08-VP20_10uM | Dose=10uM, Benzamil, ;PKD2L2 gene inhibitor;Sodium calcium exchanger 1 inhibitor targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G, PKD2L2 |
| GC-08-VP20_1uM | Dose=1uM, Benzamil, ;PKD2L2 gene inhibitor;Sodium calcium exchanger 1 inhibitor targeting SCNN1A, SCNN1B, SCNN1D, SCNN1G, PKD2L2 |
| GC-09-EG26_0.01uM | Dose=0.01uM, Carcinine, HRH3 antagonist targeting HRH3 |
| GC-09-EG26_0.1uM | Dose=0.1uM, Carcinine, HRH3 antagonist targeting HRH3 |
| GC-09-EG26_10uM | Dose=10uM, Carcinine, HRH3 antagonist targeting HRH3 |
| GC-09-EG26_1uM | Dose=1uM, Carcinine, HRH3 antagonist targeting HRH3 |
| GC-09-XF08_0.01uM | Dose=0.01uM, (2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid, Bradykinin B1 Agonists targeting BDKRB1 |
| GC-09-XF08_0.1uM | Dose=0.1uM, (2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid, Bradykinin B1 Agonists targeting BDKRB1 |
| GC-09-XF08_10uM | Dose=10uM, (2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid, Bradykinin B1 Agonists targeting BDKRB1 |
| GC-09-XF08_1uM | Dose=1uM, (2R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid, Bradykinin B1 Agonists targeting BDKRB1 |
| GC-11-YA32_0.01uM | Dose=0.01uM |
| GC-11-YA32_0.1uM | Dose=0.1uM |
| GC-11-YA32_10uM | Dose=10uM |
| GC-11-YA32_1uM | Dose=1uM |
| GC-15-JX22_0.01uM | Dose=0.01uM |
| GC-15-JX22_0.1uM | Dose=0.1uM |
| GC-15-JX22_10uM | Dose=10uM |
| GC-15-JX22_1uM | Dose=1uM |
| GC-21-AN18_0.01uM | Dose=0.01uM, SR-31747 free base, sigma1 Receptor Ligands;sigma2 Receptor Ligands targeting SIGMAR1 |
| GC-21-AN18_0.1uM | Dose=0.1uM, SR-31747 free base, sigma1 Receptor Ligands;sigma2 Receptor Ligands targeting SIGMAR1 |
| GC-21-AN18_10uM | Dose=10uM, SR-31747 free base, sigma1 Receptor Ligands;sigma2 Receptor Ligands targeting SIGMAR1 |
| GC-21-AN18_1uM | Dose=1uM, SR-31747 free base, sigma1 Receptor Ligands;sigma2 Receptor Ligands targeting SIGMAR1 |
| GC-21-IX32_0.01uM | Dose=0.01uM, Boc-Met-Leu-Phe-OH, FPR1 antagonist targeting FPR1 |
| GC-21-IX32_0.1uM | Dose=0.1uM, Boc-Met-Leu-Phe-OH, FPR1 antagonist targeting FPR1 |
| GC-21-IX32_10uM | Dose=10uM, Boc-Met-Leu-Phe-OH, FPR1 antagonist targeting FPR1 |
| GC-21-IX32_1uM | Dose=1uM, Boc-Met-Leu-Phe-OH, FPR1 antagonist targeting FPR1 |
| GC-28-YS77_0.01uM | Dose=0.01uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-n-(pyridin-2-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| GC-28-YS77_0.1uM | Dose=0.1uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-n-(pyridin-2-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| GC-28-YS77_10uM | Dose=10uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-n-(pyridin-2-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| GC-28-YS77_1uM | Dose=1uM, 4-Methyl-2-(2-oxo-3-(4-(trifluoromethoxy)benzyl)imidazolidin-1-yl)-n-(pyridin-2-ylmethyl)thiazole-5-carboxamide, SCD inhibitor targeting SCD |
| GC-29-JC76_0.01uM | Dose=0.01uM, 1-[4-(4-Benzhydryl-piperazin-1-yl)-3-cyano-phenyl]-3-(3,5-dimethyl-isoxazol-4-yl)-urea, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R |
| GC-29-JC76_0.1uM | Dose=0.1uM, 1-[4-(4-Benzhydryl-piperazin-1-yl)-3-cyano-phenyl]-3-(3,5-dimethyl-isoxazol-4-yl)-urea, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R |
| GC-29-JC76_10uM | Dose=10uM, 1-[4-(4-Benzhydryl-piperazin-1-yl)-3-cyano-phenyl]-3-(3,5-dimethyl-isoxazol-4-yl)-urea, Neuropeptide Y2 (NPY Y2) Antagonists targeting NPY2R |
| GC-32-SH41_0.01uM | Dose=0.01uM, MMP3 inhibitor 2 |
| GC-32-SH41_10uM | Dose=10uM, MMP3 inhibitor 2 |
| GC-32-SH41_1uM | Dose=1uM, MMP3 inhibitor 2 |
| GC-35-PT27_1uM | Dose=1uM, MMP-9 (Gelatinase B) Inhibitors |
| GC-40-VJ01_0.01uM | Dose=0.01uM, Pterocarpanquinone |
| GC-40-VJ01_0.1uM | Dose=0.1uM, Pterocarpanquinone |
| GC-40-VJ01_10uM | Dose=10uM, Pterocarpanquinone |
| GC-40-VJ01_1uM | Dose=1uM, Pterocarpanquinone |
| GC-42-LL86_0.01uM | Dose=0.01uM, 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)phenyl]urea, Heparanase Inhibitors;Angiogenesis Inhibitors targeting HPSE |
| GC-42-LL86_0.1uM | Dose=0.1uM, 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)phenyl]urea, Heparanase Inhibitors;Angiogenesis Inhibitors targeting HPSE |
| GC-42-LL86_10uM | Dose=10uM, 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)phenyl]urea, Heparanase Inhibitors;Angiogenesis Inhibitors targeting HPSE |
| GC-42-LL86_1uM | Dose=1uM, 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)phenyl]urea, Heparanase Inhibitors;Angiogenesis Inhibitors targeting HPSE |
| GC-42-SY57_0.01uM | Dose=0.01uM, (S)-3-(4-Hydroxy-phenyl)-N-methyl-2-[3-(5-thioxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)-ureido]-propionamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| GC-42-SY57_10uM | Dose=10uM, (S)-3-(4-Hydroxy-phenyl)-N-methyl-2-[3-(5-thioxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)-ureido]-propionamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| GC-42-SY57_1uM | Dose=1uM, (S)-3-(4-Hydroxy-phenyl)-N-methyl-2-[3-(5-thioxo-4,5-dihydro-[1,3,4]thiadiazol-2-yl)-ureido]-propionamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| GC-46-AX49_0.01uM | Dose=0.01uM, 3(S)-[1-(4'-cyanobiphenyl-4-yl)-1H-pyrrol-3-yl]-N-(4, 4-dimethyl-2-oxo-tetrahydrofuran-3(S)-yl)succinamic acid, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting MMP2, MMP3, MMP13 |
| GC-46-AX49_0.1uM | Dose=0.1uM, 3(S)-[1-(4'-cyanobiphenyl-4-yl)-1H-pyrrol-3-yl]-N-(4, 4-dimethyl-2-oxo-tetrahydrofuran-3(S)-yl)succinamic acid, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting MMP2, MMP3, MMP13 |
| GC-46-AX49_10uM | Dose=10uM, 3(S)-[1-(4'-cyanobiphenyl-4-yl)-1H-pyrrol-3-yl]-N-(4, 4-dimethyl-2-oxo-tetrahydrofuran-3(S)-yl)succinamic acid, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting MMP2, MMP3, MMP13 |
| GC-46-AX49_1uM | Dose=1uM, 3(S)-[1-(4'-cyanobiphenyl-4-yl)-1H-pyrrol-3-yl]-N-(4, 4-dimethyl-2-oxo-tetrahydrofuran-3(S)-yl)succinamic acid, Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors targeting MMP2, MMP3, MMP13 |
| GC-46-CA74_0.01uM | Dose=0.01uM, Bms-754807, IGF-1R Inhibitors targeting IGF1R |
| GC-46-CA74_10uM | Dose=10uM, Bms-754807, IGF-1R Inhibitors targeting IGF1R |
| GC-46-CA74_1uM | Dose=1uM, Bms-754807, IGF-1R Inhibitors targeting IGF1R |
| GC-49-HD44_0.1uM | Dose=0.1uM, Unc0642, EHMT1/2 targeting EHMT2, EHMT1 |
| GC-49-HD44_10uM | Dose=10uM, Unc0642, EHMT1/2 targeting EHMT2, EHMT1 |
| GC-49-HD44_1uM | Dose=1uM, Unc0642, EHMT1/2 targeting EHMT2, EHMT1 |
| GC-54-IZ89_0.01uM | Dose=0.01uM, CID 10189783, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP1 |
| GC-54-IZ89_0.1uM | Dose=0.1uM, CID 10189783, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP1 |
| GC-54-IZ89_10uM | Dose=10uM, CID 10189783, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP1 |
| GC-54-IZ89_1uM | Dose=1uM, CID 10189783, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting CASP1 |
| GC-57-HV87_0.01uM | Dose=0.01uM |
| GC-57-HV87_0.1uM | Dose=0.1uM |
| GC-57-HV87_10uM | Dose=10uM |
| GC-57-HV87_1uM | Dose=1uM |
| GC-60-XQ43_0.1uM | Dose=0.1uM, Insulin Receptor Antagonists;IGF-1R Inhibitors targeting IGF1R, INSR |
| GC-60-XQ43_10uM | Dose=10uM, Insulin Receptor Antagonists;IGF-1R Inhibitors targeting IGF1R, INSR |
| GC-60-XQ43_1uM | Dose=1uM, Insulin Receptor Antagonists;IGF-1R Inhibitors targeting IGF1R, INSR |
| GC-61-BD64_0.01uM | Dose=0.01uM, Phenoxybenzamine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| GC-61-BD64_0.1uM | Dose=0.1uM, Phenoxybenzamine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| GC-61-BD64_10uM | Dose=10uM, Phenoxybenzamine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| GC-61-BD64_1uM | Dose=1uM, Phenoxybenzamine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| GC-67-AH43_0.01uM | Dose=0.01uM, Biomed 101, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| GC-67-AH43_0.1uM | Dose=0.1uM, Biomed 101, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| GC-67-AH43_1uM | Dose=1uM, Biomed 101, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| GC-69-JF03_0.01uM | Dose=0.01uM |
| GC-69-JF03_0.1uM | Dose=0.1uM |
| GC-69-JF03_10uM | Dose=10uM |
| GC-69-JF03_1uM | Dose=1uM |
| GC-72-GY67_0.01uM | Dose=0.01uM |
| GC-72-GY67_0.1uM | Dose=0.1uM |
| GC-72-GY67_10uM | Dose=10uM |
| GC-72-GY67_1uM | Dose=1uM |
| GC-73-YI26_0.01uM | Dose=0.01uM, 4-(2,6-Difluoro-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors;Jak1 Inhibitors targeting JAK1, JAK2 |
| GC-73-YI26_0.1uM | Dose=0.1uM, 4-(2,6-Difluoro-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors;Jak1 Inhibitors targeting JAK1, JAK2 |
| GC-73-YI26_10uM | Dose=10uM, 4-(2,6-Difluoro-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors;Jak1 Inhibitors targeting JAK1, JAK2 |
| GC-73-YI26_1uM | Dose=1uM, 4-(2,6-Difluoro-4-(3-(4-(4-methylpiperazin-1-yl)phenyl)quinoxalin-5-yl)benzyl)morpholine, Jak2 Inhibitors;Jak1 Inhibitors targeting JAK1, JAK2 |
| GC-74-QF56_0.01uM | Dose=0.01uM, 2,2'-Dihydroxy-3,3',5,5'-tetrabromobiphenyl |
| GC-74-QF56_0.1uM | Dose=0.1uM, 2,2'-Dihydroxy-3,3',5,5'-tetrabromobiphenyl |
| GC-74-QF56_10uM | Dose=10uM, 2,2'-Dihydroxy-3,3',5,5'-tetrabromobiphenyl |
| GC-74-QF56_1uM | Dose=1uM, 2,2'-Dihydroxy-3,3',5,5'-tetrabromobiphenyl |
| GC-81-IA52_0.01uM | Dose=0.01uM, 2-(2-hydroxy-(1,1'-biphenyl)-3-yl)-1H-1,3-benzodiazole-5-carboximidamide, Urokinase (u-PA) Inhibitors;Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting F2, PLAT, PLAU, F10, PLG |
| GC-81-IA52_10uM | Dose=10uM, 2-(2-hydroxy-(1,1'-biphenyl)-3-yl)-1H-1,3-benzodiazole-5-carboximidamide, Urokinase (u-PA) Inhibitors;Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting F2, PLAT, PLAU, F10, PLG |
| GC-81-IA52_1uM | Dose=1uM, 2-(2-hydroxy-(1,1'-biphenyl)-3-yl)-1H-1,3-benzodiazole-5-carboximidamide, Urokinase (u-PA) Inhibitors;Tissue-Type Plasminogen Activator (t-PA) Inhibitors targeting F2, PLAT, PLAU, F10, PLG |
| GC-82-RV65_0.01uM | Dose=0.01uM, Dexrazoxane, Topoisomerase II inhibitor targeting TOP2B |
| GC-82-RV65_0.1uM | Dose=0.1uM, Dexrazoxane, Topoisomerase II inhibitor targeting TOP2B |
| GC-82-RV65_10uM | Dose=10uM, Dexrazoxane, Topoisomerase II inhibitor targeting TOP2B |
| GC-82-RV65_1uM | Dose=1uM, Dexrazoxane, Topoisomerase II inhibitor targeting TOP2B |
| GC-83-NL88_0.01uM | Dose=0.01uM, SC-58125, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| GC-83-NL88_10uM | Dose=10uM, SC-58125, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| GC-83-NL88_1uM | Dose=1uM, SC-58125, Cyclooxygenase-2 Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| GC-86-TD91_0.01uM | Dose=0.01uM, 6-Chloro-2-(1-piperazinyl)pyrazine, 5-HT2C Agonists targeting CHRNA1, CHRNA2, CHRNA3, CHRNA5, CHRNB1, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG, CHRNA6, CHRNA9, CHRNA10 |
| GC-86-TD91_0.1uM | Dose=0.1uM, 6-Chloro-2-(1-piperazinyl)pyrazine, 5-HT2C Agonists targeting CHRNA1, CHRNA2, CHRNA3, CHRNA5, CHRNB1, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG, CHRNA6, CHRNA9, CHRNA10 |
| GC-86-TD91_10uM | Dose=10uM, 6-Chloro-2-(1-piperazinyl)pyrazine, 5-HT2C Agonists targeting CHRNA1, CHRNA2, CHRNA3, CHRNA5, CHRNB1, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG, CHRNA6, CHRNA9, CHRNA10 |
| GC-86-TD91_1uM | Dose=1uM, 6-Chloro-2-(1-piperazinyl)pyrazine, 5-HT2C Agonists targeting CHRNA1, CHRNA2, CHRNA3, CHRNA5, CHRNB1, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG, CHRNA6, CHRNA9, CHRNA10 |
| GC-90-GG29_0.01uM | Dose=0.01uM, KDM1A (LSD1) inhibitor targeting KDM1A |
| GC-90-GG29_0.1uM | Dose=0.1uM, KDM1A (LSD1) inhibitor targeting KDM1A |
| GC-90-GG29_10uM | Dose=10uM, KDM1A (LSD1) inhibitor targeting KDM1A |
| GC-90-GG29_1uM | Dose=1uM, KDM1A (LSD1) inhibitor targeting KDM1A |
| GD-07-HO70_0.01uM | Dose=0.01uM |
| GD-07-HO70_0.1uM | Dose=0.1uM |
| GD-07-HO70_10uM | Dose=10uM |
| GD-07-HO70_1uM | Dose=1uM |
| GD-07-UH23_0.01uM | Dose=0.01uM, 2-[[2-(4-Propan-2-ylphenoxy)acetyl]amino]benzoic acid, HM74A) Receptor Agonists;GPR109A;Nicotinic Acid (Niacin targeting HCAR2 |
| GD-07-UH23_0.1uM | Dose=0.1uM, 2-[[2-(4-Propan-2-ylphenoxy)acetyl]amino]benzoic acid, HM74A) Receptor Agonists;GPR109A;Nicotinic Acid (Niacin targeting HCAR2 |
| GD-07-UH23_10uM | Dose=10uM, 2-[[2-(4-Propan-2-ylphenoxy)acetyl]amino]benzoic acid, HM74A) Receptor Agonists;GPR109A;Nicotinic Acid (Niacin targeting HCAR2 |
| GD-07-XY44_0.01uM | Dose=0.01uM, (2S,3S)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]-3-methylpyrrolidine-2-carboxamide |
| GD-07-XY44_0.1uM | Dose=0.1uM, (2S,3S)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]-3-methylpyrrolidine-2-carboxamide |
| GD-07-XY44_10uM | Dose=10uM, (2S,3S)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]-3-methylpyrrolidine-2-carboxamide |
| GD-07-XY44_1uM | Dose=1uM, (2S,3S)-N-[(2S)-6-amino-1-(1,3-benzoxazol-2-yl)-1-oxohexan-2-yl]-1-[(2R)-2-(methanesulfonamido)-4-piperidin-4-ylbutanoyl]-3-methylpyrrolidine-2-carboxamide |
| GD-08-JL45_0.01uM | Dose=0.01uM, (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(4-methylphenyl)-2-propan-2-ylthiophen-3-yl]-3,5-dihydroxyhept-6-enoic acid |
| GD-08-JL45_0.1uM | Dose=0.1uM, (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(4-methylphenyl)-2-propan-2-ylthiophen-3-yl]-3,5-dihydroxyhept-6-enoic acid |
| GD-08-JL45_10uM | Dose=10uM, (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(4-methylphenyl)-2-propan-2-ylthiophen-3-yl]-3,5-dihydroxyhept-6-enoic acid |
| GD-08-JL45_1uM | Dose=1uM, (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(4-methylphenyl)-2-propan-2-ylthiophen-3-yl]-3,5-dihydroxyhept-6-enoic acid |
| GD-09-QJ83_0.01uM | Dose=0.01uM, Lotamilast, PDE4 inhibitor for topical application targeting PDE4A, PDE4B, PDE4C, PDE4D |
| GD-09-QJ83_10uM | Dose=10uM, Lotamilast, PDE4 inhibitor for topical application targeting PDE4A, PDE4B, PDE4C, PDE4D |
| GD-09-QJ83_1uM | Dose=1uM, Lotamilast, PDE4 inhibitor for topical application targeting PDE4A, PDE4B, PDE4C, PDE4D |
| GD-11-LR18_0.1uM | Dose=0.1uM, acyl protein thioesterase 1 inhibitor |
| GD-17-GR17_0.01uM | Dose=0.01uM, 1-{2-[2-(5-Chloro-pyridin-2-ylamino)-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| GD-17-GR17_0.1uM | Dose=0.1uM, 1-{2-[2-(5-Chloro-pyridin-2-ylamino)-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| GD-17-GR17_1uM | Dose=1uM, 1-{2-[2-(5-Chloro-pyridin-2-ylamino)-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile, DP-IV) Inhibitors;DPP-IV;Dipeptidyl Peptidase IV (CD26 targeting DPP4 |
| GD-23-GS20_0.01uM | Dose=0.01uM, N-[3-[6-[2-(3-hydroxypyrrolidin-1-yl)ethoxy]-4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenyl]butanamide, Rho Kinase 2 (ROCK 2;ROCKalpha) Inhibitors;p160-ROCK) Inhibitors;Inhibitors of Signal Transduction Pathways;Rho Kinase 1 (ROCK 1 targeting ROCK2 |
| GD-23-GS20_0.1uM | Dose=0.1uM, N-[3-[6-[2-(3-hydroxypyrrolidin-1-yl)ethoxy]-4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenyl]butanamide, Rho Kinase 2 (ROCK 2;ROCKalpha) Inhibitors;p160-ROCK) Inhibitors;Inhibitors of Signal Transduction Pathways;Rho Kinase 1 (ROCK 1 targeting ROCK2 |
| GD-23-GS20_10uM | Dose=10uM, N-[3-[6-[2-(3-hydroxypyrrolidin-1-yl)ethoxy]-4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenyl]butanamide, Rho Kinase 2 (ROCK 2;ROCKalpha) Inhibitors;p160-ROCK) Inhibitors;Inhibitors of Signal Transduction Pathways;Rho Kinase 1 (ROCK 1 targeting ROCK2 |
| GD-23-GS20_1uM | Dose=1uM, N-[3-[6-[2-(3-hydroxypyrrolidin-1-yl)ethoxy]-4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenyl]butanamide, Rho Kinase 2 (ROCK 2;ROCKalpha) Inhibitors;p160-ROCK) Inhibitors;Inhibitors of Signal Transduction Pathways;Rho Kinase 1 (ROCK 1 targeting ROCK2 |
| GD-27-UE16_0.01uM | Dose=0.01uM, GPR41 agonist-1, GPR41 agonist targeting FFAR3 |
| GD-27-UE16_0.1uM | Dose=0.1uM, GPR41 agonist-1, GPR41 agonist targeting FFAR3 |
| GD-27-UE16_10uM | Dose=10uM, GPR41 agonist-1, GPR41 agonist targeting FFAR3 |
| GD-33-XB49_0.01uM | Dose=0.01uM, 5-Benzyl-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11 |
| GD-33-XB49_0.1uM | Dose=0.1uM, 5-Benzyl-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11 |
| GD-33-XB49_10uM | Dose=10uM, 5-Benzyl-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11 |
| GD-33-XB49_1uM | Dose=1uM, 5-Benzyl-1,1-dioxo-1,2,5-thiadiazolidin-3-one, Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitors targeting PTPN11 |
| GD-39-YG36_0.01uM | Dose=0.01uM, CID 137636547 |
| GD-39-YG36_0.1uM | Dose=0.1uM, CID 137636547 |
| GD-39-YG36_10uM | Dose=10uM, CID 137636547 |
| GD-39-YG36_1uM | Dose=1uM, CID 137636547 |
| GD-41-HR28_0.01uM | Dose=0.01uM |
| GD-41-HR28_0.1uM | Dose=0.1uM |
| GD-41-HR28_10uM | Dose=10uM |
| GD-41-HR28_1uM | Dose=1uM |
| GD-43-TP28_0.01uM | Dose=0.01uM, Vidupiprant, CRTH2 Receptor Antagonists;Prostanoid DP (DP1) Antagonists targeting PTGDR, PTGDR2 |
| GD-43-TP28_0.1uM | Dose=0.1uM, Vidupiprant, CRTH2 Receptor Antagonists;Prostanoid DP (DP1) Antagonists targeting PTGDR, PTGDR2 |
| GD-43-TP28_10uM | Dose=10uM, Vidupiprant, CRTH2 Receptor Antagonists;Prostanoid DP (DP1) Antagonists targeting PTGDR, PTGDR2 |
| GD-43-TP28_1uM | Dose=1uM, Vidupiprant, CRTH2 Receptor Antagonists;Prostanoid DP (DP1) Antagonists targeting PTGDR, PTGDR2 |
| GD-46-BU97_0.01uM | Dose=0.01uM, 2-(4-tert-butylphenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]acetamide |
| GD-46-BU97_0.1uM | Dose=0.1uM, 2-(4-tert-butylphenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]acetamide |
| GD-46-BU97_10uM | Dose=10uM, 2-(4-tert-butylphenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]acetamide |
| GD-46-BU97_1uM | Dose=1uM, 2-(4-tert-butylphenyl)-N-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]methyl]acetamide |
| GD-46-OD81_0.01uM | Dose=0.01uM, U 41792 |
| GD-46-OD81_0.1uM | Dose=0.1uM, U 41792 |
| GD-46-OD81_10uM | Dose=10uM, U 41792 |
| GD-46-OD81_1uM | Dose=1uM, U 41792 |
| GD-48-HM23_10uM | Dose=10uM, Selonsertib, MAP3K5 inhibitor targeting MAP3K5 |
| GD-51-SU60_0.01uM | Dose=0.01uM, Bafilomycin A, v-ATPase inhibitor targeting ATP5PF, ATP6V1A, ATP6V1H |
| GD-51-SU60_0.1uM | Dose=0.1uM, Bafilomycin A, v-ATPase inhibitor targeting ATP5PF, ATP6V1A, ATP6V1H |
| GD-51-SU60_10uM | Dose=10uM, Bafilomycin A, v-ATPase inhibitor targeting ATP5PF, ATP6V1A, ATP6V1H |
| GD-51-SU60_1uM | Dose=1uM, Bafilomycin A, v-ATPase inhibitor targeting ATP5PF, ATP6V1A, ATP6V1H |
| GD-56-YA39_0.01uM | Dose=0.01uM, 3-(3,5-Dimethyl-4-(6-(quinolin-2-ylcarbamoyl)-1H-benzo[d]imidazol-2-yl)phenyl)propanoic acid, DGAT1 gene inhibitor targeting SOAT1, SOAT2, DGAT1 |
| GD-56-YA39_0.1uM | Dose=0.1uM, 3-(3,5-Dimethyl-4-(6-(quinolin-2-ylcarbamoyl)-1H-benzo[d]imidazol-2-yl)phenyl)propanoic acid, DGAT1 gene inhibitor targeting SOAT1, SOAT2, DGAT1 |
| GD-56-YA39_10uM | Dose=10uM, 3-(3,5-Dimethyl-4-(6-(quinolin-2-ylcarbamoyl)-1H-benzo[d]imidazol-2-yl)phenyl)propanoic acid, DGAT1 gene inhibitor targeting SOAT1, SOAT2, DGAT1 |
| GD-56-YA39_1uM | Dose=1uM, 3-(3,5-Dimethyl-4-(6-(quinolin-2-ylcarbamoyl)-1H-benzo[d]imidazol-2-yl)phenyl)propanoic acid, DGAT1 gene inhibitor targeting SOAT1, SOAT2, DGAT1 |
| GD-59-OG21_0.01uM | Dose=0.01uM, Stavudine |
| GD-59-OG21_0.1uM | Dose=0.1uM, Stavudine |
| GD-59-OG21_10uM | Dose=10uM, Stavudine |
| GD-59-OG21_1uM | Dose=1uM, Stavudine |
| GD-59-QF63_0.01uM | Dose=0.01uM, 6,7-Dihydroxy-3,4a,5-trimethyl-4,5,6,7-tetrahydrobenzo[f][1]benzofuran-2-one, Progesterone Receptor Antagonists targeting PGR |
| GD-59-QF63_0.1uM | Dose=0.1uM, 6,7-Dihydroxy-3,4a,5-trimethyl-4,5,6,7-tetrahydrobenzo[f][1]benzofuran-2-one, Progesterone Receptor Antagonists targeting PGR |
| GD-59-QF63_10uM | Dose=10uM, 6,7-Dihydroxy-3,4a,5-trimethyl-4,5,6,7-tetrahydrobenzo[f][1]benzofuran-2-one, Progesterone Receptor Antagonists targeting PGR |
| GD-59-QF63_1uM | Dose=1uM, 6,7-Dihydroxy-3,4a,5-trimethyl-4,5,6,7-tetrahydrobenzo[f][1]benzofuran-2-one, Progesterone Receptor Antagonists targeting PGR |
| GD-63-XB79_0.01uM | Dose=0.01uM, 6-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
| GD-63-XB79_0.1uM | Dose=0.1uM, 6-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
| GD-63-XB79_10uM | Dose=10uM, 6-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
| GD-63-XB79_1uM | Dose=1uM, 6-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-[(1R)-1-phenylethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
| GD-66-LN30_0.01uM | Dose=0.01uM, 3-[4-[4-(3-chlorophenyl)piperazin-1-yl]butyl]-1H-benzimidazol-2-one, 5-HT1A Receptor Antagonists;5-HT2A Antagonists targeting HTR1A, HTR2A |
| GD-66-LN30_0.1uM | Dose=0.1uM, 3-[4-[4-(3-chlorophenyl)piperazin-1-yl]butyl]-1H-benzimidazol-2-one, 5-HT1A Receptor Antagonists;5-HT2A Antagonists targeting HTR1A, HTR2A |
| GD-66-LN30_10uM | Dose=10uM, 3-[4-[4-(3-chlorophenyl)piperazin-1-yl]butyl]-1H-benzimidazol-2-one, 5-HT1A Receptor Antagonists;5-HT2A Antagonists targeting HTR1A, HTR2A |
| GD-66-LN30_1uM | Dose=1uM, 3-[4-[4-(3-chlorophenyl)piperazin-1-yl]butyl]-1H-benzimidazol-2-one, 5-HT1A Receptor Antagonists;5-HT2A Antagonists targeting HTR1A, HTR2A |
| GD-66-XE49_0.01uM | Dose=0.01uM |
| GD-66-XE49_0.1uM | Dose=0.1uM |
| GD-66-XE49_10uM | Dose=10uM |
| GD-66-XE49_1uM | Dose=1uM |
| GD-69-GP37_0.01uM | Dose=0.01uM, RG7800, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| GD-69-GP37_0.1uM | Dose=0.1uM, RG7800, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| GD-69-GP37_10uM | Dose=10uM, RG7800, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| GD-69-GP37_1uM | Dose=1uM, RG7800, splicing modulator targeting RNU1-4, SNRPC, RNU1-3, RNU1-2, RNU1-1 |
| GD-69-KC91_0.01uM | Dose=0.01uM, Bleomycin |
| GD-69-KC91_0.1uM | Dose=0.1uM, Bleomycin |
| GD-69-KC91_10uM | Dose=10uM, Bleomycin |
| GD-69-KC91_1uM | Dose=1uM, Bleomycin |
| GD-70-NJ06_0.01uM | Dose=0.01uM, (2S)-2-[[2-(furan-2-ylmethyl)-1-[(1R,2R)-2-methylcyclohexyl]benzimidazole-5-carbonyl]amino]-4-methylpentanoic acid, Apelin receptor agonist targeting APLNR |
| GD-70-NJ06_0.1uM | Dose=0.1uM, (2S)-2-[[2-(furan-2-ylmethyl)-1-[(1R,2R)-2-methylcyclohexyl]benzimidazole-5-carbonyl]amino]-4-methylpentanoic acid, Apelin receptor agonist targeting APLNR |
| GD-70-NJ06_10uM | Dose=10uM, (2S)-2-[[2-(furan-2-ylmethyl)-1-[(1R,2R)-2-methylcyclohexyl]benzimidazole-5-carbonyl]amino]-4-methylpentanoic acid, Apelin receptor agonist targeting APLNR |
| GD-70-NJ06_1uM | Dose=1uM, (2S)-2-[[2-(furan-2-ylmethyl)-1-[(1R,2R)-2-methylcyclohexyl]benzimidazole-5-carbonyl]amino]-4-methylpentanoic acid, Apelin receptor agonist targeting APLNR |
| GD-71-OU80_0.01uM | Dose=0.01uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]phenyl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| GD-71-OU80_0.1uM | Dose=0.1uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]phenyl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| GD-71-OU80_10uM | Dose=10uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]phenyl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| GD-71-OU80_1uM | Dose=1uM, 4-chloro-N-[4-[(4-chlorophenyl)sulfonylamino]phenyl]benzenesulfonamide, Carboxylesterase Inhibitors targeting CES1, CES2, CES3, CES1P1, CES5A |
| GD-72-XO18_0.01uM | Dose=0.01uM, Inflachromene, HMGB2 gene inhibitor targeting HMGB1, HMGB2 |
| GD-72-XO18_0.1uM | Dose=0.1uM, Inflachromene, HMGB2 gene inhibitor targeting HMGB1, HMGB2 |
| GD-72-XO18_10uM | Dose=10uM, Inflachromene, HMGB2 gene inhibitor targeting HMGB1, HMGB2 |
| GD-72-XO18_1uM | Dose=1uM, Inflachromene, HMGB2 gene inhibitor targeting HMGB1, HMGB2 |
| GD-73-ZF64_0.01uM | Dose=0.01uM, 1-Phenyl-3-[2-(4-sulfamoylphenyl)ethyl]thiourea, Carbonic anhydrase inhibitor targeting CA9 |
| GD-73-ZF64_0.1uM | Dose=0.1uM, 1-Phenyl-3-[2-(4-sulfamoylphenyl)ethyl]thiourea, Carbonic anhydrase inhibitor targeting CA9 |
| GD-73-ZF64_10uM | Dose=10uM, 1-Phenyl-3-[2-(4-sulfamoylphenyl)ethyl]thiourea, Carbonic anhydrase inhibitor targeting CA9 |
| GD-73-ZF64_1uM | Dose=1uM, 1-Phenyl-3-[2-(4-sulfamoylphenyl)ethyl]thiourea, Carbonic anhydrase inhibitor targeting CA9 |
| GD-79-JJ38_0.01uM | Dose=0.01uM, 6H-Dibenzo[a,g]quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, 5-HT Release Inhibitors targeting DRD1, DRD2, DRD3, DRD4, DRD5 |
| GD-79-JJ38_0.1uM | Dose=0.1uM, 6H-Dibenzo[a,g]quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, 5-HT Release Inhibitors targeting DRD1, DRD2, DRD3, DRD4, DRD5 |
| GD-79-JJ38_10uM | Dose=10uM, 6H-Dibenzo[a,g]quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, 5-HT Release Inhibitors targeting DRD1, DRD2, DRD3, DRD4, DRD5 |
| GD-79-JJ38_1uM | Dose=1uM, 6H-Dibenzo[a,g]quinolizine, 5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-, 5-HT Release Inhibitors targeting DRD1, DRD2, DRD3, DRD4, DRD5 |
| GD-79-TW34_0.1uM | Dose=0.1uM, N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide, SIRT1;Histone Deacetylase SIRT1 Activators targeting SIRT1 |
| GD-79-TW34_10uM | Dose=10uM, N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide, SIRT1;Histone Deacetylase SIRT1 Activators targeting SIRT1 |
| GD-79-TW34_1uM | Dose=1uM, N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide, SIRT1;Histone Deacetylase SIRT1 Activators targeting SIRT1 |
| GD-82-CS38_0.01uM | Dose=0.01uM, Idasanutlin, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| GD-82-CS38_0.1uM | Dose=0.1uM, Idasanutlin, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| GD-82-CS38_10uM | Dose=10uM, Idasanutlin, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| GD-82-CS38_1uM | Dose=1uM, Idasanutlin, Mdm2 p53-binding protein inhibitor targeting MDM2 |
| GD-85-ST07_0.01uM | Dose=0.01uM, 3-Pentenoic acid, 2-amino-4-methyl-5-phosphono-, (S-(E))- |
| GD-85-ST07_0.1uM | Dose=0.1uM, 3-Pentenoic acid, 2-amino-4-methyl-5-phosphono-, (S-(E))- |
| GD-85-ST07_10uM | Dose=10uM, 3-Pentenoic acid, 2-amino-4-methyl-5-phosphono-, (S-(E))- |
| GD-85-ST07_1uM | Dose=1uM, 3-Pentenoic acid, 2-amino-4-methyl-5-phosphono-, (S-(E))- |
| GD-90-RA90_0.01uM | Dose=0.01uM, SIS3 free base targeting SMAD3 |
| GD-90-RA90_0.1uM | Dose=0.1uM, SIS3 free base targeting SMAD3 |
| GD-90-RA90_10uM | Dose=10uM, SIS3 free base targeting SMAD3 |
| GD-90-RA90_1uM | Dose=1uM, SIS3 free base targeting SMAD3 |
| GD-96-AK08_0.01uM | Dose=0.01uM, 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| GD-96-AK08_0.1uM | Dose=0.1uM, 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| GD-96-AK08_10uM | Dose=10uM, 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| GD-96-AK08_1uM | Dose=1uM, 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid, Antiamyloidogenic Agents;gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| GD-98-WZ24_0.01uM | Dose=0.01uM, Pamoic Acid, G Protein-Coupled Receptor GPR35 Agonists targeting GPR35 |
| GD-98-WZ24_0.1uM | Dose=0.1uM, Pamoic Acid, G Protein-Coupled Receptor GPR35 Agonists targeting GPR35 |
| GD-98-WZ24_10uM | Dose=10uM, Pamoic Acid, G Protein-Coupled Receptor GPR35 Agonists targeting GPR35 |
| GD-98-WZ24_1uM | Dose=1uM, Pamoic Acid, G Protein-Coupled Receptor GPR35 Agonists targeting GPR35 |
| GE-01-QX17_0.01uM | Dose=0.01uM, (-)-(Z)-Bisdehydrodoisynolic acid, Estrogen receptor beta modulator targeting ESR1, ESR2 |
| GE-01-QX17_0.1uM | Dose=0.1uM, (-)-(Z)-Bisdehydrodoisynolic acid, Estrogen receptor beta modulator targeting ESR1, ESR2 |
| GE-01-QX17_10uM | Dose=10uM, (-)-(Z)-Bisdehydrodoisynolic acid, Estrogen receptor beta modulator targeting ESR1, ESR2 |
| GE-01-QX17_1uM | Dose=1uM, (-)-(Z)-Bisdehydrodoisynolic acid, Estrogen receptor beta modulator targeting ESR1, ESR2 |
| GE-06-JX14_0.01uM | Dose=0.01uM, (4R,7S,10S,13R,16S,19S)-19-[[(2S)-2-Acetamido-3-(4-nitrophenyl)propanoyl]amino]-10-(4-aminobutyl)-N-[(2R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide, SSTR2 antagonist targeting SSTR2 |
| GE-06-JX14_0.1uM | Dose=0.1uM, (4R,7S,10S,13R,16S,19S)-19-[[(2S)-2-Acetamido-3-(4-nitrophenyl)propanoyl]amino]-10-(4-aminobutyl)-N-[(2R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide, SSTR2 antagonist targeting SSTR2 |
| GE-06-JX14_10uM | Dose=10uM, (4R,7S,10S,13R,16S,19S)-19-[[(2S)-2-Acetamido-3-(4-nitrophenyl)propanoyl]amino]-10-(4-aminobutyl)-N-[(2R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide, SSTR2 antagonist targeting SSTR2 |
| GE-06-JX14_1uM | Dose=1uM, (4R,7S,10S,13R,16S,19S)-19-[[(2S)-2-Acetamido-3-(4-nitrophenyl)propanoyl]amino]-10-(4-aminobutyl)-N-[(2R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide, SSTR2 antagonist targeting SSTR2 |
| GE-11-ZR43_0.01uM | Dose=0.01uM |
| GE-11-ZR43_10uM | Dose=10uM |
| GE-13-TV02_0.01uM | Dose=0.01uM, 4-Phenylbutylamine, Semicarbazide-Sensitive Amine Oxidase (SSAO| VAP-1) Inhibitors targeting AOC3 |
| GE-13-TV02_0.1uM | Dose=0.1uM, 4-Phenylbutylamine, Semicarbazide-Sensitive Amine Oxidase (SSAO| VAP-1) Inhibitors targeting AOC3 |
| GE-13-TV02_10uM | Dose=10uM, 4-Phenylbutylamine, Semicarbazide-Sensitive Amine Oxidase (SSAO| VAP-1) Inhibitors targeting AOC3 |
| GE-13-TV02_1uM | Dose=1uM, 4-Phenylbutylamine, Semicarbazide-Sensitive Amine Oxidase (SSAO| VAP-1) Inhibitors targeting AOC3 |
| GE-14-EF51_0.01uM | Dose=0.01uM, LL-Z1272.Episilon. targeting FNTB |
| GE-14-EF51_0.1uM | Dose=0.1uM, LL-Z1272.Episilon. targeting FNTB |
| GE-14-EF51_10uM | Dose=10uM, LL-Z1272.Episilon. targeting FNTB |
| GE-14-EF51_1uM | Dose=1uM, LL-Z1272.Episilon. targeting FNTB |
| GE-17-FE71_0.01uM | Dose=0.01uM, 4-[(E)-[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid, CFTR Channel Inhibitors targeting CFTR |
| GE-17-FE71_0.1uM | Dose=0.1uM, 4-[(E)-[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid, CFTR Channel Inhibitors targeting CFTR |
| GE-17-FE71_10uM | Dose=10uM, 4-[(E)-[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid, CFTR Channel Inhibitors targeting CFTR |
| GE-17-FE71_1uM | Dose=1uM, 4-[(E)-[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid, CFTR Channel Inhibitors targeting CFTR |
| GE-17-WR07_0.01uM | Dose=0.01uM, N-(5-(5-(2,4-Dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)pentanoyl)-2,4-dimethoxyphenyl)-4-(trifluoromethyl)benzenesulfonamide, HTR2C antagonist;5-HT2C Antagonists targeting HTR2C |
| GE-17-WR07_10uM | Dose=10uM, N-(5-(5-(2,4-Dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)pentanoyl)-2,4-dimethoxyphenyl)-4-(trifluoromethyl)benzenesulfonamide, HTR2C antagonist;5-HT2C Antagonists targeting HTR2C |
| GE-17-WR07_1uM | Dose=1uM, N-(5-(5-(2,4-Dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)pentanoyl)-2,4-dimethoxyphenyl)-4-(trifluoromethyl)benzenesulfonamide, HTR2C antagonist;5-HT2C Antagonists targeting HTR2C |
| GE-22-ME44_0.01uM | Dose=0.01uM, 6-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, KDR, ABL2 |
| GE-22-ME44_0.1uM | Dose=0.1uM, 6-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, KDR, ABL2 |
| GE-22-ME44_10uM | Dose=10uM, 6-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, KDR, ABL2 |
| GE-22-ME44_1uM | Dose=1uM, 6-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]naphthalene-1-carboxamide, Angiogenesis Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Bcr-Abl Kinase Inhibitors targeting ABL1, BCR, KDR, ABL2 |
| GE-25-DQ65_0.01uM | Dose=0.01uM, Sea 0400, Na+/Ca2+ Exchanger type 1 (NCX1) Inhibitors targeting SLC8A2 |
| GE-25-DQ65_0.1uM | Dose=0.1uM, Sea 0400, Na+/Ca2+ Exchanger type 1 (NCX1) Inhibitors targeting SLC8A2 |
| GE-25-DQ65_10uM | Dose=10uM, Sea 0400, Na+/Ca2+ Exchanger type 1 (NCX1) Inhibitors targeting SLC8A2 |
| GE-25-DQ65_1uM | Dose=1uM, Sea 0400, Na+/Ca2+ Exchanger type 1 (NCX1) Inhibitors targeting SLC8A2 |
| GE-25-YQ75_0.01uM | Dose=0.01uM, Troglitazone, CCL2 Expression Inhibitors;PPARgamma Agonists;Insulin Sensitizers;EGR1 Expression Enhancers targeting PPARG, CCL2 |
| GE-25-YQ75_0.1uM | Dose=0.1uM, Troglitazone, CCL2 Expression Inhibitors;PPARgamma Agonists;Insulin Sensitizers;EGR1 Expression Enhancers targeting PPARG, CCL2 |
| GE-25-YQ75_10uM | Dose=10uM, Troglitazone, CCL2 Expression Inhibitors;PPARgamma Agonists;Insulin Sensitizers;EGR1 Expression Enhancers targeting PPARG, CCL2 |
| GE-25-YQ75_1uM | Dose=1uM, Troglitazone, CCL2 Expression Inhibitors;PPARgamma Agonists;Insulin Sensitizers;EGR1 Expression Enhancers targeting PPARG, CCL2 |
| GE-26-BO33_0.01uM | Dose=0.01uM, USP7/USP47 inhibitor targeting USP7 |
| GE-26-BO33_0.1uM | Dose=0.1uM, USP7/USP47 inhibitor targeting USP7 |
| GE-26-BO33_10uM | Dose=10uM, USP7/USP47 inhibitor targeting USP7 |
| GE-26-BO33_1uM | Dose=1uM, USP7/USP47 inhibitor targeting USP7 |
| GE-28-EL65_0.01uM | Dose=0.01uM, 3-O-Methyldopa, DL- |
| GE-28-EL65_0.1uM | Dose=0.1uM, 3-O-Methyldopa, DL- |
| GE-28-EL65_10uM | Dose=10uM, 3-O-Methyldopa, DL- |
| GE-28-EL65_1uM | Dose=1uM, 3-O-Methyldopa, DL- |
| GE-29-BW04_0.01uM | Dose=0.01uM, Evenamide, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Nav1.3 (Brain Type III) Sodium Channel Blockers;Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers targeting SCN3A, SCN9A, SCN10A |
| GE-29-BW04_0.1uM | Dose=0.1uM, Evenamide, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Nav1.3 (Brain Type III) Sodium Channel Blockers;Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers targeting SCN3A, SCN9A, SCN10A |
| GE-29-BW04_10uM | Dose=10uM, Evenamide, Nav1.8 (SNS/PN3) Sodium Channel Blockers;Nav1.3 (Brain Type III) Sodium Channel Blockers;Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers targeting SCN3A, SCN9A, SCN10A |
| GE-29-BW54_0.01uM | Dose=0.01uM, 6-[[acetyl(methyl)amino]methyl]-N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, ATP competitive inhibitor targeting FGFR4 |
| GE-29-BW54_0.1uM | Dose=0.1uM, 6-[[acetyl(methyl)amino]methyl]-N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, ATP competitive inhibitor targeting FGFR4 |
| GE-29-BW54_10uM | Dose=10uM, 6-[[acetyl(methyl)amino]methyl]-N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, ATP competitive inhibitor targeting FGFR4 |
| GE-29-BW54_1uM | Dose=1uM, 6-[[acetyl(methyl)amino]methyl]-N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide, ATP competitive inhibitor targeting FGFR4 |
| GE-29-ZM45_0.01uM | Dose=0.01uM, Isobutyl4-(7-amino-3-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-6-yl)phenylcarbamate, Lck tyrosine kinase inhibitor targeting LCK |
| GE-29-ZM45_0.1uM | Dose=0.1uM, Isobutyl4-(7-amino-3-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-6-yl)phenylcarbamate, Lck tyrosine kinase inhibitor targeting LCK |
| GE-29-ZM45_10uM | Dose=10uM, Isobutyl4-(7-amino-3-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-6-yl)phenylcarbamate, Lck tyrosine kinase inhibitor targeting LCK |
| GE-29-ZM45_1uM | Dose=1uM, Isobutyl4-(7-amino-3-(4-(4-methylpiperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-6-yl)phenylcarbamate, Lck tyrosine kinase inhibitor targeting LCK |
| GE-32-JR10_0.01uM | Dose=0.01uM, 3-Phenylpropylamine |
| GE-32-JR10_0.1uM | Dose=0.1uM, 3-Phenylpropylamine |
| GE-32-JR10_10uM | Dose=10uM, 3-Phenylpropylamine |
| GE-32-JR10_1uM | Dose=1uM, 3-Phenylpropylamine |
| GE-34-TW62_0.01uM | Dose=0.01uM, Carnosic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Neurotrophic Factor Enhancers;Free Radical Scavengers;PPARG agonist;Antioxidants targeting LIPC, LIPE, PPARG, LIPG, KEAP1, LIPF |
| GE-34-TW62_0.1uM | Dose=0.1uM, Carnosic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Neurotrophic Factor Enhancers;Free Radical Scavengers;PPARG agonist;Antioxidants targeting LIPC, LIPE, PPARG, LIPG, KEAP1, LIPF |
| GE-34-TW62_10uM | Dose=10uM, Carnosic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Neurotrophic Factor Enhancers;Free Radical Scavengers;PPARG agonist;Antioxidants targeting LIPC, LIPE, PPARG, LIPG, KEAP1, LIPF |
| GE-34-TW62_1uM | Dose=1uM, Carnosic acid, Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors;Neurotrophic Factor Enhancers;Free Radical Scavengers;PPARG agonist;Antioxidants targeting LIPC, LIPE, PPARG, LIPG, KEAP1, LIPF |
| GE-40-GQ38_0.01uM | Dose=0.01uM, 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide, Apoptosis-independent;PIKFYVE gene inhibitor targeting PIKFYVE |
| GE-40-GQ38_0.1uM | Dose=0.1uM, 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide, Apoptosis-independent;PIKFYVE gene inhibitor targeting PIKFYVE |
| GE-40-GQ38_10uM | Dose=10uM, 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide, Apoptosis-independent;PIKFYVE gene inhibitor targeting PIKFYVE |
| GE-40-GQ38_1uM | Dose=1uM, 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide, Apoptosis-independent;PIKFYVE gene inhibitor targeting PIKFYVE |
| GE-40-VJ66_0.01uM | Dose=0.01uM, 4-Methoxyphenylsulfamide, carbonic anhydrase inhibitor targeting CA1, CA2 |
| GE-40-VJ66_0.1uM | Dose=0.1uM, 4-Methoxyphenylsulfamide, carbonic anhydrase inhibitor targeting CA1, CA2 |
| GE-40-VJ66_10uM | Dose=10uM, 4-Methoxyphenylsulfamide, carbonic anhydrase inhibitor targeting CA1, CA2 |
| GE-40-VJ66_1uM | Dose=1uM, 4-Methoxyphenylsulfamide, carbonic anhydrase inhibitor targeting CA1, CA2 |
| GE-44-AZ94_0.01uM | Dose=0.01uM, 4-[(R)-2-Cyano-2-((S)-2-phenylamino-3-m-tolyl-propionylamino)-ethoxymethyl]-benzoic acid |
| GE-44-AZ94_0.1uM | Dose=0.1uM, 4-[(R)-2-Cyano-2-((S)-2-phenylamino-3-m-tolyl-propionylamino)-ethoxymethyl]-benzoic acid |
| GE-44-AZ94_1uM | Dose=1uM, 4-[(R)-2-Cyano-2-((S)-2-phenylamino-3-m-tolyl-propionylamino)-ethoxymethyl]-benzoic acid |
| GE-47-OO30_0.01uM | Dose=0.01uM, Tacedinaline, HDAC 1/2/3 targeting HDAC1, HDAC2, HDAC3 |
| GE-47-OO30_0.1uM | Dose=0.1uM, Tacedinaline, HDAC 1/2/3 targeting HDAC1, HDAC2, HDAC3 |
| GE-47-OO30_10uM | Dose=10uM, Tacedinaline, HDAC 1/2/3 targeting HDAC1, HDAC2, HDAC3 |
| GE-47-OO30_1uM | Dose=1uM, Tacedinaline, HDAC 1/2/3 targeting HDAC1, HDAC2, HDAC3 |
| GE-53-SM76_0.01uM | Dose=0.01uM |
| GE-53-SM76_0.1uM | Dose=0.1uM |
| GE-53-SM76_10uM | Dose=10uM |
| GE-53-SM76_1uM | Dose=1uM |
| GE-54-IF41_0.01uM | Dose=0.01uM, Zinterol, beta3-Adrenoceptor Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, ADRB3 |
| GE-54-IF41_0.1uM | Dose=0.1uM, Zinterol, beta3-Adrenoceptor Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, ADRB3 |
| GE-54-IF41_10uM | Dose=10uM, Zinterol, beta3-Adrenoceptor Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, ADRB3 |
| GE-54-IF41_1uM | Dose=1uM, Zinterol, beta3-Adrenoceptor Agonists;beta2-Adrenoceptor Agonists targeting ADRB2, ADRB3 |
| GE-58-RW27_0.01uM | Dose=0.01uM, Fomepizole |
| GE-58-RW27_0.1uM | Dose=0.1uM, Fomepizole |
| GE-58-RW27_10uM | Dose=10uM, Fomepizole |
| GE-58-RW27_1uM | Dose=1uM, Fomepizole |
| GE-63-WI86_0.01uM | Dose=0.01uM, Nesbuvir |
| GE-63-WI86_0.1uM | Dose=0.1uM, Nesbuvir |
| GE-63-WI86_10uM | Dose=10uM, Nesbuvir |
| GE-63-WI86_1uM | Dose=1uM, Nesbuvir |
| GE-68-FZ64_0.01uM | Dose=0.01uM, 4-(5,7,7,10,10-Pentamethyl-2-nitro-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid, Retinoid RXR Antagonists targeting RXRB, RARA |
| GE-68-FZ64_0.1uM | Dose=0.1uM, 4-(5,7,7,10,10-Pentamethyl-2-nitro-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid, Retinoid RXR Antagonists targeting RXRB, RARA |
| GE-68-FZ64_10uM | Dose=10uM, 4-(5,7,7,10,10-Pentamethyl-2-nitro-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid, Retinoid RXR Antagonists targeting RXRB, RARA |
| GE-72-PR35_0.01uM | Dose=0.01uM |
| GE-72-PR35_0.1uM | Dose=0.1uM |
| GE-72-PR35_10uM | Dose=10uM |
| GE-72-PR35_1uM | Dose=1uM |
| GE-74-KC09_0.01uM | Dose=0.01uM, Sdz isq 844, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors;Nucleoside-Diphosphate Kinase Inhibitors targeting PDE2A, NME1, NME2 |
| GE-74-KC09_0.1uM | Dose=0.1uM, Sdz isq 844, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors;Nucleoside-Diphosphate Kinase Inhibitors targeting PDE2A, NME1, NME2 |
| GE-74-KC09_10uM | Dose=10uM, Sdz isq 844, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors;Nucleoside-Diphosphate Kinase Inhibitors targeting PDE2A, NME1, NME2 |
| GE-74-KC09_1uM | Dose=1uM, Sdz isq 844, Phosphodiesterase IV Inhibitors;Phosphodiesterase III Inhibitors;Nucleoside-Diphosphate Kinase Inhibitors targeting PDE2A, NME1, NME2 |
| GE-77-CO40_0.1uM | Dose=0.1uM, CHRM2 agonist;CHRM3 agonist;CHRM4 agonist;CHRM5 agonist |
| GE-77-CO40_10uM | Dose=10uM, CHRM2 agonist;CHRM3 agonist;CHRM4 agonist;CHRM5 agonist |
| GE-77-CO40_1uM | Dose=1uM, CHRM2 agonist;CHRM3 agonist;CHRM4 agonist;CHRM5 agonist |
| GE-77-FY84_0.01uM | Dose=0.01uM, 5-Methyl-2-(2-pyridinyl)-1,3-thiazol-4-yl 2,4-difluorobenzenecarboxylate |
| GE-77-FY84_0.1uM | Dose=0.1uM, 5-Methyl-2-(2-pyridinyl)-1,3-thiazol-4-yl 2,4-difluorobenzenecarboxylate |
| GE-77-FY84_10uM | Dose=10uM, 5-Methyl-2-(2-pyridinyl)-1,3-thiazol-4-yl 2,4-difluorobenzenecarboxylate |
| GE-77-FY84_1uM | Dose=1uM, 5-Methyl-2-(2-pyridinyl)-1,3-thiazol-4-yl 2,4-difluorobenzenecarboxylate |
| GE-77-IH08_0.01uM | Dose=0.01uM, 6-Phenyl-8-(3-nitrophenyl)-1,7-naphthyridine |
| GE-77-IH08_0.1uM | Dose=0.1uM, 6-Phenyl-8-(3-nitrophenyl)-1,7-naphthyridine |
| GE-77-IH08_10uM | Dose=10uM, 6-Phenyl-8-(3-nitrophenyl)-1,7-naphthyridine |
| GE-77-IH08_1uM | Dose=1uM, 6-Phenyl-8-(3-nitrophenyl)-1,7-naphthyridine |
| GE-84-SM43_0.01uM | Dose=0.01uM, 2-[8-(2-Naphthalenylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]acetic acid methyl ester, OPRL1 agonist targeting OPRL1 |
| GE-84-SM43_0.1uM | Dose=0.1uM, 2-[8-(2-Naphthalenylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]acetic acid methyl ester, OPRL1 agonist targeting OPRL1 |
| GE-84-SM43_10uM | Dose=10uM, 2-[8-(2-Naphthalenylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]acetic acid methyl ester, OPRL1 agonist targeting OPRL1 |
| GE-84-SM43_1uM | Dose=1uM, 2-[8-(2-Naphthalenylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-3-yl]acetic acid methyl ester, OPRL1 agonist targeting OPRL1 |
| GE-84-VZ24_0.01uM | Dose=0.01uM, 8-[5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chroman-3-yl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromen-4-one, Phospholipase A2 (PLA2) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PLA2G10 |
| GE-84-VZ24_0.1uM | Dose=0.1uM, 8-[5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chroman-3-yl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromen-4-one, Phospholipase A2 (PLA2) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PLA2G10 |
| GE-84-VZ24_1uM | Dose=1uM, 8-[5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chroman-3-yl]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromen-4-one, Phospholipase A2 (PLA2) Inhibitors;Non-Steroidal Antiinflammatory Drugs targeting PLA2G10 |
| GE-97-UL88_0.01uM | Dose=0.01uM, 6-fluoro-N-[(4-fluorophenyl)methyl]-1-methyl-4-oxospiro[3H-quinoline-2,4'-piperidine]-1'-carboxamide |
| GE-97-UL88_0.1uM | Dose=0.1uM, 6-fluoro-N-[(4-fluorophenyl)methyl]-1-methyl-4-oxospiro[3H-quinoline-2,4'-piperidine]-1'-carboxamide |
| GE-97-UL88_10uM | Dose=10uM, 6-fluoro-N-[(4-fluorophenyl)methyl]-1-methyl-4-oxospiro[3H-quinoline-2,4'-piperidine]-1'-carboxamide |
| GE-97-UL88_1uM | Dose=1uM, 6-fluoro-N-[(4-fluorophenyl)methyl]-1-methyl-4-oxospiro[3H-quinoline-2,4'-piperidine]-1'-carboxamide |
| GE-98-ZI68_0.01uM | Dose=0.01uM |
| GE-98-ZI68_0.1uM | Dose=0.1uM |
| GE-98-ZI68_10uM | Dose=10uM |
| GE-98-ZI68_1uM | Dose=1uM |
| GF-02-ER50_0.01uM | Dose=0.01uM, Ethane-1,2-diyl dicarbamimidothioate |
| GF-02-ER50_0.1uM | Dose=0.1uM, Ethane-1,2-diyl dicarbamimidothioate |
| GF-02-ER50_10uM | Dose=10uM, Ethane-1,2-diyl dicarbamimidothioate |
| GF-02-ER50_1uM | Dose=1uM, Ethane-1,2-diyl dicarbamimidothioate |
| GF-03-HI41_0.01uM | Dose=0.01uM, RS 39604, HTR4 antagonist targeting HTR4 |
| GF-03-HI41_0.1uM | Dose=0.1uM, RS 39604, HTR4 antagonist targeting HTR4 |
| GF-03-HI41_10uM | Dose=10uM, RS 39604, HTR4 antagonist targeting HTR4 |
| GF-03-HI41_1uM | Dose=1uM, RS 39604, HTR4 antagonist targeting HTR4 |
| GF-05-GQ05_0.01uM | Dose=0.01uM, 3-Hydroxy-5-methyl-1-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione, FEN1 endonuclease inhibitor targeting ERCC5, FEN1 |
| GF-05-GQ05_0.1uM | Dose=0.1uM, 3-Hydroxy-5-methyl-1-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione, FEN1 endonuclease inhibitor targeting ERCC5, FEN1 |
| GF-05-GQ05_10uM | Dose=10uM, 3-Hydroxy-5-methyl-1-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione, FEN1 endonuclease inhibitor targeting ERCC5, FEN1 |
| GF-05-GQ05_1uM | Dose=1uM, 3-Hydroxy-5-methyl-1-phenyl-1H-thieno[2,3-d]pyrimidine-2,4-dione, FEN1 endonuclease inhibitor targeting ERCC5, FEN1 |
| GF-14-RF56_0.01uM | Dose=0.01uM |
| GF-14-RF56_10uM | Dose=10uM |
| GF-14-RF56_1uM | Dose=1uM |
| GF-15-LT47_0.01uM | Dose=0.01uM, NI-57, BRPFs;Bromodomain inhibitor targeting BRPF1, BRD1, BRPF3 |
| GF-15-LT47_0.1uM | Dose=0.1uM, NI-57, BRPFs;Bromodomain inhibitor targeting BRPF1, BRD1, BRPF3 |
| GF-15-LT47_10uM | Dose=10uM, NI-57, BRPFs;Bromodomain inhibitor targeting BRPF1, BRD1, BRPF3 |
| GF-15-LT47_1uM | Dose=1uM, NI-57, BRPFs;Bromodomain inhibitor targeting BRPF1, BRD1, BRPF3 |
| GF-16-AN80_0.01uM | Dose=0.01uM, 8-(3,5-Dichlorophenyl)sulfanyl-9-[3-(propan-2-ylamino)propyl]purin-6-amine, inhibitor of Grp94 targeting HSP90B1 |
| GF-16-AN80_0.1uM | Dose=0.1uM, 8-(3,5-Dichlorophenyl)sulfanyl-9-[3-(propan-2-ylamino)propyl]purin-6-amine, inhibitor of Grp94 targeting HSP90B1 |
| GF-16-AN80_10uM | Dose=10uM, 8-(3,5-Dichlorophenyl)sulfanyl-9-[3-(propan-2-ylamino)propyl]purin-6-amine, inhibitor of Grp94 targeting HSP90B1 |
| GF-16-RR50_0.01uM | Dose=0.01uM, Gsk484, PAD4 (Protein-arginine deiminase type-4) substrate competitive reversible inhibitor targeting PADI4 |
| GF-16-RR50_0.1uM | Dose=0.1uM, Gsk484, PAD4 (Protein-arginine deiminase type-4) substrate competitive reversible inhibitor targeting PADI4 |
| GF-16-RR50_10uM | Dose=10uM, Gsk484, PAD4 (Protein-arginine deiminase type-4) substrate competitive reversible inhibitor targeting PADI4 |
| GF-19-NZ91_0.01uM | Dose=0.01uM, Fasidotril, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| GF-19-NZ91_0.1uM | Dose=0.1uM, Fasidotril, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| GF-19-NZ91_10uM | Dose=10uM, Fasidotril, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| GF-19-NZ91_1uM | Dose=1uM, Fasidotril, Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors targeting ACE, MME |
| GF-19-OF53_0.01uM | Dose=0.01uM, 2-Methyl-6-[2-[3-(trifluoromethyl)phenyl]ethynyl]pyridine, GRM5 antagonist targeting GRM5 |
| GF-19-OF53_0.1uM | Dose=0.1uM, 2-Methyl-6-[2-[3-(trifluoromethyl)phenyl]ethynyl]pyridine, GRM5 antagonist targeting GRM5 |
| GF-19-OF53_10uM | Dose=10uM, 2-Methyl-6-[2-[3-(trifluoromethyl)phenyl]ethynyl]pyridine, GRM5 antagonist targeting GRM5 |
| GF-19-OF53_1uM | Dose=1uM, 2-Methyl-6-[2-[3-(trifluoromethyl)phenyl]ethynyl]pyridine, GRM5 antagonist targeting GRM5 |
| GF-32-FY02_0.01uM | Dose=0.01uM |
| GF-32-FY02_0.1uM | Dose=0.1uM |
| GF-32-FY02_10uM | Dose=10uM |
| GF-32-FY02_1uM | Dose=1uM |
| GF-35-IT27_0.01uM | Dose=0.01uM |
| GF-35-IT27_0.1uM | Dose=0.1uM |
| GF-35-IT27_10uM | Dose=10uM |
| GF-35-IT27_1uM | Dose=1uM |
| GF-37-MB64_0.01uM | Dose=0.01uM, (3aR,5R,6S,7R,7aR)-2-(Ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol, N-Acetyl-beta-D-Glucosaminidase (O-GlcNAcase, OGA) Inhibitors;OGLcNACase inhibitor targeting OGA |
| GF-37-MB64_0.1uM | Dose=0.1uM, (3aR,5R,6S,7R,7aR)-2-(Ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol, N-Acetyl-beta-D-Glucosaminidase (O-GlcNAcase, OGA) Inhibitors;OGLcNACase inhibitor targeting OGA |
| GF-37-MB64_10uM | Dose=10uM, (3aR,5R,6S,7R,7aR)-2-(Ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol, N-Acetyl-beta-D-Glucosaminidase (O-GlcNAcase, OGA) Inhibitors;OGLcNACase inhibitor targeting OGA |
| GF-37-MB64_1uM | Dose=1uM, (3aR,5R,6S,7R,7aR)-2-(Ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-pyrano[3,2-d]thiazole-6,7-diol, N-Acetyl-beta-D-Glucosaminidase (O-GlcNAcase, OGA) Inhibitors;OGLcNACase inhibitor targeting OGA |
| GF-46-FA29_0.01uM | Dose=0.01uM, 4-[1-amino-2-[[1-(4-chlorophenyl)cyclopropanecarbonyl]amino]ethyl]-N-pyridin-4-ylbenzamide, Rho Kinase Inhibitors;Protein Kinase PKC theta Inhibitors;Protein Kinase PKC epsilon Inhibitors targeting PRKCE, PRKCQ, ROCK1, ROCK2 |
| GF-46-FA29_0.1uM | Dose=0.1uM, 4-[1-amino-2-[[1-(4-chlorophenyl)cyclopropanecarbonyl]amino]ethyl]-N-pyridin-4-ylbenzamide, Rho Kinase Inhibitors;Protein Kinase PKC theta Inhibitors;Protein Kinase PKC epsilon Inhibitors targeting PRKCE, PRKCQ, ROCK1, ROCK2 |
| GF-46-FA29_10uM | Dose=10uM, 4-[1-amino-2-[[1-(4-chlorophenyl)cyclopropanecarbonyl]amino]ethyl]-N-pyridin-4-ylbenzamide, Rho Kinase Inhibitors;Protein Kinase PKC theta Inhibitors;Protein Kinase PKC epsilon Inhibitors targeting PRKCE, PRKCQ, ROCK1, ROCK2 |
| GF-46-FA29_1uM | Dose=1uM, 4-[1-amino-2-[[1-(4-chlorophenyl)cyclopropanecarbonyl]amino]ethyl]-N-pyridin-4-ylbenzamide, Rho Kinase Inhibitors;Protein Kinase PKC theta Inhibitors;Protein Kinase PKC epsilon Inhibitors targeting PRKCE, PRKCQ, ROCK1, ROCK2 |
| GF-46-LK68_0.01uM | Dose=0.01uM, 6-chloro-2-hydroxy-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-N-pyridin-4-ylbenzenesulfonamide, CXCR2 antagonist targeting CXCR2 |
| GF-46-LK68_0.1uM | Dose=0.1uM, 6-chloro-2-hydroxy-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-N-pyridin-4-ylbenzenesulfonamide, CXCR2 antagonist targeting CXCR2 |
| GF-46-LK68_10uM | Dose=10uM, 6-chloro-2-hydroxy-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-N-pyridin-4-ylbenzenesulfonamide, CXCR2 antagonist targeting CXCR2 |
| GF-46-LK68_1uM | Dose=1uM, 6-chloro-2-hydroxy-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]-N-pyridin-4-ylbenzenesulfonamide, CXCR2 antagonist targeting CXCR2 |
| GF-53-OL28_0.01uM | Dose=0.01uM, Factor VII-IN-1, Coagulation Factor VIIa Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F7 |
| GF-53-OL28_0.1uM | Dose=0.1uM, Factor VII-IN-1, Coagulation Factor VIIa Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F7 |
| GF-53-OL28_10uM | Dose=10uM, Factor VII-IN-1, Coagulation Factor VIIa Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F7 |
| GF-53-OL28_1uM | Dose=1uM, Factor VII-IN-1, Coagulation Factor VIIa Inhibitors;Inhibitors of Blood Coagulation Pathways targeting F7 |
| GF-57-LR72_0.01uM | Dose=0.01uM, Napsagatran, Known Thrombin inhibitor targeting F2 |
| GF-57-LR72_0.1uM | Dose=0.1uM, Napsagatran, Known Thrombin inhibitor targeting F2 |
| GF-57-LR72_10uM | Dose=10uM, Napsagatran, Known Thrombin inhibitor targeting F2 |
| GF-57-LR72_1uM | Dose=1uM, Napsagatran, Known Thrombin inhibitor targeting F2 |
| GF-57-MY04_0.01uM | Dose=0.01uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors targeting ACACB |
| GF-57-MY04_0.1uM | Dose=0.1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors targeting ACACB |
| GF-57-MY04_10uM | Dose=10uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors targeting ACACB |
| GF-57-MY04_1uM | Dose=1uM, Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors targeting ACACB |
| GF-58-OL90_0.01uM | Dose=0.01uM, 3-Hydroxyanthranilic Acid, Aldehyde Dehydrogenase Inhibitor targeting ALDH2, ALDH7A1, ALDH5A1, ALDH1A2 |
| GF-58-OL90_0.1uM | Dose=0.1uM, 3-Hydroxyanthranilic Acid, Aldehyde Dehydrogenase Inhibitor targeting ALDH2, ALDH7A1, ALDH5A1, ALDH1A2 |
| GF-58-OL90_10uM | Dose=10uM, 3-Hydroxyanthranilic Acid, Aldehyde Dehydrogenase Inhibitor targeting ALDH2, ALDH7A1, ALDH5A1, ALDH1A2 |
| GF-58-OL90_1uM | Dose=1uM, 3-Hydroxyanthranilic Acid, Aldehyde Dehydrogenase Inhibitor targeting ALDH2, ALDH7A1, ALDH5A1, ALDH1A2 |
| GF-67-HH28_0.01uM | Dose=0.01uM, Sdz glc 756, Dopamine D2 Agonists;Dopamine D1 Antagonists targeting DRD1, DRD2 |
| GF-67-HH28_0.1uM | Dose=0.1uM, Sdz glc 756, Dopamine D2 Agonists;Dopamine D1 Antagonists targeting DRD1, DRD2 |
| GF-67-HH28_10uM | Dose=10uM, Sdz glc 756, Dopamine D2 Agonists;Dopamine D1 Antagonists targeting DRD1, DRD2 |
| GF-67-HH28_1uM | Dose=1uM, Sdz glc 756, Dopamine D2 Agonists;Dopamine D1 Antagonists targeting DRD1, DRD2 |
| GF-72-OO48_0.01uM | Dose=0.01uM, 1-(3-methylphenyl)-3-[1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea |
| GF-72-OO48_0.1uM | Dose=0.1uM, 1-(3-methylphenyl)-3-[1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea |
| GF-72-OO48_10uM | Dose=10uM, 1-(3-methylphenyl)-3-[1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea |
| GF-72-OO48_1uM | Dose=1uM, 1-(3-methylphenyl)-3-[1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea |
| GF-73-HI61_0.01uM | Dose=0.01uM, (3S)-5-(2,6-dichlorobenzoyl)oxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| GF-73-HI61_0.1uM | Dose=0.1uM, (3S)-5-(2,6-dichlorobenzoyl)oxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| GF-73-HI61_10uM | Dose=10uM, (3S)-5-(2,6-dichlorobenzoyl)oxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| GF-73-HI61_1uM | Dose=1uM, (3S)-5-(2,6-dichlorobenzoyl)oxy-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoic acid, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| GF-81-MU70_0.01uM | Dose=0.01uM, Betahistine, Histamine H1 Receptor Agonists;Histamine H3 Receptor Antagonists targeting HRH1, HRH3 |
| GF-81-MU70_0.1uM | Dose=0.1uM, Betahistine, Histamine H1 Receptor Agonists;Histamine H3 Receptor Antagonists targeting HRH1, HRH3 |
| GF-81-MU70_1uM | Dose=1uM, Betahistine, Histamine H1 Receptor Agonists;Histamine H3 Receptor Antagonists targeting HRH1, HRH3 |
| GF-84-NF76_0.01uM | Dose=0.01uM, Sandoz 58-035, ACAT Inhibitors targeting SOAT1 |
| GF-84-NF76_0.1uM | Dose=0.1uM, Sandoz 58-035, ACAT Inhibitors targeting SOAT1 |
| GF-84-NF76_10uM | Dose=10uM, Sandoz 58-035, ACAT Inhibitors targeting SOAT1 |
| GF-84-NF76_1uM | Dose=1uM, Sandoz 58-035, ACAT Inhibitors targeting SOAT1 |
| GF-90-DG49_0.01uM | Dose=0.01uM, Urmc-099, MAP3K11 gene inhibitor targeting MAP3K11 |
| GF-90-DG49_0.1uM | Dose=0.1uM, Urmc-099, MAP3K11 gene inhibitor targeting MAP3K11 |
| GF-90-DG49_10uM | Dose=10uM, Urmc-099, MAP3K11 gene inhibitor targeting MAP3K11 |
| GF-90-DG49_1uM | Dose=1uM, Urmc-099, MAP3K11 gene inhibitor targeting MAP3K11 |
| GF-92-IR00_0.01uM | Dose=0.01uM, N-(3-hydroxypropyl)-5-methyl-1-[4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxamide, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1 |
| GF-92-IR00_0.1uM | Dose=0.1uM, N-(3-hydroxypropyl)-5-methyl-1-[4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxamide, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1 |
| GF-92-IR00_10uM | Dose=10uM, N-(3-hydroxypropyl)-5-methyl-1-[4-[3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxamide, LFA-1/ICAM-1 Interaction Inhibitors targeting ICAM1 |
| GF-93-DV47_0.01uM | Dose=0.01uM, Alpha-Naphthoflavone, Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting CYP1A1, CYP1B1 |
| GF-93-DV47_0.1uM | Dose=0.1uM, Alpha-Naphthoflavone, Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting CYP1A1, CYP1B1 |
| GF-93-DV47_10uM | Dose=10uM, Alpha-Naphthoflavone, Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting CYP1A1, CYP1B1 |
| GF-93-DV47_1uM | Dose=1uM, Alpha-Naphthoflavone, Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;ABCG2) Inhibitors;Breast Cancer-Resistant Protein (BCRP targeting CYP1A1, CYP1B1 |
| GF-98-RS57_0.1uM | Dose=0.1uM, Cilastatin, Dehydropeptidase I Inhibitors targeting DPEP1 |
| GF-98-RS57_10uM | Dose=10uM, Cilastatin, Dehydropeptidase I Inhibitors targeting DPEP1 |
| GF-98-RS57_1uM | Dose=1uM, Cilastatin, Dehydropeptidase I Inhibitors targeting DPEP1 |
| HA-03-TL98_0.01uM | Dose=0.01uM, Ornithine Decarboxylase Inhibitors;Antimetabolites targeting ODC1 |
| HA-03-TL98_10uM | Dose=10uM, Ornithine Decarboxylase Inhibitors;Antimetabolites targeting ODC1 |
| HA-03-TL98_1uM | Dose=1uM, Ornithine Decarboxylase Inhibitors;Antimetabolites targeting ODC1 |
| HA-08-IL05_0.01uM | Dose=0.01uM, 5-(3-Carboxybenzoyl)-2-((6-(4-methoxyphenyl)-5-hexenyl)oxy)benzenepropanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| HA-08-IL05_10uM | Dose=10uM, 5-(3-Carboxybenzoyl)-2-((6-(4-methoxyphenyl)-5-hexenyl)oxy)benzenepropanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| HA-08-IL05_1uM | Dose=1uM, 5-(3-Carboxybenzoyl)-2-((6-(4-methoxyphenyl)-5-hexenyl)oxy)benzenepropanoic acid, Leukotriene BLT (LTB4) Antagonists;Leukotriene Antagonists targeting LTB4R2 |
| HA-10-LJ21_0.01uM | Dose=0.01uM, IL-1R Antagonist, Myd88 Dimerization Inhibitors targeting MYD88 |
| HA-10-LJ21_0.1uM | Dose=0.1uM, IL-1R Antagonist, Myd88 Dimerization Inhibitors targeting MYD88 |
| HA-10-LJ21_10uM | Dose=10uM, IL-1R Antagonist, Myd88 Dimerization Inhibitors targeting MYD88 |
| HA-10-LJ21_1uM | Dose=1uM, IL-1R Antagonist, Myd88 Dimerization Inhibitors targeting MYD88 |
| HA-17-MS45_0.01uM | Dose=0.01uM, Sb 225002, CXCR2 antagonist targeting CXCR2 |
| HA-17-MS45_0.1uM | Dose=0.1uM, Sb 225002, CXCR2 antagonist targeting CXCR2 |
| HA-17-MS45_10uM | Dose=10uM, Sb 225002, CXCR2 antagonist targeting CXCR2 |
| HA-17-MS45_1uM | Dose=1uM, Sb 225002, CXCR2 antagonist targeting CXCR2 |
| HA-21-ND29_0.01uM | Dose=0.01uM |
| HA-21-ND29_0.1uM | Dose=0.1uM |
| HA-21-ND29_10uM | Dose=10uM |
| HA-21-ND29_1uM | Dose=1uM |
| HA-22-CY42_0.01uM | Dose=0.01uM, 8-[5-(Ethylamino)-6-(methoxymethyl)pyridin-3-yl]-1-(1-ethyl-3-methylpyrazol-4-yl)-3-methylimidazo[4,5-c]quinolin-2-one, dual mTOR/PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| HA-22-CY42_0.1uM | Dose=0.1uM, 8-[5-(Ethylamino)-6-(methoxymethyl)pyridin-3-yl]-1-(1-ethyl-3-methylpyrazol-4-yl)-3-methylimidazo[4,5-c]quinolin-2-one, dual mTOR/PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| HA-22-CY42_10uM | Dose=10uM, 8-[5-(Ethylamino)-6-(methoxymethyl)pyridin-3-yl]-1-(1-ethyl-3-methylpyrazol-4-yl)-3-methylimidazo[4,5-c]quinolin-2-one, dual mTOR/PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| HA-22-CY42_1uM | Dose=1uM, 8-[5-(Ethylamino)-6-(methoxymethyl)pyridin-3-yl]-1-(1-ethyl-3-methylpyrazol-4-yl)-3-methylimidazo[4,5-c]quinolin-2-one, dual mTOR/PI3K inhibitor targeting MTOR, PIK3CA, PIK3CB, PIK3CD |
| HA-22-YE24_0.01uM | Dose=0.01uM, Capromorelin, Growth Hormone Secretagogues;Growth hormone secretagogue receptor (ghrelin) agonist;GHS Receptor Agonists targeting GH1, GHSR |
| HA-22-YE24_0.1uM | Dose=0.1uM, Capromorelin, Growth Hormone Secretagogues;Growth hormone secretagogue receptor (ghrelin) agonist;GHS Receptor Agonists targeting GH1, GHSR |
| HA-22-YE24_10uM | Dose=10uM, Capromorelin, Growth Hormone Secretagogues;Growth hormone secretagogue receptor (ghrelin) agonist;GHS Receptor Agonists targeting GH1, GHSR |
| HA-22-YE24_1uM | Dose=1uM, Capromorelin, Growth Hormone Secretagogues;Growth hormone secretagogue receptor (ghrelin) agonist;GHS Receptor Agonists targeting GH1, GHSR |
| HA-27-FV67_0.01uM | Dose=0.01uM, Roxindole, Dopamine Autoreceptor Agonists targeting HTR1A, PRL, SLC6A4 |
| HA-27-FV67_0.1uM | Dose=0.1uM, Roxindole, Dopamine Autoreceptor Agonists targeting HTR1A, PRL, SLC6A4 |
| HA-27-FV67_10uM | Dose=10uM, Roxindole, Dopamine Autoreceptor Agonists targeting HTR1A, PRL, SLC6A4 |
| HA-27-FV67_1uM | Dose=1uM, Roxindole, Dopamine Autoreceptor Agonists targeting HTR1A, PRL, SLC6A4 |
| HA-29-PM90_0.01uM | Dose=0.01uM, Tafamidis, Transthyretin tetramer stabilizer targeting TTR |
| HA-29-PM90_0.1uM | Dose=0.1uM, Tafamidis, Transthyretin tetramer stabilizer targeting TTR |
| HA-29-PM90_10uM | Dose=10uM, Tafamidis, Transthyretin tetramer stabilizer targeting TTR |
| HA-29-PM90_1uM | Dose=1uM, Tafamidis, Transthyretin tetramer stabilizer targeting TTR |
| HA-29-ZM35_0.01uM | Dose=0.01uM |
| HA-29-ZM35_0.1uM | Dose=0.1uM |
| HA-29-ZM35_10uM | Dose=10uM |
| HA-29-ZM35_1uM | Dose=1uM |
| HA-30-KD77_0.01uM | Dose=0.01uM, Oltipraz, S6K1 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;AMPK Activator targeting NFE2L2 |
| HA-30-KD77_0.1uM | Dose=0.1uM, Oltipraz, S6K1 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;AMPK Activator targeting NFE2L2 |
| HA-30-KD77_10uM | Dose=10uM, Oltipraz, S6K1 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;AMPK Activator targeting NFE2L2 |
| HA-30-KD77_1uM | Dose=1uM, Oltipraz, S6K1 Inhibitor;Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators;AMPK Activator targeting NFE2L2 |
| HA-32-YH61_0.01uM | Dose=0.01uM, 3-(7-(2,4-Dimethoxyphenyl)-2,3,6,7-tetrahydro-(1,4)thiazepin-5-yl)-4-hydroxy-6-methylpyran-2-one, P-Selectin Inhibitors targeting SELP |
| HA-32-YH61_0.1uM | Dose=0.1uM, 3-(7-(2,4-Dimethoxyphenyl)-2,3,6,7-tetrahydro-(1,4)thiazepin-5-yl)-4-hydroxy-6-methylpyran-2-one, P-Selectin Inhibitors targeting SELP |
| HA-32-YH61_10uM | Dose=10uM, 3-(7-(2,4-Dimethoxyphenyl)-2,3,6,7-tetrahydro-(1,4)thiazepin-5-yl)-4-hydroxy-6-methylpyran-2-one, P-Selectin Inhibitors targeting SELP |
| HA-32-YH61_1uM | Dose=1uM, 3-(7-(2,4-Dimethoxyphenyl)-2,3,6,7-tetrahydro-(1,4)thiazepin-5-yl)-4-hydroxy-6-methylpyran-2-one, P-Selectin Inhibitors targeting SELP |
| HA-33-ZI46_0.01uM | Dose=0.01uM, 1-(6-Chloropyridin-2-yl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| HA-33-ZI46_10uM | Dose=10uM, 1-(6-Chloropyridin-2-yl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| HA-33-ZI46_1uM | Dose=1uM, 1-(6-Chloropyridin-2-yl)piperazine, alpha-Adrenoceptor Antagonists targeting ADRA1B |
| HA-36-JX64_0.01uM | Dose=0.01uM, 4-(2-Acetyl-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzo[4,5]-cyclohepta[1,2-b]naphthalen-12-yl)-3-fluorobenzoic acid |
| HA-36-JX64_0.1uM | Dose=0.1uM, 4-(2-Acetyl-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzo[4,5]-cyclohepta[1,2-b]naphthalen-12-yl)-3-fluorobenzoic acid |
| HA-36-JX64_1uM | Dose=1uM, 4-(2-Acetyl-5,7,7,10,10-pentamethyl-7,8,9,10-tetrahydro-5H-5,13-diazabenzo[4,5]-cyclohepta[1,2-b]naphthalen-12-yl)-3-fluorobenzoic acid |
| HA-36-VD41_0.01uM | Dose=0.01uM, (4-nitrophenyl)methyl N-[(5S)-5-amino-6-oxo-6-piperidin-1-ylhexyl]carbamate, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9 |
| HA-36-VD41_0.1uM | Dose=0.1uM, (4-nitrophenyl)methyl N-[(5S)-5-amino-6-oxo-6-piperidin-1-ylhexyl]carbamate, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9 |
| HA-36-VD41_10uM | Dose=10uM, (4-nitrophenyl)methyl N-[(5S)-5-amino-6-oxo-6-piperidin-1-ylhexyl]carbamate, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9 |
| HA-36-VD41_1uM | Dose=1uM, (4-nitrophenyl)methyl N-[(5S)-5-amino-6-oxo-6-piperidin-1-ylhexyl]carbamate, Dipeptidyl Peptidase IX (DPP9| DPRP2) Inhibitors targeting DPP9 |
| HA-38-ML65_0.01uM | Dose=0.01uM |
| HA-38-ML65_0.1uM | Dose=0.1uM |
| HA-38-ML65_10uM | Dose=10uM |
| HA-38-ML65_1uM | Dose=1uM |
| HA-40-OT25_0.01uM | Dose=0.01uM, 11-Deoxy-PGE1 targeting PTGER2 |
| HA-40-OT25_10uM | Dose=10uM, 11-Deoxy-PGE1 targeting PTGER2 |
| HA-42-TE64_0.01uM | Dose=0.01uM, Herbacetin, ODC1 gene inhibitor targeting ODC1 |
| HA-42-TE64_0.1uM | Dose=0.1uM, Herbacetin, ODC1 gene inhibitor targeting ODC1 |
| HA-42-TE64_10uM | Dose=10uM, Herbacetin, ODC1 gene inhibitor targeting ODC1 |
| HA-42-TE64_1uM | Dose=1uM, Herbacetin, ODC1 gene inhibitor targeting ODC1 |
| HA-48-LV39_0.01uM | Dose=0.01uM, Allocryptopine |
| HA-48-LV39_0.1uM | Dose=0.1uM, Allocryptopine |
| HA-48-LV39_10uM | Dose=10uM, Allocryptopine |
| HA-48-LV39_1uM | Dose=1uM, Allocryptopine |
| HA-50-AT10_0.01uM | Dose=0.01uM, (7R,10R,13S,17R)-10,13-dimethyl-7-phenylsulfanylspiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione, 17beta-Hydroxysteroid Dehydrogenase Type 2 (17beta-HSD2) Inhibitors targeting HSD17B2 |
| HA-50-AT10_0.1uM | Dose=0.1uM, (7R,10R,13S,17R)-10,13-dimethyl-7-phenylsulfanylspiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione, 17beta-Hydroxysteroid Dehydrogenase Type 2 (17beta-HSD2) Inhibitors targeting HSD17B2 |
| HA-50-AT10_10uM | Dose=10uM, (7R,10R,13S,17R)-10,13-dimethyl-7-phenylsulfanylspiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione, 17beta-Hydroxysteroid Dehydrogenase Type 2 (17beta-HSD2) Inhibitors targeting HSD17B2 |
| HA-50-AT10_1uM | Dose=1uM, (7R,10R,13S,17R)-10,13-dimethyl-7-phenylsulfanylspiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione, 17beta-Hydroxysteroid Dehydrogenase Type 2 (17beta-HSD2) Inhibitors targeting HSD17B2 |
| HA-51-DA67_0.01uM | Dose=0.01uM, 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide, Growth hormone secretagogue receptor (ghrelin) agonist targeting GHSR |
| HA-51-DA67_0.1uM | Dose=0.1uM, 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide, Growth hormone secretagogue receptor (ghrelin) agonist targeting GHSR |
| HA-51-DA67_10uM | Dose=10uM, 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide, Growth hormone secretagogue receptor (ghrelin) agonist targeting GHSR |
| HA-51-DA67_1uM | Dose=1uM, 2-amino-N-((2R)-3-(benzyloxy)-1-(4-(4-fluorophenyl)-2-methyl-1-oxo-2,7-diazaspiro[4.5]decan-7-yl)-1-oxopropan-2-yl)-2-methylpropanamide, Growth hormone secretagogue receptor (ghrelin) agonist targeting GHSR |
| HA-53-FL63_0.01uM | Dose=0.01uM, Tipifarnib, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB |
| HA-53-FL63_0.1uM | Dose=0.1uM, Tipifarnib, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB |
| HA-53-FL63_10uM | Dose=10uM, Tipifarnib, Inhibitors of Signal Transduction Pathways;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors targeting FNTA, FNTB |
| HA-57-XH23_0.01uM | Dose=0.01uM |
| HA-57-XH23_0.1uM | Dose=0.1uM |
| HA-57-XH23_10uM | Dose=10uM |
| HA-57-XH23_1uM | Dose=1uM |
| HA-64-OZ89_0.01uM | Dose=0.01uM, 3-chloro-N-(2-((4-fluorophenyl)carbamoyl)-4-methylphenyl)-1-benzothiophene-2-carboxamide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10 |
| HA-64-OZ89_0.1uM | Dose=0.1uM, 3-chloro-N-(2-((4-fluorophenyl)carbamoyl)-4-methylphenyl)-1-benzothiophene-2-carboxamide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10 |
| HA-64-OZ89_10uM | Dose=10uM, 3-chloro-N-(2-((4-fluorophenyl)carbamoyl)-4-methylphenyl)-1-benzothiophene-2-carboxamide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10 |
| HA-64-OZ89_1uM | Dose=1uM, 3-chloro-N-(2-((4-fluorophenyl)carbamoyl)-4-methylphenyl)-1-benzothiophene-2-carboxamide, Inhibitors of Blood Coagulation Pathways;Coagulation Factor Xa Inhibitors targeting F10 |
| HA-72-NR60_0.01uM | Dose=0.01uM |
| HA-72-NR60_0.1uM | Dose=0.1uM |
| HA-72-NR60_10uM | Dose=10uM |
| HA-72-NR60_1uM | Dose=1uM |
| HA-75-LT22_0.01uM | Dose=0.01uM, Rg-4733, Drugs Acting on Notch Receptors;gamma-Secretase Inhibitors targeting PSEN1 |
| HA-75-LT22_0.1uM | Dose=0.1uM, Rg-4733, Drugs Acting on Notch Receptors;gamma-Secretase Inhibitors targeting PSEN1 |
| HA-75-LT22_10uM | Dose=10uM, Rg-4733, Drugs Acting on Notch Receptors;gamma-Secretase Inhibitors targeting PSEN1 |
| HA-75-LT22_1uM | Dose=1uM, Rg-4733, Drugs Acting on Notch Receptors;gamma-Secretase Inhibitors targeting PSEN1 |
| HA-81-VN33_0.01uM | Dose=0.01uM, Histamine, NADPH Oxidase Inhibitors;Histamine Receptor Agonists targeting NOX3, HRH1, HRH3, NOX1, NOX4 |
| HA-81-VN33_0.1uM | Dose=0.1uM, Histamine, NADPH Oxidase Inhibitors;Histamine Receptor Agonists targeting NOX3, HRH1, HRH3, NOX1, NOX4 |
| HA-81-VN33_10uM | Dose=10uM, Histamine, NADPH Oxidase Inhibitors;Histamine Receptor Agonists targeting NOX3, HRH1, HRH3, NOX1, NOX4 |
| HA-81-VN33_1uM | Dose=1uM, Histamine, NADPH Oxidase Inhibitors;Histamine Receptor Agonists targeting NOX3, HRH1, HRH3, NOX1, NOX4 |
| HA-82-OO58_0.01uM | Dose=0.01uM, Rifaximin, Inhibitor of transcription by by binding to the β-subunit of bacterial RNA polymerase, also activator of NR1I2 targeting NR1I2, rpoB |
| HA-82-OO58_0.1uM | Dose=0.1uM, Rifaximin, Inhibitor of transcription by by binding to the β-subunit of bacterial RNA polymerase, also activator of NR1I2 targeting NR1I2, rpoB |
| HA-82-OO58_10uM | Dose=10uM, Rifaximin, Inhibitor of transcription by by binding to the β-subunit of bacterial RNA polymerase, also activator of NR1I2 targeting NR1I2, rpoB |
| HA-82-OO58_1uM | Dose=1uM, Rifaximin, Inhibitor of transcription by by binding to the β-subunit of bacterial RNA polymerase, also activator of NR1I2 targeting NR1I2, rpoB |
| HA-82-XO48_0.01uM | Dose=0.01uM, 6-chloro-9H-pyrido[3,4-b]indole targeting CHUK |
| HA-82-XO48_10uM | Dose=10uM, 6-chloro-9H-pyrido[3,4-b]indole targeting CHUK |
| HA-82-XO48_1uM | Dose=1uM, 6-chloro-9H-pyrido[3,4-b]indole targeting CHUK |
| HA-83-HZ77_0.01uM | Dose=0.01uM, Cytisinicline, Nicotinic alpha4beta2 Partial Agonists targeting CHRNA1, CHRNA3, CHRNA4, CHRNB1, CHRNB2, CHRNB4, CHRND, CHRNG |
| HA-83-HZ77_0.1uM | Dose=0.1uM, Cytisinicline, Nicotinic alpha4beta2 Partial Agonists targeting CHRNA1, CHRNA3, CHRNA4, CHRNB1, CHRNB2, CHRNB4, CHRND, CHRNG |
| HA-83-HZ77_10uM | Dose=10uM, Cytisinicline, Nicotinic alpha4beta2 Partial Agonists targeting CHRNA1, CHRNA3, CHRNA4, CHRNB1, CHRNB2, CHRNB4, CHRND, CHRNG |
| HA-83-HZ77_1uM | Dose=1uM, Cytisinicline, Nicotinic alpha4beta2 Partial Agonists targeting CHRNA1, CHRNA3, CHRNA4, CHRNB1, CHRNB2, CHRNB4, CHRND, CHRNG |
| HA-83-MI31_0.01uM | Dose=0.01uM, AC-7954, UTS2R agonist targeting UTS2R, UTS2 |
| HA-83-MI31_0.1uM | Dose=0.1uM, AC-7954, UTS2R agonist targeting UTS2R, UTS2 |
| HA-83-MI31_10uM | Dose=10uM, AC-7954, UTS2R agonist targeting UTS2R, UTS2 |
| HA-83-MI31_1uM | Dose=1uM, AC-7954, UTS2R agonist targeting UTS2R, UTS2 |
| HA-88-EI28_0.01uM | Dose=0.01uM |
| HA-88-EI28_0.1uM | Dose=0.1uM |
| HA-88-EI28_10uM | Dose=10uM |
| HA-88-EI28_1uM | Dose=1uM |
| HA-88-JB21_0.1uM | Dose=0.1uM, 1,5-Dihydroxyisoquinoline, PARP) Inhibitors;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| HA-88-JB21_10uM | Dose=10uM, 1,5-Dihydroxyisoquinoline, PARP) Inhibitors;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase targeting PARP1 |
| HA-99-PM50_0.01uM | Dose=0.01uM, 7-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide |
| HA-99-PM50_0.1uM | Dose=0.1uM, 7-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide |
| HA-99-PM50_10uM | Dose=10uM, 7-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide |
| HA-99-PM50_1uM | Dose=1uM, 7-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-6-methyl-5-oxo-2,3-dihydro-1H-indolizine-8-carboxamide |
| HA-99-UT82_0.01uM | Dose=0.01uM |
| HA-99-UT82_0.1uM | Dose=0.1uM |
| HA-99-UT82_10uM | Dose=10uM |
| HA-99-UT82_1uM | Dose=1uM |
| HB-01-ZU75_0.01uM | Dose=0.01uM |
| HB-01-ZU75_0.1uM | Dose=0.1uM |
| HB-01-ZU75_10uM | Dose=10uM |
| HB-01-ZU75_1uM | Dose=1uM |
| HB-03-JZ32_0.01uM | Dose=0.01uM, 4-{[{[Amino(imino)methyl]amino}(imino)methyl]amino}-2-chloro-1-methylbenzene, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| HB-03-JZ32_10uM | Dose=10uM, 4-{[{[Amino(imino)methyl]amino}(imino)methyl]amino}-2-chloro-1-methylbenzene, 5-HT3 receptor agonist targeting HTR3B, HTR3C, HTR3D, HTR3E |
| HB-06-WU12_0.01uM | Dose=0.01uM, (1S,3S,4S,7S)-4-(1,3-benzodioxol-5-yl)-3,7,11-trimethyl-6,10-dioxo-8,9-dithia-5,11-diazatricyclo[5.2.2.01,5]undecane-3-carbonitrile, induces concomitant H3K9me3 downregulation targeting SUV39H1 |
| HB-06-WU12_0.1uM | Dose=0.1uM, (1S,3S,4S,7S)-4-(1,3-benzodioxol-5-yl)-3,7,11-trimethyl-6,10-dioxo-8,9-dithia-5,11-diazatricyclo[5.2.2.01,5]undecane-3-carbonitrile, induces concomitant H3K9me3 downregulation targeting SUV39H1 |
| HB-06-WU12_10uM | Dose=10uM, (1S,3S,4S,7S)-4-(1,3-benzodioxol-5-yl)-3,7,11-trimethyl-6,10-dioxo-8,9-dithia-5,11-diazatricyclo[5.2.2.01,5]undecane-3-carbonitrile, induces concomitant H3K9me3 downregulation targeting SUV39H1 |
| HB-06-WU12_1uM | Dose=1uM, (1S,3S,4S,7S)-4-(1,3-benzodioxol-5-yl)-3,7,11-trimethyl-6,10-dioxo-8,9-dithia-5,11-diazatricyclo[5.2.2.01,5]undecane-3-carbonitrile, induces concomitant H3K9me3 downregulation targeting SUV39H1 |
| HB-09-NP07_0.01uM | Dose=0.01uM, 4-(Cyclopentylamino)-2-(methylthio)pyrimidine-5-carbaldehyde, CDK inhibitors targeting CCND2, CCND3 |
| HB-09-NP07_0.1uM | Dose=0.1uM, 4-(Cyclopentylamino)-2-(methylthio)pyrimidine-5-carbaldehyde, CDK inhibitors targeting CCND2, CCND3 |
| HB-09-OC16_0.01uM | Dose=0.01uM |
| HB-09-OC16_0.1uM | Dose=0.1uM |
| HB-09-OC16_10uM | Dose=10uM |
| HB-09-OC16_1uM | Dose=1uM |
| HB-09-RP77_0.01uM | Dose=0.01uM, Amfenac, Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| HB-09-RP77_0.1uM | Dose=0.1uM, Amfenac, Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| HB-09-RP77_10uM | Dose=10uM, Amfenac, Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| HB-09-RP77_1uM | Dose=1uM, Amfenac, Non-Steroidal Antiinflammatory Drugs targeting SC5D |
| HB-13-XB94_0.01uM | Dose=0.01uM, Basimglurant, MGLUR5 NAM targeting GRM5 |
| HB-13-XB94_0.1uM | Dose=0.1uM, Basimglurant, MGLUR5 NAM targeting GRM5 |
| HB-13-XB94_10uM | Dose=10uM, Basimglurant, MGLUR5 NAM targeting GRM5 |
| HB-13-XB94_1uM | Dose=1uM, Basimglurant, MGLUR5 NAM targeting GRM5 |
| HB-16-NO83_0.01uM | Dose=0.01uM, Azelnidipine, Calcium Channel Blockers targeting CACNA1S |
| HB-16-NO83_0.1uM | Dose=0.1uM, Azelnidipine, Calcium Channel Blockers targeting CACNA1S |
| HB-16-NO83_10uM | Dose=10uM, Azelnidipine, Calcium Channel Blockers targeting CACNA1S |
| HB-16-NO83_1uM | Dose=1uM, Azelnidipine, Calcium Channel Blockers targeting CACNA1S |
| HB-19-DP22_0.01uM | Dose=0.01uM, Gentianine, TNF-alpha Production Inhibitors;IL-6 Production Inhibitors;Glucocorticoid Receptor agonist targeting NR3C1 |
| HB-19-DP22_0.1uM | Dose=0.1uM, Gentianine, TNF-alpha Production Inhibitors;IL-6 Production Inhibitors;Glucocorticoid Receptor agonist targeting NR3C1 |
| HB-19-DP22_10uM | Dose=10uM, Gentianine, TNF-alpha Production Inhibitors;IL-6 Production Inhibitors;Glucocorticoid Receptor agonist targeting NR3C1 |
| HB-19-DP22_1uM | Dose=1uM, Gentianine, TNF-alpha Production Inhibitors;IL-6 Production Inhibitors;Glucocorticoid Receptor agonist targeting NR3C1 |
| HB-19-OF33_0.01uM | Dose=0.01uM, N-[5-Chloro-2-[(1E)-3-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-3-oxo-1-propen-1-YL]phenyl]-acetamide, Chemokine CCR1 Antagonists targeting CCR1 |
| HB-19-OF33_0.1uM | Dose=0.1uM, N-[5-Chloro-2-[(1E)-3-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-3-oxo-1-propen-1-YL]phenyl]-acetamide, Chemokine CCR1 Antagonists targeting CCR1 |
| HB-19-OF33_1uM | Dose=1uM, N-[5-Chloro-2-[(1E)-3-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-3-oxo-1-propen-1-YL]phenyl]-acetamide, Chemokine CCR1 Antagonists targeting CCR1 |
| HB-24-AP80_0.01uM | Dose=0.01uM, 8-(4-Chlorophenyl)imidazo[1,5-a]pyridine |
| HB-24-AP80_0.1uM | Dose=0.1uM, 8-(4-Chlorophenyl)imidazo[1,5-a]pyridine |
| HB-24-AP80_10uM | Dose=10uM, 8-(4-Chlorophenyl)imidazo[1,5-a]pyridine |
| HB-24-AP80_1uM | Dose=1uM, 8-(4-Chlorophenyl)imidazo[1,5-a]pyridine |
| HB-24-GP45_0.01uM | Dose=0.01uM, 2-(4-tert-Butyl-2,6-dimethyl-benzyl)-1,4,5,6-tetrahydro-pyrimidine, 5-HT1D Agonists targeting HTR1D |
| HB-24-GP45_0.1uM | Dose=0.1uM, 2-(4-tert-Butyl-2,6-dimethyl-benzyl)-1,4,5,6-tetrahydro-pyrimidine, 5-HT1D Agonists targeting HTR1D |
| HB-24-GP45_10uM | Dose=10uM, 2-(4-tert-Butyl-2,6-dimethyl-benzyl)-1,4,5,6-tetrahydro-pyrimidine, 5-HT1D Agonists targeting HTR1D |
| HB-24-GP45_1uM | Dose=1uM, 2-(4-tert-Butyl-2,6-dimethyl-benzyl)-1,4,5,6-tetrahydro-pyrimidine, 5-HT1D Agonists targeting HTR1D |
| HB-29-DM15_0.01uM | Dose=0.01uM, 4-(4-Guanidinobenzoyloxy)phenylacetate |
| HB-29-DM15_0.1uM | Dose=0.1uM, 4-(4-Guanidinobenzoyloxy)phenylacetate |
| HB-29-DM15_10uM | Dose=10uM, 4-(4-Guanidinobenzoyloxy)phenylacetate |
| HB-29-DM15_1uM | Dose=1uM, 4-(4-Guanidinobenzoyloxy)phenylacetate |
| HB-36-FN80_0.01uM | Dose=0.01uM, N-[2-(4''-Cyano-biphenyl-4-yloxy)-ethyl]-N-hydroxy-formamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| HB-36-FN80_0.1uM | Dose=0.1uM, N-[2-(4''-Cyano-biphenyl-4-yloxy)-ethyl]-N-hydroxy-formamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| HB-36-FN80_10uM | Dose=10uM, N-[2-(4''-Cyano-biphenyl-4-yloxy)-ethyl]-N-hydroxy-formamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| HB-36-FN80_1uM | Dose=1uM, N-[2-(4''-Cyano-biphenyl-4-yloxy)-ethyl]-N-hydroxy-formamide targeting MMP11, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23A, MMP20, MMP27, MMP28, MMP21 |
| HB-43-TI61_0.01uM | Dose=0.01uM, Travoprost, Prostanoid FP Agonists targeting PTGFR |
| HB-43-TI61_0.1uM | Dose=0.1uM, Travoprost, Prostanoid FP Agonists targeting PTGFR |
| HB-43-TI61_10uM | Dose=10uM, Travoprost, Prostanoid FP Agonists targeting PTGFR |
| HB-43-TI61_1uM | Dose=1uM, Travoprost, Prostanoid FP Agonists targeting PTGFR |
| HB-45-XQ45_0.01uM | Dose=0.01uM, Apoptosis Inducers;Mcl-1 Inhibitors |
| HB-45-XQ45_0.1uM | Dose=0.1uM, Apoptosis Inducers;Mcl-1 Inhibitors |
| HB-45-XQ45_10uM | Dose=10uM, Apoptosis Inducers;Mcl-1 Inhibitors |
| HB-45-XQ45_1uM | Dose=1uM, Apoptosis Inducers;Mcl-1 Inhibitors |
| HB-49-VZ71_0.01uM | Dose=0.01uM, Krn-633, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK4, MAPK6, MAPK7, MAPK12, MAPK15 |
| HB-49-VZ71_0.1uM | Dose=0.1uM, Krn-633, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK4, MAPK6, MAPK7, MAPK12, MAPK15 |
| HB-49-VZ71_10uM | Dose=10uM, Krn-633, VEGFR-2 (FLK-1/KDR) Inhibitors;Angiogenesis Inhibitors;Inhibitors of Signal Transduction Pathways targeting MAPK4, MAPK6, MAPK7, MAPK12, MAPK15 |
| HB-51-FH64_0.01uM | Dose=0.01uM, 4-[(4,6-Dichloro-1,3,5-triazin-2-yl)amino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid, Deoxyribonuclease (DNase) gamma Inhibitors targeting DNASE1L3 |
| HB-51-FH64_0.1uM | Dose=0.1uM, 4-[(4,6-Dichloro-1,3,5-triazin-2-yl)amino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid, Deoxyribonuclease (DNase) gamma Inhibitors targeting DNASE1L3 |
| HB-51-FH64_10uM | Dose=10uM, 4-[(4,6-Dichloro-1,3,5-triazin-2-yl)amino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid, Deoxyribonuclease (DNase) gamma Inhibitors targeting DNASE1L3 |
| HB-51-FH64_1uM | Dose=1uM, 4-[(4,6-Dichloro-1,3,5-triazin-2-yl)amino]-2-(3-hydroxy-6-oxoxanthen-9-yl)benzoic acid, Deoxyribonuclease (DNase) gamma Inhibitors targeting DNASE1L3 |
| HB-54-ZC59_0.01uM | Dose=0.01uM, 2-{3-(3-Fluorophenethyloxy)phenylamino}benzamide, SIRT2 gene inhibitor targeting SIRT2 |
| HB-54-ZC59_0.1uM | Dose=0.1uM, 2-{3-(3-Fluorophenethyloxy)phenylamino}benzamide, SIRT2 gene inhibitor targeting SIRT2 |
| HB-54-ZC59_10uM | Dose=10uM, 2-{3-(3-Fluorophenethyloxy)phenylamino}benzamide, SIRT2 gene inhibitor targeting SIRT2 |
| HB-54-ZC59_1uM | Dose=1uM, 2-{3-(3-Fluorophenethyloxy)phenylamino}benzamide, SIRT2 gene inhibitor targeting SIRT2 |
| HB-55-NJ83_0.01uM | Dose=0.01uM, 2-(1-(3-cyano-4-fluorophenylsulfonyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid, CRTH2 Receptor Antagonists targeting PTGDR2 |
| HB-55-NJ83_0.1uM | Dose=0.1uM, 2-(1-(3-cyano-4-fluorophenylsulfonyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid, CRTH2 Receptor Antagonists targeting PTGDR2 |
| HB-55-NJ83_10uM | Dose=10uM, 2-(1-(3-cyano-4-fluorophenylsulfonyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid, CRTH2 Receptor Antagonists targeting PTGDR2 |
| HB-69-CT62_0.01uM | Dose=0.01uM, 2-Methylquinoline-3-carboxylic acid ethyl ester, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1 |
| HB-69-CT62_0.1uM | Dose=0.1uM, 2-Methylquinoline-3-carboxylic acid ethyl ester, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1 |
| HB-69-CT62_10uM | Dose=10uM, 2-Methylquinoline-3-carboxylic acid ethyl ester, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1 |
| HB-69-CT62_1uM | Dose=1uM, 2-Methylquinoline-3-carboxylic acid ethyl ester, Histone N-Acetyltransferase (HAT) Inhibitors targeting HAT1 |
| HB-72-BR75_0.01uM | Dose=0.01uM, (6aR,9R)-9-N,9-N-diethyl-7-N-(4-phenylphenyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-7,9-dicarboxamide, CXCR3 antagonist targeting CXCR3 |
| HB-72-BR75_0.1uM | Dose=0.1uM, (6aR,9R)-9-N,9-N-diethyl-7-N-(4-phenylphenyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-7,9-dicarboxamide, CXCR3 antagonist targeting CXCR3 |
| HB-72-BR75_10uM | Dose=10uM, (6aR,9R)-9-N,9-N-diethyl-7-N-(4-phenylphenyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-7,9-dicarboxamide, CXCR3 antagonist targeting CXCR3 |
| HB-72-BR75_1uM | Dose=1uM, (6aR,9R)-9-N,9-N-diethyl-7-N-(4-phenylphenyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-7,9-dicarboxamide, CXCR3 antagonist targeting CXCR3 |
| HB-75-KT12_0.01uM | Dose=0.01uM |
| HB-75-KT12_0.1uM | Dose=0.1uM |
| HB-75-KT12_10uM | Dose=10uM |
| HB-75-KT12_1uM | Dose=1uM |
| HB-77-UY14_0.01uM | Dose=0.01uM, Gsk8814, inhibitor of ATAD2 bromodomain;N-Ac Lysine competitive ATAD2A/B inhibitor targeting ATAD2, ATAD2B |
| HB-77-UY14_0.1uM | Dose=0.1uM, Gsk8814, inhibitor of ATAD2 bromodomain;N-Ac Lysine competitive ATAD2A/B inhibitor targeting ATAD2, ATAD2B |
| HB-77-UY14_10uM | Dose=10uM, Gsk8814, inhibitor of ATAD2 bromodomain;N-Ac Lysine competitive ATAD2A/B inhibitor targeting ATAD2, ATAD2B |
| HB-77-UY14_1uM | Dose=1uM, Gsk8814, inhibitor of ATAD2 bromodomain;N-Ac Lysine competitive ATAD2A/B inhibitor targeting ATAD2, ATAD2B |
| HB-79-CT92_0.01uM | Dose=0.01uM, Neutral Sphingomyelinase (N-SMase) Inhibitors targeting SMPD2 |
| HB-79-CT92_0.1uM | Dose=0.1uM, Neutral Sphingomyelinase (N-SMase) Inhibitors targeting SMPD2 |
| HB-79-CT92_10uM | Dose=10uM, Neutral Sphingomyelinase (N-SMase) Inhibitors targeting SMPD2 |
| HB-79-CT92_1uM | Dose=1uM, Neutral Sphingomyelinase (N-SMase) Inhibitors targeting SMPD2 |
| HB-79-CZ36_0.01uM | Dose=0.01uM, Nizax, Histamine H2 Receptor Antagonists targeting HRH2 |
| HB-79-CZ36_10uM | Dose=10uM, Nizax, Histamine H2 Receptor Antagonists targeting HRH2 |
| HB-79-CZ36_1uM | Dose=1uM, Nizax, Histamine H2 Receptor Antagonists targeting HRH2 |
| HB-87-YY34_0.01uM | Dose=0.01uM, TP-472, BRD9/BRD7 inhibitor targeting BRD7, BRD9 |
| HB-87-YY34_0.1uM | Dose=0.1uM, TP-472, BRD9/BRD7 inhibitor targeting BRD7, BRD9 |
| HB-87-YY34_10uM | Dose=10uM, TP-472, BRD9/BRD7 inhibitor targeting BRD7, BRD9 |
| HB-87-YY34_1uM | Dose=1uM, TP-472, BRD9/BRD7 inhibitor targeting BRD7, BRD9 |
| HB-90-QG69_0.01uM | Dose=0.01uM, Rucaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors;DNA Repair Inhibitors targeting PARP1, PARP2 |
| HB-90-QG69_0.1uM | Dose=0.1uM, Rucaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors;DNA Repair Inhibitors targeting PARP1, PARP2 |
| HB-90-QG69_10uM | Dose=10uM, Rucaparib, Poly(ADP-ribose)polymerase-2 (PARP-2) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors;DNA Repair Inhibitors targeting PARP1, PARP2 |
| HB-92-PE54_0.01uM | Dose=0.01uM |
| HB-92-PE54_0.1uM | Dose=0.1uM |
| HB-92-PE54_10uM | Dose=10uM |
| HB-92-PE54_1uM | Dose=1uM |
| HB-92-XE24_0.01uM | Dose=0.01uM, Gsk2334470, PDK1 inhibitor;PDK1/2 inhibitor targeting PDK1, PDPK1 |
| HB-92-XE24_0.1uM | Dose=0.1uM, Gsk2334470, PDK1 inhibitor;PDK1/2 inhibitor targeting PDK1, PDPK1 |
| HB-92-XE24_10uM | Dose=10uM, Gsk2334470, PDK1 inhibitor;PDK1/2 inhibitor targeting PDK1, PDPK1 |
| HB-92-XE24_1uM | Dose=1uM, Gsk2334470, PDK1 inhibitor;PDK1/2 inhibitor targeting PDK1, PDPK1 |
| HB-95-ZG66_0.01uM | Dose=0.01uM, WAY 267464 Dihydrochloride, Oxytocin agonist targeting OXTR |
| HB-95-ZG66_0.1uM | Dose=0.1uM, WAY 267464 Dihydrochloride, Oxytocin agonist targeting OXTR |
| HB-95-ZG66_10uM | Dose=10uM, WAY 267464 Dihydrochloride, Oxytocin agonist targeting OXTR |
| HB-95-ZG66_1uM | Dose=1uM, WAY 267464 Dihydrochloride, Oxytocin agonist targeting OXTR |
| HB-96-QD61_0.01uM | Dose=0.01uM, N-ethyl-3-[1-(3-methoxyphenyl)imidazo[1,5-a]pyridin-3-yl]piperidine-1-carboxamide, CDK4 Inhibitors targeting CDK4 |
| HB-96-QD61_0.1uM | Dose=0.1uM, N-ethyl-3-[1-(3-methoxyphenyl)imidazo[1,5-a]pyridin-3-yl]piperidine-1-carboxamide, CDK4 Inhibitors targeting CDK4 |
| HB-96-QD61_10uM | Dose=10uM, N-ethyl-3-[1-(3-methoxyphenyl)imidazo[1,5-a]pyridin-3-yl]piperidine-1-carboxamide, CDK4 Inhibitors targeting CDK4 |
| HB-96-QD61_1uM | Dose=1uM, N-ethyl-3-[1-(3-methoxyphenyl)imidazo[1,5-a]pyridin-3-yl]piperidine-1-carboxamide, CDK4 Inhibitors targeting CDK4 |
| HB-98-OB36_0.01uM | Dose=0.01uM, 3-[8-(Aminomethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH |
| HB-98-OB36_0.1uM | Dose=0.1uM, 3-[8-(Aminomethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH |
| HB-98-OB36_10uM | Dose=10uM, 3-[8-(Aminomethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH |
| HB-98-OB36_1uM | Dose=1uM, 3-[8-(Aminomethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl]-4-(1-methylindol-3-yl)pyrrole-2,5-dione, Protein Kinase C (PKC) Inhibitors targeting PRKCH |
| HC-01-CN33_0.01uM | Dose=0.01uM, 3-{2-[(5-Fluoro-2-Hydroxyphenyl)amino]-1,3-Thiazol-4-Yl}benzonitrile |
| HC-01-CN33_0.1uM | Dose=0.1uM, 3-{2-[(5-Fluoro-2-Hydroxyphenyl)amino]-1,3-Thiazol-4-Yl}benzonitrile |
| HC-01-CN33_10uM | Dose=10uM, 3-{2-[(5-Fluoro-2-Hydroxyphenyl)amino]-1,3-Thiazol-4-Yl}benzonitrile |
| HC-01-CN33_1uM | Dose=1uM, 3-{2-[(5-Fluoro-2-Hydroxyphenyl)amino]-1,3-Thiazol-4-Yl}benzonitrile |
| HC-01-FD24_0.01uM | Dose=0.01uM, 4-Amino-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinolin-1-ethanol |
| HC-01-FD24_0.1uM | Dose=0.1uM, 4-Amino-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinolin-1-ethanol |
| HC-01-FD24_10uM | Dose=10uM, 4-Amino-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinolin-1-ethanol |
| HC-01-FD24_1uM | Dose=1uM, 4-Amino-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinolin-1-ethanol |
| HC-04-ZM18_0.01uM | Dose=0.01uM, N-[(4-chlorophenyl)methyl]-N-methyl-1-[4-(1-methylpiperidin-4-yl)phenyl]methanamine, LSS gene inhibitor targeting LSS |
| HC-04-ZM18_0.1uM | Dose=0.1uM, N-[(4-chlorophenyl)methyl]-N-methyl-1-[4-(1-methylpiperidin-4-yl)phenyl]methanamine, LSS gene inhibitor targeting LSS |
| HC-04-ZM18_10uM | Dose=10uM, N-[(4-chlorophenyl)methyl]-N-methyl-1-[4-(1-methylpiperidin-4-yl)phenyl]methanamine, LSS gene inhibitor targeting LSS |
| HC-04-ZM18_1uM | Dose=1uM, N-[(4-chlorophenyl)methyl]-N-methyl-1-[4-(1-methylpiperidin-4-yl)phenyl]methanamine, LSS gene inhibitor targeting LSS |
| HC-06-EN50_0.01uM | Dose=0.01uM |
| HC-06-EN50_0.1uM | Dose=0.1uM |
| HC-06-EN50_10uM | Dose=10uM |
| HC-06-EN50_1uM | Dose=1uM |
| HC-09-KP12_10uM | Dose=10uM, Cl-316243 Free diacid, ADRB3 agonist;beta3-Adrenoceptor Agonists targeting ADRB3 |
| HC-09-KP12_1uM | Dose=1uM, Cl-316243 Free diacid, ADRB3 agonist;beta3-Adrenoceptor Agonists targeting ADRB3 |
| HC-10-FJ51_0.01uM | Dose=0.01uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]-2,4,5-trimethylbenzene-1-sulfonamide |
| HC-10-FJ51_0.1uM | Dose=0.1uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]-2,4,5-trimethylbenzene-1-sulfonamide |
| HC-10-FJ51_10uM | Dose=10uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]-2,4,5-trimethylbenzene-1-sulfonamide |
| HC-10-FJ51_1uM | Dose=1uM, N-[4-hydroxy-3-(2-hydroxynaphthalen-1-yl)phenyl]-2,4,5-trimethylbenzene-1-sulfonamide |
| HC-11-RK51_0.01uM | Dose=0.01uM, Isa-2011B, PIP5K1alpha inhibitor targeting PIP5K1A |
| HC-11-RK51_0.1uM | Dose=0.1uM, Isa-2011B, PIP5K1alpha inhibitor targeting PIP5K1A |
| HC-11-RK51_10uM | Dose=10uM, Isa-2011B, PIP5K1alpha inhibitor targeting PIP5K1A |
| HC-11-RK51_1uM | Dose=1uM, Isa-2011B, PIP5K1alpha inhibitor targeting PIP5K1A |
| HC-14-FM48_0.01uM | Dose=0.01uM, 2-[4-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]imidazo[1,2-b]pyridazin-6-yl]pyrazol-1-yl]ethanol, c-Met) Inhibitors;HGFR (MET targeting MET |
| HC-14-FM48_0.1uM | Dose=0.1uM, 2-[4-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]imidazo[1,2-b]pyridazin-6-yl]pyrazol-1-yl]ethanol, c-Met) Inhibitors;HGFR (MET targeting MET |
| HC-14-FM48_10uM | Dose=10uM, 2-[4-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]imidazo[1,2-b]pyridazin-6-yl]pyrazol-1-yl]ethanol, c-Met) Inhibitors;HGFR (MET targeting MET |
| HC-14-FM48_1uM | Dose=1uM, 2-[4-[3-[(1S)-1-(5,7-difluoroquinolin-6-yl)ethyl]imidazo[1,2-b]pyridazin-6-yl]pyrazol-1-yl]ethanol, c-Met) Inhibitors;HGFR (MET targeting MET |
| HC-15-LT47_0.01uM | Dose=0.01uM, (2R)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methylsulfanyl]phenyl]sulfonylpyrrolidine-2-carboxylic acid |
| HC-15-LT47_0.1uM | Dose=0.1uM, (2R)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methylsulfanyl]phenyl]sulfonylpyrrolidine-2-carboxylic acid |
| HC-15-LT47_10uM | Dose=10uM, (2R)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methylsulfanyl]phenyl]sulfonylpyrrolidine-2-carboxylic acid |
| HC-15-LT47_1uM | Dose=1uM, (2R)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methylsulfanyl]phenyl]sulfonylpyrrolidine-2-carboxylic acid |
| HC-16-SU62_0.1uM | Dose=0.1uM, Belnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| HC-16-SU62_10uM | Dose=10uM, Belnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| HC-16-SU62_1uM | Dose=1uM, Belnacasan, Caspase 1 (IL-1beta Converting Enzyme) Inhibitors targeting CASP1 |
| HC-16-VX59_0.01uM | Dose=0.01uM, 2-(2,4-Di-1-pyrrolidinyl-9H-pyrimido(4,5-b)indol-9-yl)-1-(1-pyrrolidinyl)ethanone, IL-5 Production Inhibitors;Mediator Release Inhibitors targeting IL5 |
| HC-16-VX59_0.1uM | Dose=0.1uM, 2-(2,4-Di-1-pyrrolidinyl-9H-pyrimido(4,5-b)indol-9-yl)-1-(1-pyrrolidinyl)ethanone, IL-5 Production Inhibitors;Mediator Release Inhibitors targeting IL5 |
| HC-16-VX59_10uM | Dose=10uM, 2-(2,4-Di-1-pyrrolidinyl-9H-pyrimido(4,5-b)indol-9-yl)-1-(1-pyrrolidinyl)ethanone, IL-5 Production Inhibitors;Mediator Release Inhibitors targeting IL5 |
| HC-16-VX59_1uM | Dose=1uM, 2-(2,4-Di-1-pyrrolidinyl-9H-pyrimido(4,5-b)indol-9-yl)-1-(1-pyrrolidinyl)ethanone, IL-5 Production Inhibitors;Mediator Release Inhibitors targeting IL5 |
| HC-18-NB46_0.01uM | Dose=0.01uM, N-Acetyl-6-methoxytryptamine |
| HC-18-NB46_0.1uM | Dose=0.1uM, N-Acetyl-6-methoxytryptamine |
| HC-18-NB46_10uM | Dose=10uM, N-Acetyl-6-methoxytryptamine |
| HC-18-NB46_1uM | Dose=1uM, N-Acetyl-6-methoxytryptamine |
| HC-19-UZ81_0.01uM | Dose=0.01uM, Galgravin |
| HC-19-UZ81_0.1uM | Dose=0.1uM, Galgravin |
| HC-19-UZ81_10uM | Dose=10uM, Galgravin |
| HC-19-UZ81_1uM | Dose=1uM, Galgravin |
| HC-20-JJ81_0.01uM | Dose=0.01uM, 1-[[6-(2-Hydroxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| HC-20-JJ81_10uM | Dose=10uM, 1-[[6-(2-Hydroxyethoxy)pyridin-2-yl]methyl]-4-(4-propan-2-ylphenyl)-6-prop-2-ynoxyquinazolin-2-one, Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants targeting CASR |
| HC-24-QF06_0.01uM | Dose=0.01uM, N(1),N(11)-Diethylnorspermine, Ornithine Decarboxylase Inhibitors;Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1, ODC1 |
| HC-24-QF06_0.1uM | Dose=0.1uM, N(1),N(11)-Diethylnorspermine, Ornithine Decarboxylase Inhibitors;Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1, ODC1 |
| HC-24-QF06_10uM | Dose=10uM, N(1),N(11)-Diethylnorspermine, Ornithine Decarboxylase Inhibitors;Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1, ODC1 |
| HC-24-QF06_1uM | Dose=1uM, N(1),N(11)-Diethylnorspermine, Ornithine Decarboxylase Inhibitors;Antimetabolites;S-Adenosyl-L-methionine Decarboxylase Inhibitors targeting AMD1, ODC1 |
| HC-26-PX74_0.01uM | Dose=0.01uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid |
| HC-26-PX74_0.1uM | Dose=0.1uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid |
| HC-26-PX74_1uM | Dose=1uM, (2R)-1-[2-[3-[[2-(4-chlorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]phenyl]-2-methylpropanoyl]-2,3-dihydroindole-2-carboxylic acid |
| HC-38-KI38_0.01uM | Dose=0.01uM, (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[5-(4-fluorophenoxy)pyridin-3-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| HC-38-KI38_0.1uM | Dose=0.1uM, (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[5-(4-fluorophenoxy)pyridin-3-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| HC-38-KI38_10uM | Dose=10uM, (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[5-(4-fluorophenoxy)pyridin-3-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| HC-38-KI38_1uM | Dose=1uM, (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[5-(4-fluorophenoxy)pyridin-3-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide, Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Apoptosis Inducers targeting BIRC2, XIAP |
| HC-40-TX80_0.01uM | Dose=0.01uM, N-[(1S)-1-[[(E,1S)-3-(benzenesulfonyl)-1-phenethyl-allyl]carbamoyl]-3-methyl-butyl]morpholine-4-carboxamide, Cathepsin S Inhibitors targeting CTSS |
| HC-40-TX80_10uM | Dose=10uM, N-[(1S)-1-[[(E,1S)-3-(benzenesulfonyl)-1-phenethyl-allyl]carbamoyl]-3-methyl-butyl]morpholine-4-carboxamide, Cathepsin S Inhibitors targeting CTSS |
| HC-43-CV47_0.01uM | Dose=0.01uM, Bergapten |
| HC-43-CV47_0.1uM | Dose=0.1uM, Bergapten |
| HC-43-CV47_10uM | Dose=10uM, Bergapten |
| HC-43-CV47_1uM | Dose=1uM, Bergapten |
| HC-48-BS22_0.01uM | Dose=0.01uM |
| HC-48-BS22_0.1uM | Dose=0.1uM |
| HC-48-BS22_10uM | Dose=10uM |
| HC-48-BS22_1uM | Dose=1uM |
| HC-49-RF93_0.01uM | Dose=0.01uM |
| HC-49-RF93_0.1uM | Dose=0.1uM |
| HC-49-RF93_10uM | Dose=10uM |
| HC-49-RF93_1uM | Dose=1uM |
| HC-63-SV27_0.01uM | Dose=0.01uM, Begacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| HC-63-SV27_0.1uM | Dose=0.1uM, Begacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| HC-63-SV27_10uM | Dose=10uM, Begacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| HC-63-SV27_1uM | Dose=1uM, Begacestat, gamma-Secretase Inhibitors targeting PSEN1, PSEN2, APH1A, PSENEN, APH1B |
| HC-69-UG51_0.01uM | Dose=0.01uM, Simvastatin, HMG-CoA Reductase Inhibitors;HDL-Cholesterol Increasing Agents targeting CES1, HMGCR |
| HC-69-UG51_0.1uM | Dose=0.1uM, Simvastatin, HMG-CoA Reductase Inhibitors;HDL-Cholesterol Increasing Agents targeting CES1, HMGCR |
| HC-69-UG51_10uM | Dose=10uM, Simvastatin, HMG-CoA Reductase Inhibitors;HDL-Cholesterol Increasing Agents targeting CES1, HMGCR |
| HC-69-UG51_1uM | Dose=1uM, Simvastatin, HMG-CoA Reductase Inhibitors;HDL-Cholesterol Increasing Agents targeting CES1, HMGCR |
| HC-74-FM38_0.01uM | Dose=0.01uM |
| HC-74-FM38_0.1uM | Dose=0.1uM |
| HC-74-FM38_10uM | Dose=10uM |
| HC-74-FM38_1uM | Dose=1uM |
| HC-74-HM63_0.01uM | Dose=0.01uM, Episilvestrol, Translation Inhibitor;Elongation factor 1 alpha inhibitor targeting EIF4A1, EIF4A2, EIF4A3 |
| HC-74-HM63_0.1uM | Dose=0.1uM, Episilvestrol, Translation Inhibitor;Elongation factor 1 alpha inhibitor targeting EIF4A1, EIF4A2, EIF4A3 |
| HC-74-HM63_10uM | Dose=10uM, Episilvestrol, Translation Inhibitor;Elongation factor 1 alpha inhibitor targeting EIF4A1, EIF4A2, EIF4A3 |
| HC-74-HM63_1uM | Dose=1uM, Episilvestrol, Translation Inhibitor;Elongation factor 1 alpha inhibitor targeting EIF4A1, EIF4A2, EIF4A3 |
| HC-76-HU27_0.01uM | Dose=0.01uM |
| HC-76-HU27_0.1uM | Dose=0.1uM |
| HC-76-HU27_10uM | Dose=10uM |
| HC-76-HU27_1uM | Dose=1uM |
| HC-76-PX74_0.01uM | Dose=0.01uM |
| HC-76-PX74_0.1uM | Dose=0.1uM |
| HC-76-PX74_10uM | Dose=10uM |
| HC-76-PX74_1uM | Dose=1uM |
| HC-76-SY22_0.01uM |
